<SEC-DOCUMENT>0001193125-26-338012.txt : 20260806
<SEC-HEADER>0001193125-26-338012.hdr.sgml : 20260806
<ACCEPTANCE-DATETIME>20260806161123
ACCESSION NUMBER:		0001193125-26-338012
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20260630
FILED AS OF DATE:		20260806
DATE AS OF CHANGE:		20260806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IN8BIO, INC.
		CENTRAL INDEX KEY:			0001740279
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				825462585
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39692
		FILM NUMBER:		261249124

	BUSINESS ADDRESS:	
		STREET 1:		EMPIRE STATE BUILDING
		STREET 2:		350 5TH AVENUE, SUITE 5330
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118
		BUSINESS PHONE:		(646) 600-6438

	MAIL ADDRESS:	
		STREET 1:		EMPIRE STATE BUILDING
		STREET 2:		350 5TH AVENUE, SUITE 5330
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Incysus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20180510
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>inab-20260630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-08-06T12:14:13.3862+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:inab="http://in8bio.com/20260630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2026" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2026" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_d8859f73-a74d-4435-9c12-18ab0671866c" name="dei:CurrentFiscalYearEndDate" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6">--12-31</ix:nonNumeric><ix:nonNumeric id="F_560563ca-36d0-401a-bd8e-26c4f3cb4ba1" name="dei:DocumentFiscalPeriodFocus" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6">Q2</ix:nonNumeric><ix:nonNumeric id="F_c7752722-91a6-4727-a73d-62a48909c881" name="dei:EntityCentralIndexKey" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6">0001740279</ix:nonNumeric><ix:nonNumeric id="F_18ec0a2d-15fb-4d1b-8eb9-326323c5cd58" name="dei:AmendmentFlag" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="inab-20260630.xsd"/></ix:references><ix:resources><xbrli:context id="C_810c253b-a933-4a17-9491-34d6f79e7d1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82df8d9b-ab44-4186-a2a5-46f09cf06bab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:AtmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_848a1210-eb49-4891-935b-80b8db44acbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8515f78c-3e2e-4acd-a27d-497da68551e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86e4d9d6-3ea9-4abe-9133-f643a5892564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:Pre-FundedWarrantsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_875d9953-bc37-4aec-b5bd-7626c7b4a282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_882fd2d9-5d3b-4094-8326-9d116fa514c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_896afe2a-d0f7-4ab2-995a-8bb585b17a31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8bad56db-9715-48c8-9c43-9f6171f27068"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cdfe491-a6d3-4390-9fa9-14cf4c1ff8ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inab:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inab:UABRFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e7cb988-8a3c-49f0-9463-9aace8979b6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ef8b035-bbb2-4994-a1c6-11a275ba8551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f720d50-af6e-4211-a827-c117c09d5ba6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareInternallyDevelopedAndPurchasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_919d5a0e-62fb-40f3-a669-87d5a9aef2e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:Pre-FundedWarrantsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95149714-844a-412e-967f-b79e9e655892"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96ec57a8-e87b-4138-894b-a4270326d386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97223205-5221-4961-859d-ce78102dadb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inab:BirminghamAlabamaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_974cfe0d-089e-4c95-bae7-273d520e56db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:SecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97eade55-36d8-4746-9262-d58691399e1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_991adedc-6fe1-457b-a3c6-48d3d6844dc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_997b28c3-e27a-4857-b095-ed0f479b1617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_999469ac-65fe-4335-aa47-cdaa7da3a24c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a174a2f5-f61d-4549-a8ce-e3d8bb86274b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a63f502f-f8b0-4607-a47f-5d8632401b59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a808f64c-72ae-4532-9ed3-19e39e466b41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8fe38f0-fd45-4ec0-b678-619335c250dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa26e47b-c5bc-46bb-be5a-e667b328aaff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:SecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa7edcfc-6c9b-4838-92c4-14a3be2c97a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-400Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab1c1654-f49e-44dd-932a-984720cd913c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_acfff60e-a022-428e-8f12-c565b3924d5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad33d33e-a055-4025-8be6-a7a64988ccbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-200Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ade5bfd8-e223-4fa2-b9eb-073902595766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:ExchangedPre-FundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aea50f9a-5f2f-47c2-a9b6-328cfc5db21b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesCWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0893cee-3d08-4109-a7b3-cdad0a9d269d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b24663f5-7497-4a9d-bd5e-d59f159c16de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b28d3e5d-1b32-48f8-88d7-6fb7eab46cd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b30464c5-22d4-4239-98ad-7e811345c69c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b52b4906-2f95-41dc-9fd6-f217e9324069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-29</xbrli:startDate><xbrli:endDate>2021-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5b1abb1-d97e-42f9-9b1f-61a28dbce843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5ee527e-59c0-4072-8224-1ae00b09c2d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8e4b9eb-c72b-49a4-a984-af719c089c73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba318ec4-b114-42ad-878b-e7d896f93026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc76b556-a6fe-4d1d-ae30-4ebf8174f5cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd29102c-0440-4bf5-9ff4-5120f836ab06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyThreePre-FundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdbee5c1-4fcd-4d7f-ba39-f1599229cc82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be7c85de-8249-4726-abb3-64537317fe59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inab:BirminghamAlabamaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8b1b3b9-2703-4083-a3de-9b291dc7e209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:AtmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c96bc108-9aae-4257-b173-6aafb51ec3cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca9afdc9-8b69-4eef-878d-9bfdecad710f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-400Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc023649-9aca-4bc0-a9c8-0b9537dfc5f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesCWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdfcacfd-7d70-4257-9404-6c997e9aadc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0886603-a24d-4329-9904-e737992b8142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1b51327-f920-40af-87a2-b87c1de36678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d225c8bf-ce7a-4314-8a8d-a6a85def5b00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d253db46-30ee-4977-a335-6cf4430b34fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d340d6b3-3a2d-4be6-b670-fb1812ea56c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d465b573-e7bb-4e0a-993f-63f0094f2438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-15</xbrli:startDate><xbrli:endDate>2023-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d489f32d-49f5-485e-b567-6dfcd8ad3fb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4c94038-e53d-43c3-abc6-12d9c67c6468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4f58c1a-28e8-4e00-ac1b-fdb6c3f10ee4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d60a61e2-303c-4252-a580-f819f238b08c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:AtmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6a03d66-c6db-44b9-acc8-f36f9f7a7dd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d771653f-d6e1-42de-90fd-133dbbf26d13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7b166d9-02a0-43d4-9686-85c3222aedbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9315813-0e95-4466-96f4-8eb12df54e55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9a12ffb-2ec7-4e7c-a5a8-b1e4e74bf9f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc8de850-dafa-4740-ad94-9a138121ba04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_deaddb12-fb85-43b4-a749-9236251e774e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_def38031-424d-4460-9cf3-5076e5af20ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inab:BirminghamAlabamaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-15</xbrli:startDate><xbrli:endDate>2021-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_def65cee-ee7e-4161-a3b8-a9cb4d0e2897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df7a4eb8-2669-4de2-88f2-acbd258098aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dff100d2-ec00-417b-a887-37746b72d7f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e188bb86-a5e4-4b84-9bc7-9b343c8b614c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1d35277-d874-4b8a-81ba-2d210f518638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e34a25b4-4b7a-448a-bf63-cb6e13b70301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e53c5f60-4e1c-4ab5-8af8-680ceacbe890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e59a07f5-ac54-4de1-8e72-5db165f3214b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e699a5d1-4c74-4461-a49a-dd3300a4a440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e772d115-96f1-449b-a86e-07213323f1c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7dbcb37-cd29-432c-9337-b9e4bc5c8fbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e92bc1aa-c2db-46f5-9911-334ad58821cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eee3fb2b-1cc6-48f7-8f7d-17cd8e684af5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eee4484b-9c91-4075-99a6-ba3ae7b09a52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:SecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef18a21f-14bd-4046-a4f2-3da805a9ad98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f08181e7-c1bc-4a25-bac2-7766dac1a770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f400a42d-0c03-47f8-b36b-2ccfd408dc51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:ExchangedPre-FundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7dd2334-9796-45e3-9723-b8b13243babf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa2c336e-3ddc-4b2c-b8dd-0e2b1adc5db0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdc21c59-3c61-4c15-b2c9-ab66b200f940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-200Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00c2fbee-81a5-4d69-b099-7ec1b71252fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0499d8bf-2153-47ac-bbac-d9cd024bdf7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05ec3e90-967f-458c-97d3-d68b6e3dd286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0da20066-bceb-4489-961d-fc1d7a76f4a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e88d318-dcf6-40a9-820a-70d59c10d5b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f67f5a8-7d2f-4836-8132-a9140b0a5dee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13d21bb4-b59b-41aa-aa09-28b17f1305e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_141ba882-944c-447d-9a26-353741846e49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyFourPre-FundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14ed354b-9858-4395-9f4f-fe4f90a1c437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15a832e8-0165-4101-a163-3b54c4539b18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyFourPre-FundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17a4c689-e630-472c-a467-89020ee064f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_198b97c6-3cda-418e-8a12-84c85860d2ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19bfb4fa-92ca-4246-b1e1-4e59f4934b59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19eea9f4-a3b3-4fe1-9029-8ab4452c1378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1adb25df-3d32-4ebb-8981-405b9b8ebad8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e264363-061d-4fec-ab8f-4a6fcd04c71e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_212bcbdc-62a3-49ef-86ac-994d2b61a1ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2175d4db-6a33-4fb4-85e3-1bf2eeb93e8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23c7fe2f-970c-4999-b6a8-53f62effb0b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2444ac2d-b0ac-4470-ad12-9bfaa60d8a45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a7caeb1-9103-4d4c-8f98-d37f1a6de338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2af03440-5a2f-4e6d-b44b-a6ccc55a7aa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b8acd72-67e8-49aa-b360-6976c9610ae0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c0017d1-6285-4171-90ff-3fa0920d4f40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c1c8162-f3f4-43b5-b9b1-dfa4747b48c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-200Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c9be926-d525-4e32-aec7-2f538b535820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f17ba0a-7fb9-42d7-bb76-df75063b2d08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30289466-5d5a-4f6a-a4fe-1eb69daf93bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3308162f-a2dc-4d95-879d-976b215e5b9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inab:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inab:UABRFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35dd4b27-e1ca-484c-8fc2-9fea1443f2b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inab:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inab:UABRFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35e2df7a-828c-48a5-bbac-98bd4ed637bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38b6bbc9-cfd4-42cc-abf5-b90814c910dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a6247f8-75f6-40db-a461-ec966fedb821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d1767c5-7281-45dd-b1c5-54289525b7fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3eba5499-8b2d-4237-9df4-85ecab51e9df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ef9e3d2-ac68-4df4-9377-90cb029dcf78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f9adad1-5ca0-4a1c-aed8-aaf191bcb64e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inab:SeriesABWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4136a492-9cb7-4b0d-90cb-607bc2ed4239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41f9322c-2c47-48ad-880f-4d68924f360c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inab:EmoryLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inab:UABRFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4222be5a-0c57-4a3d-b834-e0e79efc53a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareInternallyDevelopedAndPurchasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4236eadf-0539-4ef9-8e90-18421e8dedb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42cc5669-934a-4055-a8d8-921ebecf0195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inab:BirminghamAlabamaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47b31919-5ee3-4679-8cae-28d91f22238b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c61b704-66e8-4b64-a193-bc2b42ce834b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-200Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c7d1dff-7913-4872-846a-511db2a788b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e1d52b8-2e75-4fad-91a5-2c9038ff8c4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e6b6762-f427-4f1a-938b-da78f831260d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50d59e7d-433d-43f6-a235-2ab99ee775ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51057659-704a-481e-b321-6c1fd355a269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51d9da6d-b9b1-4235-b9df-47c847a8337b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5278b2a4-3328-41ca-a1e8-91dc5a129b3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53a7b24c-e727-4468-a624-795e8b95e8d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-400Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53e8ca8d-054b-421a-aeaf-137116bc56c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55665991-ca2b-41b7-8b4e-3d3f94dda5c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59cd43a9-96e0-48e2-a9e4-f951fd28b4a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyThreePre-FundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fdb3891-da52-4136-be69-6649196b8db1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-400Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ff0bb53-9ba3-44b1-99fb-5976079d7285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesCWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_615b0689-2e71-471d-b476-8b5d53cc4a55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6422bdd1-8860-4052-ba54-1d6d60b3e10a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6512d216-0c5d-4efe-bd6d-d941a05aec24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inab:JanuaryOneTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_652cd561-42c7-41d5-a3df-59ea80bfee2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inab:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inab:UABRFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65a4b151-c941-4db6-b342-71c02c307b1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inab:SeriesABWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_665131ec-5814-4fa4-93a2-5d902fd95bbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6719b59d-803e-4f87-b7ca-224b48a13129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68f1e9fb-5b0b-4695-96b7-d28a72a0181a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d0dc760-5d42-43c3-8497-ef5beb5bf865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:ExchangedPre-FundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d2dbaaf-c0a6-4697-b08e-5a209319a860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e10ca35-ecc2-4490-8426-dd8b4a7de900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e764d9e-722e-4667-9043-0080eb8701ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f1b8905-5d9c-4b4c-a19f-0b6187fb5d06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f940d37-a954-49ae-b661-7826cc32ebbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71b5319c-c74f-48c0-b513-7d988c5197cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_722ff75a-27ec-4522-80bd-b43a8403d7ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis"><us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76bcec81-1928-48a5-ae1a-c034ec20dc20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7af2a072-2c87-47d1-ad7d-8dab6874c286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inab:BirminghamAlabamaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ed27e52-d578-4124-a699-38d69b156df6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001740279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>inab:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d" fromRefs="F_cb679ebc-166e-4e62-8068-125f41eeed39 F_2bab2d68-a8d3-4b6b-b25d-61036d0fa408 F_6a2595ff-aceb-4232-b0b4-a4edbf870784 F_24a83f4a-7350-4950-9621-e47620552eed F_ad36cfe4-d780-4a42-a557-9cc7f141a118 F_23a96342-8aeb-4a85-a167-fd2fdb6cacdd F_6920e5a2-5153-4018-86b4-83c77154cba0 F_88fa32c1-36d1-4829-a67b-b66927b13738 F_3f57d2ec-aa0e-48a3-b9ac-f3904452b5af F_ba4bbdff-2aa4-474a-91c3-2c1ef6c55a48 F_d875ef15-491b-4022-95a5-d52c978e5661 F_ae2040ba-edc0-42b2-9e07-cec9ccc09815 F_5ddec5c6-ab9b-48f9-9d55-ff4da217f114 F_cc4c5c01-c05f-4623-9210-13aeafc82543 F_58d405c4-49a2-4611-bd85-cc3dfdd98b70 F_57f3e6ed-baf3-49bb-a055-ef3d5d7dcbe6 F_c0eaaeae-eb28-4836-a2a1-0b385f8a74ee F_68df0b86-a86f-4b00-9f88-2e8bde8ce102 F_9af372e4-b465-4f98-a518-bc53594010cc F_0c63c55e-f54c-4a7a-973a-4b8863b43643"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_b5be1cbe-74b4-4707-a935-4de0fdbab18f" fromRefs="F_bf054062-3810-4cc0-b368-e33f58f1a8b6 F_25611ed4-88a8-4ad4-9cb3-b05b081e1023 F_6d39d48d-314f-467d-8a4c-4e7dff4734f8 F_ae5f322f-0da7-45ed-a4ad-2c5c44deaae9"/></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a73bde2d-28e7-4c1c-b9f5-7ba0bc2bc617" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_12e055d4-cd9a-41cd-93c5-adaa38a1314e" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_918c5c1b-4508-4ce5-9258-ac344e65a824" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b98a488-0099-46ee-91bd-9cfec30f3b96" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_3a882774-2868-4968-8d78-251311af291d" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec668c9c-4366-4b57-bb86-1bc0bf7ef533" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-39692</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e5dd7e5-bc72-42f9-9540-defaa4b829f8" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8BIO, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_64a4fb6e-8083-4021-b9b4-c4b0836576b4" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_9919159f-51d9-494a-9f6c-1e0ef1d199f4" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82-5462585</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_613c70a1-533b-4e14-9336-ca826112cd6e" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">350 5th Avenue</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_6baa146c-5278-44bc-b97f-f4f8fa8367c0" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 5330</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_21444f2a-6046-4b32-b968-25bd41735c6f" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_8d81cf83-47e9-4f70-aaf5-79f6b075acc6" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_1007387f-70fb-4b74-8301-d06e7c165f0d" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10118</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d2800ec-c71b-4801-b568-bb870334bba6" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">646</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de2ed9d1-e279-4ebb-a8c9-5aa4875e4fff" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">600-6438</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:40%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:40%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_8d32cc00-a2d9-4881-ae5b-5b5abc7d32a1" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_b79f445d-bc20-4aaa-b541-36d6c876fea7" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INAB</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_46cb41f6-5dca-4c00-aa52-acf8d8e5fa50" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c28090c-9e76-4330-bcd0-70d6d235e50d" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Y</span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746; </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N</span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">o</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e80f19bb-ce04-49d6-9c68-bf723bf87b52" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Y</span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746; </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N</span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">o</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:15.938%;box-sizing:content-box;"/>
     <td style="width:1.002%;box-sizing:content-box;"/>
     <td style="width:59.142%;box-sizing:content-box;"/>
     <td style="width:2.005%;box-sizing:content-box;"/>
     <td style="width:19.006%;box-sizing:content-box;"/>
     <td style="width:1.002%;box-sizing:content-box;"/>
     <td style="width:1.905%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_dda64a96-679f-4e17-9625-7c94f8747546" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_bfcff022-db08-4987-9b9e-a38d8a6a4c5d" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_09b776c8-e0dc-46be-a9ee-0cedbfc07048" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19d8f803-3d5d-48b6-b4df-1b1b692fe508" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Y</span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744; </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N</span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">o</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4b537f3-3aa5-4cd3-b15b-6833ad719401" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of Registrant&#8217;s Common Stock outstanding as of August 3, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71f5ba01-120b-4844-a141-f8d53a536cec" contextRef="C_8515f78c-3e2e-4acd-a27d-497da68551e4" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,858,383</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:82.92%;box-sizing:content-box;"/>
     <td style="width:7.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ifinancial_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_financial_statements_unaudited"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Financial Statements (Unaudited)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Balance Sheets</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_operat"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Statements of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_conver"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Statements of Stockholders&#8217; Equity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_cash_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Condensed Financial Statements</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iior_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_unregistered_sales_equity_securit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_defaults_upon_senior_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_exhibits_financial_statement_sche"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ifinancial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I&#8212;FINANCI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AL INFORMATION</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1_financial_statements_unaudited"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Condensed Financial Sta</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8BIO, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDENSED BAL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANCE SHEETS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(unaudited)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Note 2)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d8238e8-5caa-4e9a-9928-bddd1d9a8d3f" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,956</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3f66b38-2df9-42b1-9cdf-f502806cf788" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,092</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc4f9bed-b847-4f54-aec2-894988f10352" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">540</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2fad889-3bcd-40e5-a778-e1d5ed9721a8" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">788</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Current Assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e699885-cede-4825-8e7b-d4dbdb72e927" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,496</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae50709c-d8c4-4a56-a784-214c10049281" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,880</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6e41298-62cc-4444-8cfd-dc623b05f6e8" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,600</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_645d1a48-eb19-4252-baea-b75aac2f8fa7" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,858</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f78a64c7-75d2-4e54-8396-5c2e1fb1c403" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12389d0b-66e2-4895-a148-d0da1bf3610d" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets - finance leases</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbef6728-f446-4a2e-a1e2-ba50a344cb58" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc5a1f02-f8b3-4b95-a5e7-a8a499073bd9" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets - operating leases</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e522586-d8f5-402f-9252-2689cae6ecb6" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,246</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25eaf803-0452-4edb-b82c-39dbeff02fd9" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,882</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5a08cd8-648a-429e-b979-76915575a8e6" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db7cb6f0-01c7-45e2-b57f-dd37c3a39bb0" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Non-Current Assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9334be02-6a23-458e-8538-f3cf6d52fce1" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,249</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee92cbbe-2c41-4b07-a9ac-d678e6d35b37" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,402</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e338ff0a-7c9e-4347-83b6-84071d81c221" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,745</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3da31e1-a0ba-4132-8d4c-5c7f9b7a82ec" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,282</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders' Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fd0d015-d9f3-4c66-a4b3-b22b023feb56" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d7b56eb-920c-47de-aced-63cf399f3bd0" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">309</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69a9988f-fb22-498a-9dac-5384b323343d" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">761</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38ffb37f-f2a7-4389-9813-486aaf4abc5e" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,633</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term finance lease liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0638276e-1702-470b-9cb0-d549ddcbd569" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38d48ba6-e722-4b6e-ba88-0151fb20080f" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term operating lease liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47473bfa-59b1-4c2b-8c73-c2fd2840cb18" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">923</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df0df7dd-2b3d-47b5-a5b0-018050dd1a5b" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">924</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Current Liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b478d50-9d44-4821-82e9-a2525089276f" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,254</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79440745-823e-42e1-b4b9-49d841bc2fad" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,161</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term finance lease liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78763102-061a-4f8a-b992-95c274f98526" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cf81ba3-bdc1-4bc7-9e8f-793b8ba6ce6e" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term operating lease liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcd5de24-198f-4dc2-9ee4-23c4067757f3" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,128</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36dbb8ba-160e-4c73-b5ea-bd30de203c03" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,563</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Non-Current Liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4585b322-7236-42ec-a79c-55986b5f62ba" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,128</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d1d89d2-dea2-490e-aa62-f7b9fec281fd" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,563</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7782a7e1-d989-403c-bd49-590d86d7a13b" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,382</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03c19c1-5318-4444-87d8-605fc9475ff0" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,724</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders' Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:11pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, par value $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa40f82b-0a87-45e6-a4f2-6a2f6d8c9f3f" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_609235f9-8b20-4b08-8926-98522a8db2ab" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c7546f8-8957-4e8f-b60e-cbb4945be81a" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f5b7402b-ce7e-46c6-b287-c7fae2b741e1" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized at June 30, 2026 and December 31, 2025, respectively; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ce21684-862b-4715-949e-0f1259d10190" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_35f329c0-1312-48be-b5e7-1ca094cf6af1" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2c447b58-62e5-49a3-90a0-f7dcb82c9edd" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d616065a-4683-474e-bcdd-cc13108d66b5" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:11pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5daf64d1-f53f-4796-b33c-1fde7866b699" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:11pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94feeb45-0908-4fce-8dbb-b3fef085a6a4" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, par value $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0a29492-3060-4b1f-b5f6-de77e7b7cae8" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1184eca5-be43-4bdc-a92e-efe5f23faae7" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_834336c6-9de1-44c3-b2a5-a207dbac31e4" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0c1e8d3c-7110-40c5-9855-b8d0b16700b8" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">490,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized at June 30, 2026 and December 31, 2025; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ab6a304-d211-427f-9bd6-a53f88ca978d" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a08cf0fc-fef4-4126-8e70-c269f7f7bf6b" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,853,121</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4526a703-bffe-49f8-9e63-61e128dcc3f3" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c7249552-98d9-4044-87ac-5939d026b189" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,766,132</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_370d18c0-150a-409d-9b0e-37b1687b0e54" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c53d308-7bf9-45f7-9b3f-79ddae959134" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ddb49e6-9efe-4f3d-90a7-6bde17f9f129" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,320</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa91b422-477e-4d1a-952b-4ed9b2d415dd" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168,644</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65289ada-73ae-4035-b9ea-96d8992a9bc8" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">150,967</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88706058-4fa0-4bf5-93b8-b7011f3f0767" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,096</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e71c3479-8065-4808-8bf7-0bd472abbad3" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,363</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42313ea4-0a70-4492-8745-1a14cd8473d5" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,558</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Liabilities and Stockholders' Equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34751ec5-a1f6-4f2c-8ef2-110ff2bb5277" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,745</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29d5f2be-3d2f-4286-9ab8-ed3fe7766755" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,282</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3.35pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_operat"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDENSED S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TATEMENTS OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.38%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.184000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.184000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.184000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.184000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2ead263-4bbe-48fa-882c-2e6c45c7e54d" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,493</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_401ab91b-b5bc-4768-9eb5-5c9be85849d1" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,487</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f9c1226-1ca8-4ce1-9b7e-4a7e9e997a25" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,106</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8e62539-acb5-454f-b095-4d7501dbb76f" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,459</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8273570c-6190-4f8b-b4ef-fb8c68d37636" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,442</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff77584c-5e74-4a46-93b1-acd49526210d" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,714</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c80ea1d0-44e7-4399-9df1-a50ae4fd8975" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,095</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_694c2498-fc49-4079-bae8-53a9d101a34e" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,402</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0837b01-3036-4401-98c3-d83e0bb7607d" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,935</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3116c44-8a9b-4076-bb99-41c3a62475a6" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,201</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eefe9aa0-e7ef-483e-910a-d25956f43e5b" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,201</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad85ea07-c397-41a5-a6a9-13fb8f3469fc" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,861</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a97fa6d-9da2-4f31-a1b7-7c261d5f2c09" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43cb1297-5003-4a5e-9b9a-359b713dade6" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00567391-3e65-423d-bc23-0b2ab8518d19" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">330</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbc555ba-587c-4bc9-8339-84d62bb016b4" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0ddb91f-fc45-4bf3-9755-3b3c130e4352" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,781</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61fa8fd9-f8e2-4210-a1f6-739b87c2dca0" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,094</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_370f3ad7-4f06-4555-902e-583cf2a73fb5" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,871</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d72f061-29be-4813-acf1-efe511cd24e5" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,644</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcb97b13-e303-463e-80af-103d077b7d76" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,781</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f02e768a-1242-4f3a-b830-ea5b2b0fd7d0" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,094</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ff13a48-1937-4b80-8937-224760cd785e" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,871</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5ac5b19-271a-48d0-b900-1d440a770493" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,644</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share &#8211;&#8201;basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43fb2e35-8a04-4350-a83c-62ef3138821d" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_58d442d6-2685-40e3-896a-1f27ba7975b0" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.25</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40862018-ca6f-4bc3-8ea7-b0ccb8ef40ed" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ffa00432-2c64-4c81-9ba0-adb1f8729dd8" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.24</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53ad4dad-8596-4ce3-bb2b-b7307b0c9356" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_890c8f2a-22c6-497c-a1f3-953c4d93604b" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.51</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae1f7546-5c1a-4ee8-913c-64f1de888cac" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3725d7f8-dd38-47e9-9784-83549eca5f7d" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.65</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares used in computing net loss per common share, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_107fd8a6-01bb-4d8d-a9e4-2dc7f7ed9f9b" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e701fc01-3222-4bda-b8fc-f90691c52fb8" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,467,091</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31dd06b2-e64d-404b-8418-0afac011aefa" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4aa5ae8f-d338-45e5-95b4-1c08a2d5551c" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,119,153</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae7fa5eb-e603-4e10-8852-92aae4d27b0d" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2afb20e6-daba-4a98-8a1d-0808a26aa807" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,468,087</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e3a0361-9c17-424c-821f-288a91852291" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_69ffcd5a-80a5-4883-8fd0-45436001806a" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,920,157</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3.35pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3.35pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8BIO INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_conver"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDENSED STATEMENTS OF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> STOCKHOLDERS&#8217; EQUITY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:44.309%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.662%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.221%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.221%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.221%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.362%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders' Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88fa32c1-36d1-4829-a67b-b66927b13738" contextRef="C_d0886603-a24d-4329-9904-e737992b8142" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,416,066</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc4c5c01-c05f-4623-9210-13aeafc82543" contextRef="C_d0886603-a24d-4329-9904-e737992b8142" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_722463d3-1f54-40a0-87bd-b75ccae582ef" contextRef="C_d340d6b3-3a2d-4be6-b670-fb1812ea56c6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,127</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d685d2e-664e-482c-8498-c6c59b88842c" contextRef="C_1adb25df-3d32-4ebb-8981-405b9b8ebad8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,656</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a80b300-6c78-4b68-97cd-0f6771629716" contextRef="C_76bcec81-1928-48a5-ae1a-c034ec20dc20" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,478</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24a83f4a-7350-4950-9621-e47620552eed" contextRef="C_0f67f5a8-7d2f-4836-8132-a9140b0a5dee" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">245,428</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f57d2ec-aa0e-48a3-b9ac-f3904452b5af" contextRef="C_0f67f5a8-7d2f-4836-8132-a9140b0a5dee" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d073a333-eabe-4298-8b89-6429325aa8b4" contextRef="C_e188bb86-a5e4-4b84-9bc7-9b343c8b614c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,734</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7469dd04-2ad1-43d3-a5f8-a3053aa1ac95" contextRef="C_c96bc108-9aae-4257-b173-6aafb51ec3cc" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,735</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of Series C warrants, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9af372e4-b465-4f98-a518-bc53594010cc" contextRef="C_0f67f5a8-7d2f-4836-8132-a9140b0a5dee" name="inab:StockIssuedDuringPeriodSharesSeriesCWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">47,088</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9c84f6d-6947-438b-9681-a7ad2472c170" contextRef="C_e188bb86-a5e4-4b84-9bc7-9b343c8b614c" name="inab:StockIssueDuringPeriodValueSeriesCWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">383</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edf5df99-5982-4c40-883d-ea660778b645" contextRef="C_c96bc108-9aae-4257-b173-6aafb51ec3cc" name="inab:StockIssueDuringPeriodValueSeriesCWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">383</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa69cffe-135e-47c2-8964-0180a0a667c6" contextRef="C_e188bb86-a5e4-4b84-9bc7-9b343c8b614c" name="inab:Stock-BasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97702608-09bc-4c20-a3cf-5db4caa4c609" contextRef="C_c96bc108-9aae-4257-b173-6aafb51ec3cc" name="inab:Stock-BasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_782cdc9f-9aae-4946-a97e-de38efaca09f" contextRef="C_97eade55-36d8-4746-9262-d58691399e1f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,550</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61702626-6ef0-40a6-b912-696b32710120" contextRef="C_c96bc108-9aae-4257-b173-6aafb51ec3cc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,550</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57f3e6ed-baf3-49bb-a055-ef3d5d7dcbe6" contextRef="C_1e264363-061d-4fec-ab8f-4a6fcd04c71e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,708,582</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bab2d68-a8d3-4b6b-b25d-61036d0fa408" contextRef="C_1e264363-061d-4fec-ab8f-4a6fcd04c71e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7841e2ae-f152-4017-aa4e-59b1ba45e19d" contextRef="C_deaddb12-fb85-43b4-a749-9236251e774e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,075</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c30d810-c810-46e4-8ed4-7e9fedd3dcbd" contextRef="C_2c9be926-d525-4e32-aec7-2f538b535820" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">127,206</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9597a74-5db6-4522-a6f0-9f74ddfa4229" contextRef="C_d489f32d-49f5-485e-b567-6dfcd8ad3fb9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,877</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad36cfe4-d780-4a42-a557-9cc7f141a118" contextRef="C_6e10ca35-ecc2-4490-8426-dd8b4a7de900" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,058,861</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae2040ba-edc0-42b2-9e07-cec9ccc09815" contextRef="C_6e10ca35-ecc2-4490-8426-dd8b4a7de900" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03337bf-e316-4d51-9587-568e4ac1a375" contextRef="C_3d1767c5-7281-45dd-b1c5-54289525b7fe" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,615</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9467cbc-d005-4d38-aeae-973097c839b0" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,617</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of Series A &amp; B warrants, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6920e5a2-5153-4018-86b4-83c77154cba0" contextRef="C_6e10ca35-ecc2-4490-8426-dd8b4a7de900" name="inab:StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">310,696</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6725740-decf-4cfa-a142-354d6f0cd9ed" contextRef="C_3d1767c5-7281-45dd-b1c5-54289525b7fe" name="inab:StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,884</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_283f4161-752f-4484-84f1-1822e6a22898" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="inab:StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,884</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34622706-4656-4126-9f28-349ac2d2eb43" contextRef="C_3d1767c5-7281-45dd-b1c5-54289525b7fe" name="inab:Stock-BasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">955</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e8396da-5e1b-4b91-a1d1-961ff42f3926" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="inab:Stock-BasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">955</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00b8cf38-32ae-4eca-9e5d-845ad75845e1" contextRef="C_8ef8b035-bbb2-4994-a1c6-11a275ba8551" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,094</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59b19735-8d3f-45e1-9c4b-8469a3db239d" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,094</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at June 30, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ddec5c6-ab9b-48f9-9d55-ff4da217f114" contextRef="C_665131ec-5814-4fa4-93a2-5d902fd95bbe" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,078,139</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58d405c4-49a2-4611-bd85-cc3dfdd98b70" contextRef="C_665131ec-5814-4fa4-93a2-5d902fd95bbe" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d5b8c4e-eabe-4001-89f4-71a645206c81" contextRef="C_ba318ec4-b114-42ad-878b-e7d896f93026" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,529</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03df1d61-2532-4c1e-8deb-8ba6e5bccc75" contextRef="C_6e764d9e-722e-4667-9043-0080eb8701ce" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">132,300</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e21e1aee-15d7-4950-880f-1cdf65196e1f" contextRef="C_0da20066-bceb-4489-961d-fc1d7a76f4a5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,239</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba4bbdff-2aa4-474a-91c3-2c1ef6c55a48" contextRef="C_6f1b8905-5d9c-4b4c-a19f-0b6187fb5d06" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,766,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb679ebc-166e-4e62-8068-125f41eeed39" contextRef="C_6f1b8905-5d9c-4b4c-a19f-0b6187fb5d06" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45c99f40-692d-49fa-8b8f-a40f09d554f1" contextRef="C_2a7caeb1-9103-4d4c-8f98-d37f1a6de338" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168,644</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4817ee99-ee6c-48cc-931f-f216531a04d3" contextRef="C_f08181e7-c1bc-4a25-bac2-7766dac1a770" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,096</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7d10c14-3f8a-46bc-9d13-51a301ecff5e" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,558</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of issuance costs from December 2025 issuance of common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdf84f19-9ef8-4ed5-82fb-d5c6234a9748" contextRef="C_212bcbdc-62a3-49ef-86ac-994d2b61a1ff" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7167f541-5176-4204-9b70-e47173f48449" contextRef="C_d9a12ffb-2ec7-4e7c-a5a8-b1e4e74bf9f6" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of prefunded warrants, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23a96342-8aeb-4a85-a167-fd2fdb6cacdd" contextRef="C_a8fe38f0-fd45-4ec0-b678-619335c250dd" name="inab:StockIssuedDuringPeriodSharesSeriesAWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">80,957</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01cae2a2-a2d4-49e9-b9d5-5ef88a06ca08" contextRef="C_212bcbdc-62a3-49ef-86ac-994d2b61a1ff" name="inab:StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63d6153e-8034-45a1-8781-2cf8f8e07a04" contextRef="C_d9a12ffb-2ec7-4e7c-a5a8-b1e4e74bf9f6" name="inab:StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89de0c52-15dd-40a8-81c9-1875c7538cb8" contextRef="C_212bcbdc-62a3-49ef-86ac-994d2b61a1ff" name="inab:Stock-BasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68ddb86d-0a7d-46b5-a23c-6345a47a06c1" contextRef="C_d9a12ffb-2ec7-4e7c-a5a8-b1e4e74bf9f6" name="inab:Stock-BasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdc30d69-cd31-4f85-974b-ae49d77c26e9" contextRef="C_fa2c336e-3ddc-4b2c-b8dd-0e2b1adc5db0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,090</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3eb49d71-b54b-4f5d-8fb1-d198f2ac3f0c" contextRef="C_d9a12ffb-2ec7-4e7c-a5a8-b1e4e74bf9f6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,090</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at March 31, 2026</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d875ef15-491b-4022-95a5-d52c978e5661" contextRef="C_5278b2a4-3328-41ca-a1e8-91dc5a129b3b" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,847,089</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0eaaeae-eb28-4836-a2a1-0b385f8a74ee" contextRef="C_5278b2a4-3328-41ca-a1e8-91dc5a129b3b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9ad7310-fa81-4a64-8adc-f78e51d70040" contextRef="C_a174a2f5-f61d-4549-a8ce-e3d8bb86274b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168,957</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d18bee01-fc5c-491a-96e2-cd2a2dca6aaa" contextRef="C_47b31919-5ee3-4679-8cae-28d91f22238b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">146,186</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e249cd15-0dc3-44a1-9d64-f77cc93b1aa9" contextRef="C_e53c5f60-4e1c-4ab5-8af8-680ceacbe890" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,781</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c63c55e-f54c-4a7a-973a-4b8863b43643" contextRef="C_e772d115-96f1-449b-a86e-07213323f1c3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,032</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5db9991-e8c3-4fe0-93a3-e5e2b02941bc" contextRef="C_eee3fb2b-1cc6-48f7-8f7d-17cd8e684af5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90b102b9-06ce-4abe-aace-5487e0307e12" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cc6323c-499d-4e5e-9a6b-57fc6556867d" contextRef="C_eee3fb2b-1cc6-48f7-8f7d-17cd8e684af5" name="inab:Stock-BasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc070e87-a8c6-463f-8e70-d297e6fbdddb" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="inab:Stock-BasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_143d79c1-2c55-418d-89cf-24c3cdcc639b" contextRef="C_896afe2a-d0f7-4ab2-995a-8bb585b17a31" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,781</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6100338b-6c68-44b4-ab69-bd884e056ae0" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,781</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at June 30, 2026</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a2595ff-aceb-4232-b0b4-a4edbf870784" contextRef="C_b5ee527e-59c0-4072-8224-1ae00b09c2d8" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,853,121</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68df0b86-a86f-4b00-9f88-2e8bde8ce102" contextRef="C_b5ee527e-59c0-4072-8224-1ae00b09c2d8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1bf1bdc-8280-432b-84f6-03c36c2dbbde" contextRef="C_2444ac2d-b0ac-4470-ad12-9bfaa60d8a45" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,320</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d25e0d6-032b-4d4e-bcce-d0c306b040ea" contextRef="C_d225c8bf-ce7a-4314-8a8d-a6a85def5b00" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">150,967</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11dd549f-e8e2-4033-82c2-a80eda103135" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,363</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3.35pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:3.35pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><ix:footnote id="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect a one-for-thirty reverse stock split effected in June 2025. See Note 1, Organization and Nature of Operations, for details.</span></ix:footnote></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_cash_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDENSED S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TATEMENTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e517dd76-5981-4061-a125-a507c12828ce" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,871</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b880e09-c652-4959-8eb3-bdca81b644ed" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,644</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6147d81d-2a0e-41a9-ad7a-7be19b8069ed" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d848527-bbe2-4b07-a2a1-e28466ff1c60" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">511</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98fcc277-e75f-46c7-8eaa-529b71544f44" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">753</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c34c866-6082-454e-85a4-da36cc4508c4" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,786</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of finance lease right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a12414da-dbd7-43e1-99f7-30c1dfbcd4e6" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ff3e9b6-2d05-4557-b253-496de7b9104d" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">526</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of operating lease right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b78d9458-263a-4979-a195-39d1979055e2" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">287</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54e04fb1-4ec7-4e2b-be01-63664d72b66b" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ed09108-1809-4f78-98f4-ff1fb9d0c580" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">248</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acdae92a-8aa1-40d4-9ee7-593aa366eb5a" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">943</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_598520ab-5337-48e4-9ce3-333388419c2a" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0011b0dc-fbf5-49c5-863b-0f665235671c" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa30c8ec-2d09-4342-8886-86b81e48dd19" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e8bc646-9fb7-4ba4-a8ca-59c9db65904c" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ae30c8f-4977-41df-82b5-fa2a5ab4eaa2" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">872</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b748ec4e-7aa5-4631-bb3d-2d1a89f4d160" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23343f6c-3a28-4145-bfe7-e3dba5b649b0" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:IncreaseDecreaseShortTermOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5c83fcd-6582-44e6-82d3-40d3b2d638aa" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="inab:IncreaseDecreaseShortTermOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8bfa399-65e8-46fc-bc9a-3f8cddd38c65" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:IncreaseDecreaseLongTermOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">434</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_104f276e-7e77-4c63-a0c2-137cfcc76279" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="inab:IncreaseDecreaseLongTermOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">390</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cee723f3-5e06-4550-9198-9adf08832f86" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,692</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdee2e71-0101-4df7-be38-d7d5a3b4e456" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,049</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed7e92a9-3486-4604-be69-fae7a7164e57" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:PaymentsForProceedsFromProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">242</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c9279c0-9bbf-48df-be4a-dce26f314835" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:PaymentsForProceedsFromProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cabeaa42-933b-4e3a-ad13-c921ee7b464f" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">242</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8751ec3f-0f8a-451b-85cd-cb161a3a11ff" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of issuance costs from December 2025 issuance of common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2be3952c-9581-4e26-ad44-554ac6d0e1a6" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_803f9668-dcaa-4ffe-9ccb-656c40786ff6" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of common stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57314fed-619e-4f6f-bbce-19e106ce759f" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad7cc827-df9f-4efc-b18d-5185d58e22cc" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,352</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the exercise of Series A &amp; B warrants, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff5e74dc-01b4-427d-a4bc-f50b5f3b4294" contextRef="C_65a4b151-c941-4db6-b342-71c02c307b1a" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b508dcbc-b93b-4cf7-9c11-191989a92db3" contextRef="C_3f9adad1-5ca0-4a1c-aed8-aaf191bcb64e" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,884</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the exercise of Series C warrants, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c6c1872-b956-43cc-9545-93e2db842a78" contextRef="C_51d9da6d-b9b1-4235-b9df-47c847a8337b" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_153c89cb-ed4c-4d42-a38e-126e6e1e7d42" contextRef="C_999469ac-65fe-4335-aa47-cdaa7da3a24c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">383</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal payments on finance leases</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd8b3e2b-c521-4c57-8717-022585942fd1" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f84f6999-ec7f-43f6-ab4b-ed7be92e2575" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">459</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd443646-7f8a-40cc-a4d7-5ffe1616ddd2" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_395de476-ef2f-4c08-90df-70f4f6292979" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,160</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_490a65fe-d772-4e92-9ae4-020b03cd4815" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,180</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c02cb95-5fa5-4a48-8902-687827a53bf3" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,111</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and restricted cash at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c729ef68-881a-44bf-804e-ba42b10a0eea" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,312</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cc25666-dcc8-49af-96c7-ce5ee85b5bcd" contextRef="C_76bcec81-1928-48a5-ae1a-c034ec20dc20" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,386</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and restricted cash at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61ee9ec3-0730-4adf-b357-2f92153bb52a" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_684ca2ef-6d84-4b54-95a6-ca26531fccac" contextRef="C_0da20066-bceb-4489-961d-fc1d7a76f4a5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,497</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6495bf39-d90a-4db1-9ddd-8977e26d3f29" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,956</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2cc2d9d-af4d-435b-b7e9-aa3d1a29cd64" contextRef="C_0da20066-bceb-4489-961d-fc1d7a76f4a5" name="us-gaap:Cash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,226</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash, end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6309f659-1ae4-462e-a15f-beb8090bf12a" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e761f06-334b-4fd4-ba40-def786e36eae" contextRef="C_0da20066-bceb-4489-961d-fc1d7a76f4a5" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and restricted cash, end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af035f65-25be-41b7-96b5-092185c4112c" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_498e359e-5f28-4a4e-99d3-7c135c363d6b" contextRef="C_0da20066-bceb-4489-961d-fc1d7a76f4a5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,497</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of non-cash financing and investing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease modification of operating lease right-of-use assets and liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43068fc9-9826-4273-837e-f19df1fbe9bc" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f85d9b17-be89-44e8-ba24-bb2c0818a908" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="inab:LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,287</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:80%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES T</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">O CONDENSED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><div><ix:nonNumeric id="F_ecda3385-2757-4fe5-bdcf-fc1b821c62a6" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:NatureOfOperations" escape="true" continuedAt="F_ecda3385-2757-4fe5-bdcf-fc1b821c62a6_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. ORGANIZATION AND NATURE OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization and Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8bio, Inc. (the "Company") is a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta ("&#947;&#948;") T cell product candidates and T cell engagers for cancer and autoimmune diseases. The Company&#8217;s pipeline is anchored by INB-600, its proprietary, internally developed &#947;&#948; T cell engager ("TCE") platform, which has potential applications across oncology and autoimmune indications. The Company&#8217;s most advanced product candidates are INB-100, currently in an ongoing investigator-sponsored Phase 1 clinical trial of acute myeloid leukemia ("AML"), and INB-200/400, evaluating its DeltEx Drug Resistant Immunotherapy ("DRI") in patients with newly diagnosed glioblastoma ("GBM"). In addition, the Company&#8217;s DeltEx platform has yielded a broad portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing a range of potential applications, from solid tumors and hematological cancers to autoimmune diseases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incysus, Inc. ("Incysus") was a corporation formed in the State of Delaware on November 23, 2015 and Incysus, Ltd. was incorporated in Bermuda on February 8, 2016. Incysus was the wholly owned United States subsidiary of Incysus, Ltd. On May 7, 2018, Incysus, Ltd. reincorporated in the United States in a domestication transaction (the "Domestication") in which Incysus, Ltd. converted into a newly formed Delaware corporation, Incysus Therapeutics, Inc. ("Incysus Therapeutics"). On July 24, 2019, Incysus Therapeutics merged with Incysus. Incysus Therapeutics subsequently changed its name to IN8bio, Inc. in August 2020. Following the Domestication in May 2018 and the merging of Incysus Therapeutics and Incysus in July 2019, the Company does not have any subsidiaries to consolidate. The Company is headquartered in New York, New York.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 5, 2025, the Company effected a reverse stock split at a ratio of one-for-thirty (the "Reverse Stock Split"). Pursuant to their terms, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all outstanding stock options and warrants, and the number of shares of the Company&#8217;s common stock authorized for issuance pursuant to the Company&#8217;s equity incentive plans was reduced proportionally. The Reverse Stock Split did not reduce the number of authorized shares of common stock and did not alter the par value.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would have otherwise been entitled to receive a fractional share received a cash payment in lieu thereof. The Reverse Stock Split affected all stockholders proportionately and did not affect any stockholder&#8217;s percentage ownership of the Company&#8217;s common stock (except to the extent that the Reverse Stock Split resulted in any stockholder owning only a fractional share). All share and per share amounts of common stock disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis in all periods presented.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has funded its operations primarily with proceeds from various public and private offerings of its common stock, preferred stock and warrants. The Company has incurred recurring losses and negative operating cash flows since its inception, including net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ff58322-700b-4033-aafc-545a1a6ee4a3" contextRef="C_30289466-5d5a-4f6a-a4fe-1eb69daf93bc" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56695fc4-c12b-4b32-badc-a67731b8ed49" contextRef="C_df7a4eb8-2669-4de2-88f2-acbd258098aa" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">10.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_961f1d9a-0367-448f-baf0-569d3ecb6f99" contextRef="C_8e7cb988-8a3c-49f0-9463-9aace8979b6d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">151.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company continues to deploy cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility. These cash preservation measures may impact the Company's ability and the timing to execute its strategy. This includes the Company's ability to achieve the anticipated milestones and the timing of data releases and/or regulatory filings for its preclinical and clinical programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not yet generated product sales and as a result has experienced operating losses since inception. The Company expects to incur additional losses in the future as it advances its product candidates through clinical trials, grows its clinical, regulatory and quality capabilities, and incurs costs associated with operating as a public company. The actual amount of cash that the Company will need to operate is subject to many factors. Based on the Company&#8217;s business strategy, its existing cash of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebca9c4b-6b31-46f4-9b68-138b094ad8e2" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:Cash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2026 is not anticipated to fund the Company&#8217;s projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company&#8217;s ability to continue to operate as a going concern.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company continues to maintain cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility. To continue to fund the operations of the Company beyond this time period, management has developed plans, which primarily consist of pipeline prioritization, raising additional capital through some combination of equity and/or debt offerings, including through ATM offerings and private placements of securities, and identifying strategic collaborations, licensing or other arrangements to support development of the Company&#8217;s product candidates.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_ecda3385-2757-4fe5-bdcf-fc1b821c62a6_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Company&#8217;s private placement completed in December 2025, the Company may also be eligible to receive up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94e51cda-51e5-4906-9780-758bd2ed78a7" contextRef="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional gross proceeds in exchange for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f05bd3fa-596a-4511-9e8b-b885fad6f662" contextRef="C_e1d35277-d874-4b8a-81ba-2d210f518638" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,579,706</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to the achievement of certain milestone-driven conditions related to preclinical data for the Company's CD19 targeting INB-619 product candidate. In addition, the Company may receive up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3b7dbcd-2e55-451c-859e-658f2bb57a8b" contextRef="C_0e88d318-dcf6-40a9-820a-70d59c10d5b7" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of proceeds from the exercise of its outstanding Series B ordinary warrants ("Series B warrants") if not otherwise redeemed by the Company and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5e6c6f4-814b-4ee9-b5fa-c150305cb556" contextRef="C_00c2fbee-81a5-4d69-b099-7ec1b71252fc" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the exercise of its outstanding Series C common stock purchase warrants ("Series C warrants"). See Note 7, Warrants, for additional information. There is no assurance, however, that the Company will receive any additional proceeds or that any additional financing or any revenue-generating collaboration will be available when needed, that management of the Company will be able to obtain financing or enter into a collaboration on terms acceptable to the Company, or that any additional financing or revenue generated through third-party collaborations will be sufficient to fund the Company's operations through this time period. If additional capital is not available on a timely basis, or at all, the Company will have to significantly delay, scale back or discontinue its research and development programs. If the Company becomes unable to continue as a going concern, it may have to terminate its operations and dispose of its assets and might realize significantly less than the values at which they are carried on its financial statements. These actions may cause the Company&#8217;s stockholders to lose all or part of their investment in the Company&#8217;s common stock. The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_a0467b90-3771-46e8-a8cc-79faa93eaf9a" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_a0467b90-3771-46e8-a8cc-79faa93eaf9a_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3508b313-74c8-4c7c-9019-db3eca8a0d2a" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Accounting Policies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the notes thereto, are included in the Company&#8217;s Annual Report on Form 10-K (the "Annual Report") that was filed with the Securities and Exchange Commission ("SEC") on March 12, 2026. Since the date of that filing, there have been no material changes to the Company&#8217;s significant accounting policies.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6aaba374-4f77-4fca-956a-0692a6fefa9a" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States ("U.S. GAAP").</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88c6dcec-c9dc-431d-a8b6-795883d7604a" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:UnauditedInterimFinancialInformationPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unaudited Interim Financial Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto in the Annual Report. The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d18dfc8-bc58-4e88-8a4b-f101ced12518" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and the related valuation allowance, stock-based compensation, the useful lives of property and equipment and the valuation of warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cae20a09-32d9-4ce9-869a-fcbec9b0103d" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash and restricted cash. All of the Company&#8217;s cash and restricted cash is deposited in accounts with major financial institutions. Such deposits are in excess of the federally insured limits.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a0467b90-3771-46e8-a8cc-79faa93eaf9a_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1816cdc-ba63-4279-b877-3daed2b1be53" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation and amortization of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4fcfe6c-f8d1-48ca-afbf-eb6bb10ddf6a" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" escape="true" continuedAt="F_f4fcfe6c-f8d1-48ca-afbf-eb6bb10ddf6a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated useful lives of the Company&#8217;s respective assets are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f4fcfe6c-f8d1-48ca-afbf-eb6bb10ddf6a_1">
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:78.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:55.128%;box-sizing:content-box;"/>
           <td style="width:1.282%;box-sizing:content-box;"/>
           <td style="width:2.564%;box-sizing:content-box;"/>
           <td style="width:38.462%;box-sizing:content-box;"/>
           <td style="width:2.564%;box-sizing:content-box;"/>
          </tr>
          <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7d7987cf-75b1-4991-a59b-6b95205da6f9" contextRef="C_2f17ba0a-7fb9-42d7-bb76-df75063b2d08" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Machinery and equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_52900a44-ceaa-475b-993e-35d21e419f5a" contextRef="C_19eea9f4-a3b3-4fe1-9029-8ab4452c1378" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_a9dc1164-7164-4770-8fc1-f61a47387a7d" contextRef="C_51057659-704a-481e-b321-6c1fd355a269" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dd81fe11-73d7-45f5-9a5e-95e54f0d5ef5" contextRef="C_68f1e9fb-5b0b-4695-96b7-d28a72a0181a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The shorter of the useful life of the leasehold improvement or the remaining term of the lease</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated and amortized in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the condensed balance sheets and any gain or loss is reflected in the condensed statements of operations.</span></p></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f180c2e-7e82-4af3-a57d-d41f0f8cbaf4" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:InternalUseSoftwarePolicy" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalized Software</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes the application development phase costs of internal use software in accordance with Accounting Standard Codification ("ASC") Topic 350-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangibles-Goodwill and Other-Internal Use Software</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Capitalized costs will be amortized on a straight-line basis over the estimated useful life of the asset upon completion.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ace285e3-f97e-4e33-b550-d1642735d880" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker ("CODM") in deciding how to allocate resources and assess performance. The Company has one operating segment, which is the business focused on the discovery, development and commercialization of gamma-delta T cell product candidates and TCEs for cancer and autoimmune diseases. The CODM is the Company&#8217;s Chief Executive Officer ("CEO"). The CEO manages the Company&#8217;s operations, assesses performance for the operating segment and decides how to allocate resources based on net loss, which is reported on the condensed statements of operations. All of the Company&#8217;s long-lived assets are held in the United States. For additional segment information, see Note 13, Segments.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_69e27fd7-dd97-494b-8d66-6b5146777e26" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Standards Updates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated all issued and unadopted Accounting Standards Updates issued by the Financial Accounting Standards Board, and believes the adoption of these standards will not have a material impact on the condensed financial statements.</span></p></ix:nonNumeric></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d5a4c56-2076-4206-864d-d5ff5a310f76" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:OtherCurrentAssetsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95123818-1959-44ab-ac35-c31bb8f34b3f" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac2217fd-a22a-4ac3-a769-d52030b4bff2" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a0b1dd2-da62-49e8-aa77-169346152ba9" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">529</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33181561-c0b5-4dc6-b2ba-8bd1ac4450a0" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">364</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbd947f2-53d8-48d0-85fa-c7953fda102b" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1947e260-c2ff-46f2-b56b-411083f979ae" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">540</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_890dcf8e-8fa0-49ce-be37-045d14e5e8cd" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">788</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38582771-48ff-4496-a805-47b8713e7090" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. PROPERTY AND EQUIPMENT, NET</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f81bb26e-baa0-4277-a3a2-c28e2d03eacb" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Machinery and equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93046344-385d-42df-b21b-80694ee8de0d" contextRef="C_bdbee5c1-4fcd-4d7f-ba39-f1599229cc82" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">627</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe73853b-6a0b-481c-8555-60248e79a3a7" contextRef="C_a808f64c-72ae-4532-9ed3-19e39e466b41" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">385</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d7f7f14-e3f1-442c-9b67-41a001d3a0e6" contextRef="C_2f17ba0a-7fb9-42d7-bb76-df75063b2d08" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88fe1e8f-7f67-4bed-9c8b-e30461241efe" contextRef="C_4c7d1dff-7913-4872-846a-511db2a788b0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fd80de3-2e00-4a84-bebf-8873f2f49f0f" contextRef="C_4222be5a-0c57-4a3d-b834-e0e79efc53a5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">346</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37b1f684-4806-40b4-bf05-f311f9e3bda6" contextRef="C_8f720d50-af6e-4211-a827-c117c09d5ba6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">346</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6df8c207-2db1-4993-bb40-affb5a0c188f" contextRef="C_a63f502f-f8b0-4607-a47f-5d8632401b59" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,924</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c92bbcfc-a56e-4c31-bc06-3e0c6ef736ea" contextRef="C_55665991-ca2b-41b7-8b4e-3d3f94dda5c4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,924</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d5a18ef-d49e-405c-ad31-45f7deab52d0" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,699</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef46f11c-52c8-4108-b7b4-01a3d8b7dba8" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,199</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2e3fcd7-93e4-4d5c-a884-95fc40fd0380" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,600</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_827b1417-3519-45cb-ac09-af8abe10fe2d" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,858</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52b51922-9585-4a3d-bb3a-d114859a116f" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97898c65-bdd3-42d3-9754-136c7a85057d" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the three months ended June 30, 2026 and 2025, respectively, and was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02ac2087-dee5-4c4d-a215-7471b49457cf" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e64b007-6800-4e74-8c9e-d5730d88c155" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the six months ended June 30, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68e86610-bcdf-41fe-b9df-21636d86c080" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c69366d9-8f66-477b-884c-47a4c2816119" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:AccruedExpensesAndCurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trials</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53d203f8-2742-494b-b928-9b198832a196" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="inab:AccruedClinicalTrials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97556226-55c1-4a0c-839c-009bf88cbd6e" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="inab:AccruedClinicalTrials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26abe417-494b-4434-a390-948bd9738727" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="inab:AccruedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_247f28bc-6d4e-47a3-98c9-85c5f3940902" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="inab:AccruedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b02fd4a9-a7a8-4481-b491-7c1ae6405fa0" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="inab:AccruedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">712</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4520da88-7149-4622-8331-99d2b80f50bf" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="inab:AccruedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,305</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued legal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76659918-6a7f-4db6-b76f-a578471d8fd0" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6584b17-dbb3-47c6-a4f3-e6220785dff0" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b1c5308-6c85-43a5-aa9a-ff319ab1a69e" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebecfda4-6e2e-42c9-8a7d-019658ffedca" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89142ffb-7e2a-41b6-9556-8e6ee7f0f925" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">761</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaf7525b-b3fe-4f1f-801f-16a326166929" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,633</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4c67327-7595-45ee-820a-fd10e78a095a" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. STOCKHOLDERS' EQUITY</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s authorized capital stock consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f34c22e4-54b7-47e8-ab9f-0d6c7727157a" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:CapitalUnitsAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, all with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69e44533-bfc1-4910-90fe-111d91fd2687" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87d5e39a-8367-481c-b7d8-dc1491c55a3b" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">490,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are designated as common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92c274f6-6227-4b99-8fc7-bf01f0f662a9" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are designated as preferred stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ATM Facility</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2022, the Company entered into a Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sales agreement with Cantor Fitzgerald &amp; Co. ("Cantor Fitzgerald") and Truist Securities, Inc. ("Truist") under which Cantor Fitzgerald and Truist agreed to act as sales agents to sell shares of the Company&#8217;s common stock, from time to time, in an at-the-market offering program. In March 2024, the Company delivered a termination notice to Truist, removing them as sales agent under the sales agreement, and on May 29, 2026, the Company and Cantor mutually agreed to terminate the sales agreement effective at the close of business on May 29, 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, the Company filed a shelf registration statement on Form S-3 (File No. 333-291393) (the "Shelf Registration Statement") with the SEC, which became effective on May 20, 2026, which permits the issuance and sale by the Company of up to a maximum aggregate offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d155993-5e62-44b1-b02d-31ff1cd56b23" contextRef="C_aa26e47b-c5bc-46bb-be5a-e667b328aaff" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of its common stock, preferred stock, various series of debt securities, warrants to purchase common stock, preferred stock or debt securities, rights to purchase equity or debt securities, and/or units to purchase any combination of such securities. On June 1, 2026, the Company entered into a Capital on Demand</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sales Agreement sales agreement, (the "Sales Agreement") with JonesTrading Institutional Services LLC ("JonesTrading") with respect to an at-the-market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, through or to JonesTrading (the &#8220;ATM Program&#8221;) pursuant to the Shelf Registration Statement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under current SEC regulations, if at any time the Company's public float is less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3798c34-25c4-423b-b481-4932a6ff3929" contextRef="C_974cfe0d-089e-4c95-bae7-273d520e56db" name="inab:PublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and for so long as the Company's public float remains less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c318c74-6678-446f-b01c-0a3d03893172" contextRef="C_eee4484b-9c91-4075-99a6-ba3ae7b09a52" name="inab:PublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, the amount the Company can raise through primary public offerings of securities in any 12-month period using shelf registration statements is limited to an aggregate of one-third of the Company's public float, which is referred to as the baby shelf rules. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company's calculated public float was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1943825e-5e05-4fb3-a9f3-33337f61545b" contextRef="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba" name="inab:PublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e45aa0f6-bfa3-4bb5-8232-635766bb6331" contextRef="C_82df8d9b-ab44-4186-a2a5-46f09cf06bab" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,865,253</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, of its common stock under the ATM, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13786172-0b5a-4b40-8ed1-d6cbbeb38b8c" contextRef="C_82df8d9b-ab44-4186-a2a5-46f09cf06bab" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the six months ended June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feffedcc-ea01-4243-a87d-35573b99866d" contextRef="C_d60a61e2-303c-4252-a580-f819f238b08c" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,032</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock under the ATM Program, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a10a3f5-522f-45c8-8a01-f3c03d8dffb9" contextRef="C_d60a61e2-303c-4252-a580-f819f238b08c" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after deducting sales agent fees and other offering expenses. As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddc5824a-4c78-4c07-98bd-24e7002e5da7" contextRef="C_c8b1b3b9-2703-4083-a3de-9b291dc7e209" name="inab:CommonStockAvailableForSaleAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million remained available for the sale of common stock under the ATM Program.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_3dd6e3b8-f8c4-4555-a144-a987bdb05ee7" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" escape="true" continuedAt="F_3dd6e3b8-f8c4-4555-a144-a987bdb05ee7_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. WARRANTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Company issued pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e44ed17-5973-4e0e-8bbf-b07085e0bf16" contextRef="C_59cd43a9-96e0-48e2-a9e4-f951fd28b4a7" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">19,141</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock ("2023 Pre-Funded Warrants"), </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca2c78f6-2147-464c-88ce-82d2089f4428" contextRef="C_4236eadf-0539-4ef9-8e90-18421e8dedb1" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">394,118</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series A warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0397698-0b0e-4cc7-ba91-108431627fd2" contextRef="C_8bad56db-9715-48c8-9c43-9f6171f27068" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">394,118</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series B warrants in a private placement. The 2023 Pre-Funded Warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50d9bf0b-873c-4675-9b4f-567a156bfa7f" contextRef="C_d1b51327-f920-40af-87a2-b87c1de36678" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.003</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, are exercisable immediately and are exercisable until the 2023 Pre-Funded Warrant is exercised in full. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a 2023 Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the 2023 Pre-Funded Warrants terms. The 2023 Pre-Funded Warrants meet the criteria for permanent equity classification. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13823725-bad8-4539-9e81-09d1fbc198b3" contextRef="C_bd29102c-0440-4bf5-9ff4-5120f836ab06" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1b8a6626-ed60-46ac-8bb5-797d7c208ff6" contextRef="C_bd29102c-0440-4bf5-9ff4-5120f836ab06" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2023 Pre-Funded warrants issued and outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series A warrants were issued with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_054ffa33-4fbc-45db-9e58-ee74e4e436ee" contextRef="C_3ef9e3d2-ac68-4df4-9377-90cb029dcf78" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">37.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Series A warrants were exercisable immediately. The Series A warrants meet the criteria for permanent equity classification.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67374f35-8310-4e07-b56b-401f67c54f20" contextRef="C_dc8de850-dafa-4740-ad94-9a138121ba04" name="inab:WarrantsModificationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the closing of the Company's private placement in October 2024, the Company amended certain of the Company&#8217;s outstanding Series A warrants, representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68a8df4a-e76d-4437-9578-040fa22ffadc" contextRef="C_6422bdd1-8860-4052-ba54-1d6d60b3e10a" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">390,462</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, to (i) reduce the exercise price from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_004702e3-f0e7-4481-b160-b2930279a7ca" contextRef="C_f7dd2334-9796-45e3-9723-b8b13243babf" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">37.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_377a1e4a-aa9e-4fe2-a2da-8d1b7cc26511" contextRef="C_b8e4b9eb-c72b-49a4-a984-af719c089c73" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and (ii) extend the termination date of such Series A warrants to October 4, 2025. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all Series A warrants have expired and there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62574ba3-6938-498e-81ed-5e275d8b23f3" contextRef="C_35e2df7a-828c-48a5-bbac-98bd4ed637bc" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series A warrants outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series B warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1df5a8c3-89fa-4564-a2a4-a23332f9a8d0" contextRef="C_d7b166d9-02a0-43d4-9686-85c3222aedbc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">45.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Series B warrants are exercisable immediately and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ff989d8-e34e-4ff4-ad49-fe50f56b6231" contextRef="C_d7b166d9-02a0-43d4-9686-85c3222aedbc" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 13, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Series B warrants allow the Company to redeem such warrants at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c9411a7-7f75-4eb2-81c8-57db15ca5777" contextRef="C_14ed354b-9858-4395-9f4f-fe4f90a1c437" name="us-gaap:WarrantExercisePriceDecrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Series B warrant upon the Company&#8217;s public announcement of its INB-100 data for all enrolled patients covering a period of at least 22 months, along with certain stock price and trading volume requirements. Holders of Series B warrants may choose to exercise such warrants at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7eb5346-e548-4867-82dc-45fdc2454dfd" contextRef="C_d7b166d9-02a0-43d4-9686-85c3222aedbc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">45.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share prior to such redemption. The Series B warrants meet the criteria for permanent equity classification. In April 2025, the Company entered into Amendment No. 1 to Securities Purchase Agreement (the "SPA Amendment") to amend the restrictions on certain equity sales by the Company set forth in the Securities Purchase Agreement, dated September 30, 2024, by and among the Company and the investors party thereto. In consideration for the SPA Amendment, the Company amended the Company's outstanding Series B warrants, representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f13d5eb5-8ccb-4c79-a29b-162d9337748c" contextRef="C_4e6b6762-f427-4f1a-938b-da78f831260d" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">303,574</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock, to (i) reduce the exercise price from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a227cc07-0d61-4119-9ee5-e3cdd0141fce" contextRef="C_2175d4db-6a33-4fb4-85e3-1bf2eeb93e8b" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">45.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aa7b6fe-cc32-4569-a2ee-463acf44bc56" contextRef="C_6719b59d-803e-4f87-b7ca-224b48a13129" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85884a04-966c-4538-9fe6-e432e92227f3" contextRef="C_d7b166d9-02a0-43d4-9686-85c3222aedbc" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">166,964</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series B warrants were issued and outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company issued pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_893bcc25-8b84-4226-9cb3-accfa087e9a0" contextRef="C_b5b1abb1-d97e-42f9-9b1f-61a28dbce843" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">188,227</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("2024 Pre-Funded Warrants") and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d97d0a8b-f728-4693-8475-8cb63d859e52" contextRef="C_cc023649-9aca-4bc0-a9c8-0b9537dfc5f6" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,044,726</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series C warrants in a private placement. The 2024 Pre-Funded Warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7de3044-f41b-4059-9efc-008fab007fb0" contextRef="C_141ba882-944c-447d-9a26-353741846e49" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.003</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, were exercisable immediately and are exercisable until the 2024 Pre-Funded Warrant is exercised in full. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a 2024 Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the 2024 Pre-Funded Warrants terms. The 2024 Pre-Funded Warrants meet the criteria for permanent equity classification. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e23412c-8a53-407e-b0d0-8dfa0434baf9" contextRef="C_15a832e8-0165-4101-a163-3b54c4539b18" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">164,593</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2024 Pre-Funded Warrants were outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series C warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e85ec157-b923-460f-ab77-89af9175b0d1" contextRef="C_aea50f9a-5f2f-47c2-a9b6-328cfc5db21b" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Series C warrants are exercisable immediately and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_950b7362-122a-4444-bdf6-691f11a8e5ef" contextRef="C_aea50f9a-5f2f-47c2-a9b6-328cfc5db21b" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 4, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Series C warrants meet the criteria for permanent equity classification. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_624fa7ba-c221-43c0-aeff-03ef040c3a9d" contextRef="C_aea50f9a-5f2f-47c2-a9b6-328cfc5db21b" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">828,863</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series C warrants were outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2025, the Company entered into privately negotiated letter agreements with certain holders of outstanding Series A warrants and Series B warrants (the "Participating Holders") to (i) exercise, for cash, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c5b81f4-1a1e-4d15-a438-a2607ace3aeb" contextRef="C_4136a492-9cb7-4b0d-90cb-607bc2ed4239" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">239,293</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series A warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4538b386-a67a-4926-bc4d-39b58bcb815c" contextRef="C_cdfcacfd-7d70-4257-9404-6c997e9aadc3" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">71,403</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series B warrants for the purchase of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8174b09-15e3-42ca-8845-f8864f766662" contextRef="C_13d21bb4-b59b-41aa-aa09-28b17f1305e4" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">310,696</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, in each case at a reduced exercise price of (a) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cab3bc4-e4b5-4220-ad44-aca7cf4415f3" contextRef="C_4136a492-9cb7-4b0d-90cb-607bc2ed4239" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for Participating Holders who are directors or executive officers of the Company and (b) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_139f7553-df71-429c-810d-507c27e7f6c4" contextRef="C_cdfcacfd-7d70-4257-9404-6c997e9aadc3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for all other Participating Holders and (ii) exchange certain Series A warrants and Series B warrants for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46cfa69e-6b5f-4917-be5d-7644c37b7fcd" contextRef="C_6d0dc760-5d42-43c3-8497-ef5beb5bf865" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">41,014</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants (the "Exchanged Pre-Funded Warrants"), in each case for a cash payment of (a) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9078dc0-7a33-4050-9522-93e0159bddac" contextRef="C_4136a492-9cb7-4b0d-90cb-607bc2ed4239" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant share for Participating Holders who are directors or executive officers of the Company and (b) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dea3769-fb9b-4ed8-854f-2366fdbca34d" contextRef="C_cdfcacfd-7d70-4257-9404-6c997e9aadc3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant share for all other Participating Holders (the "Warrant Exchanges"), for aggregate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61b6fc5e-a618-47d1-b9c3-4478ebbed8e7" contextRef="C_f400a42d-0c03-47f8-b36b-2ccfd408dc51" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Exchanged Pre-Funded Warrants issued in connection with the Warrant Exchanges have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7c87fa6-8c49-4ce3-99d0-eef8a2a791bf" contextRef="C_6d0dc760-5d42-43c3-8497-ef5beb5bf865" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.003</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Each Exchanged Pre-Funded Warrant is exercisable immediately and will be exercisable until such Exchanged Pre-Funded Warrant is exercised in full. In lieu of a cash payment to the Company in payment of the aggregate exercise price upon exercise of an Exchanged Pre-Funded Warrant, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Exchanged Pre-Funded Warrants. Under the terms of the Exchanged Pre-Funded Warrants, the Company shall not effect the exercise of any portion of any Exchanged Pre-Funded Warrant, and a holder shall not have the right to exercise any portion of any Exchanged Pre-Funded Warrant, to the extent that after giving effect to such exercise, the holder (together with its affiliates and any other persons acting as a group together with the holder or any of its affiliates) would beneficially own in excess of 4.99% or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_096aed0e-566f-4dc7-bc87-6e57de0ac443" contextRef="C_f400a42d-0c03-47f8-b36b-2ccfd408dc51" name="inab:AffiliatesPercentageOfWarrants" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, as applicable, of the number of shares of common stock outstanding immediately after giving effect to such exercise. However, a holder may, upon written notice to the Company, increase or decrease such percentage to any other percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43cfd6ce-4184-40ef-b521-0bb74dd26b51" contextRef="C_f400a42d-0c03-47f8-b36b-2ccfd408dc51" name="inab:IncreaseOrDecreasePercentageOfWarrants" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided that any increase or decrease in such percentage will not be effective until 61</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3dd6e3b8-f8c4-4555-a144-a987bdb05ee7_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">days </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after such notice is delivered to the Company. The Exchanged Pre-Funded Warrants meet the criteria for permanent equity classification. As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbe64545-ce84-4745-a0a5-b692aa438f51" contextRef="C_ade5bfd8-e223-4fa2-b9eb-073902595766" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,732</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of these Exchanged Pre-Funded Warrants were outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the Company issued pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33ec9f4d-7a39-4abe-a287-50ca1170f7aa" contextRef="C_875d9953-bc37-4aec-b5bd-7626c7b4a282" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,452,677</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the "2025 Pre-Funded Warrants") in a private placement. The 2025 Pre-Funded Warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a554132-7b41-4480-9f2e-c1b6730c0c79" contextRef="C_875d9953-bc37-4aec-b5bd-7626c7b4a282" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, were exercisable immediately and are exercisable until the 2025 Pre-Funded Warrant is exercised in full. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a 2025 Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the 2025 Pre-Funded Warrants terms. The 2025 Pre-Funded Warrants meet the criteria for permanent equity classification. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1225ddf3-2e6e-4c5f-b55b-86b36561f2e4" contextRef="C_615b0689-2e71-471d-b476-8b5d53cc4a55" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,452,677</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2025 Pre-Funded Warrants were outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_618ea081-3cf2-4bf5-a5b2-f766e5490fab" contextRef="C_e34a25b4-4b7a-448a-bf63-cb6e13b70301" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,620,002</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c2d9125-3e18-4c78-b85c-85885b6e3cb4" contextRef="C_dff100d2-ec00-417b-a887-37746b72d7f8" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">166,964</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series B warrants, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deeaeefb-9608-4301-aaec-5753a69f100e" contextRef="C_5ff0bb53-9ba3-44b1-99fb-5976079d7285" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">828,863</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series C warrants outstanding. Of these, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d80babcc-bb6b-45b8-a3a3-8c4d5b6199c1" contextRef="C_86e4d9d6-3ea9-4abe-9133-f643a5892564" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,452,677</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dab116c6-2d41-4661-9af0-5f9c8b779f43" contextRef="C_d9315813-0e95-4466-96f4-8eb12df54e55" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a99f317a-66d7-4902-9f3a-7724570ff61d" contextRef="C_919d5a0e-62fb-40f3-a669-87d5a9aef2e1" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">167,325</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56043a2f-6918-4f94-869e-9dc8fc6db41d" contextRef="C_e34a25b4-4b7a-448a-bf63-cb6e13b70301" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.003</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Series B warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5a98247-8403-4f40-ac1c-d56471cc32ef" contextRef="C_dff100d2-ec00-417b-a887-37746b72d7f8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04bfce91-4e3f-47bc-a7b8-031fc9c981b1" contextRef="C_dff100d2-ec00-417b-a887-37746b72d7f8" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 13, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Series C warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50ee5fa6-4108-4e71-94d9-bbd37d06456d" contextRef="C_5ff0bb53-9ba3-44b1-99fb-5976079d7285" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4be08ad5-a70b-4abf-8352-0ede874ddf81" contextRef="C_5ff0bb53-9ba3-44b1-99fb-5976079d7285" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 4, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_e615e071-6455-455e-9ec9-1272ba07bf63" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_e615e071-6455-455e-9ec9-1272ba07bf63_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. STOCK-BASED COMPENSATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2018 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 7, 2018, the Company established and adopted the 2018 Equity Incentive Plan (the "2018 Plan") providing for the granting of stock awards for employees, directors and consultants to purchase shares of the Company&#8217;s common stock. Upon the effectiveness of the 2020 Plan (as defined below), the 2018 Plan was terminated and no further issuances were made under the 2018 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2018 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2020 Equity Incentive Plan (the "2020 Plan") was approved by the Company's Board of Directors and the Company&#8217;s stockholders and became effective on July 29, 2021. Upon the effectiveness of the 2023 Plan (as defined below), the 2020 Plan was terminated and no further issuances were made under the 2020 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2020 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated 2023 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended and Restated 2023 Equity Incentive Plan (the "2023 Plan") was approved by the Company's Board of Directors and the Company&#8217;s stockholders and became effective on June 15, 2023. Upon the effectiveness of the 2026 Plan (as defined below), the 2023 Plan was terminated and no further issuances were made under the 2023 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2023 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated 2026 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended and Restated 2026 Equity Incentive Plan (the "2026 Plan") was approved by the Company's Board of Directors and the Company&#8217;s stockholders and became effective on May 7, 2026. The Board of Directors, or a committee thereof, is authorized to administer the 2026 Plan. The 2026 Plan provides for the grant of Incentive Stock Options ("ISO") within the meaning of Section 422 of the Internal Revenue Code of 1986 as amended, to employees, and for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to the Company&#8217;s employees, directors and consultants and any Company affiliates&#8217; employees and consultants. The number of shares initially reserved for issuance under the 2026 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d74714d8-09ee-4c92-91c0-4a672cb0c2bf" contextRef="C_2b8acd72-67e8-49aa-b360-6976c9610ae0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,054,937</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which automatically increases on January 1 of each year for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f22efa26-79c4-4757-94dc-2653dc44d25e" contextRef="C_d465b573-e7bb-4e0a-993f-63f0094f2438" name="inab:SharesReservedOfIssuanceUnderPlanIncreaseDuration" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> commencing on January 1, 2027 and ending on (and including) January 1, 2037, in an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a16f16c-4a55-46a6-92d0-9d7a1e1e4460" contextRef="C_d465b573-e7bb-4e0a-993f-63f0094f2438" name="inab:PercentageOfTotalNumberOfSharesOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of common stock, plus the total number of shares of common stock issuable upon settlement of pre-funded warrants (if any), in each case, outstanding on December 31 of the preceding year, or a lesser number of shares determined by the Board of Directors no later than the last day of the immediately preceding year. The maximum number of shares of common stock that may be issued upon the exercise of ISOs under the 2026 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_501eee3f-5183-40a8-99e0-174469356c24" contextRef="C_6512d216-0c5d-4efe-bd6d-d941a05aec24" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="0" decimals="-6" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5e99b41-017c-4359-991e-6945031f9f52" contextRef="C_d6a03d66-c6db-44b9-acc8-f36f9f7a7dd0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,474,975</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for grant pursuant to the 2026 Plan.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2020 Employee Stock Purchase Plan (the "2020 ESPP") was approved by the Board of Directors and the Company&#8217;s stockholders and became effective on July 29, 2021. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b13a8dc-710b-4696-959b-a9f4bda94394" contextRef="C_ef18a21f-14bd-4046-a4f2-3da805a9ad98" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,666</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under this plan, which automatically increases on January 1 of each year by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e45af353-542a-4e04-8ac6-7c8704ca5901" contextRef="C_b52b4906-2f95-41dc-9fd6-f217e9324069" name="inab:PercentageOfTotalNumberOfSharesOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding number of shares of common stock on the immediately preceding December 31; and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f833b89-53cf-4300-8abe-32772e2c7c09" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,333</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or such lesser number of shares as determined by the Board of Directors. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34a82ea7-7082-4023-8c24-fe1eebde8b2b" contextRef="C_ab1c1654-f49e-44dd-932a-984720cd913c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock had been issued under the ESPP and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d5b2b12-5b5e-4cbc-b132-943640f53622" contextRef="C_2c0017d1-6285-4171-90ff-3fa0920d4f40" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">26,260</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">remained available for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_e615e071-6455-455e-9ec9-1272ba07bf63_1" continuedAt="F_e615e071-6455-455e-9ec9-1272ba07bf63_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issuance under the ESPP. The Board of Directors or designated committee has not set an offering period and the Board of Directors elected not to increase the number of shares of common stock reserved for future issuance under the ESPP as of January 1, 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Activity</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54a8bdda-9a7d-450b-99a0-f42dff6e45b3" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of the stock option award activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2026:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.59%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.602%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.962%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.602%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.142000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number<br/>of Stock<br/>Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2abef2cf-edbd-4b7e-99b8-785ed22e9088" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">502,027</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68f439c8-921b-455d-bdd5-a8749d70a406" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">50.42</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f3379405-ff24-4c16-84b1-b506c04a5cd2" contextRef="C_3eba5499-8b2d-4237-9df4-85ecab51e9df" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.05</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d010aa1a-5f94-4ab1-bf0f-2b4c7beeda65" contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05d89429-1766-4084-9020-91eed4facc11" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,083,658</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10081257-7acc-4f8d-9634-6b53fcdf5cf1" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.75</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b10f16d-c765-4927-a29f-b05f6619ee0e" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d715bcba-d3b4-4354-bfc4-ef82dbe1a575" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12c18285-bc2e-40a1-9327-184f425789b6" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,723</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a4f0500-0704-4388-af76-ed10a6038472" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.01</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at June 30, 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3946c90c-d421-400e-b189-572abf70944d" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,579,962</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be47c4ac-fbd8-4ef9-b0ee-99561f36f18f" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.19</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_97a62b08-e69d-49f3-a8a7-b2ae7211c5d3" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.85</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ce5cd43-e704-4a6a-b335-a238482fed9a" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at June 30, 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e629313c-c2f2-44e4-9750-8f78e1456fce" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">415,044</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d78c0ada-37c7-4207-82a3-2b06aa86417e" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">56.48</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_cc89537a-a754-4fff-a32a-6c3477c6e80b" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.72</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9d94523-fe02-4fdf-8a08-f4cc73e9a93e" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options expected to vest as of June 30, 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8198ade-8c9f-475b-aeb4-58651b071e1a" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,164,918</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0a5c621-aabe-4af9-abd8-90c53b742bc6" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.19</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2b8d22ad-bc61-47de-aa0d-dbe2c2725c8f" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.60</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc666dc7-692f-4604-9b5f-b3b787c68d2b" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of options granted during the six months ended June 30, 2026 and 2025 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_cf1d001c-8f99-492f-a365-741e35d15a25" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d09c0b9e-5072-4927-8bae-e6ebde43b944" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The aggregate intrinsic value is calculated as the difference between the exercise price and the market price of the Company&#8217;s common stock at June 30, 2026 and December 31, 2025.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the six months ended June 30, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options. </span><span><ix:nonNumeric id="F_2b04697a-095e-409c-be01-475f18e5f259" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_2b04697a-095e-409c-be01-475f18e5f259_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the assumptions and the Company&#8217;s methodology for developing each of the assumptions used: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_2b04697a-095e-409c-be01-475f18e5f259_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.663%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:14.923%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cdd666a-f54a-4032-ad5f-dc7fe2bef4a0" contextRef="C_882fd2d9-5d3b-4094-8326-9d116fa514c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">101.73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3fee29e-c6e8-4288-8961-8d829e5b2002" contextRef="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">102.98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fe0dfa3-4d87-48db-a3b5-e29319600348" contextRef="C_acfff60e-a022-428e-8f12-c565b3924d5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">96.66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9f0bfd1-5689-4192-b89f-56bbaaa8b8df" contextRef="C_e699a5d1-4c74-4461-a49a-dd3300a4a440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">99.24</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life (years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3342540c-f28e-4b90-a13b-0eeca16f06af" contextRef="C_882fd2d9-5d3b-4094-8326-9d116fa514c2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_d013f505-413b-44fb-b40a-fd57e2941f8b" contextRef="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bc60455e-1188-45e3-ae71-73150f254d9c" contextRef="C_acfff60e-a022-428e-8f12-c565b3924d5e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;-</span><span><ix:nonNumeric id="F_c66ff5ab-ebe3-4ba5-b14f-62da6d5783cd" contextRef="C_e699a5d1-4c74-4461-a49a-dd3300a4a440" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> 6.08</span></ix:nonNumeric></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d9ae34e-d6ad-485f-a668-0547e42902ca" contextRef="C_882fd2d9-5d3b-4094-8326-9d116fa514c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.83</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d06462f-f383-4fba-bce3-328b94dcc28e" contextRef="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.07</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3268d71-311c-474a-b92a-9e7377fb8f78" contextRef="C_acfff60e-a022-428e-8f12-c565b3924d5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b46a14d-2cbe-43d1-915b-87de56c2d7ad" contextRef="C_e699a5d1-4c74-4461-a49a-dd3300a4a440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.24</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d83024d-c50a-4165-a5b8-b71c1e866bed" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_440f8909-ee01-4c44-bfc3-86e8f516c455" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Volatility&#8212;The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of comparable public companies over the expected term. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected life&#8212;The expected term represents the period that the Company&#8217;s stock option grants are expected to be outstanding. The expected term of the options granted to employees and non-employee directors by the Company has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk-free interest rate&#8212;The risk-free rate for periods within the estimated life of the stock award is based on the U.S. Treasury yield curve in effect at the time of grant. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend rate&#8212;The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. </span></div></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_e615e071-6455-455e-9ec9-1272ba07bf63_2"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51539bac-c85c-4b73-b3a0-61c5d3a1c2d5" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2026 and 2025 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b56d92f-660d-4dad-99e1-fc70c3f4c6ff" contextRef="C_722ff75a-27ec-4522-80bd-b43a8403d7ca" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13f99873-5336-4faa-b18e-bef35c31733b" contextRef="C_95149714-844a-412e-967f-b79e9e655892" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_789b6be5-f58e-4ef6-8b38-9ad70de6b9e5" contextRef="C_23c7fe2f-970c-4999-b6a8-53f62effb0b9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49cfd92e-3634-48c4-a0e1-168b51d77796" contextRef="C_d4c94038-e53d-43c3-abc6-12d9c67c6468" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">584</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bc6d3ec-5475-4819-97f1-6b0197d258ef" contextRef="C_e7dbcb37-cd29-432c-9337-b9e4bc5c8fbd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaee0c4e-6263-4c0e-bb8e-8652336a8893" contextRef="C_848a1210-eb49-4891-935b-80b8db44acbb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">657</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5debe02c-5e10-469b-b0ee-98b9fa42f9c8" contextRef="C_def65cee-ee7e-4161-a3b8-a9cb4d0e2897" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">455</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca37ccac-4fcc-4cb4-821f-2613e1516bb4" contextRef="C_b0893cee-3d08-4109-a7b3-cdad0a9d269d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,202</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a507d613-dd81-4cc7-ad79-c3c979687720" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd85df66-0d82-449c-85b5-5e9bc6d738dd" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c6e9c17-62d8-48e7-a7b1-1e047e2f3336" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">753</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c61326df-478e-4a05-81c2-aa9beec9548d" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,786</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea52ecff-14a8-4ccd-a5e4-4ff014707922" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d3ee543a-da96-4f67-bdff-ba5ca42f32f5" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3d84bf0d-46f5-425c-81aa-f4158af930ab" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_05b708a0-aaa8-497b-87f9-01108adce726" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related tax benefits from stock-based compensation expense were recognized for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2026 and 2025. As of June 30, 2026, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5998282-ad36-4be4-885c-d7902b66488c" contextRef="C_2af03440-5a2f-4e6d-b44b-a6ccc55a7aa3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6750676-d94d-4f09-8595-41d7d93d8ab1" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_72ec421d-2e46-443c-a2dc-87cace6e8a99" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_72ec421d-2e46-443c-a2dc-87cace6e8a99_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. LICENSE AGREEMENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emory University, Children&#8217;s Healthcare of Atlanta, Inc. and UAB Research Foundation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2016, the Company entered into an exclusive license agreement with Emory University, Children&#8217;s Healthcare of Atlanta, Inc. and UAB Research Foundation ("UABRF"), as amended from time to time (the "Emory License Agreement"). The Emory License Agreement was amended in October 2017 and July 2020. Under the Emory License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy related patents and know-how related to gamma-delta T cells developed by Emory University, Children&#8217;s Healthcare of Atlanta, Inc. and UABRF&#8217;s affiliate, the University of Alabama at Birmingham, to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents or otherwise incorporate or use the licensed technology. Such exclusive license is subject to certain rights retained by these institutions and also the U.S. government.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration of the license granted under the Emory License Agreement, the Company paid Emory University a nominal upfront payment. Between March 2017 and August 2020, the Company issued UABRF an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0a874b6-37de-4e01-b14f-505321c6fd7f" contextRef="C_35dd4b27-e1ca-484c-8fc2-9fea1443f2b0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,046</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock in satisfaction of these antidilution rights.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company is required to pay Emory University development milestones totaling up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05daf15c-36da-45e0-a3d7-21b55efd64a2" contextRef="C_8cdfe491-a6d3-4390-9fa9-14cf4c1ff8ce" name="inab:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, low-single-digit to mid-single-digit tiered running royalties on the net sales of the licensed products, including an annual minimum royalty beginning on a specified period after the first sale of a licensed product, and a share of certain payments that the Company may receive from sublicenses. In addition, in the event no milestone payments have been paid in certain years, the Company will be required to pay an annual license maintenance fee. The Emory License Agreement also requires the Company to reimburse Emory University for the cost of the prosecution and maintenance of the licensed patents. Pursuant to the Emory License Agreement, the Company is required to use its best efforts to develop, manufacture and commercialize the licensed product, and is obligated to meet certain specified deadlines in the development of the licensed products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_623a5a6f-2104-430a-a731-97e46491496f" contextRef="C_41f9322c-2c47-48ad-880f-4d68924f360c" name="inab:LicenseAgreementDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company may terminate the Emory License Agreement at will at any time upon prior written notice to Emory University. Emory University has the right to terminate the Emory License Agreement if the Company materially breaches the agreement (including failure to meet diligence obligations) and fails to cure such breach within a specified cure period, if the Company becomes bankrupt or insolvent or decides to cease development and commercialization of the licensed product, or if the Company challenges the validity or enforceability of any licensed patents.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive License Agreement with UABRF</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2016, the Company entered into an exclusive license agreement with UABRF, as amended from time to time (the "UABRF License Agreement"). The Company amended the UABRF License Agreement in December 2016, January 2017, June 2017 and November 2018. Under the UABRF License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy-related patents related to the use of gamma-delta T cells, certain CAR-T cells and combination treatments for cellular therapies developed by the University of Alabama at Birmingham and owned by UABRF to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents. Such exclusive license is subject to certain rights retained by UABRF and also the U.S. government.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration of the license granted under the UABRF License Agreement, the Company paid UABRF a nominal upfront payment and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fc9e4ba-9d0a-41e2-b52e-d3317d4693d8" contextRef="C_652cd561-42c7-41d5-a3df-59ea80bfee2e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,041</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock to UABRF, which were subject to certain antidilution rights.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_72ec421d-2e46-443c-a2dc-87cace6e8a99_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company is required to pay UABRF development milestones totaling up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ee423b8-b8e2-4cab-9926-609892b8db80" contextRef="C_8cdfe491-a6d3-4390-9fa9-14cf4c1ff8ce" name="inab:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, lump-sum royalties on cumulative net sales totaling up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d0cac4f-05cf-439a-972b-aab730bcc8fb" contextRef="C_3308162f-a2dc-4d95-879d-976b215e5b9d" name="inab:RoyaltiesOnCumulativeNetSales" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, mid-single-digit running royalties on net sales of the licensed products, low-single-digit running royalties on net sales of the licensed products, and a share of certain non-royalty income that the Company may receive, including from any sublicenses. The UABRF License Agreement also requires the Company to reimburse UABRF for the cost of the prosecution and maintenance of the licensed patents.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the UABRF License Agreement, the Company is required to use good faith reasonable commercial efforts to develop, manufacture and commercialize the licensed product.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the UABRF License Agreement will continue until the expiration of the licensed patents. The Company may terminate the UABRF License Agreement at will at any time upon prior written notice to UABRF. UABRF has the right to terminate the UABRF License Agreement if the Company materially breaches the agreement and fails to cure such breach within a specified cure period, if the Company fails to diligently undertake development and commercialization activities as set forth in the development and commercialization plan, if the Company underreports its payment obligations or underpays by more than a specified threshold, if the Company challenges the validity or enforceability of any licensed patents, or if the Company becomes bankrupt or insolvent.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_2efa0864-c1fe-4c88-9327-21f52ae89f49" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. NET LOSS PER SHARE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d87c7f6-d7bc-4627-82a0-2e411bf4d562" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of pre-funded warrants to purchase shares of common stock. Diluted net loss per share is the same as basic net loss per share for the periods presented since the effects of potentially dilutive securities are antidilutive given the net loss of the Company.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6381d6fa-f9ad-467e-86f5-010d3ae9b951" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:48.98%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.52%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50d31e98-ca69-46df-9d62-494782021f65" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,781</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_126a80f9-21c0-4a13-844d-0e4866a9f1a9" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,094</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4f004d5-9302-462b-b630-64a4d812676c" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,871</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52c33009-4b63-401e-8713-24a706dc774b" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,644</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share&#8212;basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_097afcae-8c94-4167-b02c-a2a0d594ed10" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f4146884-2498-4c1d-8b7b-a00908e7772c" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.25</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e345aa2a-9a40-4360-bbf3-feecfeeb494e" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_84659dd3-9ae7-4065-b776-c069ffa73469" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.24</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e726509f-4849-4136-84d9-2399cf7f1433" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8192b35c-cc08-4dbe-8636-09f6b296bf88" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.51</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae955c4a-62b7-47e2-8931-cedbf4641f79" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ef3abf66-1b81-48b9-8d8a-451a9317b4e3" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.65</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares used in computing net loss per share&#8212;basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ff5b286-43f7-4f70-9ac7-7f8f3bc0d075" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_55feb1e3-0a9f-4a8c-af41-dc6a059dd8b4" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,467,091</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d03d4b67-b91c-4bf1-bd94-4af17bcb12cc" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_198ea69f-07e9-469d-92b4-436d10512c7b" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,119,153</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6df24eb3-6104-4618-b5a8-655c19a312fb" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b42ca94f-c8fd-4d99-b6be-086c55e491b2" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,468,087</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dfe37bf-798e-4397-8b5a-c0a10c4f6664" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_942a82ea-d13b-42a0-b617-6a0e45409840" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,920,157</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4cf270ee-4a4c-45c0-9ad5-bc9e690d2506" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_4cf270ee-4a4c-45c0-9ad5-bc9e690d2506_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.09%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.418%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.418%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.418%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.658%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01f9020c-4c44-41e2-a041-12dd4de08ab9" contextRef="C_d253db46-30ee-4977-a335-6cf4430b34fa" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,338,242</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9acd1a6-f2fd-4a14-ac83-304f0ec87e43" contextRef="C_71b5319c-c74f-48c0-b513-7d988c5197cd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">504,132</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d0fd327-b7bd-4256-9bc1-a9deffbcbb7d" contextRef="C_38b6bbc9-cfd4-42cc-abf5-b90814c910dd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,073,566</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44984662-311f-42df-bda7-035e8e325a2b" contextRef="C_19bfb4fa-92ca-4246-b1e1-4e59f4934b59" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">482,622</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fc7caee-c200-4489-9232-83a55332c2ee" contextRef="C_e59a07f5-ac54-4de1-8e72-5db165f3214b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_278c960a-b274-47fe-84da-1658ed98c005" contextRef="C_3a6247f8-75f6-40db-a461-ec966fedb821" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">217,793</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f92020ce-a0a5-4b98-9b63-007b5b8aaeae" contextRef="C_810c253b-a933-4a17-9491-34d6f79e7d1e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3389141-0b14-4e60-9723-21050e424efc" contextRef="C_d771653f-d6e1-42de-90fd-133dbbf26d13" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">305,137</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9be60f14-3787-4ee8-a5de-6a8a0cc4c6bd" contextRef="C_d4f58c1a-28e8-4e00-ac1b-fdb6c3f10ee4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">166,964</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_832c4aa0-e200-4b3e-bc60-305ed411d558" contextRef="C_b28d3e5d-1b32-48f8-88d7-6fb7eab46cd1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">333,424</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd801ad2-fd3d-4212-9954-c08cc7f82e5e" contextRef="C_6d2dbaaf-c0a6-4697-b08e-5a209319a860" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">166,964</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f5d0756-f352-4717-844b-67dd7743767b" contextRef="C_96ec57a8-e87b-4138-894b-a4270326d386" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">363,603</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series C warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eb48a6c-9bab-4d20-9a22-cf50d6d45fee" contextRef="C_50d59e7d-433d-43f6-a235-2ab99ee775ac" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">828,863</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5d1b050-8b46-41a2-b5e9-e17c9fbd9dce" contextRef="C_e92bc1aa-c2db-46f5-9911-334ad58821cb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">997,638</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2ad3c0d-50a4-4024-9bdf-6c2d635781ba" contextRef="C_bc76b556-a6fe-4d1d-ae30-4ebf8174f5cf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">828,863</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9dec17c-2624-4066-a02c-97d99efadc0b" contextRef="C_6f940d37-a954-49ae-b661-7826cc32ebbc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,008,304</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f900f740-b5db-42d9-9fc7-430c154a1179" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,334,069</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_275bb2a4-b751-436f-827b-c9c93966fca1" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,052,987</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6549dd51-cbff-4c49-8928-135e310b3e67" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,069,393</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4206596e-cec9-4ad8-8db0-691de0afdf04" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,159,666</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_4cf270ee-4a4c-45c0-9ad5-bc9e690d2506_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44c3dba2-ff78-4041-9556-31c7342828dc" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. COMMITMENTS AND CONTINGENCIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has existing commitments to the licensors of the intellectual property which the Company has licensed. These commitments are based upon certain clinical research, regulatory, financial and sales milestones being achieved. Additionally, the Company is obligated to pay a single-digit royalty on commercial sales on a global basis of licensed products under the Emory License Agreement and the UABRF License Agreement. The royalty term is the later of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5cf394f4-412f-4e64-ac62-7add59661d5a" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:RoyaltyTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from first commercial sale or expiration of the last-to-expire component of the licensed intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred costs related to such legal proceedings.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_b8e30786-cdd0-4a18-8ba6-d172a0954554" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:LeaseOfLesseeDisclosureTextBlock" escape="true" continuedAt="F_b8e30786-cdd0-4a18-8ba6-d172a0954554_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.  EQUIPMENT AND Facility LEASES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has historically entered into lease arrangements for its facilities. As of June 30, 2026, the Company had four operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective date. The Company&#8217;s leases generally do not include termination or purchase options.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finance Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into an agreement with an equipment leasing company in 2018, which provided up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c3a2ea1-424e-473e-8220-eedcf94659c4" contextRef="C_53e8ca8d-054b-421a-aeaf-137116bc56c1" name="inab:SaleLeasebackTransactionAmountHeldForEquipmentPurchases" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for equipment purchases in the form of sale and leasebacks or direct leases. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026, the Company has two active </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">leases from the leasing company. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2341d3f-67aa-4e31-8760-ec92535b2087" contextRef="C_b30464c5-22d4-4239-98ad-7e811345c69c" name="us-gaap:SaleLeasebackTransactionDescriptionOfAssetS"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into an agreement with another equipment leasing company in the second quarter of 2023. As of June 30, 2026, the Company had one active lease from this leasing company. In June 2024, the Company entered into two new finance lease agreements with another leasing company. The terms of these lease are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The equipment leases require three advance rental payments to be held as security deposits. The security deposits held amounted to approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b28456c-a559-42e7-82a1-61ffd83b667d" contextRef="C_17a4c689-e630-472c-a467-89020ee064f2" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b1a159bf-d4cf-447a-8d8b-e9c9b903b804" contextRef="C_997b28c3-e27a-4857-b095-ed0f479b1617" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2026 and December 31, 2025, respectively, and are included in other non-current assets on the condensed balance sheets.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an operating lease for office space in Birmingham, Alabama, which was modified and expanded in March 2024 for a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_167cf052-2a6a-4f05-916c-a25dd4284591" contextRef="C_7af2a072-2c87-47d1-ad7d-8dab6874c286" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term ending in March 2029, with an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c9d16aa-0494-4af1-9958-60d31a7ec288" contextRef="C_42cc5669-934a-4055-a8d8-921ebecf0195" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend five years, resulting in an increase to both the right-of-use assets and operating lease liabilities.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. In April 2025, the Company terminated its operating lease for additional unutilized office space in Birmingham, Alabama. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9a69f0c-fce6-46b4-b8f4-4d66feceaa38" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:OneTimeTerminationFeeDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid a one-time termination fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbf3e5c4-652c-44f9-be7c-8b321946dae4" contextRef="C_0499d8bf-2153-47ac-bbac-d9cd024bdf7f" name="inab:TerminationFee" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and paid five monthly payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_034983b2-6a6a-48d6-98fd-14004564b1b5" contextRef="C_05ec3e90-967f-458c-97d3-d68b6e3dd286" name="inab:MonthlyPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, beginning on June 1, 2025.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of October 1, 2025, there were no payments remaining.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an operating lease for office space in New York, New York, with a term that commenced on September 15, 2021, and continues through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc738797-4004-42a5-a908-d814cd11c7ba" contextRef="C_def38031-424d-4460-9cf3-5076e5af20ee" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has identified an embedded lease within the University of Louisville Manufacturing Services Agreement, as the Company has the exclusive use of, and control over, a portion of the manufacturing facility and equipment of the facility during the contractual term of the manufacturing arrangement. The commencement date of the embedded lease was August 4, 2022 and it continues through August 2028.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The operating leases require security deposits at the inception of each lease. The security deposits amounted to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1507674-797a-4ef0-a524-80a4035b706c" contextRef="C_be7c85de-8249-4726-abb3-64537317fe59" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e45f8b91-eb6f-447c-bcaf-76ff8aac6497" contextRef="C_97223205-5221-4961-859d-ce78102dadb4" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2026 and December 31, 2025. As of June 30, 2026 and December 31, 2025, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc26620f-710c-4b76-b284-3dd2c4161984" contextRef="C_97223205-5221-4961-859d-ce78102dadb4" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_feafb40c-77de-4d1e-ba51-3d1bd14e8f02" contextRef="C_be7c85de-8249-4726-abb3-64537317fe59" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was included in restricted cash.</span></p><div><ix:nonNumeric id="F_d83b4631-ea8d-4559-ada2-d2dde6352f6c" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:LeaseCostTableTextBlock" escape="true" continuedAt="F_d83b4631-ea8d-4559-ada2-d2dde6352f6c_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains a summary of the lease costs recognized and other information pertaining to the Company&#8217;s finance and operating leases for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2026 and 2025 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of finance lease right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d17c43e8-41dc-4bd0-b9ee-3c6885f7d9d9" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="inab:AmortizationOfFinanceRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c404d9f-95fb-42f1-9613-49ee3bfd61bd" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="inab:AmortizationOfFinanceRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">525</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_407ac3bb-16cc-4f28-a939-6d53a208d7c5" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:AmortizationOfFinanceRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_891acc03-5550-41fc-9054-13d6ff7a9188" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="inab:AmortizationOfFinanceRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">765</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on finance lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cf83cc0-4614-4849-b261-265c4e8f4bfd" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e6249c8-0dc1-4da5-9b5a-9c5fdf9ddecd" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0deb75d3-67c9-4c87-aa94-d3d268204413" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4231a40b-0b49-444a-8bf0-a979cb434c1c" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19f408b6-8b86-4397-96da-7c821f661186" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ca44af7-bf9b-4850-9dc2-eefa0651dc27" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">339</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48e0517c-bef2-4ef0-b889-e8339ed104d2" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">445</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b37dfae-41de-4f20-88e3-9398f71814b1" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c75ae8fa-5267-4ed8-91e8-a0eac17f704f" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d6aa652-00c7-45d9-bb9b-82f71e5aded2" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb357631-4354-41ff-b86d-7ecfb560a0f9" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee8339dc-3546-4a79-8704-3e9e2ad9f0c8" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">248</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4e02f1b-583b-4903-b4ac-e79c30fab108" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7dbe08c-8b28-4255-8f06-6dff94ab3918" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af32a07e-4729-4465-9de3-3a69ba722790" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bce462a-9a13-4c7e-b047-448829433b09" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2a64772-3847-4fc5-82ea-b1040a8b9367" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">328</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00aed576-e3ed-42f5-8286-09db0adbbfec" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,122</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86ce6655-a3b2-489e-8bd8-b4cd6573642b" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_575341fd-28f8-43ab-9893-53d063565c1f" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,792</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_b8e30786-cdd0-4a18-8ba6-d172a0954554_1"><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_d83b4631-ea8d-4559-ada2-d2dde6352f6c_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.823%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Lease Information</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liability&#8201;&#8211;&#8201;finance leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88cc376e-c397-4470-9f61-4b9700fb67a6" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="inab:CashPaidForAmountsIncludedInFinanceLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liability&#8201;&#8211;&#8201;operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_573647b4-7fb5-40aa-99b3-ed5450a37c29" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="inab:CashPaidForAmountsIncludedInOperatingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term&#8201;&#8211;&#8201;finance leases (years)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4ac45b20-f12b-4da9-8658-710a600d7a89" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term&#8201;&#8211;&#8201;operating leases (years)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4a4a9408-f05c-48f7-97f2-16399d398d18" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.16</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate&#8201;&#8211;&#8201;finance leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_989a365b-fea0-4e12-935d-16725645f099" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.9</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate&#8201;&#8211;&#8201;operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e252bc0-8ba0-4f7a-990e-28b628ca6efe" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">14.9</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80b2c514-131a-4d44-89f0-2f6343edafc2" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_80b2c514-131a-4d44-89f0-2f6343edafc2_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the undiscounted cash flows to the operating and finance lease liabilities at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e81c6b6c-ccc6-4db5-9a04-739f214d0f98" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2206e9ff-e9c8-42c8-a64a-2516c6c0cf18" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">620</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff5c0a6c-0e97-4b6b-8834-70ef5da72b02" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68fb72bb-f938-439b-a15e-862ac4d22035" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,019</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_390585a0-b8d8-4c2d-b7eb-8edaa08e4800" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cc43d25-feac-4fc2-ba5f-92aca4a95871" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">680</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccb8b81e-6da6-4c58-9b06-1b69055f2c37" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f1d896d-36c0-4f61-a1ac-ffa456657ac9" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbb9e3b4-5df4-4187-acfc-72d9b349d219" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28a4339e-21fb-4196-b5a9-40e3ff45cd12" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,385</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a7acba2-e3fd-410a-bd0d-00d243dcc90a" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9e18ad0-5b44-484c-9bc5-90e02c51075b" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_358689ad-fe67-470a-a1eb-ba7c3989a1fe" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4ecfb9a-f2ed-4a00-be95-ebaf0f2f21eb" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,051</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: short-term lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5b749ad-b872-4d68-ac21-44f664ee3f4d" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9d1b930-1793-4344-91ed-2c43c9c80f8b" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">923</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86e09385-bb31-4ff0-8d06-9db6b838934b" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f745e47-95f8-47b5-962a-180392301407" contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,128</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_80b2c514-131a-4d44-89f0-2f6343edafc2_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2db2f21-1b2d-4e05-b309-285d2fd40f16" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_d2db2f21-1b2d-4e05-b309-285d2fd40f16_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.  SEGMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the CODM or decision making group in making decisions on how to allocate resources and assess performance. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eb80b65-5b79-48cb-a215-4c76cae17019" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a929cd00-7c75-483e-b41a-4b3107188ca5" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="inab:NumberOfReportableSegmentsNotDisclosedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">segment</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> focused on the discovery, development and commercialization of gamma-delta T cell product candidates and TCEs for cancer and autoimmune disease. The CODM is the Company&#8217;s CEO. The CEO manages the Company&#8217;s operations, assesses performance for the operating segment and decides how to allocate resources based on net loss, which is reported on the condensed statements of operations. Depreciation expense, amortization expense, stock-based compensation expense, and non-cash lease expense are significant noncash items included in net loss reviewed by the CFO and CEO and are reported on the condensed statements of cash flows. The measure of segment assets is reported on the condensed balance sheets as total consolidated assets.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89db627a-b77c-4b17-8e49-b424b66fb67b" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_89db627a-b77c-4b17-8e49-b424b66fb67b_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents certain financial data for the Company&#8217;s reportable segment:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.41%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.202%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.202%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.202%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.202%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-100 research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79e7ed7c-f973-48c5-9ce7-bc4f59b6da63" contextRef="C_b24663f5-7497-4a9d-bd5e-d59f159c16de" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37225e08-f60e-4ec5-a39a-ce19100c0a42" contextRef="C_198b97c6-3cda-418e-8a12-84c85860d2ae" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8df30c6-645b-4588-8045-c5067df6c503" contextRef="C_4e1d52b8-2e75-4fad-91a5-2c9038ff8c4d" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">623</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b05787c-38ae-4251-8ace-d99afe41cdf4" contextRef="C_991adedc-6fe1-457b-a3c6-48d3d6844dc5" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">454</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-200 research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ec9fa9a-c81b-41fb-ada4-49aa1bd50e06" contextRef="C_fdc21c59-3c61-4c15-b2c9-ab66b200f940" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_337f1612-9690-4c96-8f97-9f3adac61ec2" contextRef="C_ad33d33e-a055-4025-8be6-a7a64988ccbc" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb7a3945-596e-4b99-95d0-863c9e730512" contextRef="C_4c61b704-66e8-4b64-a193-bc2b42ce834b" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab71e92e-f7b6-4803-85d9-41a65cef90e7" contextRef="C_2c1c8162-f3f4-43b5-b9b1-dfa4747b48c7" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-400 research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8224f95a-05b6-4954-8d41-39845bf15f4e" contextRef="C_53a7b24c-e727-4468-a624-795e8b95e8d3" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6013616-cd27-46d8-9af1-f82a9264d424" contextRef="C_aa7edcfc-6c9b-4838-92c4-14a3be2c97a1" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dac2df2b-5fa4-4863-9d3b-a04a693672e4" contextRef="C_ca9afdc9-8b69-4eef-878d-9bfdecad710f" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30ddef5b-90b9-4cd2-95ab-6ea32edf2ecc" contextRef="C_5fdb3891-da52-4136-be69-6649196b8db1" name="inab:SegmentResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">626</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related indirect research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bfae27c-a512-49ee-82c2-a87315990ab9" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,266</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d878bb23-ef88-4979-a39f-0e52a7e7b19f" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,241</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58d758de-2517-4487-a1c7-c89965d8c742" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,577</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e51a188-d1b2-4737-93a9-560aa0d3e3b4" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,501</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69370843-6490-43fb-9be1-c754bdde0037" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,442</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54bbbce3-9ecd-4567-9e8a-17f9c6d3f29d" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,714</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dfa6cd9-b56a-4286-81e9-3f4b9e856242" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,095</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9144b2a-eb94-4a0a-bd95-de54473e8281" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,402</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d39d48d-314f-467d-8a4c-4e7dff4734f8" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">780</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25611ed4-88a8-4ad4-9cb3-b05b081e1023" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">725</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae5f322f-0da7-45ed-a4ad-2c5c44deaae9" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,451</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf054062-3810-4cc0-b368-e33f58f1a8b6" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,646</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adb3f311-e705-4ba2-980d-c99534f1c0c6" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,781</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0c4a542-f37b-4549-90ca-9701045c2121" contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,094</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_856e4879-c74a-41ab-938b-66a9ceed6c49" contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,871</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe74cea3-08e9-4b5d-9659-9e650aeee033" contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,644</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span><ix:continuation id="F_89db627a-b77c-4b17-8e49-b424b66fb67b_1"><span><ix:continuation id="F_d2db2f21-1b2d-4e05-b309-285d2fd40f16_1"><ix:footnote id="FNT_b5be1cbe-74b4-4707-a935-4de0fdbab18f" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items include preclinical expenses, interest income and other income.</span></ix:footnote></ix:continuation></span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_2_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q (this "Quarterly Report") contains statements that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. All statements contained in this Quarterly Report other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believes," "expects," "intends," "estimates," "projects," "anticipates," "will," "plan," "may," "should," or similar language are intended to identify forward-looking statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">It is routine for our internal projections and expectations to change throughout the year, and any forward-looking statements based upon these projections or expectations may change prior to the end of the next quarter or year. Readers of this Quarterly Report are cautioned not to place undue reliance on any such forward-looking statements. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Risks and uncertainties are identified under "Risk Factors" in Item 1A herein and in our other filings with the Securities and Exchange Commission ("SEC"). All forward-looking statements included herein are made only as of the date hereof. Unless otherwise required by law, we do not undertake, and specifically disclaim, any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise after the date of such statement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and related notes included elsewhere in this Form 10-Q, and our audited financial statements and related notes for the year ended December 31, 2025 in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "Annual Report"). Unless otherwise indicated, all information in this Quarterly Report on Form 10-Q gives effect to a 1-for-30 reverse stock split of our common stock that became effective on June 5, 2025, and all references to shares of common stock outstanding and per share amounts give effect to the reverse stock split.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates and T cell engagers ("TCEs") for cancer and autoimmune diseases. We are the most clinically advanced gamma-delta T cell-focused company and are utilizing our suite of DeltEx platform technologies as we aspire to eliminate cancer cells to achieve our mission of what we refer to as Cancer Zero</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; the safe elimination of all cancer and target cells in every patient battling disease. We develop TCEs, along with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expanded and activated gamma-delta T cell candidates based upon our deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. Our platform employs TCEs, allogeneic, autologous, induced pluripotent stem cell ("iPSC"), and genetically modified cell therapy approaches that are designed to effectively identify and eradicate tumor or target cells. To date, we have conducted two primary investigator-sponsored Phase 1 clinical trials evaluating our gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing our DeltEx Allogeneic ("Allo") gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation ("HSCT"). INB-200 evaluated our DeltEx Drug Resistant Immunotherapy ("DRI") in patients with newly diagnosed glioblastoma ("GBM"). Both trials have demonstrated encouraging clinical activity, including long-term durable remissions, with patients remaining alive and in remission or progression-free for more than four years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Most recently we introduced INB-600, our proprietary, internally developed TCE platform. We have demonstrated that INB-619, a CD19 targeted gamma-delta TCE can efficiently and completely eliminate targeted B cells in a dose-dependent manner. Data presented at The American College of Rheumatology Convergence 2025 meeting ("ACR Convergence 2025") highlighted the potential of INB-619 in B cell-driven autoimmune diseases such as systemic lupus erythematosus ("SLE") and demonstrated deep B cell depletion through selective activation and expansion of gamma-delta T cells.We expect to report initial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> data for INB-619 in the second half of 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INB-100, our first DeltEx allogeneic product candidate, was developed to assess the safety and tolerability of donor-derived manufactured expanded and activated gamma-delta T cells that do not undergo additional genetic modification. The Phase 1 trial of INB-100 has completed primary enrollment and a recommended Phase 2 dose ("RP2D") has been determined. We are currently enrolling an expansion cohort at the RP2D, with a target of up to an additional 15 patients (for a minimum of 25 total patients in the INB-100 Phase 1 trial), to confirm the improvements in relapse free and OS observed to date. We expect to complete the treatment of all patients and present a clinical update at a medical meeting in late 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our DeltEx DRI product candidate, INB-200, is being developed for newly diagnosed GBM. Patient dosing in the investigator-sponsored Phase 1 trial of INB-200 (NCT04165941) has been completed and we continue to follow patients for progression-free survival ("PFS") and overall survival ("OS"). In July 2026 we announced the publication of peer-reviewed clinical data from our Phase 1 trial of INB-200 in The Journal of Clinical Oncology ("JCO"), titled: &#8220;Intracranial injection of ex vivo expanded and activated gamma-delta T cells engineered with a MGMT-expressing lentivector in patients with primary glioblastoma.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INB-400 is our corporate-sponsored investigational new drug application ("IND") for the Phase 2, multi-center clinical trial evaluating our DeltEx DRI technology in newly diagnosed GBM. Treatment of any enrolled patients has been completed and the IND remains open. In September 2024, following a pipeline prioritization review, we suspended further enrollment in the Phase 2 trial of INB-400 to conserve capital. The trial was designed to further evaluate genetically modified, DRI gamma-delta T cells in newly diagnosed GBM patients across multiple centers in the United States. In June 2026, we presented longer-term follow-up data at the American Society of Clinical Oncology ("ASCO") Annual Meeting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This data was updated through May 15, 2026, and patients who received repeated doses (three or six) of DeltEx DRI gamma-delta T cells reported a median progression-free survival ("mPFS") of 13.0 months and an overall survival exceeding 19.5 months, with median overall survival continuing to grow. We continue to believe that our DeltEx DRI approach has the potential to address this significant unmet need and expect to provide further clinical updates, including additional mOS data from the total data set, at medical meetings in late- 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our DeltEx DRI gamma-delta T cell therapeutic approach is demonstrating clinical activity and may have the potential applicability across multiple solid tumor types. In April 2023, we received Orphan Drug Designation ("ODD") from the FDA for both the autologous and allogeneic DeltEx DRI INB-400 product candidates, covering a broad range of malignant glioma indications, including relapsed and newly diagnosed GBM. We believe there may be potential regulatory designation pathways available for the autologous DeltEx DRI program in newly diagnosed GBM and intend to seek further guidance from the FDA regarding potential development and regulatory pathways in 2026. Following such regulatory guidance, we expect to evaluate potential funding sources and strategic opportunities to support continued development of this program toward potential commercialization.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have a portfolio of preclinical programs within our DeltEx pipeline which remain suspended in development due to current market interest and prioritization. These include INB-300, a targeted non-signaling gamma-delta T cell based chimeric antigen receptor ("nsCAR") construct which is applicable to both solid and liquid tumors, and INB-500, which encompasses our ability to produce gamma-delta T cells from iPSCs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Pipeline</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img122832063_0.jpg" alt="img122832063_0.jpg" style="width:717px;height:403px;"/></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception in 2016, our operations have focused on identifying and developing potential product candidates, conducting clinical trials, organizing and staffing, business planning, establishing our intellectual property portfolio, raising capital, and providing general and administrative support for these operations. We do not have any product candidates approved for sale and have not generated any revenue. We have funded our operations primarily through the sale of equity and equity-linked securities, including through our initial public offering ("IPO"), follow-on offering, at-the-market ("ATM") programs, and multiple private placements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to incur additional losses in the future as we advance our product candidates through clinical trials, grow our clinical, regulatory and quality capabilities, and incur costs associated with operating as a public company. Based on our business strategy, our existing cash of $18.0 million as of June 30, 2026 is not anticipated to fund our projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of the accompanying condensed financial statements, and accordingly, there is substantial doubt about our ability to continue to operate as a going concern.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to maintain cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility given the ongoing market environment for biotechnology stocks. These cash preservation measures may impact our ability and the timing to execute our strategy, including our ability to achieve the anticipated milestones and the timing of regulatory filings for our preclinical and clinical programs. To continue to fund our operations, management has developed plans, which primarily consist of the pipeline prioritization, raising additional capital through some combination of equity and/or debt offerings, including through our ATM program, and identifying strategic collaborations, licensing or other arrangements to support development of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our private placement completed in December 2025, we may also be eligible to receive up to approximately $20.1 million in additional gross proceeds in exchange for up to 14,579,706 shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to the achievement of certain milestone-driven conditions related to preclinical data for our CD19 targeting INB-619 product candidate. In addition, we may receive an additional $6.7 million in aggregate proceeds if the holders of our Series C warrants exercise their warrants in full. Further, if not otherwise redeemed by us, we may also receive aggregate proceeds of up to $2.3 million from the exercise of our outstanding Series B warrants in full. There is no assurance, however, that we will receive any additional proceeds from the second closing of the 2025 private placement or the exercise of outstanding warrants or pre-funded warrants, that any additional financing or any revenue-generating collaboration will be available when needed, that management will be able to obtain financing or enter into a collaboration on terms acceptable to us, or that any additional financing or revenue generated through third-party collaborations will be sufficient to fund our operations. If additional capital is not available to us on a timely basis, or at all, we will be required to take additional actions beyond the cost preservation measures initiated to date to address our liquidity needs, including exploring other strategic options, continuing to further reduce operating expense or delaying, reducing the scope of, discontinuing or altering our research and development activities. For additional information, see "&#8212;Liquidity and Capital Resources" below.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The actual amount of cash that we will need to operate is subject to many factors, including those described in the section titled "Risk Factors." The condensed financial statements have been prepared on the basis that we will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Our Results of Operations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, we have not generated any revenue and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for one or more of our product candidates are successful and result in regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from collaboration or license agreements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates, and include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee-related expenses, including salaries, related benefits, severance payments and stock-based compensation expense for employees engaged in research and development functions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fees paid to consultants for services directly related to our product development and regulatory efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses associated with conducting preclinical studies performed by ourselves, outside vendors or academic collaborators;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred in connection with conducting clinical trials including investigator grants and site payments for time and pass-through expenses and expenses incurred under agreements with contract research organizations ("CROs") as well as contract manufacturing organizations ("CMOs") and consultants that conduct and provide supplies for our preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to manufacture drug product candidates for use in our preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs associated with preclinical activities and development activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs associated with our intellectual property portfolio; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to compliance with regulatory requirements.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our condensed financial statements as prepaid or accrued research and development expenses. We allocate our direct external research and development costs across each product candidate. Preclinical expenses consist of external research and development costs associated with activities to support our current and future clinical programs but are not allocated by product candidate due to the overlap of the potential benefit of those efforts across multiple product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development activities are central to our business. We expect that our research and development expenses will increase in the future as we continue clinical development for our product candidates and continue to discover and develop additional product candidates. If any of our product candidates enter into later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive and finance functions. General and administrative expenses also include professional fees for legal, accounting, auditing, tax and consulting services; travel expenses; director and officer insurance expenses as a publicly traded company; and facility-related expenses, which include shared expenses for rent and maintenance of facilities and other operating costs not included in research and development.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our general and administrative expenses will increase in the future, contingent on additional funding as our organization and headcount needed in the future grow to support continued research and development activities and potential commercialization of our product candidates. These increases will likely include increased costs related to building a team to support our administrative, accounting and finance, communications, legal and business development efforts. In addition, we expect increased expenses associated with being a public company, including costs of additional personnel, accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements; director and officer insurance costs; and investor and public relations costs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income includes interest earned from certain bank accounts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Three Months Ended June 30, 2026 and 2025</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth our results of operations for the three months ended June 30, 2026 and 2025 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.3%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.48%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.020000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.48%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.72%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,493</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,487</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,442</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,714</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(272</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,935</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,201</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(266</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,781</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,094</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">313</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,781</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,094</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">313</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses for the three months ended June 30, 2026 and 2025 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.151%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Direct research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-100</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-200</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-400</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(154</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated expenses</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">352</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">338</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel expenses (including stock-based compensation)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,266</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,241</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facility-related and other expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">582</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">818</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(236</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,493</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,487</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were $2.5 million for the three months ended June 30, 2026, compared to $2.5 million for the comparable prior year period. This includes non-cash items such as stock-based compensation ("SBC") and depreciation of $0.4 million for the three months ended June 30, 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $2.4 million for the three months ended June 30, 2026, compared to $2.7 million for the comparable prior year period. This includes non-cash items such as SBC and depreciation of $0.2 million for the three months ended June 30, 2026. The decrease of $0.3 million was primarily due to a decrease in personnel-related costs, including SBC and a reduction in professional services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income was $0.2 million and $0.1 million for the three months ended June 30, 2026 and 2025, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Six Months Ended June 30, 2026 and 2025</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth our results of operations for the six months ended June 30, 2026 and 2025 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.151%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,106</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,459</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(353</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,095</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,402</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(307</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,201</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,861</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(660</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">330</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9,871</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,644</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">773</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9,871</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,644</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">773</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses for the six months ended June 30, 2026 and 2025 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.151%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Direct research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-100</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">623</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">454</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-200</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-400</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">626</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(558</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated expenses</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">502</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">443</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel expenses (including stock-based compensation)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,577</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,501</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facility-related and other expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,279</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,804</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(525</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,106</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,459</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(353</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were $5.1 million for the six months ended June 30, 2026, compared to $5.5 million for the comparable prior year period. This includes non-cash items such as SBC and depreciation of $0.8 million for the six months ended June 30, 2026. The decrease of $0.4 million was primarily due to decreases in direct clinical costs of $0.6 million for INB-400 and facility related costs of $0.5 million, partially offset by increases of $0.4 million in preclinical costs related to the TCE program, $0.2 million for direct clinical costs related to INB-100 and INB-200, and $0.1 million in personnel-related costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $5.1 million for the six months ended June 30, 2026, compared to $5.4 million for the comparable prior year period. This includes non-cash items such as SBC and depreciation of $0.5 million for the six months ended June 30, 2026. The decrease of $0.3 million was primarily due to a decrease in personnel-related costs, including SBC and a reduction in professional services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income was $0.3 million and $0.2 million for the six months ended June 30, 2026 and 2025, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have funded our operations primarily through the sale of equity and equity-linked securities, including through our IPO, follow-on offering, ATM programs and multiple private placements. Through June 30, 2026, we have raised an aggregate of $163.2 million of gross proceeds from the sale of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026, we had cash of $18.0 million, which is only expected to fund our projected operating expenses and capital expenditure requirements through April 2027. We continue to deploy cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility. These cash preservation measures may impact our ability and the timing to execute our strategy, including our ability to achieve the anticipated milestones and the timing of regulatory filings for our preclinical and clinical programs. To continue to fund our operations, management has developed plans, which primarily consist of the pipeline prioritization, raising additional capital through some combination of equity and/or debt offerings, including through our ATM program, and identifying strategic collaborations, licensing or other arrangements to support development of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the private placement, completed in December 2025, we may also be eligible to receive up to approximately $20.1 million in additional gross proceeds in exchange for up to 14,579,706 shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to the achievement of certain milestone-driven conditions related to preclinical data for our CD19 targeting INB-619 product candidate. In addition, we may receive aggregate proceeds of up to $6.7 million from the exercise of our outstanding pre-funded warrants and Series C warrants, assuming the exercise in full of all of such warrants for cash. Further, if not otherwise redeemed by us, we may also receive aggregate proceeds of up to $2.3 million from the exercise in full of our outstanding Series B warrants. See Note 7, Warrants, in our unaudited condensed financial statements contained elsewhere in this Quarterly Report for additional information on our outstanding warrants. There is no assurance, however, that we will receive any additional proceeds from these warrants or that any additional financing or any revenue-generating collaboration will be available, when</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">needed. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce, or explore other strategic options for our research and development programs or other opportunities, or even terminate our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ATM Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, we entered into a Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sales agreement with Cantor Fitzgerald &amp; Co. ("Cantor Fitzgerald") and Truist Securities, Inc. ("Truist"), under which Cantor Fitzgerald and Truist agreed to act as our sales agents to sell shares of our common stock, from time to time, in an ATM program. In March 2024, we delivered a termination notice to Truist, removing them as sales agent under the sales agreement, and on May 29, 2026, we and Cantor mutually agreed to terminate the sales agreement effective at the close of business on May 29, 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, we filed a shelf registration statement on Form S-3 (File No. 333-291393) (the "Shelf Registration Statement") with the SEC, which became effective on May 20, 2026, which permits the issuance and sale of up to a maximum aggregate offering price of $200.0 million of our common stock, preferred stock, various series of debt securities, warrants to purchase common stock, preferred stock or debt securities, rights to purchase equity or debt securities, and/or units to purchase any combination of such securities. On June 1, 2026, we entered into a Capital on Demand</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sales Agreement (the "Sales Agreement") with JonesTrading Institutional Services LLC ("JonesTrading") with respect to an at-the-market offering program under which we may issue and sell, from time to time at our sole discretion, shares of our common stock, through or to JonesTrading (the &#8220;ATM Program&#8221;) pursuant to the Shelf Registration Statement. As of August 4, 2026, $2.8 million remained available for the sale of our common stock under the ATM Program.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of this Form 10-Q, our public float was less than $75 million. As a result, we are subject to the limitations of General Instruction I.B.6 to Form S-3 until such time as our public float exceeds $75 million, which means we only have the capacity to sell shares up to one-third of our public float under shelf registration statements in any 12-month period. We will remain constrained by the limitations of General Instruction I.B.6 to Form S-3 until such time as our public float exceeds $75 million, at which time the number of securities we may sell under a Form S-3 registration statement will no longer be limited by limitations of General Instruction I.B.6 to Form S-3.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses to increase substantially contingent on additional funding in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, the costs of manufacturing our clinical and preclinical product candidates, clinical costs, legal and other regulatory expenses and general overhead costs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress in these trials is uncertain. We cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Our future capital requirements will depend on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, timing, progress, costs, and results of discovery, preclinical development, and clinical trials for our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of clinical trials required for regulatory approval of our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing, and outcome of regulatory review of any of our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of manufacturing clinical and commercial supplies of our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses to attract, hire and retain skilled personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third party and government payers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any potential interruptions, delays and/or cost increases resulting from public health crises, increased interest rates and geopolitical tensions, such as wars and terrorism;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular economies and markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or invest in businesses, products and technologies.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, inflationary factors, such as increases in the cost of our clinical trial materials and supplies, interest rates, tariffs and overhead costs may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience increased operating costs in the near future (especially if inflation rates rise). Such increases may impact our labor costs and research and development costs, due to supply chain constraints, consequences associated with geopolitical tensions existing and any future tariffs enacted by the U.S. government and employee availability and wage increases, which may result in additional stress on our working capital resources.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, we have not generated any product revenue and have incurred net losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for the foreseeable future, if at all. It is likely that we will seek third-party collaborators for the future commercialization of our product candidates that are approved for marketing. However, we may seek to commercialize our products at our own expense, which would require us to incur significant additional expenses for marketing, sales, manufacturing and distribution.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time as we can generate significant revenue from product sales, if ever, we expect to continue to finance our operations from the sale of additional equity or debt financings, or other capital which comes in the form of strategic collaborations, licensing, or other arrangements. In the event that additional financing is required, we may not be able to raise it on terms acceptable to us, or at all. If we raise additional funds through the issuance of equity or convertible debt securities, it may result in dilution to our existing stockholders.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise funds through strategic collaboration, licensing or other arrangements, we may relinquish significant rights or grant licenses on terms that are not favorable to us. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions, including as a result of increases in inflation and interest rates, disruptions to, and volatility in, the credit and financial markets in the United States, tariffs and trade wars, and other geopolitical tensions, such as wars and terrorism and future U.S. government shutdowns. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or explore other strategic options for our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Cash Requirements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our material cash requirements as of June 30, 2026 included operating lease commitments, including the lease of our current headquarters office in New York, New York, laboratory and office space in Birmingham, Alabama and a manufacturing service agreement with a third party to engage in research of cell therapy products. See Note 12, Equipment and Facility Leases, in our unaudited condensed financial statements contained elsewhere in this Quarterly Report for additional information. As of June 30, 2026, we had fixed lease payment obligations of $2.5 million, with $1.3 million payable within 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as disclosed above, we have no long-term debt and no material non-cancelable purchase commitments with service providers, as we have generally contracted on a cancelable, purchase-order basis. We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manufacturing services. These contracts are cancelable by us upon prior notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation. These payments are not determinable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our sources and uses of cash for each of the periods below (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.673%;box-sizing:content-box;"/>
     <td style="width:1.74%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.923%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.74%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.923%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,692</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7,049</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(242</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(246</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,160</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9,180</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,111</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities was $8.7 million during the six months ended June 30, 2026, primarily due to our net loss of $9.9 million and changes in operating assets and liabilities of $0.5 million, partially offset by non-cash charges of $1.7 million. Increases in our operating assets and liabilities consisted primarily of $0.9 million in accrued expenses and other current liabilities relating primarily to accrued compensation, accrued clinical trials, and accrued legal, and $0.1 million in net operating lease liabilities, partially offset by of $0.4 million in prepaid expenses and other current assets and $0.1 million in accounts payable. Non-cash charges consisted primarily of $0.8 million in stock-based compensation, $0.4 million in amortization of right-of-use assets associated with our operating and finance leases for the period and $0.5 million of depreciation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities was $7.0 million during the six months ended June 30, 2025, primarily due to our net loss of $10.6 million partially offset by non-cash charges of $3.2 million and changes in operating assets and liabilities of $0.3 million. Increases in our operating assets and liabilities consisted primarily of $0.9 million in prepaid expenses and other current assets, partially offset by decreases of $0.5 million in accrued expenses and other current liabilities relating primarily to accrued compensation, accrued clinical trials, and accrued legal, and $0.1 million in operating lease liabilities. Non-cash charges consisted primarily of $1.8 million in stock-based compensation, $0.9 million in amortization of right-of-use assets associated with our operating and finance leases for the period and $0.5 million of depreciation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in investing activities was $(0.2) million during the six months ended June 30, 2026, primarily due to the purchase of property and equipment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in investing activities was nil during the six months ended June 30, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in financing activities was $(0.2) million during the six months ended June 30, 2026, primarily due to $0.2 million in principal payments of finance leases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities was $9.2 million during the six months ended June 30, 2025, primarily due to $7.4 million in net proceeds received from our ATM Program, $2.3 million in warrants exercised, partially offset by $0.5 million in principal payments of finance leases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our condensed financial statements, which are prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates and assumptions on historical experience, known trends and other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates. In making estimates and judgments, management employs critical accounting policies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have listed below our critical accounting policies that we believe to have the greatest potential impact on our financial statements. Historically, our assumptions, judgments and estimates relative to our critical accounting estimates have not differed materially from actual results.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We define our critical accounting policies as those accounting principles that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. Our significant accounting policies are more fully described in Note 2 to our financial statements located elsewhere in this Quarterly Report on Form 10-Q. We have listed below our critical accounting estimates and accounting policies that we believe to have the greatest potential impact on our financial statements. Historically, our assumptions, judgments and estimates relative to our critical accounting estimates have not differed materially from actual results.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense all costs incurred in performing research and development activities. Research and development expenses include salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to nonemployees and entities that conduct certain research and development activities on our behalf and expenses incurred in connection with license agreements. Non-refundable advance payments for goods or services that will be used for rendered or future research and development activities are deferred and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of recoverability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. We make estimates of our accrued expenses as of each condensed balance sheet date in the condensed financial statements based on facts and circumstances known to us at that time. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure all stock-based awards granted to employees, nonemployees and directors based on the fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. We account for our stock-based compensation as an expense in the condensed statements of operations based on the awards&#8217; grant date fair values. We account for forfeitures as they occur by reversing any expense recognized for unvested awards. We estimate the fair value of options granted using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to us, including stage of product development and life science industry focus. We use the simplified method as allowed by the SEC Staff Accounting Bulletin (SAB) No. 107, Share-Based Payment, to calculate the expected term for options granted to employees, as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2026, we did not adopt any new Accounting Standards Updates ("ASUs") issued by the Financial Accounting Standards Board.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have evaluated recently issued and unadopted ASUs, and believe the adoption of these standards will not have a material impact on our condensed financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We qualify as an emerging growth company ("EGC") as defined in the Jumpstart Our Business Startups Act ("JOBS Act"). As an EGC, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements, exemption from the requirements to hold non-binding advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may take advantage of these exemptions until December 31, 2026, or such earlier time that we are no longer an emerging growth company. We would cease to be an EGC earlier if we have more than $1.235 billion in annual revenue, we have more than $700.0 million in market value of our stock held by non-affiliates or we issue more than $1.0 billion of non-convertible debt securities over a three-year period. For so long as we remain an EGC, we are permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. We may choose to take advantage of some, but not all, of the available exemptions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to "opt out" of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to "opt out" of such extended transition period or (ii) no longer qualify as an EGC. Therefore, the reported results of operations contained in our financial statements may not be directly comparable to those of other public companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a "smaller reporting company," and we may continue to be a smaller reporting company until either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are a smaller reporting company at the time we cease to be an EGC, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report and, similar to EGCs, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_quantitative_qualitative_disclosu"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company as defined by Item 10 of Regulation S-K and are not required to provide the information otherwise required under this item.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Controls </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Procedures.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure Controls and Procedures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2026, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the six months ended June 30, 2026, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iior_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II&#8212;OTHER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> INFORMATION</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in various legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings that we believe could have a material adverse effect on our business, operating results or financial condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Ri</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sk Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report on Form 10-Q, including our financial statements and the related notes and "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations," before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Selected Risk Factors Associated with Our Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of the principal risks associated with an investment in our common stock:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is substantial doubt regarding our ability to continue as a going concern. We will require substantial additional funding to finance our operations through regulatory approval, and if we are unable to raise capital, we could be forced to delay, reduce or explore other strategic options for certain of our development programs, or even terminate our operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our outstanding warrants may not be exercised and we may not receive any cash proceeds from any exercise of warrants.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to raise capital may be limited by applicable laws and regulations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on the successful clinical development, regulatory approval and commercialization of our gamma-delta T cell product candidates. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interim, "topline" and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our DeltEx product candidates utilize novel approaches to cell therapies, including cancer treatment, which presents significant challenges to successfully develop, manufacture and commercialize our product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical and commercial utility of our DeltEx platform is uncertain and may never be realized. Additionally, certain aspects of the function and production of gamma-delta T cells are poorly understood or currently unknown and may only become known through further preclinical and clinical testing.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical product candidate development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and encounter substantial delays or difficulties in our clinical trials.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to file investigational new drug ("IND") applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development of a product candidate intended for use in combination with an already approved therapy may present increased complexity and more or different challenges than development of a product candidate for use as a single agent or monotherapy. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public opinion and scrutiny of our competitors, cell-based immunotherapy, T cell engagers, and genetic modification approaches may impact public perception of our company and product candidates, or may adversely affect our ability to conduct our business, raise additional capital and our business plans.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition, and many of our competitors have substantially greater experience and resources than we have.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our manufacturing processes are complex, and we may encounter difficulties in production, which would delay or prevent our ability to provide a sufficient supply of our product candidates for future clinical trials or commercialization, if approved.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may rely on third-party contractors or contract development manufacturing organization for the manufacturing of our product candidates, and failure by those parties to adequately perform their obligations could harm our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently store our gamma-delta T cells and biologic correlative and research specimens from clinical trials and development programs and clinical lentivectors at our research and development facilities and at the facilities of our clinical and/or manufacturing partners, and any damage or loss to our storage freezers and/or facilities from natural disasters or otherwise would cause delays in replacement, and our business could suffer.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently dependent on a single third-party supplier for manufacture of our automated manufacturing device and our lentiviral vectors for our cellular therapies. These are critical products required for the manufacturing of our product candidates, including INB-100, INB-200 and INB-400. Any damage or loss to the ability of our suppliers to deliver supplies in a timely manner could cause delays in manufacturing or our clinical trials and our business could suffer.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party healthcare professionals to administer gamma-delta T cells to patients, and our business could be harmed if these third parties administer these cells incorrectly.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach our license agreements with the University of Alabama at Birmingham Research Foundation, Children&#8217;s Healthcare of Atlanta, Inc. and Emory University, or any of the other agreements under which we acquired, or will acquire, the intellectual property rights to our product candidates, we could lose the ability to continue the development and commercialization of the related product.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to compete in the pharmaceuticals industry depends upon our ability to attract and retain highly qualified managerial, scientific, medical and other personnel. We are highly dependent on the services of our co-founders, William Ho, our Chief Executive Officer ("CEO"), and Dr. Lawrence Lamb, our Chief Scientific Officer ("CSO"), and of our President and Chief Operating Officer ("COO"), Dr. Kate Rochlin, and the loss of these members of our management team or other key employees could impede, delay or prevent the successful development of our product pipeline, the completion of our current and planned clinical trials, and the commercialization of our products or in-licensing or acquisition of new assets, and could negatively impact our ability to successfully implement our business plan.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our (or the third parties with whom we work) actual or perceived failures to comply with applicable data privacy and security obligations, including laws, regulations, contractual obligations, industry standards and other obligations could lead to regulatory investigations or actions, litigation (including class claims), fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, and other adverse business consequences.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions, including as a result of increases in inflation, the price of oil, and interest rates, tariffs and trade wars, public health crises or geopolitical tensions, such as wars and terrorism, and future U.S. government shutdowns, may have serious adverse consequences on our business, ability to raise capital, financial condition and share price.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Position and Capital Needs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There is substantial doubt regarding our ability to continue as a going concern. We will require substantial additional funding to finance our operations, and if we are unable to raise capital, we could be forced to delay, reduce or explore other strategic options for certain of our development programs, or even terminate our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026, we had cash of $18.0 million, which is only expected to fund our projected operating expenses and capital expenditure requirements through April 2027. We continue to maintain cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility. These cash preservation measures may impact our ability and the timing to execute our strategy. Our ability to continue as a going concern will depend on our ability to obtain additional funding, as to which no assurances can be given. We continue to analyze various alternatives, including additional debt or equity financings or other arrangements. Due to the uncertainty of our ability to meet our current operating and capital expenses, in their report on our audited annual financial statements as of and for the years ended December 31, 2025 and 2024, our independent auditors included an explanatory paragraph regarding our ability to continue as going concern. Substantial doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock and we may have a more difficult time obtaining financing. Further, the perception that we may be unable to continue as a going concern may impede our ability to raise additional funds or operate our business due to concerns regarding our ability to discharge our contractual obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for, our product candidates and advance our other programs. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Other unanticipated costs may also arise. Because the design and outcome of our ongoing and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and commercialization of any product candidate we develop. Moreover, we will need to obtain substantial additional funding in connection with our continuing operations and planned research and clinical development activities. Our future capital requirements will depend on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, progress, costs and results of our ongoing preclinical studies and clinical trials of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of other product candidates that we may pursue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish collaborations on favorable terms, if at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, reimbursement and distribution, for any of our product candidates for which we may receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we may receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of any milestone and royalty payments with respect to any approved product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may never generate the necessary data or results required to obtain regulatory approval in order to generate revenue from product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions, including as a result of increases in inflation and interest rates, disruptions to, and volatility in, the credit and financial markets in the United States and worldwide, tariffs and trade wars, public health crises or geopolitical tensions, such as wars and terrorism and future U.S. government shutdowns. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce, or explore other strategic options for our research and development programs or other opportunities, or even terminate our operations. If we do not obtain additional financing and are required to terminate our operations, our stockholders will lose all or a part of their investment.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we will need to finance our cash needs through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. We do not have any committed external source of funds. To the extent that we raise additional capital, if available, through the sale of equity or convertible debt securities, including through our ATM program, your ownership interest in our company may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. For example, in recent years we have issued a substantial number of shares of common stock and warrants to purchase shares of common stock to raise additional capital, including most recently our sale and issuance of 5,127,029 shares of common stock and pre-funded warrants to purchase up to 9,452,677 shares of common stock in a private placement in December 2025. In addition, we may also be eligible to receive up to approximately $20.1 million in additional gross proceeds in exchange for up to 14,579,706 shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to the achievement of certain milestone-driven conditions related to preclinical data for our CD19 targeting INB-619 product candidate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us, if at all. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or explore other strategic options for our product candidate development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time, including as a result of exercises of the outstanding warrants. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options, or the perception that such sales may occur, could adversely affect the market price of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our outstanding warrants may not be exercised and we may not receive any cash proceeds from any exercise of warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026, we had 9,620,002 pre-funded warrants, 166,964 Series B warrants, and 828,863 Series C warrants outstanding. Of these, 9,452,677 pre-funded warrants have an exercise price of $0.0001 per share and 167,325 pre-funded warrants have an exercise price of $0.003 per share. The Series B warrants have an exercise price of $13.50 per share and will expire on December 13, 2028. The Series C warrants have an exercise price of $8.10 per share and will expire on October 4, 2027.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may receive up to an aggregate of $9.0 million from the exercise of the Series B and Series C warrants, assuming the exercise in full of all of the warrants for cash. However, we will only receive proceeds to the extent the holders of warrants elect to exercise. We can provide no assurances as to the amount of proceeds we will receive from the exercise of warrants or whether we will receive any proceeds at all. Additionally, the warrants may, in certain circumstances, be exercised by way of cashless exercise, meaning that the holder may not pay a cash purchase price upon exercise, but instead would receive upon such exercise the net number of shares of our common stock determined according to the formula set forth in the applicable warrant. Accordingly, we may not receive any additional funds, or any significant additional funds, upon any exercise of the warrants.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses since inception. Our net loss was $9.9 million and $10.6 million for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, we had an accumulated deficit of $151.0 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Since inception, we have devoted substantially all of our efforts to research and preclinical and clinical development of our product candidates, organizing and staffing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our company, business planning, raising capital, establishing our intellectual property portfolio and conducting clinical trials. To date, we have never obtained regulatory approval for, or commercialized, any product candidates. It could be several years, if ever, before we have a commercialized product. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as, we:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conduct our current and future clinical trials for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to develop and advance our preclinical product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory and marketing approvals for any of our current and future product candidates that successfully complete clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish our manufacturing capability, including developing our contract development and manufacturing relationships, and building our internal manufacturing facilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our operational, financial, and management systems and increase personnel, including personnel to support our preclinical and clinical development, manufacturing and commercialization efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing and distribution infrastructure in the future to commercialize any current or future product candidate for which we may obtain marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to identify, discover, develop and commercialize additional product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our current and future product candidates, obtaining regulatory approval, establishing and validating commercial-scale current good manufacturing practices ("cGMP") facilities, marketing and selling any products for which we obtain regulatory approval (including through third parties), as well as discovering or acquiring and developing additional product candidates. We are only in the preliminary stages of some of these activities. As inflation expectations remain uncertain in the United States and globally, we expect the costs of certain activities will increase. Should suppliers and consultants increase prices to cover increased wages and materials costs, we expect our expenses and cash utilization could increase substantially. We may never succeed in these activities and, even if we do, may never generate revenues that are sufficient to offset our expenses and achieve profitability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product candidate development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform clinical trials or preclinical studies in addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our common stock could also cause you to lose all or part of your investment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to raise capital may be limited by applicable laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Using a shelf registration statement on Form S-3 to raise additional capital generally takes less time and is less expensive than other means, such as conducting an offering under a Form S-1 registration statement. However, our ability to raise capital using a shelf registration statement may be limited by, among other things, SEC rules and regulations. Under SEC rules and regulations, if our public float (the market value of our common stock held by non-affiliates) is less than $75.0 million, then the aggregate market value of securities sold by us or on our behalf under our Form S-3 in any 12-month period is limited to an aggregate of one-third of our public float. As our public float is currently less than $75.0 million, we are currently subject to this limitation. If our ability to utilize a Form S-3 registration statement for a primary offering of our securities continues to be limited to one-third of our public float, we may need to conduct such an offering pursuant to an exemption from registration under the Securities Act or under a Form S-1 registration statement, which would increase the cost of raising additional capital relative to utilizing a Form S-3 registration statement.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an early clinical-stage biotechnology company with a limited operating history upon which you can evaluate our business and prospects. Our operations to date have been limited to financing and staffing our company, developing our technology, identifying and developing our product candidates, undertaking preclinical studies, initiating and conducting clinical trials for INB-400, INB-200 and INB-100, business planning and raising capital. Other than INB-400, INB-200 and INB-100, all of our ongoing research programs are still in the preclinical or research stage of development, and the risk of failure in the biopharmaceutical industry for programs or products candidates at such stage of development is even higher than those in the clinical stage of development. We have not yet demonstrated an ability to successfully conduct or complete any clinical trials, including large-scale, multi-center pivotal clinical trials, obtain marketing approval, manufacture a clinical or commercial scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Typically, it takes about six to ten years to develop a new drug from the time it enters Phase 1 clinical trials to when it is approved for treating patients, but in many cases it may take longer. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing genetic medicine product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will eventually need to transition from a company with a research and clinical focus to a company, if any of our product candidates are approved, capable of supporting commercial activities. We may not be successful in such a transition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Development of Our Product Candidates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent on the successful clinical development, regulatory approval and commercialization of our gamma-delta T cell product candidates. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is dependent on our ability to successfully complete development of, obtain regulatory approval for, and, if approved, successfully commercialize our product candidates in a timely manner. We may face unforeseen challenges in our product candidate development strategy, and we can provide no assurances that our product candidate or clinical trial design will prove to be effective, that we will be able to take advantage of abbreviated regulatory pathways for any of our product candidates, or that we will ultimately be successful in our future clinical trials. We expect that a substantial portion of our efforts and expenses over the next several years will be devoted to the development of our lead product candidates, in ongoing clinical trials. Our product candidates are in early stages of development and may never be commercialized. Additionally, we announced in September 2024 that we have suspended patient enrollment in the INB-400 Phase 2 clinical trial for newly diagnosed GBM while we explore additional funding, potential regulatory pathways and/or partnership opportunities, if any, for the program. We would require substantial additional funds to recommence and advance this trial through data and BLA submission.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently anticipate seeking initial regulatory approvals in the United States and the European Union but may in the future submit applications for the regulatory approval of one or more of our product candidates to additional foreign regulatory authorities. We have not applied or obtained regulatory approval for any product candidate in the United States or abroad, and it is possible that neither our current product candidates nor any product candidates we may seek to develop in the future will obtain regulatory approval. Neither we nor any of our partners are permitted to market any of our product candidates in the United States or abroad until we receive regulatory approval from the FDA or the applicable foreign regulatory agency.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our product candidates will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before they can be successfully commercialized. Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidate is safe and effective for its intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies, assay development or clinical trials for our product candidates either pre- or post-approval, or it may object to elements of our clinical development program, requiring their alteration. We may also decide to modify clinical protocols or procedures in future clinical trials based on clinical and experimental data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the large number of products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory authorities&#8217; approval processes and are commercialized. The lengthy approval or marketing authorization process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval or marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates could fail to receive regulatory approval from the FDA or a comparable foreign regulatory authority for many reasons, including, among others:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreement with the design or conduct of any of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to demonstrate to the satisfaction of regulatory agencies that our product candidates are safe and effective, or have a positive benefit/risk profile for its proposed indication;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of clinical trials to meet the level of statistical significance required for approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreement with our interpretation of data from preclinical studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a Biologics License Application ("BLA") or other submission or to obtain regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to obtain approval of our manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies or our own manufacturing facility; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, any delay in, or termination of, our clinical trials will delay the submission of a BLA to the FDA or other similar applications with other relevant foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates, if approved, and generate product revenue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we eventually complete clinical testing and receive approval of a BLA, or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve or authorize for marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because all of our product candidates are based on the same core gamma-delta T cell technology, if any of our product candidates encounter safety or efficacy problems, developmental delays or regulatory issues or other problems including the failure to demonstrate comparability or equivalence, these could impact the development plans for our other product candidates. Our failure to timely complete clinical trials, obtain regulatory approval or, if approved, commercialize our product candidates could adversely affect our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates are in early stages of development, and therefore they will require extensive additional preclinical and clinical testing. Success in preclinical studies or early-stage clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because our product candidates are in early stages of development, they will require extensive preclinical and clinical testing. INB-100 is our only product candidate currently in active clinical trials. While the IND remains open, in September 2024, we announced that we have suspended patient enrollment in the INB-400 Phase 2 clinical trial for newly diagnosed GBM while we explore additional funding, potential regulatory pathways and/or partnership opportunities for the program, if any. Success in preclinical testing and early-stage clinical trials does not ensure that later clinical trials and/or product candidate will generate the same results or otherwise provide adequate data to demonstrate the efficacy, safety and equivalency of a product candidate. Preclinical studies and Phase 1 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical studies and earlier clinical trials does not ensure that later efficacy trials will be successful, nor does it predict final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or even if they successfully advance through earlier clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, although we have undertaken Phase 1 clinical trials for INB-200 and INB-100, and have determined the recommended RP2D for the Phase 2 trial of INB-100, the FDA has not yet made any determination regarding safety and efficacy of either product candidate in the targeted indications. Further, our novel approaches to immune cell therapies are unproven and as such, the cost and time needed to develop our product candidates is difficult to predict and our efforts may not be successful. If we do not observe favorable results in clinical trials of our product candidates, we may decide to delay or abandon clinical development of such product candidate. Any such delay or abandonment could harm our business, financial condition, results of operations and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks, including failure in late-stage clinical trials even after achieving promising results in preclinical testing and earlier clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we cannot predict with any certainty if or when we might submit a BLA for regulatory approval for any of our product candidates or whether any such BLA will be accepted for review by the FDA, or whether any BLA will be approved upon review. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our proposed indications. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for their proposed uses. This failure could cause us to abandon a product candidate and may delay development of other product candidates. Any delay in, or termination of, our clinical trials will delay and possibly preclude the filing of any BLAs with the FDA and, ultimately, our ability to commercialize our product candidates and generate product revenues.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our gamma-delta T cell engager program ("&#947;&#948; TCE"), INB-600, INB-633 and INB-619, currently in preclinical development, are subject to significant risks and uncertainties that could materially impact development of this platform and impact our results, timelines, financing or business objectives. The development is early and preclinical and the work to bring a TCE through IND-enabling development and into clinical development encompasses many critical processes including cloning into optimized GMP compliant vector and cell systems, scale-up, generation of transient or stable cell lines for production, GMP manufacturing and large-scale production. These processes present complex scientific and technical challenges and are subject to numerous risks and uncertainties, including the risk that the T cell engager&#8217;s properties, such as the stimulatory/expansion domain, binding affinity or specificity, or targeting domains may not function as anticipated when transitioning from preclinical systems to a larger-scale production system. Additionally, achieving sufficient purity during the manufacturing scale up and purification process to meet stringent regulatory standards for clinical trials poses a significant risk, as difficulties in removing impurities or ensuring product stability could lead to manufacturing delays or failures. Furthermore, in IND-enabling animal models, there is a risk that the T cell engager may not demonstrate the anticipated efficacy or may exhibit toxicity not previously identified in in vitro testing, potentially due to differences in biological systems or unforeseen off-target effects. Advancing to clinical trials introduces additional uncertainties, including challenges in obtaining regulatory approvals, potential safety or efficacy issues, difficulties in patient recruitment, and the complexities of trial execution. Failure to successfully address these risks could delay or prevent the progression of our T cell engager into clinical development.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, "topline" and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publish interim, "topline" or preliminary data from our clinical trials. Interim, "topline" or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim, "topline" and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, "topline," and preliminary data should be viewed with caution until the final data are available. Differences between interim, "topline" and preliminary data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our business in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, "topline," or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our DeltEx product candidates utilize novel approaches to cell therapies, including cancer treatment, which presents significant challenges to successfully develop, manufacture and commercialize our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our product candidates represent a novel approach to immunotherapy, including cancer treatment, and we have concentrated significant research and development efforts to date developing our INB-100, INB-200 and INB-400 product candidates, as well as our additional drug-resistant immunotherapy ("DRI") gamma-delta T cell and gamma-delta T cell engager preclinical product candidates. Gamma-delta T cell immunotherapy is a newly emerging field and our approaches, including genetic modification and DeltEx DRI gamma-delta T cells, have not been extensively tested over any significant period. We have not yet succeeded and may never succeed in demonstrating efficacy and safety for any of our product candidates in clinical trials or in obtaining marketing approval thereafter.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, INB-100, our novel allogeneic gamma-delta T cell product candidate that we are initially developing for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation, is manufactured from healthy donor T cells using our proprietary manufacturing process. Allogeneic versions of cell therapy and gamma-delta T cell product candidates is an unproven field of development and is subject to particular risks that are difficult to quantify, including understanding and addressing variability in the quality and quantity of a donor&#8217;s T cells and the patient&#8217;s potential immune reaction to the foreign donor cells, which could ultimately affect safety, efficacy and our ability to produce product in a reliable and consistent manner. As such, we may be faced with unforeseen results, delays and setbacks, in addition to the other foreseeable risks and uncertainties associated with developing immune cell therapies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we are the first company to advance a genetically modified gamma-delta T cell product candidate, INB-200, which we are currently developing for the treatment of certain solid tumors, into the clinic. The manufacture of our cell therapies involves complex processes, including, for INB-100, where blood cells are isolated from an allogeneic donor via leukapheresis, gamma-delta T cells are expanded and activated, and other cells are removed through magnetic separation and then cryopreserved. For INB-200, blood cells are isolated from the patient via leukapheresis, the gamma-delta T cells are transduced, expanded and activated, and, if required, other cells are removed through magnetic separation prior to cryopreservation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any delay or difficulties in manufacturing lentiviral vector and/or clinical supply of INB-100, INB-200 and INB-400 or any of our other current or future product candidates would adversely affect our business and operations. For additional details surrounding risks related to our manufacturing processes, see the risks highlighted in "Risks Related to Manufacturing and our Dependence on Third Parties," including "Our manufacturing processes are complex and we may encounter difficulties in production, which would delay or prevent our ability to provide a sufficient supply of our product candidates for future clinical trials or commercialization, if approved."</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advancing product candidates utilizing such novel approaches to immunotherapy creates significant challenges for us, including, among others:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing our product candidate to our specifications and in a timely manner to support our clinical trials, and, if approved, commercialization;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sourcing clinical and, if approved, commercial supplies for the raw materials used to manufacture our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">understanding and addressing variability in the quality of a donor and/or patient&#8217;s T cells, which could ultimately affect our ability to produce our product candidates in a reliable and consistent manner;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conditioning patients with chemotherapy or other lymphodepletion agents in advance of administering our product candidates, which may increase the risk of adverse side effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">educating medical personnel regarding how to properly isolate cells, perform apheresis, administer our cells and the potential side effect profile of our product candidates, such as cytokine release syndrome, neurotoxicity, tumor inflammation-associated neurotoxicities, graft versus host disease, prolonged cytopenia, infections, hygromas and neutropenic sepsis, among others;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enrolling sufficient numbers of patients in clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">training a sufficient number of technicians in how to properly manufacture our cells;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing a reliable, safe, effective and cost-effective means of consistently expanding and manufacturing our cells;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">understanding and addressing variability in demand for manufacturing and its impact on capacity utilization of available infrastructure and costs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing a reliable, safe and effective means of genetically modifying our cells;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submitting applications for and obtaining regulatory approval, as the FDA and other regulatory authorities have limited experience with commercial development of immunotherapies for cancer and viral associated infectious diseases; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales and marketing capabilities, as well as developing a manufacturing process and distribution network to support the commercialization of any approved products.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We must be able to overcome these challenges in order for us to successfully develop, commercialize and manufacture our product candidates utilizing our novel approaches to gamma-delta T cell therapies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The clinical and commercial utility of our DeltEx platform is uncertain and may never be realized. Additionally, certain aspects of the function and production of gamma-delta T cells are poorly understood or currently unknown and may only become known through further preclinical and clinical testing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, gamma-delta T cells have only been evaluated in early clinical trials. These clinical trials were primarily designed to evaluate safety and tolerability, and not designed to produce statistically significant results as to efficacy. Most of the data to date regarding gamma-delta T cells were derived from clinical trials not conducted by us, including physician-sponsored clinical trials, and utilizing gamma-delta T cells not manufactured by us. We currently have two ongoing clinical trials to evaluate gamma-delta T cells in investigator-sponsored clinical trials, which have enrolled and dosed only a limited number of patients to date. Success in early clinical trials does not ensure that large-scale clinical trials will be successful, nor does it predict final results. Even after the completion of our ongoing Phase 1 clinical trials, our gamma-delta T cell product candidates will have only been tested in a small number of patients. Results from these clinical trials may not necessarily be indicative of the safety and tolerability or efficacy of our product candidates as we expand into larger clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not ultimately be able to provide the FDA with substantial clinical evidence to support a claim of safety, efficacy, equivalency, purity and potency sufficient to enable the FDA to approve our DeltEx platform product candidates for any indication. This may be because early clinical trials do not meet their endpoints, because later clinical trials fail to reproduce favorable data obtained in earlier clinical trials, because the results of such trials are not statistically significant, because the FDA disagrees with how we interpret the data from these clinical trials, or because the FDA does not accept these therapeutic effects as valid endpoints in pivotal clinical trials necessary for market approval. For example, we are developing INB-100 for the treatment of patients undergoing hematopoietic stem cell transplantation for the treatment of AML, and our manufacturing processes are predominantly based on cells received from healthy haploidentical related donors with at least half of the major human leukocyte antigen ("HLA") types matched. Our clinical development plan for INB-100 will seek to determine the safety of HLA mismatched, donor-derived gamma-delta T cells and establish the risk of graft versus host disease ("GvHD") if any. While mismatched gamma-delta T cells are not known to initiate GvHD, we observed grade 1 and/or 2 GvHD in approximately 60% of patients treated with INB-100 as of January 17, 2025. We will also seek to better understand the persistence of mismatched gamma-delta T cells and their potential impact on immune reconstitution, clinical activity and duration of response. The grade 1/2 GvHD that we have observed has been responsive to steroid treatment, and we believe that a high degree of HLA matching will not be required to prevent or reduce the risks of GvHD or for clinically meaningful activity and durability of response. Competitor data presented at ASCO 2024 demonstrated that persistence of donor derived cells are correlated with levels of HLA matching and they are now advancing their programs to be haploidentical matched as we have in our INB-100 program. If it becomes apparent through preclinical testing or additional clinical trials that such HLA matching is always required, a future "off-the-shelf" product may not be attainable, which could prevent or delay the further advancement of "off-the-shelf" product candidates and adversely affect our business and future development plans. We will also need to demonstrate that our DeltEx platform product candidates are safe. Unexpected adverse events reported by ourselves or competitors can negatively impact the market and perception of the viability of cellular therapies broadly. In recent years a newly defined severe adverse event termed tumor inflammation-associated neurotoxicity ("TIAN") has been identified that can lead to severe neurological adverse events leading to patient death. While we have not identified or observed such toxicities in our clinical trials to date, unexpected adverse events can present significant risks. We do not have data on possible harmful long-term effects of our DeltEx platform product candidates and do not expect to have this data in the near future. As a result, our ability to generate clinical safety and efficacy data sufficient to support submission of a marketing application or commercialization of our DeltEx platform product candidates is uncertain and is subject to significant risk.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved by applicable regulatory authorities, of physicians to subscribe to the novel treatment mechanics. The FDA or other applicable regulatory authorities may impose specific post-market requirements, such as establishment of a Risk Evaluation and Mitigation Strategy ("REMS") and request additional information informing benefits or risks of our products may emerge at any time prior to or after regulatory approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Physicians, hospitals and third-party payors are often slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical product candidate development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and encounter substantial delays or difficulties in our clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not commercialize, market, promote or sell any product candidate without obtaining marketing approval from the FDA or other comparable regulatory authority, and we may never receive such approvals. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Additionally, our ongoing trials for INB-100 and INB-200 involve studying a relatively small patient population, which makes it difficult to predict whether the favorable results observed in such clinical trial will be repeated in larger and more advanced clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience numerous unforeseen events prior to, during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including the following (among other unforeseen events included in this "&#8212;Risks Related to the Development of our Product Candidates" subsection):</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching a consensus with regulatory authorities on the design, location or implementation of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or setbacks in patient enrollment;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials for our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or may be lower than we anticipate due to challenges in recruiting and enrolling suitable patients that meet the study criteria, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials may be longer than we anticipate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of future public health crises, which may slow potential enrollment, impact hospital clinical and/or administrative support staff, reduce the number of eligible patients for clinical trials, or reduce the number of patients that remain in our trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a clinical hold by regulatory authorities as a result of, among other reasons, a serious adverse event, a failure in the chemistry manufacturing and controls requirements, or a failed inspection of our clinical trial operations, trial sites or manufacturing facilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">need to conduct additional clinical trials or abandon product development programs.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future product sales or other sources. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring competing products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the clinical trial requirements of the FDA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for product candidates such as ours can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene regulation technology in a timely manner or under technically or commercially feasible conditions. Regulatory action or private litigation could result in expenses, delays or other impediments to our research programs or the commercialization of resulting products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may be delayed in obtaining marketing approval, or not obtain marketing approval at all, obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, and/or have regulatory authorities withdraw or suspend their approval or impose restrictions on distribution in the form of a modified REMS, among other results. We could also</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the FDA or an independent institutional review board ("IRB") may also suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#8217;s current Good Clinical Practice ("GCP") regulations, that we are exposing participants to unacceptable health risks, or if the FDA finds deficiencies in our INDs or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenues from our product candidates may be delayed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Development of a product candidate intended for use in combination with an already approved therapy may present increased complexity and more or different challenges than development of a product candidate for use as a single agent or monotherapy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing certain of our product candidates, including INB-400 and INB-200, to be used in combination with approved therapies, such as chemotherapy, which may present additional challenges. For example, the FDA may require us to use more complex clinical trial designs, to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of these trials could show that most or any positive results are attributable to the already approved product. Moreover, following product approval, the FDA may require that products used in conjunction with each other be cross labeled. To the extent that we do not have rights to already approved products, this may require us to work with another company to satisfy such a requirement. Moreover, developments related to the already approved therapies may impact our clinical trials for the combination as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the approved therapy&#8217;s safety or efficacy profile, changes to the availability of the approved therapy, and changes to the standard-of-care.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timely completion of clinical trials in part depends on patient enrollment, and as such identifying and qualifying patients to participate in our clinical trials is critical to our success. We may encounter difficulties in enrolling a sufficient number of eligible patients to participate in our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Because our focus includes rare disorders, there are limited patient pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner. Additionally, some of the initial indications for which we are developing our current product candidates, including glioblastoma and AML, primarily affect an elderly population over the age of 65, who might suffer from other age-related and unknown and/or pre-existing ailments or health concerns. If any such patient enrolled in our smaller-scale Phase 1 trials has to drop out due to pre-existing health issues or due to a serious adverse effect, or otherwise dies, and we are not able to recruit additional patients in a timely manner, or at all, our clinical trials could be delayed or otherwise halted. As such, despite diligent planning of our clinical trials and analysis of their feasibility regarding patient recruitment, we may experience difficulties, delays or inability in patient enrollment in our clinical trials for a variety of reasons, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity and incidence of the disease under investigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial and the complexity for patients and clinical sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the general health condition of the patient and their gamma-delta T cells and immune cells broadly;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients&#8217; general health conditions do not allow the conduct of study/screening procedures (such as leukapheresis) the manufacture of therapeutic product or application of the appropriate standard-of-care treatment or application of the Stupp regimen;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to consistently manufacture gamma-delta T cell product candidates in sufficient quantities at sufficient activity and/or transduction efficiency to provide a suitable therapeutic dose of gamma-delta T cells;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competing clinical trials for similar therapies, other new therapeutics, new combination treatments, new medicinal products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved or become standard-of-care for the indications we are investigating;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differences in clinician treatment practices and/or protocols from center to center;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to obtain and maintain patient consents due to various reasons, including but not limited to, patients&#8217; unwillingness to participate due to public health crises;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that enrolled subjects will drop out, develop complications or die before completion of the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to develop and provide appropriate screening, product characterization and release assays;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients failing to complete a clinical trial or returning for post-treatment follow-up;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to manufacture the requisite materials for a patient and clinical trial; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability of clinical sites to enroll patients as health care capacities are required to cope with natural disasters, epidemics or other health system emergencies.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. Any negative results we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible. In addition, we may rely on clinical research organizations ("CROs") and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to ensure their actual performance.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur. Many times, side effects are only detectable after investigational drugs are tested in large-scale pivotal trials or, in some cases, after they are made available to patients on a commercial scale after approval. For example, in January 2024, FDA required approved CAR-T products to add boxed warning information to their labeling concerning the risk of developing secondary T cell malignancies. If additional clinical experience indicates that any of our product candidates or the use of lentiviral vectors have side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesirable side effects caused by our product candidates, implanted devices, gene-editing methods, delivery methods or dosage levels could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. As a result of safety or toxicity issues that we may experience in our clinical trials, we may be placed on clinical hold and not receive approval to market any product candidates, which could prevent us from ever generating revenues or achieving profitability. Results of our trials could reveal an unacceptably high severity and incidence of side effects, or side effects outweighing the benefits of our product candidates. In such an event, our studies could be delayed, suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have only tested INB-100, INB-200 and INB-400 in a limited number of patients with cancer and these clinical trial participants have only been observed for a limited period of time after dosing at a limited number of sites. To date, our clinical trials have been run at academic/tertiary care centers. As we continue developing our lead product candidates and initiate multi-center clinical trials of our product candidates, including potentially at community hospitals, SAEs, undesirable or potentially fatal side effects, cytokine release syndrome, viral or bacterial infections, relapse of disease or unexpected characteristics may emerge causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, and inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Should we observe SAEs in our clinical trials or identify undesirable side effects or other unexpected findings, our trials could be delayed or even terminated, and our development programs may be halted entirely.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop alone or with collaborators.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved by applicable regulatory authorities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to file IND applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have previously announced our goals for potentially submitting additional INDs for INB-100, INB-400 and INB-619. We have suspended enrollment for INB-400 as we explore additional funding, potential regulatory pathways and/or partnership partnerships for this program. We may not be able to make additional filings on the timelines we expect, which may cause delays in commencing additional clinical trials. Even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future. Moreover, we cannot be sure that submission of an IND for any of our other product candidates will result in the FDA allowing trials to begin, or that, once begun, issues will not arise that result in a decision by us, by IRBs, or independent ethics committees, or by the FDA or other regulatory authorities to suspend or terminate clinical trials. For example, we may experience manufacturing delays or other delays with IND-enabling studies or the FDA or other regulatory authorities may require additional preclinical studies that we did not anticipate. Moreover, we cannot be assured that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that result in a decision by us, by IRBs, or independent ethics committees or by the FDA or other regulatory authorities to suspend or terminate clinical trials, including as a result of a clinical hold. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future. The inability to initiate clinical trials any of our product candidates on the timeline currently anticipated or at all could have a material adverse effect on our business, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek Breakthrough Therapy, RMAT or Fast Track designations and may pursue accelerated approval for some or all of our current product candidates, but we may be unable to obtain such designations or, where obtained, we may be unable to maintain Breakthrough Therapy or RMAT designation or obtain or maintain the benefits associated with such designations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek Breakthrough Therapy, RMAT or Fast Track designations and may pursue accelerated approval for INB-100, INB-200, INB-400 and some or all of our other and future product candidates. Breakthrough Therapy designation is intended to expedite the development and review of products that treat serious or life-threatening diseases when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a product candidate as a Breakthrough Therapy provides potential benefits that include intensive guidance on an efficient drug development program, beginning as early as Phase 1, organizational commitment involving senior managers; and eligibility for rolling review and priority review. Breakthrough Therapy designation does not change the standards for product approval. There can be no assurance that we will receive Breakthrough Therapy designation for any product candidate or any particular indication.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also seek Fast Track designation. If a drug or biologic candidate is intended for the treatment of a serious or life-threatening condition or disease and the drug demonstrates the potential to address unmet medical needs for the condition, the sponsor may apply for Fast Track designation. Even if we do apply for and receive Fast Track designation, we may not experience a faster development, review or approval process compared to conventional FDA procedures. The FDA may rescind Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we may also seek accelerated approval under the FDA&#8217;s accelerated approval programs. The FDA may approve a drug or biologic for a serious or life-threatening disease or condition that generally provides meaningful advantages over available treatments and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seeking and obtaining these designations is dependent upon results of our clinical program, and we cannot guarantee whether and when we may have the data from our clinical programs to support an application to obtain any such designation. The FDA and comparable foreign regulatory agencies have broad discretion whether or not to grant any of these or similar designations, so even if we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">believe a particular product candidate is eligible for one or more of these designations, we cannot assure you that the applicable regulatory authority would decide to grant it. Even if we do receive the designations we may apply for, we may not experience a faster development process, review or approval compared to conventional procedures, as applicable. The FDA or other regulatory agencies may also rescind any granted designations if it believes that the designation is no longer supported by data from our clinical development program.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Although we have received orphan drug designation for INB-400 in the past and may continue to seek orphan drug designation for some or all of our current or future product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for supplemental market exclusivity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2023, we received orphan drug designation for the autologous and allogeneic IND-400 product candidate, covering a broad range of malignant glioma treatments, including newly diagnosed glioblastoma. We may continue to seek orphan drug designation for one or more of our current or future product candidates, including INB-100 or its successor. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. After the FDA grants orphan drug designation, the identity of the biologic and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the particular active ingredient in the product treating the disease for which it has such orphan drug designation, that product is entitled to orphan product exclusivity. This means that the FDA may not approve any other applications, including a BLA, to market the same product for the same indication for seven years. However, that exclusivity may be nullified in limited circumstances in which another product shows clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other products that have a different active ingredient for use in treating the same indication or disease. Further, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek orphan drug designation for INB-100 and some or all of our other or future product candidates in additional orphan indications in which there is a medically plausible basis for the use of these product candidates. Even when we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we, through our manufacturer, are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, although we intend to seek orphan drug designation for other product candidates, we may never receive these designations. For example, the FDA has expressed concerns regarding the regulatory considerations for orphan drug designation as applied to tissue agnostic therapies, and the FDA may interpret the Federal Food, Drug and Cosmetic Act, and regulations promulgated thereunder, in a way that limits or blocks our ability to obtain orphan drug designation or orphan drug exclusivity, if our product candidates are approved, for our targeted indications.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to identify or discover other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our efforts to identify and develop, additional product candidates will require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. We may also broaden the reach of our DeltEx platform by selectively in-licensing technologies or product candidates. Our efforts may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development, approved products or commercial revenues for many reasons, including the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the methodology used may not be successful in identifying potential product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competitors may develop alternatives that render any product candidates we develop obsolete;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may demonstrate harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may not be accepted as safe and effective by physicians, patients, the medical community or third-party payors.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited financial and management resources and, as a result, we may forego or delay pursuit of opportunities with other product candidates or other indications that later prove to have greater market potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products, including attractive or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. In addition, we may not be successful in replicating our approach to product candidate development for other disease indications. If we are unsuccessful in identifying and developing additional product candidates or are unable to do so, our business may be harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public opinion and scrutiny of our competitors, cell-based immunotherapy, T cell engagers, and genetic modification approaches may impact public perception of our company and product candidates, or may adversely affect our ability to raise capital, conduct our business and our business plans.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our DeltEx platform utilizes a relatively novel technology involving the genetic modification of human cells and utilization of those modified cells in other individuals, and our TCE program involves engineering antibodies that bind on T cells and a tumor-associated antigen on cancer cells. Public perception may be influenced by negative claims about our DeltEx platform or T cell engagers, or that of competitor's products and/or programs such as claims that gamma-delta T cell and/or other cell-based immunotherapy is unsafe, unethical, inefficacious, expensive or immoral and, consequently, our approach may not gain the acceptance of the public or the medical community. Negative public reaction to cell-based immunotherapy in general and a recent increase in patient deaths and clinical holds by other companies could result in greater government regulation and stricter labeling requirements of cell-based immunotherapy products, including any of our product candidates, and could cause a decrease in the demand for any products we may develop. Negative public attitudes may adversely impact our ability to enroll patients in clinical trials. Moreover, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target, and their patients being willing to receive, treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. More restrictive government regulations or negative public opinion could have an adverse effect on our business, ability to raise additional capital and/or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition, and many of our competitors have substantially greater experience and resources than we have.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical and commercial landscape in the indications we are targeting, as well as in the field of immuno-oncology, is highly competitive. We may face potential competition with respect to our current product candidates and may face competition with respect to any other product candidates that we may seek to develop or commercialize in the future from pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research institutions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our current or potential competitors have greater financial and other resources, larger research and development staffs, and more experienced capabilities in researching, developing and testing products than we do. Many of these companies also have more experience in conducting clinical trials, obtaining FDA and other regulatory approvals, and manufacturing, marketing and distributing therapeutic products. Smaller or clinical-stage companies like us may successfully compete by establishing collaborative relationships with larger pharmaceutical companies or academic institutions. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of cancer and other diseases, which could give such products significant regulatory and market timing advantages over any of our product candidates. In addition, large pharmaceutical companies or other companies with greater resources or experience than us may choose to forgo therapy opportunities that would have otherwise been complementary to our product development and collaboration plans. Our competitors may succeed in developing, obtaining patent protection for, or commercializing their products more rapidly than us, which could result in our competitors establishing a strong market position before we are able to enter the market. A competing company developing or acquiring rights to a more effective therapeutic product for the same diseases targeted by us, or one that offers significantly lower costs of treatment could render our products noncompetitive or obsolete. We may not be successful in marketing any product candidates we may develop against competitors.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect the product candidates we develop will be regulated as biologics, and therefore they may be subject to competition sooner than anticipated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009 ("BPCIA") was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as "interchangeable" based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the approval of a biologic product biosimilar to one of our products could have a material adverse impact on our business as it may be significantly less costly to bring to market and may be priced significantly lower than our products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Manufacturing and Our Dependence on Third Parties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our manufacturing processes are complex, and we may encounter difficulties in production, which would delay or prevent our ability to provide a sufficient supply of our product candidates for future clinical trials or commercialization, if approved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our product candidates, including INB-200 and INB-300, as well as our INB-400 program, are genetically engineered human cells, and the process of manufacturing such product candidates, as well as the lentiviral vectors, is complex, highly regulated, variable and subject to numerous risks. Manufacturing our product candidates involves harvesting cells from a donor, isolating cells via leukapheresis, activating and expanding the gamma-delta T cells, cryopreservation, testing, storage and eventually shipment and infusion of the cell product into the patient&#8217;s body.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our manufacturing processes will be susceptible to product loss or failure, or product variation that may negatively impact patient outcomes, due to process and logistical issues associated with the collection of starting material from the donor, shipping such material to the manufacturing site, shipping the final product back to the recipient, preparing the product for administration, infusing the patient with the product, manufacturing issues or different product characteristics resulting from the inherent differences in donor starting materials, variations between reagent lots, interruptions in the manufacturing process, contamination, equipment or reagent failure, improper installation or operation of equipment and/or programs, vendor or operator error, inconsistency in cell growth and variability in product characteristics.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even minor variations in starting reagents and materials, or deviations from normal manufacturing processes could result in reduced production yields, product defects, manufacturing failure and other supply disruptions. If, for any reason in our clinical trials, we lose the starting material for a manufactured product for one of our patients at any point in the process, or the expansion or transduction procedures in the manufacturing process should fail for any reason, such patient would no longer receive a dose of the therapy and may end participation in our clinical trial. For instance, operator errors impacting machine function, gas or airflow, or reagent addition can negatively impact the process. Manufacturing by a previously contracted facility has resulted in such operator errors; however, we identified these errors through our quality control procedures prior to patient administration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If microbial, viral or other contaminations are discovered in our product candidates or in any of the manufacturing facilities in which products or other materials are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We will be required to maintain a chain of identity with respect to materials as they move from the donor to the manufacturing facility, through the manufacturing process and back to the clinical trial recipient. Maintaining a chain of identity is difficult and complex, and failure to do so could result in adverse patient outcomes, loss of product or regulatory action, including withdrawal of our products from the market, if licensed. Any failure in the foregoing processes could render a batch of product unusable, could affect the regulatory approval of such product candidate, could cause us to incur fines or penalties or could harm our reputation and that of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may make changes to our manufacturing processes for various reasons, such as to control costs, increase yield or dose, achieve commercial scale, decrease processing time, increase manufacturing success rate or for other reasons. We previously relocated clinical trial manufacturing for one of our clinical development programs to an academic GMP facility closer to our laboratory headquarters in Birmingham, Alabama to permit us contractual direct access as a means of preventing manufacturing errors. However, even with this contractual direct access and closer collaboration with the facility&#8217;s manufacturing staff, there can be no guarantee that manufacturing errors will not occur.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes to our process made during the course of clinical development could require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial. Other changes to our manufacturing processes made before or after commercialization could require us to show the comparability of the resulting product to the product candidate used in the clinical trials using earlier processes. Such showings could require us to collect additional nonclinical or clinical data from any modified process prior to obtaining marketing approval for the product candidate produced with such modified process. If such data are not ultimately comparable to that seen in the earlier trials or earlier in the same trial in terms of safety or efficacy, we may be required to make further changes to our process and/or undertake additional clinical testing, either of which could significantly delay the clinical development or commercialization of the associated product candidate, which would materially adversely affect our business, financial condition, results of operations and growth prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may rely on third-party contractors or contract development manufacturing organization for the manufacturing of our product candidates, and failure by those parties to adequately perform their obligations could harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we endeavor to build and operate a manufacturing facility in the future, we do not currently own any facility that may be used as our clinical or commercial-scale manufacturing and processing facility and expect that we will rely on outside vendors for at least a portion of the manufacturing of our cell therapy product candidates that we develop. The facilities used by our partners and contract manufacturers must be submitted and disclosed to the FDA or other foreign regulatory agencies and may be selected for inspection or audit following the submission of an application to the FDA or other foreign regulatory agencies. To the extent that we engage third parties for manufacturing services, we will not control the manufacturing process of, and will be completely dependent on, our contract manufacturing partners for compliance with confidentiality agreements and the cGMP requirements for the manufacture of our product candidates. We have not yet had any product candidates to be manufactured or processed on a commercial scale and may not be able to do so. We will make changes as we work to optimize the manufacturing process, and we cannot be sure that even minor changes in the process will result in products that meet specifications are capable or safe and effective. If such contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to secure and/or maintain regulatory approval for our product candidates. In addition, we have no control over the ability of third parties to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not agree that these facilities for the manufacture of our product candidates are acceptable or if it withdraws any such approval or acceptance in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the process of manufacturing lentiviral vector and cell therapies is susceptible to product loss due to contamination, equipment failure or improper installation, maintenance or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing and distribution processes for any of our product candidates could result in reduced production yields, increased costs, impact to key product quality attributes, and other supply disruptions. Such minor deviations did in fact occur in our previously contracted manufacturing facility due to operator error.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product defects can also occur unexpectedly. If microbial, viral or other contaminations are discovered in our product candidates, manufacturing reagents, raw materials, or in the manufacturing facilities in which our product candidates and/or their precursors are made, these manufacturing facilities may need to be closed for an extended period of time to allow us to investigate and remedy the contamination. Because some of our cell therapy product candidates are manufactured from the blood of third-party donors, the process of manufacturing is susceptible to the availability and variability of the third-party donor material. The process of developing products that can be commercialized may be particularly challenging, even if they otherwise prove to be safe and effective. The manufacture of these product candidates involves complex processes. Some of these processes require specialized equipment and highly skilled and trained personnel. The process of manufacturing these product candidates will be susceptible to additional risks, given the need to maintain aseptic conditions throughout the manufacturing process. Contamination with viruses or other pathogens in either the donor material or materials utilized in the manufacturing process or ingress of microbiological material at any point in the process may result in contaminated or unusable product and patients may not receive a dose. These types of contaminations could result in delays in the manufacture of products which could result in delays in the development of our product candidates. These contaminations could also increase the risk of adverse side effects. Furthermore, the selection and distribution of the appropriate cell product for therapeutic use in a patient requires close coordination between the manufacturing facility, clinical operations, supply chain and quality assurance personnel.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also intend to rely on third-party manufacturers to supply us with additional quantities of our product candidates to be used, if approved, for commercialization. We do not yet have a commercial supply agreement for commercial quantities of product. If we are not able to meet market demand for any approved product, it would negatively impact our ability to generate revenue, harm our reputation, and could have an adverse effect on our business and financial condition.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to meet our product specifications and quality requirements consistently;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay or inability to procure or expand sufficient manufacturing capacity;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issues related to scale-up of manufacturing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs and validation of new equipment and facilities required for scale-up;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party manufacturers may fail to comply with cGMP requirements and other inspections by the FDA or other comparable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">breach, termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on single sources for reagents and components;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of qualified backup suppliers for those components that are currently purchased from a sole or single-source supplier;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party manufacturers may not devote sufficient resources to our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">carrier disruptions or increased costs that are beyond our control.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we enter into a strategic collaboration with a third party for the commercialization of our current or any future product candidates, we will not be able to control the amount of time or resources that they devote to such efforts. If any strategic collaborator does not commit adequate resources to the marketing and distribution of our current or any future product candidates, it could limit our potential revenues.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any adverse developments affecting manufacturing operations for our product candidates may result in lot failures, inventory shortages, shipment delays, product withdrawals or recalls or other interruptions in the supply of our drug product which could prevent the administration to patients and delay the development of our product candidates. We may also have to write off inventory, incur other charges and expenses for supply of drug product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize our current or any future product candidates once approved. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure, or total or partial suspension of production.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently store our gamma-delta T cells and biologic correlative and research specimens from clinical trials and development programs and clinical lentivectors at our research and development facilities and at the facilities of our clinical and/or manufacturing partners, and any damage or loss to our storage freezers and/or facilities from natural disasters or otherwise would cause delays in replacement, and our business could suffer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specimens are stored in our freezers at our research and development facilities. If these cells are damaged, including by the loss or malfunction of our freezers or our back-up power systems, as well as by damage from fire or other natural disasters, our development program could be delayed or terminated and our business could suffer. Loss of a significant supply would require manufacturing of additional vector which could cause us to incur significant additional expenses and liability.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are currently dependent on a single third-party supplier for manufacture of our automated manufacturing device and our lentiviral vectors for our cellular therapies. These are critical products required for the manufacturing of our product candidates, including INB-100, INB-200 and INB-400. Any damage or loss to the ability of our suppliers to deliver supplies in a timely manner could cause delays in manufacturing, and our clinical trials and our business could suffer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our gamma-delta T cell products for INB-100 and INB-200, as well as our INB-400 program, are manufactured in a programmable, cell-manufacturing, closed system device. We have multiple devices, including backup devices in all facilities if the primary instrument breaks, however, if the devices are damaged and cannot be repaired or the supplier cannot deliver new devices in a timely manner, or at all, our ability to manufacture and supply sufficient quantities of our products for clinical or commercial usage could be delayed, or potentially hindered. Our current supply of vectors will cover approximately 189 patients after a large manufacturing run was completed in the first half of 2023. If our third-party contractor is unable to provide adequate lentiviral vectors for our cellular therapies in a timely manner, our ability to manufacture and supply sufficient quantities of our product candidates for clinical or commercial usage will be delayed or hindered, and our business could suffer.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third-party healthcare professionals to administer gamma-delta T cells to patients, and our business could be harmed if these third parties administer these cells incorrectly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on the expertise of physicians, nurses and other associated medical personnel to administer gamma-delta T cells to clinical trial patients. If these medical personnel are not properly trained to administer, or do not properly administer, gamma-delta T cells, the therapeutic effect of gamma-delta T cells may be diminished or the patient may suffer injury.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we achieve the ability to freeze and thaw our gamma-delta T cells, third-party medical personnel will have to be trained on proper methodology for thawing gamma-delta T cells received from us. If this thawing is not performed correctly, the cells may become damaged and/or the patient may suffer injury. While we intend to provide training materials and other resources to these third-party medical personnel, the thawing of gamma-delta T cells will occur outside our supervision and may not be administered properly. If, due to a third-party error, people believe that gamma-delta T cells are ineffective or harmful, the desire to use gamma-delta T cells may decline, which would negatively impact our business, reputation and prospects. We may also face significant liability even though we may not be responsible for the actions of these third parties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We believe we may require an updated and validated protocol for commercial-scale expansion and manufacturing of gamma-delta T cells for conducting pivotal trials and for commercialization of our product candidates, if approved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future clinical trials that we conduct, as well as any potential commercialization of our product candidates when approved, will depend on the reliability, safety and efficacy of our protocols for expanding, transducing and manufacturing gamma-delta T cells at scale. Our efforts to scale up production of our gamma-delta T cells in anticipation of future clinical trials or commercialization may reveal, an inability to overcome biology or may otherwise encounter challenges, including scrutiny from regulatory authorities. To the extent we encounter any such difficulties, our ability to conduct additional clinical trials or to scale for commercialization will be hindered or prevented, which would have an adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have not yet developed commercial-scale infrastructure for freezing and thawing large quantities of gamma-delta T cells, which we believe will be required for the storage and distribution of our gamma-delta T cell product candidates at commercial scale.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not demonstrated that gamma-delta T cells can be frozen and thawed in large commercial-scale quantities without damage, in a cost-efficient manner and without degradation over long periods of time. We may encounter difficulties not only in developing freezing and thawing, but also in obtaining the necessary regulatory approvals for using such in treatment. If we cannot adequately demonstrate similarity of our frozen product to the unfrozen form to the satisfaction of the FDA, we could face substantial delays in our regulatory approvals. If we are unable to freeze gamma-delta T cells for shipping purposes, our ability to promote adoption and standardization of our products, as well as achieve economies of scale by centralizing our production facility, will be limited. Even if we are able to successfully freeze and thaw gamma-delta T cells in large quantities, we will still need to develop a cost-effective and reliable distribution and logistics network, which we may be unable to accomplish. For these and other reasons, we may not be able to commercialize gamma-delta T cells on a large scale or in a cost-effective manner.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict or interrupt our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the generation, storage, use and disposal of hazardous materials, including the components of our product candidates, such as genetically modified cells, and other hazardous compounds and wastes. We and our manufacturers and suppliers are subject to environmental, health and safety laws and regulations governing, among other matters, the use, manufacture, generation, storage, handling, transportation, discharge and disposal of these hazardous materials and wastes and worker health and safety. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination or injury, which could result in an interruption of our commercialization efforts, research and development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">efforts and business operations, damages and significant cleanup costs and liabilities under applicable environmental, health and safety laws and regulations. We also cannot guarantee that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials and wastes generally comply with the standards prescribed by these laws and regulations. We may be held liable for any resulting damages costs or liabilities, which could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental, health and safety laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Failure to comply with these environmental, health and safety laws and regulations may result in substantial fines, penalties or other sanctions. We do not currently carry hazardous waste insurance coverage.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We intend to partner with third parties, such as academic institutions and CROs, to conduct, supervise and monitor some of our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business and delay or impair our ability to obtain regulatory approval or otherwise commercialize our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we are conducting our current clinical trials through our direct contractual agreements with hospitals, we intend to rely on CROs and clinical trial sites to conduct our future preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We intend to rely upon CROs to monitor and manage data for our clinical programs, as well as the execution of future preclinical studies. We expect to control only certain aspects of the activities of our third-party service providers, including investigators and CROs. Nevertheless, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are, and our future CROs will be, required to comply with the good laboratory practices ("GLPs") and GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities in the form of International Council for Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we rely on CROs to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations. If we or our future CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if CROs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reliance on third parties to conduct clinical trials will result in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with CROs and other third parties can be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Such parties may:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have staffing difficulties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fail to comply with contractual obligations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience regulatory compliance issues; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">undergo changes in priorities or become financially distressed.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors may adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If our future CROs, or hospitals where we conduct our clinical trials, do not successfully carry out their contractual duties or obligations with us or regulatory agencies, fail to meet necessary safety measures and protocols, fail to meet expected deadlines, or fail to comply with regulatory and/or IRB requirements, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed. While we will have agreements governing their activities, our CROs will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and preclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the FDA or other regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by investigator-sponsored trials or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored trials. If so, regulatory authorities may require us to obtain and submit additional preclinical, manufacturing or clinical data before we may initiate further clinical trials and/or obtain any regulatory approvals.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our relationships with any CROs or hospitals where we conduct our current clinical trials terminate, we may not be able to enter into arrangements with alternative CROs and other third parties or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. While we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval or rejection of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, collaborators, principal investigators, consultants, commercial partners and outside actors. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being advanced, developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products or regulatory submissions can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events, such as public health crises, that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or modifications to cleared or approved biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years including in October 2025 and February 2026, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current administration has implemented substantial reductions in force at various government agencies including the FDA, which could significantly reduce the FDA&#8217;s capacity to perform its functions in a manner consistent with its past practices and could delay reviews and negatively impact our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach our license agreements with the University of Alabama at Birmingham Research Foundation, Children&#8217;s Healthcare of Atlanta, Inc. and Emory University, or any of the other agreements under which we acquired, or will acquire, the intellectual property rights to our product candidates, we could lose the ability to continue the development and commercialization of the related product.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing of intellectual property is of critical importance to our business and to our current and future product candidates, and we expect to enter into additional such agreements in the future. In particular, our product candidates, INB-100, INB-200, INB-300 and INB-400, are dependent on our license agreements with The UAB Research Foundation ("UABRF") Children&#8217;s Healthcare of Atlanta, Inc. ("CHOA") and Emory University ("Emory" and, together with UABRF and CHOA, the "Licensors"), pursuant to which we have obtained exclusive worldwide licenses under certain immunotherapy related patents and know-how that are critically important for these product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we have been granted exclusive licenses under these license agreements, we do not have the right to control the preparation, filing, prosecution and maintenance of patents and patent applications covering the technology that we license from UABRF and Emory. Therefore, we cannot always be certain that these patents and patent applications will be prepared, filed, prosecuted and maintained in a manner consistent with the best interests of our business. Although we have a right to have our comments considered in connection with the prosecution process, if the Licensors fail to prosecute and maintain such patents, or loses rights to those patents or patent applications as a result of its control of the prosecution activities, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to meet our obligations under our license agreements in any material respect, and fail to cure such breach in a timely fashion, then the Licensors may terminate their applicable license agreement. If the license agreements are terminated, and we lose our intellectual property rights thereunder, this may result in a complete termination of our product development and any commercialization efforts for our product candidates. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the license agreements, we may not be able to do so in a timely manner, at an acceptable cost or at all. For more information on our license agreements, see Note 9, License Agreements, in our unaudited condensed financial statements contained elsewhere in this Quarterly Report.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, license agreements we enter into in the future may not provide exclusive rights to use intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the research resulting in certain of our in-licensed patent rights was funded in part by the U.S. federal or state governments. As a result, the government may have certain rights, including march-in rights, to such patent rights. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and our technology. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and our technology that are important to our business. As of June 30, 2026, we owned, co-owned or exclusively licensed five issued U.S. patents, nine issued European patents, 20 other issued foreign patents, eleven pending U.S. applications, one pending PCT application and 13 other foreign national-stage applications, including three European regional-phase applications that are important to the development of our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file a patent application relating to any particular aspect of a product candidate. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, we may be subject to a third-party pre-issuance submission of prior art or become involved in opposition, derivation, reexamination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products, if approved. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from infringing our patents in all countries outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing manner.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our owned and in-licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will have to be paid to the USPTO and various government patent agencies outside the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our service providers or our licensors to pay these fees. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, nonpayment of fees and failure to properly legalize and submit formal documents. If we, our service providers or our licensors fail to maintain the patents and patent applications covering our products or technologies, we may not be able to stop a competitor from marketing products that are the same as or similar to our product candidates, which would have an adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we fail to apply for or otherwise fail to obtain applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us, any of the foregoing could expose us to liability to the applicable patent owner.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of product candidates such as INB-100, INB-200, INB-300, INB-400, INB-500, and INB-600, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we have or will obtain patent rights. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent. However, the extension cannot extend the total patent term beyond 14 years from the date of drug approval, which is limited to the approved indication (or any additional indications approved during the period of extension). Furthermore, only one patent per approved product can be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, the period during which we can enforce our patent rights for the applicable product candidate will be shortened and our competitors may obtain approval to market competing products sooner. Additionally, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights and/or trademark, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends, in part, upon our ability and the ability of others with whom we may collaborate to develop, manufacture, market and sell our current and any future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property, trademarks and other proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, names, including interference proceedings, post grant review and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this is a high burden and requires us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Moreover, given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the future. Other companies and research institutions have filed, and may file in the future, patent applications related to gamma-delta T cell immunotherapy. Some of these patent applications have already been allowed or issued, and others may issue in the future. While we may decide to initiate proceedings to challenge the validity of these or other patents in the future, we may be unsuccessful, and courts or patent offices in the United States and abroad could uphold the validity of any such patent. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of when filed, we may fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a third-party patent is invalid or not infringed by our product candidates or activities. If a patent holder believes that our product candidate infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from nonpracticing entities that have no relevant drug revenue and against whom our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the drug or product candidate that is the subject of the actual or threatened suit.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. Under any such license, we would most likely be required to pay various types of fees, milestones, royalties or other amounts. Moreover, we may not be able to obtain any required license on commercially reasonable terms or at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may also pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have an adverse effect on our business, financial condition, results of operations and prospects. Furthermore, even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could prevent us from manufacturing and commercializing our current or any future product candidates or force us to cease some or all of our business operations, which could harm our business. Even if we are successful in defending against such claims, litigation can be expensive and time-consuming and would divert management&#8217;s attention from our core business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our owned or licensed patents at risk of being invalidated or interpreted narrowly and could put our owned or licensed patent applications at risk of not issuing. The initiation of a claim against a third party might also cause the third party to bring counterclaims against us, such as claims asserting that our patent rights are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ex parte </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reexaminations, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review, post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license, or if the license offered as a result is not on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act (the "America Invents Act"), the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review, and derivation proceedings. The America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applications and the enforcement or defense of our issued patents, all of which could have an adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we own, have licensed or might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents covering our current and any future product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents, and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since we rely on third parties to help us discover, develop and manufacture our current and any future product candidates, or if we collaborate with third parties for the development, manufacturing or commercialization of our current or any future product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations. In addition, from time to time, we may hire scientists or other employees or consultants who originate from jurisdictions, including China, that have a history of engaging in misappropriation or theft of trade secrets or other acts of trade secret espionage; if any such individuals are found to be engaging in such illegal behavior, it could have a material adverse effect on our ability to protect our intellectual property and our business prospects more generally.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third party illegally or unlawfully obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into nondisclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Further, we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or other proprietary information. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to register trademarks for our current or any future product candidates. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any proprietary name we propose to use with our current or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make cells, cell products, genetic modifications, compounds or formulations that are similar to our product candidates but that are not covered by the claims of any patents, should they issue, that we own or license;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or license;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors might not have been the first to file patent applications covering certain of our inventions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we own or license may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to compete in the pharmaceuticals industry depends upon our ability to attract and retain highly qualified managerial, scientific, medical and other personnel. We are highly dependent on the services of our co-founders, William Ho, our Chief Executive Officer, Dr. Lawrence Lamb, our Chief Scientific Officer, and of our President and Chief Operating Officer, Dr. Kate Rochlin, and the loss of these members of our management team or other key employees could impede, delay or prevent the successful development of our product pipeline, the completion of our current and planned clinical trials, and the commercialization of our products or in-licensing or acquisition of new assets, and could negatively impact our ability to successfully implement our business plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on our co-founders, our Chief Executive Officer, William Ho, our Chief Scientific Officer, Dr. Lawrence Lamb and on our President and Chief Operating Officer, Dr. Kate Rochlin. Each of them may currently terminate their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recruiting and retaining other senior executives, qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully lead, develop, gain regulatory approval of and commercialize our product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and our results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We plan to expand our organization in the future, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026, we had 18 full-time employees. As the development of our product candidates continues to progress, we expect to require additional employees and expand the scope of our operations, particularly in the areas of research, drug development, manufacturing, clinical operations, regulatory affairs, business and development, finance and accounting and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage any future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such potential growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Any expansion of our operations may lead to significant expenses, additional dilution and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may explore strategic collaborations that may not have the intended benefits or never materialize, or we may be required to relinquish important rights to and control over the development and commercialization of our product candidates to any future collaborators.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may enter into strategic partnerships, create joint ventures or collaborations or enter into licensing arrangements with third parties with respect to our product candidates that we believe will complement or augment our business. For example, our business strategy includes broadening our DeltEx platform by exploring strategic partnerships that maximize the potential of our gamma-delta T cell programs. Additionally, we are exploring partnership opportunities for the INB-400 Phase 2 clinical program. As a result, we intend to periodically explore a variety of possible strategic partnerships in an effort to gain access to additional product candidates or resources. These strategic partnerships may include partnerships with large strategic partners. At the current time, however, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, if any at all. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. We are unable to predict when, if ever, we will enter into any strategic partnerships because of the numerous risks and uncertainties associated with establishing them, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenditure of substantial operational, financial and management resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dilutive issuances of our securities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial actual or contingent liabilities; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination or expiration of the arrangement, which would delay the development and may increase the cost of developing our product candidates.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for INB-200, INB-400, INB-600 or any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and/or third parties may not view our product candidates and programs as having the requisite data and/or potential to demonstrate safety and efficacy. Strategic partners may also delay clinical trials, experience financial difficulties, provide insufficient funding, terminate a clinical trial or abandon a product candidate, which could negatively impact our development efforts. We cannot be certain that we would achieve the revenues or specific net income that justifies such strategic partnerships. Additionally, strategic partners may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation, any of which could adversely affect our business, financial position and operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems, or those of the third parties with whom we work, or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to, a significant disruption of our product development programs and our ability to operate our business effectively, regulatory investigations or actions, litigation, fines and penalties, reputational harm, loss of revenue or profits, and other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we and the third parties with whom we work process sensitive information, and as a result, we and the third parties with whom we work face a variety of evolving threats that could cause security incidents. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors and other contractors and consultants who have access to our sensitive information. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our internal computer systems, cloud-based computing services and those of any third parties with whom we work are vulnerable to damage or interruption from a variety of sources, including cyberattacks, malicious internet-based activity, and online and offline fraud, and other similar activities. These threats include, but are not limited to, social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), data corruption, intentional or accidental actions or inactions by our employees or others with access to our network, supply chain attacks, ransomware attacks, denial-of-service attacks (such as credential stuffing), credential harvesting, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by A.I., natural disasters, terrorism, war and telecommunication and electrical failures, and other similar threats that affect service reliability and threaten the confidentiality, integrity, and availability of information. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, are increasingly difficult to detect, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise, including traditional computer "hackers," threat actors, "hacktivists," organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks, including cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems or the third-party information technology systems that support us. We also face increased cybersecurity risks due to the number of our employees who are working remotely, which creates additional opportunities for cybercriminals to exploit vulnerabilities and data, as our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It may be difficult and/or costly to detect, investigate, mitigate, contain, and remediate a security incident. Our efforts to do so may not be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain, and remediate a security incident could result in outages, data losses, and disruptions of our business. Threat actors may also gain access to other networks and systems after a compromise of our networks and systems. For example, threat actors may use an initial compromise of one part of our environment to gain access to other parts of our environment, or leverage a compromise of our networks or systems to gain access to the networks or systems of third parties with whom we work, such as through phishing or supply chain attacks.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of the previously identified or similar threats were to occur and cause a security incident or other interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, access to, or other similar disruptions to our sensitive information or our information technology systems, or those of the third parties with whom we work. For example, we have been the target of unsuccessful phishing attempts in the past and we expect such attempts will continue in the future. In addition, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we (or a third party with whom we work) experience a security incident or are perceived to have experienced a security incident, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Security incidents could lead to material adverse consequences, including but not limited to: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data and clinical trial data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of clinical trial data); financial loss; and other similar harms. Additionally, applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to take other actions such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and sensitive information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties with whom we work). We may not, however, be able to detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in deploying remedial measures designed to address any such identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive information of the Company could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred substantial losses since inception and do not expect to become profitable in the near future, if ever. In general, under Section 382 of the United States Internal Revenue Code of 1986, as amended ("Code") a corporation that undergoes an "ownership change" is subject to limitations on its ability to utilize its pre-change net operating losses ("NOLs") to offset future taxable income. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of subsequent changes in our stock ownership (some of which are outside our control). As a result, if and to the extent that we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under current U.S. federal tax law, NOLs arising in tax years beginning after December 31, 2017 can be carried forward indefinitely, but the deductibility of these carryforwards is limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is uncertain if and to what extent various states will conform to the federal law. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase the state taxes owed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to realize the future tax benefits of our NOL carryforwards, we must generate taxable income, of which there is no assurance. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December 31, 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There are risks inherent in our business that may subject us to potential product liability suits and other claims, which may require us to engage in expensive and time-consuming litigation or pay substantial damages and may harm our reputation and reduce the demand for our product.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business exposes us to product liability risks, which are inherent in the testing, manufacturing, marketing and sale of biopharmaceutical products. For example, we may be sued if any product we develop allegedly causes or is perceived to cause injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties and/or trademarks. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain aspects of how gamma-delta T cells are processed and administered may increase our exposure to liability. Medical personnel administer gamma-delta T cells to patients in an outpatient procedure. This procedure poses risks to the patient similar to those occurring with infusions of other cell products, such as T cells and stem cells, including blood clots, infection and mild to severe allergic reactions. Additionally, gamma-delta T cells or components of our gamma-delta T cell therapy may cause unforeseen harmful side effects. For example, a patient receiving gamma-delta T cells could have a severe allergic reaction, severe graft versus host disease, cytokine release syndrome, or could develop an autoimmune condition to materials infused with gamma-delta T cells.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we have not conducted studies on the long-term effects associated with the media and/or expansion process that we use to grow our gamma-delta T cells. Similarly, we expect to use media in freezing our gamma-delta T cells for storage and shipment. These media and other reagents used in the manufacturing process could contain substances that have proved harmful if used in certain quantities. As we continue to develop our gamma-delta T cell therapy, we may encounter harmful side effects that we did not observe in our prior studies and clinical trials. Additionally, the discovery of unforeseen side effects of gamma-delta T cells could also lead to lawsuits against us.</span></p><p style="text-indent:3.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regardless of merit or eventual outcome, product liability or other claims may, among other things, result in:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any approved products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants or cancellation of clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to defend the related litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a diversion of management&#8217;s time and our resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to clinical trial participants or patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exhaustion of any available insurance and our capital resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a potential decrease in our stock price; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any products we develop.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of our products. We obtained product liability insurance covering our clinical trials with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If we determine that it is prudent to increase our product liability coverage due to the commercial launch of any approved product, we may be unable to obtain such increased coverage on acceptable terms, or at all. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Commercialization and Regulatory Compliance</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approvals for our product candidates, they will remain subject to ongoing regulatory oversight.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approvals for our product candidates, such approvals will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for our product candidates may also be subject to a REMS, to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or may contain requirements for potentially costly post-marketing testing, including Phase 4 trials, and for surveillance to monitor the quality, safety and efficacy of the product candidate. Such regulatory requirements may differ from country to country depending on where we have received regulatory approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, product candidate manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product candidate, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product candidate is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that product candidate, a regulatory authority may impose restrictions relative to that product candidate, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the product candidate from the market or suspension of manufacturing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with applicable regulatory requirements following approval of our product candidates, a regulatory authority may, among other things, issue warning letters or untitled letters, mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners, or require other restrictions on the labeling or marketing of such products, require us</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance, seek an injunction or impose administrative, civil or criminal penalties or monetary fines, suspend or modify any ongoing clinical trials, or suspend, modify withdraw regulatory approval or restrict the marketing or manufacturing of the product candidate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the FDA and other regulatory authorities strictly regulate the promotional claims that may be made about biologic products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and harm our business, financial condition, results of operations and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if any product candidate receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if any product candidate receives marketing approval, it may fail to gain market acceptance by physicians, patients, third-party payors and others in the medical community. If any such product candidate does not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost, efficacy, safety profile, convenience, ease of administration and other potential advantages compared to alternative treatments and therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of our relationships with patient communities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any restrictions on the use of the product candidate together with other medications.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our product candidates. Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the attention to different types of prospective treatments and proposed cures for cancers has historically varied. In recent years, various forms of oncological immunotherapy have been prominent areas for academic and clinical advancement. While gamma-delta T cell therapy has not yet received prominent negative attention from the mainstream media or the scientific press, it is possible that it could, and it is possible that if immunotherapy generally falls out of favor with these key constituencies, whether due to the failure of one or more competitive products or technologies or otherwise, our business, including our ability to conduct our planned clinical trials and to raise capital, may in turn suffer.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be successful in commercializing them, if and when they are approved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To successfully commercialize any product candidate that may result from our development programs, we will need to build out our sales and marketing capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales force to market any product candidate we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We may seek to enter into collaborations with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any current or future collaborators do not commit sufficient resources to commercialize our product candidates, or we are unable to develop the necessary capabilities on our own, we may be unable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to generate sufficient revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We will likely also face competition if we seek third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval outside the United States, which would limit our market opportunities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our product candidates outside the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable foreign regulatory authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for our product candidates in the European Union from the European Commission following the opinion of the European Medicines Agency ("EMA") if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a product candidate is approved, the EMA may limit the indications for which the product may be marketed, require extensive warnings on the labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we commercialize our product candidates outside the United States, a variety of risks associated with international operations could harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have not taken any steps to obtain approval of our product candidates outside of the United States, and do not plan to seek approval in the near term, we may do so in the future. If we market approved products outside the United States, we expect that we will be subject to additional risks in commercialization, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for approval of therapies in foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular economies and markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty due to labor unrest;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including wars and terrorism, natural disasters including earthquakes, typhoons, floods and fires, and public health emergencies.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no prior experience in these areas. In addition, there are complex regulatory, immigration, tax, labor and other legal requirements imposed by many of the individual countries in which we may operate, including the United States and, with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their products in foreign countries to be challenging.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, including anti-kickback and false claims laws, transparency laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, including physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws, health information privacy laws, transparency laws, and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and the regulations promulgated thereunder. For additional information on the healthcare laws and regulations that we may be subject to, see the section captioned "Business&#9472;Government Regulation" in our Annual Report.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians, some of whom are compensated with a stipend or stock options for services performed for us, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations. If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell profitably, if approved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement for these products and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. While no uniform policy for coverage and reimbursement exists in the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. Therefore, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. Additionally, a third-party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a payor&#8217;s list of covered products, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the U.S. Department of Health and Human Services ("HHS") imposes rebates on many Medicare Part B and Medicare Part D products to penalize price increases that outpace inflation on an annual basis. HHS has also been empowered to negotiate the price of certain single-source biologics that have been on the market for at least eleven (11) years covered under Medicare as part of the Medicare Drug Price Negotiation Program. Each year up to twenty (20) products will be selected by HHS for the Medicare Drug Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare program on a per unit basis.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Currently, in the allogeneic transplant setting, reimbursement is often made based on a capitated payment system, and obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Therefore, our product candidates may not be reimbursed separately but their cost</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may instead be bundled as part of a capitated payment received by the provider for the procedure only. We cannot be sure that the clinical results of our trials will be sufficient or meaningful to educate hospitals and/or clinicians on the benefits of our product or to get third-party payors to change reimbursement to separate outside of the current bundle. A decision by a third-party payor not to cover or separately reimburse for our product candidates or procedures using our product candidates, could reduce physician utilization of our products once approved. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize any product candidates that we develop. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and continue to be, legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "ACA"), was passed, which substantially changed the way healthcare is financed by both governmental and private payors in the United States. Since its enactment, however, there have been executive, judicial and Congressional challenges and amendments to the ACA. For example, on July 4, 2025, the One Big Beautiful Bill Act (the "OBBBA") was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance. The OBBBA also is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired ACA subsidies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, which began in 2013 and will remain in effect until 2032 unless additional Congressional action is taken.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current administration is pursuing policies to reduce regulations and expenditures across government agencies including at HHS, the FDA, the Centers for Medicare &amp; Medicaid Services ("CMS") and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. For example, the current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a direct-to-consumer platform ("TrumpRx") U.S. patients and Medicaid programs prescription drug Most-Favored Nation pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues. Other recent actions, for example, include (1) directing agencies to reduce agency workforce and cut programs; (2) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives; (3) imposing tariffs on imported pharmaceutical products; and (4) as part of the Make America Healthy Again Commission&#8217;s Strategy Report released in September 2025, working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. Additionally, the current administration recently called on Congress to enact "The Great Healthcare Plan," to codify and expand Most-Favored Nation pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand pharmaceutical drugs available for over-the-counter purchase, and enact restrictions on pharmacy benefit manager payment methodologies, among other things. These actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks. In June 2024, the U.S. Supreme Court&#8217;s Loper Bright decision greatly reduced judicial deference to regulatory agencies, which could increase successful legal challenges to federal regulations affecting our operations. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program. We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug, which could have an adverse effect on demand for our product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. For additional information on healthcare reform, see the section captioned "Business&#9472;Government Regulation" in our Annual Report.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA&#8217;s ability to review and approve new products may be hindered by a variety of factors, including budget and funding levels, ability to hire and retain key personnel, statutory, regulatory and policy changes and global health concerns.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. The ability of the FDA and other government agencies to properly administer their functions is highly dependent on the levels of government funding and the ability to fill key leadership appointments, among various factors. Delays in filling or replacing key positions could significantly impact the ability of the FDA and other agencies to fulfill their functions and could greatly impact healthcare and the pharmaceutical industry. In addition, the current administration has implemented substantial reductions in force at various government agencies including the FDA, which could significantly reduce the FDA&#8217;s capacity to perform its functions in a manner consistent with its past practices and could delay reviews and negatively impact our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our (or the third parties with whom we work) actual or perceived failures to comply with applicable data privacy and security obligations, including laws, regulations, contractual obligations, industry standards and other obligations could lead to regulatory investigations or actions, litigation (including class claims), fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, and other adverse business consequences.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about participants in connection with clinical trials, and sensitive third-party data (collectively, sensitive information). Our data processing activities subject us to numerous data privacy and security obligations, such as various state, federal and foreign laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts and other obligations relating to data privacy and security. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to process sensitive information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us or the third parties with whom we work to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of sensitive information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As our operations and business grow, we become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, federal, state, and local laws and regulations, including data breach notification laws, personal data privacy laws, state health information privacy laws, and federal and state consumer protection laws and regulations (i.e., Section 5 of the FTC Act), and other similar laws govern the collection, use, disclosure, and protection of health-related and other personal data. In addition, we obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to data privacy and security requirements under the Federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations promulgated thereunder (collectively, "HIPAA"). Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain states have also adopted comparable data privacy and security laws and regulations, some of which may be more stringent than HIPAA. Numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (collectively, the "CCPA") applies to personal data of consumers, business representatives, and employees who are California residents,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and requires business to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights related to their personal data. The CCPA allows for statutory fines for noncompliance and a private right of action for certain data breaches to recover significant statutory damages. Although the CCPA and other comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials, these developments may further complicate compliance efforts and increase compliance costs and potential liability for us and the third parties with whom we work. Similar laws have been enacted or are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future, which could further complicate compliance efforts.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, all 50 U.S. states and the District of Columbia have enacted breach notification laws that may require us to notify affected individuals or regulators in the event of unauthorized access to or disclosure of personal data experienced by us or our service providers. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and can be costly. In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time. We are, and may in the future become, subject to certain industry standards, or we may elect to comply with such standards.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the EU GDPR and the UK GDPR impose strict requirements for processing personal data. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater. Further, classes of data subjects or consumer protection organizations authorized at law to represent their interests may initiate litigation related to processing of personal data. In Canada, the PIPEDA and various related provincial laws, may apply to our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain jurisdictions have enacted data localization laws and cross-border personal data transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring or receiving personal data that originates in the EU or in other foreign jurisdictions). Existing mechanisms that facilitate cross-border personal data transfers may change or be invalidated. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the EEA that the European Commission does not consider to provide an adequate level of data privacy and security, such as the United States. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States or other countries. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. Additionally, the U.S. Department of Justice issued a rule entitled the Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons, which places additional restriction on certain data transactions involving countries of concern (e.g., China, Russia, Iran) and covered persons (i.e., individuals and entities who are designated as such by the U.S. Attorney General or considered "foreign persons" and are majority owned by, organized under the laws of, a primary resident in, or a contractor of, a covered person or country of concern, as applicable) that may impact certain business activities such as vendor engagements, sale or sharing of data, employment of certain individuals, and investor agreements. Violations of the rule could lead to significant civil and criminal fines and penalties. The rule applies regardless of whether data is anonymized, key-coded, pseudonymized, de-identified or encrypted, which presents particular challenges for companies like ours and may impact our ability to engage in transactions or agreements with certain third parties in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain countries outside Europe have also passed or are considering laws requiring local data residency or otherwise impeding the transfer of personal data across borders, which increases the cost and complexity of doing business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we cannot implement a valid compliance mechanism for cross-border data transfers, or if the requirements for a legally compliant transfer are too onerous, we may face increased exposure to regulatory actions, substantial fines and penalties, and injunctions against processing or transferring personal data from Europe or other foreign jurisdictions. The inability to import personal data to the United States could significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere, limiting our ability to collaborate with parties that are subject to such cross-border data transfer or localization laws, or requiring us to increase our personal data processing capabilities and infrastructure in foreign jurisdictions at significant expense. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to data privacy and security laws, we are bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We also publish privacy policies, marketing materials, and other statements concerning data privacy and security. Regulators in the United States are increasingly scrutinizing these statements, and if these policies, materials, or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we work to comply with applicable data privacy and security laws, regulations and standards, our contractual obligations and other legal obligations, these requirements (and individuals&#8217; data privacy expectations) are evolving, becoming increasingly stringent, and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Preparing for and complying with these obligations requires significant resources and may necessitate changes to our information technologies, systems, and practices and to those of any third parties with whom we work. In addition, these obligations may require us to change our business model. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties with whom we work may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties with who we work to comply with such requirements or adequately address data privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, or adversely affect our business, financial condition, and results of operations. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. For example, we may experience adverse consequences such as interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations; government enforcement actions (i.e., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans or restrictions on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our employees and personnel use generative artificial intelligence ("AI") technologies to perform their work, and the disclosure and use of personal data in AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws and regulations regulating AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use AI technologies, it could make our business less efficient and result in competitive disadvantages.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Ownership of Our Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">An active trading market for our common stock may not be sustained, and you may not be able to sell your shares quickly or at the market price.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although our common stock is traded on the Nasdaq Stock Market LLC ("Nasdaq"), the liquidity in our common stock on that stock market remains thin. If an active trading market for our common stock is not sustained, you may not be able to sell your shares quickly or at all at the market price. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares of our common stock and may impair our ability to acquire other companies or technologies by using our common stock as consideration.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our common stock is volatile and may fluctuate substantially, and you could lose all or part of your investment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock is volatile. The stock market in general, and the market for biopharmaceutical and pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. In addition to the factors discussed in this "Risk Factors" section, the market price for our common stock may be influenced by, among other factors:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement, enrollment or results of our planned or future clinical trials of our product candidates or those of our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success and failures of competitive products or therapies or announcements, including patient deaths and clinical holds, by potential competitors of their product development efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States and other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coordinated buying or selling activity in our common stock, including market manipulation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unusual trading in our common stock or securities derivative thereof, including pursuant to naked, or uncovered, short positions or "short squeezes;"</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commentary by investors on the prospects for our business or our common stock on the internet, including blogs, articles and message board, and/or social media and resulting in trading of our common stock;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock price and volume fluctuations attributable to inconsistent trading volume levels and a wide bid-ask in our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcement or expectation of additional financing efforts or sales by our stockholders;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad, including as a result of increases in inflation and interest rates, tariffs and trade wars, public health crises and other geopolitical tensions, such as wars and terrorism, and future U.S. government shutdowns; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investors&#8217; general perception of us and our business.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance which may limit or prevent investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming and could divert our management&#8217;s attention and our resources. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a classified board of directors such that not all members of the board are elected at one time;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that our directors may be removed for cause only upon the vote of at least 66 2/3% of our outstanding shares of voting stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit who may call stockholder meetings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize our board of directors to issue, without further action by the stockholders, shares of undesignated preferred stock with terms, rights and preferences determined by our board of directors that may be senior to our common stock; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require the approval of the holders of at least 66 2&#8725;3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law ("DGCL") which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. We have not elected to opt out of DGCL Section 203. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="text-indent:3.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, with respect to any state actions or proceedings under Delaware statutory or common law, the Court of Chancery of the State of Delaware is the exclusive forum for:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any derivative action or proceeding brought on our behalf;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action or proceeding asserting a breach of fiduciary duty;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action or proceeding asserting a claim against us or any of our directors, officers, employees or agents arising under the DGCL, our amended and restated certificate of incorporation or our second amended and restated bylaws;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our second amended and restated bylaws; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any action or proceeding asserting a claim against us or any of our directors, officers, employees or agents that is governed by the internal-affairs doctrine.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find an exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions, including as a result of increases in inflation, the price of oil, and interest rates, tariffs and trade wars, geopolitical tensions such as wars and terrorism and future U.S. government shutdowns, may have serious adverse consequences on our business, financial condition and share price.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions. For example, the macroeconomic uncertainty and volatile business environment have resulted in ongoing inflation, elevated interest rates, volatility in the capital markets, significantly reduced liquidity and credit availability, decreases in consumer demand and confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. Similarly, geopolitical tensions, such as wars and terrorism may have global economic consequences, including potential disruptions of the global supply chain, manufacturing and energy markets. Further, over the last several years the U.S. government has shut down several times. If a prolonged government shutdown occurs in the future, including as a result of any failure by the U.S. federal government to increase the debt ceiling or otherwise, it could significantly impact the ability of the FDA and the SEC to timely review and process our submissions, as well as cause interest rates and borrowing costs to further increase, which may negatively impact our ability to access the debt markets, including the corporate bond markets, on favorable terms, which could have a material adverse effect on our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade disputes, tariffs, and other geopolitical tensions between the U.S. and other countries may also exacerbate unfavorable macroeconomic conditions, including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns, which may also limit our access to capital, or otherwise negatively impact our business and operations. Additionally, current or future tariffs will result in increased research and development expenses, including with respect to increased costs associated with active pharmaceutical ingredients, raw materials, laboratory equipment and research materials and components. In addition, such tariffs will increase our supply chain complexity and could also potentially disrupt our existing supply chain. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to our development timelines. Additional and higher tariffs and sanctions may be imposed on goods imported from other countries which could increase the cost of goods needed to continue development of our product candidates. Further, such actions by the U.S. could result in retaliatory action by those countries which could impact our ability to profitably commercialize our products in those jurisdictions. As a result, our business, operations and financial condition could be materially harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ultimate impact of current or future tariffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively monitor these risks, any prolonged economic downturn, escalation in trade tensions, or deterioration in international perception of U.S.-based companies could materially and adversely affect our business, ability to access the capital markets or other financing sources, results of operations, financial condition and prospects. In addition, tariffs and other trade developments have and may continue to heighten the risks related to the other risk factors described elsewhere in this Quarterly Report on Form 10-Q.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of increases in inflation and interest rates, political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to satisfy all applicable requirements of Nasdaq and it determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock and the market price of our common stock could decrease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To maintain the listing of our common stock on Nasdaq, we are required to meet certain listing requirements, including having a minimum closing bid price of $1.00 per share, a minimum of 300 round lot holders, and a minimum of 500,000 publicly held shares. Further, if the market value of our publicly held common stock declines below $1 million, or the closing price of our common stock declines to $0.10 per share or less for 10 consecutive trading days, we would also be subject to Nasdaq delisting proceedings on that basis. Nasdaq&#8217;s staff also maintains discretionary authority under its listing rules to delist companies whose capital structure or public offerings raise public interest and investor protection concerns, including as a result of highly dilutive issuances, and it is possible that Nasdaq could assert that offerings that we have consummated, or future offerings we may consummate, raise such concerns.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, on July 22, 2026, the SEC&#8217;s Division of Trading and Markets approved a new Nasdaq continued listing standard that would require us to maintain a market value of listed securities of at least $5 million. Unlike many other of Nasdaq&#8217;s continued listing standards, this new listing standard provides no cure or compliance period, and requests for review by a Nasdaq Hearings Panel do not stay the suspension of trading. However, on July 29, 2026, the SEC stayed approval of this rule after two parties filed notices of intent to seek SEC review. As a result, we cannot predict whether or when the new listing standard will take effect.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have previously received a Nasdaq deficiency notice for failing to maintain the minimum closing bid price required for continued listing, and we transferred our listing from the Nasdaq Global Market to the Nasdaq Capital Market in connection with obtaining an extension to regain compliance. Our market capitalization has been volatile and has at times been at levels that could place us at risk under the market value of listed securities standard if it is reinstated. As of August 3, 2026, we had 9,858,383 shares of common stock outstanding, and the closing bid price was $0.96 per share, resulting in a market value of listed securities of approximately $9.5 million. If the SEC ultimately reinstates approval of the new market value of listed securities rule, our common stock would be subject to immediate suspension and delisting if the market value of our common stock falls below $5 million for a period of 30 consecutive business days.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will maintain compliance with the requirements for listing our common stock on Nasdaq. If we are unable to satisfy the Nasdaq criteria for continued listing, our common stock would be subject to delisting. A delisting of our common stock could negatively impact us by, among other things, (i) reducing the liquidity and market price of our common stock; (ii) reducing the number of investors willing to hold or acquire our common stock, which could negatively impact our ability to raise equity financing; (iii) decreasing the amount of news and analyst coverage of us; (iv) limiting our ability to issue additional securities or obtain additional financing in the future; (v) limiting our ability to use a registration statement to offer and sell freely tradable securities, thereby preventing us from accessing the public capital markets; and (iv) impairing our ability to provide equity incentives to our employees. In addition, delisting from Nasdaq may negatively impact our reputation and, consequently, our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Social media platforms and artificial intelligence-based platforms present new risks and challenges to our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Social media is increasingly being used to communicate information about us, our programs and the diseases our therapeutics are being developed to treat. Social media practices in the pharmaceutical and biotechnology industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, a product or a product candidate, which could result in reporting obligations or other consequences. Further, the accidental or intentional disclosure of non-public information by our workforce or others through media channels could lead to information loss. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us, our products, or our product candidates on any social media platform. The nature of social media prevents us from having real-time control over postings about us on social media. We may not be able to reverse damage to our reputation from negative publicity or adverse information posted on social media platforms or similar mediums. If any of these events were to occur or we otherwise fail to comply with application regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business including quick and irreversible damage to our reputation, brand image and goodwill.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, AI-based platforms are increasingly being used in the pharmaceutical industry and we are expanding the use of AI-based platforms in our operations for data analysis, summarization and automation, which subjects us to a variety of risks, including potential cybersecurity vulnerabilities, breaches of data privacy and the potential for inadvertent or unauthorized disclosure of our confidential information and intellectual property. Our use, or the use by our vendors, suppliers and contractors with access to our proprietary and confidential information, including trade secrets, may lead to the release of our proprietary and confidential information, which may negatively impact our company, including our ability to realize the benefit of our intellectual property. Moreover, AI-based platforms may create flawed, incomplete, or inaccurate outputs, some of which may appear correct. This may happen if the inputs that the model relied on were inaccurate, incomplete or flawed (including if a bad actor &#8220;poisons&#8221; the AI-based platform with bad inputs or logic), or if the logic of the AI-based platform is flawed (a so-called &#8220;hallucination&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or financial analysts publish about us or our business. We currently have research coverage by a few industry or financial analysts and may never obtain additional coverage. Equity research analysts may elect not to provide research coverage of our common stock or may drop coverage and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have additional equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our shares could decline if one or more equity research analysts downgrade our shares, reduce their price-targets, or issue other unfavorable commentary or research about us. If one or more equity research analysts cease coverage of us or fail to publish reports on us regularly, demand for our shares could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will continue to incur increased costs as a result of operating as a public company, and our management will continue to be required to devote substantial time to new compliance initiatives.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, and particularly after we are no longer an emerging growth company ("EGC") as defined under the Jobs Act, or smaller reporting company, we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 ("Sarbanes-Oxley Act") and rules subsequently implemented by the SEC and The Nasdaq Stock Market LLC impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to comply with these requirements. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could harm our business and have a negative effect on the trading price of our stock.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act ("Section 404") we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an EGC or a smaller reporting company with less than $100 million in annual revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We could be an EGC until the end of the fiscal year following the fifth anniversary of our initial public offering. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our assessment of internal controls and procedures may not detect material weaknesses in our internal control over financial reporting. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation, which could have a negative effect on the trading price of our stock. These events could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_2_unregistered_sales_equity_securit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Unregistered Sales of Equi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ty Securities and Use of Proceeds.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Recent Sales of Unregistered Equity Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Use of Proceeds from Initial Public Offering of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Issuer Purchases of Equity Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_defaults_upon_senior_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Defaults Upon</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Senior Securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ety Disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Other </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inducement Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 31, 2026, the compensation committee of our board of directors approved the IN8bio, Inc. 2026 Inducement Plan (the &#8220;Inducement Plan&#8221;), and reserved 500,000 shares of common stock to be used exclusively for grants of inducement awards to individuals who were not previously employees or directors of the Company, other than following a bona fide period of non-employment, as an inducement material to the individual&#8217;s entry into employment with us within the meaning of Rule 5635(c)(4). As permitted by Nasdaq Rule 5635(c)(4), our stockholders are not required to approve the Inducement Plan. The terms and conditions of the Inducement Plan and the inducement awards to be granted thereunder are substantially similar to our stockholder-approved Amended and Restated 2026 Equity Incentive Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing description of the Inducement Plan is not intended to be complete and is qualified in its entirety by reference to the Inducement Plan, the Form of Stock Option Grant Notice and Stock Option Agreement and the Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement adopted under the Inducement Plan, copies of which are filed herewith as Exhibits 10.1, 10.2 and 10.3, respectively, and incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of our directors or executive officers (as defined in Rule 16a-1(f) under the Exchange Act) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_780b95bc-8bcd-4c30-879c-79c3949cc233" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f9529e9f-a387-4dd6-9a33-e3571323446a" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49b31795-51a3-4441-9f82-729adaf8576a" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="inab:Rule10B51Arrmodifiedflag" format="ixt:fixed-false"><ix:nonNumeric id="F_03ce8597-51bc-407d-98a8-2b51cd8a9024" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="inab:Nonrule10B51Arrmodifiedflag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modified</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a644057-2373-4638-a9ad-ad459c590212" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_b77f7f23-4204-4ad7-b2ab-0f9aa93c2a5b" contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a "Rule 10b5-1 trading arrangement" or "non-Rule-10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K, during the fiscal quarter ended June 30, 2026.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_6_exhibits_financial_statement_sche"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)      Exhibits</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:89%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1740279/000110465921099436/tm2030088d31_ex3-1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-39692), filed with the SEC on August 3, 2021)</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1740279/000119312525134487/d927529dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-39692), filed with the SEC on June 4, 2025).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/d634027dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-39692), filed with the SEC on December 7, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IN8bio, Inc. 2026 Inducement Plan.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forms of Stock Option Grant Notice and Stock Option Agreement under the IN8bio, Inc. 2026 Inducement Plan.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the IN8bio, Inc. 2026 Inducement Plan.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1740279/000119312526212128/inab-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated 2026 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-39692), filed with the SEC on May 7, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1740279/000119312526212128/inab-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Forms of Option Grant Notice and Option Agreement under the Amended and Restated 2026 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-39692).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inab-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inab-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inab-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page formatted as Inline XBRL and contained in Exhibit 101.</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:86.667%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indicates a management contract or compensatory plan.</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">This certification is being furnished solely to accompany this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p></td>
    </tr>
   </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">URES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:5.005%;box-sizing:content-box;"/>
     <td style="width:47.047%;box-sizing:content-box;"/>
     <td style="width:3.003%;box-sizing:content-box;"/>
     <td style="width:44.945%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">IN8bio, Inc.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 6, 2026</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ William Ho</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">William Ho</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 6, 2026</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Patrick McCall</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Patrick McCall</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Secretary</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>inab-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-08-06T12:14:13.0102+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8bio, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026 Inducement Plan</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adopted by the Compensation Committee of the Board of Directors:  July 31, 2026</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eligible Award Recipients</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1.  A person who previously served as an Employee or Director will not be eligible to receive Awards under the Plan, other than following a </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period of non-employment.  Persons eligible to receive grants of Awards under this Plan are referred to in this Plan as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eligible Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;  These Awards must be approved by either a majority of the Company&#x2019;s &#x201c;Independent Directors&#x201d; (as such term is defined in Nasdaq Marketplace Rule 5605(a)(2)) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Independent Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or the Company&#x2019;s compensation committee, provided such committee is comprised solely of Independent Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Independent Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in order to comply with the exemption from the stockholder approval requirement for &#x201c;inducement grants&#x201d; provided under Rule 5635(c)(4) of the Nasdaq Marketplace Rules.  Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 (together with any analogous rules or guidance effective after the date hereof, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inducement Award Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan Purpose</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, by means of the Plan, intends to provide (i) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Marketplace Rules, (ii) incentives for Eligible Employees to exert maximum efforts for the success of the Company and any Affiliate and (iii) a means by which Eligible Employees may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Plan provides for the grant of the following Awards: (i) Nonstatutory Stock Options; (ii) SARs; (iii) Restricted Stock Awards; (iv) RSU Awards; (v) Performance Awards; and (vi) Other Awards.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Plan will come into existence on the Effective Date.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares Subject to the Plan</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to adjustment in accordance with Section 2(b) and any adjustments as necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 500,000 shares of Common Stock.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Reserve Operation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limit Applies to Common Stock Issued Pursuant to Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, the Share Reserve is a limit on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following actions do not result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1) the expiration or termination of any portion of an Award without the shares covered by such portion of the Award having been issued, (2) the settlement of any portion of an Award in cash (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Participant receives cash rather than Common Stock), (3) the withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4) the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reversion of Previously Issued Shares of Common Stock to Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following shares of Common Stock previously issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1) any shares that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares; (2) any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3) any shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award. </font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eligibility and Limitations</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eligible Award Recipients</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Awards may only be granted to persons who are Eligible Employees described in Section 1(a) of the Plan, where the Award is an inducement material to the individual&#x2019;s entering into employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the Nasdaq Marketplace Rules or is otherwise permitted pursuant to Rule 5635(c) of the Nasdaq Marketplace Rules.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on Nonstatutory Stock Options and SARs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonstatutory Stock Options and SARs may not be granted to Employees who are providing Continuous Service only to any &#x201c;parent&#x201d; of the Company (as such term is defined in Rule 405) unless the stock underlying such Awards is treated as &#x201c;service recipient stock&#x201d; under Section 409A because the Awards are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution requirements of Section 409A. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Awards must be granted either by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options and Stock Appreciation Rights</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Option and SAR will have such terms and conditions as determined by the Board.  All Options will be Nonstatutory Stock Options.  Each SAR will be denominated in shares of Common Stock equivalents.  The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise or Strike Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Procedure and Payment of Exercise Price for Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company.  The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment.  The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by cash or check, bank draft or money order payable to the Company;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to a &#x201c;cashless exercise&#x201d; program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) at the time of exercise the Common Stock is publicly traded, (2) any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3) such delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4) any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5) such shares have been held by the Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery; </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) such shares used to pay the exercise price will not be exercisable thereafter and (2) any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted form of payment; or</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in any other form of consideration that may be acceptable to the Board and permissible under Applicable Law.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Procedure and Payment of Appreciation Distribution for SARs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement.  The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount equal to the excess of (i) the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii) the strike price of such SAR.  Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in the SAR Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options and SARs may not be transferred to third party financial institutions for value.  The Board may impose such additional limitations on the transferability of an Option or SAR as it determines.  In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictions on Transfer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&#x2019;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671 of the Code and applicable U.S. state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Domestic Relations Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as determined by the Board.  Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company, vesting of Options and SARs will cease upon termination of the Participant&#x2019;s Continuous Service.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Continuous Service for Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as explicitly otherwise provided in the Award Agreement or other written agreement between a Participant and the Company, if a Participant&#x2019;s Continuous Service is terminated for Cause, the Participant&#x2019;s Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Section 4(i), if a Participant&#x2019;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)):</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months following the date of such termination if such termination is a termination without Cause (other than any termination due to the Participant&#x2019;s Disability or death);</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 months following the date of such termination if such termination is due to the Participant&#x2019;s Disability;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 months following the date of such termination if such termination is due to the Participant&#x2019;s death; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 months following the date of the Participant&#x2019;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i) or (ii) above).</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictions on Exercise; Extension of Exercisability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law.  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company, if a Participant&#x2019;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period: (i) the exercise of the Participant&#x2019;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii) the immediate sale of any shares of Common Stock issued upon such exercise would violate the Company&#x2019;s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)).</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Exempt Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of grant of such Award.  Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event of (i) such Participant&#x2019;s death or Disability, (ii) a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii) a Change in Control, or (iv) such Participant&#x2019;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#x2019;s then current employment policies and guidelines).  This Section 4(j) is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whole Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Awards Other Than Options and Stock Appreciation Rights</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Awards and RSU Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions: </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Form of Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSAs: To the extent consistent with the Company&#x2019;s Bylaws, at the Board&#x2019;s election, shares of Common Stock subject to a Restricted Stock Award may be (i) held in book entry form subject to the Company&#x2019;s instructions until such shares become vested or any other restrictions lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock Award. </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs: An RSU Award represents a Participant&#x2019;s right to be issued on a future date the number of shares of Common Stock that is equal to the number of restricted stock units subject to the RSU Award.  As a holder of an RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#x2019;s unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person.  A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award).</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSA: A Restricted Stock Award may be granted in consideration for (A) cash or check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of consideration (including future services)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee may determine and permissible under Applicable Law.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU: Unless otherwise determined by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee at the time of grant, an RSU Award will be granted in consideration for the Participant&#x2019;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the RSU Award.  If, at the time of grant, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee determines that any consideration must be paid by the Participant (in a form other than the Participant&#x2019;s services to the Company or an Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee may determine and permissible under Applicable Law.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined by the Board.  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant&#x2019;s Continuous Service. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Continuous Service.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company, if a Participant&#x2019;s Continuous Service terminates for any reason, (i) the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and the Participant will have no further right, title or interest in the Restricted Stock Award, the shares of Common Stock subject to the Restricted Stock Award, or any consideration in respect of the Restricted Stock Award and (ii) any portion of his or her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends and Dividend Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Settlement of RSU Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  An RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination thereof) or in any other form of </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment, as determined by the Board and specified in the RSU Award Agreement.  At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Other Awards may be granted either alone or in addition to Awards provided for under Section 4 and the preceding provisions of this Section 5.  Subject to the provisions of the Plan, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustments upon Changes in Common Stock; Other Corporate Events</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalization Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i) the class(es) and maximum number of shares of Common Stock subject to the Plan; and (ii) the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock subject to outstanding Awards.  The Board shall make such adjustments, and its determination shall be final, binding and conclusive.  Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created in order to implement any Capitalization Adjustment.  The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions of this Section.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dissolution or Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#x2019;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#x2019;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following provisions will apply to Awards in the event of a Corporate Transaction except as set forth in Section 11, and unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Awards May Be Assumed</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#x2019;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#x2019;s parent company, if any), in connection with such Corporate Transaction.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume or continue the Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution will be set by the Board.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Awards Held by Current Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction).  With respect to the vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction.  With respect to the vesting of Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the occurrence of the Corporate Transaction. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Awards Held by Persons other than Current Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment for Awards in Lieu of Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (1) the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (2) any exercise price payable by such holder in connection with such exercise.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appointment of Stockholder Representative</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#x2019;s behalf with respect to any escrow, indemnities and any contingent consideration.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Restriction on Right to Undertake Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The grant of any Award under the Plan and the issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#x2019;s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administration</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administration by Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board will administer the Plan; provided however, that Awards may only be granted by either (i) a majority of the Company&#x2019;s Independent Directors or (ii) the Independent Compensation Committee.  Subject to those constraints and the other constraints of the Inducement Award Rules, the Board may delegate some of its powers of administration of the Plan to a Committee or Committees, as provided in subsection (c) below. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Powers of Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan and Inducement Award Rules:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine from time to time: (1) which of the persons eligible under the Plan will be granted Awards; (2) when and how each Award will be granted; (3) what type or combination of types of Award will be granted; (4) the provisions of each Award granted (which need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5) the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such person; (6) the Fair Market Value applicable to an Award; and (7) the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment or other property that may be earned and the timing </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of payment; provided, however, that Awards may only be granted by either (i) a majority of the Company&#x2019;s Independent Directors or (ii) the Independent Compensation Committee.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration.  The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To settle all controversies regarding the Plan and Awards granted under it.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock including any Corporate Transaction, for reasons of administrative convenience.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To suspend or terminate the Plan at any time.  Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To amend the Plan in any respect the Board deems necessary or advisable; provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that stockholder approval will be required for any amendment to the extent required by Applicable Law.  Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(viii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To submit any amendment to the Plan for stockholder approval.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ix)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, a Participant&#x2019;s rights under any Award will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(x)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(xi)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Eligible Employees who are non-U.S. nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant non-U.S. jurisdiction).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delegation to Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms of Section 3(b), the Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board.  Each Committee may retain the authority to concurrently administer the Plan with the Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated.  The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 16b-3 Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent an Award is intended to qualify for the exemption from Section 16(b) of the Exchange Act that is available under Rule 16b-3 of the Exchange Act, the Award will be granted by a Committee that consists solely of two or more Non-Employee Directors, as determined under Rule 16b-3(b)(3) of the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by a Committee meeting such requirements to the extent necessary for such exemption to remain available.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effect of Board&#x2019;s Decision</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Withholding</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for (including), any sums required to satisfy any U.S. and/or non-U.S. federal, state, or local tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable.  Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Satisfaction of Withholding Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any U.S. and/or non-U.S.  federal, state, or local tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; (v) by allowing a Participant to effectuate a &#x201c;cashless exercise&#x201d; pursuant to a program developed under Regulation T as promulgated by the U.S. Federal Reserve Board; or (vi) by such other method as may be set forth in the Award Agreement. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Obligation to Notify or Minimize Taxes; No Liability to Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as required by Applicable Law the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award.  Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award.  As a condition to accepting an Award under the Plan, each Participant (i) agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii) acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so.  Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from Section 409A only if the exercise or strike price is at least equal to the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award.  Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the U.S. Internal Revenue Service asserts that such exercise price or strike price is less than the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as subsequently determined by the U.S. Internal Revenue Service.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a condition to accepting an Award under the Plan, in the event that the amount of the Company&#x2019;s and/or its Affiliate&#x2019;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Source of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds from Sales of Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Action Constituting Grant of Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholder Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until (i) such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii) the issuance of the Common Stock subject to such Award is reflected in the records of the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Employment or Other Service Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#x2019;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the U.S. state or non-U.S. jurisdiction in which the Company or the Affiliate is incorporated, as the case may be.  Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Time Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event a Participant&#x2019;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Execution of Additional Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#x2019;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Plan Administrator&#x2019;s request.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Electronic Delivery and Participation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any reference herein or in an Award Agreement to a &#x201c;written&#x201d; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#x2019;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).  By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator.  The form of delivery of any Common Stock (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clawback/Recovery</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#x2019;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#x2019;s right to voluntarily terminate employment upon a &#x201c;resignation for good reason,&#x201d; or for a &#x201c;constructive termination&#x201d; or any similar term under any plan of or agreement with the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Law Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Participant will not be issued any shares in respect of an Award unless either (i) the shares are registered under the Securities Act; or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.  Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer or Assignment of Awards; Issued Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as expressly provided in the Plan or the form of Award Agreement, Awards granted under the Plan may not be transferred or assigned by the Participant.  After the vested shares subject to an Award have been issued, or in the case of a Restricted Stock Award and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effect on Other Employee Benefit Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The value of any Award granted under the Plan, as determined upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#x2019;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides.  The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#x2019;s or any Affiliate&#x2019;s employee benefit plans.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferrals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants.  Deferrals will be made in accordance with the requirements of Section 409A.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(n)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A, and, to the extent not so exempt, in compliance with the requirements of Section 409A.  If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#x201c;deferred compensation&#x201d; under Section 409A is a &#x201c;specified employee&#x201d; for purposes of Section 409A, no distribution or payment of any amount that is due because of a &#x201c;separation from service&#x201d; (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#x2019;s &#x201c;separation from service&#x201d; or, if earlier, the date of the Participant&#x2019;s death, unless such distribution or payment can be made in a manner that complies with Section 409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(o)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Choice of Law</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of Delaware.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covenants of the Company</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will seek to obtain from each regulatory commission or agency, as may be deemed necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained.  A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law.</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Rules for Awards Subject to Section 409A</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Application</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a Non-Exempt Award. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Exempt Awards Subject to Non-Exempt Severance Arrangements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent a Non-Exempt Award is subject to Section 409A due to application of a Non-Exempt Severance Arrangement, the following provisions of this subsection (b) apply. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Non-Exempt Award vests in the ordinary course during the Participant&#x2019;s Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event will the shares be issued in respect of such Non-Exempt Award any later than the later of: (i) December 31</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the calendar year that includes the applicable vesting date, or (ii) the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day that follows the applicable vesting date. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant&#x2019;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and, therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement of such Non-Exempt Award upon the Participant&#x2019;s Separation from Service in accordance with the terms of the Non-Exempt Severance Arrangement, but in no event later than the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day that follows the date of the Participant&#x2019;s Separation from Service.  However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section 409A applicable to &#x201c;specified employees,&#x201d; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of such Participant&#x2019;s Separation from Service, or, if earlier, the date of the Participant&#x2019;s death that occurs within such six month period.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant&#x2019;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during the Participant&#x2019;s Continuous Service, notwithstanding the vesting acceleration of the Non-Exempt Award.  Such issuance schedule is </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intended to satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided under Treasury Regulations Section 1.409A-3(a)(4).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment of Non-Exempt Awards Upon a Corporate Transaction for Employees and Consultants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions of this subsection (c)shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non-Exempt Award in connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the Non-Exempt Award.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vested Non-Exempt Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following provisions shall apply to any Vested Non-Exempt Award in connection with a Corporate Transaction:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Vested Non-Exempt Award.  Upon the Section 409A Change in Control the settlement of the Vested Non-Exempt Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award.  Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or substitute each Vested Non-Exempt Award.  The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred.  In the Acquiring Entity&#x2019;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unvested Non-Exempt Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following provisions shall apply to any Unvested Non-Exempt Award unless otherwise determined by the Board pursuant to subsection (d) of this Section.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested Non-Exempt Award.  Unless otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction.  The shares to be issued in respect of any Unvested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred.  In the Acquiring Entity&#x2019;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction. </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in respect of such forfeited Unvested Non-Exempt Award.  Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section 409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of the Unvested Non-Exempt Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in Section 11(d)(ii) below.  In the absence of such discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with the Corporate Transaction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(3)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section 409A Change in Control.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the RSU Award is a Non-Exempt Award, then the provisions in this Section 11(d) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section 409A.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements of Section 409A, including pursuant to any of the exemptions available in Treasury Regulations Section 1.409A-3(j)(4)(ix).</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section 409A, the Change in Control or Corporate Transaction event triggering settlement must also constitute a Section 409A Change in Control.  To the extent the terms of a Non-Exempt Award provides that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section 409A, the termination event triggering settlement must also constitute a Separation From Service.  However, if at the time the shares would otherwise be issued to a Participant in connection with a &#x201c;separation from service&#x201d; such Participant is subject to the distribution limitations contained in Section 409A applicable to &#x201c;specified employees,&#x201d; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#x2019;s Separation From Service, or, if earlier, the date of the Participant&#x2019;s death that occurs within such six month period.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions in this Section 11(d) for delivery of the shares in respect of the settlement of an RSU Award that is a Non-Exempt Award are intended to comply with the </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements of Section 409A so that the delivery of the shares to the Participant in respect of such Non-Exempt Award will not trigger the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid.  Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of the Plan</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:7.56%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board may suspend or terminate the Plan at any time.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As used in the Plan, the following definitions apply to the capitalized terms indicated below:</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquiring Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the surviving or acquiring corporation (or its parent company) in connection with a Corporate Transaction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at the time of determination, any &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act.  The Board may determine the time or times at which &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; status is determined within the foregoing definition.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Code and any applicable U.S. or non-U.S. securities, federal, state, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any right to receive Common Stock, cash or other property granted under the Plan (including a Nonstatutory Stock Option, a Restricted Stock Award, a RSU Award, a SAR, a Performance Award or any Other Award).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.  The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided to a Participant along with the Grant Notice. </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Board of Directors of the Company (or its designee).  Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding on all Participants.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalization Adjustment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) the Participant&#x2019;s theft, dishonesty, willful misconduct, breach of fiduciary duty for personal profit, or falsification of any Company or Affiliate documents or records; (ii) the Participant&#x2019;s material failure to abide by the Company&#x2019;s Code of Conduct or other policies (including, without limitation, policies relating to confidentiality and reasonable workplace conduct and policies of any Affiliate, as applicable); (iii) the Participant&#x2019;s unauthorized use, misappropriation, destruction, or diversion of any tangible or intangible asset or corporate opportunity of the Company or any of its Affiliates (including, without limitation, the Participant&#x2019;s improper use or disclosure of Company or Affiliate confidential or proprietary information); (iv) any intentional act by the Participant which has a material detrimental effect on the Company&#x2019;s or its Affiliate&#x2019;s reputation or business; (v) the Participant&#x2019;s repeated failure or inability to perform any reasonable assigned duties after written notice from the Company (or its Affiliate, as applicable) of, and a reasonable opportunity to cure, such failure or inability; (vi) any material breach by the Participant of any employment or service agreement between the Participant and the Company (or its Affiliate, as applicable), which breach is not cured pursuant to the terms of such agreement; or (vii) the Participant&#x2019;s conviction (including any plea of guilty or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">nolo contendere</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of any criminal act involving fraud, dishonesty, misappropriation or moral turpitude, or which impairs the Participant&#x2019;s ability to perform his or her duties with the Company (or its Affiliate, as applicable).  The determination that a termination of the Participant&#x2019;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the Company&#x2019;s Chief Executive Officer with respect to Participants who are not executive officers of the Company.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events; provided, however, to the extent necessary to avoid adverse personal income tax consequences to </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Participant in connection with an Award, such event also constitutes a Section 409A Change in Control:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#x2019;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.  Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#x2019;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C) solely because the level of Ownership held by any Exchange Act Person (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subject Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur, except for a liquidation into a parent corporation;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">individuals who, on the date the Plan is adopted by the Board, are members of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Incumbent Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a committee of one or more Independent Directors to whom authority has been delegated by the Board or in accordance with Section 7(c) of the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the common stock of the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means IN8bio, Inc., a Delaware corporation, and any successor corporation thereto.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(n)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#x201c;Consultant&#x201d; for purposes of the Plan.  Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#x2019;s securities to such person.  Consultants are not eligible to receive Awards under the Plan with respect to their service in such capacity.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(o)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continuous Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that the Participant&#x2019;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#x2019;s service with the Company or an Affiliate, will not terminate a Participant&#x2019;s Continuous Service; provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#x2019;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#x2019;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Company or an Affiliate, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#x2019;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.  In addition, to the extent required for exemption from or compliance with Section 409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#x201c;separation from service&#x201d; as defined under U.S. Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(p)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a sale</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its Subsidiaries;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a sale or other disposition of at least 50% of the outstanding securities of the Company;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(q)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a member of the Board.  Directors are not eligible to receive Awards under the Plan with respect to their service in such capacity.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(r)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">determine</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">determined</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means as determined by the Board or the Committee (or its designee) in its sole discretion.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(s)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Section 22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(t)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means July 31, 2026.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(u)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#x201c;Employee&#x201d; for purposes of the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Company or the Affiliate that employs the Participant.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(w)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a corporation, partnership, limited liability company or other entity.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(x)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(y)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means any natural person, Entity or &#x201c;group&#x201d; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#x201c;Exchange Act Person&#x201d; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or &#x201c;group&#x201d; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#x2019;s then outstanding securities.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(z)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(aa)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governmental</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Body</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) U.S. or non-U.S. federal, state, local, municipal, or other government; (c) governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any tax authority) or other body exercising similar powers or authority; or (d) self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(bb)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the notice provided to a Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(cc)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Materially Impair</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means any amendment to the terms of the Award that materially adversely affects the Participant&#x2019;s rights under the Award.  A Participant&#x2019;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#x2019;s rights.  For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#x2019;s rights under the Award: (i) imposition of reasonable restrictions on the minimum number of shares subject to an Option that may be exercised, (ii) to clarify the manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section 409A; or (iii) to comply with other Applicable Laws.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(dd)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Employee Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation S-K</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a &#x201c;non-employee director&#x201d; for purposes of Rule 16b-3.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ee)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Exempt Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means any Award that is subject to, and not exempt from, Section 409A, including as the result of (i) a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company, or (ii) the terms of any Non-Exempt Severance Arrangement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ff)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Exempt Severance Arrangement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a severance arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#x2019;s termination of employment or separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder)) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and such severance benefit does not satisfy the requirements for an exemption from application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(4), 1.409A-1(b)(9) or otherwise.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(gg)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonstatutory Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any option granted pursuant to Section 4 of the Plan that does not qualify as an &#x201c;incentive stock option&#x201d; within the meaning of Section 422 of the Code.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(hh)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(jj)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant.  The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions applicable to the Option and which is provided to a Participant along with the Grant Notice.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(kk)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Optionholder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ll)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant) that is not a Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(mm)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a written agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant.  Each Other Award Agreement will be subject to the terms and conditions of the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(nn)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Own,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Owned,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Owner,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ownership</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means that a person or Entity will be deemed to &#x201c;Own,&#x201d; to have &#x201c;Owned,&#x201d; to be the &#x201c;Owner&#x201d; of, or to have acquired &#x201c;Ownership&#x201d; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(oo)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Eligible Employee to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(pp)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section 5(b) pursuant to such terms as are approved by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee.  In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee may determine that cash or other property may be used in payment of Performance Awards.  Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(qq)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Criteria</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means one or more criteria that a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee will select for purposes of establishing the Performance Goals for a Performance Period.  The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by a majority of the Company&#x2019;s Independent </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors or the Independent Compensation Committee: earnings (including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; return on equity or average stockholder&#x2019;s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders&#x2019; equity; capital expenditures; debt levels; operating profit or net operating profit; workforce diversity; growth of net income or operating income; billings; pre-clinical development related compound goals; financing; regulatory milestones, including approval of a compound; stockholder liquidity; corporate governance and compliance; product commercialization; intellectual property; personnel matters; progress of internal research or clinical programs; progress of partnered programs; partner satisfaction; budget management; clinical achievements; completing phases of a clinical study (including the treatment phase); announcing or presenting preliminary or final data from clinical studies; in each case, whether on particular timelines or generally; timely completion of clinical trials; submission of INDs and NDAs and other regulatory achievements; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; research progress, including the development of programs; investor relations, analysts and communication; manufacturing achievements (including obtaining particular yields from manufacturing runs and other measurable objectives related to process development activities); strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property); establishing relationships with commercial entities with respect to the marketing, distribution and sale of the Company&#x2019;s products (including with group purchasing organizations, distributors and other vendors); supply chain achievements (including establishing relationships with manufacturers or suppliers of active pharmaceutical ingredients and other component materials and manufacturers of the Company&#x2019;s products); co-development, co-marketing, profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and other measures of performance selected by the Company&#x2019;s Independent Directors or the Independent Compensation Committee.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(rr)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Goals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for a Performance Period, one or more goals established by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee for the Performance Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices.  Unless specified otherwise by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; (5) to exclude the effects of items that </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are &#x201c;unusual&#x201d; in nature or occur &#x201c;infrequently&#x201d; as determined under generally accepted accounting principles; (6) to exclude the dilutive effects of acquisitions or joint ventures; (7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8) to exclude the effect of any change in the outstanding shares of Common Stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9) to exclude the effects of stock based compensation and the award of bonuses under the Company&#x2019;s bonus plans; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles.  In addition, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period.  Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Award.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ss)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period of time selected by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#x2019;s right to vesting or exercise of an Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(tt)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means this IN8bio, Inc. 2026 Inducement Plan, as amended from time to time.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(uu)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the person, persons, and/or third-party administrator designated by the Company to administer the day-to-day operations of the Plan and the Company&#x2019;s other equity incentive programs.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(vv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Termination Exercise Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period following termination of a Participant&#x2019;s Continuous Service within which an Option or SAR is exercisable, as specified in Section 4(h).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ww)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(xx)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided to a </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant along with the Grant Notice.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(yy)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(zz)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a written agreement between the Company and a holder of an RSU Award evidencing the terms and conditions of an RSU Award grant.  The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to the RSU Award and which is provided to a Participant along with the Grant Notice.  Each RSU Award Agreement will be subject to the terms and conditions of the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(aaa)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 16b-3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(bbb)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 405</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Rule 405 promulgated under the Securities Act. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ccc)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Section 409A of the Code and the regulations and other guidance thereunder.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ddd)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 409A Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#x2019;s assets, as provided in Section 409A(a)(2)(A)(v) of the Code and Treasury Regulations Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(eee)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Securities Act of 1933, as amended.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(fff)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the number of shares available for issuance under the Plan as set forth in Section 2(a).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ggg)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Appreciation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SAR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 4.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(hhh)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SAR Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written agreement between the Company and a holder of a SAR evidencing the terms and conditions of a SAR grant.  The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided to a Participant along with the Grant Notice.  Each SAR Agreement will be subject to the terms and conditions of the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding Common Stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(jjj)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trading Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Company&#x2019;s policy permitting certain individuals to sell Company shares only during certain &#x201c;window&#x201d; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(kkk)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unvested Non-Exempt Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(lll)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vested Non-Exempt Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>inab-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-08-06T12:14:12.2457+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.2</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8BIO, INC.<br>Stock Option Grant Notice<br>(2026 Inducement Plan)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8bio, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), pursuant to its 2026 Inducement Plan (as may be amended and/or restated as of the Date of Grant set forth below, the</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), has granted to you (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Optionholder</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) a Nonstatutory Stock Option to purchase the number of shares of the Common Stock set forth below (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as an inducement material to you entering into employment with the Company in compliance with Nasdaq Listing Rule 5635(c)(4).  Your Option is subject to all of the terms and conditions as set forth herein and in the Plan, the Stock Option Agreement and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety.  Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.  If the Company uses an electronic capitalization table system (such as Carta or Shareworks) and the fields below are blank or the information is otherwise provided in a different format electronically, the blank fields and other information (such as exercise schedule and type of grant) shall be deemed to come from the electronic capitalization system and is considered part of this Grant Notice.</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:76.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.46%;box-sizing:content-box;"></td>
     <td style="width:33.54%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Optionholder:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date of Grant:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting Commencement Date:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of Shares of Common Stock Subject to Option:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise Price (Per Share):</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Exercise Price:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expiration Date:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;border-bottom:0.5pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Type of Grant:	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonstatutory Stock Option</font></p><p style="text-indent:-20%;padding-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise and</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-20%;padding-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: 	Subject to the Optionholder&#x2019;s Continuous Service through each applicable vesting date, the Option will vest as follows:</font></p><p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[__________]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Optionholder Acknowledgements:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Option is governed by this Stock Option Grant Notice, and the provisions of the Plan, the Stock Option Agreement and the Notice of Exercise, all of which are made a part of this document.  Unless otherwise provided in the Plan, this Grant Notice and the Stock Option Agreement (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You consent to receive this Grant Notice, the Stock Option Agreement, the Plan and any other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You have read and are familiar with the provisions of the Plan and the Stock Option Agreement.  In the event of any conflict between the provisions in this Grant Notice, the Option Agreement, the Notice of Exercise and the terms of the Plan, the terms of the Plan shall control.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of other equity awards previously granted to you and any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this Option.  </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.	</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">IN8bio, Inc.</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Optionholder:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8BIO, Inc.<br>Stock Option Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2026 Inducement Plan)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As reflected by your Stock Option Grant Notice (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) IN8bio, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has granted you a Nonstatutory Stock Option under its 2026 Inducement Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as an inducement material to you entering into employment with the Company in compliance with Nasdaq Listing Rule 5635(c)(4).  Capitalized terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice or Plan, as applicable.  The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option Agreement.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general terms and conditions applicable to your Option are as follows:</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Plan Document.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Your Option is subject to all the provisions of the Plan. Your Option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions of the Plan shall control.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may generally exercise the vested portion of your Option for whole shares of Common Stock at any time during its term by delivery of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance with the exercise procedures established by the Plan Administrator, which may include an electronic submission.  Please review the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent permitted by Applicable Law, you may pay your Option exercise price as follows:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash, check, bank draft or money order;  </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to Company and/or Committee consent at the time of exercise, pursuant to a &#x201c;cashless exercise&#x201d; program as further described in the Plan if at the time of exercise the Common Stock is publicly traded;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to Company and/or Committee consent at the time of exercise, by delivery of previously owned shares of Common Stock as further described in the Plan; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to Company and/or Committee consent at the time of exercise, by a &#x201c;net exercise&#x201d; arrangement as further described in the Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You may not exercise your Option before the commencement of its term or after its term expires.  The term of your Option commences on the Date of Grant and expires upon the earliest of the following:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> immediately upon the termination of your Continuous Service for Cause;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months after the termination of your Continuous Service for any reason other than Cause, Disability or death;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 months after the termination of your Continuous Service due to your Disability;</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 months after your death if you die during your Continuous Service;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">immediately upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate Transaction,</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Expiration Date indicated in your Grant Notice; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the day before the 10th anniversary of the Date of Grant.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, if you die during the period provided in Section 3(b) or 3(c) above, the term of your Option shall not expire until the earlier of (i) eighteen months after your death, (ii) upon any termination of the Option in connection with a Corporate Transaction, (iii) the Expiration Date indicated in your Grant Notice, or (iv) the day before the tenth anniversary of the Date of Grant.  Additionally, the Post-Termination Exercise Period of your Option may be extended as provided in the Plan.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Obligations.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regardless of any action taken by the Company or, if different, the Affiliate to which you provide Continuous Service (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Service Recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) with respect to any income tax, social insurance, payroll tax, fringe benefits tax, payment on account, or other tax&#x2011;related items associated with the grant, vesting or exercise of the Option or sale of the underlying Common Stock or other tax-related items related to your participation in the Plan and legally applicable to you (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), you hereby acknowledge and agree that the Tax Liability is your ultimate responsibility and may exceed the amount, if any, actually withheld by the Company or the Service Recipient.  You further acknowledge that the Company and the Service Recipient (i) make no representations or undertakings regarding any Tax Liability in connection with any aspect of this Option, including, but not limited to, the grant, vesting or exercise of the Option, the issuance of Common Stock pursuant to such exercise, the subsequent sale of shares of Common Stock, and the payment of any dividends on the shares; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate your Tax Liability or achieve a particular tax result.  Further, if you are subject to Tax Liability in more than one jurisdiction, you acknowledge that the Company and/or the Service Recipient (or former service recipient, as applicable) may be required to withhold or account for Tax Liability in more than one jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or the Service Recipient to satisfy all Tax Liability. As further provided in Section 8 of the Plan, you hereby authorize the Company and any applicable Service Recipient to satisfy any applicable withholding obligations with regard to the Tax Liability by one or a combination of the following methods: (i) causing you to pay any portion of the Tax Liability in cash or cash equivalent in a form acceptable to the Company; (ii) withholding from any compensation otherwise payable to you by the Company or the Service Recipient; (iii) withholding from the proceeds of the sale of shares of Common Stock issued upon exercise of the Option (including by means of a &#x201c;cashless exercise&#x201d; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company, or by means of the Company acting as your agent to sell sufficient shares of Common Stock for the proceeds to settle such withholding requirements, on your behalf pursuant to this authorization without further consent); (iv) withholding shares of Common Stock otherwise issuable to you upon the exercise of the Option, provided that to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Board or the Company&#x2019;s Compensation Committee; and/or (v) any other method determined by the Company to be in compliance with Applicable Law.  Furthermore, you agree to pay the Company or the Service Recipient any amount the Company or the Service Recipient may be required to withhold, collect or pay as a result of your participation in the Plan or that cannot be satisfied by the means previously described.  In the event it is determined that the amount of the Tax Liability was greater than the amount withheld by the Company or the Service Recipient, you agree to indemnify and hold the Company and/or the Service Recipient (as applicable) harmless from any failure by the Company or the applicable Service Recipient to withhold the proper amount.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may withhold or account for your Tax Liability by considering statutory withholding amounts or other withholding rates applicable in your jurisdiction(s), including (i) maximum applicable rates in your jurisdiction(s), in which case you may receive a refund of any over-withheld amount in cash (whether from applicable tax authorities or the Company) and you will have no entitlement to the equivalent amount in Common Stock or (ii) minimum or such other applicable rates in your jurisdiction(s), in which case you may be solely </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">responsible for paying any additional Tax Liability to the applicable tax authorities or to the Company and/or the Service Recipient.  If the Tax Liability withholding obligation is satisfied by withholding shares of Common Stock, for tax purposes, you are deemed to have been issued the full number of shares of Common Stock subject to the exercised portion of the Option, notwithstanding that a number of the shares of Common Stock is held back solely for the purpose of paying such Tax Liability.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that you may not be able to exercise your Option even though the Option is vested, and that the Company shall have no obligation to issue shares of Common Stock, in each case, unless and until you have fully satisfied any applicable Tax Liability, as determined by the Company. Unless any withholding obligation for the Tax Liability is satisfied, the Company shall have no obligation to deliver to you any Common Stock in respect of the Option. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonstatutory Stock Option.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Your Option is a Nonstatutory Stock Option and is not intended to qualify as an Incentive Stock Option within the meaning of Section 422 of the Code.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferability.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Except as otherwise provided in the Plan, your Option is not transferable, except by will or by the applicable laws of descent and distribution, and is exercisable during your life only by you.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Your Option is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Liability for Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  As a condition to accepting the Option, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the Option or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the Option and have either done so or knowingly and voluntarily declined to do so. Additionally, you acknowledge that the Option is exempt from Section 409A only if the exercise price is at least equal to the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Option.  Additionally, as a condition to accepting the Option, you agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise is less than the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations; Recoupment.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> You hereby acknowledge that the grant of your Option is additional consideration for any obligations (whether during or after employment) that you have to the Company not to compete, not to solicit its customers, clients or employees, not to disclose or misuse confidential information or similar obligations.  Accordingly, if the Company reasonably determines that you breached such obligations, in addition to any other available remedy, the Company may, to the extent permitted by Applicable Law, recoup any income realized by you with respect to the exercise of your Option within two years of such breach.  In addition, to the extent permitted by Applicable Law, this right to recoupment by the Company applies in the event that your employment is terminated for Cause or if the Company reasonably determines that circumstances existed that it could have terminated your employment for Cause.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indebtedness to the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event that you have any loans, draws, advances or any other indebtedness owing to the Company at the time of exercise of all or a portion of the Option, the Company may deduct and not deliver that number of shares of Common Stock with a Fair Market Value subject to the Option equal to such indebtedness to satisfy all or a portion of such indebtedness, to the extent permitted by law and in a manner consistent with Section 409A of the Code, if applicable.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Documents.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.  In addition, you acknowledge receipt of the Company&#x2019;s Trading Policy.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">13.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Questions. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If you have questions regarding these or any other terms and conditions applicable to your Option, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*  *  *  *</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>inab-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-08-06T12:14:12.2374+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.3</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8BIO, Inc.</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Award Grant Notice<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026 Inducement Plan)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8bio, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has awarded to you (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) the number of restricted stock units specified and on the terms set forth below as an inducement material to your entering into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Marketplace Rules and in consideration of your services (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company&#x2019;s 2026 Inducement Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the Award Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which are incorporated herein in their entirety.  Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Grant:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting Commencement Date:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Number of Restricted Stock Units:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="margin-left:0.173%;text-indent:-19.792%;padding-left:16.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.173%;text-indent:-19.792%;padding-left:16.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: 	[__________________________________________________________________].</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Notwithstanding the foregoing, vesting shall terminate upon the Participant&#x2019;s termination of Continuous Service.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </font></p><p style="text-indent:-20%;padding-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuance Schedule:	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One share of Common Stock will be issued for each restricted stock unit which vests at the time set forth in Section 5 of the Agreement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant Acknowledgements:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU Award is governed by this RSU Award Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and the provisions of the Plan and the Agreement, all of which are made a part of this document.  Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.  </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus.  In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.  </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of: (i) other equity awards previously granted to you, and (ii) any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this RSU Award.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU Award is being granted to you as an inducement material to your entering into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Marketplace Rules. You acknowledge that you qualify as an Eligible Employee under the Plan and that this RSU Award has been approved by either a majority of the Company's Independent Directors or the Independent Compensation Committee in accordance with the Inducement Award Rules.</font></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"><font style="font-variant:small-caps;color:#4f81bd;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8bio, Inc. 	Participant:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Signature	Signature</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8BIO, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026 Inducement Plan</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Agreement (RSU Award)</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As reflected by your Restricted Stock Unit Grant Notice (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), IN8bio, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has granted you a RSU Award under its 2026 Inducement Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) for the number of restricted stock units as indicated in your Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  This RSU Award is granted in compliance with Nasdaq Listing Rule 5635(c)(4) as a material inducement to you entering into employment with the Company.  The terms of your RSU Award as specified in this Award Agreement for your RSU Award (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the Grant Notice constitute your &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;. Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general terms applicable to your RSU Award are as follows:</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Plan Document.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Your RSU Award is subject to all the provisions of the Plan. Your RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant of the RSU Award.  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This RSU Award represents your right to be issued on a future date the number of shares of the Company&#x2019;s Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice subject to your satisfaction of the vesting conditions set forth therein (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of Section 3 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered by your RSU Award.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You shall receive no benefit or adjustment to your RSU Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your RSU Award after such shares have been delivered to you.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="display:inline;" id="ole_link5"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Obligations.</font><font id="ole_link6"></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regardless of any action taken by the Company or, if different, the Affiliate to which you provide Continuous Service (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Service Recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) with respect to any income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax&#x2011;related items associated with the grant or vesting of the RSU Award or sale of the underlying Common Stock or other tax-related items related to your participation in the Plan and legally applicable to you (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), you hereby acknowledge and agree that the Tax Liability is your ultimate responsibility and may exceed the amount, if any, actually withheld by the Company or the Service Recipient.  You further acknowledge that the Company and the Service Recipient (i) make no representations or undertakings regarding any Tax Liability in connection with any aspect of this RSU Award, including, but not limited to, the grant or vesting of the RSU Award, the issuance of Common Stock pursuant to such vesting, the subsequent sale of shares of Common Stock, and the payment of any dividends on the Common Stock; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your Tax Liability or achieve a particular tax result.  Further, if you are subject to Tax Liability in more than one jurisdiction, you acknowledge that the Company and/or the Service Recipient (or former service recipient, as applicable) may be required to withhold or account for Tax Liability in more than one jurisdiction. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or the Service Recipient to satisfy all Tax Liability.  As further provided in Section 8 of the Plan, you hereby authorize the Company and any applicable Service Recipient to satisfy any applicable withholding obligations with regard to the Tax Liability by any of the following means or by a combination of such means: (i) causing you to pay any portion of the Tax Liability in cash or cash equivalent in a </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.7in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">form acceptable to the Company; (ii) withholding from any compensation otherwise payable to you by the Company or the Service Recipient; (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the Award; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, however, that to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Board or the Company&#x2019;s Compensation Committee; (iv) permitting or requiring you to enter into a &#x201c;same day sale&#x201d; commitment, if applicable, with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FINRA Dealer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), pursuant to this authorization and without further consent, whereby you irrevocably elect to sell a portion of the shares of Common Stock to be delivered in connection with your Restricted Stock Units to satisfy the Tax Liability and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Tax Liability directly to the Company or the Service Recipient; and/or (v) any other method determined by the Company to be in compliance with Applicable Law. Furthermore, you agree to pay the Company or the Service Recipient any amount the Company or the Service Recipient may be required to withhold, collect, or pay as a result of your participation in the Plan or that cannot be satisfied by the means previously described.  In the event it is determined that the amount of the Tax Liability was greater than the amount withheld by the Company and/or the Service Recipient (as applicable), you agree to indemnify and hold the Company and/or the Service Recipient (as applicable) harmless from any failure by the Company or the applicable Service Recipient to withhold the proper amount.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may withhold or account for your Tax Liability by considering statutory withholding amounts or other withholding rates applicable in your jurisdiction(s), including (i) maximum applicable rates in your jurisdiction(s), in which case you may receive a refund of any over-withheld amount in cash (whether from applicable tax authorities or the Company) and you will have no entitlement to the equivalent amount in Common Stock or (ii) minimum or such other applicable rates in your jurisdiction(s), in which case you may be solely responsible for paying any additional Tax Liability to the applicable tax authorities or to the Company and/or the Service Recipient.  If the Tax Liability withholding obligation is satisfied by withholding shares of Common Stock, for tax purposes, you are deemed to have been issued the full number of shares of Common Stock subject to the vested portion of the RSU Award, notwithstanding that a number of the shares of Common Stock is held back solely for the purpose of paying such Tax Liability.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that you may not participate in the Plan and the Company shall have no obligation to deliver shares of Common Stock until you have fully satisfied the Tax Liability, as determined by the Company.  Unless any withholding obligation for the Tax Liability is satisfied, the Company shall have no obligation to deliver to you any Common Stock in respect of the RSU Award. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Issuance.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of shares in respect of the Restricted Stock Units is intended to comply with U.S. Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner. Subject to the satisfaction of the Tax Liability withholding obligation, if any, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each vested Restricted Stock Unit on the applicable vesting date. Each issuance date determined by this paragraph is referred to as an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Original Issuance Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day. In addition, if:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Original Issuance Date does not occur (1) during an &#x201c;open window period&#x201d; applicable to you, as determined by the Company in accordance with the Company&#x2019;s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act and was entered into in compliance with the Company&#x2019;s policies (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">10b5-1 Arrangement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)), </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">either (1) a Tax Liability withholding obligation does not apply, or (2) the Company decides, prior to the Original Issuance Date, (A) not to satisfy the Tax Liability withholding obligation by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date, to you under this </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.7in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award, and (B) not to permit you to enter into a &#x201c;same day sale&#x201d; commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit you to pay your Tax Liability in cash, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">then</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the shares that would otherwise be issued to you on the Original Issuance Date will not be delivered on such Original Issuance Date and will instead be delivered on the first business day when you are not prohibited from selling shares of the Common Stock in the open public market, but in no event later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), or, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if and only if</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> permitted in a manner that complies with U.S. Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock under this Award are no longer subject to a &#x201c;substantial risk of forfeiture&#x201d; within the meaning of U.S. Treasury Regulations Section 1.409A-1(d).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferability.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and distribution.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Your RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Liability for Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  As a condition to accepting the RSU Award, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Documents.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.  In addition, you acknowledge receipt of the Company&#x2019;s Trading Policy.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Questions. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If you have questions regarding these or any other terms and conditions applicable to your RSU Award, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.7in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>inab-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-08-06T12:14:12.2215+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">CERTIFICATIONS</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">I, William Ho, certify that:</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1. I have reviewed this Quarterly Report on Form 10-Q of IN8bio, Inc.;</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange act rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"></td>
     <td style="width:46.52%;box-sizing:content-box;"></td>
     <td style="width:4.04%;box-sizing:content-box;"></td>
     <td style="width:43.44%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">IN8bio, Inc.</font></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">August 6, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">/s/ William Ho</font></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">William Ho</font></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Chief Executive Officer<br></font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>inab-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-08-06T12:14:12.2215+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">CERTIFICATIONS</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">I, Patrick McCall, certify that:</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1. I have reviewed this Quarterly Report on Form 10-Q of IN8bio, Inc.;</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange act rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:6.061%;box-sizing:content-box;"></td>
     <td style="width:46.465%;box-sizing:content-box;"></td>
     <td style="width:4.04%;box-sizing:content-box;"></td>
     <td style="width:43.434%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">IN8bio, Inc.</font></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">August 6, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">/s/ Patrick McCall</font></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Patrick McCall</font></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Secretary</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"><br>(Principal Financial and Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>inab-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-08-06T12:14:12.2141+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report on Form 10-Q of IN8bio, Inc. (the &#x201c;Company&#x201d;) for the period ended June 30, 2026 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"></td>
     <td style="width:44%;box-sizing:content-box;"></td>
     <td style="width:4%;box-sizing:content-box;"></td>
     <td style="width:46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">IN8bio, Inc.</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">August 6, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">/s/ William Ho</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">William Ho</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Chief Executive Officer<br></font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">August 6, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">/s/ Patrick McCall</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Patrick McCall</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Secretary<br></font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img122832063_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img122832063_0.jpg
M_]C_X  02D9)1@ ! @$ X0#A  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" :8"[@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:XO_ ,(J?_S3Z_TM3_6_CG_HF>'O_#_C/_G3Z_TM?]'#_A8GP_\ ^AZ\'?\
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M ,_WAK_PG;?_ ./4?\-L?'/_ )_O#7_A.V__ ,>H_P!3LN_Z&N+_ /"*G_\
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M*G_\T^O]+4_UOXY_Z)GA[_P_XS_YT^O]+7_1P_X6)\/_ /H>O!W_ (4^B?\
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M_P!3LN_Z&N+_ /"*G_\ -/K_ $M3_6_CG_HF>'O_  _XS_YT^O\ 2U_T</\
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M^%/HG_R=1_PL3X?_ /0]>#O_  I]$_\ DZO\X_\ X;8^.?\ S_>&O_"=M_\
MX]1_PVQ\<_\ G^\-?^$[;_\ QZC_ %.R[_H:XO\ \(J?_P T^O\ 2U/];^.?
M^B9X>_\ #_C/_G3Z_P!+7_1P_P"%B?#_ /Z'KP=_X4^B?_)U'_"Q/A__ -#U
MX._\*?1/_DZO\X__ (;8^.?_ #_>&O\ PG;?_P"/4?\ #;'QS_Y_O#7_ (3M
MO_\ 'J/]3LN_Z&N+_P#"*G_\T^O]+4_UOXY_Z)GA[_P_XS_YT^O]+7_1P_X6
M)\/_ /H>O!W_ (4^B?\ R=1_PL3X?_\ 0]>#O_"GT3_Y.K_./_X;8^.?_/\
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M^AKB_P#PBI__ #3Z_P!+4_UOXY_Z)GA[_P /^,_^=/K_ $M?]'#_ (6)\/\
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MTM?]'#_A8GP__P"AZ\'?^%/HG_R=1_PL3X?_ /0]>#O_  I]$_\ DZO\X_\
MX;8^.?\ S_>&O_"=M_\ X]1_PVQ\<_\ G^\-?^$[;_\ QZC_ %.R[_H:XO\
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M:XO_ ,(J?_S3Z_TM3_6_CG_HF>'O_#_C/_G3Z_TM?]'#_A8GP_\ ^AZ\'?\
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M ,_WAK_PG;?_ ./4?\-L?'/_ )_O#7_A.V__ ,>H_P!3LN_Z&N+_ /"*G_\
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M*G_\T^O]+4_UOXY_Z)GA[_P_XS_YT^O]+7_1P_X6)\/_ /H>O!W_ (4^B?\
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M_P!3LN_Z&N+_ /"*G_\ -/K_ $M3_6_CG_HF>'O_  _XS_YT^O\ 2U_T</\
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M_J+]?ZWO_6KCS_HF>'?_ !(,7_\ .GU_I:_IG_PL3X?_ /0]>#O_  I]$_\
MDZC_ (6)\/\ _H>O!W_A3Z)_\G5^9G_##'P$_P"?#Q1_X4EQ_P#&*/\ AACX
M"?\ /AXH_P#"DN/_ (Q1_8.2_P#0TQ__ (;Z/E_U%^O];G^M7'G_ $3/#O\
MXD&+_P#G3Z_TM?TS_P"%B?#_ /Z'KP=_X4^B?_)U'_"Q/A__ -#UX._\*?1/
M_DZOS,_X88^ G_/AXH_\*2X_^,4?\,,? 3_GP\4?^%)<?_&*/[!R7_H:8_\
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MU<>?]$SP[_XD&+_^=/K_ $M?TS_X6)\/_P#H>O!W_A3Z)_\ )U'_  L3X?\
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M .,4?\,,? 3_ )\/%'_A27'_ ,8H_L')?^AIC_\ PWT?+_J+]?ZW/]:N//\
MHF>'?_$@Q?\ \Z?7^EK^F?\ PL3X?_\ 0]>#O_"GT3_Y.H_X6)\/_P#H>O!W
M_A3Z)_\ )U?F9_PPQ\!/^?#Q1_X4EQ_\8H_X88^ G_/AXH_\*2X_^,4?V#DO
M_0TQ_P#X;Z/E_P!1?K_6Y_K5QY_T3/#O_B08O_YT^O\ 2U_3/_A8GP__ .AZ
M\'?^%/HG_P G4?\ "Q/A_P#]#UX._P#"GT3_ .3J_,S_ (88^ G_ #X>*/\
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MZW/]:N//^B9X=_\ $@Q?_P Z?7^EK^F?_"Q/A_\ ]#UX._\ "GT3_P"3J/\
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MXH_\*2X_^,4?V#DO_0TQ_P#X;Z/E_P!1?K_6Y_K5QY_T3/#O_B08O_YT^O\
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M_P *?1/_ ).H_P"%B?#_ /Z'KP=_X4^B?_)U?F9_PPQ\!/\ GP\4?^%)<?\
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M?]1?K_6Y_K5QY_T3/#O_ (D&+_\ G3Z_TM?TS_X6)\/_ /H>O!W_ (4^B?\
MR=1_PL3X?_\ 0]>#O_"GT3_Y.K\S/^&&/@)_SX>*/_"DN/\ XQ1_PPQ\!/\
MGP\4?^%)<?\ QBC^P<E_Z&F/_P##?1\O^HOU_K<_UJX\_P"B9X=_\2#%_P#S
MI]?Z6OZ9_P#"Q/A__P!#UX._\*?1/_DZC_A8GP__ .AZ\'?^%/HG_P G5^9G
M_##'P$_Y\/%'_A27'_QBC_AACX"?\^'BC_PI+C_XQ1_8.2_]#3'_ /AOH^7_
M %%^O];G^M7'G_1,\._^)!B__G3Z_P!+7],_^%B?#_\ Z'KP=_X4^B?_ "=1
M_P +$^'_ /T/7@[_ ,*?1/\ Y.K\S/\ AACX"?\ /AXH_P#"DN/_ (Q7R'^T
MO^SW\._AA\0?V7/#?A.'6+?3?BQ\9].\%>+Q>:HU[/-H,QL6EAL)98?]!N)!
M-(AN8U:15;*;'"N.W+^$LLS+%0P>'S3&*K4IXBHG4P-.,.7#8>IBJMY+%3:?
MLZ-3E5G>5DVEJ^7&\:\;X##RQ5?AG('3A.A3?L\_Q<I<V(KTL/3LGE45;VE6
M/,[Z1N];6?[W_P#"Q/A__P!#UX._\*?1/_DZC_A8GP__ .AZ\'?^%/HG_P G
M5^9G_##'P$_Y\/%'_A27'_QBC_AACX"?\^'BC_PI+C_XQ7%_8.2_]#3'_P#A
MOH^7_47Z_P!;]7^M7'G_ $3/#O\ XD&+_P#G3Z_TM?TS_P"%B?#_ /Z'KP=_
MX4^B?_)U'_"Q/A__ -#UX._\*?1/_DZOS,_X88^ G_/AXH_\*2X_^,4?\,,?
M 3_GP\4?^%)<?_&*/[!R7_H:8_\ \-]'R_ZB_7^MS_6KCS_HF>'?_$@Q?_SI
M]?Z6OZ9_\+$^'_\ T/7@[_PI]$_^3J/^%B?#_P#Z'KP=_P"%/HG_ ,G5^9G_
M  PQ\!/^?#Q1_P"%)<?_ !BC_AACX"?\^'BC_P *2X_^,4?V#DO_ $-,?_X;
MZ/E_U%^O];G^M7'G_1,\._\ B08O_P"=/K_2U_3/_A8GP_\ ^AZ\'?\ A3Z)
M_P#)U'_"Q/A__P!#UX._\*?1/_DZOS,_X88^ G_/AXH_\*2X_P#C%'_##'P$
M_P"?#Q1_X4EQ_P#&*/[!R7_H:8__ ,-]'R_ZB_7^MS_6KCS_ *)GAW_Q(,7_
M /.GU_I:_IG_ ,+$^'__ $/7@[_PI]$_^3J/^%B?#_\ Z'KP=_X4^B?_ "=7
MYF?\,,? 3_GP\4?^%)<?_&*/^&&/@)_SX>*/_"DN/_C%']@Y+_T-,?\ ^&^C
MY?\ 47Z_UN?ZU<>?]$SP[_XD&+_^=/K_ $M?TS_X6)\/_P#H>O!W_A3Z)_\
M)U'_  L3X?\ _0]>#O\ PI]$_P#DZOS,_P"&&/@)_P ^'BC_ ,*2X_\ C%'_
M  PQ\!/^?#Q1_P"%)<?_ !BC^P<E_P"AIC__  WT?+_J+]?ZW/\ 6KCS_HF>
M'?\ Q(,7_P#.GU_I:_IG_P +$^'_ /T/7@[_ ,*?1/\ Y.H_X6)\/_\ H>O!
MW_A3Z)_\G5^9G_##'P$_Y\/%'_A27'_QBC_AACX"?\^'BC_PI+C_ .,4?V#D
MO_0TQ_\ X;Z/E_U%^O\ 6Y_K5QY_T3/#O_B08O\ ^=/K_2U_3/\ X6)\/_\
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MKCS_ *)GAW_Q(,7_ /.GU_I:_IG_ ,+$^'__ $/7@[_PI]$_^3J/^%B?#_\
MZ'KP=_X4^B?_ "=7YF?\,,? 3_GP\4?^%)<?_&*/^&&/@)_SX>*/_"DN/_C%
M']@Y+_T-,?\ ^&^CY?\ 47Z_UN?ZU<>?]$SP[_XD&+_^=/K_ $M?TS_X6)\/
M_P#H>O!W_A3Z)_\ )U'_  L3X?\ _0]>#O\ PI]$_P#DZOS,_P"&&/@)_P ^
M'BC_ ,*2X_\ C%'_  PQ\!/^?#Q1_P"%)<?_ !BC^P<E_P"AIC__  WT?+_J
M+]?ZW/\ 6KCS_HF>'?\ Q(,7_P#.GU_I:_IG_P +$^'_ /T/7@[_ ,*?1/\
MY.H_X6)\/_\ H>O!W_A3Z)_\G5^9G_##'P$_Y\/%'_A27'_QBC_AACX"?\^'
MBC_PI+C_ .,4?V#DO_0TQ_\ X;Z/E_U%^O\ 6Y_K5QY_T3/#O_B08O\ ^=/K
M_2U_3/\ X6)\/_\ H>O!W_A3Z)_\G4?\+$^'_P#T/7@[_P *?1/_ ).K\S/^
M&&/@)_SX>*/_  I+C_XQ1_PPQ\!/^?#Q1_X4EQ_\8H_L')?^AIC_ /PWT?+_
M *B_7^MS_6KCS_HF>'?_ !(,7_\ .GU_I:_IG_PL3X?_ /0]>#O_  I]$_\
MDZC_ (6)\/\ _H>O!W_A3Z)_\G5^9G_##'P$_P"?#Q1_X4EQ_P#&*/\ AACX
M"?\ /AXH_P#"DN/_ (Q1_8.2_P#0TQ__ (;Z/E_U%^O];G^M7'G_ $3/#O\
MXD&+_P#G3Z_TM?TS_P"%B?#_ /Z'KP=_X4^B?_)U'_"Q/A__ -#UX._\*?1/
M_DZOS,_X88^ G_/AXH_\*2X_^,4?\,,? 3_GP\4?^%)<?_&*/[!R7_H:8_\
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M_P!#7%_^$5/_ .:?7^EJ?ZW\<_\ 1,\/?^'_ !G_ ,Z?7^EK_HX?\+$^'_\
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M_>&O_"=M_P#X]1_J=EW_ $-<7_X14_\ YI]?Z6I_K?QS_P!$SP]_X?\ &?\
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M_'/_ $3/#W_A_P 9_P#.GU_I:_Z.'_"Q/A__ -#UX._\*?1/_DZC_A8GP_\
M^AZ\'?\ A3Z)_P#)U?YQ_P#PVQ\<_P#G^\-?^$[;_P#QZC_AMCXY_P#/]X:_
M\)VW_P#CU'^IV7?]#7%_^$5/_P":?7^EJ?ZW\<_]$SP]_P"'_&?_ #I]?Z6O
M^CA_PL3X?_\ 0]>#O_"GT3_Y.H_X6)\/_P#H>O!W_A3Z)_\ )U?YQ_\ PVQ\
M<_\ G^\-?^$[;_\ QZC_ (;8^.?_ #_>&O\ PG;?_P"/4?ZG9=_T-<7_ .$5
M/_YI]?Z6I_K?QS_T3/#W_A_QG_SI]?Z6O^CA_P +$^'_ /T/7@[_ ,*?1/\
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M6I_K?QS_ -$SP]_X?\9_\Z?7^EK_ *.'_"Q/A_\ ]#UX._\ "GT3_P"3J/\
MA8GP_P#^AZ\'?^%/HG_R=7^<?_PVQ\<_^?[PU_X3MO\ _'J/^&V/CG_S_>&O
M_"=M_P#X]1_J=EW_ $-<7_X14_\ YI]?Z6I_K?QS_P!$SP]_X?\ &?\ SI]?
MZ6O^CA_PL3X?_P#0]>#O_"GT3_Y.H_X6)\/_ /H>O!W_ (4^B?\ R=7^<?\
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MPL3X?_\ 0]>#O_"GT3_Y.H_X6)\/_P#H>O!W_A3Z)_\ )U?YQ_\ PVQ\<_\
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M_J=EW_0UQ?\ X14__FGU_I:G^M_'/_1,\/?^'_&?_.GU_I:_Z.'_  L3X?\
M_0]>#O\ PI]$_P#DZC_A8GP__P"AZ\'?^%/HG_R=7^<?_P -L?'/_G^\-?\
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M'/\ Y_O#7_A.V_\ \>H_X;8^.?\ S_>&O_"=M_\ X]1_J=EW_0UQ?_A%3_\
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M#W_A_P 9_P#.GU_I:_Z.'_"Q/A__ -#UX._\*?1/_DZC_A8GP_\ ^AZ\'?\
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ML3X?_P#0]>#O_"GT3_Y.H_X6)\/_ /H>O!W_ (4^B?\ R=7^<?\ \-L?'/\
MY_O#7_A.V_\ \>H_X;8^.?\ S_>&O_"=M_\ X]1_J=EW_0UQ?_A%3_\ FGU_
MI:G^M_'/_1,\/?\ A_QG_P Z?7^EK_HX?\+$^'__ $/7@[_PI]$_^3J/^%B?
M#_\ Z'KP=_X4^B?_ "=7^<?_ ,-L?'/_ )_O#7_A.V__ ,>H_P"&V/CG_P _
MWAK_ ,)VW_\ CU'^IV7?]#7%_P#A%3_^:?7^EJ?ZW\<_]$SP]_X?\9_\Z?7^
MEK_HX?\ "Q/A_P#]#UX._P#"GT3_ .3J/^%B?#__ *'KP=_X4^B?_)U?YQ__
M  VQ\<_^?[PU_P"$[;__ !ZC_AMCXY_\_P!X:_\ "=M__CU'^IV7?]#7%_\
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MV7?]#7%_^$5/_P":?7^EJ?ZW\<_]$SP]_P"'_&?_ #I]?Z6O^CA_PL3X?_\
M0]>#O_"GT3_Y.H_X6)\/_P#H>O!W_A3Z)_\ )U?YQ_\ PVQ\<_\ G^\-?^$[
M;_\ QZC_ (;8^.?_ #_>&O\ PG;?_P"/4?ZG9=_T-<7_ .$5/_YI]?Z6I_K?
MQS_T3/#W_A_QG_SI]?Z6O^CA_P +$^'_ /T/7@[_ ,*?1/\ Y.H_X6)\/_\
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M ,_WAK_PG;?_ ./4?ZG9=_T-<7_X14__ )I]?Z6I_K?QS_T3/#W_ (?\9_\
M.GU_I:_Z.'_"Q/A__P!#UX._\*?1/_DZC_A8GP__ .AZ\'?^%/HG_P G5_G'
M_P##;'QS_P"?[PU_X3MO_P#'J/\ AMCXY_\ /]X:_P#"=M__ (]1_J=EW_0U
MQ?\ X14__FGU_I:G^M_'/_1,\/?^'_&?_.GU_I:_Z.'_  L3X?\ _0]>#O\
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MN]=TGPM'X?UK1(="@T&XN5T2;4=6MM>:ZU6PU&2+3TLA:RW'Z)?%WP3\(_\
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MUE<^$=:TB:Y\<ZM_;WV:\35++6K:XLM*N[73]3@GL;&X6R%WYL<ZS+$QK8K
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M17+;WDHV?#;!YCC*E5R^ITG!3E"RE4J5%?F5**TO)+F=DWS7?*W(_GX\3_\
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M]/"OPUNO!'P^\.>.?BK\8;S7[+2&\42WUOH.C^&/ 0TJXU:]UD:,]IJ^JO\
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M21^;%/:>%M>U33/%%T+B+$MLEOHTDES&\;VZ2++&6_4C_@C/^Q9X"\2_M_\
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MG]K7!M-'U#Q+X>O+?0=9O%C\Z2ST7Q) EQX?U>\AB_>3VNFZG=7$"$/-'&K
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ML'>I%1G"7/07*U9)Z)2322L[=&>3?\%//V\/V@?C+^Q9\5OAKX]_X)X_M#_
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MJYT_XZ?$GQ7J?P+\4>,-,E;2=3TJ;PI;7.H>(_&.CS6?E&#7->\+KX;CEN;
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MV)QLX3Q$XUYPBXPC"\4HP7Q-JTFTG*R<?=ZW/[87=(T>21UCCC5GDD=@B(B
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M#ZPJEN>LWI-Q23;D^5N]U9M7]U)'[?\ _!(?]J_Q_P#M-? +Q#I?Q2OYM?\
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MG^&]1#G8-(UGQ/K^@6FN1LCM>:*^H6$9AENX[J#]J?VY_P!H']M+X"?\(#X
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MB;]FW_A _P!HKX?_ +2&AV'E:%\<_"W_  C_ (KN(8\HGQ$^'-O9::EU=R*
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M33M)QYI.+YKVLDE_/>G[!7[:3^--.^'8_9=^-R>-=4TE]?M/#TWP^\007O\
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M?*WP/_9F^/\ ^TGJ]]HGP)^$GC?XGWNE+"^L2^&-&GN=*T1;GS/LO]N:]/\
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M3Q$=4/A'P]?:EI^C+.)&MWUW65B71]#CN?*D6VDU>_LDN)$,<+22?+7]I?\
MP6>_9>\*?M)_L/>)?C/-X4?0_BY\"_"47Q1\+WVJ16]GXBTKPPG]GZE\1? W
MB"6UEN8IH$\.C4+\Z>EQ=0V_BG0[%[*Y6&>]:[]D_P""2_A7P9X;_P"";WP'
MN/@Q:>&K?5_%/@35?$>M:I/:O]EU?XLW=[JEGX@N?%TVGM%J>H_V5XBLO^$?
MG8S_ &VWT'1K+3;"2"VL[*.(GQ'_ ,)L<7##Q^L/$?59TY3;I0FH.I[1R2YI
M0E%>[%6=^9<S4+R(Y)?&RP\JS]C[#ZQ":BO:3CS*'+RMVC)2;N]5;E=O>LOX
MX/&/_!+?_@H-X$TJ76O$'[*7Q3DT^"TDO9W\.:?IOC6Y@MH4:262?3_!FIZ_
MJ$)BC5GDCDM5E15+,@%<[^PQ^S?\5_C;^T3\+9?"WP;\5_$OP7X"^-GP>'QA
M2R\(77B/P_X:\-ZAXYM6U"'QU;/:7%E::3>Z3HGB$7UOJ\0MI[+3M3CN(VBA
MG4?U??#W]K3_ (*@?L]>,?&DG[=/[)^H_%7X/6VD:A<^'?'/[''A/2O'^OVN
MMV^I60MWF\-#XB6^KGP3)I)U26:ZU[0-&\0Z=-!8W%T+BUDNS;_F5X;_ ."K
M^@Z'_P %&;O4/V.OA/9^%?!/[87CS]G+P3^T!I_QQ\#7&D>,K/Q]H?C;Q)X,
MU_7_  CIO@?XF-H^C7VI>'?&EM-JMUKL.IW%]XLLKK4;[2%E>]EU?2GF698B
MEBH+#X2JXT'.GB,-7<\-=N//";YI3C-4G.44W%\\5%QM*ZF>!P-&IAY.MB::
M=51J4*]'EK[/EE%<L8N#GRIZ-.$FU*ZL_P!!/^"R7["OAGQ%^R;HMC^R?^R9
MX,G^)L?QE\'W5ZGP2^#?A?3O&/\ PB4?ASQM%JK33>$= M-5?1!J,VC?;8C(
MUHUR;%YD+QQ,O\8NH>!?&FE>-+SX<:CX3\1VGQ!T_P 1S^$+WP1-HVH#Q7;^
M*[74&TF?PW)H MSJG]MQ:FC:>VF"V-Y]L'V<0F7"U_H _P#!5C]LCXG_ +#G
M[,^D?&3X2Z)X$U_Q1J'Q6\+>!9K+XA:7K^KZ$FD:WH/B_5;NXBM?#GB;PI?C
M44N/#]G';S/J<ELD$MTLEG+(\,L'PW_P1$^#>C?%NW^./_!1WXG^&_#MS\;/
MC_\ &/X@/H+6.CR1Z%X$T=]2.H^*KCP*FK7NL:GILGB3Q/J^K:3=7$VI7E_;
MZ)X?LM-349%O=9^V^=E69U\#E57$UZ:JT(U7"@W5E[6I7DXKV<KJ2C3C!.7-
M9NT6DFVD=F88"EBLQIT*,G3JNFI5DH)4Z=&*=IQM;FG)M1MHKM7:6I_-OIG_
M  2O_P""ANKZ#)XCM/V3?BO%I\:JS6^IZ;IVB:\0P+#R_"VLZG8>)Y6 !W+%
MI#LAPK ,0#\7^._A_P".OA?XHU/P3\2/!WB;P'XOT:41:KX9\7Z)J/A[7+!V
MR8S<Z9JMO:W<<<R_O+>8Q>3<1%9H'DB97/\ 3[\:O^#B?QIX(_:4\3^$OAY\
M%O 7B?X!>"O&VH>%;K4M7O\ Q%#\1?&>FZ#JK:7J?B/P_J]KJL'ASP]!JOV6
M\O- L-3\+ZW*MI+8-J5Q#.UQ;Q?H+_P5L_9]^%?[9/[ &K?M$^'=/LKCQ;\-
M_A=9_'SX4>.C9F'59?A_/I%AXQ\2:!>R1?OYM'U[P2]UJ$>GSN\%EK]II>HC
M8(+KS_1AF^/H5L)',<'2HT<;)1I5*4VY4Y2Y5%5(N4]5SQYE[K2;:NX.+XI9
M;@ZU+$2P.)J5:N%3E4A4BE&:C>[IM1CHU&7*_>NTD[*2D?QS>%?V,OVL/''P
M_M?BMX/_ &=_BYXE^&M[I>I:W:>.=&\$ZW?^&+C1]'EO(=5U*'5X+5[1[+3Y
M=.OH[NX60QPO:7 =@8VQZ=\-?^":'[>'Q<\'V/C[P%^S)\1M4\):I:17^DZM
MJ4&C^%AK&GSHLMMJ.C67BS5M#U+5].NX72:RO]-L[JSO866:UFFC(:O[//\
M@D1'9R_\$S?V98M1CMYM/D\%^-([^&\CCEM);-_B/XY6ZCNHI5:*6W> NL\<
MJM&\1974J2*_.C]F3_@O/K7Q]_;4\)? NY^#?AG0/@G\3/&MSX#\">)+?5-9
M?XA6%U>FXMO!^M>($N)!H%W!KM]#96^H:'9:7ILVAIJV^+6-7;26CU7)YUF=
M6ICX87!4*D<!4J^TJ3G))4Z<JD5[O/%RJ35.4DHO[+5FVC197@:<,%/$8JM!
MXR$'"$8Q_B3C3;][EDHPBYI-R3OS)W239_)5\1/AMX_^$GB_5_ 'Q/\ !OB/
MP#XUT&5(M7\,>*])O-%UFQ,T:SV\DME?112M;7=O)'<V5W&'M;VUEBN;6::"
M6.1MGX2_!7XM_'GQ7'X'^#/PY\8?$SQ7) UX^B^#]#OM:N;.Q22.*34M3>UB
M>WTG2XI98HIM3U.:TT^&26*.6Y1Y$#?U,?\ !RA\,?#UQ\,OV<OC)'IT$?BW
M3/'FO_#*XU6)52ZO_#^O^'KOQ19:?>,J[[J'3-1\-7MQIH=B+*35]4\H W\N
M?U#_ &=_V?;;_@G-^PJFF_!GX-7WQ=^-&F>"M*\1>*O#_ARWT[2?&'Q=^+&M
M&UCG@U36)D:2VT'P_J.KRVEI]H:_?PWX+TF8VMOJ&H1S"_UGQ!;+\)B8T8O%
M8NI.C"E*HHTHSIR4)SE-VM33E!V;BUSI.22<C..3-XW$4)56J&'A&K.JH7J.
M$X\T81@KWFTI*Z37NMJ-VHG\7'Q,_P"":O[=WP@\+WOC3Q_^S)\2=+\+Z99M
MJ&JZQIEIIGBR#2;!/]=?:O'X0U/7KG2K2V7,EW<ZA#;0VD0::Z>*)6<?*OPP
M^'VO_%KXD^ /A;X4A$_B;XC>,_#/@;0(G#&,ZOXJUFRT33VF*\I;QW-[')<2
M<+% LDC%54D?W=_L-_M3?\%$?BI\4=;\%_MC?L:VOP<\&WFBW^J>$?B+X1MM
M1T_2]*U/3Y(73PYXLLM=\:^+9]0;5[.2X-AK6E/IBV]_91VD^CS0ZD;S3/AC
MXB_L-^ _A7_P7+_9/\<>"] LM$^'_P 9]+^*'QCU'P_8(D-CIGQ2^&W@WQ=?
MZ]=Z98JOE6&G:AKE_P"!/$IAC B76=1UI;2.VMQ;1111SZJIXFABZ>&5:EA:
MV)HU,+656C4=*E*HZ;M.I:5HR?Q?9:<4N5RJKE%)QH5L-.NZ4\12H5(8BFZ=
M6'M*D8*:]V-XWDE\/5--ZV^EO^"I/C+P[^P1_P $N3\%_A$R^'/^$DTCPO\
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M,5)O=5)2Z,M8:C0S?%5:CC"AA/\ :E%M)RG**J0A!-IMQG)N*76"6S1]=_\
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M.D8NSTMUU_1S_@Y@)_X3;]D89.!X5^,) [ G5_A[DX]3@9]<#TK[X_X-W_\
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M8T/Q3XAUR^U^^;1DGN;V>/31=:C=6JZ??W.H17.F2/I^I-?V\UPLW[;>%?\
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M3)-&BO6M]3%]86?C/["?P:^''C7_ (*S_P#!37XK^*M&TC6_&OPD\;^!M/\
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MRHM-:.^D)77IW,<KQE#"0QBK.2=:E&$.6/-=I5%KV^)'[O?\&\?_ "83K/\
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M%Q&%AAZKY;2C*,JVO+>[CRU6FUK=W2=K/[Q_X)9_\$M/VO/"_P"VS\-_B/\
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MB"9&BFAT/XP12QN"KQR1_&?XH(Z.IY5D8%6!Y!!!K\R_^#;#XP>&F\&?M$_
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M=/J^62T[Z'YA_P#!O^!_P@/[29P,GQ?\.P3CD@:+XG(!/7 ).!VR?4U\5_\
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M^T_4M+2T/B+P!KWB2:V^WZ;#=7!O_$EY>R2RSE+R(-&(O<?VL_\ @FW^S?\
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M5M$M$O):+H>#.3G.4WO*4I.[;=Y-MW;U>^[U?4^!/^"HW_)A'[1O_8L>'O\
MU//"E?E+_P &^W_(6_:K_P"P=\&/_2GXHU^^_P >O@MX6_:(^$?C7X,>-K_7
M],\+^.["ST[5[_PO=:?9:_;0V6K:?K,+Z;=:KI>M:?#*;K38$D:ZTN\1H&E0
M1J[+(GS]^QW^P+\'?V);CX@W/PJ\2?$KQ!)\2(?#$&N#X@ZQX7U5;1/";Z_)
MIQTD>'/!WA,P-.WB*]^VF\-^)!#:?9Q;;)C/Q5*%26.H8A)>SITY1D[ZW:JI
M677XU^)W4L32CEV(PS;]K5JQG%6TLI46[OI\$OZ9]OT445W'GA1110 4444
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MJ=.DX-J4H5:<[Q<9J49Q<FE=2M+6[:3=C^?S]LO]B+_@GYX/^!FK_'/]G/\
M:ATF/5!966I^&/AO?^/?"WCE/&?VR\M(&T/0-.MQ8^.]'U6U@NWN+TZL-;;3
M#9RP:S:Z6J75Y:^3_L1:%\8/CG^Q?^WS\"=!GUGQ!X2T/P-\/?B)X7\.O/=W
M-IIGC/P[XV;QI>Z=X<ML21PZCXQT7P=J$4NG6P7^U-1T[3V$0N&:<_ISI_\
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MCDT"XL]>TK6&\1Z]-JNF6 T"31HK!WM;2<IJUY?O;VT=DUB]_=6OZ#_M7?L
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M(IS4N=I)2QN7SQ%!U*N*K4<,G/FK2G5=>M[O+[DI<L(0LY.T8\\K1<7%7?\
M9:/BW^SU\=_&WQS_ &3Y?$'AWQQXI\&^$K'2OC/\-[D22QKX7^(^DW=K-IMS
MN$<.IPRZ9<I:>((]-FG?0I-7TRTU-[*]U"UB;^"S_@H[^P_XF_84_:*USX=3
MK?ZE\,_$WVKQ5\'/%UTA<:[X,N+HJ-*OKI$2!_$_A&XD70_$<*K!)-(ECKJ6
M=KINO:8K^2? 7]L'XY_L[_M$P?M0^"_$PU?XISZMX@U7Q1=>+_M^K:3X_P#^
M$MEGN/%&G>.+2RU'2KS6-.UV[G-_=I#J-C=P:G!9:KIUY9:E865W;_4/[9__
M  5?^.O[=?PVTGX:?&;X5?L\Z=:>'O$=OXH\.>*_ WA/X@:7XTT"_CMYK.]M
M]+U77_BAXGL8],UJSF^S:S83Z5/#>BWL;C$5[I]A=6VV795C,JQB]A.-?!5J
M4%B5*:C.%:*LZD(VU2E=QUNZ<G"5Y1C)YXW,,-F&&;JQ=+%4JDW0<8N494FT
MU"<NC<='TYXJ2M&31_7/^S?X3UCXD?\ !(WX9> O"D<%]XB\<?L+6_@KP_;O
M=06\%QX@\0?!VX\/Z=:37<\D=M:J=4NHK>>:XDCBMCO:9T6-R/X2/CY^S9\<
M?V7O%FF>!OCU\/=5^''BK6= @\4:7I&JW>CWTE[H%SJ.I:3#J4%SH>I:I9-"
M^HZ/J5KL-R)U>U9GB6.2)Y/O[]D?_@M!^US^R'\,M&^#?ARS^&?Q)^'?AN2Y
M7PQIOQ,T'Q!>ZOX8TZ[NY[^?1M$U[PQXJ\,7+:6+ZZN;BVM]=AUTZ>DWV+3G
MM-.AMK2#YB_;D_;C^)G[>OQ.\-_%+XH^%_ GA/5_"O@BT\ Z9IW@&S\06FFR
MZ/9Z]K_B&.YO_P#A(O$/B*ZGU)KSQ%>1/-;SV=J;:&V1;-94EFFO*\#C\!C,
M7&<:$L'B:LZOM5)NHG>3II1NK74K33C))K25B,?B\'B\+AW&56.)H4X4_9N*
MY&K14VY6=[<MX-23:>L4]%\]?!?X5>)/CE\7/AM\'?",?F>)/B9XU\.^"]*<
MQO+#:3Z_J=OI[ZE=JF&6PTJ":74M1F)5(+&TN)Y'1(V8?Z'WQN^-OP._X)M?
MLHZ#XF\3Z=XA/PO^$NC_  _^%WA7PQX1M-(O_%FL"--/\,:'IND6NL:OX<TJ
M\OX--M;C7-6EN]6L2VG:7JU\K7%TB6T_^?\ _LI_M,>,?V0OC;X8^/?P^\,>
M _%?C/P?::];:#9?$;2]<UCP[9S^(=%O?#]YJ0L_#WB/PMJ/]I6^F:E?0V4Z
MZLD4#7+R/!*P3;].?MO?\%3OVC_V]O!O@SP#\7-#^%GA7POX*\377BZTT[X8
MZ'XOT9-8UZ72YM&L[S73XJ\=^,Q<G1]/O=5ATH6*Z<8O[8U(W+77F6XMZS;+
M<1F6+P4)**P%&\JSY[3E*37,E%:_#",8RWCSS?K.7XZC@<-B9*[QE2T:2<6X
M**2Y6W=+XI2DUUY(KJ?T5I_P<>_L3LZJWPI_:C16907;P?\ "@J@) +L$^,[
M.0HY(568@?*I.!7U_P#\%7/@/I?[77_!/SXBR^$5@\0ZSX2T#3/V@/A9J%DO
MVG^T9?"FEW&M70TL*OFW4GB?X>ZCXETG3(8RIGO=6L'VR%%C;_/NK]K/@I_P
M7A_;%^!OP?\ A]\%=#\$_L]^+/#7PV\):9X(T/5_'7A+XCZGXEO/#VBVPL-(
MM-8NM&^+'A_2KLZ?I<=MI4#6^C6:M8V=NDR2S"6>7CQ7#SP]3"XC*5:M1K*<
MXUJSM)1<91LVG973C)?:C-Z.QU4,Y]M#$4,Q=Z=6DX1E3IJZ;NGHGYJ2?24=
M+7/Z5_C62/\ @C!XFP2/^-?FC#CC@_!/2@1]""0?4'%?R[?\$+/^4E/P7_[%
MOXN_^JK\6UI>./\ @MQ^U-X\_9RUS]E^_P#AK^SGI/PYUSX5#X.R7>A>$OB5
M:^)=/\)KX=B\,0RZ;>7OQ;U#2(=5@TR&,PSSZ'<V2SJ&;3VB_<U^?_[*7[3O
MC_\ 8]^.'A7X^_#+2_"6M>,/"-GXCL=/TSQSI^KZGX9NH/$_AW4_#5__ &A9
MZ#KOAK59'ALM4FN+-K76K/R[V&W><7%L)K6;?!Y7BZ. S7#U(TU5QCKNBE--
M?O*;C'FE;W=79_>8XO'X>MB\NK0<G##>Q]JW%I_NZL92Y4]7HG;N?OY_P<Q?
M\C?^R%_V+?QG_P#3I\-J_:#]F_PGK'Q(_P""1OPR\!>%(X+[Q%XX_86M_!7A
M^W>Z@MX+CQ!X@^#MQX?TZTFNYY([:U4ZI=16\\UQ)'%;'>TSHL;D?QD?MR?\
M%#OC7^W_ *I\.M6^,GAKX8>&YOACI_B33O#\'PST3Q3HUM<Q>*;C1KG4I=6'
MBGQIXRGN)T?0K%+0VD]C%%&9A)%,\@=/?OV1_P#@M!^US^R'\,M&^#?ARS^&
M?Q)^'?AN2Y7PQIOQ,T'Q!>ZOX8TZ[NY[^?1M$U[PQXJ\,7+:6+ZZN;BVM]=A
MUTZ>DWV+3GM-.AMK2#GK9-C993E^&A[+ZS@ZU2K*$I^Y)2J5)I*=K-KFC=.R
MWUNE?:EF>%CF.,KS]I[#$THTXR4?>3C"G%WC>Z3Y96:N[VTLVU^B?_!#G]FS
MXX_LO?M[_$WP-\>OA[JOPX\5:S^R+KWBC2](U6[T>^DO= N?C+\-M)AU*"YT
M/4M4LFA?4='U*UV&Y$ZO:LSQ+')$\GI/_!1+XN^'?@5_P7,_8N^)WB^\ATWP
MMHGPI^'.E>(-5N?+%IH^D>,O&GQR\$7^M7KRD+%8Z-;^(WU.]G&9+>UM)IHD
M>6-$;\R[S_@N!^U')^TV/VJ+'X<_ .V\<)\#I/@ F@W7AWXA7GA/_A#I?'L?
MQ$;4Y+>+XF6.LOXF&M1):K>)K,6EC2]T+:,UT1>K\1?MI?MH?%']NKXKZ1\8
M?BYH/@'P[XFT7P+I'P^M;'X<Z7XBTC0I-&T;6_$FO6MS<6WB;Q3XOU!]3DO/
M%&H1W$T>IQ6CVT-FD=E%+'--<=$,MQN(S&6+QD*5.%? 3PU=4IWY9U*;IR4$
MW)VL]&V]3*6.PM'!+#X:52<J6+C7I.I&UXPFIIR:45>ZV26A_7)_P7#_ &+/
MBM^UW\!/AMX@^!VB2^-/'7P;\7:MJY\%6-S;1:CXD\(>,=,LK'7)] %S)%;Z
MAK6E7NC:!>P:8;B"2^TEM8-D]QJ,-EIU]^6W_!.[_@A#>_%_P;XT\:?MOZ+\
M6O@]YVH:38?#'P?X>UKPYX:\7W-K;)J+>)]=\7:9K?AGQ9-IMC<7$FDV/AVQ
MN(M*U61K/6;Z[M#I]QH]S=?'G[)__!;_ /:^_9@\$Z1\,M1B\'?&WP#X=LK;
M3/#%G\28-8'BCPQI%E#';V.AZ1XNT/4["ZN-'LX$$-G:^(K'Q!-86R6]CIMU
M8Z=:P62=E^T1_P %\_VROC7X0U?P-X+TSP!\!]'UV"XLM2UWP!:ZW?\ CZ73
M+J"2VNM.M/%7B'5KVUT9;B*5LZGH.@Z5X@MI%233]8LF#;N>C@<^PN'_ +.P
M\L-"BJKE#&J;C4A"4U.24=9*[NVN1NSE%2:LS:IB\HKUOKM:->55TTIX5Q4H
M2FH\J;EI%I+1>]%.T9.*=XO]E?\ @C+\./A#\(/VC?\ @IK\+/@1KGB#Q)\+
M_A[X^^ OA#0-<\4:KI&N:SJ%_H6C_%?3_%<DVJZ%I6BZ5?6L7B^#7K?2YK33
MH5;2X;+S'N)A)<R_-G@O_E99\?\ _8%N_P#UD7PU7X?_ +#/_!27XZ?\$_X?
MB=!\'/"WPI\3I\5YO"$_B,_$[0_%VM-9R>"U\3)I9T9O"WCGP8;?[0/%>H_V
MA]N_M'SC#9FW^R^7/]I^]/\ @F+^T3XU_:P_X+,^&_V@?B+I?A;1?&7Q"\-^
M/9]:TSP79:MIWAFU?P[\"KKPC9#2[+7-;\1ZK LNFZ!9SW0N]:O2]]+<RPF"
MW>*VA,3EV)H5LXQE22J4:F43H1JRDG5J5(8?#1E.<>G,Z-1MWWM;1H5'&T*U
M/+,-!.%6GF,*LJ:BU"$)5JK48RZI*I%);V]#]5/^"[O["7QL_:D\,_!CXI_
M;PK>^/\ Q'\*3XM\/>*O ^D26[>(;_P[XLET&]T[6] L;B6W&IOHNHZ/=VVJ
M:?:23:E-;ZO:7=I:2P:??/';_P""$7[#'QK_ &5_!GQI^)7QW\+WG@'Q)\7;
MKP;HOAKP/JTEN/$&F^'/!1\27%UK6NV5M+.--EUS4?$20:?IUW)%J,%MHTMW
M<VL,.HVC/I?\%@?^"A7Q]_8)^+O[-6L?""3PSK7AWQMX2^)<?C7P)XUTRZU'
MPYKS:+K7@@Z9J$<NF:AI&LZ3K.G0:AJ5O9WVGZG';M'?2+J5AJ<4-O%%^.'[
M0G_!P#^UQ\8_ 6K^ ? GA?P'\"8O$-E)I^K>,/!4_B/4O'T%G.JQW4/AS7]4
MU*.S\-R7<)FA?4K/1Y==LTD2;1]7TN]A2[/%A<-F^,RBA@Z4<-]2KMOV\I-5
M:<(XB4W"<;ZVJ1<DX0DW"T;KIU8BMEN%S*MB:CK_ %JDDO91BG"<Y48I3B]E
M>$N5J4DN:\K;7_:+]C^S^#'[3'_!6;_@H5\>EMO#_C#4_@-#\$_A;\+M0NK6
M.]&D:A%X:UOPI\1?$FB^<&M7OK7Q/\/K_1-.\06L<MQ'I.H3)8W<5IJ1:\Y3
M_@HS^U[_ ,%5_!'[1LOP-_8]_9S\12> 9+#PPWAGXOZ+\(]6^)#>+]3UO1[&
MZUF2;Q)J=OJ'PX\(Z=X;U>\N=%O+/7K"*ZLCI4FO:IJD6CZG9QP_RC_LK?M>
M?'']CCXJ0_%SX*^)8M/UV:!M/\2:+KEO+J_A7QOHDMS%>7.A>+=*%S:37]E/
M<PQSI=V=]IVM:?<#[5I.JV%T3/7[$Z[_ ,'(7[5=]X?%CH/P5^ ^@^(I+:6&
MXU^X@\=ZS9Q32(46[TW0I/%MD+:: GS(8]1U/6+<RJOGPSQ;X7ZZV38NEC:=
M6E0PV/P\,+0P].GBYM1I.E2IT^9P>DKRA*I9*2;JS]U2LSGI9GAZF%G3J5J^
M#K3Q%2O4GAX7E452I*?*I;JT9*%WRM*G'5JZ?](O[2&E>/M+_P""9/QWT7XG
MZNGB7XHZ;^PK\3=,^(FO6\5G%'K_ (]LO@%K5MXNUB&'3K>TL(TU3Q#%J%['
M%8VEM:*LZI:V\,(CB7\R?^#;B2,_LG_'"(.AE3]H>]D>,,"Z1R_#;X?K&[+G
M<$D:&548@!C'( 24;'Y#ZC_P7V_;5\1_"S7?A3XW\'_LZ^.]-\4^#_$'@GQ/
MXB\0^ O&=KXDU_2?$VFW^D:I+?1>%_B7X<\)Q7CZ?J$MO&-/\+6-CM2)IK&9
MS,TWQ7^Q3_P4/_:+_8-U?Q1>?!:_\+ZGH'C5;!_%/@3Q]H][KOA'5;_2EN8]
M,U=8=*U?P_KFF:M9P7EU;_:M'UW3UOK>6.'58;^.SL%M8I9'CUEN.PDU0C5K
M8BE6I<L_W4E!^]%6C>"M\"<4MD[+554S7"?7<'B(NK*G2HU*53FC[\>9)1D[
MOW_[UG?=J^B?WC^V%\!_C[^Q[_P4BNOVV?BC\-=7TKX K^W)H'Q!T7Q]:7F@
MZOI^O:-?^.Y/B)'I]K8Z?JMSJT&HW?A;2-:C-O?6%F\-[9S6QDCN/(\S^J?]
MM?Q-^U1)^S9_PG_[!EQX2\4_$RVO_#OB[3M-U"QTCQ#9^/\ X<7NFWS:C9^%
M'U.]L])FU6>/4=&\2Z3.;U&U.PTFZTS3?M-]JEG;S_QM?MN_\%=/CW^W7\)-
M'^#?Q)^'OPA\)^&])\:Z-X]74/ ^G>,X-<GUO1-&\0:+;VYN->\9ZY81Z7+;
M^)+Z6:W&G/=F:*T*7Z(DR3I^QW_P6*_:Z_8Z\(6/PST"\\)?%+X7:2CQ>'_!
MGQ0T[4]0/A*WEN'N9[;PIXBT+5]#UVPLY)'?RM*U.[UK0[!7D_LS2K)Y9'?;
M$Y5F&*P^!K5*6%>+P7[IX>;YJ%>A'D4.9MR7-[LN972:DVG&44GG0S#!X>MB
MZ4*F(^K8K]XJT5RUJ59WYK)*+Y=5RM)M-)-23;7[V?LH^,_^"Z'[0NH^(7^)
M=U\._P!F/PMHEEBRUWXG_ NQFU?Q%KAN8(UTK2/!T6NZ9K1L8K-KF[NO$%Y]
MFTP/';6EBVHS3W!L?0/V)/VB_'$?_!3/]JS]G+X]_&?P'\6_BDOP=^$NB:-X
MH\">"D\ ^';JY^$E_P"-_$^O>#(=*.H:D;GQ-H"_&O59M3=+Z[D>+1=5MY6M
MFT"6U@_&WXR?\'#?[8'Q"\+:CX8^'?@WX7_!:?5+9K6;Q=H%IK7B?QA81RPM
M%.VAW?B/4)=!TZ>3>QCO)?#E]>V9"265S;W4:7(_$;PG\3_B'X&^(>E?%GPG
MXS\1:)\2]$\1'Q9IWCBUU2Y;Q''XC>YDN[C5I]2G>:>^N;^::X.J?;VN8]5B
MNKNWU*.ZM[JXBE=/)<1B:>+6)H8'!*M15.A2PU*FY0J*<*BJ5*L4Y\O-32<8
MS:ES-VCRI24\THT)X9T*N+Q3IU7.M4KU)I3@XR@X0IMJ-[3;4G!--)7ES-K^
MC7_@M%_P3-_:;^)'[6>I_M$? ?X:>(/BYX6^+^B>#[?Q%:>$8X+[6O"/C'PC
MX<TCP-]GU+2&EBNET+5-!T'0]1L]<A$]G#>'6;?5&TY;>RFU#]T_^"5G[+OC
M;]D7]C#X>?"SXEK#:_$2_P!2\2^.O&.C6UY#J%MX<U3Q9J37-KX=2]MF>UN+
MK2=$M])M]8>SEN+$:[_:BV%W>V2V]Y/_ #I>%?\ @XX_:WT;PA_9'B3X4? [
MQAXN@B$5KXQN;#Q=HD-P550+C6_#6C^)8+.\NG;>TIT:]\.6A!58K*':2_!>
M%_\ @X:_;O\ #Q\0MJ'A[]GWQD^N^([O7K9O%'@;QN@\-V=Q8Z=8V_A7P]%X
M8^)WAJ"+PYIPT]KJT&JQ:MKTU]J&HW6IZ[J#SQ^3S5\NSW$X&C@*D,)&EAG!
M1DJGOU8TX\E.[U2C"+>\82E975T[[4<;E-#%U,9">(=2NI<T'3]VFYM2F^C<
MI2724DKRL[6/Q]^._P#R7#XR_P#95OB'_P"I?K%;_P"R[_R<S^SK_P!EU^$?
M_J?^'Z\H\5>([_QAXH\2>+=52VCU3Q3KVL>(]2CLXWALTO\ 6]1N-3O$M8I9
M9Y(K9;BZD6".2>9TB"J\LC N;O@/QAJGP\\<>#?'^B0V-QK7@;Q7X=\8:1;Z
MG%//IL^J>&=7L]:T^'4(+:YL[F:QEN[*)+N*WN[6>2!I$BN8)"LJ_7N#=%P^
MTZ3AY7Y+;^I\VI)55+I[12^7-?\ (_N$_P""^[,O_!/+Q(RL59?BK\+F5E)#
M*PU:[(92,$$$ @@Y!Y%?:G[ 7QZLOVLOV-?@/\6]7:UUG7M4\*Z1IOC=;R.&
MZ9/B5\/-071/$&I2V\RR?9;F;Q3X>_X2K2&<?:+:&\TJ_MY2_D7!_C;_ &O_
M /@L3^TW^VI\&[OX'_%+P1\"_#WA*^\1:%XEN+_X?>&/'NE^(6O?#TL\]E;K
M=^)/B9XLTY;*26<M<H-*^T/Y<:Q7,*^8).:_8I_X*Q_M+?L)?#CQ%\*_A1X?
M^$OBSPEXA\7W'C8V_P 3]!\9ZW<Z-K-[I6EZ/J"Z)-X8\?\ @Z.UL;^VT;3Y
MKFUN8+T?;(9+F!X7N;D3?'OA_%RRJ&'<::Q=+&3K0_>+E]E5A3A-<]K)WA&7
M_;FFY]*LXPT<QG73J/#5,-"E+W'=5(2E*+Y;ZI*4H_\ ;S>R/VC_ ."G/[0_
M_":_\%:_^"=O[.NCWPDT?X)_'3X!^)O%%O%(0H\>_$KXI>";^*TO8E)6232O
M!&F^&KZPE?YXE\5:A&BJLC-)])?\'%7_ "8EX-_[.3\ _P#J!?%:OY*=8_:O
M^*'B#]K2#]LS6X?#>I_%>W^,V@_&Z'3;JRU9O!:>(/#'B33O$>@^'1IJZXFN
MCP?I8TG3M"M=/'B0:LF@6D-K_;AO%^WGZQ_;0_X*X?M(?MT?";3/@Y\6O!/P
M1\.^&-*\;Z1X^M[[X=>&_'FD:\^L:+I'B#1;6VFNO$WQ)\7:>VFR6OB2^DN(
M4TN.Z>XBM'CO(HXYHI^U9-7I5\FE25-T\#37UA\Z3=24W4J.*M>2<Y2:\M&<
MLLSI5*.9J;DJF+G>BN5M*$8J$%)[)J,4GYW/ZN/%/_*$R_\ ^T9-K_ZS';U\
MR?\ !N?_ ,F+^/?^SF_'G_JM_A!7X,7W_!:W]JC4/V6Y?V2)_ 7P 'PXF^!:
M?L^OKD?A7XB+XW_X0R/P*GP^74QJ)^*C: /$_P#8J+<F]_X1HZ4=3S-_8HM?
M]"KA?V+/^"MG[1_["GPIUCX/_"3P7\$_$?AG6O'6K?$&YO?B/X;\=:OKD6LZ
MSHGAO0;JVMKKPQ\1_"%@NF)9^%]/E@AFTV:[2YFO'>]DBDAAM^9Y)CG@,=A^
M6E[2OCH5Z:]HK.FN:[;MHU=:>MCHCFN$6+PM9RJ<E'"2HS?([\[Y;65[M:/4
M_IC_ ."27QB\.:G\4?\ @I+\!I+^)/&7@_\ ;N^/?Q/ATV4QQ3W?A#QOXMD\
M-BZLDW"2\BTK7O!EU'JLBHPL&US1HYI +^U2O"/VL_C5_P %Q_AG^T=XR\%?
M WX8Z+\2OA%KGBF\N_A+XK\.?#+P_K>FP^$=7NVN-%T?Q9KMQJUO'X?U;PW#
M,NA:S?>*VT>"[GTZ3689I-,O+>[D_E=T7]K#XW>#_P!I+Q/^U;\//%/_  KC
MXO>*?'OC3X@WM_X2@9=$M]1\>ZWJ.N^(=$CT77IM=@U+PK<7&IW%J-#\12:W
M#+9);I?2WEQ"MR?V7\-_\'(?[4^GZ"MCXF^"?P,\2:]#;0P1:]:+XWT""XFB
M14>\U+1X_$VI133W!4RSIIUYI-J)6?[/;V\.R%+KY-BJ6*>)H8;!XV%:E3C4
MH8JW[JK&$(RG%MQ33E%R3C*[3E%QTC)Q1S/#U,/&A6KXK"RI5).%7#W_ 'E-
MRDXQDE=II.S3C9-*2>KBOT"_;UN/^"CGPD_84^*GC7]HC]JG]GQ-&\7_  ]M
M_ ?BWX7Z#\#A%K&JZK\3K2'PQK/@3PSXS7Q!-%<:G:6VK:LT6OVVAK&EGI-Y
MK216=M;M<V_D/[%?[ ?[9/P7_9-T/]H[]BS]O*^O)_B1\)=,^,&G_LZ3_!K0
MM8\$^)_&FH>%K34K[P#)J7BOXF:UX>TKQ.FI6S^";SQA:>&-(U)[W3(HKUM/
M@A\JT_ _]LS_ (*"?M(?MT^(-*U+XT^(M-M_#/AJ>[N/"7PX\'6$VB>!?#=Q
M>*(KB^M]/GO-1U+5M7E@'V<ZSXAU75]2@MGFM+&XL[*>6V;U7]BW_@J]^U9^
MQ#H)\!^ =3\,^.OA6;^XU&#X;?$K3M0U;1M#N[^<W&J7'A/4](U71=>\.MJ,
M[27=Q80ZE<^'VU*>YU630Y-1O;ZXN=UE>8T\O]G3^H_6)U_;5\-]6PZPU2DD
ME&B^:BTYQ:O[1\K]YQ53W8R>7U_!3QO/4^MNA&E[.E6=>LZ\*E[RJJU2Z4KM
M<B<HZ)\FKBOZA?\ @FK^VO\ M]?M ^/O$?PV_:T_9%USX::1X<\/ZA>CXQGP
M)XY^%^E'7M,OK"S3PSJ6A^-S>6.O:OJB7D]PL_A/4K4:?'8F2?1&L[DWMM^<
MW_!77P=\,O"?_!5C]@KQ)X:TW1=$\;>-/%WP:U[XF-IT-K8R:LNG?'#3-*\-
M>)]=2#RQ<:I=6=EJNDR:M=H;FZT_P_8VTD\L6G0K#X=XK_X.0_VH-3T6XL?"
M/P1^"?A36)[5X%UR_?QEXF%G.XVF]LM,?7=(MA+$I+6\5^^H6RS!&N(;J$/!
M)^%_Q9^.WQ:^.'Q5UKXV?$[QQK7B7XG:YJMMK%SXIEG6RN[*ZT]HCI,6B0Z<
MEK:Z#8:(D%O#HFG:/!966DP6\$5C#"L:UG@,GQ4,=4Q52C0P%*5"I2^KT*DJ
MBG*I!PNU=J,4WSM)I<T8I1NW(O%YEAY86&'A5K8RI&M"I[:M",'",)*5D[*3
MDTG&[3=I2O+9']Q__!:7]F_XR?M0_L=V/@'X&>#I_'?C31OC#X*\93>'+/4=
M(TV^N=#T[1?%^BW\]G)K>H:;9SRVMQX@L9I+9;H3M:K<2Q1R>2PKSG_@A/XM
M?3?V5/&/[-GBNT?PY\7OV8OC+\0?!/Q%\%7S6G]K:+)KFO7VO6EU<?8Y[B&X
MMI=9E\3:''=Q32QR7?AV]2)WM5M9IOQ'\!_\'$?[;?A7PWIV@^)?!WP'^(M_
MIMA#9CQ;XA\*^+]+\1ZM-"@0W^NIX7\=:+X>N+F4+NF&DZ!HD3R%GV DU^:O
MAK]NK]HCP#^U#X__ &M_AGXIM?AS\4/B5XO\5^+/%=CX;LFN?!FI1^,M=E\0
M:UX7O?#GB*XUV/4_"[WLB&UL]7N=0OK)[:SO[348=6M+;4(L*629A/+ZV75U
MAX0A56)PU:,Y2YJWPRC.VJINFY)/V:E&33:DE8UJ9K@XXRECJ7MIRG3]CB*<
MHJ/+2T:<.CFI)-KG<9)635[GV3\=_P#@C;^W!IG[4'C'X>^ /@]K?C/P/XC\
M?ZQ<^!_BI;75@G@:3P?K>M276E:MXJUV6=4\.7NEZ;>1+XCTR^@%_'?66H)H
MMMK5M]AN;W^FO]N[7_"O[&'_  2?\8_#/5?$=JT^E_LW:%^RQX,FN1LN_%FO
M:O\ #^W^&$*:=:'<\EVVA0:QXDN$ /V/3M+O[R0B.U<U^&=G_P '(_[5$6@/
M:WWP-^ 5YXFV(L&M0Q?$*ST8,JD,]SX=/C.YNYF=L.1!XCLT7YE50"NW\E/V
MNOVZ/VC?VV_%=GXE^.7C%+W3=&>9O"O@'PW;2Z'\/O"'VE$CNGT+P^UW>R/?
M7:H%N];UJ_UC7[F$1VD^JR65O:VT'2\!FV85L$LQCAZ.'P4XU).E+FG7E'DW
M2<DN;EL]8**<VHOW4L%B\NP=/%/!.O5K8J#@E4CRPHQES:7:BWR\VGQ-N,4V
ME=O^T3_@EH2/^"4GP*()!'PK^)I!'!!'C;XA8(/8BOXR_P#@G/\ \GY_L@?]
MG#_"K_U+M,KZQ^ 7_!:W]JC]G3]GSPI^S;X)\!? #5O W@_0->\.:9JWBKPK
M\1+WQ9/8^(=5UG5[R2^OM'^*FA:/+=0W&N745I);Z#;1);Q6RSPW$J2S3?F7
M\&/BKXC^!GQ:^&_QE\(6NCWWBCX7^-/#OCK0++Q#;7EYH5YJOAK4[?5;*TUB
MUT^_TJ_N-,N)K98;V*RU/3[M[=Y!;7MK-LF3IP.78G#O.O:*"^O3J2H6FG=3
M^L6YOY?XD;W\^QCBL;0K1RM0<KX2$(UKQ:LXJA?E_F_ARV\NY_7=_P ''ES-
M9?LL? >\MVV7%I^T=IES Y56"30?#KQ]+$Q5@5;:Z*=K J<8((.*_5GQ7\5?
MB=\>?V+&^,O[%^K^&9?BAX^^&?A_QY\)'\2V]A?:+<ZJ\NEZOJO@_58+^YAT
MVSUB[M+?6_!4AU2\MK70/$LHDU2XMDT^YDC_ (G?VV_^"JO[0_[>GP_\*?#?
MXO\ A#X-^&]!\'^,4\;Z=/\ #;P[XUT?5+G5X]%U704AU"X\4?$+QC;26"66
MLWCB&UL[2<W'E.URT:&)L#]B[_@J!^U/^PU:7?AKX7ZYH'BGX;:A?7&J7?PN
M^(NF7>N>$H=5NTCCN=6T2;3-3T3Q%X=OYEC5YX]'URVTJ^N MUJNEZC.B.OG
M?V!BWEV$IOV'UO!XBM5C2J/GHU8590DZ<VE9W]G'1KE:<HMJ]UVK-\.L;B9W
MJ_5L31I4W4@G&K3G3C**G%7NK<\M5[R?*TG:S_H%_9M^*G_!>KXY_$:;PCXX
M\.^#/V??".EPWTFO_$;XE_!72HM-MIX+>;[!8^'M&CUJTO\ QA<ZE?+%;B?1
M9GTJRM6GO[S4X]EK;7U:^^)WQV\#_P#!8[]B/X2?M*_'SX9?&'6]"\#_ !>B
M@F^'WPV_X5TG@^Y^,/@#Q%:Z5H&OQ'5=9;4=3\0:CX)\*7>GPO>1R6-GJ%K<
M?9(HM4CGNO@GQW_P<<?M8:_X;N=)\$_"?X,?#_7+NS-N?%?V?Q/XKO=.N6X;
M4-&TO5]9AT6*X3K!#K=EK]FA_P!?;W(^6OQ;\/?M$_%'2OVB?#?[4&M^)=2\
M8?%C0OB?X?\ BM=^(?$%V]S=Z[XBT#7++6TCU&4+M&GW/V&/36L((4L;;22N
MFVMK%8Q16R;T,IQ566)G7PN P4986O0I4L-3IN;JU:4Z?M'6M*44E-Z*>NB<
M;<SEC5S'#TU1C2Q&,Q4HXBE5J5*]2HH*G3J1GR*G=*3O%.[@[:M.]E'^CO\
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M35--;/V<8TVT^J<HMI]@HHHKU3SPHHHH **** "BBB@ HHHH **** "BBB@
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M[?\ B=_T,EG_ .$QXA_^-T?\.W_B=_T,EG_X3'B'_P"-T?4L5_S[7_@RE_\
M)^?Y]F'^OW"/_0XA_P"$F8>7_4)YH_.>BOT8_P"';_Q._P"ADL__  F/$/\
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MGY_GV8?Z_<(_]#B'_A)F'E_U">:/SGHK]&/^';_Q._Z&2S_\)CQ#_P#&Z/\
MAV_\3O\ H9+/_P )CQ#_ /&Z/J6*_P"?:_\ !E+_ .3\_P ^S#_7[A'_ *'$
M/_"3,/+_ *A/-'YST5^C'_#M_P")W_0R6?\ X3'B'_XW1_P[?^)W_0R6?_A,
M>(?_ (W1]2Q7_/M?^#*7_P GY_GV8?Z_<(_]#B'_ (29AY?]0GFC\YZ*_1C_
M (=O_$[_ *&2S_\ "8\0_P#QNC_AV_\ $[_H9+/_ ,)CQ#_\;H^I8K_GVO\
MP92_^3\_S[,/]?N$?^AQ#_PDS#R_ZA/-'YST5^C'_#M_XG?]#)9_^$QXA_\
MC='_  [?^)W_ $,EG_X3'B'_ .-T?4L5_P ^U_X,I?\ R?G^?9A_K]PC_P!#
MB'_A)F'E_P!0GFC\YZ*_1C_AV_\ $[_H9+/_ ,)CQ#_\;H_X=O\ Q._Z&2S_
M /"8\0__ !NCZEBO^?:_\&4O_D_/\^S#_7[A'_H<0_\ "3,/+_J$\T?G/17Z
M,?\ #M_XG?\ 0R6?_A,>(?\ XW1_P[?^)W_0R6?_ (3'B'_XW1]2Q7_/M?\
M@RE_\GY_GV8?Z_<(_P#0XA_X29AY?]0GFC\YZ*_1C_AV_P#$[_H9+/\ \)CQ
M#_\ &Z/^';_Q._Z&2S_\)CQ#_P#&Z/J6*_Y]K_P92_\ D_/\^S#_ %^X1_Z'
M$/\ PDS#R_ZA/-'YST5^C'_#M_XG?]#)9_\ A,>(?_C='_#M_P")W_0R6?\
MX3'B'_XW1]2Q7_/M?^#*7_R?G^?9A_K]PC_T.(?^$F8>7_4)YH_.>BOT8_X=
MO_$[_H9+/_PF/$/_ ,;H_P"';_Q._P"ADL__  F/$/\ \;H^I8K_ )]K_P &
M4O\ Y/S_ #[,/]?N$?\ H<0_\),P\O\ J$\T?G/17Z,?\.W_ (G?]#)9_P#A
M,>(?_C='_#M_XG?]#)9_^$QXA_\ C='U+%?\^U_X,I?_ "?G^?9A_K]PC_T.
M(?\ A)F'E_U">:/SGHK]&/\ AV_\3O\ H9+/_P )CQ#_ /&Z/^';_P 3O^AD
ML_\ PF/$/_QNCZEBO^?:_P#!E+_Y/S_/LP_U^X1_Z'$/_"3,/+_J$\T?G/17
MZ,?\.W_B=_T,EG_X3'B'_P"-T?\ #M_XG?\ 0R6?_A,>(?\ XW1]2Q7_ #[7
M_@RE_P#)^?Y]F'^OW"/_ $.(?^$F8>7_ %">:/SGHK]&/^';_P 3O^ADL_\
MPF/$/_QNC_AV_P#$[_H9+/\ \)CQ#_\ &Z/J6*_Y]K_P92_^3\_S[,/]?N$?
M^AQ#_P ),P\O^H3S1^<]%?HQ_P .W_B=_P!#)9_^$QXA_P#C='_#M_XG?]#)
M9_\ A,>(?_C='U+%?\^U_P"#*7_R?G^?9A_K]PC_ -#B'_A)F'E_U">:/SGH
MK]&/^';_ ,3O^ADL_P#PF/$/_P ;H_X=O_$[_H9+/_PF/$/_ ,;H^I8K_GVO
M_!E+_P"3\_S[,/\ 7[A'_H<0_P#"3,/+_J$\T?G/17Z,?\.W_B=_T,EG_P"$
MQXA_^-T?\.W_ (G?]#)9_P#A,>(?_C='U+%?\^U_X,I?_)^?Y]F'^OW"/_0X
MA_X29AY?]0GFC\YZ*_1C_AV_\3O^ADL__"8\0_\ QNC_ (=O_$[_ *&2S_\
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M'B'_ .-T?\.W_B=_T,EG_P"$QXA_^-T?4L5_S[7_ (,I?_)^?Y]F'^OW"/\
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M_P!#)9_^$QXA_P#C='U+%?\ /M?^#*7_ ,GY_GV8?Z_<(_\ 0XA_X29AY?\
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M#:'_ ,M.C_B(?!W_ $.H?^$>8^7_ %!^:/OJBO@7_AN_3?\ HCOC[_ONW_\
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M&[]-_P"B.^/O^^[?_P"1:/\ AN_3?^B.^/O^^[?_ .1:/[$S3_H%?_@VA_\
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M'F/E_P!0?FC[ZHKX%_X;OTW_ *([X^_[[M__ )%H_P"&[]-_Z([X^_[[M_\
MY%H_L3-/^@5_^#:'_P M#_B(?!W_ $.H?^$>8^7_ %!^:/OJBO@7_AN_3?\
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M (;OTW_HCOC[_ONW_P#D6C^Q,T_Z!7_X-H?_ "T/^(A\'?\ 0ZA_X1YCY?\
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M6A_Q$/@[_H=0_P#"/,?+_J#\T?;?BO\ Y%;Q+_V -8_]-US7PG_P2X_Y,V\
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M^#:'_P M#_B(?!W_ $.H?^$>8^7_ %!^:/OJBO@7_AN_3?\ HCOC[_ONW_\
MD6C_ (;OTW_HCOC[_ONW_P#D6C^Q,T_Z!7_X-H?_ "T/^(A\'?\ 0ZA_X1YC
MY?\ 4'YH^^J*^!?^&[]-_P"B.^/O^^[?_P"1:/\ AN_3?^B.^/O^^[?_ .1:
M/[$S3_H%?_@VA_\ +0_XB'P=_P!#J'_A'F/E_P!0?FC[ZHKX%_X;OTW_ *([
MX^_[[M__ )%H_P"&[]-_Z([X^_[[M_\ Y%H_L3-/^@5_^#:'_P M#_B(?!W_
M $.H?^$>8^7_ %!^:/OJBO@7_AN_3?\ HCOC[_ONW_\ D6C_ (;OTW_HCOC[
M_ONW_P#D6C^Q,T_Z!7_X-H?_ "T/^(A\'?\ 0ZA_X1YCY?\ 4'YH^^J*^!?^
M&[]-_P"B.^/O^^[?_P"1:/\ AN_3?^B.^/O^^[?_ .1:/[$S3_H%?_@VA_\
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M'F/E_P!0?FC[ZHKX%_X;OTW_ *([X^_[[M__ )%H_P"&[]-_Z([X^_[[M_\
MY%H_L3-/^@5_^#:'_P M#_B(?!W_ $.H?^$>8^7_ %!^:/OJBO@7_AN_3?\
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M&[]-_P"B.^/O^^[?_P"1:/\ AN_3?^B.^/O^^[?_ .1:/[$S3_H%?_@VA_\
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M'F/E_P!0?FC[ZHKX%_X;OTW_ *([X^_[[M__ )%H_P"&[]-_Z([X^_[[M_\
MY%H_L3-/^@5_^#:'_P M#_B(?!W_ $.H?^$>8^7_ %!^:/OJBO@7_AN_3?\
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M (;OTW_HCOC[_ONW_P#D6C^Q,T_Z!7_X-H?_ "T/^(A\'?\ 0ZA_X1YCY?\
M4'YH^^J*^!?^&[]-_P"B.^/O^^[?_P"1:/\ AN_3?^B.^/O^^[?_ .1:/[$S
M3_H%?_@VA_\ +0_XB'P=_P!#J'_A'F/E_P!0?FC[ZHKX%_X;OTW_ *([X^_[
M[M__ )%H_P"&[]-_Z([X^_[[M_\ Y%H_L3-/^@5_^#:'_P M#_B(?!W_ $.H
M?^$>8^7_ %!^:/OJBO@7_AN_3?\ HCOC[_ONW_\ D6C_ (;OTW_HCOC[_ONW
M_P#D6C^Q,T_Z!7_X-H?_ "T/^(A\'?\ 0ZA_X1YCY?\ 4'YH^^J*^!?^&[]-
M_P"B.^/O^^[?_P"1:/\ AN_3?^B.^/O^^[?_ .1:/[$S3_H%?_@VA_\ +0_X
MB'P=_P!#J'_A'F/E_P!0?FC[ZHKX%_X;OTW_ *([X^_[[M__ )%H_P"&[]-_
MZ([X^_[[M_\ Y%H_L3-/^@5_^#:'_P M#_B(?!W_ $.H?^$>8^7_ %!^:/X0
M:*_1C_AV_P#$[_H9+/\ \)CQ#_\ &Z/^';_Q._Z&2S_\)CQ#_P#&Z^F^I8K_
M )]K_P &4O\ Y/S_ #[,X_\ 7[A'_H<0_P#"3,/+_J$\T?G/17Z,?\.W_B=_
MT,EG_P"$QXA_^-T?\.W_ (G?]#)9_P#A,>(?_C='U+%?\^U_X,I?_)^?Y]F'
M^OW"/_0XA_X29AY?]0GFC\YZ*_1C_AV_\3O^ADL__"8\0_\ QNC_ (=O_$[_
M *&2S_\ "8\0_P#QNCZEBO\ GVO_  92_P#D_/\ /LP_U^X1_P"AQ#_PDS#R
M_P"H3S1^<]%?HQ_P[?\ B=_T,EG_ .$QXA_^-T?\.W_B=_T,EG_X3'B'_P"-
MT?4L5_S[7_@RE_\ )^?Y]F'^OW"/_0XA_P"$F8>7_4)YH_.>BOT8_P"';_Q.
M_P"ADL__  F/$/\ \;H_X=O_ !._Z&2S_P#"8\0__&Z/J6*_Y]K_ ,&4O_D_
M/\^S#_7[A'_H<0_\),P\O^H3S1^<]%?HQ_P[?^)W_0R6?_A,>(?_ (W1_P .
MW_B=_P!#)9_^$QXA_P#C='U+%?\ /M?^#*7_ ,GY_GV8?Z_<(_\ 0XA_X29A
MY?\ 4)YH_.>BOT8_X=O_ !._Z&2S_P#"8\0__&Z/^';_ ,3O^ADL_P#PF/$/
M_P ;H^I8K_GVO_!E+_Y/S_/LP_U^X1_Z'$/_  DS#R_ZA/-'YST5^C'_  [?
M^)W_ $,EG_X3'B'_ .-T?\.W_B=_T,EG_P"$QXA_^-T?4L5_S[7_ (,I?_)^
M?Y]F'^OW"/\ T.(?^$F8>7_4)YH_.>BOT8_X=O\ Q._Z&2S_ /"8\0__ !NC
M_AV_\3O^ADL__"8\0_\ QNCZEBO^?:_\&4O_ )/S_/LP_P!?N$?^AQ#_ ,),
MP\O^H3S1^<]%?HQ_P[?^)W_0R6?_ (3'B'_XW1_P[?\ B=_T,EG_ .$QXA_^
M-T?4L5_S[7_@RE_\GY_GV8?Z_<(_]#B'_A)F'E_U">:/SGHK]&/^';_Q._Z&
M2S_\)CQ#_P#&Z/\ AV_\3O\ H9+/_P )CQ#_ /&Z/J6*_P"?:_\ !E+_ .3\
M_P ^S#_7[A'_ *'$/_"3,/+_ *A/-'YST5^C'_#M_P")W_0R6?\ X3'B'_XW
M1_P[?^)W_0R6?_A,>(?_ (W1]2Q7_/M?^#*7_P GY_GV8?Z_<(_]#B'_ (29
MAY?]0GFC\YZ*_1C_ (=O_$[_ *&2S_\ "8\0_P#QNC_AV_\ $[_H9+/_ ,)C
MQ#_\;H^I8K_GVO\ P92_^3\_S[,/]?N$?^AQ#_PDS#R_ZA/-'YST5^C'_#M_
MXG?]#)9_^$QXA_\ C='_  [?^)W_ $,EG_X3'B'_ .-T?4L5_P ^U_X,I?\
MR?G^?9A_K]PC_P!#B'_A)F'E_P!0GFC\YZ*_1C_AV_\ $[_H9+/_ ,)CQ#_\
M;H_X=O\ Q._Z&2S_ /"8\0__ !NCZEBO^?:_\&4O_D_/\^S#_7[A'_H<0_\
M"3,/+_J$\T?G/17Z,?\ #M_XG?\ 0R6?_A,>(?\ XW1_P[?^)W_0R6?_ (3'
MB'_XW1]2Q7_/M?\ @RE_\GY_GV8?Z_<(_P#0XA_X29AY?]0GFC\YZ*_1C_AV
M_P#$[_H9+/\ \)CQ#_\ &Z/^';_Q._Z&2S_\)CQ#_P#&Z/J6*_Y]K_P92_\
MD_/\^S#_ %^X1_Z'$/\ PDS#R_ZA/-'YST5^C'_#M_XG?]#)9_\ A,>(?_C=
M'_#M_P")W_0R6?\ X3'B'_XW1]2Q7_/M?^#*7_R?G^?9A_K]PC_T.(?^$F8>
M7_4)YH_.>BOT8_X=O_$[_H9+/_PF/$/_ ,;H_P"';_Q._P"ADL__  F/$/\
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M^X1_Z'$/_"3,/+_J$\T?G/17Z,?\.W_B=_T,EG_X3'B'_P"-T?\ #M_XG?\
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M_P!?N$?^AQ#_ ,),P\O^H3S1^<]%?HQ_P[?^)W_0R6?_ (3'B'_XW1_P[?\
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MK]PC_P!#B'_A)F'E_P!0GFC\YZ*_1C_AV_\ $[_H9+/_ ,)CQ#_\;H_X=O\
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M_P &-Q_\R]'_  WEJG_1OOCG_P &-Q_\R]?5]%%G_,_N7^7K_2U+K^5?>_\
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M $M2Z_E7WO\ S]?Z6ORA_P -Y:I_T;[XY_\ !C<?_,O1_P -Y:I_T;[XY_\
M!C<?_,O7U?119_S/[E_EZ_TM2Z_E7WO_ #]?Z6ORA_PWEJG_ $;[XY_\&-Q_
M\R]'_#>6J?\ 1OOCG_P8W'_S+U]7T46?\S^Y?Y>O]+4NOY5][_S]?Z6ORA_P
MWEJG_1OOCG_P8W'_ ,R]'_#>6J?]&^^.?_!C<?\ S+U]7T46?\S^Y?Y>O]+4
MNOY5][_S]?Z6ORA_PWEJG_1OOCG_ ,&-Q_\ ,O1_PWEJG_1OOCG_ ,&-Q_\
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M>6J?]&^^.?\ P8W'_P R]?5]%%G_ #/[E_EZ_P!+4NOY5][_ ,_7^EK\H?\
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MJG_1OOCG_P &-Q_\R]?5]%%G_,_N7^7K_2U+K^5?>_\ /U_I:_*'_#>6J?\
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MC<?_ #+T?\-Y:I_T;[XY_P#!C<?_ #+U]7T46?\ ,_N7^7K_ $M2Z_E7WO\
MS]?Z6ORA_P -Y:I_T;[XY_\ !C<?_,O1_P -Y:I_T;[XY_\ !C<?_,O7U?11
M9_S/[E_EZ_TM2Z_E7WO_ #]?Z6ORA_PWEJG_ $;[XY_\&-Q_\R]'_#>6J?\
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M_EZ_TM2Z_E7WO_/U_I:_*'_#>6J?]&^^.?\ P8W'_P R]'_#>6J?]&^^.?\
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MG_1OOCG_ ,&-Q_\ ,O1_PWEJG_1OOCG_ ,&-Q_\ ,O7U?119_P S^Y?Y>O\
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M%%G_ #/[E_EZ_P!+4NOY5][_ ,_7^EK\H?\ #>6J?]&^^.?_  8W'_S+T?\
M#>6J?]&^^.?_  8W'_S+U]7T46?\S^Y?Y>O]+4NOY5][_P _7^EK\H?\-Y:I
M_P!&^^.?_!C<?_,O1_PWEJG_ $;[XY_\&-Q_\R]?5]%%G_,_N7^7K_2U+K^5
M?>_\_7^EK\H?\-Y:I_T;[XY_\&-Q_P#,O1_PWEJG_1OOCG_P8W'_ ,R]?5]%
M%G_,_N7^7K_2U+K^5?>_\_7^EK\H?\-Y:I_T;[XY_P#!C<?_ #+T?\-Y:I_T
M;[XY_P#!C<?_ #+U]7T46?\ ,_N7^7K_ $M2Z_E7WO\ S]?Z6ORA_P -Y:I_
MT;[XY_\ !C<?_,O1_P -Y:I_T;[XY_\ !C<?_,O7U?119_S/[E_EZ_TM2Z_E
M7WO_ #]?Z6ORA_PWEJG_ $;[XY_\&-Q_\R]'_#>6J?\ 1OOCG_P8W'_S+U]7
MT46?\S^Y?Y>O]+4NOY5][_S]?Z6ORA_PWEJG_1OOCG_P8W'_ ,R]'_#>6J?]
M&^^.?_!C<?\ S+U]7T46?\S^Y?Y>O]+4NOY5][_S]?Z6ORA_PWEJG_1OOCG_
M ,&-Q_\ ,O1_PWEJG_1OOCG_ ,&-Q_\ ,O7U?119_P S^Y?Y>O\ 2U+K^5?>
M_P#/U_I:_*'_  WEJG_1OOCG_P &-Q_\R]'_  WEJG_1OOCG_P &-Q_\R]?5
M]%%G_,_N7^7K_2U+K^5?>_\ /U_I:_*'_#>6J?\ 1OOCG_P8W'_S+T?\-Y:I
M_P!&^^.?_!C<?_,O7U?119_S/[E_EZ_TM2Z_E7WO_/U_I:_*'_#>6J?]&^^.
M?_!C<?\ S+T?\-Y:I_T;[XY_\&-Q_P#,O7U?119_S/[E_EZ_TM2Z_E7WO_/U
M_I:_*'_#>6J?]&^^.?\ P8W'_P R]'_#>6J?]&^^.?\ P8W'_P R]?5]%%G_
M #/[E_EZ_P!+4NOY5][_ ,_7^EK\H?\ #>6J?]&^^.?_  8W'_S+T?\ #>6J
M?]&^^.?_  8W'_S+U]7T46?\S^Y?Y>O]+4NOY5][_P _7^EK\H?\-Y:I_P!&
M^^.?_!C<?_,O1_PWEJG_ $;[XY_\&-Q_\R]?5]%%G_,_N7^7K_2U+K^5?>_\
M_7^EK\H?\-Y:I_T;[XY_\&-Q_P#,O1_PWEJG_1OOCG_P8W'_ ,R]?5]%%G_,
M_N7^7K_2U+K^5?>_\_7^EK\H?\-Y:I_T;[XY_P#!C<?_ #+T?\-Y:I_T;[XY
M_P#!C<?_ #+U]7T46?\ ,_N7^7K_ $M2Z_E7WO\ S]?Z6ORA_P -Y:I_T;[X
MY_\ !C<?_,O1_P -Y:I_T;[XY_\ !C<?_,O7U?119_S/[E_EZ_TM2Z_E7WO_
M #]?Z6ORA_PWEJG_ $;[XY_\&-Q_\R]'_#>6J?\ 1OOCG_P8W'_S+U]7T46?
M\S^Y?Y>O]+4NOY5][_S]?Z6ORA_PWEJG_1OOCG_P8W'_ ,R]'_#>6J?]&^^.
M?_!C<?\ S+U]7T46?\S^Y?Y>O]+4NOY5][_S]?Z6ORA_PWEJG_1OOCG_ ,&-
MQ_\ ,O1_PWEJG_1OOCG_ ,&-Q_\ ,O7U?119_P S^Y?Y>O\ 2U+K^5?>_P#/
MU_I:_*'_  WEJG_1OOCG_P &-Q_\R]'_  WEJG_1OOCG_P &-Q_\R]?5]%%G
M_,_N7^7K_2U+K^5?>_\ /U_I:_*'_#>6J?\ 1OOCG_P8W'_S+T?\-Y:I_P!&
M^^.?_!C<?_,O7U?119_S/[E_EZ_TM2Z_E7WO_/U_I:_*'_#>6J?]&^^.?_!C
M<?\ S+T?\-Y:I_T;[XY_\&-Q_P#,O7U?119_S/[E_EZ_TM2Z_E7WO_/U_I:_
M*'_#>6J?]&^^.?\ P8W'_P R]'_#>6J?]&^^.?\ P8W'_P R]?5]%%G_ #/[
ME_EZ_P!+4NOY5][_ ,_7^EK\H?\ #>6J?]&^^.?_  8W'_S+T?\ #>6J?]&^
M^.?_  8W'_S+U]7T46?\S^Y?Y>O]+4NOY5][_P _7^EK\H?\-Y:I_P!&^^.?
M_!C<?_,O1_PWEJG_ $;[XY_\&-Q_\R]?5]%%G_,_N7^7K_2U+K^5?>_\_7^E
MK\H?\-Y:I_T;[XY_\&-Q_P#,O1_PWEJG_1OOCG_P8W'_ ,R]?5]%%G_,_N7^
M7K_2U+K^5?>_\_7^EK\H?\-Y:I_T;[XY_P#!C<?_ #+T?\-Y:I_T;[XY_P#!
MC<?_ #+U]7T46?\ ,_N7^7K_ $M2Z_E7WO\ S]?Z6ORA_P -Y:I_T;[XY_\
M!C<?_,O1_P -Y:I_T;[XY_\ !C<?_,O7U?119_S/[E_EZ_TM2Z_E7WO_ #]?
MZ6ORA_PWEJG_ $;[XY_\&-Q_\R]'_#>6J?\ 1OOCG_P8W'_S+U]7T46?\S^Y
M?Y>O]+4NOY5][_S]?Z6ORA_PWEJG_1OOCG_P8W'_ ,R]'_#>6J?]&^^.?_!C
M<?\ S+U]7T46?\S^Y?Y>O]+4NOY5][_S]?Z6ORA_PWEJG_1OOCG_ ,&-Q_\
M,O1_PWEJG_1OOCG_ ,&-Q_\ ,O7U?119_P S^Y?Y>O\ 2U+K^5?>_P#/U_I:
M_*'_  WEJG_1OOCG_P &-Q_\R]'_  WEJG_1OOCG_P &-Q_\R]?5]%%G_,_N
M7^7K_2U+K^5?>_\ /U_I:_*'_#>6J?\ 1OOCG_P8W'_S+T?\-Y:I_P!&^^.?
M_!C<?_,O7U?119_S/[E_EZ_TM2Z_E7WO_/U_I:_*'_#>6J?]&^^.?_!C<?\
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M]+4NOY5][_S]?Z6ORA_PWEJG_1OOCG_P8W'_ ,R]'_#>6J?]&^^.?_!C<?\
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M[XY_\&-Q_P#,O7U?119_S/[E_EZ_TM2Z_E7WO_/U_I:_*'_#>6J?]&^^.?\
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MEK\H?\-Y:I_T;[XY_P#!C<?_ #+T?\-Y:I_T;[XY_P#!C<?_ #+U]7T46?\
M,_N7^7K_ $M2Z_E7WO\ S]?Z6ORA_P -Y:I_T;[XY_\ !C<?_,O1_P -Y:I_
MT;[XY_\ !C<?_,O7U?119_S/[E_EZ_TM2Z_E7WO_ #]?Z6OSWX%_;+U#QIXQ
M\->$Y?@CXRT2/Q#K%EI+ZO=7D\UKIHO)EA-Y<1GP];!H(-WF2YN(@L89BZ@5
M]R5Y7IW_ "$+'_K\M?\ T>E>J4U?J[_@)^2M]_ZA1113$%%%% !1110 4444
M %%%% ''^+/^7#_MZ_\ ;:N/KL/%G_+A_P!O7_MM7'T %%%% !17YL_M'_\
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MJU.FIWY'.22E:S=GL[)K[S]AZ*_&3_A_#^P7_P _WQ=_\-S_ /?ROI7]E?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:2\1VWC/QIKEMH-BL_Q%^-?Q)NBVJ^)+U-5U>.)=,TVZO8[BT;Q?XMOIKO\
MLZYU-)+'3['3]7U9[341I46CW_\ 2%_P7?TW4;[]@O4;JQ8BVT;XM_#G4M8
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M7]E<Q$I+!<V\J2(>&&2KJKJRC^<+_@WC_P"3J_C)_P!F^:G_ .K'^'E>K_\
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M]J<T[W-UJ^K^#?$'@/P3J&M7L\GSR:AK-UX=DU34&/'VV[G"_*!6LL@PKQ.
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M%_%G@_3M!AETGQKXE\/6JZ=9:C\/M8O8(S8:1:O*+C4KIGN6FD5T1UB3O_\
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MSSLRITZ>'RRE3JK&4X5:L8R4HRYX\U)JES0<EHGR*U[*RMH?U6?\0_/[$O\
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MTJ6XCV>;X=\8Z7:^(-*>">26VCO(+D-7W;XD^+?_  27_;>^*&B^)?B]X/\
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M170[Z;=+/)Q6D<7A8SE%.ZYXI6=UHW^[EKUYF^I_091117S)[H4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2TC\6:#X&^%7BGPC]ND97\K3W\3Z'I,>H3*IEALGGEA'FHE?G+^PW^T[IO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"YIW_ "$+
M'_K\M?\ T>E>J5Y7IW_(0L?^ORU_]'I7JE !1110 4444 %%%% !1110 444
M4 <?XL_Y</\ MZ_]MJX^LOXU_%CX?_"Y?#;>._$*:%_;;:NNEJ=.UC4I+O\
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MFZ+KNOO06?9_<SZ,HKYS_P"&L_V?O^A__P#+5\;?_,W1_P -9_L_?]#_ /\
MEJ^-O_F;HNNZ^]!9]G]S/HRBOG/_ (:S_9^_Z'__ ,M7QM_\S='_  UG^S]_
MT/\ _P"6KXV_^9NBZ[K[T%GV?W,^C**^<_\ AK/]G[_H?_\ RU?&W_S-T?\
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M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
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M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
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M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
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M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
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M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
M+5\;?_,W1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_
M *'_ /\ +5\;?_,W1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/
M_AK/]G[_ *'_ /\ +5\;?_,W1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]
MS/HRBOG/_AK/]G[_ *'_ /\ +5\;?_,W1_PUG^S]_P!#_P#^6KXV_P#F;HNN
MZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\ +5\;?_,W1_PUG^S]_P!#_P#^6KXV
M_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\ +5\;?_,W1_PUG^S]_P!#
M_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\ +5\;?_,W1_PU
MG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\ +5\;
M?_,W1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_
M /\ +5\;?_,W1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/
M]G[_ *'_ /\ +5\;?_,W1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HR
MBOG/_AK/]G[_ *'_ /\ +5\;?_,W1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!
M9]G]S/HRBOG/_AK/]G[_ *'_ /\ +5\;?_,W1_PUG^S]_P!#_P#^6KXV_P#F
M;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\ +5\;?_,W1_PUG^S]_P!#_P#^
M6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\ +5\;?_,W1_PUG^S]
M_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\ +5\;?_,W
M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
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M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
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M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
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M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
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M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
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M1_PUG^S]_P!#_P#^6KXV_P#F;HNNZ^]!9]G]S/HRBOG/_AK/]G[_ *'_ /\
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M)2<:=.I&*YI-R=DKMMO5LT/[6U7_ *">H?\ @;<__'*/[6U7_H)ZA_X&W/\
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M:K_T$]0_\#;G_P".5GT4?4,#_P! >$_\)Z/_ ,AY+[@_MS.O^AQFG_APQ?\
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M !RC^UM5_P"@GJ'_ (&W/_QRL^BCZA@?^@/"?^$]'_Y#R7W!_;F=?]#C-/\
MPX8O_P"7&A_:VJ_]!/4/_ VY_P#CE']K:K_T$]0_\#;G_P".5GT4?4,#_P!
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M#^UM5_Z">H?^!MS_ /'*/[6U7_H)ZA_X&W/_ ,<K/HH^H8'_ * \)_X3T?\
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M;<__ !RL^BCZA@?^@/"?^$]'_P"0\E]P?VYG7_0XS3_PX8O_ .7&A_:VJ_\
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MJ&!_Z \)_P"$]'_Y#R7W!_;F=?\ 0XS3_P .&+_^7&A_:VJ_]!/4/_ VY_\
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M (&W/_QRC^UM5_Z">H?^!MS_ /'*SZ*/J&!_Z \)_P"$]'_Y#R7W!_;F=?\
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M/HH^H8'_ * \)_X3T?\ Y#R7W!_;F=?]#C-/_#AB_P#Y<:']K:K_ -!/4/\
MP-N?_CE']K:K_P!!/4/_  -N?_CE9]%'U# _] >$_P#">C_\AY+[@_MS.O\
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M#R7W!_;F=?\ 0XS3_P .&+_^7&A_:VJ_]!/4/_ VY_\ CE']K:K_ -!/4/\
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MS3_PX8O_ .7&A_:VJ_\ 03U#_P #;G_XY1_:VJ_]!/4/_ VY_P#CE9]%'U#
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M:K_T$]0_\#;G_P".5GT4?4,#_P! >$_\)Z/_ ,AY+[@_MS.O^AQFG_APQ?\
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M !RC^UM5_P"@GJ'_ (&W/_QRL^BCZA@?^@/"?^$]'_Y#R7W!_;F=?]#C-/\
MPX8O_P"7&A_:VJ_]!/4/_ VY_P#CE']K:K_T$]0_\#;G_P".5GT4?4,#_P!
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M#^UM5_Z">H?^!MS_ /'*/[6U7_H)ZA_X&W/_ ,<K/HH^H8'_ * \)_X3T?\
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M;<__ !RL^BCZA@?^@/"?^$]'_P"0\E]P?VYG7_0XS3_PX8O_ .7&A_:VJ_\
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MJ&!_Z \)_P"$]'_Y#R7W!_;F=?\ 0XS3_P .&+_^7&A_:VJ_]!/4/_ VY_\
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M#FJW>I26E_<VEW>6WVV.XTNP\F">*QN4CG5I$\Y4A?8\L0?],?\ @F-\*O\
MA&_A=XB^*6H6VS4OB)JYT_1Y)%^9?"_A>6XM!+"Q :,:AK\NK)<(!MFCTJPE
MW, FWZP^,'ACP[^TK^SWXRT7PQ>VNM6GBC1-2G\)ZE P\A_$OAN_FETEHYF
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M@\_R?,*_U;"8^A6KN_+2]^G*?*KOV?M8051I7;5-R=DWLFU\[G' ?%^0X/\
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MF\0>&)O%5IK44FM'0HK&&VUBY:"X+Z2FH+=D:)=(JQV<L.9(&,P#2"/UY/\
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M!*;TO?1GF5%?JM:?\$JOB$^G-+?_ !5\&6VK@#98VFCZW>Z<QQR&U28Z?<H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;X"_%G7/AK::]/XEM])L=$O8]6N=/CTR:;^U]*M=1:)[2*[O47R'G:)76?\
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M_#]C+J?AG6M2T'4)+*;1/$\TUG)>Z5<VER]K+-;V\LENTIA>2"%V0M$A7/\
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MZCQ6 XBS&&=X/+\7#!8U5/KN82@ZU3VM!RIJ57#5U"52[HRPU2SAAVZ?SO\
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MG.B:9822'G[/9W-OJUU!&,!9=2N7.2_'I6K_ /)@D_\ V:;;_P#JIH:^9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![%^SO_R<
M!\#/^RQ?#+_U-=$K^JZOY4?V=_\ DX#X&?\ 98OAE_ZFNB5_5=7Y+XC?[[EO
M_8+5_P#3R/ZP^CO_ ,B7B+_L:87_ -1&%%%%?G)_1 4444 %%%% !1110 44
M44 ?CO\ \%8_^:!?]U3_ /><5^.]?L1_P5C_ .:!?]U3_P#><5^.]?O'!G_)
M-9;_ -SG_J?BC^%?&3_DY'$?_='_ /5#E84445]0?F(4444 %=SX5^)_Q*\"
M6MU8^"/B'XY\&V5[<"[O+/PKXMU_P]:W=TL:PK<W5OI&H6<-Q<+"B1":5'D$
M:J@;:H X:BHJ4Z=6+A5A"I!V;A4C&<6T[IN,DT[/5::,VH8BOA:BK8:O6P]6
M*:C5H5)TJD5)6DE.G*,DFM&D]5HS6UW7]=\4:K>:]XEUK5O$6N:@T;W^LZ[J
M-YJ^JWSPPQVT3WFHZA-<7ERT5O##!&TTSE(8HXE(2-5&31151C&,5&*48Q2C
M&,4E&,4K))+1)+1):):(SG.=2<ZE2<JE2I*4YSG)RG.<FY2G.4FY2E*3;E)M
MMMMMML[/PG\1_B'X"2^C\#>//&?@N/4VMWU*/PGXHUSPZFH/:"9;5[Y='OK-
M;MK9;BX%NUP)#")YA&5$K[L'7->USQ/JMYKOB36=5\0ZWJ+I)J&LZYJ-YJVJ
MWTD<4<$<EYJ-_-<7=R\<$44*/-,[+%%'&I"(JC*HJ%2I1J2JQITU5FK3J*$5
M4DM-)32YI+W8Z-M:+LC66*Q,Z%/"SQ%>>&I2<Z6'E6J2H4YOF;E3HN3IPDW.
M=Y1BF^:5W[SO9L[R[T^ZM[ZPNKFQO;2:.XM+RSGEMKJUN(6#Q3V]Q"R30S1.
M \<L;JZ, RL" :]TC_:H_:/BT\Z8OQK^(QMCQYDGB;49;_&-N!JLLKZH./2\
M'/S?>YKP*BHK8;#8AQ=?#T*[AK!UJ5.HX/O'GC+E^5C;"9EF. 518''XW!*J
MDJJPF*KX95$DTE45&I#G23:7->R;[ES4-0O]6O;K4M4OKS4M1O9GN+R_U"YF
MO+V[N)#F2>ZNKAY)[B9SR\LLCNQY9B:Z7P9\0O'?PZU"35/ GC#Q'X0OYT2.
MYN/#VL7VEF\BC+-'#?):31Q7T",[,L%VDT2L2P0-S7'45I*G3G!TITX3IM*+
MIRC&4'%;1<&G%I65E:VAA2Q%>A6CB:->M1Q$).<*]*I.G6C-WO.-6$E.,G=W
MDI)N[UU/8?&'[0/QN\?Z=/H_C#XI^-M<T>Z1([O1[G7KV+2+Q$(9%O-,M9+>
MQO K*KC[3;RX<!_O &O-_#_B/Q#X3U:UU_PKKVL^&M=L1.++6O#^J7VC:M9B
MYMY;2Y%KJ.G3VUY;BXM9Y[:<13)YMO-+#)NCD=3C45%/#8>E3E1I4*-*E*ZE
M2ITH0IR4ERR4H1BHOFCH[K5:/0UKYAC\3B(8O$X[&8C%4W!T\37Q-:KB*;IR
MYZ;A6J3E4@X3]Z#C)<LO>C9ZG>ZU\5/B?XEU+0M9\1_$?Q[K^K^%[HWWAK5=
M:\8>(=5U+P[>F:UN#>:%?7VHSW6DW1N+&RG-Q82V\IFM+67?OMXF1/%/Q3^)
MWCFQ@TOQM\1_'GC'3+6[2_MM.\4^+_$/B&QM[Z.&>W2]@M-6U&[MX;M+>YN(
M$N8XUF6&XGB#A)9%;@Z*%AL/%TW&A13I7]DU2@G3NVW[.T?<NVV^6UVV]V.>
M88^HJ\9X[&3CBN7ZRIXFM)8CDC&,/;IS:J\L8QC'VG-RQC%*R22])G^,OQ?N
M= ;PI<_%7XDW'A=],31&\-S^.?$\N@-HT=NMHFD-H\FJ-IQTQ+5%MDL#;&U6
MW581$(U"CD/#_B3Q%X2U:VU[PKKVM>&=<LA.MGK7A_5+[1=6M%N8)+6Y6VU'
M39[:\@%Q:S36TXBF02P2R0R;HY&4XM%.-"A&,X1HTHPJ7]I&-."C4NK/GBDE
M*ZT?,G=:,F>.QM6I1K5,9BJE7#\GU>K/$59U*'LVI0]C.4W*ER22E#D<>5I-
M6:.N\5?$#QYX[FL;CQOXV\7>,KC3$FCTV?Q5XDUGQ#-I\=P\;SI8RZO>WCVB
M3/#$\RV[1K(\4;.&**1M>(/C)\7O%FDW.@>*OBK\2/$VA7I@-YHOB#QSXGUG
M2;LVMQ%=VQN=-U'5+FSG-M=00W,!EA<PW$,4T>V2-&'F]%+ZOA[4U["C:BVZ
M*]E"U)MJ3=/W?<;DE)N-G=)[I#_M#'MXAO'8QO%Q4,6_K-:^*A&+A&.(?/>M
M&,)2@HU.9*+<4K-HZ#PSXL\4>"]6BUWP?XBUOPOK4"M'%JOA_5+W2+]8G*M)
M#]JL)H)F@E*+YT#.T,P4+*CKQ7J/B#]IC]H#Q1ILND:Y\8/'UYIEQ;O:75DG
MB&^LH+VVE4I+;WRV$EK]NAE0E)8[LS+*A*R!E)%>'44JF%PM6I&K5PU"K5A;
MDJ5*-.=2-G=<LY1<HV>JLU9ET,SS+"T*F&PN88[#8:K=U</0Q=>C0JN22DZE
M*G4C3G=))\T7=))Z!7N&C_M+?M :!H\>@:1\8OB#9Z3!;PVEK:+XEU&7[#:V
MZ"."VT^XGFENM/MX(E6.&"RFMXHHU6-%5%4#P^BG6P]#$)1KT*->,7S15:G"
MJHR[I3C))Z+5:F>$Q^.P$ISP.,Q>"G4CR3GA,16P\IP_EG*C.#E'5^ZVUKL>
MFV'QK^,NE7FJZAI?Q:^)NFW^N7,=YK=[I_CSQ397>L7<,7DQ76J7%MJL4M_<
M10_N8IKIY9(XOW:,$XJOIGQ?^+6BZGK>M:-\4?B+I.L^)IK:X\2:MIGC;Q+8
M:GX@N+))8[.?6[^UU.*ZU6:TCGG2VEOY;AX$FE6)D61PWG5%+ZKA?>_V:A[\
M8QG^YI^]&+BXQE[OO1BXQ<4[I.,;)65M%FF9ITVLQQR=&=2K2:Q>(3I5*JFJ
MM2F_:>Y.HJE15)QM*:J34F^:5]?7O$&O>*M6N]?\3ZWJ_B/7=0,+7^M:]J5[
MK&K7K6]O%:0-=ZCJ$UQ>7)@M8(+:$S3.8[>&*%-L<:*N1116T8QC&,8Q48Q2
MC&,4E&,4K*,4K))))))62T1QSG.I.=2I.52I4E*=2I.3G.<YMRE.<I-RE*4F
MW*3;;;;;;84444R0KMO"GQ+^(_@."[M? _Q \;>#+;4)8[B_M_"GBO7?#L%[
M/"ACBFNX=(O[..YEBC9DCDF5W1&*JP4D5Q-%1.G3JQ<*L(5(.UX3C&<79W5X
MR33LTFM-'J:T,17PU2-;#5JN'K1NHU:%2=*I%23C)1G3E&2NFT[-73:>C-OQ
M%XF\2>+]5GUWQ9X@UOQ1KETD$=SK/B+5K_6]5N([:%+>V2?4=2N+F[F2W@CC
M@@629EBA1(XPJ*JC(AFFMYHKBWED@N()$F@GAD:*:&:)@\4L4J%7CDC=5=)$
M8,C ,I! -1T548QC%0C&,812C&,4E&,4K**BK))+1)*R6A,ZE2I4E5J5)U*L
MYNI.I.4I5)SD^:4Y3DW*4W)MN3;;>K=ST_6?C=\:/$6EWNB>(/B[\3]=T74H
M3;ZCI&L^/O%>IZ7?VY97,%[87NK3VEU"756,4\4B%E5MN0")? GQQ^+WPQLY
M=.\ _$7Q7X7TR>9[F72M-U6X72FN9 JR70TN8S6"74JHBRW*6ZS2K&BR2,J*
M!Y716#P>$=.5%X7#NC*2E*DZ%)TY26BE*#CRN2223:OH=JS;-(XB&+CF68+%
M4X.G3Q*QF)6(ITVVW"%95/:1@VVW&,E%MMVU/4;OXW?&2]\3/XRG^*GQ"7Q6
MUA)I0\0VWB_7K+5HM*FFBN)=*M[RROK>:VTN6X@@N)-.MVBLGGBCF: RHK#D
M/$_B_P 6>-=276?&7B?Q%XMU=;:*R75?$^M:EKVI+9P-(\-HM]JMS=W0MH7F
MF>* 2^5&TLC(@+L3SM%5##T*;C*G0HTY1A[.,H4X1<8+:$7&*:@OY5IY&5;'
MX[$0G3Q&-Q=>G4JNO4A6Q-:K"=9[UIQG.4957UJ23F^K/6- ^/'QL\*Z;!HW
MASXM_$?1=(M(5M[/2M.\9^(+;3K*!.$BL;&/4!;64:CA5M8H@!P.*\[O=;UG
M4M8NO$6HZMJ5]K][J$NK7FMW=]<W&K76J33FZEU*?4996NY;Z2Y8W#W;S-.T
MY,ID+_-6713AAZ%.4YTZ-*$ZG\2<*<(RG_CE&*<O^WFQ5L=C<13I4:^,Q5>C
M0M["E6Q%:I3HV5E[*$YRC3LDDN11LE;8]Y@_:C_:+MM-;2H?C7\2!:, NZ3Q
M5JLU\BJ,*L6JS7$FJ0J!P!#>(  ..!CQC5]9U?Q!J5WK.O:KJ6MZO?R>=?:K
MJ]]=:EJ5[-M5/-N[Z\EFNKF38JKYDTKMM55S@ #-HJ:6%PU"4I4,/0HRG\<J
M5&G3E+;XG",7+9;WV78O%9EF..A3IXW'XW&4Z7\*&*Q5?$0I:-?NXU:DXPT;
M7NI:-K9GI.A?&7XO^%]'MO#WAGXK?$GP[H%DLZ6>AZ%XY\3Z1H]HEU/-=7*V
MVF:?JEO90+<7-Q/<SK% @FGGFFD#22.S9'A/XB_$'P$+\>!?'7C+P6-4-L=3
M'A/Q/K?AP:B;+SQ9F_&CWUF+PV@NKK[,;CS/(^TS^5L\Z3=QM%-X;#M5$Z%%
MJLU*JG2A:K)2<E*HN6TVI-R3E=J3;W$LQS!2P\ECL8I82#IX22Q-=2PL)05.
M4,.U.]&#IQC3<:;BG!*#7*DC7U[Q!KWBK5KO7_$^MZOXCUW4#"U_K6O:E>ZQ
MJUZUO;Q6D#7>HZA-<7ER8+6""VA,TSF.WABA3;'&BKV.M?&3XO>)-&N/#GB+
MXJ_$C7_#UW'!#=Z#K7CGQ/JNC745K-#<6L5QI=]JD]C-';7%O!/ DD#+#-!#
M+&%>)&7S>BFZ%%^SO1I/V-O8WIP?LN6UO9W7[NW+&W+:W*K;(B.-QD/K')B\
M3#ZYS+%\M>K'ZTI\_,L1::]OS<\^;VO-?GG>_,[]7X4\=^./ ES=WG@?QEXK
M\&W=_ EM?77A3Q#J_AVYO+:.3S8[>[GTB\LY;B!)?WB13,\:R?.JAN:NR_$[
MXDS>*;?QS-\0O'$WC:T@-K:^,9?%FO2>*;:V:VFLFM[?Q ^H'5H8#9W-Q:&&
M.[6,VT\T!7RI71N'HH="C*4IRHTI3G!TYS=.#E.#5G"4FKR@TDG%MII6:"&-
MQE.G2HPQ>*A1HU8UZ-*&(JQITJ\9.4:U*"FHTZL9-RC4@E-2;:E<[#Q9\0O'
MWCUK!O'7CCQAXT;2Q<KIC>+/$VM>(VTY;PP&\6P.L7MX;,79M;8W(MS&)S;P
M&7?Y,>W7\/?&+XN>$=*@T'PG\4_B/X8T.U>>2UT;P]XX\3:+I5L]S,]Q<O!I
MVFZI;6<+W%Q))/.T<*F6:1Y9"SNS'SBBD\/AW3C1="BZ47>-)TH.G%ZZQ@X\
MJ?O2U23U?=EQS#'PQ$\7#'8R.*J14*F)CB:T<1."44HSK*:J2BE""492:M"*
MM[JMJ:3K>M:#JMIKNAZOJFBZY87 N[#6=)O[O3M5LKL;L7-IJ-G+#=VUP-S8
MFAF23YF^;DUT?BOXF_$CQW;VEGXX^(/C?QE:6$SW-C:^*_%FO>(K>RN)$\J2
MXM(-7O[R*WFDB_=O+"J2,GR,Q7BN(HJG2I2G&I*E3E4@K0J.$7."UTC)KFBM
M7HFMWW,H8K%4Z-3#0Q->&'K-2K4(5JD:-62<6I5*2DH3:<8M.46TXQ[*WJG@
M3XX_%[X8V<NG> ?B+XK\+Z9/,]S+I6FZK<+I37,@59+H:7,9K!+J5419;E+=
M9I5C19)&5% 9=_&[XR7OB9_&4_Q4^(2^*VL)-*'B&V\7Z]9:M%I4TT5Q+I5O
M>65];S6VERW$$%Q)IUNT5D\\4<S0&5%8>745F\'A'4G5>%P[JU$XU*CH4G4J
M1>\9SY>::?52;3.F.;9I&C1PT<RS".'P\E/#T(XS$JC0G'X9T:2J<E*4;NTH
M1BU?1G>2_%3XGS^)[;QM/\1_'DWC.RM&T^S\72^+_$,GB>TL'CN(7LK;7WU%
MM5@M&BN[J)K:*[2%H[FX0H5FD#4?%GQ \>>/)+*;QSXV\7>,Y=-2>/3I?%GB
M36?$4EA'<M$US'9/K%[>-:I<-#"TZ0&-96BB,@8QJ1R-%6L/0C*$XT:49TX\
ME.:IP4H0LUR0DHWC&TI+EBTK-Z:LQGCL=4IU:-3&8J=*O4]M7I3Q%:5.M5O!
M^UJPE-QJ5+TX/GFI2O"&ONJW?^%_BO\ %+P1ITFD>"_B5X_\(:3-=R7\NE^%
M_&/B+0-.EOIHH89KV2RTG4;2V>[EAMK>*2X:(S/%!#&SE(D"\5=7U[?7MSJ5
M[>75YJ-Y=37UW?W5Q+<7MU>W$K3W%Y<W4SO//=3SN\TUQ+(TLLK-([L[%C5H
MIQI4H3G4A3IQG4^.<81C.=MN>22<K>;9%3%8FK2I4:N(KU:-"ZH4:E:I.E13
MLFJ5.4G"G=))\B5[+L>[Z5^U!^T1HNG#2M.^,WQ"BL5BC@BBF\2:A>R6\,2A
M(H;2YOI;FZM(XT 2-+6:)41510%  \AU_P 1^(/%>JW6N^)]<U;Q%K5ZP:[U
M;7-1N]5U&Y(X7SKV]FGN) H^5%:0JBX50% %8U%12PN%H3E4HX:A1G/XYTJ-
M.G.6WQ2A%.6RW;V1OB<SS+&4J=#%YACL51I-.E1Q.+KUZ5-I-)TZ=6I*$&DV
MDXI:-K8*569&5T8JRD,K*2K*RG(92,$$$ @@@@C(I**W.$]ZTS]J/]HG1]-3
M2-/^,WQ CL8XA#%'-XAO+R:")<A(X+R]>XO8$C4[8UAN$$:!40*B*H\Q7Q[X
MY3Q3_P )S'XS\5Q^-?->?_A,$\1:NGB@326S6<DPU];P:J)'M'>U=Q=AFMF:
M DQ,4/)T5SPP>$I.HZ>%P]-U4XU7"A2@ZD9;QJ.,5SI]5*Z?4]"MFV:XE4(X
MC,\PKQPLXU,-&MC,356'G#X)T%.I)49P^S*GRN/1H]%\1_%_XM>,=+DT/Q=\
M4?B+XJT6:6&>71_$?C;Q+KFERSV[^9;S2:?J>IW5H\L$@#PR-"7B<;D*MS7G
M5%%:TZ5*C'DI4Z=*-V^6G",(W=DW:*2NTE=VOHCFQ&)Q.+J*KBL17Q-514%4
MQ%6I6J*$6VHJ=24I<J;;4;V3;LM6.1WB=)(W:.2-E>.1&*.CH0R.C*0RLK ,
MK*05(!!!%?0FC_M8_M(Z#8)ING?&7QQ]DCC\J-;_ %3^V)XHP JI%>:Q%?7D
M:HH"QA)U$2@+'M4 5\\T5G7PV&Q*2Q.'H8A1=XJO2IU5%Z:I5(R2>BV[(VP6
M99CETISR_'XW 3J)*I+!8JOA932O93E0J4W)*[LI-I7?<[3QI\1_'WQ&O8]1
M\>>,O$OBZ[@WBVD\0:Q?:FEFLFWS([&"ZFDM[&)]BEXK.*"-BH)0GFL;P]XE
M\1^$=5M]>\*>(-;\,:Y:+.EKK/A[5;_1=5MDN89+:Y2WU'39[:\A6XMY9;>=
M8YE$L,DD4@:-V4XE%7&C2C3]C&E3C1Y7'V4815/E>CCR)<O*TVFK6?8QGBL5
M4Q'UNIB<1/%^TC5^M3K5)8CVL&G&I[:4G4]I%I.,^;F32::LCKO%GQ \>>/)
M+*;QSXV\7>,Y=-2>/3I?%GB36?$4EA'<M$US'9/K%[>-:I<-#"TZ0&-96BB,
M@8QJ1H^%_BO\4O!&G2:1X+^)7C_PAI,UW)?RZ7X7\8^(M TZ6^FBAAFO9++2
M=1M+9[N6&VMXI+AHC,\4$,;.4B0+P%%)X>@Z:HNA1=%.ZI.G!TT[MW4.7E3N
MV]%NV]V:1Q^.CB)8N.-Q<<7-6EBHXFLL1)6C&TJRG[22Y8QC9R:M&*V2+-Y>
M7FH7EUJ%_=7-]?WUS/>7M]>3RW-Y>7ES*T]S=75S,[S7%S<3.\T\\KO++*[2
M2.SL2?;=(_:>_:%T+2TT72_C'\0+?38HE@@@D\17UV]M @"I#:7-Y)<7=I%&
MH"Q1VT\21( D850 /":*57#8>O&,*^'HUHPUA&K2IU(Q>FL8SBU'9;);+L/"
MYCF&!G4J8+'8S!U*JM5J87$UL/.HKMVJ3HSA*:NV[2;5VWU-SQ%XF\1^+]5N
M-=\5Z_K/B76[L(+G5]>U.]U?4IUC7;&LM[?S7%RZ1)A(D:0I&@"(JJ *IZ5J
MVJZ%J-IJ^B:GJ&CZMI\RW%AJFE7ESI^HV5PF=D]I>VDD-S;3+D[9894=<G##
M-9]%:*$%!4U"*IJ/(H**4%"UN512Y5&VG+:UM+6.>56K*JZ\JM259S]JZTIR
M=5U'+F=1U&^=SYO>YV^;FUO?4]YN/VH_VC+G35TJ;XU_$G[(H(WQ^*M5@OG!
M&TK+JL%Q'JDRD<%9;QU.3D<G/AMS<W-[<W%Y>7$]W=W4TMS=75S+)/<W-Q.[
M233W$\K/+---(S22RR,SR.S.[%B34%%9T<-A\/S>PP]&CSZR]C2IT^9]Y<D8
MW^=SHQ>8YAC^3Z]CL9C?9)JG];Q-?$>S3234/;3GR)I)-1MHDNB/26^,OQ??
MP^?";_%;XDOX6.DC0#X:;QSXG;P^="%H+ :*=&.J'3CI(L0+(:=]F^QBT MO
M)\GY*\[@GFMIH;FVFEM[BWECF@G@D>*:":)@\4T,L95XY8W57CD1E=& 92"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/$?]%!GG_@[!_P#S$'^N^ _Z('@C_P (\X\O^IUY?CZW_3[_ (4M_P $U_\
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M_@[!_P#S$'^N^ _Z('@C_P (\X\O^IUY?CZW_3[_ (4M_P $U_\ HX_XE?\
M?ZV_^<_1_P *6_X)K_\ 1Q_Q*_[_ %M_\Y^OS!HH_L/$?]%!GG_@[!__ #$'
M^N^ _P"B!X(_\(\X\O\ J=>7X^M_T^_X4M_P37_Z./\ B5_W^MO_ )S]'_"E
MO^":_P#T<?\ $K_O];?_ #GZ_,&BC^P\1_T4&>?^#L'_ /,0?Z[X#_H@>"/_
M  CSCR_ZG7E^/K?]/O\ A2W_  37_P"CC_B5_P!_K;_YS]'_  I;_@FO_P!'
M'_$K_O\ 6W_SGZ_,&BC^P\1_T4&>?^#L'_\ ,0?Z[X#_ *('@C_PCSCR_P"I
MUY?CZW_3[_A2W_!-?_HX_P")7_?ZV_\ G/T?\*6_X)K_ /1Q_P 2O^_UM_\
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M^<_1_P *6_X)K_\ 1Q_Q*_[_ %M_\Y^OS!HH_L/$?]%!GG_@[!__ #$'^N^
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MRS,*].C2KQHPK8W!4,35A2C4KU)JE&=1J"G4G)124IR=Y/\ -G_AUO\ L_\
M_0X?&+_PH/!7_P [ZC_AUO\ L_\ _0X?&+_PH/!7_P [ZOTFHKC_ -:.(/\
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MR_/NS\V?^'6_[/\ _P!#A\8O_"@\%?\ SOJ/^'6_[/\ _P!#A\8O_"@\%?\
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M'^M'$'_0UQ7_ (%'_P"1#_B&7 /_ $2V5_\ @NI_\M\OS[L_-G_AUO\ L_\
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M@_Z&N*_\"C_\B'_$,N ?^B6RO_P74_\ EOE^?=GYL_\ #K?]G_\ Z'#XQ?\
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M+\^[/S9_X=;_ +/_ /T.'QB_\*#P5_\ .^H_X=;_ +/_ /T.'QB_\*#P5_\
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M8O\ PH/!7_SOJ/\ AUO^S_\ ]#A\8O\ PH/!7_SOJ_2:BC_6CB#_ *&N*_\
M H__ "(?\0RX!_Z);*__  74_P#EOE^?=GYL_P##K?\ 9_\ ^AP^,7_A0>"O
M_G?4?\.M_P!G_P#Z'#XQ?^%!X*_^=]7Z344?ZT<0?]#7%?\ @4?_ )$/^(9<
M _\ 1+97_P""ZG_RWR_/NS\V?^'6_P"S_P#]#A\8O_"@\%?_ #OJ/^'6_P"S
M_P#]#A\8O_"@\%?_ #OJ_2:BC_6CB#_H:XK_ ,"C_P#(A_Q#+@'_ *);*_\
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MH/!7_P [ZC_AUO\ L_\ _0X?&+_PH/!7_P [ZOTFHH_UHX@_Z&N*_P# H_\
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M^H_X=;_L_P#_ $.'QB_\*#P5_P#.^K])J*/]:.(/^AKBO_ H_P#R(?\ $,N
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MDU%'^M'$'_0UQ7_@4?\ Y$/^(9< _P#1+97_ ."ZG_RWR_/NS\V?^'6_[/\
M_P!#A\8O_"@\%?\ SOJ/^'6_[/\ _P!#A\8O_"@\%?\ SOJ_2:BC_6CB#_H:
MXK_P*/\ \B'_ !#+@'_HELK_ /!=3_Y;Y?GW9^;/_#K?]G__ *'#XQ?^%!X*
M_P#G?4?\.M_V?_\ H</C%_X4'@K_ .=]7Z344?ZT<0?]#7%?^!1_^1#_ (AE
MP#_T2V5_^"ZG_P M\OS[L_-G_AUO^S__ -#A\8O_  H/!7_SOJ/^'6_[/_\
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M_P#_ $.'QB_\*#P5_P#.^K])J*/]:.(/^AKBO_ H_P#R(?\ $,N ?^B6RO\
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M1#_B&7 /_1+97_X+J?\ RWR_/NS\V?\ AUO^S_\ ]#A\8O\ PH/!7_SOJ/\
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M_"@\%?\ SOJ/^'6_[/\ _P!#A\8O_"@\%?\ SOJ_2:BC_6CB#_H:XK_P*/\
M\B'_ !#+@'_HELK_ /!=3_Y;Y?GW9^;/_#K?]G__ *'#XQ?^%!X*_P#G?4?\
M.M_V?_\ H</C%_X4'@K_ .=]7Z344?ZT<0?]#7%?^!1_^1#_ (AEP#_T2V5_
M^"ZG_P M\OS[L_-G_AUO^S__ -#A\8O_  H/!7_SOJ/^'6_[/_\ T.'QB_\
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M7 /_ $2V5_\ @NI_\M\OS[L_-G_AUO\ L_\ _0X?&+_PH/!7_P [ZC_AUO\
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MI-11_K1Q!_T-<5_X%'_Y$/\ B&7 /_1+97_X+J?_ "WR_/NS\V?^'6_[/_\
MT.'QB_\ "@\%?_.^H_X=;_L__P#0X?&+_P *#P5_\[ZOTFHH_P!:.(/^AKBO
M_ H__(A_Q#+@'_HELK_\%U/_ );Y?GW9^;/_  ZW_9__ .AP^,7_ (4'@K_Y
MWU'_  ZW_9__ .AP^,7_ (4'@K_YWU?I-11_K1Q!_P!#7%?^!1_^1#_B&7 /
M_1+97_X+J?\ RWR_/NS\V?\ AUO^S_\ ]#A\8O\ PH/!7_SOJ/\ AUO^S_\
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M4?\ Y$/^(9< _P#1+97_ ."ZG_RWR_/NS\V?^'6_[/\ _P!#A\8O_"@\%?\
MSOJ/^'6_[/\ _P!#A\8O_"@\%?\ SOJ_2:BC_6CB#_H:XK_P*/\ \B'_ !#+
M@'_HELK_ /!=3_Y;Y?GW9^;/_#K?]G__ *'#XQ?^%!X*_P#G?4?\.M_V?_\
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MJG_R']7?E;\4?^';_P </^AJ^%/_ (//%_\ \PU'_#M_XX?]#5\*?_!YXO\
M_F&K]KJ*/]>^(/\ GYA?_":/_P D'_$#. ?^@?-/_#E4_P#D/ZN_*WXH_P##
MM_XX?]#5\*?_  >>+_\ YAJ/^';_ ,</^AJ^%/\ X//%_P#\PU?M=11_KWQ!
M_P _,+_X31_^2#_B!G /_0/FG_ARJ?\ R']7?E;\4?\ AV_\</\ H:OA3_X/
M/%__ ,PU'_#M_P".'_0U?"G_ ,'GB_\ ^8:OVNHH_P!>^(/^?F%_\)H__)!_
MQ S@'_H'S3_PY5/_ )#^KORM^*/_  [?^.'_ $-7PI_\'GB__P"8:C_AV_\
M'#_H:OA3_P"#SQ?_ /,-7[744?Z]\0?\_,+_ .$T?_D@_P"(&< _] ^:?^'*
MI_\ (?U=^5OQ1_X=O_'#_H:OA3_X//%__P PU'_#M_XX?]#5\*?_  >>+_\
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MJG_R']7?E;\4?^';_P </^AJ^%/_ (//%_\ \PU'_#M_XX?]#5\*?_!YXO\
M_F&K]KJ*/]>^(/\ GYA?_":/_P D'_$#. ?^@?-/_#E4_P#D/ZN_*WXH_P##
MM_XX?]#5\*?_  >>+_\ YAJ/^';_ ,</^AJ^%/\ X//%_P#\PU?M=11_KWQ!
M_P _,+_X31_^2#_B!G /_0/FG_ARJ?\ R']7?E;\4?\ AV_\</\ H:OA3_X/
M/%__ ,PU'_#M_P".'_0U?"G_ ,'GB_\ ^8:OVNHH_P!>^(/^?F%_\)H__)!_
MQ S@'_H'S3_PY5/_ )#^KORM^*/_  [?^.'_ $-7PI_\'GB__P"8:C_AV_\
M'#_H:OA3_P"#SQ?_ /,-7[744?Z]\0?\_,+_ .$T?_D@_P"(&< _] ^:?^'*
MI_\ (?U=^5OQ1_X=O_'#_H:OA3_X//%__P PU'_#M_XX?]#5\*?_  >>+_\
MYAJ_:ZBC_7OB#_GYA?\ PFC_ /)!_P 0,X!_Z!\T_P##E4_^0_J[\K?BC_P[
M?^.'_0U?"G_P>>+_ /YAJ/\ AV_\</\ H:OA3_X//%__ ,PU?M=11_KWQ!_S
M\PO_ (31_P#D@_X@9P#_ - ^:?\ ARJ?_(?U=^5OQ1_X=O\ QP_Z&KX4_P#@
M\\7_ /S#4?\ #M_XX?\ 0U?"G_P>>+__ )AJ_:ZBC_7OB#_GYA?_  FC_P#)
M!_Q S@'_ *!\T_\ #E4_^0_J[\K?BC_P[?\ CA_T-7PI_P#!YXO_ /F&H_X=
MO_'#_H:OA3_X//%__P PU?M=11_KWQ!_S\PO_A-'_P"2#_B!G /_ $#YI_X<
MJG_R']7?E;\4?^';_P </^AJ^%/_ (//%_\ \PU'_#M_XX?]#5\*?_!YXO\
M_F&K]KJ*/]>^(/\ GYA?_":/_P D'_$#. ?^@?-/_#E4_P#D/ZN_*WXH_P##
MM_XX?]#5\*?_  >>+_\ YAJ/^';_ ,</^AJ^%/\ X//%_P#\PU?M=11_KWQ!
M_P _,+_X31_^2#_B!G /_0/FG_ARJ?\ R']7?E;\4?\ AV_\</\ H:OA3_X/
M/%__ ,PU'_#M_P".'_0U?"G_ ,'GB_\ ^8:OVNHH_P!>^(/^?F%_\)H__)!_
MQ S@'_H'S3_PY5/_ )#^KORM^*/_  [?^.'_ $-7PI_\'GB__P"8:C_AV_\
M'#_H:OA3_P"#SQ?_ /,-7[744?Z]\0?\_,+_ .$T?_D@_P"(&< _] ^:?^'*
MI_\ (?U=^5OQ1_X=O_'#_H:OA3_X//%__P PU'_#M_XX?]#5\*?_  >>+_\
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MJG_R']7?E;\4?^';_P </^AJ^%/_ (//%_\ \PU'_#M_XX?]#5\*?_!YXO\
M_F&K]KJ*/]>^(/\ GYA?_":/_P D'_$#. ?^@?-/_#E4_P#D/ZN_*WXH_P##
MM_XX?]#5\*?_  >>+_\ YAJ/^';_ ,</^AJ^%/\ X//%_P#\PU?M=11_KWQ!
M_P _,+_X31_^2#_B!G /_0/FG_ARJ?\ R']7?E;\4?\ AV_\</\ H:OA3_X/
M/%__ ,PU'_#M_P".'_0U?"G_ ,'GB_\ ^8:OVNHH_P!>^(/^?F%_\)H__)!_
MQ S@'_H'S3_PY5/_ )#^KORM^*/_  [?^.'_ $-7PI_\'GB__P"8:C_AV_\
M'#_H:OA3_P"#SQ?_ /,-7[744?Z]\0?\_,+_ .$T?_D@_P"(&< _] ^:?^'*
MI_\ (?U=^5OQ1_X=O_'#_H:OA3_X//%__P PU'_#M_XX?]#5\*?_  >>+_\
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MJG_R']7?E;\4?^';_P </^AJ^%/_ (//%_\ \PU'_#M_XX?]#5\*?_!YXO\
M_F&K]KJ*/]>^(/\ GYA?_":/_P D'_$#. ?^@?-/_#E4_P#D/ZN_*WXH_P##
MM_XX?]#5\*?_  >>+_\ YAJ/^';_ ,</^AJ^%/\ X//%_P#\PU?M=11_KWQ!
M_P _,+_X31_^2#_B!G /_0/FG_ARJ?\ R']7?E;\4?\ AV_\</\ H:OA3_X/
M/%__ ,PU'_#M_P".'_0U?"G_ ,'GB_\ ^8:OVNHH_P!>^(/^?F%_\)H__)!_
MQ S@'_H'S3_PY5/_ )#^KORM^*/_  [?^.'_ $-7PI_\'GB__P"8:C_AV_\
M'#_H:OA3_P"#SQ?_ /,-7[744?Z]\0?\_,+_ .$T?_D@_P"(&< _] ^:?^'*
MI_\ (?U=^5OQ1_X=O_'#_H:OA3_X//%__P PU'_#M_XX?]#5\*?_  >>+_\
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MJG_R']7?E;\4?^';_P </^AJ^%/_ (//%_\ \PU'_#M_XX?]#5\*?_!YXO\
M_F&K]KJ*/]>^(/\ GYA?_":/_P D'_$#. ?^@?-/_#E4_P#D/ZN_*WXH_P##
MM_XX?]#5\*?_  >>+_\ YAJ/^';_ ,</^AJ^%/\ X//%_P#\PU?M=11_KWQ!
M_P _,+_X31_^2#_B!G /_0/FG_ARJ?\ R']7?E;\4?\ AV_\</\ H:OA3_X/
M/%__ ,PU'_#M_P".'_0U?"G_ ,'GB_\ ^8:OVNHH_P!>^(/^?F%_\)H__)!_
MQ S@'_H'S3_PY5/_ )#^KORM^*/_  [?^.'_ $-7PI_\'GB__P"8:C_AV_\
M'#_H:OA3_P"#SQ?_ /,-7[744?Z]\0?\_,+_ .$T?_D@_P"(&< _] ^:?^'*
MI_\ (?U=^5OQ1_X=O_'#_H:OA3_X//%__P PU'_#M_XX?]#5\*?_  >>+_\
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MJG_R']7?E;\4?^';_P </^AJ^%/_ (//%_\ \PU'_#M_XX?]#5\*?_!YXO\
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MBBB@ HHHH **** "BBB@#\=_^"L?_- O^ZI_^\XK\=Z_8C_@K'_S0+_NJ?\
M[SBOQWK]XX,_Y)K+?^YS_P!3\4?PKXR?\G(XC_[H_P#ZH<K"BBBOJ#\Q"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'C]%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% %S3O^0A8_]?EK_P"CTKU2O*]._P"0
MA8_]?EK_ .CTKU2@ HHHH **** "BBB@ HHHH **** /QW_X*Q_\T"_[JG_[
MSBOQWK]B/^"L?_- O^ZI_P#O.*_'>OWC@S_DFLM_[G/_ %/Q1_"OC)_R<CB/
M_NC_ /JARL****^H/S$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _I,_8$_Y-*^$__<]_^K+\95]B5\=_L"?\FE?"?_N>_P#U9?C*
MOL2OYSSS_D=9Q_V-,P_]2ZQ_HCP3_P D9PC_ -DQD'_JJP@4445Y9].%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M/T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7-._Y"
M%C_U^6O_ */2O5*\KT[_ )"%C_U^6O\ Z/2O5* "BBB@ HHHH **** "BBB@
M HHHH _'?_@K'_S0+_NJ?_O.*_'>OV(_X*Q_\T"_[JG_ .\XK\=Z_>.#/^2:
MRW_N<_\ 4_%'\*^,G_)R.(_^Z/\ ^J'*PHHHKZ@_,0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#^DS]@3_DTKX3_]SW_ZLOQE7V)7
MQW^P)_R:5\)_^Y[_ /5E^,J^Q*_G///^1UG'_8TS#_U+K'^B/!/_ "1G"/\
MV3&0?^JK"!1117EGTX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*ZU@:MID>H6%QX0EAN%ATW5+.RN=?U&[CNX8_"D:Z=JLM@ ?N!17X]?LM_\
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M'GHXG"UJ=>A5CMS4ZM*4H35TU>,GJFMT%%%%9G0%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7"0M+I^H:SI^A/?(KR16@MQ'<2_3?[$__!1GX6?MGZKXN\#Z=X5\5_"[XN^
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M7QD_9M^(WCWP+$W@&U\?:3?W&C>)I++Q#H6HRVBWMYH?AG5K*XEL8O/M+A]
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M0-R@ HHHH **** +FG?\A"Q_Z_+7_P!'I7JE>5Z=_P A"Q_Z_+7_ -'I7JE
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M6I6U_P"*KM(=22+48DT^;PO8::(5DLY0/W<_X+ _"+]JO]H;]G'0O@5^R_\
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MZO\ \%M_^";^K:K:M8ZIJG[.>C:CJ5DX"M9W]['^T+<WEJP4E0UO<2R1$*2
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M%#?^"IVN6^A:=!J/@;XP>*_!_A.>.U@4Z#X=U_XT_%=M4TW3<1@V=O<KX/\
M#\3I;F-3#811%2@"C]=?^"??PJ\>_!#]C7X!?"GXH:#_ ,(QX^\%>#I]*\3Z
M#_:FC:U_9E^^OZS>K!_:GA[4=6T6]S:W=O+YNGZC=PCS-AD$B.B_'G_!.O\
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MUM-?TJ>],&M:OX:M=9T+6_#&LKHUY::=KT'B72=5T_3]4TF"[$K2Z4 >P?\
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ME%N\<-A*+;C1H05DDKSJ2O4K3J5ISJ2****] \$**** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUS2-&N+B]L?$7Q L].D1G2P3=?&Y^@/CI^S9^W3^SG^U_P"-OVN/V,;#P_\
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MUUC]F'XX77_!77PI^U!;^"A)\#--^$-SX9O?&_\ PDGA)#!KLG@KQ)HR:?\
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M2TNHFZC]I7_DSOX@?]DNT_\ ]$Z77P9_P38_:+_LG4Y_@!XKOMNFZS-=ZO\
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MT?XP>-(?B-\5?B)X[MDECL_%?C'Q!K>GQ3_ZZ'3+[4KB73(9NF)8; VT4@
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MY?&35#%8S,\95C=V=7 T<'1HMK9N,<PKVOJKNW4JT445^KG\KA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
MS_\ P2L\=W%SHGQ1^&MU,S0Z5J&C^,M&B9MVQ=7AFTC753)RD22:7HDBHOR&
M6ZGDPKNQD_7&OP?_ ."6DDP^.?CB)<_9W^$^J22\G;YT7C#P6L&1T)V2W&TG
MD#<!U-?O!7X7QK1A1XAQ;@DE6IX>LTME.5&$9OUE*#F_.39_<?@OC*V,\/\
M*HUI.3P=?,,'3E)MMT:>+J5*4;OI3A55&"V4*<5T"BBBODS]5"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /'Z*** "BBB@ HHHH ***\:^,?[0_P/_9]TRQU?
MXT_%'P=\.+/56N$TA/$NKP6NH:PUFJ/=C1](C\[5M6-HLL)N?[.LKG[.9H%F
MV--$' /9:*^=?@S^UO\ LT_M"W+Z?\&OC5X#\>:Q':27\GAW3-82U\4QV$+(
MLU])X5U9-/\ $26<+21K-=/I@@A:2-9)%9T!]M\3>*/#7@O0-5\5>,/$&B^%
M?#&A6CW^M>(O$6J66BZ)I-E&55[O4M4U&>VLK*W5F53-<3QIO=4W;F4$ W:*
M^(?#W_!23]A;Q3XE@\):/^TS\-FUJZN4L[8:C>ZCH6DW%S*2L4,/B/7=-TWP
M[*TS@1P[-59997CBC+22QJ_VZK*RJZLK(RAE92"K*1D,K#(*D$$$'!'(XH 6
MBOC+Q-_P40_8C\'^*Y?!7B#]I;X86GB*WO;C3KRWM]8FU6PTZ_M)6@NK35-=
MTFTOM!TNXMIT>&>+4=3MFAF1XI LB,H^J_"?B_PIX]\/:7XN\#^)=!\8>%=;
MMQ=Z/XC\,:O8:[H>J6Q9D\^PU73)[FRNXUD1XW:&9PDJ/&^UT90 =%17AWQI
M_:6^ G[.UC87_P ;/BOX.^'2:L)6TFSU[5%&LZM' P6XFTKP_9I=Z[J=O;.R
M)=7-CIUQ;VTDD23R1O+&K9GP0_:N_9S_ &D/[03X(_%[P?\ $"\TJ 7>IZ/I
M=Y/9^(K"S:40+?7?AK6+?3=?@T]IV6%;^335LVF=(Q.7=%8 ^A**** "BBB@
M HHHH **** "BBB@ HHHH 9)''-&\4J)+%*C1R1R*KQR1NI5T=&!5T=2596!
M5E)!!!K\+]-_X)J?MC?LP>,O&=W^P#^U?X:\ _#'QSKLGB"[^&/Q7T!=5T_1
M+J2-8!#:SR>$?'NG:E+;6ZI:VVLV^B>&M9ETRRTK3-5N=4.GK?2_NG10!^2_
M[,'_  3D\?>$_P!H-_VN/VO/CD_[0OQZL;&73?" LM)33/!GA"*:QFL#?6-K
M+9V$9N+.VOM3@T+3-'T/PUH6B2ZAJ&K+87NL7D-WIWZT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 7-._Y"%C_P!?EK_Z/2O5*\KT[_D(6/\ U^6O_H]*]4H
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M%9?VPUJZNX>V-[Y#ACNC.37O]%% !1110 4444 %%%% !1110 4444 %%%%
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M:MI=]9R>3K&E27%A=6-[(;>PU#2=1B%MJ>G6L=YI=SJ' _\ !'/P!X8\#?\
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M1Q=2*6K]C4IX6M4=K0H4ZU232@V?D)1117[0?QL%%%% !1110 4444 %%%%
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6\N]-TBQT"]/]JV/A*TN]7U'4=7-OJGC;7)]1BU32+[AO^"@LR:%_P %9_\
M@G1X@U)FM]*OV\(>'[:Y=6$#:I<?$[7-/C@5V'E^8;GQ'I*2XPT:W$+N5#(:
M /IC]I[_ ()7?LFZM^RMXY\(_#'X/^&/!7COP5X$U36O /CO1K)SXTN?$?A?
M2Y=3LK?Q)KQE&H>*+?Q*]D^DZO'KDM_'''J<U]I\-MJ%K836_P !?"?XX_M&
M?%__ ((M:OX2^$.C_$'XA?%70?B#<_LVWDO@_1=9\3>,$^'F-*\4W#00Z/#<
MWT=A9> ?$.G^!#J'DL+;3&2#S4O#'<K_ $:_$K5K'0?AUX^US4Y%ATW1O!7B
MK5M0E?[D5CIVA7]Y=R/_ +*00R,WL#7XE_\ !"35-*\#_L1?&3QQXPU6S\-^
M$]-^.WC36]1US6[B/3M(T[1=#^&7PRDU36;F]N6C@BL;?RKB.XN6<1HUE*A.
MZ-@ #Z,_9L_X)4?LE>&/V;O!7@[XH_!'P[XR\?\ B7P3HU_\2/%7BJSO4\9P
M>*];TJ"\UNRT75DGMM6\'0:%>W,NE:;;:%-I=S!#8PS7SW&IO=W4WQ__ ,$6
M]1O?A]\:?V[O@!H'B>_\3_!/X6^/II_!^J7EVEU90/I?C#QKX3AUR![=8[-+
MCQCX;T'3K[4I;2)+>[.@V\T"(BG?M?$W]MO]J+_@H-X@\1? G_@G3X1U7PK\
M*XYVT#X@?M2^*4O/#4<%E<@1W:>'KN: S^%8;FTD:6WCLK75?B9J%C/'>Z?H
MOA0VUQ<-^A7[*_[#_@W]C+]F[QE\,O -[/XC\>^+O#^M7_C;X@3V7V34?%GB
MMM#O[/2OLNGK/=_V9HFB?:6M= T:.YN3;K-=W=Q/<ZEJ5_=3@'XT?LI6G[.?
M[6'Q@_:+_P""@7[=7BWP8OPV/Q,OOAO\$_"'Q=\0Z=IOA1(K"UM=:M=*71]1
MO;=?$,_@[P5J_A6TM?#]M:7EA<7NMZYXAU33[G4FBNX?KOPK^Q_^SG\2/VM?
M@S^U+_P3O^-7P1\(Z?\ #?5;"X^-'PZ\ :S]LM=9T":_@L]3BTWPQH4\H\)O
MXI\)7NN>'[ZVO+'3-#FN8]+O[>T^W?VG<3?GU_P1F_8=^#W[3MA\3?B1\>-,
MG\>>'/AOK^G>&/!WPZO=7U2S\/6^NZUIPU3Q!XCU>RTV^L[BZ=K6#1;*PM#+
M%I]Q)%?2ZE;W\MI8?8O7/V]?@#X(_P""<?[3G[)W[2/[+%M>?#VU\7^-[K0/
M%WP^TS5-5O-'U"#2;WPT=6LK&WO;V[U!M&\9:!K6H:1KNC"Y:PM;BWT^[TN*
MSNKA6B /Z?J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"YIW_(0L?^ORU_\ 1Z5ZI7E>G?\ (0L?^ORU_P#1
MZ5ZI0 4444 %%%% !1110 4444 %%%% 'X[_ /!6/_F@7_=4_P#WG%?CO7[$
M?\%8_P#F@7_=4_\ WG%?CO7[QP9_R366_P#<Y_ZGXH_A7QD_Y.1Q'_W1_P#U
M0Y6%%%%?4'YB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)-QK.@Z=:_Z  )B;NR^T?L310'6_K^-O\C^='Q]^QO\ MU?L'?M3_%']H_\
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M_P#FHH_MK)_^AMEG_A?A?_EOFOO#_4WB_P#Z)7B3_P ,>:?_ #*?)%%?6_\
MPPG^U=_T2.]_\*GP+_\ -11_PPG^U=_T2.]_\*GP+_\ -11_;63_ /0VRS_P
MOPO_ ,M\U]X?ZF\7_P#1*\2?^&/-/_F4^2**^M_^&$_VKO\ HD=[_P"%3X%_
M^:BC_AA/]J[_ *)'>_\ A4^!?_FHH_MK)_\ H;99_P"%^%_^6^:^\/\ 4WB_
M_HE>)/\ PQYI_P#,I\D45];_ /#"?[5W_1([W_PJ? O_ ,U%'_#"?[5W_1([
MW_PJ? O_ ,U%']M9/_T-LL_\+\+_ /+?-?>'^IO%_P#T2O$G_ACS3_YE/DBB
MOK?_ (83_:N_Z)'>_P#A4^!?_FHH_P"&$_VKO^B1WO\ X5/@7_YJ*/[:R?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 >/T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 7-._Y"%C_U^6O_ */2O5*\KT[_
M )"%C_U^6O\ Z/2O5* "BBB@ HHHH **** "BBB@ HHHH _'?_@K'_S0+_NJ
M?_O.*_'>OV(_X*Q_\T"_[JG_ .\XK\=Z_>.#/^2:RW_N<_\ 4_%'\*^,G_)R
M.(_^Z/\ ^J'*PHHHKZ@_,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#^DS]@3_DTKX3_]SW_ZLOQE7V)7QW^P)_R:5\)_^Y[_ /5E
M^,J^Q*_G///^1UG'_8TS#_U+K'^B/!/_ "1G"/\ V3&0?^JK"!1117EGTX44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!X_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!<T[
M_D(6/_7Y:_\ H]*]4KRO3O\ D(6/_7Y:_P#H]*]4H **** "BBB@ HHHH **
M** "BBB@#X9_;,_9<\1?M+7/PSBT3Q1HGA>#P;!XWDO;G68+JX^U3:_)X.6R
M@MHK4JWRIHU[)-(S;4Q$N"9,CXF_X=9>./\ HKO@C_P5:O\ _'*_8_Q9_P N
M'_;U_P"VU<?7T>!XJSG+<)1P6$KTJ>'H>T]G&6'HSE^\JSK3O*<92=YU)6UT
M3LMD?G>>>%O!W$>:XO.LUP.)KX_&N@Z]2&/Q5"#^KX:AA*2C2HU(0BE1P]-.
MRO*7-)N[5OR@_P"'67CC_HKO@C_P5:O_ /'*/^'67CC_ **[X(_\%6K_ /QR
MOU?HKK_UXXB_Z"J/_A)A_P#Y7_5WY6\G_B"7A[_T+,9_X=,?_P#+OZN_*WY0
M?\.LO''_ $5WP1_X*M7_ /CE'_#K+QQ_T5WP1_X*M7_^.5^K]%'^O'$7_051
M_P#"3#__ "O^KORL?\02\/?^A9C/_#IC_P#Y=_5WY6_*#_AUEXX_Z*[X(_\
M!5J__P <H_X=9>./^BN^"/\ P5:O_P#'*_5^BC_7CB+_ *"J/_A)A_\ Y7_5
MWY6/^()>'O\ T+,9_P"'3'__ "[^KORM^4'_  ZR\<?]%=\$?^"K5_\ XY1_
MPZR\<?\ 17?!'_@JU?\ ^.5^K]%'^O'$7_051_\ "3#_ /RO^KORL?\ $$O#
MW_H68S_PZ8__ .7?U=^5OR@_X=9>./\ HKO@C_P5:O\ _'*/^'67CC_HKO@C
M_P %6K__ !ROU?HH_P!>.(O^@JC_ .$F'_\ E?\ 5WY6/^()>'O_ $+,9_X=
M,?\ _+OZN_*WY0?\.LO''_17?!'_ (*M7_\ CE'_  ZR\<?]%=\$?^"K5_\
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M/]>.(O\ H*H_^$F'_P#E?]7?E8_X@EX>_P#0LQG_ (=,?_\ +OZN_*WY0?\
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M5'VBW_Y[P_\ ?U/_ (JO):* /6OM%O\ \]X?^_J?_%4?:+?_ )[P_P#?U/\
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M#UK[1;_\]X?^_J?_ !5'VBW_ .>\/_?U/_BJ\EHH ]:^T6__ #WA_P"_J?\
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M5'VBW_Y[P_\ ?U/_ (JO):* /6OM%O\ \]X?^_J?_%4?:+?_ )[P_P#?U/\
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M#UK[1;_\]X?^_J?_ !5'VBW_ .>\/_?U/_BJ\EHH ]:^T6__ #WA_P"_J?\
MQ5'VBW_Y[P_]_4_^*KR6B@#UK[1;_P#/>'_OZG_Q5'VBW_Y[P_\ ?U/_ (JO
M):* /6OM%O\ \]X?^_J?_%4?:+?_ )[P_P#?U/\ XJO):* /6OM%O_SWA_[^
MI_\ %4?:+?\ Y[P_]_4_^*KR6B@#UK[1;_\ />'_ +^I_P#%4?:+?_GO#_W]
M3_XJO):* /6OM%O_ ,]X?^_J?_%4?:+?_GO#_P!_4_\ BJ\EHH ]:^T6_P#S
MWA_[^I_\51]HM_\ GO#_ -_4_P#BJ\EHH ]:^T6__/>'_OZG_P 51]HM_P#G
MO#_W]3_XJO):* /6OM%O_P ]X?\ OZG_ ,51]HM_^>\/_?U/_BJ\EHH ]:^T
M6_\ SWA_[^I_\51]HM_^>\/_ ']3_P"*KR6B@#UK[1;_ //>'_OZG_Q5'VBW
M_P">\/\ W]3_ .*KR6B@#UK[1;_\]X?^_J?_ !5'VBW_ .>\/_?U/_BJ\EHH
M ]:^T6__ #WA_P"_J?\ Q5'VBW_Y[P_]_4_^*KR6B@#UK[1;_P#/>'_OZG_Q
M5'VBW_Y[P_\ ?U/_ (JO):* /6OM%O\ \]X?^_J?_%4?:+?_ )[P_P#?U/\
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M#UK[1;_\]X?^_J?_ !5'VBW_ .>\/_?U/_BJ\EHH ]:^T6__ #WA_P"_J?\
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M_P!E1_PCO_42L_\ OK_[*N;HH Z3_A'?^HE9_P#?7_V5'_"._P#42L_^^O\
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MN;=]B'YG*S(0J_-U8\#Z]#TKMJ\KT[_D(6/_ %^6O_H]*]4H **** "BBB@
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M-I-[)M7?HNIV]%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLN<Y0H.'M:BB[<[2J3?2S:C!1A=-1E)NQ\Q_&3_@@5^TI\.?AOJ7C?P1\1/
MOQ<U_0=+FU;6/ &A:7KNBZ[>P6EO)/>VW@ZXOUNK?Q+J,:H6M-.NX] N]3 :
M&QBFU%[73[GMO^"(W[>OQ#\-_&+P_P#LB?$CQ)JGB;X9_$&UU2T^&?\ ;=Y)
M>W'P\\8Z1I5SK%MH^EWMY*]Q;>$_$>GZ7?::GA^,R6EEXDDTFYTJ"P6_UQKW
M^N*O ]$_93_9=\,^)K'QIX;_ &;?@'X?\8Z9J7]M:;XLT3X/?#S2?$VGZP)&
MF&K6.O6'AVWU2TU(3.\OV^WNH[KS&9_-W,2>5Y]+%8/$X7,:2Q,JD;T*L(TZ
M<J4[.TFDDO=ERM.*4FN:,FU+3H63QP^)H5\%4=!0?[ZG)SFJD+JZ3O?WH\R:
MDVK\LE9H]:\6>+O"G@/P]JGBWQQXFT#P=X5T2W^U:SXE\4:QI^@:#I5MO2(3
MZCJ^JW%K86432R1Q+)<7$:M)(D:DNZJ?E'PY_P %%?V&_%GB*'PKH?[4/PCN
M-;N;J*QM(+OQ-%I%I>WEQ)Y-O;6.K:Q'8:1>S3RE8H$M;^8S2/&D>YI$#?R]
M_P#!6+]ISQ=^T]^VOJ/[/=QXZMO OP8^%?Q"TWX3V*:MJUW;>"=.\30:K%HO
MC3XG^-88"899=&U.\U.T-VT$\FC^&-&\JR2*ZO-5>]A_:/\ V*?^"<?@CX :
M[XJ^ O[=VF_$'XW>$])AU:3POKWB#PC)H'Q -IY7]L:3X6T;1]"L]9\/ZM/;
MFYO-"@O/$'BA;FYMX=&G;=>C5;7:AD-!4<-+&5\3"MC(QE2CAZ$JM.BI\O(Z
M\U":5^9<UW34==6HRD95LWK.K76&I4)4L,Y1G*M6C3G5<;\RI1<HMVL[:3O9
M;.2B?U;?MO,K_L5_M<.C*Z/^S#\=V1U(965OA9XI*LK D,K @@@D$$$'%?S2
M?\&\?_)U?QD_[-\U/_U8_P /*['_ ()T?M6^+_B%_P $^_\ @H#^S)XZUF[U
MQ?A/^RA\8?%OPPN[]I+J]L/!6I_#SQEI?B#PQ)>R,7;2_#^LS:)<>'X)C++;
M6^NWVGP21:9ING6EMQW_  ;Q_P#)U?QD_P"S?-3_ /5C_#RNJ&#J8#*\]PM1
MJ3ISI6FDTIPE&G*$DG>UXM75WRR3C=VN83Q,,9C\HQ$$XJ<:EXMW<)1<HRBW
MI>S3L[+FC:5E>R^7?#7_ "FKD_[2/^)?_6AM5K^S'XC?M-?LY_!_7XO"OQ7^
M.WPB^&OB:?3;?68/#_CKXA^%/"NLS:3=SW5M:ZG%INMZK97CV%S<V-[!!=K"
M8)9K2YC1V>&0+_&=X:_Y35R?]I'_ !+_ .M#:K7M?_!?_P#Y/>\+_P#9O?@3
M_P!3/XE5OC<!#,<7E>&G4E3C_9CJ<T$F[PY+*STL[F.%Q<L%A<=7A",W]?Y.
M63:5I)W>FM]#^R:QU;2]3TJTUS3M1L;_ $74-/M]6L-7LKN"ZTR]TN[MDO+7
M4;2^@D>VN+&YM)([J"[AE>":W=)HY&C8,?%/ /[5/[,WQ4\26W@WX9_M!?!C
MX@>+;V"[NK/PQX-^)?@_Q)K]W;6$#W5]/;:3I&KW=_/%9VT<ES=/% ZP01R3
M2E8T9A#\"?\ DU;X-_\ 9OWP\_\ 5<Z/7\>O_!$+_E(9\,?^Q0^*?_J!ZU7S
MV#RVGB</FE:52<7@(.<$E%JH^6L[2OJOX2V[L]G$X^="ME]-4XR6,DHR;;O"
M\J2O&VCTJ/?LC)\-?\IJY/\ M(_XE_\ 6AM5K^X+Q1XL\+>"-#O_ !/XT\2Z
M!X1\-:5%Y^I^(?$^L:=H&AZ=#D#S;[5=5N+2PM(\D#?<3QKD@9R:_A]\-?\
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MBBB@ HHHH **** "BBB@#C_%G_+A_P!O7_MM7'UV'BS_ )</^WK_ -MJX^@
MHHHH ^-OV_\ ]G.[_:I_9*^+_P 'M' /BS5-"A\0>!09HK=9O&WA"^M_$GAW
M39+BX=+>VM]>O=-'AZ[NIV$5I::M/=$JT*LO\A'_  3F_;2US_@G=^T/XJC^
M(OA7Q')X(\4QCP!\8_!@A?3O$_AS4O#NL2_8O$$.D7XMO/\ $?@R\DUNQET2
M_DLOM%CJ^M68GMKUK::+^\"OSF_:[_X);_LJ_MB:E<>+O&7A[5? GQ.N!%]J
M^)GPVN;#1/$.M?9[=+:VC\56-_IVJZ!XF6*&&V@%]J.E?V_'9VL%C9ZY9VD:
MQ#WLJS/#T*&(P&/IRJ8+$OF;AK*G-J*<K73<?=A)./O1E!-*5W;R,PP%:M6H
MXS"3C#$T%9*>D9Q3;2O9I/WI1:EI*,K-QLK_ #W\:O\ @N/^Q9X-^&6L:_\
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M_P#&5QXXFTX:<OPR77?^$;75KF2WCL_^$D_M-=/"PMK#W(-VWTO^V/\ L-_
MW]M_P9I'A7XNV.LV6J^%KB]N_!7CGPI>P:=XL\)W&IBS&JQ64M[9ZCI=]I>L
M)I]C'JNE:MIM[;3K:V]Q;?8M1MK2_M^G^W,)#'9=7C[25*A@WAJ[Y+2C*2C[
MT4W[ZC**O9IVNU=V3P_LK$RP>,HODC4JXE5Z2YKQ:3VDTGRMQ;MNKVO9:KX2
M^'?_  55_9&\*_L$>#M>NOBMH(^)WA3X!Z+X1D^$R-=?\)U<_$?P]X*MO#2Z
M';Z,+-YQIE]XAM$-KXDDC&A)I,Z:G<WD4,<R1_A-_P $0O\ E(9\,?\ L4/B
MG_Z@>M5^W'P>_P""!?[*WP]\:Z;XM\=^-?B+\8-/T:]BO[+P5X@70M"\*ZA-
M;NLD$7B>'1[$ZIK=DDBJ\FGP:GI5E>[?L^I07MA)<6<WT+^S!_P2)_9J_9-^
M-FD_'CX;>,?C7JGBO1;/Q)8V.C^+_$?@2_\ "R6_B?3+O2;U6L=#^&WAW5/]
M&M;R3[ $UE%BD2(SK<HK(T+'9/A<-FE#"U,34GCJ<[2J4[1YI1J*%*.D6E3<
MW>4HZ\VC=BGA,SQ%?+ZN(A0A#"3A>,)WERQE3<IOXDW)05HQEHXNZ5U?^:SP
MU_RFKD_[2/\ B7_UH;5:]5_X+H?&GXC^+OVS_$?P>U?7-8@^&WPJ\/>!8_"?
MAC[3)#H$]_XH\':-XKUKQ0UA 1%>:I->ZY+HS:A=)-=0VNC1V=NT<*LK_OA9
M?\$>OV9[#]J!OVLX?''QT/Q&;XUWOQX.B2>)O +>"?\ A+[_ ,97'CB;3AIR
M_#)==_X1M=6N9+>.S_X23^TUT\+"VL/<@W;>I?MI?\$T?V=/VW[O1_$?Q"B\
M2>#_ (B:#9+I=C\0_ -WIMAKE]HL37$MOH7B*UU?2]7TK7=*M+JZENK,RV=O
MJ]C(TD-AJ]K9W%W:W&L<[R^..P->4:DZ=# O#2DZ>M*LW3?M(IN\ERQE!N.M
MIMI/9YRRK&/"8JBG",ZN+5>,>?2I32DN236B=VI)/2\5=K<_%;XL_L@_\$DO
MV=/V0?'7Q!L?C)H/Q^^+NJ_"[Q!9?#&_7XO6-_J>K?$KQ'X>N=+\-ZOHGPX\
M ZGIS6FE^'O$%];:O=6OB2TU=/#]K9/'X@OKB\A!D\)_X(&.H_:<^.\98!V_
M92\=.JY^8JGQ ^%RNP'<*9$!/8NOK7ZK_#'_ ((!_LB>$+YM2\>>,?BS\5)!
M:WEO%I6HZMHGA;P]'+<PO%;Z@]IX>T>/6I[[3F9;BS27Q"VERW$8&H:9?6S-
M;'Z._92_X)+_ +//['GQ*U+XH_"[Q_\ '75-;U?P5X@\ ZGIGC/Q-X"U'0;W
MP_XCFTVZO$GMM"^&?AO4#<V][I&G7UE(NIK#'=6L;307" QF:N:X+ZECL-]=
MQF+JXA7A5KTVH+56IPBG^[BK-M\D4W+1:6'3R[%/%82O]5PV&IT6E*G2FG+K
M><W9\[=]/>DTE9MO5_S<?\$0X(9?^"AOPQDDC5WM?"'Q3GMV89,4S> M:MFD
M3T8P7$\1/]R5QWK^XNORM_97_P""0O[-G[(?QDT3XW_#;QO\<=;\5Z#I>OZ3
M9Z?XX\2^ M2\/26WB+2[C2+U[FTT'X:>&M2>>*VN'>U:+5H8TG"--'/&#$WZ
MI5Y6>XZAF&,A7P[FZ<</"F^>+B^:,ZDFK-O2TUKWN>CE&$K8/#2I5E%3=:<U
MRRYERN%.*U[WB] KQ_\ :%_Y(#\<?^R/_$S_ -0O6Z]@KG/&/A?3_&_A'Q5X
M+U:6\@TKQ?X;USPOJ<^GR0PW\.GZ_IEUI-[+8RW$%U;Q7D=M=R/;23VMS"DR
MHTL$R!HV\BG)1J0D]HSC)^BDFSTIIRA**W<9)>K31_$-_P $4/\ E(M\&?\
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M=*/+2IPI1O?EIPC"-[)7M%)7LDKVO9+L%%%%9EA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY.UXMZR;>^[/T:_X>+>+/^B7^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\
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MXS_PCRO_ .8?+\^[#^ULQ_Z"I_\ @-/_ .0/T:_X>+>+/^B7^$?_  9:E_\
M&J/^'BWBS_HE_A'_ ,&6I?\ QJOSEHH_XC1XG_\ 16XS_P (\K_^8?+\^[#^
MULQ_Z"I_^ T__D#]&O\ AXMXL_Z)?X1_\&6I?_&J/^'BWBS_ *)?X1_\&6I?
M_&J_.6BC_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G_P" T_\ Y _1K_AX
MMXL_Z)?X1_\ !EJ7_P :H_X>+>+/^B7^$?\ P9:E_P#&J_.6BC_B-'B?_P!%
M;C/_  CRO_YA\OS[L/[6S'_H*G_X#3_^0/T:_P"'BWBS_HE_A'_P9:E_\:H_
MX>+>+/\ HE_A'_P9:E_\:K\Y:*/^(T>)_P#T5N,_\(\K_P#F'R_/NP_M;,?^
M@J?_ (#3_P#D#]&O^'BWBS_HE_A'_P &6I?_ !JC_AXMXL_Z)?X1_P#!EJ7_
M ,:K\Y:*/^(T>)__ $5N,_\ "/*__F'R_/NP_M;,?^@J?_@-/_Y _1K_ (>+
M>+/^B7^$?_!EJ7_QJC_AXMXL_P"B7^$?_!EJ7_QJOSEHH_XC1XG_ /16XS_P
MCRO_ .8?+\^[#^ULQ_Z"I_\ @-/_ .0/T:_X>+>+/^B7^$?_  9:E_\ &J/^
M'BWBS_HE_A'_ ,&6I?\ QJOSEHH_XC1XG_\ 16XS_P (\K_^8?+\^[#^ULQ_
MZ"I_^ T__D#]&O\ AXMXL_Z)?X1_\&6I?_&J/^'BWBS_ *)?X1_\&6I?_&J_
M.6BC_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G_P" T_\ Y _1K_AXMXL_
MZ)?X1_\ !EJ7_P :H_X>+>+/^B7^$?\ P9:E_P#&J_.6BC_B-'B?_P!%;C/_
M  CRO_YA\OS[L/[6S'_H*G_X#3_^0/T:_P"'BWBS_HE_A'_P9:E_\:H_X>+>
M+/\ HE_A'_P9:E_\:K\Y:*/^(T>)_P#T5N,_\(\K_P#F'R_/NP_M;,?^@J?_
M (#3_P#D#]&O^'BWBS_HE_A'_P &6I?_ !JC_AXMXL_Z)?X1_P#!EJ7_ ,:K
M\Y:*/^(T>)__ $5N,_\ "/*__F'R_/NP_M;,?^@J?_@-/_Y _1K_ (>+>+/^
MB7^$?_!EJ7_QJC_AXMXL_P"B7^$?_!EJ7_QJOSEHH_XC1XG_ /16XS_PCRO_
M .8?+\^[#^ULQ_Z"I_\ @-/_ .0/T:_X>+>+/^B7^$?_  9:E_\ &J/^'BWB
MS_HE_A'_ ,&6I?\ QJOSEHH_XC1XG_\ 16XS_P (\K_^8?+\^[#^ULQ_Z"I_
M^ T__D#]&O\ AXMXL_Z)?X1_\&6I?_&J/^'BWBS_ *)?X1_\&6I?_&J_.6BC
M_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G_P" T_\ Y _1K_AXMXL_Z)?X
M1_\ !EJ7_P :H_X>+>+/^B7^$?\ P9:E_P#&J_.6BC_B-'B?_P!%;C/_  CR
MO_YA\OS[L/[6S'_H*G_X#3_^0/T:_P"'BWBS_HE_A'_P9:E_\:H_X>+>+/\
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MB?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G_P" T_\ Y _1K_AXMXL_Z)?X1_\
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M&O\ AXMXL_Z)?X1_\&6I?_&J/^'BWBS_ *)?X1_\&6I?_&J_.6BC_B-'B?\
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MI?\ QJOSEHH_XC1XG_\ 16XS_P (\K_^8?+\^[#^ULQ_Z"I_^ T__D#]&O\
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MI_\ @-/_ .0/T:_X>+>+/^B7^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\
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ME_A'_P &6I?_ !JC_AXMXL_Z)?X1_P#!EJ7_ ,:K\Y:*/^(T>)__ $5N,_\
M"/*__F'R_/NP_M;,?^@J?_@-/_Y _1K_ (>+>+/^B7^$?_!EJ7_QJC_AXMXL
M_P"B7^$?_!EJ7_QJOSEHH_XC1XG_ /16XS_PCRO_ .8?+\^[#^ULQ_Z"I_\
M@-/_ .0/T:_X>+>+/^B7^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\ QJOS
MEHH_XC1XG_\ 16XS_P (\K_^8?+\^[#^ULQ_Z"I_^ T__D#]&O\ AXMXL_Z)
M?X1_\&6I?_&J/^'BWBS_ *)?X1_\&6I?_&J_.6BC_B-'B?\ ]%;C/_"/*_\
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M[6S'_H*G_P" T_\ Y _1K_AXMXL_Z)?X1_\ !EJ7_P :H_X>+>+/^B7^$?\
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M>+>+/^B7^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\ QJOSEHH_XC1XG_\
M16XS_P (\K_^8?+\^[#^ULQ_Z"I_^ T__D#]&O\ AXMXL_Z)?X1_\&6I?_&J
M/^'BWBS_ *)?X1_\&6I?_&J_.6BC_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'
M_H*G_P" T_\ Y _1K_AXMXL_Z)?X1_\ !EJ7_P :H_X>+>+/^B7^$?\ P9:E
M_P#&J_.6BC_B-'B?_P!%;C/_  CRO_YA\OS[L/[6S'_H*G_X#3_^0/T:_P"'
MBWBS_HE_A'_P9:E_\:H_X>+>+/\ HE_A'_P9:E_\:K\Y:*/^(T>)_P#T5N,_
M\(\K_P#F'R_/NP_M;,?^@J?_ (#3_P#D#]&O^'BWBS_HE_A'_P &6I?_ !JC
M_AXMXL_Z)?X1_P#!EJ7_ ,:K\Y:*/^(T>)__ $5N,_\ "/*__F'R_/NP_M;,
M?^@J?_@-/_Y _1K_ (>+>+/^B7^$?_!EJ7_QJC_AXMXL_P"B7^$?_!EJ7_QJ
MOSEHH_XC1XG_ /16XS_PCRO_ .8?+\^[#^ULQ_Z"I_\ @-/_ .0/T:_X>+>+
M/^B7^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\ QJOSEHH_XC1XG_\ 16XS
M_P (\K_^8?+\^[#^ULQ_Z"I_^ T__D#]&O\ AXMXL_Z)?X1_\&6I?_&J/^'B
MWBS_ *)?X1_\&6I?_&J_.6BC_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G
M_P" T_\ Y _1K_AXMXL_Z)?X1_\ !EJ7_P :H_X>+>+/^B7^$?\ P9:E_P#&
MJ_.6BC_B-'B?_P!%;C/_  CRO_YA\OS[L/[6S'_H*G_X#3_^0/T:_P"'BWBS
M_HE_A'_P9:E_\:H_X>+>+/\ HE_A'_P9:E_\:K\Y:*/^(T>)_P#T5N,_\(\K
M_P#F'R_/NP_M;,?^@J?_ (#3_P#D#]&O^'BWBS_HE_A'_P &6I?_ !JC_AXM
MXL_Z)?X1_P#!EJ7_ ,:K\Y:*/^(T>)__ $5N,_\ "/*__F'R_/NP_M;,?^@J
M?_@-/_Y _1K_ (>+>+/^B7^$?_!EJ7_QJC_AXMXL_P"B7^$?_!EJ7_QJOSEH
MH_XC1XG_ /16XS_PCRO_ .8?+\^[#^ULQ_Z"I_\ @-/_ .0/T:_X>+>+/^B7
M^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\ QJOSEHH_XC1XG_\ 16XS_P (
M\K_^8?+\^[#^ULQ_Z"I_^ T__D#]&O\ AXMXL_Z)?X1_\&6I?_&J/^'BWBS_
M *)?X1_\&6I?_&J_.6BC_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G_P"
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MX1_\&6I?_&J_.6BC_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G_P" T_\
MY _1K_AXMXL_Z)?X1_\ !EJ7_P :H_X>+>+/^B7^$?\ P9:E_P#&J_.6BC_B
M-'B?_P!%;C/_  CRO_YA\OS[L/[6S'_H*G_X#3_^0/T:_P"'BWBS_HE_A'_P
M9:E_\:H_X>+>+/\ HE_A'_P9:E_\:K\Y:*/^(T>)_P#T5N,_\(\K_P#F'R_/
MNP_M;,?^@J?_ (#3_P#D#]&O^'BWBS_HE_A'_P &6I?_ !JC_AXMXL_Z)?X1
M_P#!EJ7_ ,:K\Y:*/^(T>)__ $5N,_\ "/*__F'R_/NP_M;,?^@J?_@-/_Y
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MXS_PCRO_ .8?+\^[#^ULQ_Z"I_\ @-/_ .0/T:_X>+>+/^B7^$?_  9:E_\
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MO_YA\OS[L/[6S'_H*G_X#3_^0/T:_P"'BWBS_HE_A'_P9:E_\:H_X>+>+/\
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MB?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G_P" T_\ Y _1K_AXMXL_Z)?X1_\
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M&O\ AXMXL_Z)?X1_\&6I?_&J/^'BWBS_ *)?X1_\&6I?_&J_.6BC_B-'B?\
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MI?\ QJOSEHH_XC1XG_\ 16XS_P (\K_^8?+\^[#^ULQ_Z"I_^ T__D#]&O\
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MI_\ @-/_ .0/T:_X>+>+/^B7^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\
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ME_A'_P &6I?_ !JC_AXMXL_Z)?X1_P#!EJ7_ ,:K\Y:*/^(T>)__ $5N,_\
M"/*__F'R_/NP_M;,?^@J?_@-/_Y _1K_ (>+>+/^B7^$?_!EJ7_QJC_AXMXL
M_P"B7^$?_!EJ7_QJOSEHH_XC1XG_ /16XS_PCRO_ .8?+\^[#^ULQ_Z"I_\
M@-/_ .0/T:_X>+>+/^B7^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\ QJOS
MEHH_XC1XG_\ 16XS_P (\K_^8?+\^[#^ULQ_Z"I_^ T__D#]&O\ AXMXL_Z)
M?X1_\&6I?_&J/^'BWBS_ *)?X1_\&6I?_&J_.6BC_B-'B?\ ]%;C/_"/*_\
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M[6S'_H*G_P" T_\ Y _1K_AXMXL_Z)?X1_\ !EJ7_P :H_X>+>+/^B7^$?\
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M>+>+/^B7^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\ QJOSEHH_XC1XG_\
M16XS_P (\K_^8?+\^[#^ULQ_Z"I_^ T__D#]&O\ AXMXL_Z)?X1_\&6I?_&J
M/^'BWBS_ *)?X1_\&6I?_&J_.6BC_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'
M_H*G_P" T_\ Y _1K_AXMXL_Z)?X1_\ !EJ7_P :H_X>+>+/^B7^$?\ P9:E
M_P#&J_.6BC_B-'B?_P!%;C/_  CRO_YA\OS[L/[6S'_H*G_X#3_^0/T:_P"'
MBWBS_HE_A'_P9:E_\:H_X>+>+/\ HE_A'_P9:E_\:K\Y:*/^(T>)_P#T5N,_
M\(\K_P#F'R_/NP_M;,?^@J?_ (#3_P#D#]&O^'BWBS_HE_A'_P &6I?_ !JC
M_AXMXL_Z)?X1_P#!EJ7_ ,:K\Y:*/^(T>)__ $5N,_\ "/*__F'R_/NP_M;,
M?^@J?_@-/_Y _1K_ (>+>+/^B7^$?_!EJ7_QJC_AXMXL_P"B7^$?_!EJ7_QJ
MOSEHH_XC1XG_ /16XS_PCRO_ .8?+\^[#^ULQ_Z"I_\ @-/_ .0/T:_X>+>+
M/^B7^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\ QJOSEHH_XC1XG_\ 16XS
M_P (\K_^8?+\^[#^ULQ_Z"I_^ T__D#]&O\ AXMXL_Z)?X1_\&6I?_&J/^'B
MWBS_ *)?X1_\&6I?_&J_.6BC_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G
M_P" T_\ Y _1K_AXMXL_Z)?X1_\ !EJ7_P :H_X>+>+/^B7^$?\ P9:E_P#&
MJ_.6BC_B-'B?_P!%;C/_  CRO_YA\OS[L/[6S'_H*G_X#3_^0/T:_P"'BWBS
M_HE_A'_P9:E_\:H_X>+>+/\ HE_A'_P9:E_\:K\Y:*/^(T>)_P#T5N,_\(\K
M_P#F'R_/NP_M;,?^@J?_ (#3_P#D#]&O^'BWBS_HE_A'_P &6I?_ !JC_AXM
MXL_Z)?X1_P#!EJ7_ ,:K\Y:*/^(T>)__ $5N,_\ "/*__F'R_/NP_M;,?^@J
M?_@-/_Y _1K_ (>+>+/^B7^$?_!EJ7_QJC_AXMXL_P"B7^$?_!EJ7_QJOSEH
MH_XC1XG_ /16XS_PCRO_ .8?+\^[#^ULQ_Z"I_\ @-/_ .0/T:_X>+>+/^B7
M^$?_  9:E_\ &J/^'BWBS_HE_A'_ ,&6I?\ QJOSEHH_XC1XG_\ 16XS_P (
M\K_^8?+\^[#^ULQ_Z"I_^ T__D#]&O\ AXMXL_Z)?X1_\&6I?_&J/^'BWBS_
M *)?X1_\&6I?_&J_.6BC_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G_P"
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MX1_\&6I?_&J_.6BC_B-'B?\ ]%;C/_"/*_\ YA\OS[L/[6S'_H*G_P" T_\
MY _1K_AXMXL_Z)?X1_\ !EJ7_P :H_X>+>+/^B7^$?\ P9:E_P#&J_.6BC_B
M-'B?_P!%;C/_  CRO_YA\OS[L/[6S'_H*G_X#3_^0/T:_P"'BWBS_HE_A'_P
M9:E_\:H_X>+>+/\ HE_A'_P9:E_\:K\Y:*/^(T>)_P#T5N,_\(\K_P#F'R_/
MNP_M;,?^@J?_ (#3_P#D#]&O^'BWBS_HE_A'_P &6I?_ !JC_AXMXL_Z)?X1
M_P#!EJ7_ ,:K\Y:*/^(T>)__ $5N,_\ "/*__F'R_/NP_M;,?^@J?_@-/_Y
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MSC0<<-.$6I3C6<)1BTY))W!4:S4VJ55J#:FU3DU!K=3:5HM=4['E6B^']?\
M$ES)9>'=#U?7KR&!KJ6TT73;W5+F*V22.)[B2"Q@GE2!99H8FF9!&LDL:%@T
MB@MUC0=<\.W:V'B#1M5T*^:%+A;+6-.O-,NVMY&=(YUMKV&"8PR/'(J2A-C-
M&ZJQ*,!]-?L@>._$7P^^(FOZOX:^'?B'XE7MWX+O=.FT7PVS+>V=K)KF@7+:
MI,5LKX_98I;6&T<&)/WMY#^\'W6I_M<>.M>^(/Q.T[6?$7P_\0?#?4+7P=I6
MEKH/B0N;Z>WAU77;N/5(B]E8YM;A[V2VC*Q.HELYQYI8,B>]+AW)EP-#B3^U
M<=_;<LS>#>4O*<8L!]74Y1]LLW]C]2=7E2DZ"KNI=\O)=&_L*7U/ZQ[6?M?:
M<GLO93Y.7^;VUN1O^ZG?RT/ERBO5_!OP+^+WQ LTU+PC\/O$FKZ9)CR=4%F+
M'2[CD@_9=2U)[.RN@A4B0V\\HC.!)M)&;'B_X _&;P'82ZKXJ^'7B33=*MU9
M[K4X[6/4].LXUQF6^OM)EOK6RAR0!-=RPQLQ"JY8XKPUPWQ%+!?VG'(<Z>6J
MG[5Y@LKQSP2I)7=3ZVJ'L/9I:\_M.6VMS'V%?D]I[&KR6OS^SGR6[\UK6\[G
MD%%:FC:)K/B+4;;1_#^DZEKFK7C%+33-(L;G4;^Y95+L(+2SBFN)=B*SOLC.
MU%9FPH)'MS?LJ_M"K:?;3\+/$1AP#L5M,>[P1D?\2]+]K_..J_9MP/RD \5E
ME^19YFU.I5RO)LUS*E1=JU7+\NQ>,ITG9.U2>&HU(P=FG:33LT]F*%&M53=.
ME4J);N$)32]7%.WS/GVBM;7- USPSJ=SHOB/1]3T+5[-@MUIFKV-SIU] 6&Y
M3+:W<<4RJZD/&Q3;(A#H64@G)KS:E.I1J3I5J<Z56G*4*E*I"4*E.<6U*$X2
M2E"46FI1DDTTTTF0TTVFFFM&FK-/LT]@HHHJ!!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY-+$UL9E./EB)^TE"K3<6U%<OOTI65DM$]NUVKV/5/VV?^3;/'__ %\>$/\
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M(H(WN)V2&%6=@#)*ZHHY8@5]._\ ##?[1?\ T*ND?^%7X>_^3Z^:_!?BO4O
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MHW[)?_)Q7PN_[#5[_P"F+5:_0?\ X**_\D?\(?\ 92=/_P#47\55^?'[)?\
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M+X<T_6K2ZDNTLKNP"3R:GX@U>)K?R;V5MD<$4GF!&\W:&1NE\>?MF_%#XA^
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M?%'_ **3X^_\+'Q%_P#+&C_A:WQ1_P"BD^/O_"Q\1?\ RQH^N>%/_0AXZ_\
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MI/C[_P +'Q%_\L:/KGA3_P!"'CK_ ,2/)/+_ *I[U_K8Y\M_Y\8S_P *:/\
M\S'O7_##O[1O_0HZ7_X5GAK_ .65'_##O[1O_0HZ7_X5GAK_ .65>"_\+6^*
M/_12?'W_ (6/B+_Y8T?\+6^*/_12?'W_ (6/B+_Y8T?7/"G_ *$/'7_B1Y)Y
M?]4]Z_UL<^6_\^,9_P"%-'_YF/>O^&'?VC?^A1TO_P *SPU_\LJ/^&'?VC?^
MA1TO_P *SPU_\LJ\%_X6M\4?^BD^/O\ PL?$7_RQH_X6M\4?^BD^/O\ PL?$
M7_RQH^N>%/\ T(>.O_$CR3R_ZI[U_K8Y\M_Y\8S_ ,*:/_S,>]?\,._M&_\
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M6>&O_EE1_P ,._M&_P#0HZ7_ .%9X:_^65>"_P#"UOBC_P!%)\??^%CXB_\
MEC1_PM;XH_\ 12?'W_A8^(O_ )8T?7/"G_H0\=?^)'DGE_U3WK_6QSY;_P ^
M,9_X4T?_ )F/>O\ AAW]HW_H4=+_ /"L\-?_ "RH_P"&'?VC?^A1TO\ \*SP
MU_\ +*O!?^%K?%'_ **3X^_\+'Q%_P#+&C_A:WQ1_P"BD^/O_"Q\1?\ RQH^
MN>%/_0AXZ_\ $CR3R_ZI[U_K8Y\M_P"?&,_\*:/_ ,S'O7_##O[1O_0HZ7_X
M5GAK_P"65'_##O[1O_0HZ7_X5GAK_P"65>"_\+6^*/\ T4GQ]_X6/B+_ .6-
M'_"UOBC_ -%)\??^%CXB_P#EC1]<\*?^A#QU_P")'DGE_P!4]Z_UL<^6_P#/
MC&?^%-'_ .9CWK_AAW]HW_H4=+_\*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+
M*O!?^%K?%'_HI/C[_P +'Q%_\L:/^%K?%'_HI/C[_P +'Q%_\L:/KGA3_P!"
M'CK_ ,2/)/+_ *I[U_K8Y\M_Y\8S_P *:/\ \S'O7_##O[1O_0HZ7_X5GAK_
M .65'_##O[1O_0HZ7_X5GAK_ .65>"_\+6^*/_12?'W_ (6/B+_Y8T?\+6^*
M/_12?'W_ (6/B+_Y8T?7/"G_ *$/'7_B1Y)Y?]4]Z_UL<^6_\^,9_P"%-'_Y
MF/>O^&'?VC?^A1TO_P *SPU_\LJ/^&'?VC?^A1TO_P *SPU_\LJ\%_X6M\4?
M^BD^/O\ PL?$7_RQH_X6M\4?^BD^/O\ PL?$7_RQH^N>%/\ T(>.O_$CR3R_
MZI[U_K8Y\M_Y\8S_ ,*:/_S,>]?\,._M&_\ 0HZ7_P"%9X:_^65'_##O[1O_
M $*.E_\ A6>&O_EE7ZB?L@ZMJFN?L[?#S5-:U+4-7U.Z_P"$M^TZCJEY<:A?
M7'D>.?$UO#Y]W=R37$WDV\,4$7F2-Y<,4<281%4?2E?TED7T??#W/,DR;.J>
M)XKP]/.,JR[-(4)YGEDYT(9AA*.+C1G..31C.5.-50E*,8J33:2327T%'(\#
M6HTJREB8JK2IU%%U*;<5."E9OV*O:]KV5S\)_P#AAW]HW_H4=+_\*SPU_P#+
M*C_AAW]HW_H4=+_\*SPU_P#+*OW8HKU/^):> /\ H/XI_P##CEO_ ,Y_ZN_*
MVO\ J]@?^?F)_P#!E/\ ^4GX3_\ ##O[1O\ T*.E_P#A6>&O_EE1_P ,._M&
M_P#0HZ7_ .%9X:_^65?NQ11_Q+3P!_T'\4_^''+?_G/_ %=^5C_5[ _\_,3_
M .#*?_RD_"?_ (8=_:-_Z%'2_P#PK/#7_P LJ/\ AAW]HW_H4=+_ /"L\-?_
M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
MSG_J[\K'^KV!_P"?F)_\&4__ )2?A/\ \,._M&_]"CI?_A6>&O\ Y94?\,._
MM&_]"CI?_A6>&O\ Y95^[%%'_$M/ '_0?Q3_ .''+?\ YS_U=^5C_5[ _P#/
MS$_^#*?_ ,I/PG_X8=_:-_Z%'2__  K/#7_RRH_X8=_:-_Z%'2__  K/#7_R
MRK]V**/^):> /^@_BG_PXY;_ /.?^KORL?ZO8'_GYB?_  93_P#E)^$__##O
M[1O_ $*.E_\ A6>&O_EE1_PP[^T;_P!"CI?_ (5GAK_Y95^[%%'_ !+3P!_T
M'\4_^''+?_G/_5WY6/\ 5[ _\_,3_P"#*?\ \I/PG_X8=_:-_P"A1TO_ ,*S
MPU_\LJ/^&'?VC?\ H4=+_P#"L\-?_+*OW8HH_P"):> /^@_BG_PXY;_\Y_ZN
M_*Q_J]@?^?F)_P#!E/\ ^4GX3_\ ##O[1O\ T*.E_P#A6>&O_EE1_P ,._M&
M_P#0HZ7_ .%9X:_^65?NQ11_Q+3P!_T'\4_^''+?_G/_ %=^5C_5[ _\_,3_
M .#*?_RD_"?_ (8=_:-_Z%'2_P#PK/#7_P LJ/\ AAW]HW_H4=+_ /"L\-?_
M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
MSG_J[\K'^KV!_P"?F)_\&4__ )2?A/\ \,._M&_]"CI?_A6>&O\ Y94?\,._
MM&_]"CI?_A6>&O\ Y95^[%%'_$M/ '_0?Q3_ .''+?\ YS_U=^5C_5[ _P#/
MS$_^#*?_ ,I/PG_X8=_:-_Z%'2__  K/#7_RRH_X8=_:-_Z%'2__  K/#7_R
MRK]V**/^):> /^@_BG_PXY;_ /.?^KORL?ZO8'_GYB?_  93_P#E)^$__##O
M[1O_ $*.E_\ A6>&O_EE1_PP[^T;_P!"CI?_ (5GAK_Y95^[%%'_ !+3P!_T
M'\4_^''+?_G/_5WY6/\ 5[ _\_,3_P"#*?\ \I/PG_X8=_:-_P"A1TO_ ,*S
MPU_\LJ/^&'?VC?\ H4=+_P#"L\-?_+*OW8HH_P"):> /^@_BG_PXY;_\Y_ZN
M_*Q_J]@?^?F)_P#!E/\ ^4GX3_\ ##O[1O\ T*.E_P#A6>&O_EE1_P ,._M&
M_P#0HZ7_ .%9X:_^65?NQ11_Q+3P!_T'\4_^''+?_G/_ %=^5C_5[ _\_,3_
M .#*?_RD_"?_ (8=_:-_Z%'2_P#PK/#7_P LJ/\ AAW]HW_H4=+_ /"L\-?_
M "RK]V**/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_\&4__E)^$_\
MPP[^T;_T*.E_^%9X:_\ EE1_PP[^T;_T*.E_^%9X:_\ EE7[L44?\2T\ ?\
M0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\ *3\)_P#AAW]HW_H4=+_\
M*SPU_P#+*C_AAW]HW_H4=+_\*SPU_P#+*OW8HH_XEIX _P"@_BG_ ,..6_\
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M/_/S$_\ @RG_ /*3\?O^&'?VC?\ H4=+_P#"L\-?_+*C_AAW]HW_ *%'2_\
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MO_Q='VV\_P"?NY_[_P O_P 71_Q+3P!_T'\4_P#AQRW_ .<_]7?E8_U>P/\
MS\Q/_@RG_P#*3\?O^&'?VC?^A1TO_P *SPU_\LJ/^&'?VC?^A1TO_P *SPU_
M\LJ_8'[;>?\ /W<_]_Y?_BZ/MMY_S]W/_?\ E_\ BZ/^):> /^@_BG_PXY;_
M /.?^KORL?ZO8'_GYB?_  93_P#E)^/W_##O[1O_ $*.E_\ A6>&O_EE1_PP
M[^T;_P!"CI?_ (5GAK_Y95^P/VV\_P"?NY_[_P O_P 71]MO/^?NY_[_ ,O_
M ,71_P 2T\ ?]!_%/_AQRW_YS_U=^5C_ %>P/_/S$_\ @RG_ /*3\?O^&'?V
MC?\ H4=+_P#"L\-?_+*C_AAW]HW_ *%'2_\ PK/#7_RRK]@?MMY_S]W/_?\
ME_\ BZ/MMY_S]W/_ '_E_P#BZ/\ B6G@#_H/XI_\..6__.?^KORL?ZO8'_GY
MB?\ P93_ /E)^/W_  P[^T;_ -"CI?\ X5GAK_Y94?\ ##O[1O\ T*.E_P#A
M6>&O_EE7[ _;;S_G[N?^_P#+_P#%T?;;S_G[N?\ O_+_ /%T?\2T\ ?]!_%/
M_AQRW_YS_P!7?E8_U>P/_/S$_P#@RG_\I/Q^_P"&'?VC?^A1TO\ \*SPU_\
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M&4__ )2?C]_PP[^T;_T*.E_^%9X:_P#EE1_PP[^T;_T*.E_^%9X:_P#EE7[
M_;;S_G[N?^_\O_Q='VV\_P"?NY_[_P O_P 71_Q+3P!_T'\4_P#AQRW_ .<_
M]7?E8_U>P/\ S\Q/_@RG_P#*3\?O^&'?VC?^A1TO_P *SPU_\LJ/^&'?VC?^
MA1TO_P *SPU_\LJ_8'[;>?\ /W<_]_Y?_BZ/MMY_S]W/_?\ E_\ BZ/^):>
M/^@_BG_PXY;_ /.?^KORL?ZO8'_GYB?_  93_P#E)^/W_##O[1O_ $*.E_\
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MTO\ \*SPU_\ +*C_ (8=_:-_Z%'2_P#PK/#7_P LJ_8'[;>?\_=S_P!_Y?\
MXNC[;>?\_=S_ -_Y?_BZ/^):> /^@_BG_P ..6__ #G_ *N_*Q_J]@?^?F)_
M\&4__E)^/W_##O[1O_0HZ7_X5GAK_P"65'_##O[1O_0HZ7_X5GAK_P"65?L#
M]MO/^?NY_P"_\O\ \71]MO/^?NY_[_R__%T?\2T\ ?\ 0?Q3_P"''+?_ )S_
M -7?E8_U>P/_ #\Q/_@RG_\ *3\?O^&'?VC?^A1TO_PK/#7_ ,LJ/^&'?VC?
M^A1TO_PK/#7_ ,LJ_8'[;>?\_=S_ -_Y?_BZ/MMY_P _=S_W_E_^+H_XEIX
M_P"@_BG_ ,..6_\ SG_J[\K'^KV!_P"?F)_\&4__ )2?C]_PP[^T;_T*.E_^
M%9X:_P#EE1_PP[^T;_T*.E_^%9X:_P#EE7[ _;;S_G[N?^_\O_Q='VV\_P"?
MNY_[_P O_P 71_Q+3P!_T'\4_P#AQRW_ .<_]7?E8_U>P/\ S\Q/_@RG_P#*
M3\?O^&'?VC?^A1TO_P *SPU_\LJ/^&'?VC?^A1TO_P *SPU_\LJ_8'[;>?\
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M?NY_[_R__%T?\2T\ ?\ 0?Q3_P"''+?_ )S_ -7?E8_U>P/_ #\Q/_@RG_\
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M\LJ/^&'?VC?^A1TO_P *SPU_\LJ_8'[;>?\ /W<_]_Y?_BZ/MMY_S]W/_?\
ME_\ BZ/^):> /^@_BG_PXY;_ /.?^KORL?ZO8'_GYB?_  93_P#E)^/W_##O
M[1O_ $*.E_\ A6>&O_EE1_PP[^T;_P!"CI?_ (5GAK_Y95^P/VV\_P"?NY_[
M_P O_P 71]MO/^?NY_[_ ,O_ ,71_P 2T\ ?]!_%/_AQRW_YS_U=^5C_ %>P
M/_/S$_\ @RG_ /*3\?O^&'?VC?\ H4=+_P#"L\-?_+*C_AAW]HW_ *%'2_\
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MO_Q='VV\_P"?NY_[_P O_P 71_Q+3P!_T'\4_P#AQRW_ .<_]7?E8_U>P/\
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MC?\ H4=+_P#"L\-?_+*C_AAW]HW_ *%'2_\ PK/#7_RRK]@?MMY_S]W/_?\
ME_\ BZ/MMY_S]W/_ '_E_P#BZ/\ B6G@#_H/XI_\..6__.?^KORL?ZO8'_GY
MB?\ P93_ /E)^/W_  P[^T;_ -"CI?\ X5GAK_Y94?\ ##O[1O\ T*.E_P#A
M6>&O_EE7[ _;;S_G[N?^_P#+_P#%T?;;S_G[N?\ O_+_ /%T?\2T\ ?]!_%/
M_AQRW_YS_P!7?E8_U>P/_/S$_P#@RG_\I/Q^_P"&'?VC?^A1TO\ \*SPU_\
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M1110 4444 %%%% !1110!X_1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!<T[_ )"%C_U^6O\ Z/2O5*\KT[_D(6/_ %^6O_H]*]4H
M **** "BBB@ HHHH **** "BBB@#\M_^"E/_ #1?_NHW_NB5^6]?J1_P4I_Y
MHO\ ]U&_]T2ORWK_ #K\=O\ DZO%7_=#_P#6<R<^#SK_ )&>)_[@_P#J/2"B
MBBOR,\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
M>S]BW_DV?X:_]SC_ .I_XJKZDKY;_8M_Y-G^&O\ W./_ *G_ (JKZDK_ %"\
M/_\ D@^"?^R1X;_]4V"/T; _[E@_^P7#_P#IF 4445]<=04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X_1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!<T[_D(6/_7Y:_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM,T^_P!4U'3?"^L:'?:O=JUGI+:EX9BTB\N=ML=7BNI8+>4 _7:BOA7]K_\
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MXXC=?9':!1HS^#[BY64B%+9_B#;J]T?LQN$;YJ /W<HKYO\ AG^U3\(_C/\
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M;6](#>($^UKKUCH=UX7T_P";PKKRBWU36[&Z)L.(3]IL_M'\PW@']O67P_\
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MEZ[J-Y)Y6GZ&U]J>D^%]6TK6M9EWQ:!#J'A^/3M8NHFTVVU0:O<:=I]_^L]
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M+'_K\M?_ $>E>J5Y7IW_ "$+'_K\M?\ T>E>J4 %%%% !1110 4444 %%%%
M!1110!^6_P#P4I_YHO\ ]U&_]T2ORWK]2/\ @I3_ ,T7_P"ZC?\ NB5^6]?Y
MU^.W_)U>*O\ NA_^LYDY\'G7_(SQ/_<'_P!1Z04445^1GEA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '[V?L6_P#)L_PU_P"YQ_\
M4_\ %5?4E?+?[%O_ ";/\-?^YQ_]3_Q57U)7^H7A_P#\D'P3_P!DCPW_ .J;
M!'Z-@?\ <L'_ -@N'_\ 3, HHHKZXZ@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[;2F2PU"ZA!D,9D\Q'5?E+]@O]F+XX?!;]KG_@H)\4/B7X*'AOP-\;_BK?\
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M3X1T=[ >&HM>?Q?"5U'3+Z#[5<:!#9$6YE6Y,,L$DOD'QL_9&_;&_9E_:O\
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M=\D_I!^R)XT_:X\;>"/$M_\ MA?"#P7\'?'5IXJ>T\,Z+X'UW2]=TW5?"?\
M9&F3)JEU-I?COX@107PUB35+1HI=5M)&@@@<:>BXN+@ ^L:*** "BBB@ HHH
MH **** "BBB@ HHHH N:=_R$+'_K\M?_ $>E>J5Y7IW_ "$+'_K\M?\ T>E>
MJ4 %%%% !1110 4444 %%%% !1110!^6_P#P4I_YHO\ ]U&_]T2ORWK]2/\
M@I3_ ,T7_P"ZC?\ NB5^6]?YU^.W_)U>*O\ NA_^LYDY\'G7_(SQ/_<'_P!1
MZ04445^1GEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '[V?L6_P#)L_PU_P"YQ_\ 4_\ %5?4E?+?[%O_ ";/\-?^YQ_]3_Q57U)7
M^H7A_P#\D'P3_P!DCPW_ .J;!'Z-@?\ <L'_ -@N'_\ 3, HHHKZXZ@HHHH
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M^$3I_B2>W1%58K>XURSU">" #,$4B0EF,98@'TK_ ,%A/V_O^%5:K\&_AQ\
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MA^"M7_:;\<VZ%F^R7]]=Z3X'T*&1"7;3)KNUD\MA-Y_]5]K_ ,>UO_UPA_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG7E7B^:&'HQ49U/EL?GT^:5+!644VG7E%2<GM>G%^ZH[^])-RTLH]?N/7_\
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M_P#*BC_AM_\ :/\ ^ATT_P#\)+PK_P#*BODNBC_B(O'_ /T6O%7_ (?LS_\
MFGR_/NP^OX[_ *#,3_X/J?\ R1]:?\-O_M'_ /0Z:?\ ^$EX5_\ E11_PV_^
MT?\ ]#II_P#X27A7_P"5%?)=%'_$1>/_ /HM>*O_  _9G_\ -/E^?=A]?QW_
M $&8G_P?4_\ DCZT_P"&W_VC_P#H=-/_ /"2\*__ "HH_P"&W_VC_P#H=-/_
M /"2\*__ "HKY+HH_P"(B\?_ /1:\5?^'[,__FGR_/NP^OX[_H,Q/_@^I_\
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M (?LS_\ FGR_/NP^OX[_ *#,3_X/J?\ R1]:?\-O_M'_ /0Z:?\ ^$EX5_\
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MATT__P )+PK_ /*BODNBC_B(O'__ $6O%7_A^S/_ .:?+\^[#Z_CO^@S$_\
M@^I_\D?6G_#;_P"T?_T.FG_^$EX5_P#E11_PV_\ M'_]#II__A)>%?\ Y45\
MET4?\1%X_P#^BUXJ_P##]F?_ ,T^7Y]V'U_'?]!F)_\ !]3_ .2/K3_AM_\
M:/\ ^ATT_P#\)+PK_P#*BC_AM_\ :/\ ^ATT_P#\)+PK_P#*BODNBC_B(O'_
M /T6O%7_ (?LS_\ FGR_/NP^OX[_ *#,3_X/J?\ R1]:?\-O_M'_ /0Z:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q^BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH _.K_@FS^Q7XK_8>^$WCKX=^+O&GA[QO?>+
M/B/<^-K;4?#EEJ5C:VEI-X:\/:&+*>/4U69[E9M&EG+QYB\N:-0=RM7Z*T44
M %%%% !17A/Q@_:8^"'P$\0_#'PK\6O'$?A+7OC)K\WA?X;6#^'_ !5K/_"2
M:[;WV@:=-8BZ\.Z'J]EI.R]\3Z'";G7;C3+,_;A(MP8K:[DM_=J "BBB@ HH
MHH **** "BBB@ HHKS'XQ?&3X;? 'X>:]\5_BYXD7PCX \,OI,>N>(&TG7-;
M6Q?7-9T_P_I8.F>&],UC6+C[5J^J6%F#::?.(3.)[@Q6T<TT8!Z=17+^"/&G
MAGXC^#?"OQ \%ZHNM^$/&WA[1_%?A?6$M;VR75- U^P@U32=06RU*VLM1M!=
MV-S!/]FO[.UO(-_E7-O#,KQKU% !1110!^27[4O_  3K^*?BW]HF3]KW]D'X
M]_\ "A?COJNC6NA^+X-:TO\ M+PCXLM[/3=-T:WN;AH;'5D@632](TR'5='U
M?PSXHTC5KO3-*U2.'3-1LGN+OR*\_P"":?[6_P"TWXT\#:I_P4$_:KT#XC_#
MKP%JB:W:?"SX4Z"FAZ+K5_"8T\J_N8?"O@>PMQ?V_P!HM=1UF7P]JVOQZ9=W
M^DZ+?Z/'?F\MOW*JM>WMGIMG=ZCJ-W;6&GV%M/>WU]>SQ6MG96=K$\]U=W=U
M.\<%M;6T$;S3SS.D4,2/)(ZHI( '6MK;6-M;V5E;P6EG9P0VMI:6L4<%M:VU
MO&L4%O;P1*D4,$$2)'%%&JQQQJJ(JJH GK'T'Q#H'BG3(-:\,:YH_B/1KIID
MMM6T'4[+5],N'MYGM[A(+_3Y[BUE:">.2"98Y6,4T;QN%=64;% !17A'QI_:
M=_9^_9VAL)?C9\6_!GP[EU6">ZTK3==U1?[<U6UMG$5Q=:9X?LDN]<U&VAE9
M8I)[/3YXDF98BXD(4M^#7[4/[//[0JW2_!;XP^!?B'>6-HE_J&CZ%K<!\1:=
M8R2")+S4?#5Y]E\0:?:-,PA%Q>:;!#YQ$6_S#MH ]YHKEO&OCGP9\-_#.J>,
M_B!XJ\/^"O"6B0K/JWB3Q1J]CH>BZ?&\B0Q?:=1U&>WMHWGGDCM[:(R>;<W,
ML5O;I)/+'&WRMX)_X**?L1_$3Q3:>"_"?[2'P[O?$>H7<>GZ=9:A=ZCX=@U*
M^F(6WLM-U3Q)IVDZ3J%W=2,L%G;V=]/+=W+I;6R2W#I&P!]I445\9>)O^"B'
M[$?@_P 5R^"O$'[2WPPM/$5O>W&G7EO;ZQ-JMAIU_:2M!=6FJ:[I-I?:#I=Q
M;3H\,\6HZG;-#,CQ2!9$90 ?9M%<[X3\7^%/'OA[2_%W@?Q+H/C#PKK=N+O1
M_$?AC5[#7=#U2V+,GGV&JZ9/<V5W&LB/&[0S.$E1XWVNC*/'_C9^U9^SG^SD
M;&/XV?&#P9\/[[5(#=Z;HVK:B]SXCOK(/+&;^T\-:5#J'B"XT\30RP'4(M-:
MS^T(;?S_ #\1D ^@J*\,^"?[3'P$_:-T^_U'X(_%7PC\1(M)$+:O::)?LFLZ
M0ERTBVLNK^']0BLM=TN"Z:*5;6>_TZWAN6BE6!Y&B<+[G0 4444 %%%% !11
M10 4444 %%%% !1110 5^=7[;?[%?BO]J?XL_L@?$3P[XT\/>%K']FWXCZEX
MVU[3M:LM2NKOQ):7WB7X7ZXEEI$EBK0VUS'#X"O(&>\Q$9+^V8';'+7Z*T4
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MO[BP\/>*_@CJ][!8QW-Q:6TMY+;6DB6T=Q=6T+S-&LMQ#&6D7VR\_P"#A_\
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M2_:,F&2WN_!^F^#/ UE-(LKZ=K_B/5+,B,SW"']R?^&+_P!CO_HT_P#9I_\
M#$_"[_YEJ^EJ* /Y:/CGH^A?\$SO^"Q7P;^*_@[0M)\!_L^_M):)IGAS7M$\
M-Z79>'O!^A6&OOI_@3QOI]IINFP6ME9V'A?Q/8^"OBQ?6ME;K"KWT<-O%AA
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M^BLY/ZAJ9'''#&D42)%%&BQQQQJJ1QH@"HB(H"HBJ JJH 4    4^@ HHHH
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M?XCG]HWQ1JGAM=87QTOA$>#SIOB#P)H7VQM//@_Q,=?\[_A-A=?9Q>Z+Y?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!UW@/QKKOPZ\7Z#XT\-W!M]7T"_BO;?)80W,0REW87:HRM)9:A:
MO-97D093);3RJK*Q5A_1QX'\7Z5X^\(>'/&>BN6TSQ)I%GJMLK,K26YN8@T]
MG.5^47-C<":SNE'"7,$J#[M?S,U^S7_!/;Q9-K'PCUSPQ<RF1_!_BNY2R4MD
M0:5KUM%J<,07)(!U9=:FSPK&; &58G^EOHU\48C!<28_A6K4E+ 9SA*V.PU)
MMN-+,\!",YSIQ>D?K& 595VM9O"X9/2&GT'#^)E#$3PS?N5H.<5VJ4TG==N:
M'-S=^6/8^]J***_MH^P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH \?HHHH **** "BBB@ K\Z_VN/^"DWP>_96
M\9:/\)+;PQXU^-/QRUV*WN+3X4_#.P%_K&GVU];/=Z;)KEVRRBTN-4@3[18:
M5IEEK.N/9F/49]+M].N+2[N?T4K^2']F+XK_ +6>E_MJ_MQ_%_X(_LQ:9^T5
M\29/B;X@\-^)+_Q+X@AT_4_A;HM_XW\90V'A[3)+O6=-D^S:G:^%K31%$!E%
MCIW@RST^(P6TICE /UW_ &=?^"LWP\^+'Q?T[X"_&?X/_$3]EOXI^(3;Q>%-
M(^)^Z/2]=U&\D\K3]#:^U/2?"^K:5K6LR[XM AU#P_'IVL743:;;:H-7N-.T
M^_\ 5OBK_P %%/ OP-_:N\(?LQ?%WX=^,/!%EX_?2E\&_&74+[19/A[K$>M0
M&WL+F1DG6_T^VC\3*WA759+I%;1KYH-2U*.#0KB+4C^0'[:?A_\ X*8_MH:)
M\/K?Q#^P79_#[Q=\,_%J>)_"WQ"\)^+=$G\4V$#6DZ7>A07-_P"+2L.GWFII
MHNMLR'SH=1T"PD@*!YR_Z0_\%2OAI\+OB9^P-?>-?VAKJW\#_$'X?>$]'\5^
M#-<-M:SZYI_Q:U/2+*&;P#96UK*!?6GC75 ?#VL:?:3R6-K'#;^)Y/W7AB&Z
MMP#Z'_;/_;U^&?[&4?P_TK7_  [XD^)'Q$^)NLKIGA'X9^!C9S>*;VS$@M'U
MF2&Y?$=G+JTUCHFF0+'+?:UJMVUOIEO<+8:G)9\O^U7_ ,%$/!O['-E^SM=?
M&7X;^+=.F^.R:M)JMKIFHZ3JC_"]?#P\#MXC3Q"UD9VUV;1T\;1^;%X:CO?M
M<FD7T=@USYMFT_XK?\$?+[PW^T3^UQK/Q%_:@\=:YXX_:!^'/PS\'1? K0O'
M42-!<>'M'T<:>WB3399Q$NHZ]X6\.OI6H:3 ]L;J_'B36OB+)-K&N)=Z[8?4
M/_!</PQHGC7XO?\ !.?P;XEF:V\.>+?B9\1O#&OW"RM T&B:]XG_ &?]*U69
M9T^:%HK&[G<2K\T97>.5% 'HNI?\%O-&2W_X3?0?V-_VB=9^!D-Y+!>?%ZXL
MH]-TV.UBG:'[5;0Q:3J?A>:5@C$6MYX[TYD<>5+*CA]OZL?L\?M+?"+]J#X4
MZ?\ &+X3^(AJ'A.Y:YM=6AU1(=-UKPCK&GP0W.J>'_%MA]HN(](U;3(+BWN+
MA1=7%C<6-Q:ZIIM]?:3>V=]<>N6GA7PQ8^&(/!5GX>T6W\'6VB)X:@\+1Z99
M+X>B\/1V0TU-#71_)_L_^R1IX^PG3S;FU:TS;M$8B5/\Y'_!-U_ ?PD^-?\
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MQU:W<NAQQSSQ01:KJD6M^'/!FJQ:!&T\ O\ 5])L-;CT\S1R7,0LQ+=Q7_\
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MR$+'_K\M?_1Z5ZI7E>G?\A"Q_P"ORU_]'I7JE !1110 4444 %%%% !1110
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MCA'X[\&S?"CQ/<I<>(_!E@%T@W961M:\&92UBMV5]PFET!I8M-F1E ?2Y],
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M>A>VT72K36!IUJ[^9]DMKVZO]16SC? 8V]HUVUM;;R\HMXHA+)+('D?\T?\
M@F[_ ,C%\5/^P+X8_P#2[5Z^IXOVU_V=-2T%)KGQQ/I6HW^DK)<:1<^%?&5Q
M<:=>7-INET^>ZL?#MSI\\MK,[6\D]I=36DC(9(9GB*N?@S]B;XP_#GX1:UX_
MN_B'XB_X1ZWUO2]"M],E_LC7-6%S-97>HR7,>S0],U*2'RTN(FW7"1(^XA&9
ME8#Z7B?BG@R?B#X/XC+.(N'7E&44^*:6(K8;-LO^IY5AZV38.A@*6+G&O[/
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M$%]?7FHV_P 2?#T6IZ=+JFKWNI:79ZK8>'_$L=I<"TO;.1X$M+>'X#_LJ_\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /WL_8M_Y-G^&O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=K]K**/^)<_#G^3//_#HO_F4/[ P'>O_ .#(_P#R!^*?_#OKXZ_\_P#\/_\
MPH-5_P#F=H_X=]?'7_G_ /A__P"%!JO_ ,SM?M911_Q+GX<_R9Y_X=%_\RA_
M8& [U_\ P9'_ .0/Q3_X=]?'7_G_ /A__P"%!JO_ ,SM'_#OKXZ_\_\ \/\
M_P *#5?_ )G:_:RBC_B7/PY_DSS_ ,.B_P#F4/[ P'>O_P"#(_\ R!^*?_#O
MKXZ_\_\ \/\ _P *#5?_ )G:/^'?7QU_Y_\ X?\ _A0:K_\ ,[7[644?\2Y^
M'/\ )GG_ (=%_P#,H?V!@.]?_P &1_\ D#\4_P#AWU\=?^?_ .'_ /X4&J__
M #.T?\.^OCK_ ,__ ,/_ /PH-5_^9VOVLHH_XES\.?Y,\_\ #HO_ )E#^P,!
MWK_^#(__ "!^*?\ P[Z^.O\ S_\ P_\ _"@U7_YG:/\ AWU\=?\ G_\ A_\
M^%!JO_S.U^UE%'_$N?AS_)GG_AT7_P RA_8& [U__!D?_D#\4_\ AWU\=?\
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MD?\ Y _%/_AWU\=?^?\ ^'__ (4&J_\ S.T?\.^OCK_S_P#P_P#_  H-5_\
MF=K]K**/^)<_#G^3//\ PZ+_ .90_L# =Z__ (,C_P#('XI_\.^OCK_S_P#P
M_P#_  H-5_\ F=H_X=]?'7_G_P#A_P#^%!JO_P SM?M911_Q+GX<_P F>?\
MAT7_ ,RA_8& [U__  9'_P"0/Q3_ .'?7QU_Y_\ X?\ _A0:K_\ ,[1_P[Z^
M.O\ S_\ P_\ _"@U7_YG:_:RBC_B7/PY_DSS_P .B_\ F4/[ P'>O_X,C_\
M('XI_P##OKXZ_P#/_P##_P#\*#5?_F=H_P"'?7QU_P"?_P"'_P#X4&J__,[7
M[644?\2Y^'/\F>?^'1?_ #*']@8#O7_\&1_^0/Q3_P"'?7QU_P"?_P"'_P#X
M4&J__,[1_P .^OCK_P __P /_P#PH-5_^9VOVLHH_P")<_#G^3//_#HO_F4/
M[ P'>O\ ^#(__('XI_\ #OKXZ_\ /_\ #_\ \*#5?_F=H_X=]?'7_G_^'_\
MX4&J_P#S.U^UE%'_ !+GX<_R9Y_X=%_\RA_8& [U_P#P9'_Y _%/_AWU\=?^
M?_X?_P#A0:K_ /,[1_P[Z^.O_/\ _#__ ,*#5?\ YG:_:RBC_B7/PY_DSS_P
MZ+_YE#^P,!WK_P#@R/\ \@?BG_P[Z^.O_/\ _#__ ,*#5?\ YG:/^'?7QU_Y
M_P#X?_\ A0:K_P#,[7[644?\2Y^'/\F>?^'1?_,H?V!@.]?_ ,&1_P#D#\4_
M^'?7QU_Y_P#X?_\ A0:K_P#,[1_P[Z^.O_/_ /#_ /\ "@U7_P"9VOVLHH_X
MES\.?Y,\_P##HO\ YE#^P,!WK_\ @R/_ ,@?BG_P[Z^.O_/_ /#_ /\ "@U7
M_P"9VC_AWU\=?^?_ .'_ /X4&J__ #.U^UE%'_$N?AS_ "9Y_P"'1?\ S*']
M@8#O7_\ !D?_ ) _%/\ X=]?'7_G_P#A_P#^%!JO_P SM'_#OKXZ_P#/_P##
M_P#\*#5?_F=K]K**/^)<_#G^3//_  Z+_P"90_L# =Z__@R/_P @?BG_ ,.^
MOCK_ ,__ ,/_ /PH-5_^9VC_ (=]?'7_ )__ (?_ /A0:K_\SM?M911_Q+GX
M<_R9Y_X=%_\ ,H?V!@.]?_P9'_Y _%/_ (=]?'7_ )__ (?_ /A0:K_\SM'_
M  [Z^.O_ #__  __ /"@U7_YG:_:RBC_ (ES\.?Y,\_\.B_^90_L# =Z_P#X
M,C_\@?BG_P .^OCK_P __P /_P#PH-5_^9VK-K_P3T^-TTBK/K?PZLX]P#22
M:WKLI"]RJ6_AB3<0.BLR G@LHYK]HZ*<?HZ>'$9)NEG<TGK&6:-)^3Y,/&5O
M22?F"R# )W_?OR=16?W03^YH_,SP1_P3FTBVFANOB'X_O-4C4JTFC^%-/33(
MF92#L?6M3>]GE@D^[(D.DV4X7/EW,;D,OWUX"^&O@7X8:0-#\"^&].\/6#%&
MN#:H\E[?RQJ52?4]2N7FU#49U4E5EO;F=HU)2,I'A1W-%?HG#'A[P=P>_:9!
MD6$P>)<7"6.J.KC,?*,E:<5C<74KXBG"?VZ5&=.E+3]W9*WH8; 83":T*,8R
MVYW><]=_?FW))]4FEY!1117V9UA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'C]%%% !165KMY>Z?HFL7^
MFV9U#4;'2M0O+"P <F^O;:TFFM;,"/,A-S.D<("#>=_R_-BOY6M,_;!_:?C^
M)=MXYB^*GCG4/$$NN13_ /"+RZOJL_A6^:2[_P"1<_X0E)_[%&ESLYLXM,MM
M/C>%I!+:-%?A+E?Q[Q4\9,E\*:_#U#-<JS/,GG]3%\LLO]A&.%PV!GA(8FJW
M7G!5Z]\92='#4W'G49^UK4;TO:>)F^>4,GEA8UJ-6J\3*=O9\JY(4W!2E[S]
MZ7OKE@M[.[CI?^KJBHX7DDABDEB,$KQ1O)"65S#(RAGB+I\CF-B4+*=K$97@
MBI*_8$TTFKV:35TT[/75-)I^32:ZH]O^NWYA7\RGQ?M?VH/VCO\ @K!\=_V9
M?AY^V+\;/@%X4TK0M%\3:/'X7\7>.KOPYI,>F_"_X<ZA>:=IWA#1O'?A"PLQ
MJFH:S=7UQ/;742_:Y;BXDMYYKF1Q_377\IGQ5_:&U/\ 9D_X+1_M"_$S2?A3
MXN^,MX/#6C>'U\%^"/M!UV2/5OA!\,'DU.-;;2=:E>VL!9YN0+/:%E#--&%P
MS ^M_&G_  3?_P""D7@C0=0\4_"S_@IC\7?B1XNT2UFU+2_!_BW6?B)X?T_7
MKBR4W":7'<ZK\2_'VB27=Z(C;V<.M:0FDSW4D4&HW=E923W</T__ ,$L/VY/
M$_[4_P  O&&H_'"_T>Q^(?P8\0V?AOQGXKECT_PYINNZ/JEA]IT#Q)J]LK6F
MF:1K$]Q::OINL0VEM8:6]QI\-W9V]M]MDL;3YB\9?\%=OVF/%6@:IX?^"?\
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M/%5J[QW/AG1/&WAK5?$%O)'&\TB3Z+8:G/J4+I#&\KK);*RQH\C *I(_F_\
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MJD-M/;VMN =]9_%KXH2?\%K]0^$X^)'CB3X5#X(QZO%\./\ A+-<?P$NIMX
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M^\+ZSXCN?#.G66HP6\UI->>'=*@T7Q9X@UC1FN?)\036&FVK*@LRL_?^,O\
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MEJVEZK'&WV(V98 _1&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN\TZ;7M(LRVK:JWV73[^W@SJ>H'9F]N?, /Q4?\ Y3Y0_P#9 S_ZK>6OH_\
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MIX;;5?#VIZ'J^H2JD-K<Z]I,3.?MGR_N)XG^#7P@\;>#]$^'GC/X5?#;Q=X
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MA[\,-!_X17X:^ _!GP\\+_:[F_\ ^$;\#>%]$\):#]NO1&+R]_L?0+'3]/\
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M]$T/3K/2=(TVU4EEMK#3;"&WL[.!69BL-O#'&"Q(4$FM:@#^1O\ X)P>)O\
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MITM+H3$S+<+9"990LBN'52/JA$2-$CC18XXU5$1%"HB* JHBJ JJJ@!5
M   H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 7-._Y"%C_P!?
MEK_Z/2O5*\KT[_D(6/\ U^6O_H]*]4H **** "BBB@ HHHH **** "BBB@#\
MM_\ @I3_ ,T7_P"ZC?\ NB5^6]?J1_P4I_YHO_W4;_W1*_+>O\Z_';_DZO%7
M_=#_ /6<R<^#SK_D9XG_ +@_^H](****_(SRPHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#][/V+?^39_AK_W./_J?^*J^I*^6_P!B
MW_DV?X:_]SC_ .I_XJKZDK_4+P__ .2#X)_[)'AO_P!4V"/T; _[E@_^P7#_
M /IF 4445]<=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!X_1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!<T[_ )"%C_U^6O\ Z/2O5*\KT[_D(6/_ %^6O_H]*]4H ***
M* "BBB@ HHHH **** "BBB@#\M_^"E/_ #1?_NHW_NB5^6]?J1_P4I_YHO\
M]U&_]T2ORWK_ #K\=O\ DZO%7_=#_P#6<R<^#SK_ )&>)_[@_P#J/2"BBBOR
M,\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _>S]B
MW_DV?X:_]SC_ .I_XJKZDKY;_8M_Y-G^&O\ W./_ *G_ (JKZDK_ %"\/_\
MD@^"?^R1X;_]4V"/T; _[E@_^P7#_P#IF 4445]<=04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X_1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!<T[_D(6/_7Y:_\ H]*]
M4KRO3O\ D(6/_7Y:_P#H]*]4H **** "BBB@ HHHH **** "BBB@#\^OVZ?A
M1\0OBG/\*K?P!X:NO$<VC1>/)M32VN=/MOLD5X_@J.U9VU"\LT;SGMY@JQL[
M#RV+ #!/P)_PR)^T;_T3#5/_  ;>&O\ Y=5[3_P5O^.OQ=^"4O[/D_PH\>:Y
MX&G\1Q_%J+6YM#>WBEU&+2V^&+V$4\DUO._EV[W]VZI&45FEW2!RD93\;_\
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MO#7_ ,NJ_-C_ (;T_;#_ .C@?'__ (&V7_R#1_PWI^V'_P!' ^/_ /P-LO\
MY!H_XIMX'_HML7_X54?_ *&_7^EJ?Z_<-?\ 0#GGWX#_ .6'Z3_\,B?M&_\
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M\&WAK_Y=4?\ #(G[1O\ T3#5/_!MX:_^75?FQ_PWI^V'_P!' ^/_ /P-LO\
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M^#;PU_\ +JOS8_X;T_;#_P"C@?'_ /X&V7_R#1_PWI^V'_T<#X__ / VR_\
MD&C_ (IMX'_HML7_ .%5'_Z&_7^EJ?Z_<-?] .>??@/_ )8?I/\ \,B?M&_]
M$PU3_P &WAK_ .75'_#(G[1O_1,-4_\ !MX:_P#EU7YL?\-Z?MA_]' ^/_\
MP-LO_D&C_AO3]L/_ *.!\?\ _@;9?_(-'_%-O _]%MB__"JC_P#0WZ_TM3_7
M[AK_ * <\^_ ?_+#])_^&1/VC?\ HF&J?^#;PU_\NJ/^&1/VC?\ HF&J?^#;
MPU_\NJ_-C_AO3]L/_HX'Q_\ ^!ME_P#(-'_#>G[8?_1P/C__ ,#;+_Y!H_XI
MMX'_ *+;%_\ A51_^AOU_I:G^OW#7_0#GGWX#_Y8?I/_ ,,B?M&_]$PU3_P;
M>&O_ )=4?\,B?M&_]$PU3_P;>&O_ )=5^;'_  WI^V'_ -' ^/\ _P #;+_Y
M!H_X;T_;#_Z.!\?_ /@;9?\ R#1_Q3;P/_1;8O\ \*J/_P!#?K_2U/\ 7[AK
M_H!SS[\!_P#+#])_^&1/VC?^B8:I_P"#;PU_\NJ/^&1/VC?^B8:I_P"#;PU_
M\NJ_-C_AO3]L/_HX'Q__ .!ME_\ (-'_  WI^V'_ -' ^/\ _P #;+_Y!H_X
MIMX'_HML7_X54?\ Z&_7^EJ?Z_<-?] .>??@/_EA^D__  R)^T;_ -$PU3_P
M;>&O_EU1_P ,B?M&_P#1,-4_\&WAK_Y=5^;'_#>G[8?_ $<#X_\ _ VR_P#D
M&C_AO3]L/_HX'Q__ .!ME_\ (-'_ !3;P/\ T6V+_P#"JC_]#?K_ $M3_7[A
MK_H!SS[\!_\ +#^J?]EOPAXC\!_ GP+X4\6Z7+HWB'2O^$G_ +0TV:6VGEMO
MMWC'Q#J5INELY[BV;SK&\MKA?+F?:LH5]L@9%^@*_C8_X;T_;#_Z.!\?_P#@
M;9?_ "#1_P -Z?MA_P#1P/C_ /\  VR_^0:_?LF^C'Q#DF3Y5DV&S_)JN&RC
M+<#E>'J5Y8YUZE# 86EA*4ZSIY?3INK.G2C*HX4X0<VW&$8VBO<H^+F24:5*
MC'+,U<:5.%.+?U2[4(J*;M72NTM;)*_0_LGHK^-C_AO3]L/_ *.!\?\ _@;9
M?_(-'_#>G[8?_1P/C_\ \#;+_P"0:]+_ (EVXG_Z'>0_?F'_ ,Q&G_$8,E_Z
M%>:?^6G_ ,T']D]%?QL?\-Z?MA_]' ^/_P#P-LO_ )!H_P"&]/VP_P#HX'Q_
M_P"!ME_\@T?\2[<3_P#0[R'[\P_^8@_XC!DO_0KS3_RT_P#F@_LGHK^-C_AO
M3]L/_HX'Q_\ ^!ME_P#(-'_#>G[8?_1P/C__ ,#;+_Y!H_XEVXG_ .AWD/WY
MA_\ ,0?\1@R7_H5YI_Y:?_-!_9/17\;'_#>G[8?_ $<#X_\ _ VR_P#D&C_A
MO3]L/_HX'Q__ .!ME_\ (-'_ !+MQ/\ ]#O(?OS#_P"8@_XC!DO_ $*\T_\
M+3_YH/[)Z*_C8_X;T_;#_P"C@?'_ /X&V7_R#1_PWI^V'_T<#X__ / VR_\
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MOXV/^&]/VP_^C@?'_P#X&V7_ ,@T?\-Z?MA_]' ^/_\ P-LO_D&C_B7;B?\
MZ'>0_?F'_P Q!_Q&#)?^A7FG_EI_\T']D]%?QL?\-Z?MA_\ 1P/C_P#\#;+_
M .0:/^&]/VP_^C@?'_\ X&V7_P @T?\ $NW$_P#T.\A^_,/_ )B#_B,&2_\
M0KS3_P M/_F@_LGHK^-C_AO3]L/_ *.!\?\ _@;9?_(-'_#>G[8?_1P/C_\
M\#;+_P"0:/\ B7;B?_H=Y#]^8?\ S$'_ !&#)?\ H5YI_P"6G_S0?V3T5_&Q
M_P -Z?MA_P#1P/C_ /\  VR_^0:/^&]/VP_^C@?'_P#X&V7_ ,@T?\2[<3_]
M#O(?OS#_ .8@_P"(P9+_ -"O-/\ RT_^:#^R>BOXV/\ AO3]L/\ Z.!\?_\
M@;9?_(-'_#>G[8?_ $<#X_\ _ VR_P#D&C_B7;B?_H=Y#]^8?_,0?\1@R7_H
M5YI_Y:?_ #0?V3T5_&Q_PWI^V'_T<#X__P# VR_^0:/^&]/VP_\ HX'Q_P#^
M!ME_\@T?\2[<3_\ 0[R'[\P_^8@_XC!DO_0KS3_RT_\ F@_LGHK^-C_AO3]L
M/_HX'Q__ .!ME_\ (-'_  WI^V'_ -' ^/\ _P #;+_Y!H_XEVXG_P"AWD/W
MYA_\Q!_Q&#)?^A7FG_EI_P#-!_9/17\;'_#>G[8?_1P/C_\ \#;+_P"0:/\
MAO3]L/\ Z.!\?_\ @;9?_(-'_$NW$_\ T.\A^_,/_F(/^(P9+_T*\T_\M/\
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MWI^V'_T<#X__ / VR_\ D&C_ (EVXG_Z'>0_?F'_ ,Q!_P 1@R7_ *%>:?\
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M?_(-'_#>G[8?_1P/C_\ \#;+_P"0:/\ B7;B?_H=Y#]^8?\ S$'_ !&#)?\
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M_P#^!ME_\@T?\-Z?MA_]' ^/_P#P-LO_ )!H_P")=N)_^AWD/WYA_P#,0?\
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M?_-!_9/17\;'_#>G[8?_ $<#X_\ _ VR_P#D&C_AO3]L/_HX'Q__ .!ME_\
M(-'_ !+MQ/\ ]#O(?OS#_P"8@_XC!DO_ $*\T_\ +3_YH/[)Z*_C8_X;T_;#
M_P"C@?'_ /X&V7_R#1_PWI^V'_T<#X__ / VR_\ D&C_ (EVXG_Z'>0_?F'_
M ,Q!_P 1@R7_ *%>:?\ EI_\T']D]%?QL?\ #>G[8?\ T<#X_P#_  -LO_D&
MC_AO3]L/_HX'Q_\ ^!ME_P#(-'_$NW$__0[R'[\P_P#F(/\ B,&2_P#0KS3_
M ,M/_F@_LGHK^-C_ (;T_;#_ .C@?'__ (&V7_R#1_PWI^V'_P!' ^/_ /P-
MLO\ Y!H_XEVXG_Z'>0_?F'_S$'_$8,E_Z%>:?^6G_P T']D]%?QL?\-Z?MA_
M]' ^/_\ P-LO_D&C_AO3]L/_ *.!\?\ _@;9?_(-'_$NW$__ $.\A^_,/_F(
M/^(P9+_T*\T_\M/_ )H/[)Z*_C8_X;T_;#_Z.!\?_P#@;9?_ "#1_P -Z?MA
M_P#1P/C_ /\  VR_^0:/^)=N)_\ H=Y#]^8?_,0?\1@R7_H5YI_Y:?\ S0?V
M3T5_&Q_PWI^V'_T<#X__ / VR_\ D&C_ (;T_;#_ .C@?'__ (&V7_R#1_Q+
MMQ/_ -#O(?OS#_YB#_B,&2_]"O-/_+3_ .:#^R>BOXV/^&]/VP_^C@?'_P#X
M&V7_ ,@T?\-Z?MA_]' ^/_\ P-LO_D&C_B7;B?\ Z'>0_?F'_P Q!_Q&#)?^
MA7FG_EI_\T']D]%?QL?\-Z?MA_\ 1P/C_P#\#;+_ .0:/^&]/VP_^C@?'_\
MX&V7_P @T?\ $NW$_P#T.\A^_,/_ )B#_B,&2_\ 0KS3_P M/_F@_LGHK^-C
M_AO3]L/_ *.!\?\ _@;9?_(-'_#>G[8?_1P/C_\ \#;+_P"0:/\ B7;B?_H=
MY#]^8?\ S$'_ !&#)?\ H5YI_P"6G_S0?V3T5_&Q_P -Z?MA_P#1P/C_ /\
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M=N)_^AWD/WYA_P#,0?\ $8,E_P"A7FG_ ):?_-!_9/17\;'_  WI^V'_ -'
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MO3]L/_HX'Q__ .!ME_\ (-'_ !+MQ/\ ]#O(?OS#_P"8@_XC!DO_ $*\T_\
M+3_YH/[)Z*_C8_X;T_;#_P"C@?'_ /X&V7_R#1_PWI^V'_T<#X__ / VR_\
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MOXV/^&]/VP_^C@?'_P#X&V7_ ,@T?\-Z?MA_]' ^/_\ P-LO_D&C_B7;B?\
MZ'>0_?F'_P Q!_Q&#)?^A7FG_EI_\T']D]%?QL?\-Z?MA_\ 1P/C_P#\#;+_
M .0:/^&]/VP_^C@?'_\ X&V7_P @T?\ $NW$_P#T.\A^_,/_ )B#_B,&2_\
M0KS3_P M/_F@_LGHK^-C_AO3]L/_ *.!\?\ _@;9?_(-'_#>G[8?_1P/C_\
M\#;+_P"0:/\ B7;B?_H=Y#]^8?\ S$'_ !&#)?\ H5YI_P"6G_S0?V3T5_&Q
M_P -Z?MA_P#1P/C_ /\  VR_^0:/^&]/VP_^C@?'_P#X&V7_ ,@T?\2[<3_]
M#O(?OS#_ .8@_P"(P9+_ -"O-/\ RT_^:#^R>BOXV/\ AO3]L/\ Z.!\?_\
M@;9?_(-'_#>G[8?_ $<#X_\ _ VR_P#D&C_B7;B?_H=Y#]^8?_,0?\1@R7_H
M5YI_Y:?_ #0?V3T5_&Q_PWI^V'_T<#X__P# VR_^0:/^&]/VP_\ HX'Q_P#^
M!ME_\@T?\2[<3_\ 0[R'[\P_^8@_XC!DO_0KS3_RT_\ F@_LGHK^-C_AO3]L
M/_HX'Q__ .!ME_\ (-'_  WI^V'_ -' ^/\ _P #;+_Y!H_XEVXG_P"AWD/W
MYA_\Q!_Q&#)?^A7FG_EI_P#-!_9/17\;'_#>G[8?_1P/C_\ \#;+_P"0:/\
MAO3]L/\ Z.!\?_\ @;9?_(-'_$NW$_\ T.\A^_,/_F(/^(P9+_T*\T_\M/\
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MWI^V'_T<#X__ / VR_\ D&C_ (EVXG_Z'>0_?F'_ ,Q!_P 1@R7_ *%>:?\
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MV)JO_/F__?<7_P <K^2/_AO3]L/_ *.!\?\ _@;9?_(-'_#>G[8?_1P/C_\
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M1@R7_H5YI_Y:?_-!_6Y_8FJ_\^;_ /?<7_QRC^Q-5_Y\W_[[B_\ CE?R1_\
M#>G[8?\ T<#X_P#_  -LO_D&C_AO3]L/_HX'Q_\ ^!ME_P#(-'_$NW$__0[R
M'[\P_P#F(/\ B,&2_P#0KS3_ ,M/_F@_K<_L35?^?-_^^XO_ (Y1_8FJ_P#/
MF_\ WW%_\<K^2/\ X;T_;#_Z.!\?_P#@;9?_ "#1_P -Z?MA_P#1P/C_ /\
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M (EVXG_Z'>0_?F'_ ,Q!_P 1@R7_ *%>:?\ EI_\T'];G]B:K_SYO_WW%_\
M'*/[$U7_ )\W_P"^XO\ XY7\D?\ PWI^V'_T<#X__P# VR_^0:/^&]/VP_\
MHX'Q_P#^!ME_\@T?\2[<3_\ 0[R'[\P_^8@_XC!DO_0KS3_RT_\ F@_K<_L3
M5?\ GS?_ +[B_P#CE']B:K_SYO\ ]]Q?_'*_DC_X;T_;#_Z.!\?_ /@;9?\
MR#1_PWI^V'_T<#X__P# VR_^0:/^)=N)_P#H=Y#]^8?_ #$'_$8,E_Z%>:?^
M6G_S0?UN?V)JO_/F_P#WW%_\<H_L35?^?-_^^XO_ (Y7\D?_  WI^V'_ -'
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M_CE?R1_\-Z?MA_\ 1P/C_P#\#;+_ .0:/^&]/VP_^C@?'_\ X&V7_P @T?\
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M_ON+_P".4?V)JO\ SYO_ -]Q?_'*_DC_ .&]/VP_^C@?'_\ X&V7_P @T?\
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M6Y_8FJ_\^;_]]Q?_ !RC^Q-5_P"?-_\ ON+_ ..5_)'_ ,-Z?MA_]' ^/_\
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MB:K_ ,^;_P#?<7_QROY(_P#AO3]L/_HX'Q__ .!ME_\ (-'_  WI^V'_ -'
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M#^MS^Q-5_P"?-_\ ON+_ ..4?V)JO_/F_P#WW%_\<K^2/_AO3]L/_HX'Q_\
M^!ME_P#(-'_#>G[8?_1P/C__ ,#;+_Y!H_XEVXG_ .AWD/WYA_\ ,0?\1@R7
M_H5YI_Y:?_-!_6Y_8FJ_\^;_ /?<7_QRC^Q-5_Y\W_[[B_\ CE?R1_\ #>G[
M8?\ T<#X_P#_  -LO_D&C_AO3]L/_HX'Q_\ ^!ME_P#(-'_$NW$__0[R'[\P
M_P#F(/\ B,&2_P#0KS3_ ,M/_F@_K<_L35?^?-_^^XO_ (Y1_8FJ_P#/F_\
MWW%_\<K^2/\ X;T_;#_Z.!\?_P#@;9?_ "#1_P -Z?MA_P#1P/C_ /\  VR_
M^0:/^)=N)_\ H=Y#]^8?_,0?\1@R7_H5YI_Y:?\ S0?UN?V)JO\ SYO_ -]Q
M?_'*/[$U7_GS?_ON+_XY7\D?_#>G[8?_ $<#X_\ _ VR_P#D&C_AO3]L/_HX
M'Q__ .!ME_\ (-'_ !+MQ/\ ]#O(?OS#_P"8@_XC!DO_ $*\T_\ +3_YH/ZY
M;/2-1AO+262U=8X[JV=V+QD*HF0DD!R>!Z UZ%7\FO[/G[9?[4?C;]H#X#>$
MO%7QN\;ZUX;\0_&WX2Z7K>D7=];BUU+3KKX@^'4N;*Y$-K%(]O<1YCGC#A98
MF:-PT;LI_K*K\WXYX#S#@/%8#"9CC<%C*F/P]7$4Y8+V_)"%*HJ5INO2I2<Y
M2;=HQ:22]YMV7V?"_%6$XJH8O$83#8C#0PE6%&:Q+I<TY3@YWBJ4YKE226KN
MVWI9791117PI]2%%%% !1110 4444 %%%% 'X'_\%PO^;8?^ZU?^\EK\#Z_?
M#_@N%_S;#_W6K_WDM?@?7]X>#'_)M>&_^ZQ_ZO\ -3^5_$C_ )+3.?\ NG?^
MJG A1117Z@?#A1110 445?TO2]3US4K#1M%TZ^U?5]5O+?3]+TK3+2>_U'4;
M^\E2"TLK&RM8Y;F[N[F=TAM[>"*2::5UCC1G8 J4HQC*4I*,8IRE*32C&*5W
M*3=DDDFVV[):L:3DU&*;DVDDDVVV[))+5MO1):ME"BOU0^&__!(;]J+QMI%I
MK7B:[\!?#&.[CCFCT?Q5K&HWWB6.&5=Z/<Z=X;TC6+"T?85+VEYK%O?0.3#<
MVL$R2(F1\6?^"3?[4GPUT2[\0Z#%X2^*UA8Q//=:?X"U'4W\3Q6\89I)8O#^
MN:3I$NILJA2MGH=UJNI2LQ6&QDVDU\7'Q&X%GC5E\>*,H>)=3V27UE>P=1OE
M48XQI8-MRT5J[3=DFVT?1RX/XHCAOK<LCS%4%#G;]A+VJA:[D\/_ +PDEJ[T
ME97;T39^8U%=CX%\#:[\0O'WA+X;Z(MM;^)/&?BK1?!NE)JTDME:0:SKNJ6^
MCV:ZC*L$\UK!'>7,8NG%M++"BN1"[+L/TY^TA^PG\</V6O".B^-OB9+X*GT/
M7?$<7A:S?PQK]WJMU'JT^F:EJT*W-O=Z/IA2"2STF^(FB:8+)$J2*ADC+?08
MG/,HP>88+*L5F.%H9CF2<L!@ZE51KXM1;3=&+^/6+6CU::5SR:.69AB<)B<?
M0PE>K@\&TL5B80<J5!RM95)+2-[K?N?&5%??EY_P3=_:'LO@DWQ]EN?AX_@9
M/AG%\5VAC\2Z@=>'A6;PU'XK"_V>^@);'4TTJ0%[/[?Y?VE6A2Y<;7;X#HRO
M/,HSI8EY3F&&QZP5=X;%/#5%4]AB$KNE4M\,TKW7D^P8W+,PRUT%C\)7PCQ-
M)5Z'MX.'M:3VJ0OO%W6H4445ZIPA17WY>?\ !-W]H>R^"3?'V6Y^'C^!D^&<
M7Q7:&/Q+J!UX>%9O#4?BL+_9[Z EL=332I 7L_M_E_:5:%+EQM=O@.O*RO/,
MHSI8EY3F&&QZP5=X;%/#5%4]AB$KNE4M\,TKW7D^QW8W+,PRUT%C\)7PCQ-)
M5Z'MX.'M:3VJ0OO%W6H4445ZIPA1110 45]!_LX?LT_$7]J3QGJ_@3X9S>'(
M=;T3PQ=>+;QO$VIW.E6)TJTU71]'E6&>UT[4Y'NS=ZW9E(6@1#")G,H9%1ZG
M[1'[.GQ#_9B\=VGP[^)9T%]>OO#FG^*;67PYJ<NJZ=+I.I7VJ:=;M]HGLK"9
M)UN]'OHY89+9"HC216>.1&/E+.\H>;/(EF&&_MB-#ZR\N]HOK2P]E+VOL]^3
MEDG?L[]&=W]F9@L LT^J5_[.=7V"QG(_8>UNU[/GVYKIJW?3<\'HHHKU3A"B
MBB@ HKT[X2?!OXE_'3Q?;^!?A5X3U#Q=XDG@DO)+2S:VMK:PT^&2**?4M6U.
M_GM=-TK3H99X(GO-0N[> SSP6T;/<3PQ2?III?\ P1?_ &BKK3A<ZI\1/@]I
M6H/'')'IJ:EXOU 1LZY:&\O8O",,44L1.QS:)?P%@WES.FUV^9SOC+A?ARM#
M#YUGF P&(J14XX>K5<\1[.3M&I*A1C4JPIR=U&I.$82Y9<LGRRM[66<.9YG%
M.5;+<LQ6+HPDXRK4X<M'G6K@JM1PIRG%-.4(R<HW5TKJ_P"/M%?8G[1?["O[
M0W[,EB=?\>^&[#5_!?VJ.S/CKP7?R:YX:@N)Y$BMH]3,UII^LZ(+J:6*WM9M
M;TC3[6[NI$M+2XGN"(Z^.Z];+,VRS.L)#'Y3CL+F.#J-QCB,)6A6I\\;<].3
M@WR5877/2FHU(72E%-G!C<!C<MQ$L+C\+7P>(@DY4<13E2GRRORS2DES0E9\
MLXWA)*\6T%%%%>@<@45]K_LZ?L$?'+]J#P-J'Q"^&MSX%AT'3?$]_P"$KA?$
MNOW^EWYU73M,T?5;AH[>UT/4HVM#:ZY9".8SJ[2B=#$HC5W@^"_[!_QQ^.WB
MKXN^#O!DO@FUUKX)^)XO"7C5-?\ $%W8VW]L2:CXDTO;I%Q9Z/J2W]NEWX6U
M0/.ZVP\LVSHKB9A'\Y7XNX9PTLSAB,[R^C/)71CFL9UTG@'7K0P]%8A6O#VE
M>I3I1>JYYQB[-GKTL@SJLL#*EEF,J+,E4> <:4FL6J5.5:HZ+^WR4H2G*VT8
MM]#XOHKT_P",WPD\5_ GXE^*/A1XX;2V\4^$9M-AU5M%O)-0TMFU71M.UVT:
MTNY;:SEF1K#5+4OOMH628R1E?DR?,*]S#8FAC,-A\9A:L*^%Q5"EB<-7IOFI
MUJ%>G&K1JTY+24*E.49P?6,DSS*U&KAZU7#UZ<J5:A4G1K4IIQG3JTI.%2G.
M+U4H3BXR3U33045]??LU_L2_&7]JK1?$VO?#"X\&0V/A/5+/2-4'BC7+W29V
MN[ZT>]@-K'::-J:S1"%#O=WB*OA0C#FO /BG\-O$7P?^(?BSX9>+'TY_$?@S
M5I=&U=])N9+S36NXHXI6-G=36]I+-#ME3#O;0L3D%!CGAP^>91B\SQF38;,,
M-6S7 4XU<;@:=12Q&&IR5)QG5A]F+]M2L_[\3JJY9CZ&"P^8UL)7IX'%RE##
M8J<&J-:<7-2C3GM)ITYW7]U]C@**],^#GPG\4?''XE>%OA5X+?2H_$_B^YOK
M727UN[FL=+673]*O]9G^UW<%K>RPJ;33K@1E+64M,8T(56+K^@__  YZ_:T_
MY_\ X2?^%CK'_P R=<6;\6\-9!B*>$SK.L!EN)JT8XBG1Q594ZDZ$JE2E&K%
M-.\'4I5()]X2['3E^09UFM&=?+<LQ>-HTZCHSJ8>DYPC5483<&UM)0G"37:2
M?4_*RBOU3_X<]?M:?\__ ,)/_"QUC_YDZ\!_:._8+^./[+O@?2_B!\2[GP--
MH.K^*K'P?:KX9U^_U6_&K:AI.N:S;M+;W6B:;&EH+/P_?B299W=9C @A99&>
M/DP/'G!N98NA@<!Q'E>*QF*J*EA\/1Q"E5K5&KJ$(VUDTGIY/LSHQ/"W$6"P
M]7%8K)L?A\/0BYUJU6A*-.G!-)RE)[*[2N?%5%%%?6G@!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'OG[*?\
MR=%^S;_V7SX._P#JP_#M?VR5_$W^RG_R=%^S;_V7SX._^K#\.U_;)7\E_2,_
MY'7#G_8KQ?\ ZEH_?O!W_D6YS_V'4/\ U'84445_.9^Q!1110 4444 %%%%
M!1110!^!_P#P7"_YMA_[K5_[R6OP/K]\/^"X7_-L/_=:O_>2U^!]?WAX,?\
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M\)8.AC\^Q<L'A<1B8X2E4AAL3BG+$2I5:R@X86E6G%.G1J2YI14?=LW=I/\
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MP1I!7]EGQ@#U'QS\6 X((R/!/PX!P1D'Z@D'M5'_ ()M?\G"?\%&?^R\P?\
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M[@_U1S3_ *"<C_\ $AR7_P";3\C:*_7+_AD3_@G7_P!'W?\ E'TW_P"1*/\
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MBVFF?D717ZZ?\.8/VHO^A\^ ?_A4?$/_ .=91_PY@_:B_P"A\^ ?_A4?$/\
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M(G\ ?]%5E?\ X,J__*@_U(XL_P"A%CO_  "'_P F?D717ZZ?\.8/VHO^A\^
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M'_\ .LH_X<P?M1?]#Y\ _P#PJ/B'_P#.LH_XB?P!_P!%5E?_ (,J_P#RH/\
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M47_0^? /_P *CXA__.LH_P"(G\ ?]%5E?_@RK_\ *@_U(XL_Z$6._P# (?\
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M,_(NBOUT_P"','[47_0^? /_ ,*CXA__ #K*/^','[47_0^? /\ \*CXA_\
MSK*/^(G\ ?\ 1597_P"#*O\ \J#_ %(XL_Z$6._\ A_\F?D717ZZ?\.8/VHO
M^A\^ ?\ X5'Q#_\ G64?\.8/VHO^A\^ ?_A4?$/_ .=91_Q$_@#_ **K*_\
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M ,*CXA__ #K*/^(G\ ?]%5E?_@RK_P#*@_U(XL_Z$6._\ A_\F?D717ZZ?\
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M#_\ "H^(?_SK*/\ AS!^U%_T/GP#_P#"H^(?_P ZRC_B)_ '_1597_X,J_\
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M<P?M1?\ 0^? /_PJ/B'_ /.LH_XB?P!_T565_P#@RK_\J#_4CBS_ *$6._\
M (?_ "9^1=%?KI_PY@_:B_Z'SX!_^%1\0_\ YUE'_#F#]J+_ *'SX!_^%1\0
M_P#YUE'_ !$_@#_HJLK_ /!E7_Y4'^I'%G_0BQW_ (!#_P"3/R+HK]=/^','
M[47_ $/GP#_\*CXA_P#SK*/^','[47_0^? /_P *CXA__.LH_P"(G\ ?]%5E
M?_@RK_\ *@_U(XL_Z$6._P# (?\ R9^1=%?KI_PY@_:B_P"A\^ ?_A4?$/\
M^=91_P .8/VHO^A\^ ?_ (5'Q#_^=91_Q$_@#_HJLK_\&5?_ )4'^I'%G_0B
MQW_@$/\ Y,_(NBOUT_X<P?M1?]#Y\ __  J/B'_\ZRC_ (<P?M1?]#Y\ _\
MPJ/B'_\ .LH_XB?P!_T565_^#*O_ ,J#_4CBS_H18[_P"'_R9^1=%?KI_P .
M8/VHO^A\^ ?_ (5'Q#_^=91_PY@_:B_Z'SX!_P#A4?$/_P"=91_Q$_@#_HJL
MK_\ !E7_ .5!_J1Q9_T(L=_X!#_Y,_(NBOUT_P"','[47_0^? /_ ,*CXA__
M #K*/^','[47_0^? /\ \*CXA_\ SK*/^(G\ ?\ 1597_P"#*O\ \J#_ %(X
ML_Z$6._\ A_\F?D717ZZ?\.8/VHO^A\^ ?\ X5'Q#_\ G64?\.8/VHO^A\^
M?_A4?$/_ .=91_Q$_@#_ **K*_\ P95_^5!_J1Q9_P!"+'?^ 0_^3/R+HK]=
M/^','[47_0^? /\ \*CXA_\ SK*/^','[47_ $/GP#_\*CXA_P#SK*/^(G\
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M!^U%_P!#Y\ __"H^(?\ \ZRC_B)_ '_1597_ .#*O_RH/]2.+/\ H18[_P
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M_P &5?\ Y4'^I'%G_0BQW_@$/_DS\BZ*_73_ (<P?M1?]#Y\ _\ PJ/B'_\
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M_P F?D717ZZ?\.8/VHO^A\^ ?_A4?$/_ .=91_PY@_:B_P"A\^ ?_A4?$/\
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M3^ /^BJRO_P95_\ E0?ZD<6?]"+'?^ 0_P#DS\BZ*_73_AS!^U%_T/GP#_\
M"H^(?_SK*/\ AS!^U%_T/GP#_P#"H^(?_P ZRC_B)_ '_1597_X,J_\ RH/]
M2.+/^A%CO_ (?_)GY%T5^NG_  Y@_:B_Z'SX!_\ A4?$/_YUE'_#F#]J+_H?
M/@'_ .%1\0__ )UE'_$3^ /^BJRO_P &5?\ Y4'^I'%G_0BQW_@$/_DS\BZ*
M_73_ (<P?M1?]#Y\ _\ PJ/B'_\ .LH_X<P?M1?]#Y\ _P#PJ/B'_P#.LH_X
MB?P!_P!%5E?_ (,J_P#RH/\ 4CBS_H18[_P"'_R9^1=%?KI_PY@_:B_Z'SX!
M_P#A4?$/_P"=91_PY@_:B_Z'SX!_^%1\0_\ YUE'_$3^ /\ HJLK_P#!E7_Y
M4'^I'%G_ $(L=_X!#_Y,_(NBOUT_X<P?M1?]#Y\ _P#PJ/B'_P#.LH_X<P?M
M1?\ 0^? /_PJ/B'_ /.LH_XB?P!_T565_P#@RK_\J#_4CBS_ *$6._\  (?_
M "9^1=%?KI_PY@_:B_Z'SX!_^%1\0_\ YUE6[#_@B_\ M*-?V2ZI\0/@=%IA
MN[8:C)8>)/'L]_'8&9!=O90W'PRM[>:[2W\QK:*>X@ADF")+-$A9U3\4. $F
M_P#6G+'9-V4ZK;LKV25*[?9+5O0:X'XL;2_L+&J[2NXP25^K?/HN[/R HK^A
MO_AS-\'/^B]>-_\ PGO#_P#\71_PYF^#G_1>O&__ (3WA_\ ^+KPO^(W>'7_
M $-L5_X:LR_^9CT_^(9<8_\ 0NH_^%^!_P#EY_/)17]#?_#F;X.?]%Z\;_\
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MXW_\)[P__P#%T?\ #F;X.?\ 1>O&_P#X3WA__P"+H_XC=X=?]#;%?^&K,O\
MYF#_ (AEQC_T+J/_ (7X'_Y>?SR45_0W_P .9O@Y_P!%Z\;_ /A/>'__ (NC
M_AS-\'/^B]>-_P#PGO#_ /\ %T?\1N\.O^AMBO\ PU9E_P#,P?\ $,N,?^A=
M1_\ "_ __+S^>2BOZ&_^',WP<_Z+UXW_ /">\/\ _P 71_PYF^#G_1>O&_\
MX3WA_P#^+H_XC=X=?]#;%?\ AJS+_P"9@_XAEQC_ -"ZC_X7X'_Y>?SR45_0
MW_PYF^#G_1>O&_\ X3WA_P#^+H_X<S?!S_HO7C?_ ,)[P_\ _%T?\1N\.O\
MH;8K_P -69?_ #,'_$,N,?\ H74?_"_ _P#R\_GDHK^AO_AS-\'/^B]>-_\
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M_P"B]>-__">\/_\ Q='_ !&[PZ_Z&V*_\-69?_,P?\0RXQ_Z%U'_ ,+\#_\
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M_P"%^!_^7G\\E%?T-_\ #F;X.?\ 1>O&_P#X3WA__P"+H_X<S?!S_HO7C?\
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MZ&V*_P##5F7_ ,S!_P 0RXQ_Z%U'_P +\#_\O/YY**_H;_X<S?!S_HO7C?\
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M>'__ (NC_AS-\'/^B]>-_P#PGO#_ /\ %T?\1N\.O^AMBO\ PU9E_P#,P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH N:=_P A
M"Q_Z_+7_ -'I7JE>5Z=_R$+'_K\M?_1Z5ZI0 4444 %%%% !1110 4444 %%
M%% 'X'_\%PO^;8?^ZU?^\EK\#Z_?#_@N%_S;#_W6K_WDM?@?7]X>#'_)M>&_
M^ZQ_ZO\ -3^5_$C_ )+3.?\ NG?^JG A1117Z@?#A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% ']='_!,'_DQKX'_]U+_]6_X_K[XK
MX'_X)@_\F-? _P#[J7_ZM_Q_7WQ7^<_''_):<7_]E1Q!_P"K;%G]B<,?\DUP
M]_V(\I_]0,.%%%%?+GN!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'C]%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% %S3O\ D(6/_7Y:_P#H]*]4KRO3O^0A8_\ 7Y:_^CTK
MU2@ HHHH **** "BBB@ HHHH **** /P/_X+A?\ -L/_ '6K_P!Y+7X'U^^'
M_!<+_FV'_NM7_O):_ ^O[P\&/^3:\-_]UC_U?YJ?ROXD?\EIG/\ W3O_ %4X
M$****_4#X<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH _KH_X)@_\ )C7P/_[J7_ZM_P ?U]\5\#_\$P?^3&O@?_W4O_U;_C^OOBO\
MY^./^2TXO_[*CB#_ -6V+/[$X8_Y)KA[_L1Y3_Z@8<****^7/<"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'Z***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!X_1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \?HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTKPC:^,O%6N>)H/#&ES:S\2H9--T"/6;Z\72-/>+3=/C-E8""V"6=LHB B3
M!^U%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!<T[_D(6/\ U^6O
M_H]*]4KRO3O^0A8_]?EK_P"CTKU2@ HHHH **** "BBB@ HHHH **** /P/_
M ."X7_-L/_=:O_>2U^!]?OA_P7"_YMA_[K5_[R6OP/K^\/!C_DVO#?\ W6/_
M %?YJ?ROXD?\EIG/_=._]5.!"BBBOU ^'"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /ZZ/^"8/_)C7P/_ .ZE_P#JW_']??%? _\
MP3!_Y,:^!_\ W4O_ -6_X_K[XK_.?CC_ )+3B_\ [*CB#_U;8L_L3AC_ ))K
MA[_L1Y3_ .H&'"BBBOESW HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:+X1M_$4WV:+7+>QOM5A\.>)[*^LO#WB#4[ :J-+N;^U@U#4+"^FU#5/./\
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MBI\2M-\ VNK3PJPBL=*L9?&MR]Y!LU2$7#6NFSVAO[F\M_N#]C+_ )3*?\%
M?^Q(G_\ 3_\ "RE_X)._\GG_ /!5O_LOA_\ 5K?'Z@#YM_:[_9>^'7_!.;]K
M/]A_XN?LN3>)? VG_$'XG+X0\8>$I?$FL:[8W6F6&O\ @BSU:VAOM;O+[5I]
M/\6:#XHU33=:TW4-1NK2*6UL+O3DM9MQC_IZK\%O^"U'_)0_^">7_9>]4_\
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M'T6U\2_\%$O^"JOAV^S]AU_6_$NBWF!N/V75?'7B>QN,+E=Q\F=^,C/3(ZT
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MNE?$?P)X1\>:9:SNLDUMI_B_P_I_B"SMYG3"/+!;ZA'%(R@*SJQ P17Y!?\
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M_!7+Q!\2?#7[!WQBU'X97&L66H22>%=/\3ZCH#W$6JZ?X%U'Q+IMIXHFBEM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^/2_#/@WP[K7BKQ%J<W^JT_0_#VFW.K:M>R<CY+6PM+B=AD9"$"OY,/@T/\
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MBE5*C7?%=_K.L;6&4^V[#G;7]5- !1110 4444 %%%% !1110 4444 %%%%
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M:_X>L_MI_P#10?#O_AOO!G_RHH_X>L_MI_\ 10?#O_AOO!G_ ,J*_.6BMO\
M4#@?_HDN'?\ PT8'_P"4F?\ K5Q-_P!%!G/_ (<L7_\ +3]&O^'K/[:?_10?
M#O\ X;[P9_\ *BC_ (>L_MI_]%!\._\ AOO!G_RHK\Y:*/\ 4#@?_HDN'?\
MPT8'_P"4A_K5Q-_T4&<_^'+%_P#RT_1K_AZS^VG_ -%!\._^&^\&?_*BC_AZ
MS^VG_P!%!\._^&^\&?\ RHK\Y:*/]0.!_P#HDN'?_#1@?_E(?ZU<3?\ 109S
M_P"'+%__ "T_1K_AZS^VG_T4'P[_ .&^\&?_ "HH_P"'K/[:?_10?#O_ (;[
MP9_\J*_.6BC_ % X'_Z)+AW_ ,-&!_\ E(?ZU<3?]%!G/_ARQ?\ \M/T:_X>
ML_MI_P#10?#O_AOO!G_RHH_X>L_MI_\ 10?#O_AOO!G_ ,J*_.6BC_4#@?\
MZ)+AW_PT8'_Y2'^M7$W_ $4&<_\ ARQ?_P M/T:_X>L_MI_]%!\._P#AOO!G
M_P J*/\ AZS^VG_T4'P[_P"&^\&?_*BOSEHH_P!0.!_^B2X=_P##1@?_ )2'
M^M7$W_109S_X<L7_ /+3]&O^'K/[:?\ T4'P[_X;[P9_\J*/^'K/[:?_ $4'
MP[_X;[P9_P#*BOSEHH_U X'_ .B2X=_\-&!_^4A_K5Q-_P!%!G/_ (<L7_\
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MI_\ 10?#O_AOO!G_ ,J*_.6BC_4#@?\ Z)+AW_PT8'_Y2'^M7$W_ $4&<_\
MARQ?_P M/T:_X>L_MI_]%!\._P#AOO!G_P J*/\ AZS^VG_T4'P[_P"&^\&?
M_*BOSEHH_P!0.!_^B2X=_P##1@?_ )2'^M7$W_109S_X<L7_ /+3]&O^'K/[
M:?\ T4'P[_X;[P9_\J*/^'K/[:?_ $4'P[_X;[P9_P#*BOSEHH_U X'_ .B2
MX=_\-&!_^4A_K5Q-_P!%!G/_ (<L7_\ +3]&O^'K/[:?_10?#O\ X;[P9_\
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MC_AZS^VG_P!%!\._^&^\&?\ RHK\Y:*/]0.!_P#HDN'?_#1@?_E(?ZU<3?\
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MX;U>*PM]>L=3B6^$<7L'[$'@'XN?M2?MTZK^W=XR^$&J_ CX)_#SP#<_#?X
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MJN.\@^ /P0M?BG+\<+;X2_#VW^,$T$L$OQ*A\)Z-'XS<3Z?+I%Q,=>2T%_\
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M:#%X(O[:>\ATOP]-X@;2TOW\231PRS)$;5;IK61$9O-,# ;#^0E?V6_M"?\
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M/C[X5N;H#]W#=^!]7LH&.#]^YAU_4)(QG'*VLG!)QQ@_J]^W;KOQ4\-?LO\
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MB;B3,*N&IK+^%\%BVZE55)J/U?VGL<)AZ=6M.<_K&.<5)WG)TU.;C=^RA/\
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MDUIK\T\VIR_:8-/_ +,$4+3>:5ZZWB'G&-\2Z>38+,,'_9<N)LKR^E1HYO\
MN:N%PF%S!8J-OJ+O+,*N+PWMJ7,^7,<!1RZ%6I&<L33YJ?".78;@N>98G"8E
MXU9+CL7.K4R[WX5L3B,$\.[_ %NZCA*>'K^SJ67-@\75QDJ<'!4*G\Q=%%%?
MTB?C@4444 %%%% !1110!_71_P $P?\ DQKX'_\ =2__ %;_ (_K[XKX'_X)
M@_\ )C7P/_[J7_ZM_P ?U]\5_G/QQ_R6G%__ &5'$'_JVQ9_8G#'_)-</?\
M8CRG_P!0,.%%%%?+GN!1110!^9FK?\%B_P#@G!H>J:EHNJ?M'P6NIZ1J%YI>
MHVW_  JKXX3?9[[3[B2TNX/.M_AI+;R^3<0R1^9!++#)MW12.A5CZ=\*?^"E
MO["7QJUBR\/?#[]I?X>W>NZG>P:;I>C^)GUOX>:EJVHW4B0VEAI-E\1-'\*W
M&J7UW-(D%I:6$=Q<7,[K#!')*P0_B+_P14^ ?P-^-OQ _;UD^,GP=^&'Q6D\
M-_$WP.GAY_B+X%\,^-&T)-6UOXS-JBZ0WB+3-1.G+J3:;IYOA:&$79L;0S^9
M]FAV?IU^U;_P1[_8^^.GPU\5:?\ #GX2>#_@M\5%TN_O? WB_P"'&GP>$-.@
M\2P65PVDV'B'P]I<2^'=0\,ZA??9X-9B72(M3BLS)-I.H6%VBRD _66BOPZ_
MX(:_M/>//BW^SO\ $7X2_%W5;S4O%?[,7BFR\,GQ#K^J27NK?\(7K\.M76C:
M;KU_>S3R32>%M0\.^)='M;Z6[:&/0+/2;!%2/2S+/-X]_P""VW@*?QCXH\+?
MLO?LT_'+]K33?!%RD'B?QS\.](U&U\'PQ?O//OM,N;#PWXKU>YTU&AN([74=
M6T?0;#4VMI[C3;FZTW[/J%P ?M_7@'P0_:D^!'[1VH_$?2?@QX]B\::C\)/$
M2>$_B%;)X>\6Z"WAW7Y9]5MH[!W\4:#HD>I!Y]$U2-;O1GU&Q)M'(N=KPF3Q
M;]B'_@H%\$?VZ?"NM:E\._[6\*^.?!\L4'CCX7>+_L4'BSP\)F\J#5;<6=Q/
M;ZSX;N[E9;2VUBU\J6&ZB-IJVGZ5>206\OXU?\$QOC/_ ,,]:'_P5=^,0\">
M+_B8?!GQ]\(S+X'\!V7]H>*]>;6/B'\1O#JQZ5:;7\W[$VKC4[Y@CF'3;*\F
M",8PI /Z6M'\8^$?$.IZUHN@>*O#>N:SX;N/LGB+2='US3-3U/0+HRSVXMM:
ML+*ZGNM*N#/:W,/DWT4$GFVT\>W?#(J_'_QT_P""D?[%G[-7Q"O_ (5?&SXU
M1>"?'VF:?I>J7V@/X ^*7B!H+'6K1;[3)SJ7A7P1KFCR?:;5UE\N+4))H<[)
MXXI 4'\Z/_!/;]O&7X3_ +8W[:_CA?V<_C1XS/[3'QM757\/>&-':YUGX3_V
MU\4?B-JYLOB#"+20V%U8'Q<;*\4K!LNM%U1,#R\+]/?%_P"'_@7XH?\ !PAX
M.\$_$GP;X7\?^#=7^&6_5?"GC/0=+\3>'-2?3OV=_%^IZ>U_HNLVMYIUVUCJ
M5G:7]H9[>0V][:V]S%LFAC=0#],/^'S_ /P32_Z.7@_\-+\=?_G85]D?L[_M
M._ W]J[P9JOQ!^ /CE/'_A#1/$]WX-U/6$\.^+?#(M?$EAI6C:W=Z;]A\8Z#
MX>U*8Q:7X@TBZ^UV]G+8N+P0QW3W$%S%#Q7_  P;^Q#_ -&@?LR_^&-^&G_S
M-5P/Q^^(/PQ_X)N_L^ZW\1_A5^S#:3?#?3O%5MJGCWPI\"M \&^!8=#&LVEM
MI$WQ UC2+.TTRSU"".33?#^A:KJ$,$]_:VKZ;<7972=.N)[, ^[J*^3?A=^V
ME\"/BA^RQ%^U[9^*(-!^$]GX5U'Q'XMGUF2$:IX*O="C*>(?"NN6=K).S>)-
M-U%?[,M=/L_M$FO3W&F2Z$+^WUC3);KYN^ O[1&O_P#!3GX1:OXM^%TO[07[
M(?@[PWXZMK;0?B9I%U\-+C7/B4UAI^M6>NZ#I^G^(/#OC73QX=TJXO=+GU;4
M8K6,MK]M!I6G:K.^EZ];1@'ZAT5^*O[(7AS]HGXE6_[0WCKQC^VI^T#JT?[.
MW[5OQW^$6C^%);'X0Q^'O&?A;X+ZG91Z1_PE_D_#./56N]?AEDAUY]#U+1XR
MC9TV.P8;JV/^"2O[6_Q0^*_P1\<Z1^U%XS_MKXA^ M+\.?%^V\;ZPFG:<FN?
M WXE>'KC6-"UR4V5EIMM,OA37_#GCCP]KEW#:+%8MIUG;2O(?*N+D#7^G_P/
M7^MOV2HK\:_^"7W[37QZ_:/^,G[8>L?%O7]1E\#74/P4^)GP)\#7UII]L/ ?
MPN^+-S\7]5\)6V^UL+6YN+K7/!>B>#]5NIKRZOC*&@N(VMWGG@7]E* /S,U;
M_@L7_P $X-#U34M%U3]H^"UU/2-0O-+U&V_X55\<)OL]]I]Q):7<'G6_PTEM
MY?)N(9(_,@EEADV[HI'0JQ].^%/_  4M_82^-6L67A[X??M+_#V[UW4[V#3=
M+T?Q,^M_#S4M6U&ZD2&TL-)LOB)H_A6XU2^NYI$@M+2PCN+BYG=88(Y)6"'\
M1?\ @BI\ _@;\;?B!^WK)\9/@[\,/BM)X;^)O@=/#S_$7P+X9\:-H2:MK?QF
M;5%TAO$6F:B=.74FTW3S?"T,(NS8VAG\S[-#L_3K]JW_ ((]_L??'3X:^*M/
M^'/PD\'_  6^*BZ7?WO@;Q?\.-/@\(:=!XE@LKAM)L/$/A[2XE\.ZAX9U"^^
MSP:S$ND1:G%9F2;2=0L+M%E(!^IGB/Q!I'A/P]KOBKQ!>#3]!\,Z-JGB#6[\
MP7-R+'2-&L9]1U*\-M9PW%Y<"VLK::8P6EO/<R[/+@AEE9$;\U?^'S__  32
M_P"CEX/_  TOQU_^=A7PW_P2\_:8^(7QD_X)\?M<?!WXJ7^H:UXS_9J\#_$#
MPG#K6LZA/J6N3^$?$G@3QK/H.D:Q=7,MQ/=7/AK4_#_B31+&Z:YDC&A6ND:=
M$BKIGFS\O_P0K_9E_9R^,?['OC/Q3\6_@+\'?B=XFM/V@?&6B6OB#Q_\-O!_
MB_6K;1K3P'\,+RUTF#4]?TB_O8M-M[O4;^Z@LHYEMHKB]NYDC62XE9P#]2?A
M_P#\%5?^"?'Q.UJU\/>%?VG?!$>JWMU!96</BW2_&7PZM[F[N76.W@AU'XA>
M&?"^FR232.D486[.Z5EC'SL%/V3\3OB=X&^#GP^\4_%/XD:ZOASP%X+TF37/
M$VO_ -GZKJZ:;I43QQO=_P!G:%8ZIJUZ \T8$6GV%W.V[*Q%02/Q._X*Z?L1
M_L4>!_V*OB=\4/#_ ,'OA9\&_B!X,?PS+X U[X>^'=$\!76L>(=2\3:3II\,
M7&E>'X-+L?$\>KZ3=:IYEI=6=[<Z?#;2ZY;M FE3RK1TO7/&WB+_ (-]+W5?
MB!=7E[XB?]G+Q+9175_))-=S^%])^(&J:1X$>668"24?\(-8^'5BE<NTD(C<
MR2[O,8 _3G7/VZOV=M/_ &<-*_:LT3Q1K?BOX+^(KC7K#0?%^B^ /B3/9-J&
M@3>*=.NI/$EG#X-N/$'@OP\FO^$=3T&Z\6^)M!L- L;Z6PDGO/LVH6,UQL?L
MB?M;> ?VPOA9HOQ(\#:?KNFR2>'?"-]XLT^^T'Q9#H&@>*_$.B)J6M^#?#_C
M?7O"_AC1OB%-X-U)+S0==UGPM!/807UM']I2RDNX;>OA#_@EC\)?!'QS_P""
M1_P2^%GQ(T^^U;P1XJE^)\7B'2;'6=6T)M6L],_:.\?:RNF7E]HMY8WTNDZA
M/IT-IK.FFX^R:OI4MWI=_%/97<\+_J-\(?@M\.?@1X;U3P=\+-!/A;PGJ?BW
MQ+XT3PU;7]_/H6B:KXMU!M4UFS\+:5=7$UCX5\.OJ#S7=GX8\/P:=H&G7%S=
MS66GP2W=R\H!ZI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7PU_P4=_9EU3]K7]D#XK_"'PTD;^.);+3O%OP_CFN(K6*Z\8^#]0AUO3=)
MDN+@K;0+XBM[>^\-_:;IX[>T.L"[FEB2 R+]RT4 ?@/_ ,$EO^"CWPME^#7A
MK]DS]HOQ7IGP<^./P'M9OAW8VOQ)N;3P5IOB?PSX:NWTK0M*M=0UR:QM++QE
MX3LH[?PMJ_A;46M-6NUTN#5=.CU!I=7ATGZ4_;H_X*$?LB?LZ_"+QL?#'BOX
M2_$SXVZ]HNL:)\/_ (?^!KKPWXQUE_%FIVCVFGZIXI_X1PZ@?#FC:;<W::G=
M3ZS/IUSJZ6LVGZ)]KU*14C^@/VE?^"</['G[66M'Q9\8?A)8W?CAH(+:7QUX
M6U75_!OBJ\@MH_)MTUB^\/7EE;>(3;P!+>VD\16>JS6EO%#;VLD,$21CA/V?
M_P#@D[^PW^SCXLT[Q[X*^$AU_P ;Z+<Q7NA>)OB)K^K>-;C0;V!EEM[_ $?2
M=3G'AJQU2TG1+FQUF+0QK&GW"++87]LPS0!^5?\ P1=!7_@F9^W$K JR^(?C
M$&4@@@CX >& 00>00>"#R#UKJ/\ @A1^TK^SI\'_ -COQGX7^+/Q[^#'PP\2
MW7[07C/6K7P]\0OB?X)\&:W<Z-=> _AA9VNK0:5XCUO3KZ;3;F[T^_M8+Z.!
MK66YLKN".5I;:94_<7X:_LI_ 'X/^$/BGX"^''P^A\,>$/C3K_BKQ/\ $K1+
M?Q#XMOK?Q!K7C73(]&\2W,$NJZ_?W7A^'4-,BCM(]/\ #-QHVFZ=&BMI=I92
M#?7QW_PY8_X)G?\ 1M7_ )F/X_?_ #U* / /^"JW[<_[$?B+]C#XO_#;3?C#
M\)OC5XT\>Z);:/X$\*?#SQ1X>^(EU9>*AJ5G<:9XHNKWPW=:MI_AN+PLT$FM
MF_U&\L)I_L?]FV'VF\OHK:;Y)\8>!O&WP^_X-Q9=$\>VU_I^L7]IX+\5:?I6
MIHR7>F^%_&/[5_AKQ-X41D=F=(M1T#5+#7;>%Q&]M!JT=L\43PLB_KC\//\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>+PN&Q=)MTL50HXBDWNZ=>G&K!OSY9*X4445RFX4444 %%%% !1110 4444
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M;7<7DRR^*['4$7YCFVU;PSH6JV4OSEC^^L[R";@[07P@5 JC^AG]F9&\*_\
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MKGAF^LO$NE>,-0\)V$%QH>H06$T>LZ_I\T&H:7>M+#!:36,DX!ZW_P $4_\
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MGQA*DOB;4O!OA/1?#UYK)CE>>.&\FTRTMV-I'<2RW*6492S2YEEN5@$\LDC
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MG?VGOV3/A7XZTNY7PI^P+X+^)_B:]@OR9'/B27XAZI>Z'YA/[JUO-)\1ZQX
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MARLR,KHS(Z,&1U)5E92"K*P(*LI (((((!!S71:KXQ\7:[:1:?K?BKQ)K-A
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0RL RLI!5E(R""."".01P1R*_G4_X+\:[IOQ+^"_['?P_P# VIZ;XFO?C/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /'Z*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** +FG?\A"Q_Z_+7_P!'I7JE>5Z=_P A"Q_Z
M_+7_ -'I7JE !1110 4444 %%%% !1110 4444 ?@?\ \%PO^;8?^ZU?^\EK
M\#Z_?#_@N%_S;#_W6K_WDM?@?7]X>#'_ ";7AO\ [K'_ *O\U/Y7\2/^2TSG
M_NG?^JG A1117Z@?#A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% ']='_!,'_DQKX'_ /=2_P#U;_C^OOBO@?\ X)@_\F-? _\ [J7_
M .K?\?U]\5_G/QQ_R6G%_P#V5'$'_JVQ9_8G#'_)-</?]B/*?_4##A1117RY
M[@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<?\ /3X6?^%I??\ S.U_4K11_P 1[X\[9)_X;JG_ ,U_U=^5C_B%'"O?,_\
MPLA_\SG\M7_#H#]KC_GI\+/_  M+[_YG:/\ AT!^UQ_ST^%G_A:7W_S.U_4K
M11_Q'OCSMDG_ (;JG_S7_5WY6/\ B%'"O?,__"R'_P SG\M7_#H#]KC_ )Z?
M"S_PM+[_ .9VC_AT!^UQ_P ]/A9_X6E]_P#,[7]2M%'_ !'OCSMDG_ANJ?\
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M^5C_ (A1PKWS/_PLA_\ ,Y_+5_PZ _:X_P">GPL_\+2^_P#F=H_X= ?M<?\
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MRU?\.@/VN/\ GI\+/_"TOO\ YG:/^'0'[7'_ #T^%G_A:7W_ ,SM?U*T4?\
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M/_PLA_\ ,Y_+5_PZ _:X_P">GPL_\+2^_P#F=H_X= ?M<?\ /3X6?^%I??\
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MF;9KD*=0T;Q1;B>YMIK.6XLM.\*1Z;H378TNX\4W^HP7$L0!^^]%?D'^Q/\
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MNI_91&);SQYX)\5:UH'B*91'+<PZ0M^[2:A=W=RVM_P5CT?XG_!']M;]F?\
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MO\/#XF\70WFB+=>()=3-Q\6(LV&LFY0V5N%\&Z-B);9SD71+GSP(_D_XZ?\
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M+F\W]XQD&T;,GZ%K^:C_ ((CK^V1_P (CX3;PQ)\-1^Q^/B5\0O^$[2_"?\
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M>'KCQ&GAW2IM3T?7[::?2M).I:IINL37-IK']GW>OV-A?:I9F\_8Z@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** +FG?\A"Q_Z_+7_T>E>J5Y7IW_(0L?\ K\M?_1Z5ZI0 4444 %%%
M% !1110 4444 %%%% 'X'_\ !<+_ )MA_P"ZU?\ O):_ ^OWP_X+A?\ -L/_
M '6K_P!Y+7X'U_>'@Q_R;7AO_NL?^K_-3^5_$C_DM,Y_[IW_ *J<"%%%%?J!
M\.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?UT?\
M!,'_ ),:^!__ '4O_P!6_P"/Z^^*^!_^"8/_ "8U\#_^ZE_^K?\ ']??%?YS
M\<?\EIQ?_P!E1Q!_ZML6?V)PQ_R37#W_ &(\I_\ 4##A1117RY[@4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,Z_ ;X8?!'_A)?\ A,/^%;^&8?#O_"3_ -C?\(__ &SY5U=7/VS^Q?[5UO\
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M\_#VQMM*TOQUH&FRZE#J.EZ?=W^HZ4EQ'IVM>&]7TS6=+O=2O5LM?L-7D/\
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M#?BE?$6K6Z%3(+*RM-5M--O95*JL^MZ?&Y)E45^NGP*_Y(C\'/\ LE?P]_\
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M<GA6V\/ZO-JVD_:1!$CJ^C^.]!T35->:TMK:TNO%%CI_A.^N(;6V1[8QPI&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X_1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S=^U%^R
MI\)OVO\ X?Z1\-/C';:_=>&-$\8:?XXL8_#FM/H5\NNZ9HWB#0;5Y;N."X,E
MJ-/\2ZFLEL4 >5H)=P,(#?0]C9PZ?96=A;AA;V-K;V< =MSB&VB2&(.V!N;8
MB[FP,G)QS5JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"YI
MW_(0L?\ K\M?_1Z5ZI7E>G?\A"Q_Z_+7_P!'I7JE !1110 4444 %%%% !11
M10 4444 ?@?_ ,%PO^;8?^ZU?^\EK\#Z_?#_ (+A?\VP_P#=:O\ WDM?@?7]
MX>#'_)M>&_\ NL?^K_-3^5_$C_DM,Y_[IW_JIP(4445^H'PX4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!_71_P3!_Y,:^!_\ W4O_
M -6_X_K[XKX'_P""8/\ R8U\#_\ NI?_ *M_Q_7WQ7^<_''_ "6G%_\ V5'$
M'_JVQ9_8G#'_ "37#W_8CRG_ -0,.%%%%?+GN!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C]%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% %S3O^0A8_P#7Y:_^CTKU2O*]
M._Y"%C_U^6O_ */2O5* "BBB@ HHHH **** "BBB@ HHHH _ _\ X+A?\VP_
M]UJ_]Y+7X'U^^'_!<+_FV'_NM7_O):_ ^O[P\&/^3:\-_P#=8_\ 5_FI_*_B
M1_R6F<_]T[_U4X$****_4#X<**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _KH_X)@_\F-? _\ [J7_ .K?\?U]\5\#_P#!,'_DQKX'
M_P#=2_\ U;_C^OOBO\Y^./\ DM.+_P#LJ.(/_5MBS^Q.&/\ DFN'O^Q'E/\
MZ@8<****^7/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ']='_!,
M'_DQKX'_ /=2_P#U;_C^OOBO@?\ X)@_\F-? _\ [J7_ .K?\?U]\5_G/QQ_
MR6G%_P#V5'$'_JVQ9_8G#'_)-</?]B/*?_4##A1117RY[@4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X_1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!<T[_D(6/_7Y:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"YIW_ "$+'_K\M?\ T>E>J5Y7IW_(0L?^ORU_]'I7
MJE !1110 4444 %%%% !1110 4444 ?FG_P4(_8[\2?M<7WP?M= \:^'?!<'
MP_M/B)<:E<Z]::C>F[E\53> X]-@M;?3U+@!/#FJ23S2,%CV0IM)F!'YT?\
M#FGQ]_T7CX>?^$]XF_PK^D$HC'+*K'IDJ"<>G(I/+C_YYI_WRO\ A7Z)D?BG
MQGPYE6$R7*<PP^'R_!*NJ%*>7X.O-?6,37Q=5RJUJ,ZDFZV(J-7E:,;12LCX
M[-.!.',YQ^(S+'X6O5Q>)=+VLXXO$4HOV-"EAZ:C"G.,8I4Z4$]+MW;>I_-_
M_P .:?'W_1>/AY_X3WB;_"C_ (<T^/O^B\?#S_PGO$W^%?T@>7'_ ,\T_P"^
M5_PH\N/_ )YI_P!\K_A7K?\ $;O$7_H;87_PU9;_ /,QP?\ $,>$/^@'$?\
MA?B__EI_-_\ \.:?'W_1>/AY_P"$]XF_PH_X<T^/O^B\?#S_ ,)[Q-_A7]('
MEQ_\\T_[Y7_"CRX_^>:?]\K_ (4?\1N\1?\ H;87_P -66__ #,'_$,>$/\
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M_P -66__ #,'_$,>$/\ H!Q'_A?B_P#Y:?S?_P##FGQ]_P!%X^'G_A/>)O\
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M?_\ #FGQ]_T7CX>?^$]XF_PH_P"'-/C[_HO'P\_\)[Q-_A7]('EQ_P#/-/\
MOE?\*/+C_P">:?\ ?*_X4?\ $;O$7_H;87_PU9;_ /,P?\0QX0_Z <1_X7XO
M_P"6G\W_ /PYI\??]%X^'G_A/>)O\*/^'-/C[_HO'P\_\)[Q-_A7]('EQ_\
M/-/^^5_PH\N/_GFG_?*_X4?\1N\1?^AMA?\ PU9;_P#,P?\ $,>$/^@'$?\
MA?B__EI_-_\ \.:?'W_1>/AY_P"$]XF_PH_X<T^/O^B\?#S_ ,)[Q-_A7]('
MEQ_\\T_[Y7_"CRX_^>:?]\K_ (4?\1N\1?\ H;87_P -66__ #,'_$,>$/\
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M_P -66__ #,'_$,>$/\ H!Q'_A?B_P#Y:?S?_P##FGQ]_P!%X^'G_A/>)O\
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M?_/-/^^5_P *XSH,[^VM+_Y_(_\ OF3_ .(H_MK2_P#G\C_[YD_^(K1\N/\
MYYI_WRO^%'EQ_P#/-/\ OE?\* ,[^VM+_P"?R/\ [YD_^(H_MK2_^?R/_OF3
M_P"(K1\N/_GFG_?*_P"%'EQ_\\T_[Y7_  H SO[:TO\ Y_(_^^9/_B*/[:TO
M_G\C_P"^9/\ XBM'RX_^>:?]\K_A1Y<?_/-/^^5_PH SO[:TO_G\C_[YD_\
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MT?+C_P">:?\ ?*_X4>7'_P \T_[Y7_"@#._MK2_^?R/_ +YD_P#B*/[:TO\
MY_(_^^9/_B*T?+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"@#._MK2_\ G\C_ .^9
M/_B*/[:TO_G\C_[YD_\ B*T?+C_YYI_WRO\ A1Y<?_/-/^^5_P * ,[^VM+_
M .?R/_OF3_XBC^VM+_Y_(_\ OF3_ .(K1\N/_GFG_?*_X4>7'_SS3_OE?\*
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MG_?*_P"%'EQ_\\T_[Y7_  H SO[:TO\ Y_(_^^9/_B*/[:TO_G\C_P"^9/\
MXBM'RX_^>:?]\K_A1Y<?_/-/^^5_PH SO[:TO_G\C_[YD_\ B*/[:TO_ )_(
M_P#OF3_XBM'RX_\ GFG_ 'RO^%'EQ_\ /-/^^5_PH SO[:TO_G\C_P"^9/\
MXBC^VM+_ .?R/_OF3_XBM'RX_P#GFG_?*_X4>7'_ ,\T_P"^5_PH SO[:TO_
M )_(_P#OF3_XBC^VM+_Y_(_^^9/_ (BM'RX_^>:?]\K_ (4>7'_SS3_OE?\
M"@#._MK2_P#G\C_[YD_^(H_MK2_^?R/_ +YD_P#B*T?+C_YYI_WRO^%'EQ_\
M\T_[Y7_"@#._MK2_^?R/_OF3_P"(H_MK2_\ G\C_ .^9/_B*T?+C_P">:?\
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M+_Y_(_\ OF3_ .(H_MK2_P#G\C_[YD_^(K1\N/\ YYI_WRO^%'EQ_P#/-/\
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M?]\K_A1Y<?\ SS3_ +Y7_"@#._MK2_\ G\C_ .^9/_B*/[:TO_G\C_[YD_\
MB*T?+C_YYI_WRO\ A1Y<?_/-/^^5_P * ,[^VM+_ .?R/_OF3_XBC^VM+_Y_
M(_\ OF3_ .(K1\N/_GFG_?*_X4>7'_SS3_OE?\* ,[^VM+_Y_(_^^9/_ (BC
M^VM+_P"?R/\ [YD_^(K1\N/_ )YI_P!\K_A1Y<?_ #S3_OE?\* ,[^VM+_Y_
M(_\ OF3_ .(H_MK2_P#G\C_[YD_^(K1\N/\ YYI_WRO^%'EQ_P#/-/\ OE?\
M* ,[^VM+_P"?R/\ [YD_^(H_MK2_^?R/_OF3_P"(K1\N/_GFG_?*_P"%'EQ_
M\\T_[Y7_  H SO[:TO\ Y_(_^^9/_B*/[:TO_G\C_P"^9/\ XBM'RX_^>:?]
M\K_A1Y<?_/-/^^5_PH SO[:TO_G\C_[YD_\ B*/[:TO_ )_(_P#OF3_XBM'R
MX_\ GFG_ 'RO^%'EQ_\ /-/^^5_PH SO[:TO_G\C_P"^9/\ XBC^VM+_ .?R
M/_OF3_XBM'RX_P#GFG_?*_X4>7'_ ,\T_P"^5_PH SO[:TO_ )_(_P#OF3_X
MBC^VM+_Y_(_^^9/_ (BM'RX_^>:?]\K_ (4>7'_SS3_OE?\ "@#._MK2_P#G
M\C_[YD_^(H_MK2_^?R/_ +YD_P#B*T?+C_YYI_WRO^%'EQ_\\T_[Y7_"@#._
MMK2_^?R/_OF3_P"(H_MK2_\ G\C_ .^9/_B*T?+C_P">:?\ ?*_X4>7'_P \
MT_[Y7_"@#._MK2_^?R/_ +YD_P#B*/[:TO\ Y_(_^^9/_B*T?+C_ .>:?]\K
M_A1Y<?\ SS3_ +Y7_"@#._MK2_\ G\C_ .^9/_B*/[:TO_G\C_[YD_\ B*T?
M+C_YYI_WRO\ A1Y<?_/-/^^5_P * ,[^VM+_ .?R/_OF3_XBC^VM+_Y_(_\
MOF3_ .(K1\N/_GFG_?*_X4>7'_SS3_OE?\* ,[^VM+_Y_(_^^9/_ (BC^VM+
M_P"?R/\ [YD_^(K1\N/_ )YI_P!\K_A1Y<?_ #S3_OE?\* ,[^VM+_Y_(_\
MOF3_ .(H_MK2_P#G\C_[YD_^(K1\N/\ YYI_WRO^%'EQ_P#/-/\ OE?\* ,[
M^VM+_P"?R/\ [YD_^(H_MK2_^?R/_OF3_P"(K1\N/_GFG_?*_P"%'EQ_\\T_
M[Y7_  H SO[:TO\ Y_(_^^9/_B*/[:TO_G\C_P"^9/\ XBM'RX_^>:?]\K_A
M1Y<?_/-/^^5_PH SO[:TO_G\C_[YD_\ B*/[:TO_ )_(_P#OF3_XBM'RX_\
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M]'\N/_GFG_?*_P"%'EQ_\\T_[Y7_  H \X_L^S_Z"]K_ -^I_P#XBC^S[/\
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M *"]K_WZG_\ B*/[/L_^@O:_]^I__B*]'\N/_GFG_?*_X4>7'_SS3_OE?\*
M/./[/L_^@O:_]^I__B*/[/L_^@O:_P#?J?\ ^(KT?RX_^>:?]\K_ (4>7'_S
MS3_OE?\ "@#SC^S[/_H+VO\ WZG_ /B*/[/L_P#H+VO_ 'ZG_P#B*]'\N/\
MYYI_WRO^%'EQ_P#/-/\ OE?\* /./[/L_P#H+VO_ 'ZG_P#B*/[/L_\ H+VO
M_?J?_P"(KT?RX_\ GFG_ 'RO^%'EQ_\ /-/^^5_PH \X_L^S_P"@O:_]^I__
M (BC^S[/_H+VO_?J?_XBO1_+C_YYI_WRO^%'EQ_\\T_[Y7_"@#SC^S[/_H+V
MO_?J?_XBC^S[/_H+VO\ WZG_ /B*]'\N/_GFG_?*_P"%'EQ_\\T_[Y7_  H
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M5_PH \X_L^S_ .@O:_\ ?J?_ .(H_L^S_P"@O:_]^I__ (BO1_+C_P">:?\
M?*_X4>7'_P \T_[Y7_"@#SC^S[/_ *"]K_WZG_\ B*/[/L_^@O:_]^I__B*]
M'\N/_GFG_?*_X4>7'_SS3_OE?\* /./[/L_^@O:_]^I__B*/[/L_^@O:_P#?
MJ?\ ^(KT?RX_^>:?]\K_ (4>7'_SS3_OE?\ "@#SC^S[/_H+VO\ WZG_ /B*
M/[/L_P#H+VO_ 'ZG_P#B*]'\N/\ YYI_WRO^%'EQ_P#/-/\ OE?\* /./[/L
M_P#H+VO_ 'ZG_P#B*/[/L_\ H+VO_?J?_P"(KT?RX_\ GFG_ 'RO^%'EQ_\
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M^^5_PH \X_L^S_Z"]K_WZG_^(H_L^S_Z"]K_ -^I_P#XBO1_+C_YYI_WRO\
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M^S_Z"]K_ -^I_P#XBC^S[/\ Z"]K_P!^I_\ XBO1_+C_ .>:?]\K_A1Y<?\
MSS3_ +Y7_"@#SC^S[/\ Z"]K_P!^I_\ XBC^S[/_ *"]K_WZG_\ B*]'\N/_
M )YI_P!\K_A1Y<?_ #S3_OE?\* /./[/L_\ H+VO_?J?_P"(H_L^S_Z"]K_W
MZG_^(KT?RX_^>:?]\K_A1Y<?_/-/^^5_PH \X_L^S_Z"]K_WZG_^(H_L^S_Z
M"]K_ -^I_P#XBO1_+C_YYI_WRO\ A1Y<?_/-/^^5_P * /./[/L_^@O:_P#?
MJ?\ ^(H_L^S_ .@O:_\ ?J?_ .(KT?RX_P#GFG_?*_X4>7'_ ,\T_P"^5_PH
M \X_L^S_ .@O:_\ ?J?_ .(H_L^S_P"@O:_]^I__ (BO1_+C_P">:?\ ?*_X
M4>7'_P \T_[Y7_"@#SC^S[/_ *"]K_WZG_\ B*/[/L_^@O:_]^I__B*]'\N/
M_GFG_?*_X4>7'_SS3_OE?\* /./[/L_^@O:_]^I__B*/[/L_^@O:_P#?J?\
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MI_\ XBO1_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"@#SC^S[/\ Z"]K_P!^I_\
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MP8U[X:TZ_P!5U22_76M&TQ['3(VFO)=)UO6=*L-&\0R11(TB6WA^_P!4NKA
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4KK3[V\TA]2UG1V>[TJ[COK">+4O#^HZ5JUK)!<1*Q-K?PB:(R6TXEMIIHG
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MAK.F6GB?5;N[N];O=&8:G:C4;NYTXBZ2' !['X?\1^'O%ND6?B'PKKVC>)M
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M/QW$<D,HT*#Q-K>K6VFS&*:>);Z&'^T8X;BXACO%AGE1_<_AM\)/A[\(=/\
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M _.OP5\)/ 7Q$_X*A_M/^(O&_AK1_%4G@/X<?"6;P[8:_I]KJNFV6JZ_X/\
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M=TEIXONF#VU@/!+OK4GB.5(5$;65E+I$VH71AC2(Q),[!$8FOV^\7?\ !/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXU?"/]J?]GOX,WG[3UA^UQ\4O%WQ5\$6ND>+_B!\/_%%[;7?P5URQNM1LO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKC6?AK0]1\(ZM<:#XXUS7]=6&&5O#>@ZI;;H5QI]Y?6,_P!I::U%E>;.@_8
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MFT]QI45O?65K<7NI:?X!\+_@Y\=]5_8^_;6\(Z=X/^,&G?#OQ=%"W[,_PO\
MBY)+/\4+#0]-^TW^MV9TF>XENM/BU."+1H-&T5% N;ZSNFLC?S7C7]_UWC72
M_C'\3?@E^R9\;_ /P)^*>E_$+]CGQGH6F>(O@]\1_#%QX/\ %?CK1-.\(^"K
M;Q5J_@>RN9)KS5]+FFT^WLM"O#8PW]XZ:U)!I4EWI*:??@'N,/[4?[4/P5^)
M/PN\,_M<?#+X46'@/XR^)K+P3X9\?_!O5_$MS:^$?&&K$+I&A>,+3Q/=7CW,
MEU(ZK->V)L+&.UAO]1LYM133KNVCP],_:I_;!^+/Q1^/_P +O@/\)?@Y.WP0
M^(NO>&KKQQ\1M:\4V/AZZTJUN9[3P_HJZ7H]XNHZAXOU0Z9JUU=7EM>66A6%
MLMD+R&T-S!)<</\ %+QA\1OV\O&'P%^'/@_]G_XT?"[X;^ _BSX9^+GQ2\>_
M&;P>W@>.S/@Z*^MX_#'AF.2_NAK-_=PZOJ%JYLYQ?1WTEA.]E!I5OJ-ZGT3^
MQIX,\7>%OB?^VSJ/B;PKXB\.V/BS]I37M<\+WVN:)J6DVOB70Y8I_(UC0;F_
MMK>+6-)D,@$6HZ>]Q9NS$),3D4 <7X7_ ."@\-M^R9XW^/OQ+\ MH_CWX<?$
M/6/@WKWPZT2^E,&L_%'39=,6WTK2+VZCO;C3["Y@U>WO+YKI=1GTN"SU18#J
M\EO;"\R)_P!K;]J+X-:M\.?$/[4'PS^#.F_"/XC^*-%\)W>K_"OQ5K.H^*OA
M5J?B.,C23X\M-9OKK3]3M8)TE&JWOA\BPM88+CR[N:^_L^PU/YHO?V4_BM\4
M?V4_VKO"$7@+7+3QE:_MW?$7XS>"/"7BS3]4\*K\1/#MI9^'+ ?V3=Z@^CO<
M:3XAT>]UU-$UFRNEL=1OK-;>SU"&0_:[;A;7X-_!SXDZY\/?!?P6_P"";7Q)
M\$>.;WQ'HA^)/B+X^VWQCT3X;> ?#T1+^(;BPU>R^*.BW.OZE VRXT/SQI;Z
ME:Q@Q:-=W5R+*W /K1OVQ?VJ/BK\2/C=X>_9S\"? "YT;X'^,/$?@Z]\'_$S
MQ/XCA^+WCJY\*7%U:ZA?^%]!TC4M+M["UU&>SGBTPZO:?9DG(M);^:\ANX+?
M]$/@QX]U[XG?"_P?XZ\4> ?$7PO\1>(--EGUKP%XKM;RSUWPWJ5I?7>G7=G<
MPW]CIEXUM-+9M>Z7<W.GV4M[I5U97C6L'VCRU_'GXYZ%X+\0^/\ XI6'[3O[
M"WQ>U;XD)XOUI_A=\:?V3O!'B)+;QIX9"Q0^$=8UG5[3Q=<6$_CH0PI<ZBVL
M6NN&SC\B"?1K&>R6"\_1C]A3P]\:?"_[,GP]T?X^3ZS+\0(%UB5K?Q+>R:CX
METSP]<:M=R^'-,U^]FN+F>74;72VA_<W$OVK3K1[32[N.&ZL9HD .5^+_P 9
M?VL+OXQ:Q\)OV</A%X(&F^$/#.E>(/$_Q:^.8\8Z7\/;^[U>-+B'0/"<WAS[
M"^KW=E:RQF_N[6^OX[:[2^L[VUT_["DU[XGI7[?/Q#E_9;_:3^*.L^"? <'Q
M<_9N\=P> ]<TK1=6U+7/ASXBN9O%&@:$NKZ5>V]\NH"R=-1U2.*"/5[PM)IU
MM?&[$5\VGVOB?[0&@:I<_M=?%&?]J+X$?M,_M"_!FYTGPN?V>_#GPCTSQ/X@
M^'EE<#1K0Z]#J>D>'O$'A^UCUN;4H;A+C^T+QKLW$%S>7NG76DW&B7=OX7H/
MPY^*=G^SK_P4%^$=M^S+\4OA_KOCCQ#X&^(?@#P-HW@_5O$.B0>&+CQOX6FL
M?"/A[6=(2^3Q%KVC:/(MQ?6FDQ7/DV^G:O+<_8YM-O;.V /O2+]N'XP^%/A!
MXQ_:5^+WP8T;P=\'=1T30'^!7ABWUR6?XG_$'7O$VH"+03KWEW-_IOA[2=7T
MD_VV$_LE[VQT])YX&UG;:I>,G_:V_:B^#6K?#GQ#^U!\,_@SIOPC^(_BC1?"
M=WJ_PK\5:SJ/BKX5:GXCC(TD^/+36;ZZT_4[6"=)1JM[X?(L+6&"X\N[FOO[
M/L-3[/\ ;)_9X\5_'+]C;PWX&\(:$FH^,? \7PY\9:3X*OI9=(_MZ?PMHYTS
M5?"DLS76G2Z?=7&C:GJL-NCW%K(+^""T$UG-(MU;_GW:_!OX.?$G7/A[X+^"
MW_!-KXD^"/'-[XCT0_$GQ%\?;;XQZ)\-O /AZ(E_$-Q8:O9?%'1;G7]2@;9<
M:'YXTM]2M8P8M&N[JY%E;@'] 6L:MIV@:1JNNZO=)8Z3HNG7VK:I>RAC'::=
MIMM+>7MU($5G*6]M#+*X168JAVJ3@'\J+']L_P#:V\>^ M=_:+^%GP7^#]Q\
M =(?Q#?Z5X7\7>,=;M/C7XP\*^%KJYM-6\0Z5'8S#PWIK?\ $MU.:/2;NQO-
M0=H#;Z7'KF+2XU+].?B%X2A\?> ?''@6XN6L[?QIX0\2^$I[M59VM8?$>BWN
MCRW*HKQL[0)>-*%62-F*X#J3N'\[_AGX&?#GX7_#R\^%WQ5_X)T_&?XC?M+:
M&VMZ+H7C#PO#\1]8^$7Q!OI;JZ?P[XGO/%'A[QUI=IIVCPQ7-C'KMMI%@5@M
MK?S6GTFXN;FUT@ ^^O&G[?OC3QQXR^"WP^_9ET;X3VFK_%SX3V?Q:B\4?M!>
M(-3T+PS96]YJVK:&_@FSM?#U[9WFJ^+-.U70M3L[Y-,O]0C:YMKB*TMIXK*^
MNH*'Q>^+O[7/C?\ 91_:=\->,_@=X4\!^-O ?A_Q9H7C_7=2N?%47PX\:_"7
M6/AUXWN/$'B_X-:G+"\FJ^)-+-E80PZ7>:CJFG0"]@?5+JUN[EM,LO*_'OPX
ME^'?A/X*?#W]H3]AS2OB=\#K'X53O+-^SMX<\<^*?B!\'_B?KWB74-?\1>&8
M];NOB5JGBA?!D<=X+FYNSKT5I>ZU=.]AJE[!8QZ8R_L[_"/XMW?PD_;G\.>"
M?!/QI\'_  &\=_"?Q!X;_9V^%_QQEFM_'"^)M0\!>(+#4H]+TC4+Z:31-*O=
M4NX;.T>1S;:C;7&C!]2U"[TO4;N@""P\>_$#PC^P%^SUJ'QB^%GP@\9>'9/&
M?[/N@?##3)+SQ1>K)X2OM'"Z/XJ\110W^FR6'C?3C )(HK"[ETG_ $B1);5U
MS&?HW4_VH?VKO''[07Q[^ /P%^%GPDU&;X07WAB0>/\ XB:SXHT_PYIVF:[X
M>CU&'3]>T[0YY-2U/7M9U"2X71#I4NG6D%CI&I&_C8E+F+YJ\2P?$_XG?L)_
M GX9VGP ^.WAOQI\&_BC\ ?"_B'1?$WPVURRN]7M/"UA<0:IXN\-VD$5UJ-]
MX1M L?V[6;NQL(+":3RKCY%$S_9_[-'@WQ?H'[6_[>WB77?"WB/1O#GC'Q%\
M#)_".OZKHFI:?HOBF'2/!WBBVU:;PYJEW;0V.MQ:9<W-O;ZA)ID]REE<3Q0W
M+1RNJD ^?_AW^V'^W!\<?!'C'6_A?\"O@QHNK?!J^\0>&_BG=>._$/BN>P\1
M>-O#1N;O5?"WPYT/1;NWOK2^M=+&G23/XCUVXLEO=2AMUOW1?,?VR+]LKXA^
M-OV6_@W\9O@Y\$]1\;?$?XU>(X?!6F>$HFU:\\*>#M;@UO7/#NM>(?&&O65A
M#)8^#M.U309@+V[?2HVAOK5[G4;6&"ZND;^P]X*\9>$O /[6=GXJ\)>)_#-Y
MXC_:O^/'B/P]:^(-!U71KG7O#VL:+X2BTG7=%@U&TMI=4T;5);:XCT[5+%9[
M&]DMYDMIY6BD"_ *^ /VA?"O["G['GAFX^'_ ,=[?P+H?Q(^(4O[2GPR^'VD
M^(?#OQ:O_!5]\3M?U'2;630@FF>)/[*O-)FU6YD@D6TL+C[?HM_=W5G#]CU.
MW /LS0?VH_VLO#'QPTC]G/XP^"_V>;KXC?$WX=>/_$/PHU#X;>(_%W]@6/B_
MPKX7UOQ#I6C?$.QUJZU#6[32;^31WM;R_LXK#,9DFTJ;4&CGBM_%OV#O'WQ?
M\!:E^V?XT^)FE?#?2_A/X5^.?QW\9?&+6-%U#7[OQ)HWQ&T2WM-4\0Z=X/L)
ME-MJG@Z&WM95T^6^$>M7,CQ("[L8Z\H\">%M%\(_M>?LK_%;X,?L5?';X3?!
M72M7\:^#M6UO7/!^O77C7Q#XC\<>$-1\+0>(?%&DZEKWB#5M%\'^'W\06%_'
MXCUO5([>^TQ?%-[8K<7&EW%F/<_A9\/_ !_J%Y^WW^RSXJ^%'Q3\--\?OB=\
M?_'?@7XP77A*[?X0G3?%UJL'AG[9XN2:.)KVYF2QOX].LH[M[B!KFRN6L[NV
MFAH WE_;1_:]NOAI)^TY8_ [X/M^SY';W'B/_A"YO&NLCXYM\/[.[<7/BTRA
MT\*I"NEP3ZK]C&F/>BSVW26TUFHN)>T^*W[<7CK5OB3\'_A3^S5IGPC75/BS
M\(M&^,VG>-?C[KVK>'O";Z%XBGO8=)\.:=8:'>66I7_B<BPF:ZMK.]O9(YA-
M:)9N=/U&>V_.S2?@W\.?#7PSLOAGKO\ P33^,GB7]JW2]/B\,)K,\7Q(N?@O
MXFU^T=-.7QSJ/C/0?B1I.G+HEX$_M358M&2QT5;N1[2SUW3].D%_9_7OQN\"
MQ>"+#X,?#[X[_L7V/QG^ NA_!?1=&&L_L_>%_&GB/Q_\*_B:DD1\1^']/U>?
MQ]+XKB^&\:1&?3[J]U.VN+V2XM7GU74;VRGL9@#[O_9I^*OQN\?Q>/O#?Q\^
M$#?#+QO\/-<L=+.N:(FKS?#?XB:?J<-Y/;Z[X U/5XFEN[6U%F8M2MH]1U5K
M+[3I[W5S;7=Y-IEC\A_\%(?%/B;P7\5/V'O$O@OPHWCGQ?I_Q9\6IX7\(K>K
MIPU_7[_3/#6FZ1ITM^\<B6=O+?7D!N;F15CAMUE>2:! T\=W_@G3X)^(/A;Q
M3\<[W3O"WQF^'G[,FIW'A9/@IX!^.[W,/C/3;VWLYSXENK#1KR\N;C1=%-P_
MEPG]Y%J5G)HZ_;]2OM+U"Y.M_P %"-,^+L/Q _9 ^('PB^%GBGXK:E\,OB9X
MF\5:OHOAS2;Z]@73;>P\/2SVFIZI;VT]GH+ZO8VNHV6E7NH,JOJ C2U@O;E4
MM)0#0MOVHOVH/@S\4OA=X2_:T^&?PHT[P)\:/$MKX*\)^/O@[J_B2[M?"WC#
M5#&FCZ!XOM_$]U<O<RW<\BQ2WMG'IMDEN+O4+.6_BTV]@78\:_'3]M'Q+\0/
MBCI/P,^#WPL\+?#GX3ZL^A77C7]HFY\:>'3\0+VS@:74;[P2-,GT>RCT-)8Y
M(;+6KN6\T>[MWM;XZI$;B:RL_$_BAXQ^(O[=?CW]G[X>>$OV?OC9\+OA[\-_
MC!X:^,'Q1\<_&?P8_@6*Q?P9#=P0^&/#T;ZA=C5]0O8-8U*S=;:X%[%>3:?=
MM8+IEM?7L/@>H^&-0N/C9\=D_:Q_97_:;_:;^(5Q\2->?X#IHUGXCU'X)1>
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M4=AIVF#6KGQCXK\8:D?$=QI&D6$VJ0V^I6ME:EH;8Z587\5^C@'E'QN_:O\
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MM;^&6L6NA1233>$9+G7_ +>T'B74+>VO;G3HIM5M;F=8K9(])FMKZ#4*^=?
MG[:W[9WQ#\!0_'WP1\%_@=\1_A2=5:.^^$WP[\4>+?$'[0VE:4=;?10;VVLG
MOM+_ +01]E^T$?AEKQM,SJ,FDVMDSW$'F?[-W@'Q=I_[1,OB7]C_ .$/QX^"
M7P1A^&/CM?&?A3]HNTU_2O 'B'XBW6A:O'X&L]&\/ZGXFO\ 5-1@MO$\OAZ?
M6;R#79;^WTVTU>VANM)@N5EO_#_B%X,TCQ;X;F3PY^PM^TC\#_VW(IUM[/Q+
M\#_#'B#PE\((_$L>K!9];T_68?%=WH5EX3N+:.::34-/L,+-*JQ>)9[)!K"
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M74+N[%K>6\$TYE_8_P"(OBZ;P#X"\8^-;?P[K?BZY\+>'-7UVU\+>&[.XO\
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M\'&^CETJ?S=8U0WR7-[;P1R7=A:V%Q?W>G7UJ #D?@9\8O&ND_MN?M2?$/\
M:+\':;\.?$GPK_9;@D\=:?X9U"?7=#OM,\)ZMX?UQ/$7A>:<"XFT_7M'F@N]
M,L)KBZNXI9!975PMZL]O;]AJW[2_[<GQ"^!7BWX[:1\ OA)%\!M<\&^*-2L_
M"5QXI\2#XTW/@*?3]0MW\6VMTC-X7ECM]+\S65LGT:/4-1LX"^G6$Z75F\O"
M^$_!'QE_:E_: _:]\0>+?@U\1/@EX7^,O[+-Y\/?AK>_$+PSJ6DB(I>Z)8Z
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MI>(FD71+:.;3YX]2N;:^M[AP9]@>(/VM/VW_ (;?%OPA\%/'OP,^"GB/QO\
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M.XUB_9=-U'4)DDD2VMC:)=P7EQ%HH!]1#_@HW)I7P2\7:YXF^%\EO^T1X/\
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MM1N8;6"WATO_ (F5W/HX!^R4DD<,<DTKK'%$CR22.0J1QHI9W=C@*JJ"S$\
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M!OPST*X\9>,?'.GRV=O?KJ.@:1:RV\<NGFTN[:9+N\O+."?SECMGFE61$M?
M3]J?X7_M#S>)](\)Q^*_#'C3P5);)XO^'/Q%\/3>$O'GAU+Q0;:XU#0YI[M&
MM9'/DO/9WEW';S^7'=& W-IYX!](45XM\<_CY\/?V=_#7A[Q=\2[J_L/#_B+
MQOH'@.'4K.WMY[?3-3\0Q:A/;ZCK,ES>6266AV5OIEW<:G?J\TEK"@=;:49V
M^(:/^W]^SYJOPR\9_&&XN?&F@?#WPGK^G^&=-UWQ#X2N]-?XAZSJUK/=Z;:?
M#G2Q//JOB%KM+:51]HLM,-N(YKF\6VL+:ZNX #[8HKXA\$?M\_"#QCJ^M^%K
MWP?\9_A]XYTWP=XA\=:+X ^)'PYNO#'C'Q]H/AO3;W5[W_A -+_M&]B\1ZE=
M6%A<SZ7I*7=MJ&H)%,T$!2UO'M_CC]B[XS:C\<?VI?C5X]\<>*OVF;8>&?&_
MQ+M_ OA?64NM"^ _@WX<Z?$]I;:!\0=)E:33]%^(>F6EW;3W.F3/;S6U_I\5
M]=W-Y<^<X /VEHK\]I?^"F/[.D5^UR-)^,$WPV37/^$>;XZ0_#/57^#(U/[:
MM@T0\5&Y6_:-;@D>:FALK(C21[T,9?O/BW^WE^S[\%_%UYX(\7ZIXAN=?7P?
MX;\9Z%;^&M&B\0)XSL?%=^;'1=/\'M8Z@9-7U6Y"O?%'BM=/73T-S_:+;HT<
M ^S:*\YM?B5I]U\)+?XP#P[XQCTJX^'47Q)'A)]#\SQ^FGR^&E\3CPZWAJVN
MI_,\8+;-_9IT.WO9M^L_Z!%=2964_G]^P_\ MF:Y\8O&GQY\*?$"W^),L6G?
M%KXEZQX)USQ)X$L?#OACP!\,]':RDTKP-XNURRBLXM'\6Z-;M<O>:7K@O-1C
M59#<ZK,R8 !^H]%?G3>_\%/?V=[:>]U"T\.?&W6_AMIFLMH>I_&S1?A=J-[\
M)-/OEG2VQ<>(6OH=49'EEC$*V^@SW%P)(FMX)5FB+_H!H&O:-XIT/2/$OAS4
M[+6M U_3++6=%UC3ITNK#5-*U*VCN["_L[B,F.:VNK::.:&120Z.IH UJ*_*
M#6OVX]=TG]O=OA8WA_XS2_"RR^'UYX0N_!MI\,+>YN;SXEVGQ-O]";XH:?,(
MSKUU\-'TB&.UA\46^HC1Y8HVF&E&;?*>,^%?[:UC\)_C#^V%X3\=P_'3XQ:Y
M9_'[Q;+X1\$> - UWXDZCX2\ Z([6EQ<VMK?:G::/X8\+65U(D*VT%]:Q*Z,
MT=GM3=0!^R5%?+6@?ME? #7_ (!7G[2:^+I-*^&>F37&GZO-K&G7-MK^EZ_;
M7$-JWA>YT*W%W=3>(9;BZM$MK*P:]CNXKNVO+:XEL)/M0Y#X7?MX?!WXF>/-
M!^&]YX<^+/PJ\4>,8)[KP'!\8? 4_@BR\>P01K,)/"E^^H:C;7WVB%B]DER]
ME)>,!!;))=2P03 'VI17&_$7QOI7PT\ >-_B+KJ32:-X$\)^(?%^J16VPW4]
MAX<TF[U>ZM[42,J-=7$5HT-LC, \\D:9&ZORS^"'P"^+G[:/@>V_:"_:'^/_
M ,:?!5I\17N=9^'GPI^#/C$^!O"O@[PO'=7-KH=]=P-9:M#JFI7D,,>I6%U)
M;K?&S:UN=6O]0N;N6TL0#]"/C9\!?#_QPO?A!>Z]K6L:.WP=^+OA/XP:.FD+
M9%=6UGPC)/+9:5J9O+>X*Z9<O,?M36OE76U0(IHR=P]VK\O_ (!^,?B[^SQ^
MU0W['?Q9^(6N?%WP/XZ\$WWCSX$?$#Q8_P!K\:6L6C&^EU3P?XCU0L\NJ/:Z
M=I.LS/=W4TCQ/IEA/90V=EK8TW3/M7X-_'OP/\<_AS=_%'P5%KL7AJRU/Q)I
M,R:WI]O8ZF;KPK<2VVIE+6WOKV)HFDB8VKFY#2K@ND1)  /:Z*^,+W]O'X#V
M'P,\ ?'N:3QE+X>^*6L:KX>^'WA*R\-_VA\1/%6N:-KNJ^'K[3=+\-V-_<0M
M,E_H]SMGFU2&SV3Z?&]S'>:A:6LMCX1?MO?"OXM^)_$O@4>%/BW\,_'OAGPA
M>>/+CP3\6_ K>#?$6I>%M/D6*\U32+==4U.TN4B>2$+!/>6MQ<)*TUK%/!::
MA+9@'V/17YPVW_!4']GK7H-&'@7PS\;/B-?ZMI3ZGJ&F^ /AN_B6_P#!Z,^H
MQ6]OXKBMM86&SO9_[/,R6NG3:JT=O<VLMR8%:<08/[ _[9-S\3/V>=1\2?'+
M5?%J:]\.M+\2>)/'?Q6\4>$K/P]X#U/0XO$6M?8UT'6]%M;/2M6O=$TF"TLM
M2L;+3(;U+F,0B.\N7W. ?IY17P-X4_X*.? /Q-XB\+Z1?:'\7O WAWQUJD.C
M>!/B=\0/AU>^&?ACXRO[IG2SCT3Q/-?3MY5VZHL=QJ.GZ?;Q>:CW4EO&)7CZ
M+XM?M]_ 3X,>.O&GPS\6MXUN_'G@UO"42>%_#?AI=;U?Q9<>,=$D\06%OX0M
M8-1C?4#8:<B'6;C4!I-E87%U96WVJ66\MUD /M>BOR&\*_M>67PG^/G[;'CO
MXJ:E\4;[X6:3J_[*]AH/A\B[UN'X9I\0OA]KE_<7,OAN]UI-/\+V5SJ4=G;>
M(VT4233:U-9))!>R,)D_0WXU_'[P%\!_"OASQ;XO_MG4[3QAXN\/>"/"NF^%
M+*WUG6?$'B+Q.MQ)I-II=I)?6,-RDT%I<7#2BZ"B&,&,2/)&C@'ME%<9\1[J
MYL?A[X\O;*XGM+RS\&>*+JTN[662"YM;FWT.^E@N+>>)DEAG@E1)8I8V62.1
M5=&5E!'Y#?L<_LQ^)?VA_P!FOX=_&3QA^U_^V?HWB?Q>GC!M0L_#?QUO[;0+
M1O#_ (Z\4>%[)[2VU32=5U!%>QT2TN+L3ZK*7NI+AXGMX7CAA /VLHK\N/V)
M?CKXHT>+]K?PC\9/BV?B+\.?V9O&JV>@_&WQ%=0W=QJ'AF5?$\^J6NL:W;^=
M)K-]H<>AV<T[>;J-XMWJSZ=:W%S;+ID"^G>%/^"CGP#\3>(O"^D7VA_%[P-X
M=\=:I#HW@3XG?$#X=7OAGX8^,K^Z9TLX]$\3S7T[>5=NJ+'<:CI^GV\7FH]U
M);QB5XP#[YHKX8^(7_!03X+_  ]^)?C3X.-X6^,'C7XG>"KW2+.?P9\._ #>
M*]8UY=5T,>()+WP[';ZK!%<V.D64MDFK2ZC+I<D-QJ%JMI#>0K=SVOJ/P6_:
MU^"_QR\(>-/&'AO6K_PY'\-#=?\ "R_#_CW3_P#A%O$_P^%G;7EY<2^*M-GG
MN(;*UC@T[4B;ZWO+NQ\W3=1MOM/VJPNX80#Z6HK\Z(_^"GW[.SSVNHS>'/C=
M9_#2]UA]#M?C?>_"W4H/A%/?+=26@">(#?'5RKS1-\A\/"YB7/VBWA:.98_6
M_C)^W!\ O@3XETWPOX\UO5EO-<^'=I\2_#EYH6F1Z[IWB;1]2UX^'M)TSP]+
M8WK7.JZ]JMT'N[&TMK1K)]*BGU.;48;6"9T /KRBOQL\2_\ !1J_?]ISX.V^
MB>"_V@],^$NJ_#_Q'=^*?AW<_"*RE\6>)]:NK.XO-!US1+&.:_U>_P!/T1&@
M.KS:/K,-M9O;74=U;W'DS _LG0 45\">-?\ @HY\"?"?B;Q=X>T;PS\9?B?9
M?#V]ET_X@^-/A;\.YO%'@;P3<6K2)?GQ!XBFU32XHK>P>"=;F[LH+ZU8V\_V
M::X$3$>B^-OVW?V>O OPR^&7QDU+Q5>:E\-/BMKL7A_P[XJT+2YM0MK&\-KJ
M-S=R:_9,]OJNFII3:5?V>JVB6%UJUCJ%O)92:;YZ.J@'UM17Q/\ "W]O/X0?
M%#XG:)\)6\*_%_X<>+/%EC>:CX'_ .%K> )O!VF^.;2RLY-1DF\-7+ZE?S31
MRV$%S=6LFHVNFQ78MW@MY)+N6VMY_;/VEM4U/0_V<?C_ *WHFHW^CZSH_P $
M_BKJFD:OI=W<:?J>EZGI_@37KNPU'3K^TDANK*_L;J&*YM+NVEBN+:XBCFAD
M21%8 'ME%?BY^S?^SIIWQ;^!?PR^)/C3]N?]KC0_%/C#PS;ZQK>DZ7^TE!I^
MGV%]+/<1/!:66JZ5J&HVT2K$A$=W>W,P+$F0@@#[8\7?'/X2_L7^ /AIX"\7
M^-?BG\6O$FMI=6'@BP;S?BA\9OB()+V6]DOII;5-,@U,0OJ,%A:7MU)I\4\2
MVEG9FYEAD"@'V717R7\&?VS_ (0_&J\\:>'],L?'?@;Q]X T:X\0^*/AA\3_
M  LWA#X@6.AVT:22:G'HSWU]:W=NOG6J2BVU*66T:^T\WT5K'?V;S>:^$/\
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MR7]SK/CGQ]XSUM_&.MPZ7H&BP7=Q=ZIJEU':6ZQ6Z3W,-C8VT444EQ;1F%6
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M/XITLK;6>J7MN\ERD=OK=M MWI-HMLMR!W\O\D_U/VAHK\(O$?[0OQQ\4?\
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M\>>*_AY8>"/C9\5=<\ +;_\ "P;KX1?#M_%VB>!9+B W*P^)=5N-7T>&U>.
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M*:YOO&, \0ZU>1Z/H4>D7]E;2V-]K5[_ &/I^GI;:>TC+:1 'Z8T5\*> /\
M@H3\$_&_COPI\/\ 5?#/Q@^%FH_$":*V^'6L?%OX?2^#O#7C^XN#$MI#X7U8
MZGJ N&OI)[:WL7O[?3X;N[N[.R@DDN[RU@F['XQ_MI?"KX.^.&^&7_"/_%#X
MJ?$2TTN'7-=\&?!KP/<^.M;\+:+<+!);ZIXD1+S3;33;>:WN([P0_:YKV.R>
M"ZFM(H;W3WNP#ZZHK\IOVJ_VH=#^*/[+OP]^*?P ^(/B/2K6_P#VB/AMX1UJ
MXT74-6\)>)]+E^W7HUSPCXFM;.YM=0LWDA>SFO-+N9)+._LI[*[C-W97%M/)
M['H/QB\#_#WXP?MT^+M8^(/Q9\4VOPGT;X7>(O&G@35;9+KPEX T^+P5J^H1
M1?"JVF\1203S>([2WDO_ !%&UCX?635(+;?)>$FX0 ^]J*_.6;_@J%^SE"FB
MZRWA_P"-3?#S5[G3;"3XNCX8WR_#'2-4OX[9I])U+Q!)J"7<FHZ3-/)::I!I
M&E:J([JSNTM'O(TAEF]]^./[6OPK^!.H^%_#>K6WC/Q_X\\:64FJ^%?AQ\)_
M#,WCCQOK6BQ+.7UNVTNVN;2TCTMFMYH[>YNM0M_MK0W+627,5C?R6H!].T5X
M!\ _VE?AC^T;IGB&Z\!7&N6&M>#M3CT?QIX)\8Z--X;\;>$=1F65K>WU[0;B
M29[9;DVUW';W,$]S:2W%E?VJS_:K&[AAZCXT?&SX=? 'P+>_$/XG:Y_8OA^U
MN;?3K5(+:?4-5UK6;U93I^A:'IEJKW.HZM?>1,8;>,+'%##<7EY/:V-K=74(
M!ZO17Q#X(_;Y^$'C'5];\+7O@_XS_#[QSIO@[Q#XZT7P!\2/AS=>&/&/C[0?
M#>FWNKWO_" :7_:-[%XCU*ZL+"YGTO24N[;4-02*9H("EK>/;_ /[.W[3]SX
MI^.?[0/QP^($O[9GBB/P)X[\;6/@/X9>%O#6IW_PYT/P!/JEEX9TSPQXE\#P
M2B&#XE:4NNV%[J&C>;;7-BVE2:M=7%]<0S9 /U!^*7[+WAGXP_&+X7_%?QEX
MT\?2Z?\ ".[T37_"OPRL-7M;3X?R^-_#^L:AJ^F>--6TYK&>[N]8B-[!9N8+
MRT$MIIEC;R.UJU[;7GTW7XG?\$^/C[IUQX$^*?[1_P ?/BA\?9]6T_2=2N_&
MVM_$*?4)?@#8:-<^+3;Z'9_"^RA@N([CQ+;SVD>ER:7H\2S176I7&CV&FR/-
M%O\ J_PE_P %)/@+XC\1>$]&UKPU\9?AKHOCV[M['P+\0OB;\.Y?#'P[\775
MXT:V::-XD35=0W07+2Q[;Z]L[+3X5=9+J[MXB'H _0*BOBCXM?M]_ 3X,>.O
M&GPS\6MXUN_'G@UO"42>%_#?AI=;U?Q9<>,=$D\06%OX0M8-1C?4#8:<B'6;
MC4!I-E87%U96WVJ66\MUD^:?AI^WCK?BW]M;Q%\/KKPU\;8OAEK_ (5\&:%X
M3\%ZC\+K2UU#PCXQU/7=*TR^\:>*I+;?K&E>"[D7<A.OW6J7VCI;RI<I;1KY
M3@ _6VBOSW\2_P#!2CX$^'];\3VECX.^.7C+PCX)URZ\.^,/BQX*^&<^M_"W
MPYJEA,L&I1ZCXE?5K.Y\K3V8O--:Z5<QW$ 6XTXWL$UM)-]S^$O%?A[QWX7\
M/^-/"6J6^M^&/%.CZ?KV@ZO:B58-0TK5+:.[LKI(YXX;B$R02H7M[F&&YMY-
M\%S#%/')&H!T-%%% !1110 4444 %%%% $-S;P7EO/:74,=Q:W4,MO<V\R!X
MIX)T:*:&5&!5XY8V9'1@0RL01@U^;B?\$YH]+\/:O\+_  E^TY\>O"7P#UNX
MU$W?P@T[4M$N;2TTK6;V:^U;PYI/B:^TZ;5+#0+^2[O([NP>"Z.H1W4[:Q+J
MEQ<7D]U^E-% ')^!/!'AGX:^#/#/@#P;IL>C^%O"&C6.@Z'IT;/)]GL-/@6&
M+SIY"TUU=3%6GO+R=WN;R[EFNKF22>:1VZRBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_+#_@I+I'QG\2R? OP#X/\ %_@W3? _Q6^,WPL\"CP]JOAN\U#7(_&MOK>N
M^)T\67NIQWL<$W@[2+31]';4=#CM#>7,\#NERJ3[5_4^L'6/"OACQ#>:%J.O
M^'-!US4/"^I?VSX9OM8T?3]3O/#NL>1):_VKH5S>V\\VD:E]FFEM_MVGO;W7
MD2R0^;Y;LI /R\_81T3X\ZS\>?VK?BAXR\=>!-:T>X^,%_\ "GXB1Z/X3OM.
MO?$WB[X/^&M.T#2-1\,W,VH2IHN@:9;:O]EFL;D7\US-#)LDA)<U]4?MZ?\
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M^%=[XV>[747\4W?@+PQ<:W)J22K,FJ27\VF//)JJ2HLD>J.S7Z,H*7 Q7LU
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MK:XC:*>WN()5>*>">)WBFAE1HY(V9'5E8@XWA;PGX6\#Z%8^%O!7AKP_X/\
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MYHFF:''K7B751"NJ>(=633+6U74M<U);:W%_JUX)K^\%O"+BXD$4>T _._\
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MP>AC_P"$8\&>&KG6H_$6KZCJ-U;Z;I=A/KE[J?VD&33H7BG34+QYC$D5E;Q
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MP%\?O%-]^TI\)OV+O!%MXZ^(5OJ7P"^&_@3P+'\5?&%\UA;1W>N:K>Z]<_\
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M4=$\)Z%INI6?@YM0;5G\*P:C:6,5\GAZ35GDU271A/\ V?+J4DE_);O=NTQ
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MFK&*Y %S;QZAI^GV]U;VMQ@&>UMY8K:9OGDB9B36A\0?@U\)/BPMB/B=\,_
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>inab-20260630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-08-06T12:14:14.6410+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://in8bio.com/20260630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2026" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2026" xmlns:inab="http://in8bio.com/20260630" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2026/ecd-sub-2026.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2026"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd" namespace="http://fasb.org/srt/2026"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" namespace="http://fasb.org/us-gaap/2026"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd" namespace="http://xbrl.sec.gov/ecd/2026"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" namespace="http://xbrl.sec.gov/dei/2026"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1" id="StatementCondensedBalanceSheets1">
        <link:definition>75010 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" id="StatementCondensedBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" id="StatementCondensedStatementsOfOperationsUnaudited">
        <link:definition>75030 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" id="StatementCondensedStatementsOfStockholdersEquityUnaudited">
        <link:definition>75040 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3" id="StatementCondensedStatementsOfCashFlowsUnaudited3">
        <link:definition>75050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperations" id="Role_DisclosureOrganizationAndNatureOfOperations">
        <link:definition>995455 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets1" id="DisclosurePrepaidExpensesAndOtherCurrentAssets1">
        <link:definition>995475 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNet1" id="DisclosurePropertyAndEquipmentNet1">
        <link:definition>995485 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgress" id="DisclosureConstructionInProgress">
        <link:definition>995495 - Disclosure - Construction in Progress</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995505 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>995515 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995525 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureWarrants1" id="DisclosureWarrants1">
        <link:definition>995535 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensation" id="DisclosureStockbasedCompensation">
        <link:definition>995545 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreements" id="DisclosureLicenseAgreements">
        <link:definition>995555 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995565 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995575 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingencies1" id="DisclosureCommitmentsAndContingencies1">
        <link:definition>995585 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeases1" id="DisclosureEquipmentAndFacilityLeases1">
        <link:definition>995595 - Disclosure - Equipment and Facility Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSegments" id="DisclosureSegments">
        <link:definition>995605 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEvent" id="DisclosureSubsequentEvent">
        <link:definition>995615 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995625 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995635 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>995645 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995655 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressTables" id="DisclosureConstructionInProgressTables">
        <link:definition>995665 - Disclosure - Construction in Progress (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995675 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>995685 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>995695 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995705 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesTables" id="DisclosureEquipmentAndFacilityLeasesTables">
        <link:definition>995715 - Disclosure - Equipment and Facility Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsTables" id="DisclosureSegmentsTables">
        <link:definition>995725 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" id="Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails">
        <link:definition>995735 - Disclosure - Organization and Nature of Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>995745 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>995755 - Disclosure - Prepaid Expenses And Other Current Assets - Schedule of Prepaid expenses and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails">
        <link:definition>995765 - Disclosure - Property And Equipment, Net - Schedule of Components of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>995775 - Disclosure - Property And Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails" id="DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails">
        <link:definition>995785 - Disclosure - Construction in Progress - Schedule of Construction In Progress (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995795 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtSummaryOfLoanPayableDetails" id="Role_DisclosureDebtSummaryOfLoanPayableDetails">
        <link:definition>995815 - Disclosure - Debt - Summary of Loan Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>995825 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" id="DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>995845 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails" id="DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails">
        <link:definition>995855 - Disclosure - Stock-based Compensation - Schedule of Stock Option Award Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails" id="DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails">
        <link:definition>995865 - Disclosure - Stock-based Compensation - Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" id="DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails">
        <link:definition>995875 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetailsDefault" id="DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetailsDefault">
        <link:definition>995875 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) [Default]</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" id="DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>995885 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995895 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>995905 - Disclosure - NET LOSS PER SHARE (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>995915 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>995925 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995935 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails" id="DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails">
        <link:definition>995945 - Disclosure - Equipment and Facility Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails" id="DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails">
        <link:definition>995955 - Disclosure - Equipment and Facility Leases - Schedule of Lease Costs and Other Information to Company's Finance and Operating Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails" id="DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails">
        <link:definition>995965 - Disclosure - Equipment and Facility Leases - Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2" id="DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2">
        <link:definition>995975 - Disclosure - Equipment and Facility Leases - Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Finance Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails" id="DisclosureSegmentsAdditionalInformationDetails">
        <link:definition>995985 - Disclosure - SEGMENTS (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails" id="DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails">
        <link:definition>995995 - Disclosure - Segments - Schedule of financial data for the company's reportable segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>996005 - Disclosure - Subsequent Event - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1" xlink:href="inab-20260630.xsd#StatementCondensedBalanceSheets1" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2" xlink:href="inab-20260630.xsd#DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" xlink:href="inab-20260630.xsd#StatementCondensedStatementsOfOperationsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3" xlink:href="inab-20260630.xsd#StatementCondensedStatementsOfCashFlowsUnaudited3" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="inab-20260630.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails" xlink:href="inab-20260630.xsd#DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails" xlink:href="inab-20260630.xsd#DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="inab-20260630.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails" xlink:href="inab-20260630.xsd#DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails" xlink:href="inab-20260630.xsd#DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" xlink:href="inab-20260630.xsd#StatementCondensedStatementsOfStockholdersEquityUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" xlink:href="inab-20260630.xsd#Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="inab-20260630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:href="inab-20260630.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="inab-20260630.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:href="inab-20260630.xsd#DisclosureWarrantsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="inab-20260630.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails" xlink:href="inab-20260630.xsd#DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" xlink:href="inab-20260630.xsd#DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetailsDefault" xlink:href="inab-20260630.xsd#DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetailsDefault" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="inab-20260630.xsd#DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="inab-20260630.xsd#DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails" xlink:href="inab-20260630.xsd#DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails" xlink:href="inab-20260630.xsd#DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="inab-20260630.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="inab-20260630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" xlink:href="inab-20260630.xsd#StatementCondensedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperations" xlink:href="inab-20260630.xsd#Role_DisclosureOrganizationAndNatureOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="inab-20260630.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets1" xlink:href="inab-20260630.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets1" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNet1" xlink:href="inab-20260630.xsd#DisclosurePropertyAndEquipmentNet1" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgress" xlink:href="inab-20260630.xsd#DisclosureConstructionInProgress" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="inab-20260630.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebt" xlink:href="inab-20260630.xsd#Role_DisclosureDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquity" xlink:href="inab-20260630.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureWarrants1" xlink:href="inab-20260630.xsd#DisclosureWarrants1" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensation" xlink:href="inab-20260630.xsd#DisclosureStockbasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreements" xlink:href="inab-20260630.xsd#DisclosureLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="inab-20260630.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShare" xlink:href="inab-20260630.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:href="inab-20260630.xsd#DisclosureCommitmentsAndContingencies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeases1" xlink:href="inab-20260630.xsd#DisclosureEquipmentAndFacilityLeases1" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSegments" xlink:href="inab-20260630.xsd#DisclosureSegments" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEvent" xlink:href="inab-20260630.xsd#DisclosureSubsequentEvent" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="inab-20260630.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="inab-20260630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="inab-20260630.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="inab-20260630.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressTables" xlink:href="inab-20260630.xsd#DisclosureConstructionInProgressTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="inab-20260630.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtTables" xlink:href="inab-20260630.xsd#Role_DisclosureDebtTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="inab-20260630.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="inab-20260630.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesTables" xlink:href="inab-20260630.xsd#DisclosureEquipmentAndFacilityLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsTables" xlink:href="inab-20260630.xsd#DisclosureSegmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="inab-20260630.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtSummaryOfLoanPayableDetails" xlink:href="inab-20260630.xsd#Role_DisclosureDebtSummaryOfLoanPayableDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails" xlink:href="inab-20260630.xsd#DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="inab-20260630.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:href="inab-20260630.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="inab-20260630.xsd#DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="inab-20260630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails" xlink:href="inab-20260630.xsd#DisclosureSegmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedCompensation" xlink:label="inab_AccruedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities" xlink:label="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LaboratoryMember" xlink:label="inab_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_INB-100Member" xlink:label="inab_INB-100Member"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock" xlink:label="inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases" xlink:label="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Rule10B51Arrmodifiedflag" xlink:label="inab_Rule10B51Arrmodifiedflag"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_BirminghamAlabamaMember" xlink:label="inab_BirminghamAlabamaMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_MaturityOfIncreaseOrDecreasePercentage" xlink:label="inab_MaturityOfIncreaseOrDecreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_CashPaidForAmountsIncludedInFinanceLeases" xlink:label="inab_CashPaidForAmountsIncludedInFinanceLeases"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ConstructionInProgressTextBlock" xlink:label="inab_ConstructionInProgressTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_YearOfMaturity" xlink:label="inab_YearOfMaturity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_NewYorkOperatingLeaseMember" xlink:label="inab_NewYorkOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ScheduleOfConstructionInProgressTableTextBlock" xlink:label="inab_ScheduleOfConstructionInProgressTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrivatePlacementTwoThousandTwentyFourMember" xlink:label="inab_PrivatePlacementTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_NumberOfReportableSegmentsNotDisclosedFlag" xlink:label="inab_NumberOfReportableSegmentsNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AffiliatesPercentageOfWarrants" xlink:label="inab_AffiliatesPercentageOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_WarrantsModificationDescription" xlink:label="inab_WarrantsModificationDescription"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_BorrowingInterestRate" xlink:label="inab_BorrowingInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="inab_UnauditedInterimFinancialInformationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ExchangedPre-FundedWarrantsMember" xlink:label="inab_ExchangedPre-FundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OrganizationAndNatureOfOperationsTextBlock" xlink:label="inab_OrganizationAndNatureOfOperationsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_UABRFMember" xlink:label="inab_UABRFMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrivatePlacementTwoThousandTwentyThreeMember" xlink:label="inab_PrivatePlacementTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OrganizationAndNatureOfOperationsTable" xlink:label="inab_OrganizationAndNatureOfOperationsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Pre-FundedWarrantsShares" xlink:label="inab_Pre-FundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PreFundedWarrantMember" xlink:label="inab_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract" xlink:label="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PercentageOfReductionInCashCompensation" xlink:label="inab_PercentageOfReductionInCashCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SecMember" xlink:label="inab_SecMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_EquityIncentivePlanMember" xlink:label="inab_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AntidilutionProvisionMember" xlink:label="inab_AntidilutionProvisionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LoansPayableAbstract" xlink:label="us-gaap_LoansPayableAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="us-gaap_LongTermDebtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ReclassificationOfPriorPresentationsPolicyTextBlock" xlink:label="inab_ReclassificationOfPriorPresentationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LicenseAgreementsAbstract" xlink:label="inab_LicenseAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_INB-400Member" xlink:label="inab_INB-400Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PipelinePrioritizationAndWorkforceReductionMember" xlink:label="inab_PipelinePrioritizationAndWorkforceReductionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="us-gaap_InternalUseSoftwarePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_JanuaryOneTwoThousandTwentyThreeMember" xlink:label="inab_JanuaryOneTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrivatePlacementTwoThousandTwentyFiveMember" xlink:label="inab_PrivatePlacementTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_JanuaryOneTwoThousandTwentyFourMember" xlink:label="inab_JanuaryOneTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesABWarrantsMember" xlink:label="inab_SeriesABWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="inab_TwoThousandTwentyFivePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NotesAndLoansPayable" xlink:label="us-gaap_NotesAndLoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration" xlink:label="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ExclusiveLicenseAgreementMember" xlink:label="inab_ExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LeaseExpirationMonthAndYear" xlink:label="inab_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseOrDecreasePercentageOfWarrants" xlink:label="inab_IncreaseOrDecreasePercentageOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleLeasebackTransactionDescriptionOfAssetS" xlink:label="us-gaap_SaleLeasebackTransactionDescriptionOfAssetS"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrepaymentPenalties" xlink:label="inab_PrepaymentPenalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockOptionsToPurchaseCommonStockMember" xlink:label="inab_StockOptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities" xlink:label="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesAWarrantsMember" xlink:label="inab_SeriesAWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OrganizationAndNatureOfOperationsLineItems" xlink:label="inab_OrganizationAndNatureOfOperationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AmortizationOfFinanceRightOfUseAssets" xlink:label="inab_AmortizationOfFinanceRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="inab_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PreFundedWarrantsMember" xlink:label="inab_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_MilestonePayment" xlink:label="inab_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesCWarrantMember" xlink:label="inab_SeriesCWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_CommonStockPurchaseAgreementMember" xlink:label="inab_CommonStockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedClinicalTrials" xlink:label="inab_AccruedClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:label="us-gaap_StatementOfIncomeLocationBalanceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedResearchAndDevelopment" xlink:label="inab_AccruedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyFourPre-FundedWarrantsMember" xlink:label="inab_TwoThousandTwentyFourPre-FundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SoftwareInternallyDevelopedAndPurchasedMember" xlink:label="us-gaap_SoftwareInternallyDevelopedAndPurchasedMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TerminationFee" xlink:label="inab_TerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesBWarrantsMember" xlink:label="inab_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Pre-FundedWarrantsTwoMember" xlink:label="inab_Pre-FundedWarrantsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_EmoryLicenseAgreementMember" xlink:label="inab_EmoryLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesAWarrantMember" xlink:label="inab_SeriesAWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SegmentResearchAndDevelopmentExpenses" xlink:label="inab_SegmentResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentySixEquityIncentivePlanMember" xlink:label="inab_TwoThousandTwentySixEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Stock-BasedCompensationExpense" xlink:label="inab_Stock-BasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="inab_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_MonthlyPayments" xlink:label="inab_MonthlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LeaseOfLesseeDisclosureTextBlock" xlink:label="inab_LeaseOfLesseeDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PercentageOfEmployeesTerminated" xlink:label="inab_PercentageOfEmployeesTerminated"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised" xlink:label="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_RoyaltyTerm" xlink:label="inab_RoyaltyTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_RoyaltiesOnCumulativeNetSales" xlink:label="inab_RoyaltiesOnCumulativeNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_INB-200Member" xlink:label="inab_INB-200Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OneTimeTerminationFeeDescription" xlink:label="inab_OneTimeTerminationFeeDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_NetProceeds" xlink:label="inab_NetProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PublicFloat" xlink:label="inab_PublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PaycheckProtectionProgramMember" xlink:label="inab_PaycheckProtectionProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AtmMember" xlink:label="inab_AtmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_CashPaidForAmountsIncludedInOperatingLeases" xlink:label="inab_CashPaidForAmountsIncludedInOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Pre-FundedWarrantsOneMember" xlink:label="inab_Pre-FundedWarrantsOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyThreePre-FundedWarrantsMember" xlink:label="inab_TwoThousandTwentyThreePre-FundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LicenseAgreementDescription" xlink:label="inab_LicenseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesBWarrantMember" xlink:label="inab_SeriesBWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesCWarrantsMember" xlink:label="inab_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Nonrule10B51Arrmodifiedflag" xlink:label="inab_Nonrule10B51Arrmodifiedflag"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PurchaseOfAggregateShare" xlink:label="inab_PurchaseOfAggregateShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_JanuaryOneTwoThousandTwentyTwoMember" xlink:label="inab_JanuaryOneTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrepaidResearchAndDevelopment" xlink:label="inab_PrepaidResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_CommonStockAvailableForSaleAmount" xlink:label="inab_CommonStockAvailableForSaleAmount"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding" xlink:label="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AdditionalPurchaseCommonStockShares" xlink:label="inab_AdditionalPurchaseCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Short Term Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DEBT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment arrangement, unrecognized stock based compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful lives of Leasehold Improvement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property Plant And Equipment Estimated Useful Lives 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares used in computing net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of shares used in computing net loss per share - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_INB-100Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INB-100</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_INB-100Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">INB-100 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_INB-100Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">INB-100 Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses and Current Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount held for equipment purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Leaseback Transaction, Amount Held for Equipment Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale leaseback transaction, amount held for equipment purchases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Rule10B51Arrmodifiedflag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule10B51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Rule10B51Arrmodifiedflag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule10B51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Rule10B51Arrmodifiedflag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_BirminghamAlabamaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Birmingham, Alabama [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_BirminghamAlabamaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Birmingham Alabama [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_BirminghamAlabamaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Birmingham, Alabama</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended and Restated Equity Incentive Plan Two Thousand Twenty Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and Restated Equity Incentive Plan Two Thousand Twenty Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2026 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Share-Based Payment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate of common stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_MaturityOfIncreaseOrDecreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity of increase or decrease percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_MaturityOfIncreaseOrDecreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity of Increase or Decrease Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_MaturityOfIncreaseOrDecreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturity of Increase or Decrease Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Series A Warrants Exercised Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Value Series A Warrants Exercised Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of Series A warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CashPaidForAmountsIncludedInFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Paid For Amounts Included in Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CashPaidForAmountsIncludedInFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CashPaidForAmountsIncludedInFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liability &#8211; finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ConstructionInProgressTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Construction in Progress [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ConstructionInProgressTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ConstructionInProgressTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_YearOfMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Year of Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_YearOfMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Year of Maturity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_YearOfMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Year Of Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived, Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_NewYorkOperatingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New York Operating Lease Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_NewYorkOperatingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New York Operating Lease Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_NewYorkOperatingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New York [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, Date of first required payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Date of First Required Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ScheduleOfConstructionInProgressTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of construction in progress [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ScheduleOfConstructionInProgressTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of construction in progress [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ScheduleOfConstructionInProgressTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrivatePlacementTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Two Thousand Twenty Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrivatePlacementTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Two Thousand Twenty Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrivatePlacementTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, Payment terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Payment Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due After Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Costs and Other Information to Company's Finance and Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on finance lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options granted, weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets - finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right of use assets - financing leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_NumberOfReportableSegmentsNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Reportable Segments not Disclosed Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_NumberOfReportableSegmentsNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments not Disclosed [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_NumberOfReportableSegmentsNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Reportable Segments not Disclosed [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AffiliatesPercentageOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliates Percentage of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AffiliatesPercentageOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Affiliates Percentage of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AffiliatesPercentageOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliates percentage of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Financing Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating and Finance Lease Liability Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Operating and Finance Lease Liability Maturity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_WarrantsModificationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Modification Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_WarrantsModificationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Modification Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_WarrantsModificationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Modification Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_BorrowingInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowing Interest Rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_BorrowingInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowing Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_BorrowingInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, aggregate intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from private placement common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unaudited interim financial information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Interim Financial Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unaudited Interim Financial Information [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Productive Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments for (Proceeds from) Productive Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ExchangedPre-FundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchanged Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ExchangedPre-FundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchanged pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ExchangedPre-FundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchanged Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OrganizationAndNatureOfOperationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OrganizationAndNatureOfOperationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and Nature of Operations [Text Block].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OrganizationAndNatureOfOperationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, weighted average remaining contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of fnancial data for the company's reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_UABRFMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">UABRF</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_UABRFMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U A B R F [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_UABRFMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UABRF [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrivatePlacementTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrivatePlacementTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrivatePlacementTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OrganizationAndNatureOfOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and nature of operations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OrganizationAndNatureOfOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Operations [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OrganizationAndNatureOfOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Nature Of Operations [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Pre-FundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Pre-FundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Severance and related charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Utilities, Property, Plant and Equipment, Plant in Service [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of Series C warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PercentageOfReductionInCashCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Reduction in Cash Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PercentageOfReductionInCashCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of reduction in cash compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PercentageOfReductionInCashCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reduction in cash compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Real Estate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and Restated Equity Incentive Plan Two Thousand Twenty three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended and Restated Equity Incentive Plan Two Thousand Twenty three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2023 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax benefit from stock based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value $0.0001 per share; 490,000,000 shares authorized at June 30, 2026 and December 31, 2025; 9,853,121 and 9,766,132 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SecMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SecMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SEC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during period shares new issues, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AntidilutionProvisionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilution Provision [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AntidilutionProvisionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilution Provision [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan maturity, date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity amount ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity amount beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, Series A, (Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Non-Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ReclassificationOfPriorPresentationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification of Prior Presentations [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ReclassificationOfPriorPresentationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of Prior Presentations [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ReclassificationOfPriorPresentationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of Prior Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">StockIssued During Period Value Series A and B Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">StockIssued During Period Value Series A and B Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of Series A&amp;B warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">New operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Asset, Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares of outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Offering related cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of issuance costs from December 2025 issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_INB-400Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INB-400</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_INB-400Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">INB - 400 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_INB-400Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">INB - 400 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PipelinePrioritizationAndWorkforceReductionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pipeline Prioritization and Workforce Reduction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PipelinePrioritizationAndWorkforceReductionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pipeline Prioritization and Workforce Reduction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PipelinePrioritizationAndWorkforceReductionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pipeline Prioritization and Workforce Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalUseSoftwarePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalUseSoftwarePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software, Internal-Use [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived, Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_JanuaryOneTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January One Two Thousand Twenty Three Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_JanuaryOneTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January One Two Thousand Twenty Three Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based Award [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds From warrant exchanges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exerciseable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrivatePlacementTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrivatePlacementTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrivatePlacementTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate, Type of Property [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Real Estate, Type of Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_JanuaryOneTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January One Two Thousand Twenty Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_JanuaryOneTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January One Two Thousand Twenty Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesABWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A &amp; B Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesABWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A &amp; B Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesABWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A &amp; B Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyFivePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyFivePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Five Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyFivePreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Five Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon closing of IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares used in computing net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of shares used in computing net loss per share - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes and Loans Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes and Loans Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Reserved of Issuance Under the Plan Increase Duration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved Of Issuance Under Plan Increase Duration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved of issuance under the plan increase duration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, aggregate intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value conversion of share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Conversion Of Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity conversion of convertible preferred stock to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, weighted average exercise price, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, weighted average exercise price, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_IncreaseOrDecreasePercentageOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase or Decrease percentage of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_IncreaseOrDecreasePercentageOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase or Decrease percentage of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_IncreaseOrDecreasePercentageOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase or decrease percentage of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleLeasebackTransactionDescriptionOfAssetS_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Leaseback Transaction, Description of Asset(s)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleLeasebackTransactionDescriptionOfAssetS_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leaseback transaction, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, shares issued in period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate &#8211; operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Segment net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of property plant and equipment estimated useful lives.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Property Plant and Equipment Estimated Useful Lives [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Modification of Operating Lease Right-of-use Assets And Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Modification of Operating Lease Right-of-use Assets And Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease modification of operating lease right-of-use assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Asset, Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loans Payable, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrepaymentPenalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment penalties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrepaymentPenalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrepaymentPenalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits and Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits And Share Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised, weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficeBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Building [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficeBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Building</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options to purchase common stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options to Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term finance lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Long Term Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares authorised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Series A Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period, Shares, Series A Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of Series A warrants, net of issuance costs , Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities excluded from calculation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesAWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesAWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesAWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OrganizationAndNatureOfOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Detail information of organization and nature of operations by type.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OrganizationAndNatureOfOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Operations [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OrganizationAndNatureOfOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Nature Of Operations [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, number of shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre funded warrants issued for purchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity shares ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity shares beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, Series A, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from the issuance of common stock, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AmortizationOfFinanceRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization Of finance right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AmortizationOfFinanceRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of finance right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited, weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Options forfeited, weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel-related indirect research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 Equity Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Losses from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesCWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesCWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesCWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CommonStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock purchase agreement,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CommonStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CommonStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeLocationBalanceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Location, Statement of Income, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares conversion of share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Conversion Of Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity conversion of convertible preferred stock to common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyFourPre-FundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyFourPre-FundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyFourPre-FundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Four Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeeem warrant exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant, Exercise Price, Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareInternallyDevelopedAndPurchasedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareInternallyDevelopedAndPurchasedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software, Internally Developed and Purchased [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Pre-FundedWarrantsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Pre-FundedWarrantsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Pre-FundedWarrantsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_EmoryLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emory License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_EmoryLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emory License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_EmoryLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emory License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesAWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesAWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesAWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested or expected to vest, aggregate intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auction Market Preferred Securities, Stock Series [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auction Market Preferred Securities, Stock Series</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Cost, Software to be Sold, Leased, or Marketed, before Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal use software not yet in service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SegmentResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SegmentResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Segment Rresearch and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SegmentResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Award Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds From warrant exchanges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received Per Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentySixEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentySixEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Six Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentySixEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Six Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Stock-BasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Stock-BasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Stock-BasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auction Market Preferred Securities, Stock Series, Title [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auction Market Preferred Securities, Stock Series, Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Non-Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Share-Based Payments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during period shares new issues, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Loan Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_MonthlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monthly Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_MonthlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monthly payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_MonthlyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement Threshold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollateralAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collateral Held [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollateralAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collateral Held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LeaseOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Of Lessee DisclosureText Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LeaseOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Of Lessee DisclosureText Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LeaseOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment and Facility Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PercentageOfEmployeesTerminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Employees Terminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PercentageOfEmployeesTerminated_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Of Employees Terminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PercentageOfEmployeesTerminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of workforce reduction due to restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issue During Period Value Series C Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issue During Period Value Series C Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of Series C warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_RoyaltyTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_RoyaltyTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_RoyaltyTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term finance lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate net proceeds from offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Series C Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Shares Series C Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of Series C warrants, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_RoyaltiesOnCumulativeNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties On Cumulative Net Sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_RoyaltiesOnCumulativeNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties On Cumulative Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_RoyaltiesOnCumulativeNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties on cumulative net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollateralDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collateral Held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollateralDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collateral Held [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_INB-200Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INB-200</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_INB-200Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">INB-200 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_INB-200Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">INB-200 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate &#8211; finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Standards Updates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to Purchase Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OneTimeTerminationFeeDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One time termination fee description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OneTimeTerminationFeeDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One TimeTermination Fee Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_OneTimeTerminationFeeDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One TimeTermination Fee Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price per unit of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period over which cost not yet recognized is expected to be recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_NetProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_NetProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_NetProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares of common stock issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 Employee Stock Purchase Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use assets - operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development, Contract to Perform for Others [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and restricted cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PaycheckProtectionProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paycheck Protection Program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PaycheckProtectionProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paycheck Protection Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PaycheckProtectionProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paycheck Protection Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AtmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Atm [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AtmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ATM [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AtmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Leases:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from the issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Purchase of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CashPaidForAmountsIncludedInOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Paid For Amounts Included in Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CashPaidForAmountsIncludedInOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CashPaidForAmountsIncludedInOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liability &#8211; operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Pre-FundedWarrantsOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Pre-FundedWarrantsOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Pre-FundedWarrantsOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyThreePre-FundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyThreePre-FundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_TwoThousandTwentyThreePre-FundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon closing of IPO, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of preferred stock - Series A into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_LicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, weighted average remaining contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested or expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">StockIssued During Period Shares Series A And B Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">StockIssued During Period Shares Series A and B Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of Series A&amp;B warrants, net of issuance costs , Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term &#8211; finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease Right Of Use Asset Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization of finance right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of finance lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesBWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesBWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesBWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested or expected to vest, weighted average remaining contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesCWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesCWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_SeriesCWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash financing and investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Nonrule10B51Arrmodifiedflag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NonRule10b51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Nonrule10B51Arrmodifiedflag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NonRule10b51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_Nonrule10B51Arrmodifiedflag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PurchaseOfAggregateShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of Aggregate Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PurchaseOfAggregateShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of Aggregate Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PurchaseOfAggregateShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of Aggregate Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term &#8211; operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_JanuaryOneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January One Two Thousand Twenty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_JanuaryOneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January One Two Thousand Twenty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_JanuaryOneTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 1, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrepaidResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrepaidResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PrepaidResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Current Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful lives of Leasehold Improvement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units, Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital units, authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CommonStockAvailableForSaleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Available For Sale , Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CommonStockAvailableForSaleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Available For Sale , Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_CommonStockAvailableForSaleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Available For Sale , Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of Total Number of Shares of Common Stock Outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Total Number Of Shares Of Common Stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares of common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested or expected to vest, weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AdditionalPurchaseCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional purchase common stock shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inab_AdditionalPurchaseCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional purchase common stock shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other assets current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on financing leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AccruedCompensation" xlink:to="inab_AccruedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities" xlink:to="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_LaboratoryMember" xlink:to="inab_LaboratoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:to="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_INB-100Member" xlink:to="inab_INB-100Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock" xlink:to="inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases" xlink:to="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_Rule10B51Arrmodifiedflag" xlink:to="inab_Rule10B51Arrmodifiedflag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_BirminghamAlabamaMember" xlink:to="inab_BirminghamAlabamaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember" xlink:to="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_MaturityOfIncreaseOrDecreasePercentage" xlink:to="inab_MaturityOfIncreaseOrDecreasePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue" xlink:to="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_CashPaidForAmountsIncludedInFinanceLeases" xlink:to="inab_CashPaidForAmountsIncludedInFinanceLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_ConstructionInProgressTextBlock" xlink:to="inab_ConstructionInProgressTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_YearOfMaturity" xlink:to="inab_YearOfMaturity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_NewYorkOperatingLeaseMember" xlink:to="inab_NewYorkOperatingLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_ScheduleOfConstructionInProgressTableTextBlock" xlink:to="inab_ScheduleOfConstructionInProgressTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PrivatePlacementTwoThousandTwentyFourMember" xlink:to="inab_PrivatePlacementTwoThousandTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_NumberOfReportableSegmentsNotDisclosedFlag" xlink:to="inab_NumberOfReportableSegmentsNotDisclosedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AffiliatesPercentageOfWarrants" xlink:to="inab_AffiliatesPercentageOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_WarrantsModificationDescription" xlink:to="inab_WarrantsModificationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_BorrowingInterestRate" xlink:to="inab_BorrowingInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="inab_UnauditedInterimFinancialInformationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_ExchangedPre-FundedWarrantsMember" xlink:to="inab_ExchangedPre-FundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_OrganizationAndNatureOfOperationsTextBlock" xlink:to="inab_OrganizationAndNatureOfOperationsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_UABRFMember" xlink:to="inab_UABRFMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PrivatePlacementTwoThousandTwentyThreeMember" xlink:to="inab_PrivatePlacementTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="inab_OrganizationAndNatureOfOperationsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_Pre-FundedWarrantsShares" xlink:to="inab_Pre-FundedWarrantsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PreFundedWarrantMember" xlink:to="inab_PreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAMember" xlink:to="us-gaap_SeriesAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract" xlink:to="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PercentageOfReductionInCashCompensation" xlink:to="inab_PercentageOfReductionInCashCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember" xlink:to="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SecMember" xlink:to="inab_SecMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_EquityIncentivePlanMember" xlink:to="inab_EquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AntidilutionProvisionMember" xlink:to="inab_AntidilutionProvisionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableAbstract" xlink:to="us-gaap_LoansPayableAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_ReclassificationOfPriorPresentationsPolicyTextBlock" xlink:to="inab_ReclassificationOfPriorPresentationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised" xlink:to="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_LicenseAgreementsAbstract" xlink:to="inab_LicenseAgreementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_INB-400Member" xlink:to="inab_INB-400Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PipelinePrioritizationAndWorkforceReductionMember" xlink:to="inab_PipelinePrioritizationAndWorkforceReductionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalUseSoftwarePolicy" xlink:to="us-gaap_InternalUseSoftwarePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_JanuaryOneTwoThousandTwentyThreeMember" xlink:to="inab_JanuaryOneTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PrivatePlacementTwoThousandTwentyFiveMember" xlink:to="inab_PrivatePlacementTwoThousandTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_JanuaryOneTwoThousandTwentyFourMember" xlink:to="inab_JanuaryOneTwoThousandTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SeriesABWarrantsMember" xlink:to="inab_SeriesABWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_TwoThousandTwentyFivePreFundedWarrantsMember" xlink:to="inab_TwoThousandTwentyFivePreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayable" xlink:to="us-gaap_NotesAndLoansPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration" xlink:to="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_ExclusiveLicenseAgreementMember" xlink:to="inab_ExclusiveLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_LeaseExpirationMonthAndYear" xlink:to="inab_LeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare" xlink:to="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_IncreaseOrDecreasePercentageOfWarrants" xlink:to="inab_IncreaseOrDecreasePercentageOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionDescriptionOfAssetS" xlink:to="us-gaap_SaleLeasebackTransactionDescriptionOfAssetS_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:to="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PrepaymentPenalties" xlink:to="inab_PrepaymentPenalties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_StockOptionsToPurchaseCommonStockMember" xlink:to="inab_StockOptionsToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities" xlink:to="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised" xlink:to="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SeriesAWarrantsMember" xlink:to="inab_SeriesAWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_OrganizationAndNatureOfOperationsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AmortizationOfFinanceRightOfUseAssets" xlink:to="inab_AmortizationOfFinanceRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="inab_TwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PreFundedWarrantsMember" xlink:to="inab_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_MilestonePayment" xlink:to="inab_MilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SeriesCWarrantMember" xlink:to="inab_SeriesCWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_CommonStockPurchaseAgreementMember" xlink:to="inab_CommonStockPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AccruedClinicalTrials" xlink:to="inab_AccruedClinicalTrials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:to="us-gaap_StatementOfIncomeLocationBalanceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare" xlink:to="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AccruedResearchAndDevelopment" xlink:to="inab_AccruedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_TwoThousandTwentyFourPre-FundedWarrantsMember" xlink:to="inab_TwoThousandTwentyFourPre-FundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareInternallyDevelopedAndPurchasedMember" xlink:to="us-gaap_SoftwareInternallyDevelopedAndPurchasedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_TerminationFee" xlink:to="inab_TerminationFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SeriesBWarrantsMember" xlink:to="inab_SeriesBWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_Pre-FundedWarrantsTwoMember" xlink:to="inab_Pre-FundedWarrantsTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_EmoryLicenseAgreementMember" xlink:to="inab_EmoryLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SeriesAWarrantMember" xlink:to="inab_SeriesAWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SegmentResearchAndDevelopmentExpenses" xlink:to="inab_SegmentResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_TwoThousandTwentySixEquityIncentivePlanMember" xlink:to="inab_TwoThousandTwentySixEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_Stock-BasedCompensationExpense" xlink:to="inab_Stock-BasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="inab_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_MonthlyPayments" xlink:to="inab_MonthlyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_LeaseOfLesseeDisclosureTextBlock" xlink:to="inab_LeaseOfLesseeDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PercentageOfEmployeesTerminated" xlink:to="inab_PercentageOfEmployeesTerminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised" xlink:to="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_RoyaltyTerm" xlink:to="inab_RoyaltyTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised" xlink:to="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_RoyaltiesOnCumulativeNetSales" xlink:to="inab_RoyaltiesOnCumulativeNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_CollateralDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_INB-200Member" xlink:to="inab_INB-200Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_OneTimeTerminationFeeDescription" xlink:to="inab_OneTimeTerminationFeeDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_NetProceeds" xlink:to="inab_NetProceeds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:to="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PublicFloat" xlink:to="inab_PublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PaycheckProtectionProgramMember" xlink:to="inab_PaycheckProtectionProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AtmMember" xlink:to="inab_AtmMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_CashPaidForAmountsIncludedInOperatingLeases" xlink:to="inab_CashPaidForAmountsIncludedInOperatingLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_Pre-FundedWarrantsOneMember" xlink:to="inab_Pre-FundedWarrantsOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_TwoThousandTwentyThreePre-FundedWarrantsMember" xlink:to="inab_TwoThousandTwentyThreePre-FundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_LicenseAgreementDescription" xlink:to="inab_LicenseAgreementDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised" xlink:to="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SeriesBWarrantMember" xlink:to="inab_SeriesBWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_SeriesCWarrantsMember" xlink:to="inab_SeriesCWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_Nonrule10B51Arrmodifiedflag" xlink:to="inab_Nonrule10B51Arrmodifiedflag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PurchaseOfAggregateShare" xlink:to="inab_PurchaseOfAggregateShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_JanuaryOneTwoThousandTwentyTwoMember" xlink:to="inab_JanuaryOneTwoThousandTwentyTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PrepaidResearchAndDevelopment" xlink:to="inab_PrepaidResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_CommonStockAvailableForSaleAmount" xlink:to="inab_CommonStockAvailableForSaleAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding" xlink:to="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inab_AdditionalPurchaseCommonStockShares" xlink:to="inab_AdditionalPurchaseCommonStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SeveranceCosts1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised" xlink:label="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Stock-BasedCompensationExpense" xlink:label="inab_Stock-BasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_21"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_22"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_23"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_24"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_Stock-BasedCompensationExpense" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesABWarrantsMember" xlink:label="inab_SeriesABWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesCWarrantsMember" xlink:label="inab_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities" xlink:label="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities" xlink:label="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inab_SeriesABWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inab_SeriesCWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Nonrule10B51Arrmodifiedflag" xlink:label="inab_Nonrule10B51Arrmodifiedflag"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Rule10B51Arrmodifiedflag" xlink:label="inab_Rule10B51Arrmodifiedflag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="inab_Nonrule10B51Arrmodifiedflag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="inab_Rule10B51Arrmodifiedflag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OrganizationAndNatureOfOperationsTextBlock" xlink:label="inab_OrganizationAndNatureOfOperationsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inab_OrganizationAndNatureOfOperationsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNet1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgress" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract" xlink:label="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ConstructionInProgressTextBlock" xlink:label="inab_ConstructionInProgressTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract" xlink:to="inab_ConstructionInProgressTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureWarrants1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LicenseAgreementsAbstract" xlink:label="inab_LicenseAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_LicenseAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeases1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LeaseOfLesseeDisclosureTextBlock" xlink:label="inab_LeaseOfLesseeDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="inab_LeaseOfLesseeDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSegments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="inab_UnauditedInterimFinancialInformationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="us-gaap_InternalUseSoftwarePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ReclassificationOfPriorPresentationsPolicyTextBlock" xlink:label="inab_ReclassificationOfPriorPresentationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inab_UnauditedInterimFinancialInformationPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InternalUseSoftwarePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inab_ReclassificationOfPriorPresentationsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract" xlink:label="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ScheduleOfConstructionInProgressTableTextBlock" xlink:label="inab_ScheduleOfConstructionInProgressTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract" xlink:to="inab_ScheduleOfConstructionInProgressTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock" xlink:label="inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LoansPayableAbstract" xlink:label="us-gaap_LoansPayableAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansPayableAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OrganizationAndNatureOfOperationsTable" xlink:label="inab_OrganizationAndNatureOfOperationsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PipelinePrioritizationAndWorkforceReductionMember" xlink:label="inab_PipelinePrioritizationAndWorkforceReductionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesAWarrantsMember" xlink:label="inab_SeriesAWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OrganizationAndNatureOfOperationsLineItems" xlink:label="inab_OrganizationAndNatureOfOperationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PercentageOfEmployeesTerminated" xlink:label="inab_PercentageOfEmployeesTerminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesBWarrantsMember" xlink:label="inab_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SecMember" xlink:label="inab_SecMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesCWarrantsMember" xlink:label="inab_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AtmMember" xlink:label="inab_AtmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PercentageOfReductionInCashCompensation" xlink:label="inab_PercentageOfReductionInCashCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_NetProceeds" xlink:label="inab_NetProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AdditionalPurchaseCommonStockShares" xlink:label="inab_AdditionalPurchaseCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PublicFloat" xlink:label="inab_PublicFloat"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inab_PipelinePrioritizationAndWorkforceReductionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesAWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_PercentageOfEmployeesTerminated" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inab_OrganizationAndNatureOfOperationsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesBWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_RestructuringCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inab_SecMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesCWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inab_AtmMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_PercentageOfReductionInCashCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="inab_OrganizationAndNatureOfOperationsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_Cash" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_NetProceeds" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_AdditionalPurchaseCommonStockShares" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_PublicFloat" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrepaidResearchAndDevelopment" xlink:label="inab_PrepaidResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="inab_PrepaidResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SoftwareInternallyDevelopedAndPurchasedMember" xlink:label="us-gaap_SoftwareInternallyDevelopedAndPurchasedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_SoftwareInternallyDevelopedAndPurchasedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract" xlink:label="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract" xlink:to="us-gaap_ConstructionInProgressGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedClinicalTrials" xlink:label="inab_AccruedClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedResearchAndDevelopment" xlink:label="inab_AccruedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedCompensation" xlink:label="inab_AccruedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="inab_AccruedClinicalTrials" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="inab_AccruedResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="inab_AccruedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PaycheckProtectionProgramMember" xlink:label="inab_PaycheckProtectionProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="us-gaap_LongTermDebtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrepaymentPenalties" xlink:label="inab_PrepaymentPenalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermLoansPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inab_PaycheckProtectionProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inab_PrepaymentPenalties" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtSummaryOfLoanPayableDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LoansPayableAbstract" xlink:label="us-gaap_LoansPayableAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_YearOfMaturity" xlink:label="inab_YearOfMaturity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_BorrowingInterestRate" xlink:label="inab_BorrowingInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NotesAndLoansPayable" xlink:label="us-gaap_NotesAndLoansPayable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansPayableAbstract" xlink:to="inab_YearOfMaturity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansPayableAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansPayableAbstract" xlink:to="inab_BorrowingInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansPayableAbstract" xlink:to="us-gaap_NotesAndLoansPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_CommonStockPurchaseAgreementMember" xlink:label="inab_CommonStockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AtmMember" xlink:label="inab_AtmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SecMember" xlink:label="inab_SecMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PublicFloat" xlink:label="inab_PublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_CommonStockAvailableForSaleAmount" xlink:label="inab_CommonStockAvailableForSaleAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inab_CommonStockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inab_AtmMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inab_SecMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="inab_PublicFloat" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="inab_CommonStockAvailableForSaleAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyThreePre-FundedWarrantsMember" xlink:label="inab_TwoThousandTwentyThreePre-FundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrivatePlacementTwoThousandTwentyThreeMember" xlink:label="inab_PrivatePlacementTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyFourPre-FundedWarrantsMember" xlink:label="inab_TwoThousandTwentyFourPre-FundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrivatePlacementTwoThousandTwentyFourMember" xlink:label="inab_PrivatePlacementTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="inab_TwoThousandTwentyFivePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrivatePlacementTwoThousandTwentyFiveMember" xlink:label="inab_PrivatePlacementTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ExchangedPre-FundedWarrantsMember" xlink:label="inab_ExchangedPre-FundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PreFundedWarrantsMember" xlink:label="inab_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Pre-FundedWarrantsOneMember" xlink:label="inab_Pre-FundedWarrantsOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_WarrantsModificationDescription" xlink:label="inab_WarrantsModificationDescription"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Pre-FundedWarrantsTwoMember" xlink:label="inab_Pre-FundedWarrantsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesAWarrantMember" xlink:label="inab_SeriesAWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesBWarrantMember" xlink:label="inab_SeriesBWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesCWarrantMember" xlink:label="inab_SeriesCWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AffiliatesPercentageOfWarrants" xlink:label="inab_AffiliatesPercentageOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseOrDecreasePercentageOfWarrants" xlink:label="inab_IncreaseOrDecreasePercentageOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_MaturityOfIncreaseOrDecreasePercentage" xlink:label="inab_MaturityOfIncreaseOrDecreasePercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_TwoThousandTwentyThreePre-FundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_PrivatePlacementTwoThousandTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_TwoThousandTwentyFourPre-FundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_PrivatePlacementTwoThousandTwentyFourMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_TwoThousandTwentyFivePreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_PrivatePlacementTwoThousandTwentyFiveMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_ExchangedPre-FundedWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_PreFundedWarrantsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_Pre-FundedWarrantsOneMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="inab_WarrantsModificationDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_Pre-FundedWarrantsTwoMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_SeriesAWarrantMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_SeriesBWarrantMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_SeriesCWarrantMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="inab_AffiliatesPercentageOfWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="inab_IncreaseOrDecreasePercentageOfWarrants" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="inab_MaturityOfIncreaseOrDecreasePercentage" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_JanuaryOneTwoThousandTwentyTwoMember" xlink:label="inab_JanuaryOneTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_EquityIncentivePlanMember" xlink:label="inab_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_JanuaryOneTwoThousandTwentyThreeMember" xlink:label="inab_JanuaryOneTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration" xlink:label="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding" xlink:label="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="inab_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentySixEquityIncentivePlanMember" xlink:label="inab_TwoThousandTwentySixEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_JanuaryOneTwoThousandTwentyFourMember" xlink:label="inab_JanuaryOneTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="inab_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="inab_JanuaryOneTwoThousandTwentyTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_EquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_AwardDateAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="inab_JanuaryOneTwoThousandTwentyThreeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_TwoThousandTwentyThreeEquityIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_TwoThousandTwentySixEquityIncentivePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="inab_JanuaryOneTwoThousandTwentyFourMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_TwoThousandAndTwentyEquityIncentivePlanMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:label="us-gaap_StatementOfIncomeLocationBalanceAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementOfIncomeLocationBalanceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AntidilutionProvisionMember" xlink:label="inab_AntidilutionProvisionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_EmoryLicenseAgreementMember" xlink:label="inab_EmoryLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LicenseAgreementDescription" xlink:label="inab_LicenseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LicenseAgreementsAbstract" xlink:label="inab_LicenseAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_UABRFMember" xlink:label="inab_UABRFMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ExclusiveLicenseAgreementMember" xlink:label="inab_ExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_RoyaltiesOnCumulativeNetSales" xlink:label="inab_RoyaltiesOnCumulativeNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_MilestonePayment" xlink:label="inab_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="inab_AntidilutionProvisionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inab_EmoryLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inab_LicenseAgreementDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inab_LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inab_UABRFMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inab_ExclusiveLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inab_RoyaltiesOnCumulativeNetSales" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inab_MilestonePayment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PreFundedWarrantsMember" xlink:label="inab_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockOptionsToPurchaseCommonStockMember" xlink:label="inab_StockOptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesAWarrantsMember" xlink:label="inab_SeriesAWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesBWarrantsMember" xlink:label="inab_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesCWarrantsMember" xlink:label="inab_SeriesCWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_StockOptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesAWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesBWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesCWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_RoyaltyTerm" xlink:label="inab_RoyaltyTerm"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inab_RoyaltyTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_BirminghamAlabamaMember" xlink:label="inab_BirminghamAlabamaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases" xlink:label="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_NewYorkOperatingLeaseMember" xlink:label="inab_NewYorkOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LaboratoryMember" xlink:label="inab_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleLeasebackTransactionDescriptionOfAssetS" xlink:label="us-gaap_SaleLeasebackTransactionDescriptionOfAssetS"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TerminationFee" xlink:label="inab_TerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OneTimeTerminationFeeDescription" xlink:label="inab_OneTimeTerminationFeeDescription"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_MonthlyPayments" xlink:label="inab_MonthlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LeaseExpirationMonthAndYear" xlink:label="inab_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inab_BirminghamAlabamaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_CollateralAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inab_NewYorkOperatingLeaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="inab_LaboratoryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SaleLeasebackTransactionDescriptionOfAssetS" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="inab_TerminationFee" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="inab_OneTimeTerminationFeeDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="inab_MonthlyPayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="inab_LeaseExpirationMonthAndYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RestrictedCash" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AmortizationOfFinanceRightOfUseAssets" xlink:label="inab_AmortizationOfFinanceRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_CashPaidForAmountsIncludedInFinanceLeases" xlink:label="inab_CashPaidForAmountsIncludedInFinanceLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_CashPaidForAmountsIncludedInOperatingLeases" xlink:label="inab_CashPaidForAmountsIncludedInOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="inab_AmortizationOfFinanceRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="inab_CashPaidForAmountsIncludedInFinanceLeases" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="inab_CashPaidForAmountsIncludedInOperatingLeases" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_NumberOfReportableSegmentsNotDisclosedFlag" xlink:label="inab_NumberOfReportableSegmentsNotDisclosedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="inab_NumberOfReportableSegmentsNotDisclosedFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SegmentResearchAndDevelopmentExpenses" xlink:label="inab_SegmentResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_INB-100Member" xlink:label="inab_INB-100Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_INB-200Member" xlink:label="inab_INB-200Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_INB-400Member" xlink:label="inab_INB-400Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="inab_SegmentResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="inab_INB-100Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="inab_INB-200Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="inab_INB-400Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PreFundedWarrantMember" xlink:label="inab_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesAWarrantMember" xlink:label="inab_SeriesAWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesBWarrantMember" xlink:label="inab_SeriesBWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PurchaseOfAggregateShare" xlink:label="inab_PurchaseOfAggregateShare"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Pre-FundedWarrantsShares" xlink:label="inab_Pre-FundedWarrantsShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_PreFundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_SeriesAWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_SeriesBWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inab_PurchaseOfAggregateShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inab_Pre-FundedWarrantsShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised" xlink:label="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised" xlink:label="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare" xlink:label="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Stock-BasedCompensationExpense" xlink:label="inab_Stock-BasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inab_Stock-BasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesABWarrantsMember" xlink:label="inab_SeriesABWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesCWarrantsMember" xlink:label="inab_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities" xlink:label="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities" xlink:label="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inab_SeriesABWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="inab_SeriesCWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OrganizationAndNatureOfOperationsLineItems" xlink:label="inab_OrganizationAndNatureOfOperationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OrganizationAndNatureOfOperationsTable" xlink:label="inab_OrganizationAndNatureOfOperationsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PipelinePrioritizationAndWorkforceReductionMember" xlink:label="inab_PipelinePrioritizationAndWorkforceReductionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesAWarrantsMember" xlink:label="inab_SeriesAWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PercentageOfEmployeesTerminated" xlink:label="inab_PercentageOfEmployeesTerminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesBWarrantsMember" xlink:label="inab_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SecMember" xlink:label="inab_SecMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesCWarrantsMember" xlink:label="inab_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AtmMember" xlink:label="inab_AtmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PercentageOfReductionInCashCompensation" xlink:label="inab_PercentageOfReductionInCashCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_NetProceeds" xlink:label="inab_NetProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AdditionalPurchaseCommonStockShares" xlink:label="inab_AdditionalPurchaseCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PublicFloat" xlink:label="inab_PublicFloat"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_OrganizationAndNatureOfOperationsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inab_PipelinePrioritizationAndWorkforceReductionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesAWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_PercentageOfEmployeesTerminated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesBWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_RestructuringCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inab_SecMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesCWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inab_AtmMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_PercentageOfReductionInCashCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inab_OrganizationAndNatureOfOperationsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_NetProceeds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_AdditionalPurchaseCommonStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inab_OrganizationAndNatureOfOperationsLineItems" xlink:to="inab_PublicFloat" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SoftwareInternallyDevelopedAndPurchasedMember" xlink:label="us-gaap_SoftwareInternallyDevelopedAndPurchasedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_SoftwareInternallyDevelopedAndPurchasedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PaycheckProtectionProgramMember" xlink:label="inab_PaycheckProtectionProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="us-gaap_LongTermDebtMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrepaymentPenalties" xlink:label="inab_PrepaymentPenalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermLoansPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inab_PaycheckProtectionProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inab_PrepaymentPenalties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_CommonStockPurchaseAgreementMember" xlink:label="inab_CommonStockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AtmMember" xlink:label="inab_AtmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SecMember" xlink:label="inab_SecMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PublicFloat" xlink:label="inab_PublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_CommonStockAvailableForSaleAmount" xlink:label="inab_CommonStockAvailableForSaleAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inab_CommonStockPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inab_AtmMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inab_SecMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="inab_PublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="inab_CommonStockAvailableForSaleAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyThreePre-FundedWarrantsMember" xlink:label="inab_TwoThousandTwentyThreePre-FundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrivatePlacementTwoThousandTwentyThreeMember" xlink:label="inab_PrivatePlacementTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyFourPre-FundedWarrantsMember" xlink:label="inab_TwoThousandTwentyFourPre-FundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrivatePlacementTwoThousandTwentyFourMember" xlink:label="inab_PrivatePlacementTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="inab_TwoThousandTwentyFivePreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrivatePlacementTwoThousandTwentyFiveMember" xlink:label="inab_PrivatePlacementTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ExchangedPre-FundedWarrantsMember" xlink:label="inab_ExchangedPre-FundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PreFundedWarrantsMember" xlink:label="inab_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Pre-FundedWarrantsOneMember" xlink:label="inab_Pre-FundedWarrantsOneMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_WarrantsModificationDescription" xlink:label="inab_WarrantsModificationDescription"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Pre-FundedWarrantsTwoMember" xlink:label="inab_Pre-FundedWarrantsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesAWarrantMember" xlink:label="inab_SeriesAWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesBWarrantMember" xlink:label="inab_SeriesBWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesCWarrantMember" xlink:label="inab_SeriesCWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AffiliatesPercentageOfWarrants" xlink:label="inab_AffiliatesPercentageOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseOrDecreasePercentageOfWarrants" xlink:label="inab_IncreaseOrDecreasePercentageOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_MaturityOfIncreaseOrDecreasePercentage" xlink:label="inab_MaturityOfIncreaseOrDecreasePercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_TwoThousandTwentyThreePre-FundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_PrivatePlacementTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_TwoThousandTwentyFourPre-FundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_PrivatePlacementTwoThousandTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_TwoThousandTwentyFivePreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_PrivatePlacementTwoThousandTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_ExchangedPre-FundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_Pre-FundedWarrantsOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="inab_WarrantsModificationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_Pre-FundedWarrantsTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_SeriesAWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_SeriesBWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_SeriesCWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="inab_AffiliatesPercentageOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="inab_IncreaseOrDecreasePercentageOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="inab_MaturityOfIncreaseOrDecreasePercentage" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_JanuaryOneTwoThousandTwentyTwoMember" xlink:label="inab_JanuaryOneTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_EquityIncentivePlanMember" xlink:label="inab_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_JanuaryOneTwoThousandTwentyThreeMember" xlink:label="inab_JanuaryOneTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration" xlink:label="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_JanuaryOneTwoThousandTwentyFourMember" xlink:label="inab_JanuaryOneTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember" xlink:label="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding" xlink:label="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="inab_TwoThousandTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandTwentySixEquityIncentivePlanMember" xlink:label="inab_TwoThousandTwentySixEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="inab_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="inab_JanuaryOneTwoThousandTwentyTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_EquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_AwardDateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="inab_JanuaryOneTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="inab_JanuaryOneTwoThousandTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_TwoThousandTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_TwoThousandTwentySixEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inab_TwoThousandAndTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfIncomeLocationBalanceAxis" xlink:label="us-gaap_StatementOfIncomeLocationBalanceAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementOfIncomeLocationBalanceAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetailsDefault">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AntidilutionProvisionMember" xlink:label="inab_AntidilutionProvisionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_EmoryLicenseAgreementMember" xlink:label="inab_EmoryLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LicenseAgreementDescription" xlink:label="inab_LicenseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_UABRFMember" xlink:label="inab_UABRFMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_ExclusiveLicenseAgreementMember" xlink:label="inab_ExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_RoyaltiesOnCumulativeNetSales" xlink:label="inab_RoyaltiesOnCumulativeNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_MilestonePayment" xlink:label="inab_MilestonePayment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="inab_AntidilutionProvisionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inab_EmoryLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inab_LicenseAgreementDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inab_UABRFMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inab_ExclusiveLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inab_RoyaltiesOnCumulativeNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="inab_MilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PreFundedWarrantsMember" xlink:label="inab_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_StockOptionsToPurchaseCommonStockMember" xlink:label="inab_StockOptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesAWarrantsMember" xlink:label="inab_SeriesAWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesBWarrantsMember" xlink:label="inab_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesCWarrantsMember" xlink:label="inab_SeriesCWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_StockOptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesAWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesBWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_SeriesCWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_BirminghamAlabamaMember" xlink:label="inab_BirminghamAlabamaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases" xlink:label="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_NewYorkOperatingLeaseMember" xlink:label="inab_NewYorkOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LaboratoryMember" xlink:label="inab_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleLeasebackTransactionDescriptionOfAssetS" xlink:label="us-gaap_SaleLeasebackTransactionDescriptionOfAssetS"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_TerminationFee" xlink:label="inab_TerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_OneTimeTerminationFeeDescription" xlink:label="inab_OneTimeTerminationFeeDescription"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_MonthlyPayments" xlink:label="inab_MonthlyPayments"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LeaseExpirationMonthAndYear" xlink:label="inab_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inab_BirminghamAlabamaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_CollateralAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inab_NewYorkOperatingLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="inab_LaboratoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SaleLeasebackTransactionDescriptionOfAssetS" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="inab_TerminationFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="inab_OneTimeTerminationFeeDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="inab_MonthlyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="inab_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OtherAssetsCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SegmentResearchAndDevelopmentExpenses" xlink:label="inab_SegmentResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_INB-100Member" xlink:label="inab_INB-100Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_INB-200Member" xlink:label="inab_INB-200Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_INB-400Member" xlink:label="inab_INB-400Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="inab_SegmentResearchAndDevelopmentExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="inab_INB-100Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="inab_INB-200Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="inab_INB-400Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PreFundedWarrantMember" xlink:label="inab_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesAWarrantMember" xlink:label="inab_SeriesAWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_SeriesBWarrantMember" xlink:label="inab_SeriesBWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PurchaseOfAggregateShare" xlink:label="inab_PurchaseOfAggregateShare"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_Pre-FundedWarrantsShares" xlink:label="inab_Pre-FundedWarrantsShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="inab_PreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_SeriesAWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inab_SeriesBWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inab_PurchaseOfAggregateShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inab_Pre-FundedWarrantsShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCash" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SeveranceCosts1" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities" order="14" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities" xlink:label="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities" xlink:label="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="inab_PrepaidResearchAndDevelopment" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_PrepaidResearchAndDevelopment" xlink:label="inab_PrepaidResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_FurnitureAndFixturesGross" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="inab_AccruedResearchAndDevelopment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="inab_AccruedClinicalTrials" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="inab_AccruedCompensation" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedResearchAndDevelopment" xlink:label="inab_AccruedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedClinicalTrials" xlink:label="inab_AccruedClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AccruedCompensation" xlink:label="inab_AccruedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="inab_AmortizationOfFinanceRightOfUseAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_AmortizationOfFinanceRightOfUseAssets" xlink:label="inab_AmortizationOfFinanceRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="inab-20260630.xsd#inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="inab_Pre-FundedWarrantsTwoMember" name="Pre-FundedWarrantsTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_PercentageOfReductionInCashCompensation" name="PercentageOfReductionInCashCompensation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding" name="PercentageOfTotalNumberOfSharesOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_PercentageOfEmployeesTerminated" name="PercentageOfEmployeesTerminated" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_CommonStockPurchaseAgreementMember" name="CommonStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_INB-400Member" name="INB-400Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_RoyaltyTerm" name="RoyaltyTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_EquityIncentivePlanMember" name="EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_SegmentResearchAndDevelopmentExpenses" name="SegmentResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_UnauditedInterimFinancialInformationPolicyTextBlock" name="UnauditedInterimFinancialInformationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_TwoThousandTwentyFourPre-FundedWarrantsMember" name="TwoThousandTwentyFourPre-FundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_StockOptionsToPurchaseCommonStockMember" name="StockOptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_INB-100Member" name="INB-100Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_Nonrule10B51Arrmodifiedflag" name="Nonrule10B51Arrmodifiedflag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_NetProceeds" name="NetProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_PrivatePlacementTwoThousandTwentyThreeMember" name="PrivatePlacementTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue" name="StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_Stock-BasedCompensationExpense" name="Stock-BasedCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised" name="StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_LaboratoryMember" name="LaboratoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_PrepaymentPenalties" name="PrepaymentPenalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_PrepaidResearchAndDevelopment" name="PrepaidResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_PreFundedWarrantMember" name="PreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_ConstructionInProgressTextBlock" name="ConstructionInProgressTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_RoyaltiesOnCumulativeNetSales" name="RoyaltiesOnCumulativeNetSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_PropertyPlantAndEquipmentEstimatedUsefulLives1" name="PropertyPlantAndEquipmentEstimatedUsefulLives1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_PurchaseOfAggregateShare" name="PurchaseOfAggregateShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_TwoThousandTwentyThreeEquityIncentivePlanMember" name="TwoThousandTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_OrganizationAndNatureOfOperationsTextBlock" name="OrganizationAndNatureOfOperationsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_Rule10B51Arrmodifiedflag" name="Rule10B51Arrmodifiedflag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_BirminghamAlabamaMember" name="BirminghamAlabamaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities" name="IncreaseDecreaseShortTermOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised" name="StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_JanuaryOneTwoThousandTwentyTwoMember" name="JanuaryOneTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_TwoThousandAndTwentyEquityIncentivePlanMember" name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_CashPaidForAmountsIncludedInFinanceLeases" name="CashPaidForAmountsIncludedInFinanceLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_AccruedClinicalTrials" name="AccruedClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_MaturityOfIncreaseOrDecreasePercentage" name="MaturityOfIncreaseOrDecreasePercentage" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_OneTimeTerminationFeeDescription" name="OneTimeTerminationFeeDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_PrivatePlacementTwoThousandTwentyFourMember" name="PrivatePlacementTwoThousandTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised" name="StockIssueDuringPeriodValueSeriesCWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_SeriesABWarrantsMember" name="SeriesABWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_TwoThousandTwentySixEquityIncentivePlanMember" name="TwoThousandTwentySixEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_WarrantsModificationDescription" name="WarrantsModificationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised" name="StockIssuedDuringPeriodSharesSeriesAWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_BorrowingInterestRate" name="BorrowingInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_MonthlyPayments" name="MonthlyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised" name="StockIssuedDuringPeriodSharesSeriesCWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock" name="AccruedExpensesAndCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_AtmMember" name="AtmMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_NewYorkOperatingLeaseMember" name="NewYorkOperatingLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_LeaseOfLesseeDisclosureTextBlock" name="LeaseOfLesseeDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_TerminationFee" name="TerminationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_PaycheckProtectionProgramMember" name="PaycheckProtectionProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_AffiliatesPercentageOfWarrants" name="AffiliatesPercentageOfWarrants" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_SeriesBWarrantMember" name="SeriesBWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour" name="FinanceLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_JanuaryOneTwoThousandTwentyFourMember" name="JanuaryOneTwoThousandTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_Pre-FundedWarrantsShares" name="Pre-FundedWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_IncreaseOrDecreasePercentageOfWarrants" name="IncreaseOrDecreasePercentageOfWarrants" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_SeriesCWarrantsMember" name="SeriesCWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_AmortizationOfFinanceRightOfUseAssets" name="AmortizationOfFinanceRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_NumberOfReportableSegmentsNotDisclosedFlag" name="NumberOfReportableSegmentsNotDisclosedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_PipelinePrioritizationAndWorkforceReductionMember" name="PipelinePrioritizationAndWorkforceReductionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_CommonStockAvailableForSaleAmount" name="CommonStockAvailableForSaleAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_UABRFMember" name="UABRFMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_PrivatePlacementTwoThousandTwentyFiveMember" name="PrivatePlacementTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_SecMember" name="SecMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_EmoryLicenseAgreementMember" name="EmoryLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_SeriesAWarrantMember" name="SeriesAWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember" name="AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_AntidilutionProvisionMember" name="AntidilutionProvisionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_YearOfMaturity" name="YearOfMaturity" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_AccruedCompensation" name="AccruedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_CashPaidForAmountsIncludedInOperatingLeases" name="CashPaidForAmountsIncludedInOperatingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" name="LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_SeriesAWarrantsMember" name="SeriesAWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_SeriesCWarrantMember" name="SeriesCWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_TwoThousandTwentyThreePre-FundedWarrantsMember" name="TwoThousandTwentyThreePre-FundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_AdditionalPurchaseCommonStockShares" name="AdditionalPurchaseCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases" name="SaleLeasebackTransactionAmountHeldForEquipmentPurchases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_OrganizationAndNatureOfOperationsLineItems" name="OrganizationAndNatureOfOperationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_Pre-FundedWarrantsOneMember" name="Pre-FundedWarrantsOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_ReclassificationOfPriorPresentationsPolicyTextBlock" name="ReclassificationOfPriorPresentationsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration" name="SharesReservedOfIssuanceUnderPlanIncreaseDuration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities" name="IncreaseDecreaseLongTermOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inab_LicenseAgreementDescription" name="LicenseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_ScheduleOfConstructionInProgressTableTextBlock" name="ScheduleOfConstructionInProgressTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_JanuaryOneTwoThousandTwentyThreeMember" name="JanuaryOneTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_TwoThousandTwentyFivePreFundedWarrantsMember" name="TwoThousandTwentyFivePreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities" name="LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember" name="AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_PublicFloat" name="PublicFloat" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inab_SeriesBWarrantsMember" name="SeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_INB-200Member" name="INB-200Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_ExchangedPre-FundedWarrantsMember" name="ExchangedPre-FundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_LicenseAgreementsAbstract" name="LicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inab_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inab_OrganizationAndNatureOfOperationsTable" name="OrganizationAndNatureOfOperationsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Aug. 03, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IN8BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001740279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-5462585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">350 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 5330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">600-6438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INAB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,858,383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 17,956<span></span>
</td>
<td class="nump">$ 27,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">18,496<span></span>
</td>
<td class="nump">27,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets - finance leases</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets - operating leases</a></td>
<td class="nump">1,246<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Non-Current Assets</a></td>
<td class="nump">3,249<span></span>
</td>
<td class="nump">4,402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">21,745<span></span>
</td>
<td class="nump">32,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Short-term finance lease liability</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liability</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,254<span></span>
</td>
<td class="nump">3,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">1,128<span></span>
</td>
<td class="nump">1,563<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Non-Current Liabilities</a></td>
<td class="nump">1,128<span></span>
</td>
<td class="nump">1,563<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">4,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001 per share; 490,000,000 shares authorized at June 30, 2026 and December 31, 2025; 9,853,121 and 9,766,132 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">169,320<span></span>
</td>
<td class="nump">168,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(150,967)<span></span>
</td>
<td class="num">(141,096)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">18,363<span></span>
</td>
<td class="nump">27,558<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 21,745<span></span>
</td>
<td class="nump">$ 32,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478482/942-210-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorised</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">490,000,000<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">9,853,121<span></span>
</td>
<td class="nump">9,766,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">9,853,121<span></span>
</td>
<td class="nump">9,766,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,493<span></span>
</td>
<td class="nump">$ 2,487<span></span>
</td>
<td class="nump">$ 5,106<span></span>
</td>
<td class="nump">$ 5,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,442<span></span>
</td>
<td class="nump">2,714<span></span>
</td>
<td class="nump">5,095<span></span>
</td>
<td class="nump">5,402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,935<span></span>
</td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">10,201<span></span>
</td>
<td class="nump">10,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,781)<span></span>
</td>
<td class="num">(5,094)<span></span>
</td>
<td class="num">(9,871)<span></span>
</td>
<td class="num">(10,644)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,781)<span></span>
</td>
<td class="num">$ (5,094)<span></span>
</td>
<td class="num">$ (9,871)<span></span>
</td>
<td class="num">$ (10,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (1.24)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (3.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (1.24)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (3.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per common share, basic</a></td>
<td class="nump">19,467,091<span></span>
</td>
<td class="nump">4,119,153<span></span>
</td>
<td class="nump">19,468,087<span></span>
</td>
<td class="nump">2,920,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per common share, diluted</a></td>
<td class="nump">19,467,091<span></span>
</td>
<td class="nump">4,119,153<span></span>
</td>
<td class="nump">19,468,087<span></span>
</td>
<td class="nump">2,920,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares beginning at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,416,066<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14,478<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 136,127<span></span>
</td>
<td class="num">$ (121,656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period shares new issues, amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,735<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised', window );">Issuance of common stock upon exercise of Series C warrants, net of issuance costs, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,088<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised', window );">Issuance of common stock upon exercise of Series C warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_Stock-BasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,550)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares ending at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,708,582<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,877<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">141,075<span></span>
</td>
<td class="num">(127,206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs from December 2025 issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares beginning at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,416,066<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,478<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">136,127<span></span>
</td>
<td class="num">(121,656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares ending at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,078,139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,239<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">147,529<span></span>
</td>
<td class="num">(132,300)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares beginning at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,708,582<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,877<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">141,075<span></span>
</td>
<td class="num">(127,206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period shares new issues, amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,617<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised', window );">Issuance of common stock upon exercise of Series A&amp;B warrants, net of issuance costs , Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,696<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised', window );">Issuance of common stock upon exercise of Series A&amp;B warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_Stock-BasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,094)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,094)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares ending at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,078,139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,239<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">147,529<span></span>
</td>
<td class="num">(132,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs from December 2025 issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares beginning at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,766,132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,558<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">168,644<span></span>
</td>
<td class="num">(141,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised', window );">Issuance of common stock upon exercise of Series A warrants, net of issuance costs , Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,957<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue', window );">Issuance of common stock upon exercise of Series A warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_Stock-BasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,090)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares ending at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,847,089<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,781<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">168,957<span></span>
</td>
<td class="num">(146,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs from December 2025 issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares beginning at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,766,132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,558<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">168,644<span></span>
</td>
<td class="num">(141,096)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares ending at Jun. 30, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,853,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,363<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">169,320<span></span>
</td>
<td class="num">(150,967)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares beginning at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,847,089<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Mar. 31, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,781<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">168,957<span></span>
</td>
<td class="num">(146,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period shares new issues, amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,032<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_Stock-BasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,781)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares ending at Jun. 30, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,853,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Jun. 30, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18,363<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 169,320<span></span>
</td>
<td class="num">$ (150,967)<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect a one-for-thirty reverse stock split effected in June 2025. See Note 1, Organization and Nature of Operations, for details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_Stock-BasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_Stock-BasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issue During Period Value Series C Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>StockIssued During Period Shares Series A and B Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Series A Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Series C Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>StockIssued During Period Value Series A and B Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Series A Warrants Exercised Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (9,871)<span></span>
</td>
<td class="num">$ (10,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">753<span></span>
</td>
<td class="nump">1,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">135<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(872)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities', window );">Short-term operating lease liabilities</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities', window );">Long-term operating lease liabilities</a></td>
<td class="num">(434)<span></span>
</td>
<td class="num">(390)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,692)<span></span>
</td>
<td class="num">(7,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromProductiveAssets', window );">Purchases of property and equipment</a></td>
<td class="num">(242)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(242)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs from December 2025 issuance of common stock</a></td>
<td class="num">(77)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on financing leases</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(246)<span></span>
</td>
<td class="nump">9,160<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and restricted cash</a></td>
<td class="num">(9,180)<span></span>
</td>
<td class="nump">2,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash at beginning of period</a></td>
<td class="nump">27,312<span></span>
</td>
<td class="nump">11,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash at end of period</a></td>
<td class="nump">18,132<span></span>
</td>
<td class="nump">13,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">17,956<span></span>
</td>
<td class="nump">13,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash, end of period</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, end of period</a></td>
<td class="nump">18,132<span></span>
</td>
<td class="nump">13,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities', window );">Lease modification of operating lease right-of-use assets and liabilities</a></td>
<td class="num">(349)<span></span>
</td>
<td class="num">(1,287)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=inab_SeriesABWarrantsMember', window );">Series A &amp; B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of Series C warrants, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=inab_SeriesCWarrantsMember', window );">Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of Series C warrants, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Modification of Operating Lease Right-of-use Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478482/942-210-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=inab_SeriesABWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=inab_SeriesABWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=inab_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=inab_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (4,781)<span></span>
</td>
<td class="num">$ (5,090)<span></span>
</td>
<td class="num">$ (5,094)<span></span>
</td>
<td class="num">$ (5,550)<span></span>
</td>
<td class="num">$ (9,871)<span></span>
</td>
<td class="num">$ (10,644)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_Nonrule10B51Arrmodifiedflag', window );">Non-Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_Rule10B51Arrmodifiedflag', window );">Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_Nonrule10B51Arrmodifiedflag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NonRule10b51ArrModifiedFlag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_Nonrule10B51Arrmodifiedflag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_Rule10B51Arrmodifiedflag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule10B51ArrModifiedFlag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_Rule10B51Arrmodifiedflag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of Operations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. ORGANIZATION AND NATURE OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization and Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN8bio, Inc. (the "Company") is a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta ("&#947;&#948;") T cell product candidates and T cell engagers for cancer and autoimmune diseases. The Company&#8217;s pipeline is anchored by INB-600, its proprietary, internally developed &#947;&#948; T cell engager ("TCE") platform, which has potential applications across oncology and autoimmune indications. The Company&#8217;s most advanced product candidates are INB-100, currently in an ongoing investigator-sponsored Phase 1 clinical trial of acute myeloid leukemia ("AML"), and INB-200/400, evaluating its DeltEx Drug Resistant Immunotherapy ("DRI") in patients with newly diagnosed glioblastoma ("GBM"). In addition, the Company&#8217;s DeltEx platform has yielded a broad portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing a range of potential applications, from solid tumors and hematological cancers to autoimmune diseases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incysus, Inc. ("Incysus") was a corporation formed in the State of Delaware on November 23, 2015 and Incysus, Ltd. was incorporated in Bermuda on February 8, 2016. Incysus was the wholly owned United States subsidiary of Incysus, Ltd. On May 7, 2018, Incysus, Ltd. reincorporated in the United States in a domestication transaction (the "Domestication") in which Incysus, Ltd. converted into a newly formed Delaware corporation, Incysus Therapeutics, Inc. ("Incysus Therapeutics"). On July 24, 2019, Incysus Therapeutics merged with Incysus. Incysus Therapeutics subsequently changed its name to IN8bio, Inc. in August 2020. Following the Domestication in May 2018 and the merging of Incysus Therapeutics and Incysus in July 2019, the Company does not have any subsidiaries to consolidate. The Company is headquartered in New York, New York.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 5, 2025, the Company effected a reverse stock split at a ratio of one-for-thirty (the "Reverse Stock Split"). Pursuant to their terms, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all outstanding stock options and warrants, and the number of shares of the Company&#8217;s common stock authorized for issuance pursuant to the Company&#8217;s equity incentive plans was reduced proportionally. The Reverse Stock Split did not reduce the number of authorized shares of common stock and did not alter the par value.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would have otherwise been entitled to receive a fractional share received a cash payment in lieu thereof. The Reverse Stock Split affected all stockholders proportionately and did not affect any stockholder&#8217;s percentage ownership of the Company&#8217;s common stock (except to the extent that the Reverse Stock Split resulted in any stockholder owning only a fractional share). All share and per share amounts of common stock disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis in all periods presented.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has funded its operations primarily with proceeds from various public and private offerings of its common stock, preferred stock and warrants. The Company has incurred recurring losses and negative operating cash flows since its inception, including net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">151.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company continues to deploy cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility. These cash preservation measures may impact the Company's ability and the timing to execute its strategy. This includes the Company's ability to achieve the anticipated milestones and the timing of data releases and/or regulatory filings for its preclinical and clinical programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not yet generated product sales and as a result has experienced operating losses since inception. The Company expects to incur additional losses in the future as it advances its product candidates through clinical trials, grows its clinical, regulatory and quality capabilities, and incurs costs associated with operating as a public company. The actual amount of cash that the Company will need to operate is subject to many factors. Based on the Company&#8217;s business strategy, its existing cash of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2026 is not anticipated to fund the Company&#8217;s projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company&#8217;s ability to continue to operate as a going concern.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company continues to maintain cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility. To continue to fund the operations of the Company beyond this time period, management has developed plans, which primarily consist of pipeline prioritization, raising additional capital through some combination of equity and/or debt offerings, including through ATM offerings and private placements of securities, and identifying strategic collaborations, licensing or other arrangements to support development of the Company&#8217;s product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Company&#8217;s private placement completed in December 2025, the Company may also be eligible to receive up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional gross proceeds in exchange for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,579,706</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to the achievement of certain milestone-driven conditions related to preclinical data for the Company's CD19 targeting INB-619 product candidate. In addition, the Company may receive up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of proceeds from the exercise of its outstanding Series B ordinary warrants ("Series B warrants") if not otherwise redeemed by the Company and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the exercise of its outstanding Series C common stock purchase warrants ("Series C warrants"). See Note 7, Warrants, for additional information. There is no assurance, however, that the Company will receive any additional proceeds or that any additional financing or any revenue-generating collaboration will be available when needed, that management of the Company will be able to obtain financing or enter into a collaboration on terms acceptable to the Company, or that any additional financing or revenue generated through third-party collaborations will be sufficient to fund the Company's operations through this time period. If additional capital is not available on a timely basis, or at all, the Company will have to significantly delay, scale back or discontinue its research and development programs. If the Company becomes unable to continue as a going concern, it may have to terminate its operations and dispose of its assets and might realize significantly less than the values at which they are carried on its financial statements. These actions may cause the Company&#8217;s stockholders to lose all or part of their investment in the Company&#8217;s common stock. The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Accounting Policies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the notes thereto, are included in the Company&#8217;s Annual Report on Form 10-K (the "Annual Report") that was filed with the Securities and Exchange Commission ("SEC") on March 12, 2026. Since the date of that filing, there have been no material changes to the Company&#8217;s significant accounting policies.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States ("U.S. GAAP").</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unaudited Interim Financial Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto in the Annual Report. The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and the related valuation allowance, stock-based compensation, the useful lives of property and equipment and the valuation of warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash and restricted cash. All of the Company&#8217;s cash and restricted cash is deposited in accounts with major financial institutions. Such deposits are in excess of the federally insured limits.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation and amortization of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated useful lives of the Company&#8217;s respective assets are as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:78.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:55.128%;box-sizing:content-box;"></td>
           <td style="width:1.282%;box-sizing:content-box;"></td>
           <td style="width:2.564%;box-sizing:content-box;"></td>
           <td style="width:38.462%;box-sizing:content-box;"></td>
           <td style="width:2.564%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Machinery and equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The shorter of the useful life of the leasehold improvement or the remaining term of the lease</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated and amortized in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the condensed balance sheets and any gain or loss is reflected in the condensed statements of operations.</span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalized Software</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes the application development phase costs of internal use software in accordance with Accounting Standard Codification ("ASC") Topic 350-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangibles-Goodwill and Other-Internal Use Software</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Capitalized costs will be amortized on a straight-line basis over the estimated useful life of the asset upon completion.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker ("CODM") in deciding how to allocate resources and assess performance. The Company has one operating segment, which is the business focused on the discovery, development and commercialization of gamma-delta T cell product candidates and TCEs for cancer and autoimmune diseases. The CODM is the Company&#8217;s Chief Executive Officer ("CEO"). The CEO manages the Company&#8217;s operations, assesses performance for the operating segment and decides how to allocate resources based on net loss, which is reported on the condensed statements of operations. All of the Company&#8217;s long-lived assets are held in the United States. For additional segment information, see Note 13, Segments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Standards Updates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated all issued and unadopted Accounting Standards Updates issued by the Financial Accounting Standards Board, and believes the adoption of these standards will not have a material impact on the condensed financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">529</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">540</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. PROPERTY AND EQUIPMENT, NET</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Machinery and equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">627</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">346</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">346</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,924</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,924</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,699</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,199</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,600</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,858</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the three months ended June 30, 2026 and 2025, respectively, and was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the six months ended June 30, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trials</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">712</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,305</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued legal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">761</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,633</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. STOCKHOLDERS' EQUITY</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s authorized capital stock consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, all with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">490,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are designated as common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are designated as preferred stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ATM Facility</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2022, the Company entered into a Controlled Equity Offering</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sales agreement with Cantor Fitzgerald &amp; Co. ("Cantor Fitzgerald") and Truist Securities, Inc. ("Truist") under which Cantor Fitzgerald and Truist agreed to act as sales agents to sell shares of the Company&#8217;s common stock, from time to time, in an at-the-market offering program. In March 2024, the Company delivered a termination notice to Truist, removing them as sales agent under the sales agreement, and on May 29, 2026, the Company and Cantor mutually agreed to terminate the sales agreement effective at the close of business on May 29, 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, the Company filed a shelf registration statement on Form S-3 (File No. 333-291393) (the "Shelf Registration Statement") with the SEC, which became effective on May 20, 2026, which permits the issuance and sale by the Company of up to a maximum aggregate offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of its common stock, preferred stock, various series of debt securities, warrants to purchase common stock, preferred stock or debt securities, rights to purchase equity or debt securities, and/or units to purchase any combination of such securities. On June 1, 2026, the Company entered into a Capital on Demand</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sales Agreement sales agreement, (the "Sales Agreement") with JonesTrading Institutional Services LLC ("JonesTrading") with respect to an at-the-market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, through or to JonesTrading (the &#8220;ATM Program&#8221;) pursuant to the Shelf Registration Statement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under current SEC regulations, if at any time the Company's public float is less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and for so long as the Company's public float remains less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, the amount the Company can raise through primary public offerings of securities in any 12-month period using shelf registration statements is limited to an aggregate of one-third of the Company's public float, which is referred to as the baby shelf rules. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company's calculated public float was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,865,253</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, of its common stock under the ATM, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the six months ended June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,032</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock under the ATM Program, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after deducting sales agent fees and other offering expenses. As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million remained available for the sale of common stock under the ATM Program.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.D.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.B.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. WARRANTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Company issued pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,141</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock ("2023 Pre-Funded Warrants"), </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">394,118</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series A warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">394,118</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series B warrants in a private placement. The 2023 Pre-Funded Warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.003</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, are exercisable immediately and are exercisable until the 2023 Pre-Funded Warrant is exercised in full. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a 2023 Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the 2023 Pre-Funded Warrants terms. The 2023 Pre-Funded Warrants meet the criteria for permanent equity classification. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2023 Pre-Funded warrants issued and outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series A warrants were issued with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Series A warrants were exercisable immediately. The Series A warrants meet the criteria for permanent equity classification.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the closing of the Company's private placement in October 2024, the Company amended certain of the Company&#8217;s outstanding Series A warrants, representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">390,462</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, to (i) reduce the exercise price from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and (ii) extend the termination date of such Series A warrants to October 4, 2025. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all Series A warrants have expired and there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series A warrants outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series B warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Series B warrants are exercisable immediately and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 13, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Series B warrants allow the Company to redeem such warrants at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Series B warrant upon the Company&#8217;s public announcement of its INB-100 data for all enrolled patients covering a period of at least 22 months, along with certain stock price and trading volume requirements. Holders of Series B warrants may choose to exercise such warrants at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share prior to such redemption. The Series B warrants meet the criteria for permanent equity classification. In April 2025, the Company entered into Amendment No. 1 to Securities Purchase Agreement (the "SPA Amendment") to amend the restrictions on certain equity sales by the Company set forth in the Securities Purchase Agreement, dated September 30, 2024, by and among the Company and the investors party thereto. In consideration for the SPA Amendment, the Company amended the Company's outstanding Series B warrants, representing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303,574</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock, to (i) reduce the exercise price from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,964</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series B warrants were issued and outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company issued pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,227</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("2024 Pre-Funded Warrants") and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,044,726</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series C warrants in a private placement. The 2024 Pre-Funded Warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.003</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, were exercisable immediately and are exercisable until the 2024 Pre-Funded Warrant is exercised in full. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a 2024 Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the 2024 Pre-Funded Warrants terms. The 2024 Pre-Funded Warrants meet the criteria for permanent equity classification. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,593</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2024 Pre-Funded Warrants were outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Series C warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Series C warrants are exercisable immediately and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 4, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Series C warrants meet the criteria for permanent equity classification. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">828,863</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series C warrants were outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2025, the Company entered into privately negotiated letter agreements with certain holders of outstanding Series A warrants and Series B warrants (the "Participating Holders") to (i) exercise, for cash, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239,293</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series A warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series B warrants for the purchase of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310,696</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, in each case at a reduced exercise price of (a) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for Participating Holders who are directors or executive officers of the Company and (b) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for all other Participating Holders and (ii) exchange certain Series A warrants and Series B warrants for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,014</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants (the "Exchanged Pre-Funded Warrants"), in each case for a cash payment of (a) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant share for Participating Holders who are directors or executive officers of the Company and (b) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant share for all other Participating Holders (the "Warrant Exchanges"), for aggregate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Exchanged Pre-Funded Warrants issued in connection with the Warrant Exchanges have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.003</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Each Exchanged Pre-Funded Warrant is exercisable immediately and will be exercisable until such Exchanged Pre-Funded Warrant is exercised in full. In lieu of a cash payment to the Company in payment of the aggregate exercise price upon exercise of an Exchanged Pre-Funded Warrant, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Exchanged Pre-Funded Warrants. Under the terms of the Exchanged Pre-Funded Warrants, the Company shall not effect the exercise of any portion of any Exchanged Pre-Funded Warrant, and a holder shall not have the right to exercise any portion of any Exchanged Pre-Funded Warrant, to the extent that after giving effect to such exercise, the holder (together with its affiliates and any other persons acting as a group together with the holder or any of its affiliates) would beneficially own in excess of 4.99% or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, as applicable, of the number of shares of common stock outstanding immediately after giving effect to such exercise. However, a holder may, upon written notice to the Company, increase or decrease such percentage to any other percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided that any increase or decrease in such percentage will not be effective until 61</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">days </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after such notice is delivered to the Company. The Exchanged Pre-Funded Warrants meet the criteria for permanent equity classification. As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,732</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of these Exchanged Pre-Funded Warrants were outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the Company issued pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,452,677</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the "2025 Pre-Funded Warrants") in a private placement. The 2025 Pre-Funded Warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, were exercisable immediately and are exercisable until the 2025 Pre-Funded Warrant is exercised in full. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a 2025 Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the 2025 Pre-Funded Warrants terms. The 2025 Pre-Funded Warrants meet the criteria for permanent equity classification. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,452,677</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2025 Pre-Funded Warrants were outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,620,002</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,964</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series B warrants, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">828,863</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series C warrants outstanding. Of these, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,452,677</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,325</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.003</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Series B warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 13, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Series C warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 4, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. STOCK-BASED COMPENSATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2018 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 7, 2018, the Company established and adopted the 2018 Equity Incentive Plan (the "2018 Plan") providing for the granting of stock awards for employees, directors and consultants to purchase shares of the Company&#8217;s common stock. Upon the effectiveness of the 2020 Plan (as defined below), the 2018 Plan was terminated and no further issuances were made under the 2018 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2018 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2020 Equity Incentive Plan (the "2020 Plan") was approved by the Company's Board of Directors and the Company&#8217;s stockholders and became effective on July 29, 2021. Upon the effectiveness of the 2023 Plan (as defined below), the 2020 Plan was terminated and no further issuances were made under the 2020 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2020 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated 2023 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended and Restated 2023 Equity Incentive Plan (the "2023 Plan") was approved by the Company's Board of Directors and the Company&#8217;s stockholders and became effective on June 15, 2023. Upon the effectiveness of the 2026 Plan (as defined below), the 2023 Plan was terminated and no further issuances were made under the 2023 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2023 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated 2026 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended and Restated 2026 Equity Incentive Plan (the "2026 Plan") was approved by the Company's Board of Directors and the Company&#8217;s stockholders and became effective on May 7, 2026. The Board of Directors, or a committee thereof, is authorized to administer the 2026 Plan. The 2026 Plan provides for the grant of Incentive Stock Options ("ISO") within the meaning of Section 422 of the Internal Revenue Code of 1986 as amended, to employees, and for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to the Company&#8217;s employees, directors and consultants and any Company affiliates&#8217; employees and consultants. The number of shares initially reserved for issuance under the 2026 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,054,937</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which automatically increases on January 1 of each year for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> commencing on January 1, 2027 and ending on (and including) January 1, 2037, in an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of common stock, plus the total number of shares of common stock issuable upon settlement of pre-funded warrants (if any), in each case, outstanding on December 31 of the preceding year, or a lesser number of shares determined by the Board of Directors no later than the last day of the immediately preceding year. The maximum number of shares of common stock that may be issued upon the exercise of ISOs under the 2026 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,474,975</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for grant pursuant to the 2026 Plan.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2020 Employee Stock Purchase Plan (the "2020 ESPP") was approved by the Board of Directors and the Company&#8217;s stockholders and became effective on July 29, 2021. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,666</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under this plan, which automatically increases on January 1 of each year by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding number of shares of common stock on the immediately preceding December 31; and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,333</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or such lesser number of shares as determined by the Board of Directors. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock had been issued under the ESPP and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,260</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">remained available for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issuance under the ESPP. The Board of Directors or designated committee has not set an offering period and the Board of Directors elected not to increase the number of shares of common stock reserved for future issuance under the ESPP as of January 1, 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Activity</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of the stock option award activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2026:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.59%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.602%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.962%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.602%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.142000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number<br/>of Stock<br/>Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">502,027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.42</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.05</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,083,658</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.75</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,723</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at June 30, 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,579,962</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.85</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at June 30, 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">415,044</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56.48</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.72</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options expected to vest as of June 30, 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,164,918</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.60</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of options granted during the six months ended June 30, 2026 and 2025 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">1.41</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The aggregate intrinsic value is calculated as the difference between the exercise price and the market price of the Company&#8217;s common stock at June 30, 2026 and December 31, 2025.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the six months ended June 30, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the assumptions and the Company&#8217;s methodology for developing each of the assumptions used: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.663%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:14.923%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.73</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102.98</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96.66</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.24</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life (years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> 6.08</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.83</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.07</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Volatility&#8212;The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of comparable public companies over the expected term. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected life&#8212;The expected term represents the period that the Company&#8217;s stock option grants are expected to be outstanding. The expected term of the options granted to employees and non-employee directors by the Company has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk-free interest rate&#8212;The risk-free rate for periods within the estimated life of the stock award is based on the U.S. Treasury yield curve in effect at the time of grant. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend rate&#8212;The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2026 and 2025 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">584</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">657</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">455</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,202</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">753</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,786</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related tax benefits from stock-based compensation expense were recognized for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2026 and 2025. As of June 30, 2026, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. LICENSE AGREEMENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emory University, Children&#8217;s Healthcare of Atlanta, Inc. and UAB Research Foundation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2016, the Company entered into an exclusive license agreement with Emory University, Children&#8217;s Healthcare of Atlanta, Inc. and UAB Research Foundation ("UABRF"), as amended from time to time (the "Emory License Agreement"). The Emory License Agreement was amended in October 2017 and July 2020. Under the Emory License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy related patents and know-how related to gamma-delta T cells developed by Emory University, Children&#8217;s Healthcare of Atlanta, Inc. and UABRF&#8217;s affiliate, the University of Alabama at Birmingham, to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents or otherwise incorporate or use the licensed technology. Such exclusive license is subject to certain rights retained by these institutions and also the U.S. government.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration of the license granted under the Emory License Agreement, the Company paid Emory University a nominal upfront payment. Between March 2017 and August 2020, the Company issued UABRF an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,046</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock in satisfaction of these antidilution rights.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company is required to pay Emory University development milestones totaling up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, low-single-digit to mid-single-digit tiered running royalties on the net sales of the licensed products, including an annual minimum royalty beginning on a specified period after the first sale of a licensed product, and a share of certain payments that the Company may receive from sublicenses. In addition, in the event no milestone payments have been paid in certain years, the Company will be required to pay an annual license maintenance fee. The Emory License Agreement also requires the Company to reimburse Emory University for the cost of the prosecution and maintenance of the licensed patents. Pursuant to the Emory License Agreement, the Company is required to use its best efforts to develop, manufacture and commercialize the licensed product, and is obligated to meet certain specified deadlines in the development of the licensed products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company may terminate the Emory License Agreement at will at any time upon prior written notice to Emory University. Emory University has the right to terminate the Emory License Agreement if the Company materially breaches the agreement (including failure to meet diligence obligations) and fails to cure such breach within a specified cure period, if the Company becomes bankrupt or insolvent or decides to cease development and commercialization of the licensed product, or if the Company challenges the validity or enforceability of any licensed patents.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive License Agreement with UABRF</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2016, the Company entered into an exclusive license agreement with UABRF, as amended from time to time (the "UABRF License Agreement"). The Company amended the UABRF License Agreement in December 2016, January 2017, June 2017 and November 2018. Under the UABRF License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy-related patents related to the use of gamma-delta T cells, certain CAR-T cells and combination treatments for cellular therapies developed by the University of Alabama at Birmingham and owned by UABRF to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents. Such exclusive license is subject to certain rights retained by UABRF and also the U.S. government.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration of the license granted under the UABRF License Agreement, the Company paid UABRF a nominal upfront payment and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,041</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock to UABRF, which were subject to certain antidilution rights.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company is required to pay UABRF development milestones totaling up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, lump-sum royalties on cumulative net sales totaling up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, mid-single-digit running royalties on net sales of the licensed products, low-single-digit running royalties on net sales of the licensed products, and a share of certain non-royalty income that the Company may receive, including from any sublicenses. The UABRF License Agreement also requires the Company to reimburse UABRF for the cost of the prosecution and maintenance of the licensed patents.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the UABRF License Agreement, the Company is required to use good faith reasonable commercial efforts to develop, manufacture and commercialize the licensed product.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the UABRF License Agreement will continue until the expiration of the licensed patents. The Company may terminate the UABRF License Agreement at will at any time upon prior written notice to UABRF. UABRF has the right to terminate the UABRF License Agreement if the Company materially breaches the agreement and fails to cure such breach within a specified cure period, if the Company fails to diligently undertake development and commercialization activities as set forth in the development and commercialization plan, if the Company underreports its payment obligations or underpays by more than a specified threshold, if the Company challenges the validity or enforceability of any licensed patents, or if the Company becomes bankrupt or insolvent.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. NET LOSS PER SHARE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of pre-funded warrants to purchase shares of common stock. Diluted net loss per share is the same as basic net loss per share for the periods presented since the effects of potentially dilutive securities are antidilutive given the net loss of the Company.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:48.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.52%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,781</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,871</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share&#8212;basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.65</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares used in computing net loss per share&#8212;basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,467,091</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,119,153</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,468,087</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,920,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.09%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.418%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.418%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.418%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.658%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,338,242</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">504,132</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,073,566</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">482,622</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,793</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,137</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333,424</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">363,603</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series C warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">828,863</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">997,638</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">828,863</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,008,304</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,334,069</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,052,987</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,069,393</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,159,666</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. COMMITMENTS AND CONTINGENCIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has existing commitments to the licensors of the intellectual property which the Company has licensed. These commitments are based upon certain clinical research, regulatory, financial and sales milestones being achieved. Additionally, the Company is obligated to pay a single-digit royalty on commercial sales on a global basis of licensed products under the Emory License Agreement and the UABRF License Agreement. The royalty term is the later of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from first commercial sale or expiration of the last-to-expire component of the licensed intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred costs related to such legal proceedings.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment and Facility Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_LeaseOfLesseeDisclosureTextBlock', window );">Equipment and Facility Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.  EQUIPMENT AND Facility LEASES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has historically entered into lease arrangements for its facilities. As of June 30, 2026, the Company had four operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective date. The Company&#8217;s leases generally do not include termination or purchase options.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finance Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into an agreement with an equipment leasing company in 2018, which provided up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for equipment purchases in the form of sale and leasebacks or direct leases. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026, the Company has two active </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">leases from the leasing company. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into an agreement with another equipment leasing company in the second quarter of 2023. As of June 30, 2026, the Company had one active lease from this leasing company. In June 2024, the Company entered into two new finance lease agreements with another leasing company. The terms of these lease are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The equipment leases require three advance rental payments to be held as security deposits. The security deposits held amounted to approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2026 and December 31, 2025, respectively, and are included in other non-current assets on the condensed balance sheets.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an operating lease for office space in Birmingham, Alabama, which was modified and expanded in March 2024 for a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term ending in March 2029, with an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend five years, resulting in an increase to both the right-of-use assets and operating lease liabilities.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. In April 2025, the Company terminated its operating lease for additional unutilized office space in Birmingham, Alabama. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid a one-time termination fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and paid five monthly payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, beginning on June 1, 2025.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of October 1, 2025, there were no payments remaining.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an operating lease for office space in New York, New York, with a term that commenced on September 15, 2021, and continues through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has identified an embedded lease within the University of Louisville Manufacturing Services Agreement, as the Company has the exclusive use of, and control over, a portion of the manufacturing facility and equipment of the facility during the contractual term of the manufacturing arrangement. The commencement date of the embedded lease was August 4, 2022 and it continues through August 2028.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The operating leases require security deposits at the inception of each lease. The security deposits amounted to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2026 and December 31, 2025. As of June 30, 2026 and December 31, 2025, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was included in restricted cash.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains a summary of the lease costs recognized and other information pertaining to the Company&#8217;s finance and operating leases for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2026 and 2025 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of finance lease right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">525</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">765</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on finance lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">339</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">445</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">646</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">248</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,792</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Lease Information</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liability&#8201;&#8211;&#8201;finance leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liability&#8201;&#8211;&#8201;operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term&#8201;&#8211;&#8201;finance leases (years)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term&#8201;&#8211;&#8201;operating leases (years)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.16</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate&#8201;&#8211;&#8201;finance leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.9</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate&#8201;&#8211;&#8201;operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.9</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the undiscounted cash flows to the operating and finance lease liabilities at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,019</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">680</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,385</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">334</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,051</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: short-term lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">923</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,128</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_LeaseOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Of Lessee DisclosureText Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_LeaseOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.  SEGMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the CODM or decision making group in making decisions on how to allocate resources and assess performance. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">segment</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> focused on the discovery, development and commercialization of gamma-delta T cell product candidates and TCEs for cancer and autoimmune disease. The CODM is the Company&#8217;s CEO. The CEO manages the Company&#8217;s operations, assesses performance for the operating segment and decides how to allocate resources based on net loss, which is reported on the condensed statements of operations. Depreciation expense, amortization expense, stock-based compensation expense, and non-cash lease expense are significant noncash items included in net loss reviewed by the CFO and CEO and are reported on the condensed statements of cash flows. The measure of segment assets is reported on the condensed balance sheets as total consolidated assets.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents certain financial data for the Company&#8217;s reportable segment:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.41%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-100 research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">623</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">454</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-200 research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-400 research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">626</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related indirect research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,266</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,241</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,577</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,442</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,714</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,095</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,402</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">725</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,451</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,646</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,781</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,871</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items include preclinical expenses, interest income and other income.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant Accounting Policies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the notes thereto, are included in the Company&#8217;s Annual Report on Form 10-K (the "Annual Report") that was filed with the Securities and Exchange Commission ("SEC") on March 12, 2026. Since the date of that filing, there have been no material changes to the Company&#8217;s significant accounting policies.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States ("U.S. GAAP").</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unaudited Interim Financial Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto in the Annual Report. The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and the related valuation allowance, stock-based compensation, the useful lives of property and equipment and the valuation of warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash and restricted cash. All of the Company&#8217;s cash and restricted cash is deposited in accounts with major financial institutions. Such deposits are in excess of the federally insured limits.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation and amortization of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated useful lives of the Company&#8217;s respective assets are as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:78.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:55.128%;box-sizing:content-box;"></td>
           <td style="width:1.282%;box-sizing:content-box;"></td>
           <td style="width:2.564%;box-sizing:content-box;"></td>
           <td style="width:38.462%;box-sizing:content-box;"></td>
           <td style="width:2.564%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Machinery and equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The shorter of the useful life of the leasehold improvement or the remaining term of the lease</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated and amortized in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the condensed balance sheets and any gain or loss is reflected in the condensed statements of operations.</span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Capitalized Software</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalized Software</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes the application development phase costs of internal use software in accordance with Accounting Standard Codification ("ASC") Topic 350-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangibles-Goodwill and Other-Internal Use Software</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Capitalized costs will be amortized on a straight-line basis over the estimated useful life of the asset upon completion.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker ("CODM") in deciding how to allocate resources and assess performance. The Company has one operating segment, which is the business focused on the discovery, development and commercialization of gamma-delta T cell product candidates and TCEs for cancer and autoimmune diseases. The CODM is the Company&#8217;s Chief Executive Officer ("CEO"). The CEO manages the Company&#8217;s operations, assesses performance for the operating segment and decides how to allocate resources based on net loss, which is reported on the condensed statements of operations. All of the Company&#8217;s long-lived assets are held in the United States. For additional segment information, see Note 13, Segments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards Updates</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Standards Updates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated all issued and unadopted Accounting Standards Updates issued by the Financial Accounting Standards Board, and believes the adoption of these standards will not have a material impact on the condensed financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for internal-use software. Excludes software to be sold, leased, or marketed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated useful lives of the Company&#8217;s respective assets are as follows:</span>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:78.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:55.128%;box-sizing:content-box;"></td>
           <td style="width:1.282%;box-sizing:content-box;"></td>
           <td style="width:2.564%;box-sizing:content-box;"></td>
           <td style="width:38.462%;box-sizing:content-box;"></td>
           <td style="width:2.564%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Machinery and equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
          </tr>
          <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The shorter of the useful life of the leasehold improvement or the remaining term of the lease</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated and amortized in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the condensed balance sheets and any gain or loss is reflected in the condensed statements of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">529</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">540</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Machinery and equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">627</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">346</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">346</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,924</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,924</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,699</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,199</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,600</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,858</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trials</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">712</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,305</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued legal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">761</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,633</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and current liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Award Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of the stock option award activity during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2026:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.59%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.602%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.962%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.602%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.142000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number<br/>of Stock<br/>Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">502,027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.42</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.05</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,083,658</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.75</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,723</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at June 30, 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,579,962</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.85</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at June 30, 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">415,044</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56.48</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.72</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options expected to vest as of June 30, 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,164,918</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.60</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the assumptions and the Company&#8217;s methodology for developing each of the assumptions used: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.663%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:14.923%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.73</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102.98</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96.66</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.24</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life (years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> 6.08</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.83</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.07</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2026 and 2025 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">584</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">657</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">455</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,202</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">753</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,786</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:48.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.52%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,781</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,871</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share&#8212;basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.65</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares used in computing net loss per share&#8212;basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,467,091</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,119,153</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,468,087</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,920,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.09%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.418%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.418%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.418%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.658%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,338,242</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">504,132</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,073,566</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">482,622</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,793</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,137</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333,424</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">363,603</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series C warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">828,863</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">997,638</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">828,863</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,008,304</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,334,069</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,052,987</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,069,393</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,159,666</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment and Facility Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs and Other Information to Company's Finance and Operating Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains a summary of the lease costs recognized and other information pertaining to the Company&#8217;s finance and operating leases for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2026 and 2025 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of finance lease right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">525</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">765</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on finance lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">339</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">445</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">646</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">248</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,792</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2026</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Lease Information</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liability&#8201;&#8211;&#8201;finance leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liability&#8201;&#8211;&#8201;operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term&#8201;&#8211;&#8201;finance leases (years)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term&#8201;&#8211;&#8201;operating leases (years)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.16</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate&#8201;&#8211;&#8201;finance leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.9</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate&#8201;&#8211;&#8201;operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.9</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Financing Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the undiscounted cash flows to the operating and finance lease liabilities at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2026 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,019</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">680</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,385</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">334</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,051</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: short-term lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">923</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,128</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating and Finance Lease Liability Maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of fnancial data for the company's reportable segment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents certain financial data for the Company&#8217;s reportable segment:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.41%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-100 research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">623</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">454</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-200 research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INB-400 research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">626</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related indirect research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,266</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,241</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,577</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,442</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,714</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,095</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,402</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">725</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,451</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,646</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,781</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,871</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items include preclinical expenses, interest income and other income.</span></span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Losses from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,781<span></span>
</td>
<td class="nump">$ 5,094<span></span>
</td>
<td class="nump">$ 9,871<span></span>
</td>
<td class="nump">$ 10,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (141,096)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (141,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,956<span></span>
</td>
<td class="nump">$ 13,226<span></span>
</td>
<td class="nump">17,956<span></span>
</td>
<td class="nump">13,226<span></span>
</td>
<td class="nump">27,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,579,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_PublicFloat', window );">Public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inab_SecMember', window );">SEC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_PublicFloat', window );">Public float</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inab_SecMember', window );">SEC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_PublicFloat', window );">Public float</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inab_AtmMember', window );">ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember', window );">Series A Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Losses from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesBWarrantsMember', window );">Series B Warrants | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesCWarrantsMember', window );">Series C Warrants | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_OrganizationAndNatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of organization and nature of operations by type.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_OrganizationAndNatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_PublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Float</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_PublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inab_SecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inab_SecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inab_AtmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inab_AtmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 905<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478704/905-360-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482222/360-10-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of property, plant, and equipment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses And Other Current Assets - Schedule of Prepaid expenses and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property And Equipment, Net - Schedule of Components of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">$ (3,699)<span></span>
</td>
<td class="num">$ (3,199)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareInternallyDevelopedAndPurchasedMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant, and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">$ 3,924<span></span>
</td>
<td class="nump">$ 3,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480204/360-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 905<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478704/905-360-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482222/360-10-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478443/942-360-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareInternallyDevelopedAndPurchasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareInternallyDevelopedAndPurchasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_AccruedClinicalTrials', window );">Accrued clinical trials</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_AccruedCompensation', window );">Accrued compensation</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">$ 1,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_AccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_AccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Capital units, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_PublicFloat', window );">Public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,579,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inab_AtmMember', window );">ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_CommonStockAvailableForSaleAmount', window );">Common Stock Available For Sale , Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inab_SecMember', window );">SEC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_PublicFloat', window );">Public float</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inab_SecMember', window );">SEC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_PublicFloat', window );">Public float</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_CommonStockAvailableForSaleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Available For Sale , Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_CommonStockAvailableForSaleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_PublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Float</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_PublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inab_AtmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inab_AtmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inab_SecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inab_SecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,853,121<span></span>
</td>
<td class="nump">9,766,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,853,121<span></span>
</td>
<td class="nump">9,766,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inab_TwoThousandTwentyFourPre-FundedWarrantsMember', window );">2024 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inab_TwoThousandTwentyFivePreFundedWarrantsMember', window );">2025 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,452,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Pre funded warrants issued for purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,452,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inab_ExchangedPre-FundedWarrantsMember', window );">Exchanged Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">41,014<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds From warrant exchanges</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_AffiliatesPercentageOfWarrants', window );">Affiliates percentage of warrants</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_IncreaseOrDecreasePercentageOfWarrants', window );">Increase or decrease percentage of warrants</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inab_SeriesAWarrantMember', window );">Series A Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="nump">$ 5.53<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">239,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inab_SeriesBWarrantMember', window );">Series B Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="nump">$ 5.35<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">71,403<span></span>
</td>
<td class="nump">166,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Redeeem warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 13,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inab_SeriesBWarrantMember', window );">Series B Warrant | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inab_SeriesBWarrantMember', window );">Series B Warrant | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inab_SeriesCWarrantMember', window );">Series C Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  04,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyThreeMember', window );">2023 Private Placement | 2023 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyThreeMember', window );">2023 Private Placement | Series A Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyThreeMember', window );">2023 Private Placement | Series B Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">303,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyThreeMember', window );">2023 Private Placement | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFourMember', window );">2024 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_WarrantsModificationDescription', window );">Warrants Modification Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with the closing of the Company's private placement in October 2024, the Company amended certain of the Company&#8217;s outstanding Series A warrants, representing approximately 390,462 shares of the Company&#8217;s common stock, to (i) reduce the exercise price from $37.50 to $13.50 per share and (ii) extend the termination date of such Series A warrants to October 4, 2025.  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFourMember', window );">2024 Private Placement | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFourMember', window );">2024 Private Placement | Series A Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFourMember', window );">2024 Private Placement | Series A Warrant | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFourMember', window );">2024 Private Placement | Series A Warrant | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFiveMember', window );">2025 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">310,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFiveMember', window );">2025 Private Placement | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,620,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFiveMember', window );">2025 Private Placement | Pre-Funded Warrants One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,452,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFiveMember', window );">2025 Private Placement | Pre-Funded Warrants Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFiveMember', window );">2025 Private Placement | Series B Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 13,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFiveMember', window );">2025 Private Placement | Series C Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per unit of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  04,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_AffiliatesPercentageOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Affiliates Percentage of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_AffiliatesPercentageOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_IncreaseOrDecreasePercentageOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase or Decrease percentage of warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_IncreaseOrDecreasePercentageOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_WarrantsModificationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Modification Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_WarrantsModificationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_TwoThousandTwentyFourPre-FundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_TwoThousandTwentyFourPre-FundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_TwoThousandTwentyFivePreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_TwoThousandTwentyFivePreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_ExchangedPre-FundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_ExchangedPre-FundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_SeriesAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_SeriesAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_SeriesCWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_SeriesCWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_TwoThousandTwentyThreePre-FundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_TwoThousandTwentyThreePre-FundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inab_PrivatePlacementTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_Pre-FundedWarrantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_Pre-FundedWarrantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_Pre-FundedWarrantsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_Pre-FundedWarrantsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2023</div></th>
<th class="th"><div>Jul. 29, 2021</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">4,054,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares of common stock issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit from stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which cost not yet recognized is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based payment arrangement, unrecognized stock based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember', window );">Amended and Restated 2026 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration', window );">Shares reserved of issuance under the plan increase duration</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding', window );">Percentage of number of shares of common stock outstanding</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember', window );">Amended and Restated 2026 Equity Incentive Plan | January One Two Thousand Twenty Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_TwoThousandTwentySixEquityIncentivePlanMember', window );">2026 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based payment award, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,474,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,474,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based payment award, shares issued in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,666<span></span>
</td>
<td class="nump">26,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding', window );">Percentage of number of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Total Number of Shares of Common Stock Outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Reserved of Issuance Under the Plan Increase Duration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=inab_JanuaryOneTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=inab_JanuaryOneTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inab_TwoThousandTwentySixEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inab_TwoThousandTwentySixEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock Option Award Activities (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance</a></td>
<td class="nump">502,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">1,083,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="num">(5,723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance</a></td>
<td class="nump">1,579,962<span></span>
</td>
<td class="nump">502,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exerciseable</a></td>
<td class="nump">415,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested or expected to vest</a></td>
<td class="nump">1,164,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price, beginning balance</a></td>
<td class="nump">$ 50.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price</a></td>
<td class="nump">1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted average exercise price</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited, weighted average exercise price</a></td>
<td class="nump">8.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price, ending balance</a></td>
<td class="nump">17.19<span></span>
</td>
<td class="nump">$ 50.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price</a></td>
<td class="nump">56.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested or expected to vest, weighted average exercise price</a></td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term</a></td>
<td class="text">8 years 10 months 6 days<span></span>
</td>
<td class="text">8 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted average remaining contractual term</a></td>
<td class="text">6 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested or expected to vest, weighted average remaining contractual term</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested or expected to vest, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested option for which requisite service period has not been rendered but that is expected to vest based on achievement of performance condition, if forfeiture is recognized when it occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">101.73%<span></span>
</td>
<td class="nump">96.66%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate minimum</a></td>
<td class="nump">3.83%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">102.98%<span></span>
</td>
<td class="nump">99.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate maximum</a></td>
<td class="nump">4.07%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">$ 955<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 1,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense', window );">Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense', window );">Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 584<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">9,853,121<span></span>
</td>
<td class="nump">9,766,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inab_EmoryLicenseAgreementMember', window );">Emory License Agreement [Member] | UABRF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_LicenseAgreementDescription', window );">License agreement description</a></td>
<td class="text">The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inab_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | UABRF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">3,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_RoyaltiesOnCumulativeNetSales', window );">Royalties on cumulative net sales</a></td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inab_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | UABRF [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_LicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_LicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_RoyaltiesOnCumulativeNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties On Cumulative Net Sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_RoyaltiesOnCumulativeNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inab_EmoryLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inab_EmoryLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inab_UABRFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inab_UABRFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inab_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inab_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Additional Information) (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted-average number of shares of outstanding</a></td>
<td class="nump">9.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,781)<span></span>
</td>
<td class="num">$ (5,090)<span></span>
</td>
<td class="num">$ (5,094)<span></span>
</td>
<td class="num">$ (5,550)<span></span>
</td>
<td class="num">$ (9,871)<span></span>
</td>
<td class="num">$ (10,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (3.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (3.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per share - basic</a></td>
<td class="nump">19,467,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,119,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,468,087<span></span>
</td>
<td class="nump">2,920,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per share - diluted</a></td>
<td class="nump">19,467,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,119,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,468,087<span></span>
</td>
<td class="nump">2,920,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">2,334,069<span></span>
</td>
<td class="nump">2,052,987<span></span>
</td>
<td class="nump">2,069,393<span></span>
</td>
<td class="nump">2,159,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inab_StockOptionsToPurchaseCommonStockMember', window );">Stock Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">1,338,242<span></span>
</td>
<td class="nump">504,132<span></span>
</td>
<td class="nump">1,073,566<span></span>
</td>
<td class="nump">482,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">217,793<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">305,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">166,964<span></span>
</td>
<td class="nump">333,424<span></span>
</td>
<td class="nump">166,964<span></span>
</td>
<td class="nump">363,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">828,863<span></span>
</td>
<td class="nump">997,638<span></span>
</td>
<td class="nump">828,863<span></span>
</td>
<td class="nump">1,008,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inab_StockOptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inab_StockOptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inab_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_RoyaltyTerm', window );">Royalty term</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_RoyaltyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_RoyaltyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment and Facility Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Sep. 15, 2021</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_TerminationFee', window );">Termination fee</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_OneTimeTerminationFeeDescription', window );">One time termination fee description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company paid a one-time termination fee of $0.1 million and paid five monthly payments of $20,000, beginning on June 1, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_MonthlyPayments', window );">Monthly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=inab_BirminghamAlabamaMember', window );">Birmingham, Alabama</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember', window );">Office Building | Birmingham, Alabama</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">March 2027<span></span>
</td>
<td class="text">option to extend five years, resulting in an increase to both the right-of-use assets and operating lease liabilities.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_EquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionDescriptionOfAssetS', window );">Leaseback transaction, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_EquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases', window );">Amount held for equipment purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_MonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_MonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_OneTimeTerminationFeeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One TimeTermination Fee Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_OneTimeTerminationFeeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale leaseback transaction, amount held for equipment purchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_TerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_TerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482645/405-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.W.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478482/942-210-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionDescriptionOfAssetS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the transaction and the assets involved in the sale of property to another party and the lease of the property back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionDescriptionOfAssetS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=inab_BirminghamAlabamaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=inab_BirminghamAlabamaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment and Facility Leases - Schedule of Lease Costs and Other Information to Company's Finance and Operating Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_AmortizationOfFinanceRightOfUseAssets', window );">Amortization Of finance right-of-use assets</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance lease liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="nump">445<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">$ 1,122<span></span>
</td>
<td class="nump">717<span></span>
</td>
<td class="nump">$ 1,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_CashPaidForAmountsIncludedInFinanceLeases', window );">Cash paid for amounts included in the measurement of lease liability &#8211; finance leases</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_CashPaidForAmountsIncludedInOperatingLeases', window );">Cash paid for amounts included in the measurement of lease liability &#8211; operating leases</a></td>
<td class="nump">$ 245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8211; finance leases</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8211; operating leases</a></td>
<td class="text">2 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8211; finance leases</a></td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8211; operating leases</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_AmortizationOfFinanceRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of finance right-of-use assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_AmortizationOfFinanceRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_CashPaidForAmountsIncludedInFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid For Amounts Included in Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_CashPaidForAmountsIncludedInFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_CashPaidForAmountsIncludedInOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid For Amounts Included in Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_CashPaidForAmountsIncludedInOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equipment and Facility Leases - Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Finance Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2026</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payment</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Short-term finance lease liability</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2026</a></td>
<td class="nump">620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2027</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2028</a></td>
<td class="nump">680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2029</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payment</a></td>
<td class="nump">2,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">2,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liability</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">$ 1,128<span></span>
</td>
<td class="nump">$ 1,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_NumberOfReportableSegmentsNotDisclosedFlag', window );">Number of Reportable Segments not Disclosed Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_NumberOfReportableSegmentsNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Reportable Segments not Disclosed [Flag]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_NumberOfReportableSegmentsNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of financial data for the company's reportable segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Personnel-related indirect research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,577<span></span>
</td>
<td class="nump">$ 2,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,095<span></span>
</td>
<td class="nump">5,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Segment net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,781<span></span>
</td>
<td class="nump">$ 5,090<span></span>
</td>
<td class="nump">5,094<span></span>
</td>
<td class="nump">$ 5,550<span></span>
</td>
<td class="nump">9,871<span></span>
</td>
<td class="nump">10,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=inab_INB-100Member', window );">INB-100</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_SegmentResearchAndDevelopmentExpenses', window );">Segment research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=inab_INB-200Member', window );">INB-200</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_SegmentResearchAndDevelopmentExpenses', window );">Segment research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=inab_INB-400Member', window );">INB-400</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inab_SegmentResearchAndDevelopmentExpenses', window );">Segment research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 626<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items include preclinical expenses, interest income and other income.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inab_SegmentResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment Rresearch and Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inab_SegmentResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=inab_INB-100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=inab_INB-100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=inab_INB-200Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=inab_INB-200Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=inab_INB-400Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=inab_INB-400Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>171</ContextCount>
  <ElementCount>251</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets1</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNet1</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureWarrants1</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995555 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingencies1</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Equipment and Facility Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeases1</Role>
      <ShortName>Equipment and Facility Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureSegments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets1</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNet1</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Equipment and Facility Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesTables</Role>
      <ShortName>Equipment and Facility Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeases1</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://in8bio.com/20260630/taxonomy/role/DisclosureSegments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Organization and Nature of Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails</Role>
      <ShortName>Organization and Nature of Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Prepaid Expenses And Other Current Assets - Schedule of Prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses And Other Current Assets - Schedule of Prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Property And Equipment, Net - Schedule of Components of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property And Equipment, Net - Schedule of Components of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Property And Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property And Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails</Role>
      <ShortName>Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Stock-based Compensation - Schedule of Stock Option Award Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock Option Award Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Stock-based Compensation - Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995885 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995905 - Disclosure - NET LOSS PER SHARE (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>NET LOSS PER SHARE (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Equipment and Facility Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails</Role>
      <ShortName>Equipment and Facility Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Equipment and Facility Leases - Schedule of Lease Costs and Other Information to Company's Finance and Operating Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails</Role>
      <ShortName>Equipment and Facility Leases - Schedule of Lease Costs and Other Information to Company's Finance and Operating Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Equipment and Facility Leases - Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Finance Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Equipment and Facility Leases - Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Finance Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995985 - Disclosure - SEGMENTS (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails</Role>
      <ShortName>SEGMENTS (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="inab-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Segments - Schedule of financial data for the company's reportable segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails</Role>
      <ShortName>Segments - Schedule of financial data for the company's reportable segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="inab-20260630.htm">inab-20260630.htm</File>
    <File>inab-20260630.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img122832063_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="509">http://fasb.org/us-gaap/2026</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "inab-20260630.htm": {
   "nsprefix": "inab",
   "nsuri": "http://in8bio.com/20260630",
   "dts": {
    "inline": {
     "local": [
      "inab-20260630.htm"
     ]
    },
    "schema": {
     "local": [
      "inab-20260630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd",
      "https://xbrl.sec.gov/ecd/2026/ecd-sub-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    }
   },
   "keyStandard": 211,
   "keyCustom": 40,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 16,
   "memberCustom": 31,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2026": 4
   },
   "contextCount": 171,
   "entityCount": 1,
   "segmentCount": 49,
   "elementCount": 590,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2026": 509,
    "http://xbrl.sec.gov/dei/2026": 31,
    "http://xbrl.sec.gov/ecd/2026": 4
   },
   "report": {
    "R1": {
     "role": "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1",
     "longName": "75010 - Statement - CONDENSED BALANCE SHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:Cash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
     "longName": "75020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited",
     "longName": "75030 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited)",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
     "longName": "75040 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_d0886603-a24d-4329-9904-e737992b8142",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c96bc108-9aae-4257-b173-6aafb51ec3cc",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3",
     "longName": "75050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperations",
     "longName": "995455 - Disclosure - Organization and Nature of Operations",
     "shortName": "Organization and Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets1",
     "longName": "995475 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNet1",
     "longName": "995485 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995505 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquity",
     "longName": "995525 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrants1",
     "longName": "995535 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensation",
     "longName": "995545 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreements",
     "longName": "995555 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "995575 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingencies1",
     "longName": "995585 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeases1",
     "longName": "995595 - Disclosure - Equipment and Facility Leases",
     "shortName": "Equipment and Facility Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "inab:LeaseOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "inab:LeaseOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureSegments",
     "longName": "995605 - Disclosure - Segments",
     "shortName": "Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995635 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "inab:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "inab:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "995645 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "995655 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995675 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "inab:AccruedExpensesAndCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "inab:AccruedExpensesAndCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "995695 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995705 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesTables",
     "longName": "995715 - Disclosure - Equipment and Facility Leases (Tables)",
     "shortName": "Equipment and Facility Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "inab:LeaseOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "inab:LeaseOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsTables",
     "longName": "995725 - Disclosure - Segments (Tables)",
     "shortName": "Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails",
     "longName": "995735 - Disclosure - Organization and Nature of Operations - Additional Information (Details)",
     "shortName": "Organization and Nature of Operations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e18de340-3840-49e9-a880-e2fa0ca3b8ba",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "995745 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_2f17ba0a-7fb9-42d7-bb76-df75063b2d08",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2f17ba0a-7fb9-42d7-bb76-df75063b2d08",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "995755 - Disclosure - Prepaid Expenses And Other Current Assets - Schedule of Prepaid expenses and other current assets (Details)",
     "shortName": "Prepaid Expenses And Other Current Assets - Schedule of Prepaid expenses and other current assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails",
     "longName": "995765 - Disclosure - Property And Equipment, Net - Schedule of Components of Property and Equipment, Net (Details)",
     "shortName": "Property And Equipment, Net - Schedule of Components of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "995775 - Disclosure - Property And Equipment, Net - Additional Information (Details)",
     "shortName": "Property And Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995795 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "inab:AccruedClinicalTrials",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inab:AccruedExpensesAndCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "inab:AccruedClinicalTrials",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inab:AccruedExpensesAndCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "995825 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:CapitalUnitsAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:CapitalUnitsAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Warrants - Additional Information (Details)",
     "shortName": "Warrants - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_141ba882-944c-447d-9a26-353741846e49",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "longName": "995845 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_2b8acd72-67e8-49aa-b360-6976c9610ae0",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2b8acd72-67e8-49aa-b360-6976c9610ae0",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails",
     "longName": "995855 - Disclosure - Stock-based Compensation - Schedule of Stock Option Award Activities (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock Option Award Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_5aedac8f-e138-47d1-88fb-74d7d9c0feca",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails",
     "longName": "995865 - Disclosure - Stock-based Compensation - Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted (Details)",
     "shortName": "Stock-based Compensation - Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails",
     "longName": "995875 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
     "longName": "995885 - Disclosure - License Agreements - Additional Information (Details)",
     "shortName": "License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41f9322c-2c47-48ad-880f-4d68924f360c",
      "name": "inab:LicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
     "longName": "995905 - Disclosure - NET LOSS PER SHARE (Additional Information) (Details)",
     "shortName": "NET LOSS PER SHARE (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "995915 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "995925 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995935 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "inab:RoyaltyTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "inab:RoyaltyTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails",
     "longName": "995945 - Disclosure - Equipment and Facility Leases - Additional Information (Details)",
     "shortName": "Equipment and Facility Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_0499d8bf-2153-47ac-bbac-d9cd024bdf7f",
      "name": "inab:TerminationFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "span",
       "inab:OneTimeTerminationFeeDescription",
       "span",
       "p",
       "inab:LeaseOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0499d8bf-2153-47ac-bbac-d9cd024bdf7f",
      "name": "inab:TerminationFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "span",
       "inab:OneTimeTerminationFeeDescription",
       "span",
       "p",
       "inab:LeaseOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails",
     "longName": "995955 - Disclosure - Equipment and Facility Leases - Schedule of Lease Costs and Other Information to Company's Finance and Operating Liabilities (Details)",
     "shortName": "Equipment and Facility Leases - Schedule of Lease Costs and Other Information to Company's Finance and Operating Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "inab:AmortizationOfFinanceRightOfUseAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "inab:LeaseOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "inab:AmortizationOfFinanceRightOfUseAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "inab:LeaseOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails",
     "longName": "995965 - Disclosure - Equipment and Facility Leases - Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Finance Lease Liabilities (Details)",
     "shortName": "Equipment and Facility Leases - Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Finance Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inab:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5d20a02-97de-4fad-9d67-9830ebf05b96",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inab:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails",
     "longName": "995985 - Disclosure - SEGMENTS (Additional Information) (Details)",
     "shortName": "SEGMENTS (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ed27e52-d578-4124-a699-38d69b156df6",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails",
     "longName": "995995 - Disclosure - Segments - Schedule of financial data for the company's reportable segment (Details)",
     "shortName": "Segments - Schedule of financial data for the company's reportable segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inab-20260630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r960",
      "r965"
     ]
    },
    "inab_AccruedClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AccruedClinicalTrials",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trials",
        "label": "Accrued Clinical Trials",
        "terseLabel": "Accrued clinical trials"
       }
      }
     },
     "auth_ref": []
    },
    "inab_AccruedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AccruedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Compensation",
        "documentation": "Accrued compensation"
       }
      }
     },
     "auth_ref": []
    },
    "inab_AccruedExpensesAndCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AccruedExpensesAndCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities",
        "label": "Accrued Expenses and Current Liabilities [Table Text Block]",
        "documentation": "Accrued expenses and current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued expenses and other current liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "inab_AccruedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AccruedResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development",
        "label": "Accrued Research And Development",
        "documentation": "Accrued Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "label": "Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "terseLabel": "Less accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r226",
      "r235",
      "r568",
      "r569",
      "r581",
      "r1058"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "totalLabel": "Additional Paid in Capital, Total",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r334",
      "r551",
      "r552",
      "r559",
      "r831",
      "r1198"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r626",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1128",
      "r1200"
     ]
    },
    "inab_AdditionalPurchaseCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AdditionalPurchaseCommonStockShares",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional purchase common stock shares",
        "label": "Additional purchase common stock shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "inab_AffiliatesPercentageOfWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AffiliatesPercentageOfWarrants",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliates Percentage of Warrants",
        "documentation": "Affiliates Percentage of Warrants",
        "terseLabel": "Affiliates percentage of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r880",
      "r890",
      "r922"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r883",
      "r893",
      "r925"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r884",
      "r894",
      "r918",
      "r926",
      "r930",
      "r938"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r396",
      "r398"
     ]
    },
    "inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended and Restated Equity Incentive Plan Two Thousand Twenty Six [Member]",
        "documentation": "Amended and Restated Equity Incentive Plan Two Thousand Twenty Six [Member]",
        "terseLabel": "Amended and Restated 2026 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "inab_AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AmendedAndRestatedEquityIncentivePlanTwoThousandTwentyThreeMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated Equity Incentive Plan Two Thousand Twenty three [Member]",
        "label": "Amended and Restated Equity Incentive Plan Two Thousand Twenty three [Member]",
        "terseLabel": "Amended and Restated 2023 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "inab_AmortizationOfFinanceRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AmortizationOfFinanceRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of finance right-of-use assets",
        "label": "Amortization Of finance right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "inab_AntidilutionProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AntidilutionProvisionMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilution Provision [Member]",
        "documentation": "Antidilution Provision [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from calculation of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r61",
      "r103",
      "r105",
      "r106",
      "r141",
      "r155",
      "r180",
      "r184",
      "r197",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r337",
      "r433",
      "r437",
      "r468",
      "r551",
      "r552",
      "r553",
      "r563",
      "r564",
      "r572",
      "r666",
      "r756",
      "r757",
      "r779",
      "r831",
      "r848",
      "r849",
      "r861",
      "r1076",
      "r1077",
      "r1140"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r89",
      "r103",
      "r105",
      "r106",
      "r197",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r337",
      "r433",
      "r437",
      "r468",
      "r831",
      "r956",
      "r1076",
      "r1077",
      "r1140"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total Non-Current Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r103",
      "r105",
      "r106",
      "r197",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r337",
      "r433",
      "r437",
      "r468",
      "r1076",
      "r1077",
      "r1140"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "inab_AtmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "AtmMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Atm [Member]",
        "label": "ATM [Member]",
        "documentation": "ATM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auction Market Preferred Securities, Stock Series [Axis]",
        "terseLabel": "Auction Market Preferred Securities, Stock Series",
        "documentation": "Information by title of series or issue of auction market preferred securities."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesTitleDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auction Market Preferred Securities, Stock Series, Title [Domain]",
        "terseLabel": "Auction Market Preferred Securities, Stock Series, Title",
        "documentation": "Title of series or issue of auction market preferred securities based on rights (names are typically labeled by day of the week, duration between intervals, or combination of both)."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "inab_BirminghamAlabamaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "BirminghamAlabamaMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Birmingham, Alabama [Member]",
        "label": "Birmingham Alabama [Member]",
        "terseLabel": "Birmingham, Alabama"
       }
      }
     },
     "auth_ref": []
    },
    "inab_BorrowingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "BorrowingInterestRate",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtSummaryOfLoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing Interest Rate.",
        "label": "Borrowing Interest Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Accounting Policies [Text Block]",
        "verboseLabel": "Significant Accounting Policies",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CapitalUnitsAuthorized",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Units, Authorized",
        "terseLabel": "Capital units, authorized",
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails": {
       "parentTag": "us-gaap_ConstructionInProgressGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Cost, Software to be Sold, Leased, or Marketed, before Accumulated Amortization",
        "terseLabel": "Internal use software not yet in service",
        "documentation": "Amount, before accumulated amortization, of capitalized cost for software to be sold, leased, or marketed. Excludes capitalized cost for internal-use software."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r729"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, Beginning Balance",
        "label": "Cash",
        "terseLabel": "Cash",
        "periodEndLabel": "Cash, end of period",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r99",
      "r100",
      "r574",
      "r638",
      "r661",
      "r831",
      "r848",
      "r849",
      "r861",
      "r962",
      "r1145",
      "r1146",
      "r1148"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "periodEndLabel": "Cash and restricted cash at end of period",
        "periodStartLabel": "Cash and restricted cash at beginning of period",
        "totalLabel": "Cash and restricted cash, end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r99",
      "r100"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net (decrease) increase in cash and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r17"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "inab_CashPaidForAmountsIncludedInFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "CashPaidForAmountsIncludedInFinanceLeases",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid For Amounts Included in Finance Leases",
        "label": "Cash Paid For Amounts Included In Finance Leases",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liability \u2013 finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "inab_CashPaidForAmountsIncludedInOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "CashPaidForAmountsIncludedInOperatingLeases",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid For Amounts Included in Operating Leases",
        "label": "Cash Paid For Amounts Included In Operating Leases",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liability \u2013 operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r52",
      "r53",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r103",
      "r106",
      "r130",
      "r131",
      "r133",
      "r135",
      "r143",
      "r144",
      "r197",
      "r258",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r297",
      "r298",
      "r300",
      "r301",
      "r303",
      "r307",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338",
      "r468",
      "r551",
      "r552",
      "r556",
      "r557",
      "r558",
      "r570",
      "r619",
      "r620",
      "r621",
      "r622",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639",
      "r653",
      "r674",
      "r692",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r949",
      "r1029",
      "r1031",
      "r1038",
      "r1088",
      "r1090"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r77",
      "r81",
      "r82",
      "r143",
      "r300",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r326",
      "r327",
      "r329",
      "r330",
      "r332",
      "r333",
      "r336",
      "r338",
      "r443",
      "r551",
      "r552",
      "r557",
      "r558",
      "r619",
      "r620",
      "r621",
      "r622",
      "r949",
      "r1027",
      "r1029",
      "r1088"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per unit of warrants",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r108",
      "r327"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Pre funded warrants issued for purchase of common stock",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r429",
      "r430"
     ]
    },
    "us-gaap_CollateralAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollateralAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collateral Held [Axis]",
        "terseLabel": "Collateral Held",
        "documentation": "Information by category of collateral or no collateral, from lender's perspective."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r764",
      "r765",
      "r766",
      "r840",
      "r841"
     ]
    },
    "us-gaap_CollateralDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollateralDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateral Held",
        "label": "Collateral Held [Domain]",
        "documentation": "Category of collateral or no collateral, from lender's perspective."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r764",
      "r765",
      "r766",
      "r840",
      "r841"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r551",
      "r552",
      "r555",
      "r573",
      "r652"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingencies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r717",
      "r1065",
      "r1070",
      "r1071"
     ]
    },
    "inab_CommonStockAvailableForSaleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "CommonStockAvailableForSaleAmount",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Available For Sale , Amount",
        "documentation": "Common Stock Available For Sale , Amount",
        "terseLabel": "Common Stock Available For Sale , Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r333",
      "r551",
      "r552",
      "r558",
      "r851",
      "r852",
      "r853",
      "r855",
      "r856",
      "r857",
      "r858",
      "r1034",
      "r1035",
      "r1037",
      "r1128",
      "r1197",
      "r1200"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r973",
      "r1086",
      "r1145",
      "r1146",
      "r1152"
     ]
    },
    "inab_CommonStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "CommonStockPurchaseAgreementMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase agreement,",
        "label": "Common Stock Purchase Agreement [Member]",
        "terseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r333",
      "r551",
      "r552",
      "r558",
      "r653"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate of common stock shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r333",
      "r551",
      "r552",
      "r558"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r333",
      "r551",
      "r552",
      "r558",
      "r653",
      "r672",
      "r1081",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.0001 per share; 490,000,000 shares authorized at June 30, 2026 and December 31, 2025; 9,853,121 and 9,766,132 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r298",
      "r306",
      "r333",
      "r551",
      "r552",
      "r558",
      "r576",
      "r831"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r467"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total construction in progress",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "inab_ConstructionInProgressTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "ConstructionInProgressTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgress"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction in Progress [Text Block]",
        "label": "Construction in Progress [Text Block]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of IPO, Value",
        "verboseLabel": "Conversion of preferred stock - Series A into common stock",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of IPO",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r320",
      "r855",
      "r856",
      "r857",
      "r858",
      "r957",
      "r972",
      "r1082",
      "r1083",
      "r1084",
      "r1085"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r56",
      "r57",
      "r63",
      "r64",
      "r67",
      "r69",
      "r70",
      "r72",
      "r73",
      "r103",
      "r104",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r256",
      "r257",
      "r267",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r283",
      "r290",
      "r291",
      "r293",
      "r443",
      "r479",
      "r551",
      "r552",
      "r554"
     ]
    },
    "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentDateOfFirstRequiredPayment1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, Date of first required payment",
        "label": "Debt Instrument, Date of First Required Payment",
        "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r961",
      "r967"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtSummaryOfLoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r479",
      "r480",
      "r829",
      "r961",
      "r967",
      "r1145",
      "r1146",
      "r1149"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r73",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r327",
      "r443",
      "r551",
      "r552",
      "r554",
      "r567",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r829",
      "r1027",
      "r1028",
      "r1030",
      "r1033",
      "r1133",
      "r1134"
     ]
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentPaymentTerms",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, Payment terms",
        "label": "Debt Instrument, Payment Terms",
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r961",
      "r968"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r28",
      "r29",
      "r30",
      "r57",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r73",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r327",
      "r443",
      "r551",
      "r552",
      "r554",
      "r567",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r829",
      "r1027",
      "r1028",
      "r1030",
      "r1033",
      "r1133",
      "r1134"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r60"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangement with Individual, Share-Based Payments [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r96",
      "r224",
      "r737",
      "r738",
      "r740",
      "r742"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r362",
      "r391",
      "r392",
      "r394",
      "r784"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share - basic",
        "terseLabel": "Net loss per share attributable to common stockholders - basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r95",
      "r113",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r128",
      "r130",
      "r133",
      "r134",
      "r135",
      "r140",
      "r220",
      "r296",
      "r354",
      "r395",
      "r423",
      "r428",
      "r460",
      "r461",
      "r562",
      "r586",
      "r744"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share - diluted",
        "terseLabel": "Net loss per share attributable to common stockholders - diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r95",
      "r113",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r130",
      "r133",
      "r134",
      "r135",
      "r140",
      "r220",
      "r296",
      "r354",
      "r395",
      "r423",
      "r428",
      "r460",
      "r461",
      "r562",
      "r586",
      "r744"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r136",
      "r137",
      "r138",
      "r139",
      "r342"
     ]
    },
    "inab_EmoryLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "EmoryLicenseAgreementMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emory License Agreement [Member]",
        "documentation": "Emory License Agreement.",
        "terseLabel": "Emory License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Employee Benefits And Share Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based payment arrangement, unrecognized stock based compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period over which cost not yet recognized is expected to be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Tax benefit from stock based compensation expense",
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquipmentMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r52",
      "r81",
      "r82",
      "r92",
      "r93",
      "r94",
      "r110",
      "r111",
      "r112",
      "r114",
      "r121",
      "r123",
      "r125",
      "r142",
      "r198",
      "r199",
      "r219",
      "r220",
      "r221",
      "r295",
      "r326",
      "r331",
      "r332",
      "r333",
      "r336",
      "r338",
      "r341",
      "r352",
      "r353",
      "r355",
      "r356",
      "r395",
      "r412",
      "r413",
      "r420",
      "r421",
      "r422",
      "r424",
      "r427",
      "r428",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r481",
      "r498",
      "r512",
      "r551",
      "r552",
      "r557",
      "r558",
      "r570",
      "r585",
      "r610",
      "r611",
      "r612",
      "r626",
      "r692",
      "r1090"
     ]
    },
    "inab_EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "EquityIncentivePlanMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 equity incentive plan.",
        "label": "Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r419",
      "r468",
      "r950",
      "r951",
      "r952",
      "r1122",
      "r1123",
      "r1124",
      "r1125"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r880",
      "r890",
      "r922"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r877",
      "r887",
      "r919"
     ]
    },
    "inab_ExchangedPre-FundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "ExchangedPre-FundedWarrantsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchanged Pre-Funded Warrants [Member]",
        "documentation": "Exchanged pre-funded warrants.",
        "terseLabel": "Exchanged Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "inab_ExclusiveLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "ExclusiveLicenseAgreementMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exclusive License Agreement [Member]",
        "documentation": "Exclusive License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on finance lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r489",
      "r830"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finance Leases:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease liability",
        "totalLabel": "Finance Lease, Liability, Total",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r496"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Short-term finance lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term finance lease liability",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payment",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1028",
      "r1033",
      "r1153"
     ]
    },
    "inab_FinanceLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1028",
      "r1033",
      "r1153"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1028",
      "r1033",
      "r1153"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1028",
      "r1033",
      "r1153"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments on financing leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r493"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets - finance leases",
        "totalLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "verboseLabel": "Right of use assets - financing leases",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finance Lease Right Of Use Asset Amortization, Total",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "verboseLabel": "Amortization of finance right-of-use assets",
        "terseLabel": "Amortization of finance lease right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r489",
      "r830"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate \u2013 finance leases",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r830"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term \u2013 finance leases",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r830"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived, Class [Axis]",
        "documentation": "Information by class of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r515",
      "r516",
      "r617",
      "r729",
      "r732",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r1058",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived, Class [Domain]",
        "documentation": "Class of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r617",
      "r729",
      "r732",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r1058",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r884",
      "r894",
      "r926"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r884",
      "r894",
      "r926"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r884",
      "r894",
      "r926"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r884",
      "r894",
      "r926"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r884",
      "r894",
      "r926"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FurnitureAndFixturesGross",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails": {
       "parentTag": "us-gaap_ConstructionInProgressGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressScheduleOfConstructionInProgressDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures, Gross",
        "terseLabel": "Furniture",
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative",
        "terseLabel": "Total general and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r676"
     ]
    },
    "inab_INB-100Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "INB-100Member",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INB-100",
        "label": "INB-100 [Member]",
        "documentation": "INB-100 Member"
       }
      }
     },
     "auth_ref": []
    },
    "inab_INB-200Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "INB-200Member",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INB-200",
        "label": "INB-200 [Member]",
        "documentation": "INB-200 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_INB-400Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "INB-400Member",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INB-400",
        "label": "INB - 400 [Member]",
        "documentation": "INB - 400 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IPOMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r107",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r416",
      "r417",
      "r418",
      "r571",
      "r616",
      "r624",
      "r786"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r40",
      "r103",
      "r124",
      "r125",
      "r141",
      "r163",
      "r184",
      "r405",
      "r406",
      "r415",
      "r587",
      "r733",
      "r739",
      "r741",
      "r743",
      "r786"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "terseLabel": "Other non-current assets",
        "negatedLabel": "Other non-current assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "inab_IncreaseDecreaseLongTermOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "IncreaseDecreaseLongTermOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "documentation": "Long-term operating lease liabilities.",
        "label": "Increase Decrease Long Term Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "inab_IncreaseDecreaseShortTermOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "IncreaseDecreaseShortTermOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term operating lease liabilities.",
        "label": "Increase Decrease Short Term Operating Lease Liabilities",
        "terseLabel": "Short-term operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "inab_IncreaseOrDecreasePercentageOfWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "IncreaseOrDecreasePercentageOfWarrants",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase or Decrease percentage of warrants",
        "documentation": "Increase or Decrease percentage of warrants",
        "terseLabel": "Increase or decrease percentage of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r884",
      "r894",
      "r918",
      "r926",
      "r930",
      "r938"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r942"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r942"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r942"
     ]
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InternalUseSoftwarePolicy",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized Software",
        "label": "Software, Internal-Use [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for internal-use software. Excludes software to be sold, leased, or marketed."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r158",
      "r184",
      "r756",
      "r978"
     ]
    },
    "inab_JanuaryOneTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "JanuaryOneTwoThousandTwentyFourMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January One Two Thousand Twenty Four [Member]",
        "documentation": "January One Two Thousand Twenty Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_JanuaryOneTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "JanuaryOneTwoThousandTwentyThreeMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January One Two Thousand Twenty Three Member",
        "documentation": "January One Two Thousand Twenty Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "inab_JanuaryOneTwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "JanuaryOneTwoThousandTwentyTwoMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January One Two Thousand Twenty Two [Member]",
        "label": "January One Two Thousand Twenty Two [Member]",
        "terseLabel": "January 1, 2022"
       }
      }
     },
     "auth_ref": []
    },
    "inab_LaboratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "LaboratoryMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory [Member]",
        "label": "Laboratory [Member]",
        "terseLabel": "Laboratory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "terseLabel": "Agreement Threshold",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r830"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Costs and Other Information to Company's Finance and Operating Liabilities",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "inab_LeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "LeaseExpirationMonthAndYear",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration month and year",
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year"
       }
      }
     },
     "auth_ref": []
    },
    "inab_LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Modification of Operating Lease Right-of-use Assets And Liabilities",
        "label": "Lease Modification of Operating Lease Right-of-use Assets And Liabilities",
        "terseLabel": "Lease modification of operating lease right-of-use assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "inab_LeaseOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "LeaseOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeases1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Of Lessee DisclosureText Block",
        "documentation": "Lease Of Lessee DisclosureText Block",
        "terseLabel": "Equipment and Facility Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "inab_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Financing Lease Liabilities",
        "label": "Lessee Operating and Finance Lease Liability Maturity [Table Text Block]",
        "documentation": "Lessee Operating and Finance Lease Liability Maturity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payment",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1028",
      "r1033",
      "r1153"
     ]
    },
    "inab_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1028",
      "r1033",
      "r1153"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1028",
      "r1033",
      "r1153"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r1028",
      "r1033",
      "r1153"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease, option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r103",
      "r105",
      "r106",
      "r197",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r337",
      "r434",
      "r437",
      "r438",
      "r468",
      "r651",
      "r749",
      "r779",
      "r861",
      "r975",
      "r1076",
      "r1140",
      "r1141"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r551",
      "r552",
      "r560",
      "r579",
      "r831",
      "r848",
      "r849",
      "r1027",
      "r1032",
      "r1056",
      "r1132"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r51",
      "r66",
      "r103",
      "r105",
      "r106",
      "r197",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r337",
      "r434",
      "r437",
      "r438",
      "r468",
      "r831",
      "r1076",
      "r1140",
      "r1141"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total Non-Current Liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r103",
      "r105",
      "r106",
      "r197",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r337",
      "r434",
      "r437",
      "r438",
      "r468",
      "r975",
      "r1076",
      "r1140",
      "r1141"
     ]
    },
    "inab_LicenseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "LicenseAgreementDescription",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement description.",
        "label": "License Agreement Description",
        "terseLabel": "License agreement description"
       }
      }
     },
     "auth_ref": []
    },
    "inab_LicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "LicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LicenseMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement [Member]",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_LoansPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LoansPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongTermDebtMaturityDate",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity Date",
        "terseLabel": "Loan maturity, date",
        "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loans Payable, Noncurrent, Total",
        "label": "Loans Payable, Noncurrent",
        "terseLabel": "Loan",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r969"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r551",
      "r552",
      "r554",
      "r1066",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r551",
      "r552",
      "r554",
      "r1066",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r237",
      "r250",
      "r251",
      "r252",
      "r255",
      "r400",
      "r615",
      "r773",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r237",
      "r250",
      "r251",
      "r252",
      "r255",
      "r400",
      "r615",
      "r773",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1062",
      "r1063"
     ]
    },
    "inab_MaturityOfIncreaseOrDecreasePercentage": {
     "xbrltype": "durationItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "MaturityOfIncreaseOrDecreasePercentage",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of increase or decrease percentage",
        "label": "Maturity of Increase or Decrease Percentage",
        "documentation": "Maturity of Increase or Decrease Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MaximumMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r150",
      "r251",
      "r252",
      "r253",
      "r254",
      "r358",
      "r386",
      "r387",
      "r388",
      "r400",
      "r462",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r606",
      "r608",
      "r615",
      "r643",
      "r644",
      "r697",
      "r699",
      "r701",
      "r702",
      "r704",
      "r712",
      "r713",
      "r715",
      "r716",
      "r727",
      "r728",
      "r762",
      "r783",
      "r787",
      "r789",
      "r790",
      "r823",
      "r824",
      "r825",
      "r826",
      "r843",
      "r1078",
      "r1080"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "inab_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MinimumMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r150",
      "r251",
      "r252",
      "r253",
      "r254",
      "r358",
      "r386",
      "r387",
      "r388",
      "r400",
      "r462",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r606",
      "r608",
      "r615",
      "r643",
      "r644",
      "r697",
      "r699",
      "r701",
      "r702",
      "r704",
      "r712",
      "r713",
      "r715",
      "r716",
      "r727",
      "r728",
      "r762",
      "r783",
      "r787",
      "r789",
      "r790",
      "r823",
      "r824",
      "r825",
      "r843",
      "r1078",
      "r1080"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "inab_MonthlyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "MonthlyPayments",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly Payments",
        "documentation": "Monthly payments",
        "terseLabel": "Monthly payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]",
        "terseLabel": "Real Estate, Type of Property"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726"
     ]
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]",
        "terseLabel": "Real Estate"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Nature of Operations",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r146",
      "r746",
      "r747"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash (used in) provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "negatedLabel": "Segment net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r19",
      "r26",
      "r44",
      "r47",
      "r48",
      "r90",
      "r91",
      "r94",
      "r103",
      "r105",
      "r106",
      "r109",
      "r113",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r132",
      "r197",
      "r220",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r296",
      "r299",
      "r302",
      "r308",
      "r337",
      "r354",
      "r395",
      "r423",
      "r428",
      "r461",
      "r468",
      "r584",
      "r673",
      "r690",
      "r691",
      "r739",
      "r741",
      "r743",
      "r859",
      "r1076"
     ]
    },
    "inab_NetProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "NetProceeds",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Net proceeds",
        "documentation": "Net proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards Updates",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "inab_NewYorkOperatingLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "NewYorkOperatingLeaseMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New York Operating Lease Member",
        "documentation": "New York Operating Lease Member",
        "terseLabel": "New York [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r884",
      "r894",
      "r918",
      "r926"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "inab_Nonrule10B51Arrmodifiedflag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "Nonrule10B51Arrmodifiedflag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NonRule10b51ArrModifiedFlag",
        "documentation": "NonRule10b51ArrModifiedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesAndLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NotesAndLoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtSummaryOfLoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan payable",
        "totalLabel": "Notes and Loans Payable, Total",
        "label": "Notes and Loans Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r969",
      "r1154"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r1043"
     ]
    },
    "inab_NumberOfReportableSegmentsNotDisclosedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "NumberOfReportableSegmentsNotDisclosedFlag",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Reportable Segments not Disclosed Flag",
        "label": "Number of Reportable Segments not Disclosed [Flag]",
        "documentation": "Number of Reportable Segments not Disclosed [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficeBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "OfficeBuildingMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Office Building"
       }
      }
     },
     "auth_ref": [
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206"
     ]
    },
    "inab_OneTimeTerminationFeeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "OneTimeTerminationFeeDescription",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One time termination fee description",
        "label": "One TimeTermination Fee Description",
        "documentation": "One TimeTermination Fee Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r954",
      "r955",
      "r1056"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "negatedLabel": "Losses from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r743",
      "r750",
      "r954",
      "r955",
      "r1041",
      "r1044",
      "r1050",
      "r1053",
      "r1054",
      "r1056"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "verboseLabel": "New operating lease",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r830"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liability",
        "verboseLabel": "Lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Short-term operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r736"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfReconciliationOfUndiscountedCashFlowsToOperatingAndFinanceLeaseLiabilitiesDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use assets - operating leases",
        "verboseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate \u2013 operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r830"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term \u2013 operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r830"
     ]
    },
    "inab_OrganizationAndNatureOfOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "OrganizationAndNatureOfOperationsLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of organization and nature of operations by type.",
        "label": "Organization And Nature Of Operations [Line Items]",
        "terseLabel": "Organization And Nature Of Operations [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_OrganizationAndNatureOfOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "OrganizationAndNatureOfOperationsTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and nature of operations.",
        "label": "Organization And Nature Of Operations [Table]",
        "terseLabel": "Organization And Nature Of Operations [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_OrganizationAndNatureOfOperationsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "OrganizationAndNatureOfOperationsTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Nature of Operations",
        "documentation": "Organization and Nature of Operations [Text Block].",
        "label": "Organization And Nature Of Operations [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "verboseLabel": "Other assets current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r831"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r60"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrants1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Warrants",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r75",
      "r1064"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel-related indirect research and development expenses",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r882",
      "r892",
      "r924"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r927"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r927"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_PaycheckProtectionProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PaycheckProtectionProgramMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program.",
        "label": "Paycheck Protection Program [Member]",
        "terseLabel": "Paycheck Protection Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsForProceedsFromProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Productive Assets",
        "totalLabel": "Payments for (Proceeds from) Productive Assets, Total",
        "negatedLabel": "Purchases of property and equipment",
        "terseLabel": "Purchases of property and equipment",
        "documentation": "The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Offering related cost",
        "terseLabel": "Payment of issuance costs",
        "negatedTerseLabel": "Issuance costs",
        "negatedLabel": "Payment of issuance costs from December 2025 issuance of common stock",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "inab_PercentageOfEmployeesTerminated": {
     "xbrltype": "percentItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PercentageOfEmployeesTerminated",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Employees Terminated",
        "documentation": "Percentage Of Employees Terminated",
        "terseLabel": "Percentage of workforce reduction due to restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "inab_PercentageOfReductionInCashCompensation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PercentageOfReductionInCashCompensation",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Reduction in Cash Compensation",
        "documentation": "Percentage of reduction in cash compensation.",
        "terseLabel": "Percentage of reduction in cash compensation"
       }
      }
     },
     "auth_ref": []
    },
    "inab_PercentageOfTotalNumberOfSharesOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PercentageOfTotalNumberOfSharesOfCommonStockOutstanding",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Total Number of Shares of Common Stock Outstanding.",
        "label": "Percentage Of Total Number Of Shares Of Common Stock Outstanding",
        "terseLabel": "Percentage of number of shares of common stock outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Based Award [Member]",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118"
     ]
    },
    "inab_PipelinePrioritizationAndWorkforceReductionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PipelinePrioritizationAndWorkforceReductionMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pipeline Prioritization and Workforce Reduction [Member]",
        "documentation": "Pipeline Prioritization and Workforce Reduction [Member]",
        "terseLabel": "Pipeline Prioritization and Workforce Reduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "inab_Pre-FundedWarrantsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "Pre-FundedWarrantsOneMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants One",
        "label": "Pre-Funded Warrants One [Member]",
        "documentation": "Pre-Funded Warrants One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_Pre-FundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "Pre-FundedWarrantsShares",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants Shares",
        "documentation": "Pre-Funded Warrants Shares"
       }
      }
     },
     "auth_ref": []
    },
    "inab_Pre-FundedWarrantsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "Pre-FundedWarrantsTwoMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants Two [Member]",
        "documentation": "Pre-Funded Warrants Two [Member]",
        "terseLabel": "Pre-Funded Warrants Two"
       }
      }
     },
     "auth_ref": []
    },
    "inab_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrant [Member]",
        "documentation": "Pre-Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrants [Member]",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r81",
      "r331",
      "r332",
      "r341",
      "r551",
      "r552",
      "r557",
      "r851",
      "r852",
      "r855",
      "r856",
      "r857",
      "r858",
      "r1197",
      "r1200"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, per share",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r957",
      "r972",
      "r1085",
      "r1145",
      "r1146",
      "r1151"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock shares authorised",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r81",
      "r332",
      "r551",
      "r552",
      "r557",
      "r653"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r81",
      "r313",
      "r332",
      "r551",
      "r552",
      "r557"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r81",
      "r332",
      "r551",
      "r552",
      "r557",
      "r653",
      "r672",
      "r1081",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r81",
      "r298",
      "r305",
      "r332",
      "r551",
      "r552",
      "r557",
      "r575",
      "r831"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r767",
      "r1057"
     ]
    },
    "inab_PrepaidResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PrepaidResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Research And Development",
        "documentation": "Prepaid Research And Development",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "auth_ref": []
    },
    "inab_PrepaymentPenalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PrepaymentPenalties",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment penalties.",
        "label": "Prepayment Penalties",
        "terseLabel": "Prepayment penalties"
       }
      }
     },
     "auth_ref": []
    },
    "inab_PrivatePlacementTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PrivatePlacementTwoThousandTwentyFiveMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Private Placement",
        "label": "Private Placement Two Thousand Twenty Five [Member]",
        "documentation": "Private Placement Two Thousand Twenty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_PrivatePlacementTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PrivatePlacementTwoThousandTwentyFourMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Two Thousand Twenty Four [Member]",
        "documentation": "Private Placement Two Thousand Twenty Four [Member]",
        "terseLabel": "2024 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "inab_PrivatePlacementTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PrivatePlacementTwoThousandTwentyThreeMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Two Thousand Twenty Three [Member]",
        "documentation": "Private Placement Two Thousand Twenty Three [Member]",
        "terseLabel": "2023 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from the issuance of common stock, net of offering costs",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from the issuance of common stock, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from private placement common stock, net of issuance costs",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Net proceeds From warrant exchanges",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of Series C warrants, net of issuance costs",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Net proceeds From warrant exchanges",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r514",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r730",
      "r738",
      "r741",
      "r743",
      "r780",
      "r781",
      "r842",
      "r843",
      "r844",
      "r847",
      "r850",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1074",
      "r1075",
      "r1156",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r514",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r730",
      "r738",
      "r741",
      "r743",
      "r780",
      "r781",
      "r842",
      "r843",
      "r844",
      "r847",
      "r850",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1074",
      "r1075",
      "r1156",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47",
      "r48",
      "r90",
      "r91",
      "r98",
      "r103",
      "r105",
      "r106",
      "r109",
      "r113",
      "r121",
      "r124",
      "r125",
      "r197",
      "r220",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r296",
      "r337",
      "r354",
      "r395",
      "r423",
      "r428",
      "r432",
      "r435",
      "r436",
      "r461",
      "r468",
      "r563",
      "r565",
      "r583",
      "r625",
      "r673",
      "r690",
      "r691",
      "r733",
      "r818",
      "r819",
      "r860",
      "r976",
      "r1076"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Asset, Class [Axis]",
        "documentation": "Information by class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r497",
      "r769",
      "r770",
      "r771",
      "r772",
      "r1058",
      "r1059",
      "r1142"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNet1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant, and Equipment [Text Block]",
        "documentation": "The entire disclosure for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38",
      "r39",
      "r222",
      "r223",
      "r228",
      "r231",
      "r232",
      "r236"
     ]
    },
    "inab_PropertyPlantAndEquipmentEstimatedUsefulLives1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful lives of Leasehold Improvement",
        "label": "Property Plant And Equipment Estimated Useful Lives 1",
        "documentation": "Property Plant And Equipment Estimated Useful Lives 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "label": "Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount, before accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r58",
      "r225",
      "r582",
      "r1058"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r497",
      "r769",
      "r770",
      "r771",
      "r772",
      "r1058",
      "r1059",
      "r1142"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "documentation": "Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r551",
      "r552",
      "r561",
      "r568",
      "r569",
      "r582",
      "r831",
      "r1062"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment [Policy Text Block]",
        "verboseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38",
      "r227",
      "r229",
      "r580",
      "r1058"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Components of Property and Equipment, Net",
        "documentation": "Tabular disclosure of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Asset, Class [Domain]",
        "documentation": "Class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r497",
      "r769",
      "r770",
      "r771",
      "r772",
      "r1058",
      "r1059",
      "r1142"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives of Leasehold Improvement",
        "label": "Property, Plant, and Equipment, Useful Life",
        "documentation": "Useful life of property, plant, and equipment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "inab_PublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PublicFloat",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "Public Float",
        "terseLabel": "Public float"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PublicUtilitiesPropertyPlantAndEquipmentPlantInServiceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Utilities, Property, Plant and Equipment, Plant in Service [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_PurchaseOfAggregateShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "PurchaseOfAggregateShare",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of Aggregate Share",
        "documentation": "Purchase of Aggregate Share",
        "terseLabel": "Purchase of Aggregate Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r150",
      "r251",
      "r252",
      "r253",
      "r254",
      "r357",
      "r358",
      "r386",
      "r387",
      "r388",
      "r394",
      "r400",
      "r462",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r606",
      "r608",
      "r615",
      "r643",
      "r644",
      "r697",
      "r699",
      "r701",
      "r702",
      "r704",
      "r712",
      "r713",
      "r715",
      "r716",
      "r727",
      "r728",
      "r762",
      "r783",
      "r787",
      "r789",
      "r790",
      "r823",
      "r824",
      "r825",
      "r826",
      "r843",
      "r853",
      "r1069",
      "r1078",
      "r1080",
      "r1130"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r150",
      "r251",
      "r252",
      "r253",
      "r254",
      "r357",
      "r358",
      "r386",
      "r387",
      "r388",
      "r394",
      "r400",
      "r462",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r606",
      "r608",
      "r615",
      "r643",
      "r644",
      "r697",
      "r699",
      "r701",
      "r702",
      "r704",
      "r712",
      "r713",
      "r715",
      "r716",
      "r727",
      "r728",
      "r762",
      "r783",
      "r787",
      "r789",
      "r790",
      "r823",
      "r824",
      "r825",
      "r826",
      "r843",
      "r853",
      "r1069",
      "r1078",
      "r1080",
      "r1130"
     ]
    },
    "inab_ReclassificationOfPriorPresentationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "ReclassificationOfPriorPresentationsPolicyTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of Prior Presentations [Policy Text Block]",
        "documentation": "Reclassification of Prior Presentations [Policy Text Block]",
        "terseLabel": "Reclassification of Prior Presentation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r877",
      "r887",
      "r919"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of loan",
        "totalLabel": "Repayments of Long-term Debt, Total",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r622"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r1121"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r1121"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r1121"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r729",
      "r739",
      "r740",
      "r756",
      "r1143"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r878",
      "r888",
      "r920"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r879",
      "r889",
      "r921"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r928"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total",
        "label": "Restricted Cash",
        "verboseLabel": "Restricted cash, end of period",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r962",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1155"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Costs",
        "totalLabel": "Restructuring Costs, Total",
        "terseLabel": "Restructuring Costs",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r334",
      "r551",
      "r552",
      "r559",
      "r578",
      "r613",
      "r614",
      "r623",
      "r654",
      "r831"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r110",
      "r111",
      "r112",
      "r114",
      "r121",
      "r123",
      "r125",
      "r198",
      "r199",
      "r219",
      "r220",
      "r221",
      "r295",
      "r331",
      "r341",
      "r352",
      "r353",
      "r355",
      "r356",
      "r395",
      "r412",
      "r413",
      "r420",
      "r421",
      "r422",
      "r424",
      "r427",
      "r428",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r452",
      "r459",
      "r481",
      "r512",
      "r570",
      "r610",
      "r612",
      "r626",
      "r1087",
      "r1089",
      "r1200"
     ]
    },
    "inab_RoyaltiesOnCumulativeNetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "RoyaltiesOnCumulativeNetSales",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties On Cumulative Net Sales.",
        "label": "Royalties On Cumulative Net Sales",
        "terseLabel": "Royalties on cumulative net sales"
       }
      }
     },
     "auth_ref": []
    },
    "inab_RoyaltyTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "RoyaltyTerm",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Royalty term",
        "label": "Royalty term",
        "documentation": "Royalty term"
       }
      }
     },
     "auth_ref": []
    },
    "inab_Rule10B51Arrmodifiedflag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "Rule10B51Arrmodifiedflag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule10B51ArrModifiedFlag",
        "documentation": "Rule10B51ArrModifiedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "inab_SaleLeasebackTransactionAmountHeldForEquipmentPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SaleLeasebackTransactionAmountHeldForEquipmentPurchases",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount held for equipment purchases",
        "label": "Sale Leaseback Transaction, Amount Held for Equipment Purchases",
        "documentation": "Sale leaseback transaction, amount held for equipment purchases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleLeasebackTransactionDescriptionOfAssetS": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleLeasebackTransactionDescriptionOfAssetS",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Leaseback Transaction, Description of Asset(s)",
        "terseLabel": "Leaseback transaction, description",
        "documentation": "A description of the transaction and the assets involved in the sale of property to another party and the lease of the property back to the seller."
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from sale of common stock",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate net proceeds from offering",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Gross proceeds",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "inab_ScheduleOfConstructionInProgressTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "ScheduleOfConstructionInProgressTableTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureConstructionInProgressTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of construction in progress [Table Text Block]",
        "label": "Schedule of construction in progress [Table Text Block]",
        "terseLabel": "Schedule of construction in progress"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Loan Payable",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangement with Individual, Share-Based Payment [Table]",
        "terseLabel": "Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]",
        "documentation": "Disclosure of information about equity-based arrangements (such as stock or unit options and stock or unit awards) with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r419",
      "r468",
      "r950",
      "r951",
      "r952",
      "r1122",
      "r1123",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "inab_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of property plant and equipment estimated useful lives.",
        "label": "Schedule of Property Plant and Equipment Estimated Useful Lives [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment [Table]",
        "documentation": "Disclosure of information about property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r497",
      "r769",
      "r770",
      "r771",
      "r772",
      "r1058",
      "r1059",
      "r1142"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r1121"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Table]",
        "documentation": "Disclosure of information about segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of fnancial data for the company's reportable segment",
        "label": "Segment Reporting [Table Text Block]",
        "documentation": "Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total."
       }
      }
     },
     "auth_ref": [
      "r1042",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1051",
      "r1052",
      "r1055"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r394"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Award Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r52",
      "r81",
      "r82",
      "r143",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r326",
      "r327",
      "r329",
      "r330",
      "r332",
      "r333",
      "r336",
      "r338",
      "r443",
      "r551",
      "r552",
      "r557",
      "r558",
      "r619",
      "r620",
      "r621",
      "r622",
      "r949",
      "r1027",
      "r1029",
      "r1088"
     ]
    },
    "inab_SecMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SecMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC [Member]",
        "documentation": "SEC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "terseLabel": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r964"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r141",
      "r152",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r192",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r217",
      "r230",
      "r234",
      "r245",
      "r247",
      "r425",
      "r426",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r753",
      "r756",
      "r757",
      "r768",
      "r846",
      "r1156",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1195",
      "r1196"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r147",
      "r190",
      "r191",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r563",
      "r564",
      "r565",
      "r566",
      "r640",
      "r641",
      "r642",
      "r698",
      "r700",
      "r703",
      "r705",
      "r712",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r731",
      "r745",
      "r780",
      "r782",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r845",
      "r853",
      "r1156",
      "r1158",
      "r1159",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Text Block]",
        "terseLabel": "Segments",
        "documentation": "The entire disclosure for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r167",
      "r169",
      "r170",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r192",
      "r751",
      "r754",
      "r755",
      "r756",
      "r758",
      "r760",
      "r761"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r169",
      "r170",
      "r184",
      "r756"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r187",
      "r190",
      "r752",
      "r753",
      "r759"
     ]
    },
    "inab_SegmentResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SegmentResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Research and Development Expenses",
        "documentation": "Segment Rresearch and Development Expenses",
        "terseLabel": "Segment research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "inab_SeriesABWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SeriesABWarrantsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A &amp; B Warrants [Member]",
        "documentation": "Series A &amp; B Warrants [Member]",
        "terseLabel": "Series A &amp; B Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SeriesAMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Financing",
        "label": "Series A [Member]",
        "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series B."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r957",
      "r958",
      "r970",
      "r971",
      "r972",
      "r1079",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1145",
      "r1146",
      "r1150",
      "r1151"
     ]
    },
    "inab_SeriesAWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SeriesAWarrantMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Warrant [Member]",
        "label": "Series A Warrant [Member]",
        "terseLabel": "Series A Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "inab_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Warrants [Member]",
        "label": "Series A Warrants [Member]",
        "terseLabel": "Series A Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "inab_SeriesBWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SeriesBWarrantMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Warrant [Member]",
        "label": "Series B Warrant [Member]",
        "terseLabel": "Series B Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "inab_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Warrants [Member]",
        "label": "Series B Warrants [Member]",
        "terseLabel": "Series B Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "inab_SeriesCWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SeriesCWarrantMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Warrant [Member]",
        "documentation": "Series C Warrant [Member]",
        "terseLabel": "Series C Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "inab_SeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SeriesCWarrantsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Warrants",
        "label": "Series C Warrants [Member]",
        "documentation": "Series C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Severance payments",
        "verboseLabel": "Severance and related charges",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum number of shares of common stock issuable",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award, number of shares available for grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exerciseable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Options forfeited",
        "negatedLabel": "Options forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r957",
      "r972",
      "r973",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r957",
      "r972",
      "r973",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant-date fair value of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance",
        "periodStartLabel": "Options outstanding, beginning balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, weighted average exercise price, ending balance",
        "periodStartLabel": "Options outstanding, weighted average exercise price, beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested or expected to vest, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested or expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested or expected to vest, weighted average exercise price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Share-based payment award, shares issued in period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, weighted average exercise price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited, weighted average exercise price",
        "negatedTerseLabel": "Options forfeited, weighted average exercise price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options granted, weighted average exercise price",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfEstimatingFairValueOfTheStockOptionsAndCommonStockWarrantsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, weighted average remaining contractual term",
        "documentation": "Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining contractual term",
        "documentation": "Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term",
        "terseLabel": "Options vested or expected to vest, weighted average remaining contractual term",
        "documentation": "Weighted-average contractual term remaining for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested option for which requisite service period has not been rendered but that is expected to vest based on achievement of performance condition, if forfeiture is recognized when it occurs."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesIssued",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Shares, Issued, Ending Balance",
        "periodStartLabel": "Shares, Issued, Beginning Balance",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Shares ending",
        "periodStartLabel": "Shares beginning",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1087",
      "r1089"
     ]
    },
    "inab_SharesReservedOfIssuanceUnderPlanIncreaseDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "SharesReservedOfIssuanceUnderPlanIncreaseDuration",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Reserved of Issuance Under the Plan Increase Duration.",
        "label": "Shares Reserved Of Issuance Under Plan Increase Duration",
        "terseLabel": "Shares reserved of issuance under the plan increase duration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r830"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102"
     ]
    },
    "us-gaap_SoftwareInternallyDevelopedAndPurchasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SoftwareInternallyDevelopedAndPurchasedMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software [Member]",
        "label": "Software, Internally Developed and Purchased [Member]",
        "documentation": "Internally developed and purchased software. Excludes in-development software."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1058",
      "r1207",
      "r1208",
      "r1209",
      "r1210"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSegmentsScheduleOfFinancialDataForTheCompanysReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r141",
      "r152",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r192",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r217",
      "r230",
      "r234",
      "r245",
      "r247",
      "r425",
      "r426",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r753",
      "r756",
      "r757",
      "r768",
      "r846",
      "r1156",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r52",
      "r53",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r103",
      "r106",
      "r130",
      "r131",
      "r133",
      "r135",
      "r143",
      "r144",
      "r197",
      "r258",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r297",
      "r298",
      "r300",
      "r301",
      "r303",
      "r307",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338",
      "r468",
      "r551",
      "r552",
      "r556",
      "r557",
      "r558",
      "r570",
      "r619",
      "r620",
      "r621",
      "r622",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639",
      "r653",
      "r674",
      "r692",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r949",
      "r1029",
      "r1031",
      "r1038",
      "r1088",
      "r1090"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r52",
      "r81",
      "r82",
      "r92",
      "r93",
      "r94",
      "r110",
      "r111",
      "r112",
      "r114",
      "r121",
      "r123",
      "r125",
      "r142",
      "r198",
      "r199",
      "r219",
      "r220",
      "r221",
      "r295",
      "r326",
      "r331",
      "r332",
      "r333",
      "r336",
      "r338",
      "r341",
      "r352",
      "r353",
      "r355",
      "r356",
      "r395",
      "r412",
      "r413",
      "r420",
      "r421",
      "r422",
      "r424",
      "r427",
      "r428",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r481",
      "r498",
      "r512",
      "r551",
      "r552",
      "r557",
      "r558",
      "r570",
      "r585",
      "r610",
      "r611",
      "r612",
      "r626",
      "r692",
      "r1090"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r147",
      "r190",
      "r191",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r563",
      "r564",
      "r565",
      "r566",
      "r640",
      "r641",
      "r642",
      "r698",
      "r700",
      "r703",
      "r705",
      "r712",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r731",
      "r745",
      "r780",
      "r782",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r845",
      "r853",
      "r1156",
      "r1158",
      "r1159",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r56",
      "r57",
      "r62",
      "r72",
      "r74",
      "r77",
      "r80",
      "r81",
      "r82",
      "r85",
      "r110",
      "r111",
      "r112",
      "r142",
      "r297",
      "r298",
      "r300",
      "r303",
      "r310",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r340",
      "r341",
      "r351",
      "r481",
      "r514",
      "r551",
      "r552",
      "r556",
      "r557",
      "r558",
      "r618",
      "r627",
      "r639",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r692",
      "r734",
      "r741",
      "r743",
      "r854",
      "r1199"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeLocationBalanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfIncomeLocationBalanceAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Location, Statement of Income, Balance [Axis]",
        "documentation": "Information by location in statement of income line item where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r243",
      "r244",
      "r246",
      "r439",
      "r440",
      "r441",
      "r442",
      "r463",
      "r464",
      "r465",
      "r469",
      "r470",
      "r471",
      "r607",
      "r609",
      "r677",
      "r729",
      "r787",
      "r788",
      "r820",
      "r821",
      "r822",
      "r827",
      "r828",
      "r1126",
      "r1127",
      "r1157"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited3",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r52",
      "r53",
      "r56",
      "r57",
      "r62",
      "r72",
      "r74",
      "r77",
      "r80",
      "r81",
      "r82",
      "r85",
      "r110",
      "r111",
      "r112",
      "r142",
      "r193",
      "r297",
      "r298",
      "r300",
      "r303",
      "r310",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r340",
      "r341",
      "r351",
      "r481",
      "r514",
      "r551",
      "r552",
      "r556",
      "r557",
      "r558",
      "r570",
      "r618",
      "r627",
      "r639",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r692",
      "r734",
      "r741",
      "r743",
      "r854",
      "r1199"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r881",
      "r891",
      "r923"
     ]
    },
    "inab_Stock-BasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "Stock-BasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Stock-based compensation expense",
        "documentation": "Stock-based compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118"
     ]
    },
    "inab_StockIssueDuringPeriodValueSeriesCWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "StockIssueDuringPeriodValueSeriesCWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issue During Period Value Series C Warrants Exercised",
        "documentation": "Stock Issue During Period Value Series C Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of Series C warrants, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r327",
      "r957",
      "r972",
      "r973",
      "r1081",
      "r1085",
      "r1086",
      "r1087",
      "r1089",
      "r1145",
      "r1146",
      "r1151",
      "r1152"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period shares new issues, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued and sold",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r692",
      "r707",
      "r957",
      "r972",
      "r973",
      "r1081",
      "r1085",
      "r1086",
      "r1087",
      "r1089",
      "r1145",
      "r1146",
      "r1151",
      "r1152"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": [
      "r957",
      "r972",
      "r973",
      "r1085",
      "r1086"
     ]
    },
    "inab_StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssued During Period Shares Series A And B Warrants Exercised",
        "documentation": "StockIssued During Period Shares Series A and B Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of Series A&amp;B warrants, net of issuance costs , Share"
       }
      }
     },
     "auth_ref": []
    },
    "inab_StockIssuedDuringPeriodSharesSeriesAWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesSeriesAWarrantsExercised",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Series A Warrants Exercised",
        "documentation": "Stock Issued During Period, Shares, Series A Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of Series A warrants, net of issuance costs , Share"
       }
      }
     },
     "auth_ref": []
    },
    "inab_StockIssuedDuringPeriodSharesSeriesCWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesSeriesCWarrantsExercised",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Series C Warrants Exercised",
        "documentation": "Stock Issued During Period Shares Series C Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of Series C warrants, net of issuance costs, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionAwardActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Options exercised",
        "negatedLabel": "Options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r957",
      "r972",
      "r973",
      "r1081",
      "r1085",
      "r1086",
      "r1087",
      "r1089",
      "r1145",
      "r1146",
      "r1151",
      "r1152"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r957",
      "r972",
      "r973",
      "r1081",
      "r1085",
      "r1086",
      "r1087",
      "r1089",
      "r1145",
      "r1146",
      "r1151",
      "r1152"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period shares new issues, amount",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r692",
      "r707",
      "r860",
      "r957",
      "r972",
      "r973",
      "r1081",
      "r1085",
      "r1086",
      "r1087",
      "r1089",
      "r1145",
      "r1146",
      "r1151",
      "r1152"
     ]
    },
    "inab_StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssued During Period Value Series A and B Warrants Exercised",
        "documentation": "StockIssued During Period Value Series A and B Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of Series A&amp;B warrants, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "inab_StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Series A Warrants Exercised Value",
        "documentation": "Stock Issued During Period Value Series A Warrants Exercised Value",
        "terseLabel": "Issuance of common stock upon exercise of Series A warrants, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "inab_StockOptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "StockOptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options to purchase common stock member.",
        "label": "Stock Options To Purchase Common Stock [Member]",
        "terseLabel": "Stock Options to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance beginning",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance ending",
        "totalLabel": "Total Stockholders' Equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r655",
      "r672",
      "r693",
      "r694",
      "r831",
      "r861",
      "r975",
      "r1027",
      "r1031",
      "r1032",
      "r1056",
      "r1132",
      "r1200"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r81",
      "r82",
      "r86",
      "r309",
      "r312",
      "r314",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r332",
      "r333",
      "r336",
      "r338",
      "r339",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r443",
      "r457",
      "r458",
      "r502",
      "r695",
      "r696",
      "r711"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r500"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r500"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r500"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r500"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r500"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r501"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Temporary equity amount ending",
        "periodStartLabel": "Temporary equity amount beginning",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Convertible preferred stock, Series A, (Note 7)",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r77",
      "r80",
      "r258",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r297",
      "r298",
      "r300",
      "r304",
      "r337",
      "r397",
      "r399",
      "r551",
      "r552",
      "r556",
      "r577"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Temporary equity shares ending",
        "periodStartLabel": "Temporary equity shares beginning",
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Convertible preferred stock, Series A, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r77",
      "r300",
      "r551",
      "r552",
      "r556"
     ]
    },
    "inab_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares conversion of share.",
        "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Share",
        "terseLabel": "Temporary equity conversion of convertible preferred stock to common stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "inab_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period value conversion of share.",
        "label": "Temporary Equity Stock Issued During Period Value Conversion Of Share",
        "terseLabel": "Temporary equity conversion of convertible preferred stock to common stock"
       }
      }
     },
     "auth_ref": []
    },
    "inab_TerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "TerminationFee",
     "crdr": "debit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Fee",
        "documentation": "Termination Fee",
        "terseLabel": "Termination fee"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "inab_TwoThousandAndTwentyEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "TwoThousandAndTwentyEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Employee Stock Purchase Plan.",
        "label": "Two Thousand And Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "inab_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Equity Incentive Plan.",
        "label": "Two Thousand And Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "inab_TwoThousandTwentyFivePreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "TwoThousandTwentyFivePreFundedWarrantsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Pre-Funded Warrants",
        "label": "Two Thousand Twenty Five Pre Funded Warrants [Member]",
        "documentation": "Two Thousand Twenty Five Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_TwoThousandTwentyFourPre-FundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "TwoThousandTwentyFourPre-FundedWarrantsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Pre-Funded Warrants",
        "label": "Two Thousand Twenty Four Pre-Funded Warrants [Member]",
        "documentation": "Two Thousand Twenty Four Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_TwoThousandTwentySixEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "TwoThousandTwentySixEquityIncentivePlanMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026 Equity Incentive Plan",
        "label": "Two Thousand Twenty Six Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty Six Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_TwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "TwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "label": "Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "terseLabel": "2023 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "inab_TwoThousandTwentyThreePre-FundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "TwoThousandTwentyThreePre-FundedWarrantsMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three Pre-Funded Warrants [Member]",
        "documentation": "Two Thousand Twenty Three Pre-Funded Warrants [Member]",
        "terseLabel": "2023 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "inab_UABRFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "UABRFMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UABRF",
        "label": "U A B R F [Member]",
        "terseLabel": "UABRF [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inab_UnauditedInterimFinancialInformationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "UnauditedInterimFinancialInformationPolicyTextBlock",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim financial information.",
        "terseLabel": "Unaudited Interim Financial Information",
        "label": "Unaudited Interim Financial Information [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r145",
      "r148",
      "r149",
      "r150",
      "r563",
      "r565",
      "r748"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureEquipmentAndFacilityLeasesScheduleOfLeaseCostsAndOtherInformationToCompanysFinanceAndOperatingLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r830"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeeem warrant exercise price",
        "label": "Warrant, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantMember",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants to Purchase Preferred Stock",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r852",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "warrants outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "inab_WarrantsModificationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "WarrantsModificationDescription",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Modification Description",
        "label": "Warrants Modification Description",
        "documentation": "Warrants Modification Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares of outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares used in computing net loss per common share, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted-average number of shares used in computing net loss per share - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r135"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://in8bio.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares used in computing net loss per common share, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted-average number of shares used in computing net loss per share - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r135"
     ]
    },
    "inab_YearOfMaturity": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://in8bio.com/20260630",
     "localname": "YearOfMaturity",
     "presentation": [
      "http://in8bio.com/20260630/taxonomy/role/Role_DisclosureDebtSummaryOfLoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year of Maturity",
        "documentation": "Year of Maturity.",
        "label": "Year Of Maturity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482943/710-10-55-8"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.Z.5.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-5"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-40/tableOfContent"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-13"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480204/360-10-S45-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482645/405-30-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 5.Q.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.D.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479921/505-20-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.B.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480148/855-10-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478443/942-360-45-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479255/942-310-S50-4"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.H.2.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478116/942-310-S99-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482558/350-40-50-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482222/360-10-30-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405/tableOfContent"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "905",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478704/905-360-25-4"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478482/942-210-50-1"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001193125-26-338012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-338012-xbrl.zip
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M3WO7BO:^QO92E$O!F(/G-?W8=KM 8:6<QU.W7>\=^RZ_?E.-<RA/N-Z>M_!
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MOSJQQWWDD8G]?/%R(&PK^.!_ZZ;_%/JN>NY!!XNXSIX^6%1TQB[F'0 82CT
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M[V K4UM72\<'^WI[^XIV:[>N>9*NWFWB.%ULJ-CWONNX7WO)CPOR16F_V=!
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MM=@5MM^NP98QK[@.Y?TC75QB</5$W&8*:;XN<[#UP*7NXU[O, O;M ?@H$E
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MES&8X*: 1E"U)N%%20@^SCO/DU5QJQ:)V[BC,L L.%6YU8JL[4(Z(TW#L&S
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M.GV@(#&3N""1)0&4O/5>Y1M.T3+U&5)\4UKQ!ZISFD;1YC)YU4>-^*:UZ;[
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M(S:D'D)W1\$EN\#!S5)_<*S2%([[W&AF%V7PAF,;$#&1YFTL0<3:*I*@&XW
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MZOZV8^J7B14(QCQ<9YU8<G#V*J):N<4C9OOZ6.V(:J?'\BA?7IXK2>;()^V
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MKAR/TP2S[4L^F4-GTMTYFU5/^/$LV'Z,#N CR(J+"V92$ 95M4#50&H\*JS
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M"_U.F[KEN6'+48-,&:G0$D^\.=HM5]_R<>P2R>M>NQZU*9SKOAC7NH(39>V
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M&S8ZI[Q$^<LI8)G:ILH2Z^PPJQE?Y^J'%R/QI+S>F#;;!8Q$0(M9$QWGR),
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M#90.I^9J,5'>CB^P)J9&$Q_ZD.6]DS<OI?Y:A-]O?ICEF>5[:A@^-TM@<E\
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M/B\296W6(8T[QR^G'!RO,\O& _F0IV[M34FW_WH5ZKQ(G&?@?^GJ'.5/^6=
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M5@;%F\"E/XS8TL\>''&..AEX)6 .GO#O>.K3Q]X/=>3O$GNTW\U#96'>>FU
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M9>,H?W&%&#91CN[H!!<9UU+&5.<.-4&"<>.M5V?UW"T_1'G <P_O?(.XO$:
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MG<G^!:6($'&@Z2Y[B<CJ6W!.=-;&<\%X(&*#+.T1M:"^T1)_=Q2E'QE<&O]
MLV1L"W+Q$%H;?>]W8$QRIGA" [O'2_-9_O-CV^2Y5%G_EPUX<60EB2??--*
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ME<;*SME17M@5J=GSCA@6JE:P-^=%)O6R1C:JS_T#4;(;)'*0=+;2,\S \C
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M#1]M,+I#>1]5^7\_*Y6U5"$_#G".BW\6M?F%$HTC0*B0;+&_ "2D JL\W$%
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MC,_IAJ<;,6]+LTIO.1:5Z98_"RJV:'D^/G_&6[R"N\+FAYA]4)^=6 ;5BD'
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M<8BM7;A .4C0U[TEHRKV&S/Y,>"^'TWO*USMACI.7+S[Q41S(D@@FQ9%<TU
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M@6NT-%Z@R%:@)AE=9E+WHN', SES5G_P#1]6K0=NM#HAP#?,*-F- ?]/J-H
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M%-"63!,"TVU0U*^NH_,F>5R#C$I6A Y7?\*7] :6_#6^K9-+2<UONI7Q4:G
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MMIR$)0QVL42[:2,N'V8I[$M(7U.4,/I[>QR=M;?[43HG?HI*QLR)O*SG:N;
M:-@-P4/>Y0^9Z/S/O@ F\CNOL:>6L-)#&&^V<"?6&.\Z8B3C78F<.4[!'>4=
M;@)2_QE>I0R@NAY5"6ODO789#-/8K!S>&O[:?^CI-+/N6=?\EURIVA1O<]47
M_MX2;^1J,L+][>.@(L>M@Y<^+HX&TJ/<3&/-Y*]2C&I%]C$<"[P.UY06CIX\
MY%@QZJ51KOK<'(6ZMFG'%V[F'L+<WRDWT@*\F/CWJ,,S C+NPAV&)V.,F:2]
M2^)N]0DHGB'S0YC\M*';Y_-!2O5R>8M-:>F1@15(3H95N16JDN9!<[4\@,>P
MIWZO?,%V0N4$?@!W (,$L]CTCJV"/6R5[BG2@<4V.<"$J-3 /I#'&-P/%7?W
M"'!E99%K4W4]0FW8XE<(2Q,A-\K: XLL(T,#CABD%IGD\*2%^(>EV%N<0V S
M5R< >O ,\(G"H,L+\K$[5@=020WK)YIUYO[T:YIX>O1EF9G&RS*DW*?,JJ7/
M_G)9K?D<?'EOT!#]9E-6'$%2EWT#9'"OXMK?PRB]/; ]_OP]@$HL3PA0UCPV
M:4Y8GKD V/-/C[9$[W^U_&[Z&F, 9S]:5 M\S7GP\DVTQ:!9CD>MN7@@U&EX
M_8YE;7=LIP_XL3#NZ(L'=-OJ*<Z/3 =DAWZB54=P6UVYS!G&(3UATQ6"XZDZ
MM]B/E7?]#78AKL49')ND!Z_F3<]9:WJC+;/*S34"^J80G&0.K!:\R+V%:W>A
MSKY!*&9/=?(OC/+W7@/@#%0'Z^KRN.%0L;\8.L -('0AQ/W:'@0XM5'8L,Z5
M'0EK]OZJD*]FQ<L22JE?'7.?!WRRXQ_6XGKN0MH=>&)<TWY CV.\\XIW0^7Q
MO;= )]J7R4\&TAW!?V8T1S=;%7M67#)0XOX1V_&=Z0>79N3'UC7"W/J-'W6H
M59XN,2?YYQ:[FA!\3\#Z8*M$KB<F>"?-1/4:.W26E'AW9'/R=2"L*U>C$:5!
M8B#D%S.^=C\,?8.NMY#1S41,PD./A)9,YW/RB<BMO2Q7Z\H[8;<VN1+5@@?[
M#T'QV(KO3HL!G&9-8ICGU$OBYA -,;V/!E[9W8R57K?Z7,P._*<N]P_,?UZC
MX<9WO_95?N\T<F-@FR9U-;)U\UWM+WSA&5T@7]A88BZ,(@WLRT<6'CRR^/&L
MPN6<\O+@M&WMY24?]*-_74;*7=N.DME2:J,%BC)9-VR+"7TE3>1[;R+[A@D*
MKDVX84W6R1(TUU(0M/=XD4-8E>4E)B+) +6JQM:[!2:2W+I])1\)=.U^VYX
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M_!OM?-U=2, N!#P/9^EQ_3'RS2"4;=D._8-GS%!;%_/S5&J@@M&,=,4E[,D
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MIPLM>9F/D-4\C-#_^']X[7HM8*<!)</ZO@*=NL8_S.#>Q$Y##Y$'8_#2+1*
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MM6%MB?EAVQ3'[Q<'Y/&V/;K:@@4U9MN9-%<*)HY]".D ^-$S6T4;]+;B]<6
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MC8^2J;(_LLS'Y+9)2:510=^R*YL'O>L4,8;&\<?B'T&\,1,!=H!(&%D@+_%
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M?M;B,H;T#=LYV_!/R5E=F#Z<W[OZ"%L:T),5T3=NO9A:UZ1NK^X5VDC0.UG
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MN^?,:^IJ1I"RLRB^SF+HH7S?GTV?K0%SROR\];RFW:.\1'HS@C[A>['B\-'
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MWD?S#WD$U0ANBVNQUS_,[B/@!"-Z."!A_#ZZ ?%)/CSW^) D16ND+OHP$=C
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MQYYPM_3G#^="[1XK/_=F]1LM./?TU;5P;7HJ^XC,KC+B&;FYL(@I/HP/HG%
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M[5=N605^_7X3$!9+A)15H%7TSU(=S@*^FJG\PN7V]\4BN!=I%>-#6TUJUDR
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M$!,P7SKGR7BV7(RGIF(*:LK])E;$^3?Y)]U+)\G_T\-"^4T'+[T,SIT:+)#
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MDO[UYW_LL> _34KU4L%_G(36HX9LY,\Y!2:@/4*."4CG^X\]IB#=W5IV.$9
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M7)/JAU7](PX3UO6Q6[0Q6J0-5G'\9W/?G ]I8V-S]E7I)\!% *OM*+"Z_NO
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M6[[JK//CH.CG&\1;JZ<3W@57M!HFB%TOCUJ>3Q=I98NY[]PP>M-NBUK(/VT
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MX1VTU_+QJ(Y[X6<)O(3B;DI0]R#BWC_D4;L6_X-S@<+%G)CCRG#*NW> W\?
MUT@VBNN!,@V,!$*B]2C[J7=*R+X\<&+!&D-\@E4'>COI'.348*IE$ U_U&8_
MO?Y?W-14:&-EI8*N,LH=G6#;+M*^\.DED$/A458_P8)(A[F2-I7<;5/!E.6/
M"[-0H@G^7?X3/J4N'*KXTBQ9(WUS4:]'\L$+D\*:%D+,[G=MF;2=(X$[FNQF
MY8L#F^[[BJ[\!R]25LH7R[#L[@(8:0-&A9:VPN5O6IH+.>&2D4@F -AC+^H2
M0WA87"HG =PL?KQF=M"$O1S**OYT-.E&39=9!-8L9W,OD\Z-6JSO4HS,LB4D
M7Z%K4T4+2.!D/C!9V]QQ0B4X,:_RV9[89X*+BWMX_$&VFH\/"/QQ6[PV8X[$
MZ/5FS_)>:HB#>9]$A$LCZLG#7S5%X#U'A4=;[?FT;$=*R]3X,A%5,O53'[O&
MJSS?'_>&O"7D!-&4:G+;W;(<EVI*"6V4RH/%Z2Z4H7=NT4\-WQ?5Q/:]9D+@
M7A"=2XAA.GDJ'ZK19-C);9IE3?<CRI<%K0N2:B%@#CF'G+)B?4AJAA2/\:XU
M.+?W5\^M)=^,'U&9<>[.-MG+@<B X>K5Q2K+@=4EDW0MUK(QA(D?-M,MD$R*
M?A%0H.NKD1Z\>%XG!!^V;F:\._]%D1#&9TSMW00MVI7+,WZY4AVZ8%=KP>_B
MJCV/#%++G-9"$G.K%7CY?9U7[GN^<E0]\&[*OY+ WM..G]QTH>8@PZGAD0O#
MHK3L#F<A6BA.-SH@48K0E#N4?GYV.6;@*K88[C?U[?UZU*$-N CL;:H@9V7N
MX "KYJSITQV9K^KM9;]*NW?P^B0_G(-6\+!NU#"Q31Y1#Z4D+OW^S ).O@:E
M1=M7C:G8N[^/N#V[EF'L(IDA?EN^ZX#KE^Q <)"KKY3M\3TFH$.SLDT>"1UK
MNX'0[!4TCU)A GAG'6"(,O!X[4!S8WD@!_?+HR1L_DEL0=+>FBSGW !V?M M
MT<"A\4+AOPUQ0LYK-A0[4:ENV^%%H&O,P//ALPY<)C9_=HY9E9#O?Y=L@P1K
M9]("LLI$1,#@%2J_\+HF94#ZZW/A-2W(V9@:?G>$5CL?*R_(^FC+Y:;&N';%
M11DOF^?C8Q*66PE?QN5(T3[H(2: X]0I?=8P[P:^F?N7YDK&1?+Q02=CM82S
M0(RV/+$:4Y"6!4\AYUVRIO>_?QY0.N"X:4(Y='4]:%GO1M(O19XT1_9V73=3
M66.:]K$HPK_K(.N9HCI%H9X*=MJYS7TTOC\8N=R2Z*_LKJSPWA?K>=O(X&?%
MQL)_MS[JW#N&T-P/$/][=\]=",TRC> C[?<F!:*N="S SL_-(< $51WE,9P.
MX>K'8EK;NI4I*)!_NW9=MW;M4'"+UKGNZ\9M*3$XWF1K?'P!":-$=Z->\Z(N
MX;.S5:F&;_;@3  +/%RD,74@VYX21G3LP*Z]]%.^T%C%&&QV$K+8$?E=VUS'
MZ2A1JQ$9G=O]H5Q!++JM)MVM(4?25G@-Y&>]!,'H.W-@9'PY+@UY6WTN7-0O
MQE\:7X)J!#G/7QU6^8IX4[TE3=:JN4,.R1&P9<F 1 FQW%VBQ7THM8M9VB^U
MQ%R,Z6[0JY17[['!1@5*XECUL7_AI.1I]X/7HPPI.QH38$>+)HO S,-\A%KA
M'=7S#Y#7_0L&_+,W;Q (2=M%GB4'TA+UU4WX>O"Q/2]+,MY8*]PU_ NJPU!+
M $-+/G@V@03[_W,'NR 22@B92 W:*1^1K*JP0S@\K+MJL%S?]!::Y/GIG%SJ
M+^B#N_  '%KK]BD:-PN:=ZW+.]C1(EW+D,I$4 />J#9Y8R""JE/F @\\R YC
MMWJW.9IO;',=/Q8H"WG9^&I&NP[M*E[U5T27SEV_F!FU@3SO33$T'//& [EI
M\1!B((P;^FM67Y4N=B29J!*2F-Y6^EY913"JHH2%)5Y6_>6W.HC5[/?WO:!X
MQQ#^K+]/7;NT5!DX/>&?(7%%2@@OSGQ^%S$-I8/ L'Y/-8ND&YQ-3$!F%39(
M^F;>5:?79#,1RF&7#?D\="W/Q7#MKS;K )#5&]J(,;$K]6D#'OZ,&G=TW#D:
M^POU74N7W>F\EG[O3RN,\8 3=:PRC3JQ_C&9==J$*DB>(@\80)(: 'G'YM[K
M+#/AHX@'H%>M/-N .7^RW")21,.'W?U]RYSN\G^U#Y3-5%?LQ7@Q 3N/4IF
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MN?+NI0^/F$!W[59V0JK9L$U1PE34C3;>SQ51. =VB'3Q>+YE0*F^,=38+*=
M/&ND<!^J[. TN3_/[56?=1@;6.'0!5W^--+*J*E<4\UJ*T-2""*UYL'%:UR.
MSHZU$ KAG+?*D"5_0:R1T;B!*;>-P>T$Z\=IKMP%_-T2_-VRXBDCXK7&'ADQ
M0_ZYQD,8XWZ,24K:BGI?OW].=AI6W;C1Q#+5Q]*[;MJ[;FBX$\7!N$Z[K%A
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M,<6[3A9?[%GW/?)S_8?A@,RM1EW;RGJ9"G]XX5B7X"3A\\1HAE2RQ9LF'[,
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MJ WRK@H4Q(UBJ[B@Y68&W_0#"H;4*.K4Q!FM9[P2,2L$\DA.-G7Z";(X=^_
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MW%'6$^$\0PEL$YH.HOLQ()0QD]?:(G_F%"ZX'NPCK%BWRQX<E.CL:&^2'&R
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M=]'Y26\)]6XLT("K9_8>^J$<BAN_YLKZ@[I8BDRY;;K?/;NEU>JU0@GG&6>
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MBJI1].(RC7TN4XBIX+$@U@" V9)%#V,95G"4*0UV#'6-B6NC4BRL^SC'4'I
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M/</K\+@U7^:M7_W,/Z2T#H/]!6OT=)OE&K^Z'-+LG_8#+MN0(_9$L71-,:,
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M+I+V(E-KYM;MP9^79O6V#89\2119_V=ZH23_#9&#J5.2:**GHM)DFV1##"0
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MVA/(BG?;XBJ.ZQ9LC&6^L"BIOX\I%&Z"N9D1)Z(37D=ZS]C!BQA:@TGP'(#
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M"&'B(4'KCXL4><5' 6*^/HCFUD0^EQ!NVL:8FIYRNNWS'2VP%2X1T4)^J%H
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M%S2R]/:%9'OIII9,6%_Q77$9,U)@5U55C[VXW!]N%MPQ9A(6L&/[W30PF<P
M7)P^>W=;J"5T><'8!L!$(Q[_K+Y),6.YN"C81/[DTSI+J92U*1-'8*G:(/[@
M&2,WSP 4ZU'#TQX"=^'M6SQ>ZZAF0, A_#&%/54GQ1Z?W7%PW[^L^W)I8!^%
M 3A+?<9U"K1R.GT/\4N)![Q0:=/<V8OMS<TT];%;AHN;=E[B>$=7GY%0O09E
M718]$A68[CS*SE5XPGJLG?+1 @\4IO..S3*D@C&Z "PU$GH Y>[=+'\/EL+3
MQW]&M*I4W/+,&JP=B_RP?*MFUG/?[-VDP-W'S9"-P\\@D9?=D]'!PG_]"S-
M,Y;_T\I)"SS#' GI<ANYM<9VMJ['VVP7>9=G#_!S?19;\SOJWZJ-]6?FAR-#
M59^H_K3^V5/] K#DUO!?;D&"I=@[P*.<V,XMR%X]PW*1Z;+B^>BL"3"MJ[]T
MK\X:(ZDQ/<X$GN 4/.'G_=MPK#XX_ZA,3J0;9$/Z/UQ__!D[[0Y&6'/L4[5=
MBFU4[QQOOV.]<&5X.-[=QN7*\W@WE[,[%'EZ5.Q,;F&3R5+GK)["E. ]K!&;
MU+X=Z.TU72HXU ;Z<^!_^[@[#>N69%S;2Q_4>(B.+0MQF?2N])I$&&]H)#6^
MB.S3T;HP%A9E65:]2FJ-O"3ZE;0DG,".KYSUAUN0(!-^#0PQF.FT>8YWKZXN
MQQ&X_W;$]0(0^/!(;@]B>YP_0B?_X4W6 'W3->$<U3!.BNPEEZI;5![2YQ=;
MY6L9789I^'^ 7/]?CJO_XS67UL?5E=^[/+8@X]\( IS]FOU_S'!>M%#*U&U!
M^O_:@K26;4':623E1>[1__-=V/0I X%=5;-@#K8&VX\5^W.-H7%4R&F7<5N0
MRH-5PE_:2/BU]S_=J_V 313/MO#SB:J%*99=Y!X%@(M_E7]T$RG8)S Z?:MT
M\](H[*U1^P&)?U2</COEJL(Z<,C^*0$-VNC'+]=%2\!XA_S?+\Z\,[/:ZP3:
M#:9>+$&?54];^B8DA"I#(J\:%4_>;].]T#/S=#CF&NQ?0_=";?PVLYX"A+8Y
M9[6B]3)'A?;V6T*B?9C%A\N7X2UNX>T5+;'C'2,(1FFW EL%2KG=:!:M:YE.
ML9%-><_WWLDO18T5>1ELC-:N*"A=(5_*T=;?E_"U'J?]IG3#FZ,G$%-E[+.0
M1 @I;'*7R/"D#]!!2,*E2.$R7^M8M=*/3DMH"/:VR>@_";TX&5%I]>W%-@/;
MO<F\F9$U<TNKT09^H%W[.VJCC_K&N L5R58-"JM"+@5F?A]8IE\Y7%Q 9VE^
M3[,Z;;?/X\[QC/W73K;O]+2O/BBI[%SJ55(YEE#A5IEO9WTB"T,OM<YZY/+-
MT<8IV3W"G/5H/57_U-6;4;AL YEX,ED\$7_00G[W<<-CH_D>Y[1$+*7D-4=?
MEE3:G\3?[=C4+-U@_GE:SFTT,S[TS2),1&=-^>K\/L^0W(XRBL$;.B-D9_^U
M]M'0U>(9[UD_D?[>%Q&R\:.Z@D^935L01%[@2\9AP4=XHP+_GT;D@04LD""E
MA).;ISO&"ZD\$K3.+(C$YTW&F^3]H1LD;A%L4NP #X_4ZY/X;L$N_MJJE9DC
M\;7A!/A)35LZ":HR;^:C!I<-(?:$E6J9^'Q\^O K_7* HWENL&H'VCVE/2#C
MT\E'X[+Y]DU^3[3M/]89O/_V\C.RQB5QC\,S_P>7.2?Q]OO2LW5EO^9&I#_Z
M4K(%N0YC+F'7_B;].K8% =_5^%.V(, 5[ %X\/J?VR25>.:4M6W:66P-^&:S
M^\2D[1>%Q(PWJ4P_K2-?>YY>_8<2[W4Y]\0P[.N:;)^D)/.=G5W DS#=>2>9
MC KE,UVH%^<</CH'K]E4>'<+2Q/>]?DQCIIM3W!WJV>84W)YEMLZXE)?Q5@"
M6_/B2:?+5%/20=1L-VP?[TH52.VYU]'3PG*\]V,JQ#1QH%N[T^W4M>8':K8Z
MVM6';/\4JN(T^@A-LWHF]4C&Y3O/G.%VN\Z]/'SQI;_8[4=^N\YJ=NU-<W[D
MO_^I<#QSL5-]:M\[9X2_0KF"]^WP>HZG59@VXJ^\K+R"=RMYN7"YPB5T($K#
M^-OI#RWVCDV3H;GW=.LKP6AWJA%;4C!G3XM$;/HXV8]6?3TQ]9DQ<2%'KMGM
M)^&8MHSUT\-? VZ?W9&PT2\D.P*QHMC 8B\/G@-XDTZK#Q6S"F=)B2WN#:X+
MN94BSY;YX4YSL0J,T-)[<3O4"/;6[.GIIK<-J2YBO*37[5_ZU/LB4-1,OZ2,
M:'O!0$C4L=%DHY:G%?:7"K7>MBN%AVKT1>9N6"C-JAQE'G^^<./T\PO2E/(J
M1WG[) T)SR[>TP*HC'VCFLON1L7:1R'ES;(6GJ=(0PPZ3""V>U;OD4")"$ 3
MVLU(4NU0_'MNP9$G:VIC/"N6DL9Q^,582OW;YA'#MOMF;8L.IY;#D*]W3H?:
M>@Q&^</FGN]WF\!X/_CX(\Y[>W*22H[!RV=72X_U_UFTEZ6G/WY0_:9QX]F5
MUT^O>J[O"[SJF!F3&8/#X[KO'+_T<LPT\L=(>IAA^:5BL4A-5Y<[61G';[N\
M+'5!4Y\) \_.$ MJN@;#MUW[X[XL]NCJ 8L#3L 75+% AKH7>8:<A4(C-,YO
M01Z>/&>\VVJ"2FH4W'FS#9W7_HWW@VJDQ5=RKAU;Q?=EP"Z/$$*CE(T%(VY)
M"Q\%'R-;&MJ:7NQ"E36]2SM=],3VQA/9^!UBI5;:<N[W^P3U:_9B.;2%UL_/
M%JY45H[F&'T="WF^W_7[\UF1 XM ;N!!QX+ /AW/&G-6MG-2DI1N.)EY>X3L
M-_.J:%??[G,/*T]MGO(J#72I9A6:3Y(62602>#R*GY0<6,9S!,,VN(W!.VX/
MLF#B"USZ]87J@WX6U*@B7X^.COS1JM<..6]'18H_'&UL3'QI_]@]#3-<"%R"
M*_)N F/K\6:'F=_ &*:R[]%0PD<C5SPJW;?N5DSNK>;AB7GNAF].U+K>$OMP
M 6M#UK@^!'JM8/GC[*^!M%]!0(UE<G=5@#;Q)<(:,[)[M/JXX8)&U*E+SVWL
M=?4\="]Z&+X\*O><F*S 2E;^KG#U)]H-FU*1@+=B+IX:ZASI=G\U^^'XE;J&
M6J![]-$L:BRK>M!+U[GZ>)K+A==I6C^<_B_M:6$E@__3*74OME:#E^O>A=T4
M*LFU / CD4*8,_LEL/'LY6<82/$=JK"OS62V(*J!N[8@$_J/L0OX7<(R'!-(
M3?SOS\0+&<!E4J+@./AA4T0PA)5"2S!# WL*3HRM8D6GP6BRKS)U;BRJW_42
ML$+!BJ(>6;WQ\"K),3'9C2P9U+(*RSCZ/DO3;4?%ZN!GDRZ,*J"Q%+!I@#+I
M45'H )!I[49 1*<7+ 5M4#%?9CNZFN';9Y>DM1GG>A'%RAYWC;W_:T'+#'%G
MO=Y)AQ:FX@;S&OY;Q9-C,X/LQ&;0Y.X%]N@)F9$D47,BF!1D>M7" D F\]PB
M<]KVB5=$ID956_P,/1X;O^=(\.J\SIO'5BIS9^3EB H\1= &@-N^&\+LY9T
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M$ICRG)K\H"HO][/7\"*GM6ZC32 6#4QV0H79ZB=%#^GKE9,SN00Z,&&/+(Z
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M[<3WM+V_]>YOO_M<>Y_S[7W\,2\NY@6YYQQSS#'N^\DSQQ0"XS'0WPRO&(U
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MZ?9+N<K\08MWRY;3<Q/=G]Z[X)"T;<9&&'EP-<]CEO8[]@CZ$-/S&:%]'Y4
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MN)], TDMXKD@-7&+R'/AN#Y?HM&$$(D^^&N0_#[9," <:3R)M<F[N+FOYFS
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MT6L%O.#NT5-K'6?:"-BA0&+A1$U1BNY+Y[' (2=K"EW>XF%#"[YN$KM8:H!
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MG.AXTA0_*;F%N[%W UU: 8>&!\*!*^U^/[*CN+H:.>Z;&D4!/61VQ*^8XG+
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MD"8SE)M7^ZS VP5%A*2=9- *R$3&F3!0^@?H5O%JQ:H$#C4MT=@8/:O#RAV
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M@0VHA_[[KF,+LDPA&W"*BPU()1<BIY6_X'=NT'S"$S]PGL?=CHGE5$3O9'N
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M98S!0J]9PK*[EUM/7KR#0Y2NP]O[\[->SC"5B8M;=!^<>% 0 "H.#A> P!)
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MVO.,V=P9)8A=V2RN;,YU5J(F?XB9J:M-2W;FU&C7SG?6Z,NLX[BW6<-IGGG
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M-.SG_$^^T T"4'/7/U$D>_V?*?(;I'H8WSG4R1. A/U'Y<R1,G^M"%6$'Q>
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M=S/^NVU>'.'O% 91+01_6I<_F;B*1A1"6!:9J]D"T(HY>>5R67N@ *3'?20
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M;\C[?AYM&04%FUKF ^AK-.WG_+ZB:9U'603?U20)W?0'=T@Q=I9,!'V!OS.
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M_<C)E*IW^1%4Z":P27G?BH>!5/]<0\^;(8^D6U,3E@\4/U3%"XO&U14A!2>
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MW#VP5J&V=86U\>:FX8,-];UU9UGKS(Z)A-'"A:/Q=WM\YUPH->H?BC"!'_^
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MSY>AT'G?LYYHJN6D'CITJ;UV?>ZP81WY0UU5WT?]!?Y.55&L:S]Y-*I: )*
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M8JY?BXS\MXJDS2;8 X6)N[S\_$-389OF4*49>I[:U5[GP'*T7"&\*>SL!??
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MPB>H_O.$V5!5SWX0Q\Q,;R#Y8ZE!]1LN^N8W/;#7;V0T);NS((=ZQWZ,VN\
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M+%6:$\'E.4JZ5OR#Y ]/@BI(H3[$]SD'!*KMD0Q=L== (XZ;Q=":^0M/;LE
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MX6QEX2L UY(-%Y* U:#H N#\D'"A=$Y(XU$40)]0$4)B<B(&^2Q?D)%H:ZW
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MW$])=_<37%7(8B-SK*XI/2UH]:1;O>*L# +NT^E404PMSV^5<S86V$$M1=#
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M,OF=39SQ U%N^)AF45VHQ.1TU9T#!U6>*Y,?&ZWYR1"N^W.OZ,]O#.@>\X^
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MI2H<=+L,?+%&0>-WU8[P6 OT=Q;93OZ5U>0S"7J//A+<Y;$;+;XNR;3?2_Q
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MNAU;-9$<#S^,JD]=RCWK[FX37MPIT:/=8.&]*S_/P[V\O/$0/I#0K(/6(-N
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MWT2NGZZ0"7YU8B:_?GY*)I>\+/H&XR\ N>KS"?R?#&*M__R 0 >=Q<S4WCI
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MOG3B8&WH"82QP'Y'\@?=F^\_7DQ''V@;-8B9]-7XA(O2A%^O"IM$&!^PR?9
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M^;1 &'2V$=N3$E ?\HB<'N+/_<3+ERUEP:<Y70KYJMB*^C==H/]NW25E+]*
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M\$3=AUIR[BRJ]_- #=]ZHQ%$<6WJ*:=^V(+I ;V?.C]Z/P<^$S.'MWWKLJ[
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M8>MQ:V7*F+CPZH--D^OW09YO6:1/O&9KT YXX>2$UI)TI,)<O>].@>."2W&
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M>]Z]O/VL_)JF:.W5G>[>35DV?%8</A)%J6":"_.V9+*OI_O,.#?=\9_/X!>
MFZ8$*1.."6(]@0M730:IA \&$(@ZVD&!39K8GXO:6)'"G1%/?^^GPJ+_XN/W
M-'5G+F0Z'.SR-L\N""P):?SDQ+9#O%RW^LW&3DDW==#VJVM8V.7WT^\.-QY^
M7%;V4O6R[9Z8S1MST7DDO@/J'FH7T=]Q:%YL"I0*9$Q(/<S24=DGB+0%83,!
MW3Z'U.L-XZUA?_$XB"-HV;CWA-V]:;2<$WU>"CD7T^9PYO,P[ +&P_A:O>R3
MMJ0\4Z$\S%G8^Y [L^=9^?-,E_4NHT8WK\1[,O_Z^]KCX\4_$@L/E:HKT<9>
MKDL2D%L=XZ$*<35X:R!M @XIGT5D!D^B=^*B6EH636YI?K@9WGGFW?G$KSI4
M[X%+<;HJR4-\\@/JWLGR ^'L]3@R@W"H1]O]GBEIRUPC.C&L*,_4!N?NU&M,
MAFE<M-/Q?W#.Q[4G<<U3TI1CLQ12I3@_Q"&JX%T DBQT8(%??'(K6@OASRU-
M/<MH^2"8<^YY7LD?S73+<D);%P::^VX3E-6?^?']Y[F^,$O-0(15_K3&C2?8
M(F_BRYWEU YP\PP7%3N^1F;!93@2IWT^>K)+!4.OL4FE*G&/.CPL"B]'9A3/
M:L#O!XNMS8=>L&#S6(H'_A@WRG .KHB+=:G4*.Y=Q"Y<[C>5EY^A*#BM6\6C
MU0&'Q? 470$JP>LGH^H9]41 XV VRV*W3EDC<^W7CE=G_OAKI62M8+"2JB=
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MQB[8I\P\LFSUW_$H<)#@$Y=1=HCX!ZG&GTD?D>/0%SZ(\*/@>_1ZJJ&@U&>
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M=BLJ8$2D%V*'J'0V- I(-B(@1HR(]$)$I T0%9 ((1'I!(0H""@*D;X3(KU
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M+4L7/N1U!ZH_.-G)3SA?OA7$=X;ZP&FZ[/,LE7E-CH(WK@+RP.#,&&Y(F/K
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MA/F!.G)_Y91)<S5OE*E+(423Q;0@@ E6'@ W$\ &FNSZEP(08,H5IX=*MCB
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MZYG9P>(_O 6@8)Q_[>\WEK;<9HXF&&[C]XR6!W'W;&[ARY%8'I'\7<[3AA)
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M#?.N>YQV$9T*ZZ=>#EDMKW"D5NRJZJ4YQ'QZ.+(O R$ B=ER% 2@GES^IU'
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M-&V@:0--&VC:0-,&FC;0M(&F#31MH&D#31MH^G\.38,_V8>+!2!#E  4VB8
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M]:1C:M3:QCW["J8^YRDEO3IH;2IYV]=7>7N+Q;W$4/C'CZJK</[>58X#KEL
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MT#4'\EHB=2P4AT:?$( .4Z,$H(4R :B8V\^W91WDPR[]Y$^/KA<V1>ZQ1!1
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MK2?')W]V@9@"DOP=NAP+=-"X'X'EV@:1P%@SNG8X!7P'4NF/T[X/$,.(7/W
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MPO))V!7:0_Z>CB)'<F!U>W&.8.H,2=IX;3Z34^)%*X*FB*+G6\3 5^.A%BR
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M4#)/Q(+T>_HY8K"W/:)+K83NFLOUGY*W]9/5=H?8Y5DC#4O>EO(#'PQ.E[
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M;+8W.J6G?Z'S[%A12J9 8^#/8*3.H&%>U:<\047907QYI;*]L+6^']OR:BS
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MC$GU=8+'F<Y1,ND2 :,6-"4@/1>.0>PK$4#,5Y$@% ;Q98AIWKL=R@+48^9
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MC6)75C!M8V-KL0C*BA7^%H+):R;CD(A9;9E04,X7*QF2R95,5(9C7H)\5?:
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M *E\M$/,Q&JV1G_8L@#SEYDE0=Z,HW6SM,.@7;4-Y41&R*\U( X FP09/(4
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MVZ9VFR)SD8K^*JN*ONTF/\X;@ZM@>\JK],>OT45H6K!6U]">BIL6V\@1&!:
M[LHV2T!4X:9;1P +$+W#UI361D&3M*"A[.7=M6>*-*@PO2Z!:+$N'FS#+(-H
MX"?L#5S\^=$ ?A7^KT/9UIKE 'U_!YUE 3C7V7:GAL"Q]R@KS-@O*+J&%Y@^
M *0>;^UEQHS"*6CV3O</+:8F,F/9N_2OXS#9G2?@P^%4-)-OAHT#Z3O;4::)
M$PSN.C#-=P"]^Q)$$@Y",+C*V:,CV0!F%0Y)\3.X68!?#(Q3@XFR-WJ+#*?+
M=(!8@)YAM@>W8U![9VZC*6/9\)_GX=@+9.">(-NINNGLZZN "DP4]L[\>N0)
M+YH.&\$5''O)%E X"Y!4S)0(BP-O:O; B5476("%6VQ=/7&@3>5BMF/0@$PW
MN%ZZ_:;6KX>*#E*"F4D3*6S "BA_'Z\L:$0W7#^!_NZ?R%Z,G2<+,-#% ISL
M3X9_=S5B ;@H('H'\Z$LZGO +X?JY,XM,@11;-V)EX@L %,904N9$8-_GN)G
M 6*K^UF ["CFV2PA%N!S&X(I. ???4C?L 1_GOW5P'_%A7JF0Y?-=3/;9;@=
MLU@ -0[Z5655]CNA0+K*>[8__MS]]G]-&NB?0.,YX.R LP/.#C@[X.R LP/.
M#C@[X.R LP/.#C@[X.R_B3-:UZ\/VZ9-4Z:8G%J4=F(+%A$'/Z6.2&8JC3>!
M?J/M=!6HUH\$A#P2&,%;%F+TI? :Z0T%I&GO'.W%_5/)NS["&WR#CU4+0),B
MS$AJ6O(%\?,#&RYV5Q,K$HNCWI-D;TM9<X./$ZV@,59R1J?,\TKR0A<2???<
M%E<B10.W_3!?%/MB_>)2CKU,MA5I3%>PK"T].A+HWY>\>'JTL0&RU?0T41:%
M0PQW)\J^^OW_)3QLT/_IMX@[@?]TQ'>''GOI:7X8^(X#"S#&](4KT%ZP %)E
MP2Q R#K#9NX*>^I1GKACLJ\?_T\+J!9!D^:AOYQ@J[E? =]KH</!,'OV"\H-
MX*XJBNU9.U8LP%8 C=E)0_TL? ;ZUDAB_Z>\=A0+8/>E89\O%O0MA[B^?VH>
MM/?D;PT[779^_R<3',A_AO  7R?* OY+Y?>%?!;@+!=PC][$ @PON56XV2/A
M'Z[T,M%*\,UP^\I??\OW?_2'P_^'!3AA1.?C8-[PFX,S1M$,9R8(U:DP!_^%
MN^X.]0(WG(+@C S1RRQ U5U'1@(&N&$6N,.(WRAD_/6W=F#EB"?_ 5^K/I!?
M0(@8-C@-L/SOE-^"S5F YS$(1J03"_!]$V6#4L"COYUE5V[@3/3>)86Q7SKS
M(0J(R17# FBRJ\'0*A;@H5(DQ\1ZW#_YZCK/'Z!O!,HL8QRT!<\I[&-*PC]"
M\EB Z8LL@*WVR=>)"EN'B-W_CD"Z4LSD9"= :0VVGLM@9@T+ )R8Y6<70?_B
MK_1%,F)721O-['OV)SNW-RLRL43$KG1K!!/[T(+YRIVM'BKKTOO_@ !Z(+_@
ML/?[ZT2 ['^IO/V'!&F?L32[<;*.!4#U@QGB&<OIOW1G&KM[.=+- N2ZLQ/@
M& O0D8D^M+*#^5=OW8F+ F[X0P.8*\ ]]*#%/)R773I^@O]@9^G*O*.6!OQ[
M3RC$?T<TW6)W0X?9S4F:R-^ZAJJPZU06 +&RGLCN>7[AM,Q@:B\],P_, G@:
MG80O3PG ;P?VTM-<+K$ M_60+,#-\VPM[?L+YOX#@NF!_()(\J:E >#T?ZFX
M_&.R5.C;7-\]RFX2)^913(3)ELDO_?KOFP5/B?#!-^Q4Z,L"S)B"GVSM$W_A
MM_N8+L2N9H<6VTT0#/ "<@.=P*XCO4$[[)P]9GZ8/1?C+UK@OR.N[OU]'.XM
M=H.? F,KVY;%KEKAO5L[/7^_^J7SL@ Z-#+3U)S]3GUQ/&C+/PE4I^W!-*X5
M9P'JQ*U9@'(AMJ(*\T.!_]M1]4!^+=2]?\/MB_\448;\0^[,F \/HT<KPE<V
M_OYUCM+PTE\Z]]]W"+L"T0M?X#^:X.M2J/=[#,J_>BZ#.-=+SW4[PW:37B;J
MI_4N&,NN*-4*]Y'P9>3O['DB7\&T_QV!E1$"[SH/_X;K9*LY;<J."&CRWC[I
M[U>_\EQX'CV(!9!""K( DY98X%YS3^&7/%460'*"!_X%(<<"C!YG:\F_L=CZ
MOQU3#^37 F7\PPT(>Z+]VOJ^%W,X4HM1W C\PK,MW-:"9\HL:P::4=5(&HW;
M==,TQ]I59_NVX;M;$:W*_GJJWL1U;G61Q428D1_W0D>:KX 33YP='MR4.6$)
M8(R]1A_A8Q[=VO^+!;BC%0]F'@-1IR.5W[6[ZG=DZ:LS<<S1NY_&RS;IIF#>
M=Q6%.S*V6J8ZPIVZANN;(N.,6+0_F*#V'MA8AMS_/7+:RJ"2;F&3QN2/PX[I
MAM%M@@A+?"N:X0^0%9/.2]N=Y_ =QJ\F/Y9#G;%I3E/0F*WKRGH@DH^RQDJ=
MP,O?]JL,(N57P(*1,@1XEU^'!J4$9D)M0G<_9!YU]1-$GT D:933?]^+=@-0
MQ5^'.M(5)S!_"0[/.%V&!A"P+HJ?J\MNV6OL]131[]"NDN"GS.98 &Z8#2V
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MLNI?NF_SB7P9EA?[*3<R!-<PO>S#;GK FQ@("W%>RIVWE\/6H*3YB_ ["G.
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M'%;:>'?G?^B$WUO.:V3I#+]3ZSBST5+<+"4CIK)XJHA0BGXX>0/!-/P6NZ]
MJ\L'#B3/.JF E;70:;:#A]#]3Y*80!8X(HZWL9P,PU>B*F\5GFB--GS&7V)&
M[FK.Z0RS>)&D[.C:$V0G0G<C0-OWB7&]>=QB@>--UK<NF8'=)TJ<M;CT1BF(
M$5<,QP2N4ZUJ38TOM[N2'EH^;;-@U$B^7$?3//0Z-%R&@#"*M)[!.TGS\8F
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M3.O D^,#L7P#S&E)@(W74;7%5::D%/P[HZ]R&-9R V0!(A0@^ ?H)PF!0L#
M4%&^V$7Z'%+CS\*U(C1Q5P(33@\O5>#U,?Q)2Z_"3O&>%QZG)H[7 ]GIBPF8
MKL@*#.JXT\ZZX?G+C.$HFU5L=*"C&<._$"[Q@A2"(NDR_D_PAE+/P)B_^$'V
M&W0CHC-_TK2[4+-^B!XIC+Q.W/H9A>;TQ6WPQ"6Q?B2:=.]'T=DKL;W/XH*+
M/S^UB*EQ=\]AG_'/WS@@4SDD$O; &W/GO!0JA ].EMN/XX^*XNY9BQP_9KB$
MTP3(E+S^3KOVTK(>E:?5SU^+R*2%6#6;R7.9[O$U@NU//R5FBO^6/E=XF&S9
M*O!L;+5L@+$&$3J0Q="ELNKK%?*YQFDSIO+*,CNN">B/%PPTAMNI?<T/";_Z
MLQ&%"NB@1.3.AX>&A.UX^$/<_T!Q:ZE@\#D@>XZM6,[ ,)67ZK0!/$ )P'OG
MHME.NKC5IUJ''"RG"OQ[=&^9I"W$V'M8K"R?;6D8,;\RNIXM?"B>LDW3/_?0
M5J-E7[(3E8V82B<WK&6\R=9V$00Z]P7M!9=M[\86Q'F"[ IP(##OYZQ 79S(
MJHI]2>RT6UY]E#Y82_W8[UA;4\;#T.R\]I.#9&,/EB)^*80JKY.G)..1@=..
M6GS7>2.3=(= /ODNPM!ZTJ1S(5)@[GQJ]'F30CY;3;H?:<SUH3V@1,5(=PX(
M@AI*Q_P&C%PPY5WEOF_J.---#_HD-"'VMY9#H,+"]S+DL+*J%D@AK9-6$]\]
MPRW+/B%Z&2NU!,U!I3XBH.#^<=4I2@]:98;<&'?/JB9J5D#JA-^_,M"!2B&G
M6<[%M)ZT&E@/^OLUZG(<-IA;K_.?O_)[LO8/2_V^K;^#42MQ,N44.6SOFO_V
M;137NCS*6+H*>5-4%.>&A&'RNG8M'+H/W>#:C=9!I! .@CQAXT_0M3-N13WM
MJ]V_;$.=00<GL<9,CIT']T$YFA-1:-!.:VYB81O9:^<_!$4M:ZS0(*WZR*@)
M\6?%)5L_XR+6M(@,&-UH78_G_FZ-?=$U/2(3 91W;N.VS>/6/SOTL6MOUGU>
M_W%5 E[XN_@!<:Q\JA)DBHJ%6$B[6$CN;!W8C.M#2T*[L*0^X4<VZ<(P!-]%
M^\7AM!6T@K8]PQW%O@:'7($?#_@_\V*II07SH\/H *[1!#0K,<40&Q84$@0T
MI70AULNZ@A BPRI M4\&9S>B]<*O1QCN('>Q.72$.A1?]?F[CJW3CE2>MT@G
MY<4,"DF*G3<Y-^JQ",R:$]<6EL9>R/AU#0&<'M!28(*3A;Y@^3YBZ@7J22%-
M<O*C2-^G]:*HP5U4GF;U#$)("\JHBS^G-TTOKU@4"[Z)SHK4VJG! G_W F^6
M:J"Q@=ZG-;+!7[9P<8GTZ0_&U$MX [9W@%2H/=RN0NA7+.9P%=X1^)91@U_%
M7:4 @)2R3-&)B3.BF\_X4A.7ADV^_0+&MBZ^^.^Q3#!RSCR*^M1J/ AC?R24
MA]B ^.*$;D1+_W94E\/.,][D2;]3.HBI\)]D2XZE[*TA20Y[R9OR("R>V4UO
M(QXG[I/#FK!=Z RX/F/JE=,>T !HZ,UEJ%,(^_%60%P2/5S0O]8\N@QOA8:%
MR7:+WJZRSS=-?SA[$IA%.15@*WP-KGDH8%8Z^OD6H0I'6<3.8Z;@R@JF)UY:
MT/Z.;E!*I\?#N^&<0WU!NL#YY2P(*5!5AEQ>^$\3#$6&I=5@;A=QK,4B/;(T
MR)B,M4D/$P]FMMD(N[U72ML6)JSZXZ+Z_CI.!"W+T_R>^!6#JJM[3ZXI)J?F
M;0MY3&[I/6R@O,4^,+=8(VA2 :T5TD)\H&A ?(K&QJ\M_CPK,P$/"1/4TVSU
M; I"'64UE:"3AXGWH(/7QB<AD=L>!@2$"[V&(;>X+=XF;H/6EN:[R>^R[I#S
MVU6D^8RI>Y; 0[8+6"SQG #SA=[4XIIOF4YFXZ"P5V>YB7!@Y(*M'?53<I'3
M(Y/4'S']@9[A[>\=7$HPJ*Q%C73LDK*%R0-VE30-@27K0%ND"F,=.;!JQO!/
MDJ";7._T%,$_BA,?84[GL4ET5X'I0*I,?5.6FPLDTV+BSW'UV8WF",]#DWU\
M:2*$V-S$0D7EARN50WNDSQE3Z88'0&0).-%'5)8I08=%I4UW(J.%<%(>I3/Q
M]"R*"3FKU6>=ZNOZYCY(545J^@9P2VJ*)L-IUS^:WVNBO)P(MR5'-% [00W@
M$WPB6^PJ?1U%T"*\1Z]GA/+6XP0]#@<DB(AV#:"&1Z+[BXZ 6CT#PGF$N\B[
M^$9-P/=EM\@J'+IC9=M*63866]0CR/\8'?P@]WCA),R:>!$-&BMU8CG$J=+<
M>5<)>L;)%J2)W(7_<FB9.?Z4K9@\N^]Y?[5D_<@OX?7?* [T"YI1&&7LE;P*
M6[976,M-LDUN\?CWP;Z+]I.@20=ZG'E&^@0Q147 VE5Z!&W$GO95"C"5;9]!
MKP\5[>;31QK1I*!=H+.H')W==54[F)IBE;UEQO! UL=[-JR6K ^Y>NQQLQ_6
M[IF^!$7\DW"*KCVCH*$D7D-.B@1!&"%L9\DV0F? 39QOR0I@CNL(LAK92"T-
M;_GTPC&+?I,+'XS-_&C:K;?91Y4_Z>_,BIRSX,YZ^/<C':.BMK_Z73Y5/K\/
M@;$$S<D=\'NHTRG5WX/^&+%"I 49@JB6I4?C$7J,._0#0+!PXT/K98_A8_U5
M8*VZ=L#OF\/NA@4['KD6^F%C)IJWK)Y#_#^[\S+>$CONW*T0-.QY:R5(^Z9$
M8$#N?H<G.N:F;JR+5V2D(^=:7R7F@$<P,6[J2V8/BO!DXU.NOAQV5_,:JU =
MJ7*W\' Q-<&6R$2G)BC<F@S>B,TYYR:'J2BYC 5HWE%\Y(]7X03L]=ZGKW_[
MPLFW:PPQ.0!BGBG9#Q'9[<9X T7(2J&MH#70*ECNXFEYO/BNT,P/<$KHU\S2
MX4C^IL"),;#EM[7"JN 2SC>U9PA^F):,+D::^@\N.>[[YI(#9)9MSUE@+[K&
M2;80>@JUP42)&S@@L)W+DAS''Q;)87-G129O5F@I4"+ = >?$04#6WPG(U;6
M_NM]YK?>E4?Q)9D%6MUNZF*G2LJL75S&XN1J3];BNW];GGY6\^$;N/\/Y3A!
M[/"Q4A^W,%?J[IIBO0"*L#J?IUU[6JHP'M7ER=8UX2&!.-K$0SAM;**9IO;E
MZ6BQI#JB[TV-_E14K@(QPD#[2(6J^,QR\*J =MOM8A.W>'\B;D'C3$XSUS+2
M'O6VQ*!(:>>M%1%4*CB,MUBYVFY$/LLT I/CRBRR*SZ?;/&@E@_R&HF]"$7F
M&M"03E\'4;O]T*RNH3H8;_EF(B$<_]?*B;JJB0F+JBG>%ARA<WHNQE0-Z?V:
MFH]NC-SI=M5*PF@(>)TS?;$Q]>M76.A#8L=IV39<PQLX]=N<+N CQHQ:PY5Q
MC_X"S?F*TE59NE%Y:H5,JHE%:V!X&V-FV:PO:G%K605%O'=F>7-7\U(RNSFE
M)8/<C@WO5@X #)GR/>)E9#)CJR4QA)%F:,R2PR*0Z6C5$F ;8A.=6,L)*]S6
M,!KK@3S=/ (Y%TVO($E+^I2-'R\-?9YI.4QO%EE#MCFLOSTJ/BSL'OM=)7XE
MBDMU4GC9#D_$U%.N/9!:NK&-K[X5A'<5F@&]=09MHW2[,E(-IGT?RRKPM+V_
M),%_(CHZW)$Z<HV+FIA\\Z'*8=.'>YG+MI!V?S=<$V\M4<)?&B%L#<#HH.X^
MQ/D@14[%SQV[4;7DJ4#7[I;(\@SC#/\C41?K7S<\L))&A-W#Z*0D5+Z+WG4S
MT_ZV^@?L:D(/&G#')I%54W+G6T7]_(5[Q+#,GE%LNQ$ZC&Q =WXY0X"S+2A8
M^!Q'-]5!O>)H+=HC_(\[Y2TB),D:,X_TT6V@K^+Z5K_(EJV?+L(AA>A4!!8[
M?G.YFV ARIX;B"?R6XEKIE=J7\25S-2!7MTK ]V9RK'N8<]]B7SX*'2^*(R[
MK8U]L3YI7/=L_<97KCOR$['CE@(DI)$PM3S'GD+JXA9< 9-[3@<Y.%N7=C"[
M!'\$C!>HI[4?IH./=/(W<WX4\&O@W7D6Q7QW<P=,4"*%9&GE9_51^:I.YS?O
MT6"&[G+2 J1!$;HF?Y%2&%=K3+I9J@"CE]&HGE$#A0(2?E1I&3><-HB:P* W
MTQ.JP9OO1Z^:SU<K6GP+P&T-/^C_*6>O18%R3J_N_8,9RK_CT'F,*=RWN7Y%
MY2])\PA[B!W'Y##,P#B[IT4]O9:P!3(<#J$#)\CA@DGOOG.-!=8,U;'*]E'^
MQ;@*R_$E_YZ):R?-WDX&HR2AW76[&9 NC7]5(\F()";2,_:[[=I%W"#;OC,)
MN2OE[,-X1TPW04<V#%<B7N:!IMCY_AK"H-.^1_RO*4*U/=,<P[JXYV"V'_7U
MB*4E?JW T8;CZV!;,JLK[J\,R[(I#D]PS OO-;UYW_]M>>&P:396Y)!N">DR
M^/BZ5[@OX.J$75%V!Q%=R+0-U8[/3AJ-#1[J(^P T=T,X!P1W&O;HWZ;8"O*
M38,0DOVR][TR-62GD_YHT&CL?%P7Z@DC-7:KK]4A7TJZ@[,@?_(2QR-"\!Y3
M ^]8<5CQSC5O?W&(.U J471^QR&"ONP]0ADNKI-F66/U\#O %."@'.8L6E<:
MCA&JW?!//C]T9?2J57Z;9^=LX.N16%-']%^OVV@CEI'P,UCUB!:]6;U$[H,=
M.9,;-RO@DBU3SE9@SRF0+23>:SG1$"EQDK%,_-F+O#2[J <)Q/#R(# SL$Z4
M^*/(?*[[YXP:7WWSY"P*GMZ8J=W,$@Q;1]IWWVS!O[MQ\2)QF@%X8L&]B#<#
MF7(8+)8X3A$'L!?:;16T-NV4SC]/ T))>#<'/9M,&TIYA.VU[:U,LZC8; W,
M;$2>3O[S:9ME9J<EMI9Z*'1W:4UAT1^_LJ'-K<+L=&(896Q"IOQ.1'.#CQ<Z
MB"@92_Z=*^$G/=D"XZS(,AS1JYFY*M4_3.F>54)K@=W.K347][L8?TM/EX0&
M*(C#F/!!1PY;Y7!>-SU6W0!7+OS,U6#%3KH+@XJ%CC<Q_90TQ/@RJH:EL!_K
M9S^KK?MUK(5M:R9N:<I/K/T\_5=G8H+DDNMHE1 Q09LJK)+8$=[Q '=R\JWE
M\=SNH(W@8P43/>RY,FM>0TN'G(DEN/+NG&NGJ]_=,"ALKD5SS#F;<B_!&XMV
MOM<@EF'UB6^?"18D.@JFDEH'#BH)72%-HL"VEY=!!#S@V[YS-[&?MX&54P88
M ;F3<5>/G6E9@G$T_HW?P?^/VW8LN?^NL0XO&Z8?J,*]\V0I5R]HJAEY- Y-
MT72\62+7G\M=V6/),N4O +$#U?,-VAPLI'61M\F8>C^H G.?OFAGR1%<THP<
M=K0PT5-DYM13@O/W&J*'5,_0;N[%OIQ9YAH/4;X\\J.WU"?I-C6ZOOZU,%85
M!&;SR>!.TGQV#622[],DHI)[*-JEU*])S+YJ7QSA5Q=OE1D^NF(,&5$3&^Y4
M,(4A:_!49[T,/F;X4__5FNA?A=PFA[VB9#&F[O/4Y+ K<M@&7(,PMOP.WE7$
M4G-:F16<+A"YON'N 5-J/03KEPQ.^;O#5<&X,X-+%*5WY>\N-T5/YZ*TZTGW
MW6^*S"'4WZW[;]^RA320/5Q#)C'"DO.+;]DQL!4L[F8TW-/Q,30#,4KIAC_W
M[FYDTL-UTHO V^&Y.6*/\AE4V9V7->WE-Z3/2G@1@W[3UR/$.K_&_3E^"3Z0
M1JCLE"NTV576SU60<?E"IO8O=4A3#A/RNC('P+V6\_#J&;N=D!X57'J.A'?P
M2)Q:DG%RM/7]8@HNKINK-6R^V*^_F]DHJ?%Z,SB!N\_]\Q[J_,=JBE-N7!QF
M=S53ZJA .#\Y[.$#1;MIR&'URZ5RV+1$T ,C+ [];UX_\O^_./#_Y(L#:[&]
M09; -T48E7'DOJ#]H^:-"!6<;==*7X:#>S7W@'^@Y;'!JQ;6CMZRZR^>]F%"
M,%8?*JI_:$68'C[ON)O@2.R(H4=7@ B9\H*PP-:C\,=X^W;< I]]9\&D(?Y2
M=+E;#2UCX4*A[ZEZ%-J9[UP^:?0JXZL^K>&Q0YR:_FW\?\^A.129RG\#R$=$
M??<LY+#@+->CTB>*3LI6B6B8UN%MPI\O'>]_.5M_;&*JH4VT1F8H2A07"Y6K
MOY(\VP<=5,/+OA=NI15^Z@H4J7U@ZQ&*JY&B&YX*:!P@=C@L&H/C@NQ[LO72
MFG9E\'J">S;\>Z[>\;B5U.SB_,=)B>[>?G1S/F]KN%U$=;\^IG";R+ AM-1M
M^XC#T5+B%90];0X):97SV22"KJP+7<].A:S#,9&8"KPV ,^BVE(O[D2#N0+#
M.R%"BM;,B2G-*,(X!9<D\PVYLB.2,+#AZ/;4+<Q?<I@@&]*%BU?3D6G$]8KX
MF BSTV(R[P@&2$'60R6 >DI43"(&^6A>IB?2^><#3R.RC'QZ)/+CER9!SL]W
MD3;SKYH[;R=*@ 5QPR CC#B6B9)6.FGV.Z7<B <R!;IID6:6Q=012VBKD*?T
M78\3<<M\T>=F34A%^QU!H(5+T^OF5SIV7__)03UMD&PLWN8*=(D/@XK^7-LB
MI<ET9GBZ3IH$%GEM(W+#=YGM*'YU;+A0#OL#?WC8NIP5DZC?U?)EM%NG16EN
M5I!IP@QB=K,T.JSR[OI81FMS'$NB^S8WR!X1^M$*OKULF0%_Y3KO;#L7""QW
MDS>TZX)QSF!_Z:RAGLC\L=C'7*A/N<MJ*7Q1B7)%9$ 7/H;'E4Z&B;[$_NDS
M;\.&?S][(/P'0E<.FWK" \X@,WCU[+EI 9;DI"1-)QPB#+6<>"%*Z"XT)_>A
MU?6[R6-YA!>5..2;ELM<W68]URZT[H2:9R?/A3KR3?VE"V(\-G\GZ^R.^YC;
MZE6R/PE#/ "E#II\I*02+ A#7&/07'($TB-N#D>9I)-2%A$;QCG'8I4>ESV[
M41%FN K$"(CJW(@F,?O,]Q5)V HK/>1E_I]+^@E-A6K[)(L-XBDIQ<&/OP :
M^Z0A,'+8>'^WC^%&T4:&HIR3@JP!FX:*[P1#MF5CI+W LEN=U$)X$5P1UKZ#
MN<13'ZAP?0%F>@XM> K>B^W]&\Q8GM6 _Z0)GPAM-I&IN(J2Q55 M@(\0M$9
MO(:!#,8E;++L@(A'LL1'BU8+HK*$/-W9.+TK)!QMZ&/Y=QYP&[2(O[KX+,_\
MRL+)H7GK1/]SKYG5YOR1Q8G#ECK$402XYQ,)$';!@>-28A=ZO8-+I& A168(
M8B56880UHO.EW;;1N$==MY ]R+LLO:C6W3TM)9Z!,Z_>6%+$?1KNTS^,<!<?
MH';!JOX;Q/]O6ACRDE*@0R+2&W(C/#,2\A%A^3)*$5AU8K2/!!WB^RUA203C
M>O<U3=DG@<+L%],WU-5F.9<?3D8@+KBG/Q=%/=CPZ'1=;[\$*537_NZT&LC-
M<(@6_%_LO6=4D^O[+ABW!942.@I"+ A*E:ZTB&Y 0+KT$A$10L2(M @A49#>
M% 2V(* @(-*DAA*($ (JTD*3FL(6I002A? *(9PX,Q]FK9DY_SEGK9EU/OP^
MO/F4];QW[G+=UY7U/,^=#VP0!  ]8MMD,MZT8H!;:3O,,2J;79YN6GV9D3G1
M3::''S]^^'+MOT3J\!XH_@RPRS.G=;>2@:4[,7'LJMT"_'XF<N'@9\QBM^H#
M(RDB5ZQU7,?MJ8INCFX.F7.!]5#T?!X;R8>*^??AH((&]QVVZWZG?B !O ?R
M4]6B(F.L29,]M=/EO6VP[ET^B]$9KL)DX;&F]O=C:$\57P'#/1##Z@5>AUKY
MS^'3".SQ:Z\J]CWBOU$4\FN!>X3$*R93GF((Q +GP/'&)X =NK@BM3S='^BH
MA>^!A&XQU8GMXF3M(+WN>546WY.- +1C.<IFE(1[!H0C9/AMFV<1O^8"%;IZ
MRX-1Y-G?1>-GL4J4!MR' 64V_ ^2<0<@^[4?W_O$@P!8X\BF1[O3S*%*>A+W
M(*K/D17?DNQDF19!BM@>K&N*=V2T"X5/;CK^=\[$.9L1:@,Z)88WL:) AF/#
M2*C@?NN."9UJF-V+H-70.2T;7.8RF[T6<>I6S/3\^;//ADP=']GL>]OK^-SG
M\.>0E[S/\O.6#G SC63KSPY!\IE!S9DNXJ7'>AV>/_<5_W;>HO082;G5HET^
MT[IY+G,\3TI/=\)Y4BHW5]C=W?VJZL#X^)>ZKJ @Y%_:#;.>MLKR=D2!0+*5
M2FI=;_+@JK@H5*43RB-X&!!'N;V3N0<B(I3W0&F="@WPFSG?+W>DF#'/-GVY
M;E^"E)J=@1E7-]*O+3(7,RJ7(LX==W1)VL9<Y\[R2*N=[7$,>7NQE)JQWWO9
M6P*0*O<VE'3_6UTUIW1A-.C"SS"*U.IY93<+>418*<KO8\-[.=/!U[+SE>*.
M[IB[DYM2?P'@A$+I>/_>^FJE\1+IQI\J1FYV:<<L%$K^H5?HN#OE8=@0?GT>
MQRQ/K%#4#]T#"=(S))25QN][:E?T%ERR%!U0=G3R<[8R8SY74K31'IVN1MT(
MDZPK/0BWVDSAY0O3M78ZP;,EERN2)D9+B%'1RPJ2+4IH4HUPN-;P%!<QO=84
MYAMR\L=MW,CJC8S?M\&*@V".A#^;+/^,!\Y"Y^2?EM"V8M\;Q3/.YN]OMC!^
M,_G]K,2.*5BH10QLH[W$+#0_1W+3!XY>S$N?CAH/UJATMK7^ICO/F&OXY8Z'
MD73*OO,26L>ZO<GJN/L38[L2I?M6GTS/;""X<@T[O(P;,6&N<V76#V%_%F<
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M7CR,*T?N@=[FI,#N<:>*&N+C=EPY@BQP;-79T=NLPL?!454<PXD)E)?VD'1
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MRZ/"'KNE4.HK+/-Z[1/I]2Y;2124Q\^3,>?<W/9 W2P6))%C&TP=4$ * =I
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M.[1 PDH;^E';"<DN$!&T&VU'5<;JOQ%WGD%-=>&^CQ4%,10%!2$J3:59*()
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M -]48;N:.Q6C6QP?!5VV4&CV[91)O73]1=["T$P)!..>V<[ZHLDB++Y.C@G
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M P[)MB"]?;;2C4^9[-QSXDRE9!Y]M9E_$B>^9/@G?!O>6/BF!O($6N73VJN
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M\.?:.ZHZR L<PFMBH1T+[W"N0V;*.MFJ@(E1*HD4=]>,$%RXIZYOK;NP?VH
M_2M+V3GE82%[3U/8R9]7R!EAJK!S,^PO7PAT5X-Q4[3)K[B[.OD#MZO01C ]
M.Q?(E90K6.GJK^8IUNCL3V5Q=2BGV ]]\K)/.Q[2/]<2*E86 PN!1#-W;_YQ
MW*Y:^E2]^U?,80#)LM_;/'_))VF5#C>].8C&J+W^TS_N/MII>G'OP-F/>2"\
M*;[5E!@KUA,$H$'H(#'2VQNVM7F> IZ0;F '6Y0LFE4^PXLL2TDQ> CN>,/0
MXHW\*20C.0Y3 ]X#/W@<5H1U6I4:>^05[JLW-D/]&L.&"N0G4'_$BVJLDQ=1
M ]3Q[;%45^H(@I9MP4&T)<MC UE=;N)Q7;^4:-'=XA83O=9\VWVLG5 0RR#L
M AQ:P_0O<3I2O /R$B]AYKTZB&#!-JX:K1I[G@T)-U.;8NZ\T8TT[(P2(%EE
MRNT6*MFHG0[L5B09=K^+?SG-_>A4$LI6=32;<<WVT)'Y4C-'T3X2SW@#E&LG
M?$7ET 0Z&Z 9I\<FS"?4.L+B*_Y%;!<FAKB5HH\4&7/#:F-"V4<-[ A2P.R%
M9P8PHYG6+ZM</9PM*U$9'H"QR/?>7Q<_5_[JSD^U)^QXGV1NX >$G-G?5Q8[
MQ<*?)1IX2#VP&(39C=LOS!^[R@T.IZAK/@LM1C)"%D0:A'UC)C!3QH)]?=^O
M1'<7KF*D8>5-3/"[N?6HZ&>AP3Z:F?ICG2N]CS= /M#1%=:=]Q.:8J;5FJ33
MDN7,$SO21(<X$!IX*_;\C;"3RQ<U&@8SG3B\F$)$3>+GVMJ!;V[*$1B#-([9
MLVJK_9X);)M6>!1U'_D"A]E.B,%+ <DYYZ$,,68H 9B+7(VL_)'-PO(N<Z>!
MA47CT&M'&LC'OVU3OI!Y_\B6/RM_LS3COVZ I*AHJ"1._Z^GO9W02$P467![
MVYC@!?IZ<HR!A_<#]&&58]TNU=6#;QN&R&,FF@T9:!<_1D<9<D^&34P3-']>
MWJ^N?V>^.^:'#XL0065Y" R 8 Y_Z=QOD0QB,V#7PD1O/R>6'M:^/@.A_-+9
M;OZ G@5M)D)K90>!.-,3@) DW"&._IY$]TR+-14< 946J?B%1-574T;,M%FZ
M$+N1%9V,"R^^CJ.N,A*=0B%&IZ?Y>^H2_32L_KV@<MZYKN^_>8_E?VG;>LZ(
MSBE U_Z($3%WH-FAB?2_5<#Z+P_T@/_N$.HI"L; PA&2\'L- $%0(/_;69TF
MLWT;H!04C?#;90,T+/(C: //-D :!8$;H <KPFN3Y^*/D(; ,9)'WC[^OS53
M<ZT."[T^M'=EG\"1;:[0=;_'/#NEW"\DJ/0S,#$P-CI^?E=4;3G[AQUZ_Y=M
M@5]6U)J>G[%5?_IE>=%U_&N:S\-;KJ]>/O]LJ_[<5GW0]UWBL7LO9B7O/9TW
MF#W=>N(%8_2+K99F@T?5ZUF-?5T. 4G/KL#>E??#1G$QVB=/-IQ2R]UNXW ]
M]45X:>F.8UUG#X;O."@3Z*%0,@511-4^0ZXSXYML2[^>O9Y3-1S4 []*CDHY
MHZ2-:BS*>5IP92!6\OO4?L.>_@M%@Z]SC@Y&3L,FY%ZH';5L_J8,:_]1 SON
M^/I:[GY;:S?;HP9YC;9:/C]-$;NQO1VJNY_/(W8 I#:*0MJ?PTD\Q&Y40T&,
MQO=[I\@GQBU>!?G1=TK9JEVH5G1AV!S9=$<+8C]4HW)+M')MF+02!+LB>J1'
MJE&QG@\=XX^]<B'7*08'G[0+"#0KM;,U&#!+:DN[]:CXFL,UI'5>B76JH1O2
M.NC:X>(KQT:>%J0;/*^J0N=[H_\=MWUOG?EZ_'3ME(0F2^%W0 *NJ+&1G!(F
MOG%E.R2S1^;GN]C*C=JOEO26OKNBE\ON/)]@[[PZK1[M^TH]WLJL)%?[Z'?9
MJ_:V>8,PS0QD07E&B,%@?T'=V<PK<Z-ECNZ%WR9&FJZS"7([)&*;;$BHUC'H
M':61RG=^X<QC>_YL7F<3M(]M)NK[7]O4M\G%P-Y1\E[^7LE[4:>U&3+QD=?'
MQW/W/&\<'O4WN>3H[_@B7ZLI[UOFFO_B>#_.D8V1_C-+HZC1'\C?!]6;ZI'>
M(0F^H+V;"17?+&<>EW9MS:S8]Z3%,#4X.(@0:#B]UM,^/?XY\7^P]^912>[O
MWR^-ED-JF::F5%96#E1.90:[S,S,R"QGI7*;(AFUT\1$*,TY8Y>I.]U*6LX#
M.2#E "FBN]QF3N",8),H>9.*MS(=^IW_GG/6.<\ZZSSK>=:SOBYOERSE]KH_
M]W5]WJ\W^/E<2E$>Z_/W[S'[H\_-X=^?72;0YA__=KXM7[A0UO_HB[M'7)GU
ML_)]3N==;A3M?IOCZ>E67VEW]$WI6Y<.N]MI&;?=?O2U9*X,K]-Q]SSSWW:5
MDT406P\2/W?05120<257#C*F5B3\7X_BKB@@[]/Q2J9NS%9 *HB=BTLLXM_2
MV\I"*=%30(;=VZ$K#2SRT-^'%)#='$WB$&F_ C*@?L3=:>O/;V_^1VXL1#A,
M;(V&[Q$8KY+=7^Q606:^(*81=1Q6 2,_O3^'%@?86E5*3S6?^GWGHR@TL!PA
M>?6/RXTYTSBWW@__<&/E/=RUS7J%<J7\K)>O 3.8]V#)4B,T8/4N?Y,(D41-
MMY^8/RW:_)YG8>-P*C+<EF]+:W3#7GRZ(KF0&IK:<SO*ROY+.@&MY-Y6PB:&
M"#I[J  CMNUSTV,J("3X6I%ES6'UJN(G9>"=3KCJYNXAY[TT?M6F,3MW\]Y]
M1^Z0.>0'^?MJ19VMB/@)Z_[K?NG'6%PU A3,;XOH>%^Y.+=QVKZJOGS5#I7$
MZ6V0,_J=81#Y'<1D(Z)V;O8; )O4;,5JXPW /4 /+[&I0GJGKC?2#=5JK-TK
M/58:9N"(@[&B.L\WO>T/OY(58Q4=@KGS^4PW- ^K\]?8?<ZB!JJ')-V.5$#V
M]@!Z\H\&RB&XH&G@M6#T6S;*M&2,]'5.OE%# =F_57GSBXC#%T0E<@HB.5.V
MR^LG5RG8G\!^(&JR4ZIC)E<-)XKB^0PF,<'3_AN+9.SSG<;0EM[FD=?ZABW=
M)1O2=[A%8HK]<=D>_3L9;QH2O8O>) Y^>;KML_.3RP$NLF]*E!3(4HC? 6+P
MG!1!5E5 ELM?A'PND>K9_T3%3QR4Q1,Q1AI.C&2"IO1F4\V;'*UKY,O]CR:V
MBZC5V=&'-7X.F1,V<2I'!H=8>^B,LE.]C?YGS5:V>'I>^.!H!OGPX83GQ<,;
M3.(V?-9NW9XJCT1,,@Q^Y(I@DXS9*$ !>3>2G\O'<!\I( 8[./A5486!OH)&
M8DH]!WCEN_=YV??&A&=UO@+[FP6P]MC5KF9=1XNHS?$7&O(W!AXUN2M/,1=>
MJZVGUB9%9:"QZRK]ANJ6/47F[C^"NFP'#/_Z>=YEYC<BBK.0]O^X*2:HY.AU
M<;*_L#9"LY.R8OS.DN/=G$3S*NE^D?U$GVYT+O.KP!G@IKXZ\VXL1VET.](J
MQ@YF$6M0WQ]/!#S.O+T;]3;3\7+?POB=<P,1 =?;^B_WV<08MEA=[K=1PU7/
M1AK9RS=:8&]@PZ][)7[M^S'B<^5-W*70+ZG.Z8.9R0BW5JE;&F_3CG<A;\Y(
MD!5NS"V)?WQY#%OG\\>U6WV9.6EYME_.WCQ\J:(M,]#''HW8DEQ[#J'U95LS
M16OY>/VE4D_J!'2+V[Q[99;P-";KE<?YB**+>1P;#A#@1"@AC'.!\T1=_*K!
M2%(*:N-"MS,+L=;R*_G"6QK5AZJ!Y?WYY-^GZ)61ZWY-<VK,-^EV[4//1OQ*
M:T5;F)%;&THJY=Z<):7_$NEZL/2#U4?WLARW)%0^?>IV  P;*_NU #3JP+94
MK[.WLM)M+OY=<O96&>SSV.B^?P^?"_=?'W3RDEG_S>[B:<^2NR]]$USW>#Z:
M'0LQRINRT>^XD.*DX]40_3_S#9!5J)=DP$US.'%^BMN9;L9JG/C[)]X*=(HM
M48IIMIWVEN *,&X$6P]ZM)7^J^ZE&57F5UQ5/EKKLNK30E>7'V7_HAGL6)L"
M$LP8WL*G";WXW^NQZ]&UTP3MUTV)"#WIJ0%AL +R\ [3]I7YTPY*(U28=^_,
M-B,$DVT56\UWV97S,\#.5<\^C[9(44)RU'U&"#&Q40G(23G1];WUS]!SV!\.
MM,%FIVK_5XX>(MVW?R3'S5P:"-RW5%ON-^++Q!0/.8:7^/B,,,'LM(G=5X_<
M,6,!<J^4A,"=_X8B-=W=<S(^W,KD=7EI![HSZEB#1:;;]QB6O[[C_?:/-IU,
M8K\#?'+L])W'!;E!I1_RW>,K##Y%[NKKY.]W.>)>I \C/#S@Y.#D>@3N==*A
M[]DXXFIAJAGX6O[LOP?"_D<>#H3_!5:I_^^^^OW_SX,8  7.09</4911+EU4
M0!:QH)P._GHT^1?B9Q!JC3*D(@5$P!7)8D6H;XCMQ/=HE@(BOG1;15Y5$R(V
M52>^MV%RQ28?B(MK?D6(?_OC?^3.E<;ZDG-XC4\(-.H^<2M]'9C9IV''1\8O
M6JPW7'+<U[O(^KFHJ8Y[< TZ$PS,I=RH3_]C6[*9^<B]TX(/_Y;,*R#R#?,B
M8L @,406(_8!7VX?078BAT99]\AM4$,<0?X;YV6;*.S>W_EK!ZNV$7[,."5V
M3$C:<L+'&[[?-)<>PA >L4?RGBTAJB,3E)Y3 [TR4<;WT]STW1-NPC&A)?ER
M9A?2X:-^[%WUCX]4[1JT\0[ODUQXS-Y7F#IN^>WYE<?[^G:4IT)4'LE[$;6,
M=]@1)M-7)5Z. +5P$F:^GDB'8/ZI?HI/U,=Y>\^(O .GT82;4CT^=!,J8%W-
M ':'9(^PFY46/1'DI_\R]=3*IM1]:^8Q'43@#!$T36J';<-1.B=@LGP%A"KU
MF2)MGJ'#1*?+X>;X6_T=)7S89D&V+YM6&AOO"F8'%WO+:!=;WKZ5&.<%HZ^&
M?UVVS6H03V]WZ28RLQ"3S[D+X:CEO^0(XOP 9:!<Z=J_ 5RF;(U8Z1?C7N*/
M ]^8LD-)L[E*T*D#HI*D6UYI1\64AF;@ X"52@/C!Z_"<M('?[PL1>&(OI^:
M$=A2_XFQ0%=KU(;B+/E/3_:"))?[_=KK>I@:&-(FXCKQR)N^!QJE71HP':0>
M6; P0?:9#$2Z9CJ]&:!D(&DTOY:3O*#TD.8WF_T_U+QX>EKUS?C_:[&NKZVH
M,"EOM,^,N*+OXZVEI!SURHUKM4ZLC3N$RB5"&9-9W+JHCK2F.2W<'Q^4V3[W
M".:+_CK0K*;Q AA<G"W9^^T2$-!7_7PIS647>.\;T\/_WVZ;\?:?5H=D>PM;
M'N4B/KZ)VKKX;X85Z\N;Q*=_OQ[TO^I[*.I"NWNVS78GZ_%!^P7!R96?7(^/
M_];^33M2L(CO6>>H[Q+ \DSXXM:RO>PRR<+W,-KGXS/>WOH6TE>&LJ8 IQZ2
M0>0  W@H/0\&\*N.^FF]KR9OP3E>SCQFA1:/V*7>V(6=V\D>T^1=IQQ# ,X*
MR,CDYK4,U:$U]YD=42!\*BII5>L29.4!:J!HZTJXIA$HSSS25H2OV++[:23F
MR^MTE^CW5\NO3@<L?BG9.FS"#P.]VB+W?E'%K6RDA474U-X*=&$GH(<CFD=_
M#$NI1.8+!(:T/ W4*2!JKG/RD% %).DW @<ZW\\+D>MF<Z4?.8MF3N$*B/8<
MZ=CO9/!FF0+231SD9BJ?D.S>UC*/D)HG*2!6Y"XOJ?T:\1L%))^LA@#JZ0K(
MU[LD,$)%J'1'Q^&Z1!XZ5@'Y5TB\6._^?ST9"4S8;L:U4D#:_B'.'_WO#@LJ
M,@;G&UQ^H3-9RI$%+'O_)ZC_!/6?H/X3U'^"^D]0_PGJ?^^@.KZC@-.4D:@+
M>>NI_+GX"6C]A^4^6C+>O3R@/"/^\\@PSL'O@^#PW2[BC9+[NS]/_2#&*?G+
M63,^4+.Q?E!^$.P)!.MBL+O..2!*1NWB\#L^0\[IB8:Y OCN0=W]D/WF!N(T
M=8'JV)##S2!H3817>@[8U;E<I7]U JO>^*S_$?MR8E%\>;_<_W)YT'Z$_9%4
M;%/(R_O U$-@JXF7!.[]X4\T:ZIBH/V$S40"+XE<=-8CX.E!!Q@/J0Z:G.C'
M6TP*US@#C"1KW+J&[(+O]K'5V45#[S9>RV)[WG9:&S.>X^*_=[DH*LLSVFAL
MKM>)</7B*\''R /*STO/2BX6N1S]>"?CCV??CMKM/WLQ_,/%\(;1\(;8]IVJ
MMQ_MW-:FE?IHYX;2CD.I]4';7CV[]O37FRD^.PI3#ZC^+_+B055,#*;$9UR@
MUU]$S4RH8@F_M#_7'AT9:9\?0^Z$_/G$R?"?H;5"C_O(K<MZO]KQW@*<.MNW
M+<10$G)8V<SGD9=?&UMAM5F63>OBSU\+N/>MS:4@^=0JU6YX]B:&Q9@MWV57
MON"S11K>2P^7TOKW1@^S(M;S+^KYT=V^S_X !PL>M<=X.?6FAV4::VHD>_L?
MW^]56'ZMYOQCX^TS.>5GSSML&^M9DVUOII^<KA)XWOK9RZ-W_OA99O=>_X^3
M#KU?_UZ^1JD8D\46YE16EW__\%V@;W0F./B*:NWKW8=?[XC[94!8]G1.[&.
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MJN@RADWEVC 5T'L":DAL0]T1 \X);D"#\>;:'8+5HT*5V<28%YJ'^QB3:0@
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M *H-H?L]<!>P .#@2*/*+ -H0K,/KV?V;>57$3;!TGCI0B[K\(Q!8LN=\HF
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MM2V--';XY1^+73$2F%YIJ$EDG6AK8=X[,^@@:BA&OE$H,A3;BH[_G"!PC(^
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M#'0(*4GA"D^1V$>X)$E< FB9+-FXBQ?K .>=A9-1"C*/\6^QZ:R&\AKL>XW
MFR9N?O3UR05"V;)T:,DU3_10<+59[38AV5;YT$8.<:.K8GY/=YGI?5*="L&
M-V0GCB:H<@S6,2?W-4D.\N')N4#^&X\]BH4.G*1]3<SV9SF3X9\GO#G[%UAK
MJ3$_C&K,W-2VS2P>>=. VU39UM.V2)_)$QXCV ';>=/-,#E@2&B-IPJ**4T9
MXM'G&4N-7AKGZ)D./+$D-F]B@*ADDC&79!&A\^/!7P)Z:$KC@$"0S'STV1;9
MVF8D!3TSE9W!&60"?*,%FM.&$^B)RRPBA99XPV9Z4L@;@B7&$G.^[.UHS_7D
M(9?N:N2KX@*U)ZJ-%<RME;4)R^.9_FL<\0D_?-,F;UF0F]Q-8RU^/S;W$[B$
MY=W0,%>@J@#JP@M :^[$)6SPMX%%9 Q\"RYDO!^K=ZLBYONY3CT"A)/Y*&M_
M+8MC7F7ISOW<2TWJ976%$/\BRHCF69GS_)WQ/4&R'Q_;DK43&.%+02WW1YD
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M\J&QW_NNQAS?FZ:Y&:?B5VGYJLKLY-:RQ\&8Q$E"W,O'NY)-+\U_CV*,9:/
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MOC9&00:KJ_+3Q6LRU^[%\W/+?X&(34X8D?ZU!-<A'AAF&TI4&JA"?RH73T$
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MCLK]0'1L0.HHBR)1_!MU1!V]?3*%(P<E[0KK^SFI*G$#.G.F=4&4S!)X0HG
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M(@V.5OX8$F56S&BHB<XOYH9ZC@9UM#]M5?S)?XLSKGI:]/C]BV5_?Y3WF%_
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MS^GT(\JF&+-!J>2_L;P3?,EJM9GNG!,IQP&?>R2*SU-$%FH;I"*"]*,048J
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MA,^LHM%'?\;A1L1\VRZTM?8GRBE-,\==BAOZWB*IT\%!NIMWS3AM'8&W29T
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M&:6[-25T,OP2GK*19(?*%O+(-NU0R9,YXQ H-ZQ([&!_3# ?\;R5T\Y^<=W
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M8<#[_:5K6?6'Y%OBE];<I_XVG:V-ZY<3%.]<F]]@9AJL3DZE(F8H;UF=R.^
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M7!2+B+?\ 7[&E^MVK/RSW+;&4?J7$N0OK26WJYC13WN2^DEF4"Q(ED@9\RQ
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MUT8)EP28BM\O77*^\R-,/0*LP!2U*HSZ%YJ,FJ-=13H &=(AA#0QV_/H8S[
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M$6'5T_TM(OGT4;(G68#2^>RK.7 JHM'G-AW:B;C)79N %?&DDK0PH>=>\(
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MLUFDO[Y5,[M\K'ETLOG6I9NC@M.M9D91_F$'Z3U-SZOS2;]K&I!;2!O F+O
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MD*!9][HGX]:H/(($9&[:!#O?C7&Z9XDP -(4.&4!F$C.@[^(5=II:FP+Z5D
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MFZUYNOJ<6?F<[>ZZB'+<@]H9_TI9B5,?/]7L/'0,?4!1>7X1V[G7#K'UI;^
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MUO'%^,&&NTW%#SG##6.Q[%)\^-Y<1LF_2]'Q5^LN+)K9SY 3"Y;@MK9_)Q>
MR1<YW:PSA3-9"XEE(RX!I3_6.F,K2XJ"W4-5J[VQ,ZL?T+B'A%_%AK ]GS52
M]^]X"VW52=:!:\G[X56IM$K*6&2:R$5HIM-!%'"49Z@J%'7ID?H^J561IWEV
M*>D5"R]8W$':@*"SN;EP\>[D6X.KP6;2,V&#&=6CJMM]?T].7>(KQ9-1@L4G
M5.#ZXBZ2K4ERFL;<1 U:Y%+TH]8=W[!XE=78=R@QK-RM/C2TW "135PR-VIP
M?/YL:!;VB*(DU0:O/WP7C%1%["4[ %IY9>TW^XE2 [ZJRNDF5MWQQ-C"U<B
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MVA51@AGQ^7(O^N&)OWI]_NYR'Y%$@= []J:UU.T(K6'&XVEV Q#I38)RM7K
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MTAFQ<PL=A%WD-'OAGH&W>:X3U=DR84%-G-NK58CS/8+1.>R%D_Y['T?;2?)
MG1)Y0=M'B>6+D G%XL]#;2E!PK]C(''>+S.[WHFP;^'*JA5,[=0(KB'GF2NK
MSGCP>FT:2M:M1+"\975J%5);S_L-L"X1]>AUCV3&2DU+"=/LN@A=$D6*B1:.
M&\QU9FLF?/)Z./[Q&\_H=4WZI?[OL_D#X9NK+"KHAF0"?<[HB8YEB4JKKZR'
M5M-355-)(/,%0>U[&2RUD:D,G]EBA#YX<GR*FSW3TE/<A(LVPNP9.UXUXC\^
MBKWUVJSB>*B];6)#JM?Y=3^A<D\CTP9AR\ZR+N1VQ&'T,"%"N/A [DWSH$KV
M2G+]&NP*JP&Z*41,4,$WG]0R;'C%N&9UWU><\=S,+,PT@Z=![;QS#G6H,]0(
M%A$D=A32N_C@OI:%Q79]E*O8+R]K>3^AIJV1GB1%FMOX()/L/30_KTSB["[4
MC0=5.@443]M:IZ^4X^ =,(ORX4X[=H :O4)>A-/B6+H,NS1*GU3>9=I4$ED*
M\L8N%K)49?_2-(@P83E4X7)EK .+ N<K3*4(WW'R_;]E1W46C4Q2PTN"1\)3
M:2'F%3=]HA(YF2M9I.NDI+O:73,!DGL@0YB6@-ZJ3&$7@5Y DZ"W[5O *B0^
MH"U/MX%;(-:BET[9>"[=S+R":(@J6RG4L?KFOX]SMCGR@:OFD^9CV2P>;6R6
MF+)\5,:!;FC>N K9T#HH51/A$V-T.(A=P08;P7%!>1HE\R[C+X,C#6(DU=YE
MXFVS78DWP=^5S C5>I9GR/&FBUY%F5DMW\A,;\\.GZ3<!S[3VII6(13DR[\-
M=H&=$ZQARH0?J[7E^G_"^N[RX\)W)#*^."7T4OV@O;:HO 7KS]F3>3:E.$-D
MMH]4/9\U Q<'1;[PZRGS_>BT?)Y?T]WJ++ZX"DE%"^CM#?8!+_2Z!XANIO>(
M,).::,MGC[OE6D0S,S@]$:5.]@"?9Y=3_O%ZAEY94=+PMKIZP%>PF&2_JTB*
M&))I2NT&I4KY";)V('P5$F?O<$N8N_GY/X^82<]=2_3M7!Y;90<F^UGS1D[&
M5V\>CJ@[3GO"6B<S SD=4%46EAXOVRNV:>M-&R&G+R.F\@PS)4]!#R%2>5*7
ME?2)ZISFW-^L,^$>U/XRQ<:;55?+?(BI\US4+CAEJ[Q2QFR\#7R,/BX?WQZQ
M7/-NR[ND\DY,D7H\PR)V YYQH8$3R@KN@S>J%NA*?B'^^\0G1FX@#/N%6?1:
M\H" T?":XRY5-<G';^ ,UXJ=9Q&=@"E;A0)5JBV;1Y)EZP'*?2MJF5/G%YH0
MIH+QV<B8:3T?*UIRL.9^]!_;$+#C==-_Q3_>]RP3"MI82C)=XM%,;YIPCLWZ
M#=Q.4G/%VB2: /CX6A6E=U4]5V_V_-7X;[8)[>K2WQG79>#(V[M!V-"H.U?V
MWKS.6_?3;_DV:";LI,TT+!L1SX(_ TMZ )/%W\7:]Q=F'#L.Z#3K7!&-[R2D
M^0&5]0_V9%MS*N<K'3V'YD?):>=O!41B"D-NA^Q=0N26_74]:16BB/W?7A%$
MW8:5OTC"K9FN')DZN,!$^A&-=8\"ZL$_)FV?L!)V#P0"3'LDXJ6]BRDE86XX
MZXLWASU-\,%ZI2*Y<QH$MW:F35]5\]$)I'*P@26P,LN.S =S7#@+X[N_=;D^
M&,,T%K4,_MVCI]]7^_"5\\^_XGK^(*P7HMC0!$\OGP@VDL+<"FQ\LMQIDJ\0
M;P\O)$2&Z_RQ?;/Q@*];;5WZV6S-C(O)OMUY)[DN%P(]#>\%$>%@+_!.),VS
MI J[DRN;4:;WI"ZA0IB610N9'K"2)C*S?G0S;/A,><E'I:S=!T]NE3A_&:S+
M37]IA$3(1E@,N6&K0<<1C8*$I<T'81V]R;P]!JJ !N\(U\)*97WP(1>)1P7(
MZO)IF9FE;:13I';**^F7R<UU*K>B0P*S[2Z\#EE RL/VNK#>6 NQLTSYS#LO
MKLR<Z#84LWNZ7A=-KF5M#I;L7OFCNF_> ?9[OZY;<'Y_;=.E&'Y9K]52*JMR
M;*I1DF_8,."_MVENI]08]!([U':!F4"O<+'#NF^CZ%O/!&T3(;2SLM#R.>[,
M,RLV?;+Q_DOMKJXW/"747C\].P^$_ XZ7ZX7((<#VDDU7]+%UL@DGOU*!5-+
MUD]CI*58&/=5+C0ADPRV#.SZ@+MIF.U+5R+N!ZYGE;^UI%W+Z)H=G\69/V_(
M:^51'>P<:P;"??5H\!4*PE:Z=R6G66?Y&%$+Y$_05(AP<68[+86O!L>FP#JS
MXVV-OR;:'WRQ"@D:F[1ED<WG>'HTU;KGW*'MWA^_O?3W&QN^/*G]T-'<MK+\
M[9*3D#_\3G(7(#-*P/1VTF\(94) A\_IKJ^GAJ1V *M-UY)1?-D*OX6&&@P;
MWS:R]$^ 1O6)P+H\FX-OOOEB7UK;WP+6"_ =/2&C'215F2K16LQD837..E;*
M190'Y2Z@:H[3=G-]QW]OCZ)23RH=)/>+7'$B\\[=YSL>JG3Q8TFUJ2W+<-G;
MQX3N,_U6%G8BTYG(97?B:;%+^R7F[JD#A("VD6W42MK62:\\:W%&22EO$A@E
M!#GIAH7^+(_:H$TMQ2R:W;ZAZTV;AOT_'.<6>U_@UX=G:3-A9E!]Z3X0-^$+
M4_+I"112D5J@=KML#P/X_*3CSBT4)M]W6M?ONX]3A1@S0O3PG9S$:SSZ.%Q0
M8%&Q[H#4;OEH3*^_*K=V%;*=@!*XM-&W$JBN3\<F?>25/T8;-'+BUKXCIP@/
M3RY5Y>2/HKU/7\TX^:".T_7EJ+X2[LZ&]>()R7Z ]CT!*.Z59 ,*,VXX(,<=
MK!&2DGD6G/!2V:&V9T7CB^RG%3>Z$B($KT2E\?5UMK6]Y5.[I-9I+Z;<H@O&
M7V?SOAX/F",!J-XDV380NFP(<D3:'6FJ(08JH"[-P#Z,M24<K>:-C?CA*[7]
M=8X!DBUVPEX)*IUR5J*KTQ/5DD=>ZZ:'J/<8NMJD]?7J215!,S'L0LT08I=T
M#XB?2+G>ZIS16$^UUQ2.D\XE[XW;7-DS6U)R><PU.(=J\7>U0^F?]$]S3E?>
M26- E4(I'H27$37)<R<!"B4\X-DE=W.$6A_\4S_1H7!**]3/FQ#@-N#I #O.
MU3M=EXX"9"UXO#E/^W6&/NH, YMS4O.8 ]M]P'PAVI9]D5.B;1M3$H@MO33V
MX@WU5E#4A@CKFA>G'OT3>\G8];<W2;O)[.<O#6/PA-M*HW1PG]>,.J[XO05#
MCS;LTO[PTN7T^_@H:T:A"_;HD2-J9_K>G-EF/0]?<BS&<+.=<THFK=4VFX<U
MZ;G;_J/JJCKB?5R?47LL[V3JCD>'(H^\_5+]!Q 1CR.>BYZ@HA7!VZ-=V<69
MFY+*"$QEE=.43MU4*G8_"E>()L3:71RLFF^*?)X:;+5,;;#8E6'U^,C%OI/K
M!Z29\K(>*26""H"7Q&\0H2>])$Z+9VH3G4&TB)7X4.H%U*? E9%.8LNR%V]%
MRLXBNVEWW5FG :+7P;YM6<)76NGX,M[;B,+BIX97):[(3IX"8'7W:RM_6&NH
M Z&?_4[8VYD&[E,"X]J86H.53W8AE>!?^ZVBHO=5#&=MRHJRSJHZ4:IYI:'N
M-3:'9#TBTOF\(A63OB\"1B*%Q (Q/C5&F7A 3$D27<I<CNI@;@)XC!?_/C1,
M';>DPY5M1=B/,P_7W<C$V?K^L4/KT#K]+KJ M)$0)U.KH1.0[2/#P,VR@$KP
MV)0,VA\. YW@E0=_QS2RR+)1C(W$H*SDV9: 4@PIL*GVK-:6 HCBAL%5B$I;
MR9+^H=W.U)TAI8DO$A/SSZD=NWCQ(F1_*63_/0@$<L!,7-_-UX&G!$G>@BL"
M!^@$M WZD0E;'^R_-:Z#I-'L).!O"$%K(@[XCA&BW <L_M#M3IV[847IG]<[
M*O!#[-BP*/$)RR:*V403HU,K?]'WBEFM:;&D[0LY,#7B"= %X'?;2G*WWN'>
M[:;::\MG\_EDKM8C88U-=C$MU+[N[%NKZL[ PV^Q&OWV;Q7?='[3D<X%=S:3
MEDWEL<#9"@\!?RR+4DMCK AXD7Y7Y5V+F6;T!'_=I(%Y+8O;''WK&?O397;)
MY4AED5)#0#5YA*=TI_Y VU[?<XMI,RG+%V+^B3F\$KLPH]Z.L $0KVY-J&PF
MN#C+/0SNL ?'DNC]+*3.:\2X)X&9+TPTCD:QT0"9?97C?SG$FNO9I[3C^TQ)
M'LX11?YO >8(^@(<ML$>;G. L!="L#LN]DJ<GW8P]1=KI0E[C-RY\!08*GFS
M>>V*L^Q]OUY.DUTP#K<KF8?1W:595!AXRF<T$8Q"#Y,DN&KFX((=^AYZDX@Y
M]*R!P;548*,5:D*TZM\$L!BO7?I&K.M8SE=*?>,OX:F'_0K_=36$9D#7V6,$
M<[%HAMQB2UW%Y5[]4OWGTHLKR;*-D[^.L\6+FJC1A]ER4Q- L&N5R(P $1B[
M=&E^W&1V\7P?0Z_>]QWU8I"O;\0C$V[8&\:V=VRD.E-+ZBE7RS,"RP_T*/_&
MV\.QH@\?]@.^)DI1PI\S<[4X4J=M3 LFU&$\M3*XWP=[T#LX8FE;\DA*!6>T
M-MMWI/-PT?/L%3<QOETE >$ \+($<[I2&P"93#1[[HC#YX-1EP%F2NFD[D[K
M/YTP&*VD@-#K0/ D#K/5.F/"W>V<<@4&9_#Q@K&+D!:'W&RO&1E0"B*%:#9-
M<<KV9L(M833R'# 72X07A&CYZS:S<BXV RN5DMQBW_'CS\>G,FUT<WE9.]\%
MAI:.H:+M#_FY[ZE8!_[.Z0R2F]UH4(UT6W8Q+U=<-[*T)"C?,8,S!(43;'A'
MD:-FRJ%U1XY>OPBI@<0,@PLBG)((-O/DUT$-8FUVFN8WA'&_W*6KR 8/RKV(
MO]Y@17C+]B^S,/*0[I6\W@N<ZXTUKV6]@[@OC$:U4U]XL_VBD4!7X6/XBCI%
M&,36(VU8A;37UH.A@B.(G;@GO^Y'J*+2*<A-GX*5OZ<!R29_-VH-,S#7!HW1
M+Z^Z.[NT_#EDV?\T+"V>IDA$R%33CX.!P.*)=.'4=)) NU\NF1:X=%N>Z>'Z
M)/5VY:#B=IXN6I71\PY+?9ZSJUPOJ0=\?>CMZ_4_1F5;OHK_$T#;T,,1%T"\
M.* +L1WT$^O)VYILMZ,8W<ZS&K!:T>YH+"XW383K)<Y56F$;M,^)+W>?L TB
M=_BX,TNBC'F/L_^X3QW>LPHQ(-H#M37$;2MI5>%HE9X2@KK(2ZK!EYN(>U*;
M%Z.[.[79[M>_NO??,%=.STQ;MA7-N7%_=WGI.^[[[Y#JS[KZ@RC87 15;IA8
MO\Y/<H)2B:$ 5DAY8(_:WL$:Y1D#-N2%2L]K]S?<F0R/+,4,J?MWW[BG=*T)
MTS\*:7WU</,L/&T]".LP8F/IH&/[D@BTN\A9F-NL''"L/_R@T"_4U2_;OT;X
M*@ISY,."'QSACCS'0;R+O,ZRJ.U+W;M>0!K=O9<RXR)_J#\:U9XUH*AY#G5N
M]UZ8^$;.JZCH"+R/\78][=3).#"Z9V_"_9&#P%"<S+97K-"*AC9[1"^?(IJL
M4)O5<!/T1,^ES%886;8!,"=I$J\0N5I]X]/9E;,MH7+5N<]1[<_%]P<.-%L4
M_+LX-!+>EE2Q\4'&'7[SW>XXJ;'( L4>X2?*X_9XA#>0\FDI+0$>'7"" W=
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M])*$+,5@6_U/(YN>7IILW%GO$YA0\0.C&WG=VA;;4%UKWL7;_.-V[R:Y^C'
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MI+:Y[@GAL5+BM:3NK?%G%43*G2EI5%*(RK +:@AYL\5%4BC.2)FH%_]:")_
MVA*C,38IT^VOT'8?:#[%@XLCXNU))3W"7A60XO0*&\70DADV8MV\9S?%6;YQ
MZN:2 -3<SQVKD)OT98=52 II"8U#!X(* E(;/<$KFUP <(1>;/ZZ$-V*Z_K.
M<D>!4/U0JS3Z+G3O4Q]41/&ET<L.CT]M>#0<2;N6U!HL_'UCN P*1,0332V;
M;!*(9L+>K3VBW-N+'3R33/:205:!FPBV/>2TGKQ^-YGD8F\L,1MB_JF,*@_9
M)))-_J4SN\?PK,)_/8'/L;ITJ=HJ1%A<%%#D/WU7(4X&[Y%[.>BD]<&LHA;
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MJR0@!! \1P0$Z:@H$L$1*1*CI-S)!64=Q:WG*"-*8ZP(!'&?'0_/ 3TW%H7
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M21X(5S=+9KOY-T#0&),&$'/ST0YG,7<K:;I.[<4=MGQ13$RUIANJ7$Z9Q+D
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ML4@CXM8'9*D"B&I4L%(+02*_H6-;Q\>.C0<=OU]_YN56,QL-YK?_X_U<&K8
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MP8JW7'LFJCW+]DR\+^B0LQOYM?]Y,=6 50.VP9JV7 ,FJP'+!DR^CR>' S>
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M 60!9($> V1M%;(P%E(Q0Q"+4B!.64#.4X:PH]9I070@&U[6?5* .X8LQC!
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MI\WMV1'+ _/->SY$%O#"3\:6VGO3QWC7YAF'XY /?,Z/!&-_>K&#U[_$Y_M
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M8TR0-HDC1:SD@F+I]4;^U5E&=,S@YT@!,FH#TDH[%%701B;#<%D/^%A QM5
M4'#+ ,VZ*4E ,T"S0T6SWB=@<?;V2) $4<&R&^A)1#I$A[2S,@KGO5=B<S-7
M)7DP$2E*,^)*J9#!G"&,-8Y.*TS\5MW NV5A":,#AL$I[(;M@3*F0RMC D@%
M2.VD@Q@IB<3&B(@("G$C,-(:)T1\2%(0(R-)UR$.!TLQEA(YG\&0<VU*KYB
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M1:0.4\.)VUAT%F-DR5&'B/<2<9T4RO\/B"@?=)2:VR3N2.&;36]O9O /J+R
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MC- $\4@ELJ&$M@2W7@8<B=U*/X]E9<V[]*&8P..%:7Q=;.>6BC:5@G(:R.T
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M)C9#I<B.-*+"99^8N.P.2R<0-I1HX3DA=*/^'Q:[0?W_7CLL714E@-U3CP"
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M^YGQ:@\R[DK7O5J[@B<7V:KFJ0>C#%"(IC,[:1JH5[\ ^M<?G]DOL4Y<(9N
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MG/S\6_6+]648:>]G7]+E]_'7>I05Q90>E6F_C=M=E0P9,-Q@-!N#[_0&SIF
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M@D\=<A+I3>&,.A8=WX&^<!)K[V$#-V[P'3>=LYVKT47-< >B;\ (E(HIGIA
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M+5/2H.1RE!*#1EKPA"B3,@7G+>,M!=E;]@XP[$T6OE:]B_J@A0HNZK:<?A&
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M+7!1<(.3;;7;1@:^F' <#L_MEUQ;Y))DR#L9"7,*,]PJO'MP:9<4'V'<\83
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M(5X$MK.-[V<Q$4;W$V%Z.7]J<O:&J8^V]LY"/6*TI7T4/G"&8JGWLM(BQYA
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MDH55D+3$.>4V%QL'T@X!AG*>'W.<%D >5-TOO>*WU[K?JU3W^]KXQ3WWB![
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MA5"H3=BT'9O TTUJT.%YT\"/HTMPT@%KP%N'7\?! 0;%'D5Y3J_D"7Y_ECE
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MTP//J,*_W>Q'HO$RTI:_S2<NR_%Q1C'EQ]=B?PLWSH%1@6*KR%?BHX%J5;/
MROXUKT*C?CX#HX8 ?E*-Y^,0@\=&UZF,=2'L!=?5!<K1N54>NK\2PD"O^P9@
M%-IMMMN1,A/  _X(VH=JC^9AM.!A9MT%W?!'E=+]4 -[Z@F:\S[0&2!G@4FN
M]3">F5N^:!=M 2&#UH-P;1T))1"P4"7*NG'T_08R.6_,>6BQGH:OVNV!U"H"
MI4!J3;%_C,D@ET6P2%'4#2:_9N'0-;7,/45CA&^".4[C-T&#^T1@%X%-P+J)
M..[S>S%NL3%E%PSMWQ^8>GJ"\G!I<D6="F>?,H=8F3LD*,4(0AWC)>.%-!MD
MI<B=,$I8A L67ITA"BFG/")Y20C7IN"&K)&5]VKDH@Z&-S _!%CO^M 5??_;
MC>R/=?-F(>1?>[-OUZK!?W__&I@9^&1X*%\M"J/B<U7AD^+&>O 0=#'D9T=A
M1@*47*G:PON%^#1ZV##(X&UCGFKICH-(V^ MNWBR][$+#!K2.&_%0P"F"["^
M#D&&U.L>LV+*,.;ZUCW R2.EESW-&;&Y1[Q4"C&7$R1*#G9I)"WR0E,L-E8K
MZAPSSDR!*+4,[#*72 IE4>D$(3DK#)<;+]C?9)JO(7QHJFFW6.-EH #O!^2Z
M U%8,H\%@VE".@A<=Y_D#182H^X+U=AVX9H[(ZMB.DM-)B%/"P)TDS[9%+[,
MZODL,J 5 M)SG(5QGAQ"KCOA_3WQOH[:<2OH!VUH@2Z#COUKKIJ^T@2.+;\C
M^X?.+KQ=QZI[!U.UFQ[FITGW-'@2NY:B71U*<* 3D(WO65\?K"Q&UZX/;Z.5
MZW;5+I^P#\,:@M(D"[IF0>LFX=I%H-JKA[(?H^*%8D3(F/?1:A]RG@/-"_%B
MVRT.#'%KS*OUT>S&U_T-D2)VV7@U!5W[5(6Z!L2.0]*4 R#Z0!D$ V:.5%%(
M( >N!*(/O)\3[ZW(->?EQNG%I%3,<"&1XV%;NI+"W8S#C1)3[!SFS-,-0M'/
MX^MN&G?$X6_8A8@H4DCMD67&(\9*A805&CEII)8XUV)S;:N4)4C"Y,A1N)R)
M(AQ )@OD+/:LE)IP4C[-F/ )V1*7'$*@HC81+J+":V?<6 , Y"1^6X2U*>VT
MRPN%!281.AJW2/@$X,HZ.(*&45_'7&2<Z@YF \AVU76M1M&_M.<.?D_9H"_,
M!KU;YOQ2/NAS*>! 5M93I)'?U-Y700%#CX+N_E"%A.79N1H?9R]'2JNQ6J2"
M+N IX]I6O@+-#7KO/L'3>YW_)2S<BGPN/E8]4A!)>&D\+BBBBH.O@S^1) $"
M:&$M"W@@-]_T5IXJ7,(])IQR7UJ"E"TM.%:EN2B9H9LG8W55J*5^1?4*:Y;>
M^; \-[BRK:N7PBY;K9L,1 4@N![#A_-#".WB.C<W"27C-762Q\N<Y>-H5&FD
M)5PIA)EDB"E/PI&? G%L<Z)*!]JQ<?(TH\84G$LD<P9:B(L"*8!I)"EQVH&"
M$EG<1:/>Q6S$A_I-""OL0+2F*TT$=AJC'0O1U\<^4(K@-Q_-^DF"O@+L-=&7
M!$8,N!?Q[:9BRW7_LU)V.8CTPX?SIIZ?G4/,%X<9578U8[.QW#10!8@5J[ 4
M*'A%B!]B@+I8^!H7Y_2>-*[=.8YB[5>P+M;C!@9Q'.,,X!V=]^WC];[5CGO$
M9;!QB5Y8_U1/(*;(X@M'H8\0: "TQC5),_4I-'0U&5<+AZ G\]FRY@=!^LMI
M4XUZWK,ZMD59*W0E\)HMP**6ZW"!6\:G_@E7WP%N'BO_Z*3BTF.#O''AG%[-
MD!9AM:OEW /-4RK?,/0O7L3P;N)"=SY<E?U^=&XE\S@0&U\E!U-5 9R'] V:
MP0/72I;>1>TY@&#0:)^[PC#$"XCI&/,2:5<:)'1.B63<*K<1.(''EQ!<>41)
MD0,Q4 9I#?^QTE@@,MKZTJ_-[OJTWA@TR;6@2=PK:!J0VUO&2. >HK)$0(C,
M(B[0[',BAZ$G.&=2Y)HB'@DDV#&2PEM$&,:LX$P376SH2>%,[B1&DI<0E!<B
M[@J<(\N%YBZW=H5 1CWYI9/-K[UH;E24?$U1\L]5_? QB&70NG*<:0?Q4;@P
M!+LQGNX#YX- ^"[1_<[,ZA#S+T/^$,^[["+\9U)?:7SCPGH[>.H.UL-_]8%G
M:.I_Z^:/XY6_.N;?$:VX+CJ^VS Q@4A,LO=N.NN2,Z2(,T6Z=,QB86!X:282
MML<J:)HR%Z6$D!)<!V)4010@L4!6$&8L(:;</"##.I\+G,?%"19@"D(T:7R.
M"EQR5T"@BMW&?IL'$SDL@[;R &S]Y"NC\\E%W>RBJB" 15XK"S[%AK16YZR"
M$^HGZ.\38#Y-&VHZ, D_U_.J_0CDR&6_J,G< Q[/FS #[UWS$7Q;>_5.7YSO
MC>4AH?X4=I-H Y^:Q]KAE0=KZE%60VO'\>649O7EK?%::WZQ2#=JWK*>U5^[
M_-5V5_?YYYC""A7-5:U??^[*FM"NGK5POO'Q84GDLM9Y36 PMI?S,YCRC$6_
M3&/7JMD6S]Q?!Q>)I*'7-'1C1>NB-KE96%2S_D5=XZ8+38EO0\4[;RI'KE8B
MA^2:#R",<"0@=LD0X']8S.0Q4@5E2&#%<%[H$O.-K2%"/"H*&Y8C,AEJCQPI
MK7/$69&7.2F]*^0^:X^.%5YH29#3/-8>(1PVRJ.2>R^4,IS)C05:LJ0TI[A
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MIEW4&9];K\86RW>3%JLFMY3>NI>\PDU#,J%^S5W8Y:7ZU"68VU 3!AEL0EY
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M(3U&U/.<Y<XJ;^A#-EZ,BZ5^=FWKW-*47T[L:@CQ\V(IZ"]J-F_@WP]ANC]
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M73J(8IU5"@O'!,9/$<"&M/>'BSK%K<ET#U^<"6N2PB:LV8Q;C6&YI478&,<
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M]#HB$2FT+ U'N;$*,2(<$HI0))@1A>#84K5'1!KJ9A5#M=^O$)%2"'3($DZ
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M=R0CM$S^_(YDLD:9#^_>D("F^!Q^8 .@.@=,^^X<@&@)M9IFT@DH=84%Y!#
M MR#$F2!G.=T[4@*:/+-0YT/QX$FB^/B%6(R:13TSE45E#XH><86F)F:EC'Z
M$)8B(_G\P-]FJ*D'X648Q13LTNJ)<_"JLV.:A?-UTI'C7YCP3^EQ2GTS5#PM
M 2(8A:C VA96V+W6DWR<O9O]PON)8(,/1@&A8(3S6_U"P@3+78PZ8%\X*3E7
M+P<\'TEJD%1HP#VG"^36V.4CDJR_DCXQ_'%<V;'.6M>0*E+,&';>MI*SY+E.
M+6LLSE-F"*!3 J!!*8I2\A,YQ?,"WES7/KE)#EH/Y7@[Z[".ZADEE0L;LX03
M'S*03O9-%;8DGSVGKD)+2B<E>W!-/U+_(7K[0AOP@S,>$)F1+[HI)X3R2$:S
MB'2[ (MM@*\0QUJ@>VA_+\G?OOG"%6* C,A6^#R8#R"L,6;9C+R*^2%N-H[^
M6VK6*&5%N,-CW"&O@*'P^8+B"IQ1+#R692_&6!O5%B)<3/)8$ZE^&+_*CXQC
M>/BL5'1,"KH](DQL'Z=H#FPK&_U]#_[H#P9GAX/>R>&?O>Y_%M,](*2B^0OM
MIZ 3G?9/%]]?B^/EJ'<(_]C[V7OWMM>[=^J]>]Z[=X\]"G:YK. ?E.7V-L5,
MO<3K8<Z0H@AU=?R?A2[(&?3Z)YS.X!1"D9[F).SK5$U=^R*:5E7#;[:3*$FS
M8B9R,A\6R4W#A)/C63</)Q/*ES4%U9B)F-!'H+.!8A3E,^TS14V.$F)+?C/F
MZBZM8MD!@RS*):\6?8KB^2$G!"EO8.YE:(^B^3?&Z#_;LU2LSI: V$RY6Z;-
MV=J<2L'*;+)LK$-84 X !X;S,.; /SV!C_+;V2^[I"(AL#AL%AN:+I)AZ5P*
MAQ(! 8QKB[-'8K([L4)23&_^\P#@_0U6R4TQIVM^ZB48EIQ&Q0%<6&S"MNW^
MWL??*;XJ#DR*H4YT4G-Q *\_$,5Z?^_-UT^@UFH%GL%M['K8^B599UC.^ZPJ
MPF]J'EE3%NX(M7?K L-I8LJXH*725(I$N"1%ITS6L5!?\@KIH3>0XQ[R3<>U
ML?'J_@MTA?A434MG3\"( B9Y02G,*=B\A0Z."[8B16/!K""4%,5T@U]"X2>-
M;1.8"ZGO0(E,N/D,$?M%_PP=I%$<4ZX@%>:1U_VPQTY=M)V0J&QK XD42&FE
ME+/CF\WV=)<VSO)D%L$? MBY#015',]-ZD2(!7]12E7N88'E3V!&]@?:<VO\
M'[K&-\KSDN^&"YS#D8"!SK:QF%0*$^$!<J+$RXXX@-#7ZG32P":=<.PA5OS7
M+#[7R\NG5GPEG  ^8M'HB;!*A"[44 %#I8OQD ([F>2KSN'NRXS=1F.JSP#\
MR!29V$P70JL)UM-2" A]&:C[LC6N*N$N3549IM\Z"($&4R17.J5L75PS3?@*
MA?&JY#+*TH1\'N3BC%(GADAEI[EV;6PX";H6(T#/4163=-2PP-QGBB.H[R!.
M"N8XEG"M7*GAH:Y0(PIPZ!/N"D0Z7$=>?P>0B\.*=&L"W1/#=181Z=8]1U0H
M4DF#TFS [;5B6VI1>,/F<4G7%O:H6(&+WAI@2YJ6U\1$K=+A<&]]R28#&EM!
M BL8.@5D5G;_G&+UT; P@G:MT 9YJP\M?-G1T:R?$\N&@$.8DP,_!L9#@-;M
M'\*,G-?2I<AZ0FO^SV89XUF(FU2 $?<DD7PSTT1@1?MQXO+ &$RI/1>E7[&C
MG_RE0ZHUG$;B$Y3(A\YI11WS.[7Y 11],>AU^T9,1I5\URE%6>#7&$7DFD3=
MT@,)BY?K'W6.3U]U3GLGZRK@]].LPT6TW(-$,B3((8F %;7UBA"*N6 <J;*^
M#BB4(,7^XU3)"Y?0F*:7-TQ"5RN8'@ZY:8? _+2672C,PJGW0(37J>XK2$Q!
M)@TN<P$:V-74X1<GW=,*E*=3C'84R@$O,XD9F+?2\ 8W<P'D##!]:\$#K#0;
M87TA_#K**F";E''<#3YPD*6#*Z*"X_9#&2L %_5#P2(^%V?,OE=W9M*A7PRZ
MA^841G4Q&Y(MNQT/9/N_-&SSJ]9-$DIK+S..S\S2*ZQ\E4Y@L$/L->5 =>F"
MU6S1;$8J$48Q)\X*YZ5:F%5ZDNA6]0!V\V;/E *[@JBRQ=J61! SIW3,M ,Q
MWEB/<K@K'Q!(UH;=KF8JH6 XYJ1( S@C><S/A;K3(6%]Y;V</@2:"+;!J+X-
MJVI M<"<%33G]2HEMY^Y]D1R&L<4M59EE(T/%B$:U%7Q8;:<E[I0:HV(!9*:
M-$E!K:H;"-&.J:,3*@#(R(8AB%HZ YX@CCL&=X9.(R#D'.$WY;XCE)950[5,
M1:= ;6R-QL-&;V%3\-VT!CP,1UQ0+N,%5N0P& H@8 B0W!7:"2N*G*UF7^AP
MJ2B)*W9(0&(_#I=D6M.O6-X#J$?P:T#H#G=,,*LB?.*"#77<+AXRS+!R*ZF&
M+B4J3RWV/J05R[+2PBA7*MB34O=?S=EQM;=R>5^4Q%+W,#"=7GG97TE"4KI-
M&/>#(4F&&G>%_U%FC&.4L4FGA>&<&F5PZZZJXH=5,V.5C[)HJ#LB$H_DZCK*
M?Z]V_NKN41;=-6V+N&P94P4!.D#RMC\'D6%U[T:M7K4D&>O8+Z8CJ.$8K\AM
M?HEN7]U%RS!Z8-34'EV'V&V+LZ6/2 IRO05]$;Z7[I88GVQL.+O-]/@C,+QC
M8>87%H';#+4'#A#8;@MKO=8NY5LGIOYIY9=6MQ.?M6CBUK>9HA13G+%$?D[2
M([@EAY5H:@(_%+<<'";0E?=KC50J)\Q+T)/R''16IP,<U^=9SR>Y[=$=BK4\
M$\HQLAI83?_*Q)A&53M3PE"EAV*$R4&@07$S#];.#4PT/*H>78).6'<-Z,,@
MR%A_#9?BE,3?WV!+]R"EMS16>$>V\-EH9^_%2]P(03>ZO!L<XLYLU-$\WSET
M6@=?.[?OV[NMN\L*S]4!$^T*M<Y1<N^PUYO2[<;& 6-M$F.#U'W%I@V<X>K:
M'WPC]Z,)2:'&>>[>Y*TF5-5H>7#VT^MU0ZOPKG=\;-7I\:!_>G9R]&IP>'IT
M.CB^IQE65/5Z8C)?KIUC]=2TP/VSE#K0OD9WM)-I)Q_&849XK7\U!#$/"^5H
M46--!BI41FASHD,Z^G8@J:*@V,.:++ZU,P#)1[\\ESZ&TH%H#75.P&@B"\#F
M%3ECF#PI>%+X,5*8("(NPFBLR_5 =0YU9!R=:Q%FV'/6:+QTG?,NV]Y0 B#,
MWZ.O1]^'X.0FVZ.6K^*DI[E1I+P YHX8STW^.<X"F Q(<,DC 8H<:]G C!NG
M&9EEX2@<4[,L:Y'!-XWX[/.OMS'_^LSG7_O\ZYOF7WN1Y476/8DL8U1'J\DE
MZ[.K'0O%[3453#D.3F8(]B*WWD2,&4<RI1:KR YT.+B2*KFZ+1XZ4_> XD%P
MRKDU623;6P+)^WMOOWS&GNR4QQK'09C;9ZJ-D5<>_,0/4GM.JXE2A$D XN1Z
M<SIW'*GF'#(MZ2NY9 Q"KXMZPGX PF97&<=Z=3=';BO3$+>@["SN0.XQUV-N
M&S"W;D)5,G*-FW=#%HK'3H^=CX:=-R@5>XVXZG'2X^1#X:3C#:6\;QYB2>CI
M>$#=@J-N$SH^]]"D%,DEE/Z\)@ZBF8 Q3[K!6_J(0BK?99YJLURB)!'L6#T%
M:P-=?KI8#7M.2\,^SLF@$A#I[>5T:Y9OS7R7(L2IG:7T_;53\,0P&4ON*[L6
MM2\1.P:[)AD5[M0V:79&93.4 RR[PEY#L#8E(1J+3)>S8 X*#R:UF3B+L$"@
MK,9P.V:$5:8F,9?/B19ZW23$G',)HS'[14=92=W5K@DL<]OO.$YI" R'AM$)
M:J_MNEOG7E(JI,J=E13_WQT]92683:V!;_B:FH1Q[L:IG2$X2>\9FAW-.3ZK
MC6Z&)0_)H:QH.3VYFU>.H%O:4,[DI<KB<&&0T=1@2_"1OZ"ALSJJ7NNTY2MY
M[I8'42-%]&!GW!+/K6FMM'/7S?6N)0'.LC65@$T%OR8%UU:\N&%@X^%H'(SG
MEL7IO MW,[6"C#I^4$I_LMR09N?DRJ'(0]]X.)5"HH;]4EGKDD\M]?BQ-(W#
M:28J:R _FJ[#J(UE3&$61S=XCTU6<8A( QI=87])'F.9&2Y/)Y"IAC4#>[M3
MZAX^I>H?3G.%-]7F"CXGK$WW>^O;K+7*V)P5IG-C>*B %,"P+DS$7,FC69,4
MPP6'8&GEZ/N.M0["9<AZ.!?K(<JFP72#FVR:RN5TM0*PLPGW:L5**27.MUA-
MJ7?(:(0E'=SX B<UTU]%^-UU0],Q)!?B-8Y2 P9D7O9:U)F4.6Z*]5/$*Z5>
MSMF5[9R K3ZR<&SGBK[FXX8C*K!N2$R29G)R)JKC=)SV$ZK[$I6$"MQ5HGL4
MR*+5Z[*%2LQ]G?*.C0E)7I=H[NZA58$-W6=NH@SH\K(IY496ZE-UUTN9$.D&
M3[@%C0K'A,M2EEC3,J@Q2&,WS!O4EW'897U+S U5Y+;Y8L9#R.CT<?2-!D4*
M.EN!O6)8#\LHYG.#043].2NJ>!7&+CV[_*-#6RX3VZZ5R)]^8KJ5-!0BK-8/
MRWW;#:_-0.%!,O56*2YGY+.FE7)*PP\;6%-',ZU:1Q?@5H9AF)2M^G9TUPM^
M<=5986K&8^G0@JM>O'];<5U<R^?H.*\E;9?+QQEO&  <1<=('_W0:UK7=1R0
MAJ8?L?NG+V5J DU$H-%<)+=-8(&?X50!+J21G@/#,/FF:>I1.Z*VO:?>QH+#
M5NYXJY7X)ZA[PB)3T-=SZ^3\2B,0/J74X>H]]4RH=MY"QHTM&;89T@]1"&X'
MJ'!?AERQ/U<B4IFE):>_G^[1SH,GI*^8V@#U8)^4M[3,X9/\Y?DCV=0_0'P/
ME6EXRV3"Z]CT#R03_J\@"/XFE[X:&:3,3\G"Q.WA^G :_/E!'"[34G["K^KW
M>MW>3_KWE%B\R-5YCH7ZH+)5,RKIN3UZ/VS I*5>1KGT$#O7"^A?P<_&U:;1
MQR<_N>FB.OV1\D5_7O=0_[&>&70/'^M5W:.SQWI5O]L;])S_>S1P/N(9>]W3
MP8.\ZV\_%]D*RDL^]!D0^3 <?0.3%FSB V&$$_J_9D;HQ*@Y,1L_:. U*]NM
M9FCW^IB'+1]Q\C-\< D*)KJ092EF92NI_,Z3DBC-RSUPNK9M/7\S-GK71.MB
MO(/ NYT$NA?0 3+C5W_?.]E[$#":0@%=8+(H9!:%UB1N >BS!T72.RO4-U3F
MUFK CXO8&VZ$65KOL#UWLMN,X[Y@]Y1\8_ P?,-CH(?=!MCMHKIVKZ)RFW62
M+9!ZVPS>AV;=7N63BT 7VU9C^;9*AUV2K)Y![#2#./8,PC,(SR \@V@.I%*:
MC&<1+;,P2?M?-3%' )O)Z#8FYOV8E/#3&_.B!L;QV.;-34GFEBU6=6+<>0LX
M?@N@O.4BX#JP6G;PD("EM^^J6N*AZ4G>D_QS15(/34_RGN2?%9+N)#3O8*?I
M4. /F&1N1C*]I?& CV6XN8FA_>[9\>%/E0WV-F1+M]>R6U<X?Q>:NM/M>&EP
M)_@FZ8Y"MXK=-P?KBRW V"<4#??*- :=HU>''H/78/!CLP+/:CVK]:QV=UGM
MV:G'8,]J/:O=9NAZ5MM^5GNG+,)G@;U/'>KW+J0VNY#6M^[: N;EQ>V/0/>.
M*60M@/\6:HX_#NQ=D=1@%!T-VHS\FU/X//I[3NXY^3-&9<_)+2<_[1^U&?D]
M)_><W'-RC\J>DU]S)?N#4Z^2/X6+^&6+$K:>U+FVC;ZSKVD1QD[;=E4;M^"E
M](Y*Z;9"=PME\'.1L$>=5X=W*F3WB+N=B.LY["Y"=P<1=5<X['%GT.M[Q'T^
MB.LY["Y"=P<1=5<X[/[@Q*=9M=8#= _Y5MX#=$N*J(T]V@)>Y(6F#\]LB5CU
MX1E])?UC'V9_9LC?5E!Z/NY1V?/QN_+QWM-7 WH^[OFXY^-/#O\M1&7/QTTP
MU[/Q)\=]GR.U%1ZR7],\YZ'?Z<H@:R^6O5AN&?R]6-YBL;Q_U#D]>_H4@&T6
MS?<;Q?(\W?/TIX>_Y^G;S-./.[U7/OKA>7J[8.IYNN?IGJ??$?L/^T_??W:;
M&?I3^<]\AMGC^\]^4T40I[GWF3TO63SH#I CC=-R&*O62^-M;I!Y'W#?%<'<
M2@=:[4I:+YV]N>59O&?QGL6WE,6WT9_F6;QG\9[%/_4->!:_&RR^?>ZU;>/O
M]^M@@S]".'>;6*I]]Z;7_1 8QM$EGOYO\%^]G[^H5?[W\\'K2:R^'XRC3(TP
M(>P<T+^<)Z_'4;Z(P^4Y?KN"5-UCP U\O_@H^8/_E'D1399Z*_3H@4K&KQ=I
M'M':F8JIG3V@Y'<\-Y[%8.?W&V)7?W -J#;<C+ 5^063DOZ7(/Y=V<%]7V/_
M5>,5SHQ_6+8=)7&4P):*,"O.P[)(7U>_@ O@CQ?A5+&K^""< !3.P_@J7.:O
M]WZNXT:5(>'56FQ9N?7[O=P?H[G;W&MK"'(4AWF.UPF/RT/T7_BWRO;J]'K<
M ' 7M 02F8)QU#T^//QIPRB,'R$EH?9'(!=:^3PJX+VC6X"],I#UG1W(&KRO
MM09LY_8#%V'N=KTGVW"[-^ON.%/!)(WC] I^&I (#_)R#@> %^5!6F9!MF;^
MKND$"0MD00$+%;-,J6 .B\_R -BC&@?_*A,5'/8ZP: W.*$5X(_C8#]*X-=I
MF<,G^<OS1T*8QT*/._/:-<AQW>&O8S8_P%%)M1.TJ$A'$@4D_D04X?9P?3@0
M_OP =)RTE)_PJ_H]4'Y_TK^'^XW#1:[.<[4(L[!05;%"S^VMQ&XOHSP:1G%4
M+,_U DU!67[A\6FW?]S_R96;6@Z0X/QYW8/][O%=GKK+,[WNZ=G@L5[FC]7:
M8VW*5#C;6.C3Q!R:LQ=6+:F;F,SW[(5K5E?/[HF#6O=&*]QN'G;7P0Z0&;_Z
M^][)WH/ \8X):4\!Z9MJ/%?,%89I/+Z5IH?*V2=6SMY7E+/'Q>P[)Z7M(/9[
MSG$/G&/P,)SCN<#1P^[>4TNW56%KI;!L51S5B[UM8-VMQ..G4/K0Z^;1W$O6
M[8.=9Q&/QR+N-++%LPC/(CR+: FD'Y9%O)V%R?1.?;\]DWBZ L:;FYGW8U;N
M: 'CW4CF':5]71\[/V^!:&C!96RYI&AQTNVNZ"\>FI[D/<D_5R3UT/0D[TG^
M62'I3D+S:?HYN\FK])8G;5#C)I#VNV?'AS]5-MA[B,3:!^]@\_&W7P[ZO5X+
MB@2?*?._&7S]8,86EK6V6!+<*X\8'-TIT/(L\/>Q&8%GM)[1>D:[JXQV<.;Q
MUS-:SVBW&;J>T;:?T?:??D186]'WJ:/_WEW4=G?1P+N+O'#=9N[4+D3=%9DZ
M>/K6Q!YK/7OU[-4CZBZR5^^"?T9(Z[GK+D)W!Q%U5[AK_T[5IAYK??Z0=P@=
M''F'D)>IV\R=VH6HNR)3!S[(\HRPUK/7783N#B+JKK#7?@MF 7JT]?S5\U>/
MJ+O(7_?[QT\_B:^M>'N_,_9\LY"G]O7<K5G('TD8Q^DH+-38- 9I5S'FCDI-
M7S'L*X8]-#W)>R3=4B3UT/0D[TG^62'I3D+3Q_5W-*[_>Z9&<90@N'[(M/->
M4N\E]5[25DF#^QUG?SSP:/M\T-;SUUV$[@XBZJ[PU[Z/03TCK/7L=1>ANX.(
MNBOL]?#0=UQJ6^&'[P2R%0XBE>5IDBCK'@KVHV04EP@;>&,Z^G8P#'.%;NPY
M_B LHC1ISO]H%V_S0G@7H>N%<&N%<+\S./'UE\\(<3V'W47H[B"B[A"'/?+5
M(L\(<3V'W47H[B"B[@J'O=LL:H^U/M'HF?N1/H2C*(Z*Y4&F8BHDP8FS:3%3
MF<\[>B[R]HX#RUL _RV4R#\.[%V1V<=G3Y^[=.=Q\1[Y/1_W?/P9H[+GX_I*
MSOI/'\3W?-SS<<_'GQS^6XC*GH^;CBN#PZ</ V\S(V]-5Y9[<KD-6N5R.^R>
M]DYWP>7V-2W".,A4KL)L-".'VUA=JCA=S.$'WNWV/,7\H#M 7C=.RV&L6B_H
MMWG*XGW ?5=D_J!S].JPW930>K&_A4IO6T'I&?M3WX!G[#O#V,^>O@&\9^R>
ML7O&WHH;\(Q]-QA[VUQTSY*I&]\<_!'"N9UCN/ZIH^[QX>%/#^&D^D^9%]%D
M>7,VRZ\?P.LWO?%'@',W"%RWH]O#X*;49K=S/Q#Y<IU#+[A2F0I>#+K' ;PJ
MCM(DF*194,P4_'^F5#"'M69YH !TX^!?9:*"PUXG&/0&)QVJX@PS^+Q(FY?@
M'R R!HLL@@^7L)M@H>#O<3?X.HOR@.M#82-PCH-1F,\"@,T\#_(2=YVOK1H-
M]O<N?GF[]U).!F <1?Q%.@E>]+I'MSY/]\<1YUI<;@7FT,KG40'O'=T"E_ZA
M$I6%,0'\S1A^%>5%!B"_5,'[!O?PW2!XL@T O#6XPBJX5HCO]LBZ0GRG#T%\
M0&'KZ&MP>_J"=RI8:I0IH&99YM L<P7O@WW"!0/<@W&I\&"A_7V4X-ZYOMPD
M!H_2O,@[@2TRUSL. P!-.:(-XY-9.E%Y#O^"&\E5=AF-5&X(O@WH$GCNLWFH
M)&K**B^"CPD@MO*<I@$T$8&&**E"H4@0\$'_UB1+3\(?QQT,#2[4"-E7O-QN
M2;DRU^+AD?<ML>(H9^Z)D+^(O@>?&.[O-\#=H[D3H@:P3=(X3J^0T9.) ZR\
MR!&;BUF0EADB:1G#)P#D%(0%R:O<8'L.,+\!KF//$OA]6N;P2?[RO/U2XLG]
M90]NR)%9*U>^FH41ED6J/0"X/5P?3H,_/XC#95K*3_A5_1X8_C_IW\--QN$B
M5^>Y0FVI4!HJ[".@Y_964EXNHSP:4HW2N5Z@*9>%7WA\VNT?]_&-WQ%2N#LY
M*H#^^^N]G]<]V.\>W^6INSS3ZYZ>#1[K9?Y8K3W6I@2OLXTEE3>?NK7*9IZ@
M"_\#>_FL9[<5$8?M MX3!&O,7(V3AYFK<<>,WF9 GSTHDC[L?+BUBN_CHO6=
M4WJ?XD9VFVW<%^R>DFL\YC0>CX$>=KNKK-VKH-QFC60+I-XV@_>A6;=7^'32
M7V]PI_20UF#YMDJ'79*LGD'L-(.X4Z,TSR \@_ ,HA4X^K ,XNTL3*;*LXB6
M69C7U'O?W,2\'Y/ROLJ[GR3U_0=O\#,'NY.I22T[;P'';P&4MUP$M+A^8%?4
M$@]-3_*>Y)\KDGIH>I+W)/^LD'0GH>E;X>]H*_QU!7PM*(!^IM+@9O#=V<D=
MVURRWV+1<+]-[#O]WM.7Y+<5@Q^;%7A6ZUFM9[4[RVJ/CE]Y#/:LUK/:;8:N
M9[7M9[7[A\=/WQ5VUQ"XK6W>O3OI06AH?5.:+6!D7O3Z 2Y;HD7Z 2[60.J]
M>OHYR-L\P64+T;^MH/2<W*.RY^1W=W7U_'#<9X;^;06EY^0>E3TGO[,GK=>V
M,1S;Q<B?W-MV#\E;3^I<VT;?&8](3%=*;5K VMH*_]V0TFV%[A;*X.<B8?N]
MSJ#7]YC[?##7L]A=A.X.(NH.L=BS$\]BGQ'F>A:[B]#=043=%1:[?W+2\WC;
M5A_0/61<>1_0+2FB-FIG"WB1%YH^0+,E8M4':/25'!X^O=S=YOC,%B)_6T'I
M^;A'9<_'[XC]@[Z/LS\SY&\K*#T?]ZCL^?A=8PW]IZ\\?/9\W*=);86+[-<T
MSX-)ELZ=$;PM8&9MA;V7RSO FKQ<?J( U:O.V>G3YP!LLVB^WS"6Y^F>IS\]
M_#U/WV:>WN]U3HZ.VHS^GJE[INZ9NF?JGJG?]$I.3[T#[<F1W^>8;84#[3=5
M!'&:>Z?9\Y+%@^X .=(X+8>Q:KTTWN:&F?<!]UT1S*WTH-6NI/72V9M;GL5[
M%N]9?$M9?"L=:I['>Q[O>?Q3WX#G\;O!X]OG7]LV_GZ_'C;X(X1SMXFEVG=O
M>MT/@6$<7>+I_P;_U?OYB_KE?S\?O)[$ZOO!.,K4"%/"S@']RWGR>ASEBSA<
MGN.W*TC5/0;<P/>+DY(_^$^9%]%DJ;="CQZH9/QZD>81K9VIF'K: TI^QW/C
M60QV?K\A=O4'UX!JP\T(6Y%?,"GI?PGBWY4=W/<U#GJ-5S@S#F+9=I3$40);
M*L*L. _+(GU=_0(N@#]>A%/%ON*#< )0. _CJW"9O][[N8X;58:$5VNQ9>76
M[_=R?XSF;G.OK2'(41SF.5XG/"X/T7_AWRK;J]/K<0/ 7= 22&04QE'W^/#P
MIPWS,'Z$E(3:'X%<:.7SJ(#WCFX!]LJ$UG=V0FOPOM8?L)W;#UR$N=OUGFS#
M[=ZLQ>-,!9,TCM,K^&E (CS(RSD< %Z4!VF9!=F:@;RF'20LD 4%+)1'WX,Y
M+#W+ V".:AS\JTQ4<-CK!(/>X(2>AS^.@_TH@=^G90Z?Y"_/'PE='@LY[I_T
MGY"CDFHG:%&1CB0*2/R)*,+MX?IP(/SY >@X:2D_X5?U>Z#\_J1_#S<<AXM<
MG>=J$69AH:IBA9[;6PG>7D9Y-(SBJ%B>ZP6:HK+\PN/3;O^X_Y,K-[4<(,'Y
M\[H'^]WCNSQUEV=ZW=.SP6.]S!^KM<?:E*IPMK'4IXDY-*<OK%I2-S&9[]D+
MUZRNGMV3MFK=&ZUPNWG870<[0&;\ZN][)WL/ L<[9J0]!:1OJO-<,5<8IO'X
M%A=Q <K9)U;.WE>4L\?%ZSOGI.T@[GN^<0]\8_ P?..YP-'#[MXS2[=576NE
MJ&Q5%-6+O6U@W:W$XZ=0^=#KYM'<2];M@YUG$8_'(NXTJ]BS",\B/(MH":0?
MED6\G87)]$Z-OSV3>+KZQ9N;F?=C5NYH_>+=2.8=)7U='SD_;X%H:,%E;+FD
M:''*[:[H+QZ:GN0]R3]7)/70]"3O2?Y9(>E.0O-I^CF[R:OTEB?M3^.FC_:[
M9\>'/U4VV-N06-O>!C8??_OEH-_[X0E&OO"UY86O;87N-A>UME@2W"N/.!D\
M?<%J6_'WL1F!9[2>T7I&NZ.,]NCXZ3N_M!5_/:/UC'8KH.L9;?L9;?_DE<??
M1VFN\JCMB[V_Z%'\10/O+_+2=9NY4[L0=5>$ZO'3ST_V6.O9JV>O'E%WD;WV
M[U3MX+%V.['6L]==A.X.(NJNL->C@<?:EGF$? ;1MGB$CKQ'R,O4;>9.[4+4
M79&I)V<>:Y\/UGKVNHO0W4%$W1GV>K<>.1YMMQ-M/7_=1>CN(*+N"G_=/S[V
M"NQ]I[DUS]CS[4*>VM=SMW8A?R1A'*>CL%!CTQJD7>68.RHU?<VPKQGVT/0D
M[Y%T2Y'40].3O"?Y9X6D.PE-']??T;C^[YD:Q5&"X/HAT\Y[2;V7U'M)6R4-
M[K?LH^<SYYX1VGK^NHO0W4%$W1G^ZDO5GQ'6>O:ZB]#=043=%?9Z=.2;V[6M
M\,.W MD*!Y'*\C1)E'4/!?M1,HI+A V\,1U].QB&N4(W]AQ_$!91FC3G?[2+
MMWDAO(O0]4*XM4)XT#D^]=U#GA'B>@Z[B]#=043=(0[;ZWO$?3Z(ZSGL+D)W
M!Q%U5SCLJ2_&:YL?R2<:;8,?Z4,XBN*H6!YD*J9"$IPYFQ8SE?F\H^<B;^\X
MLKP%\-]"B?SCP-X5F=WO#$Z?/KQ^YY'Q'OT])_><_!FCLN?DEI.?]9Y^>)+G
MY)Z3>T[^Y/#?0E3VG-QV71D\?:?S;6;DK>G,<D]NMT&KW&Z'W=/>Z2ZXW;ZF
M11@'F<I5F(UFY'0;JTL5IXLY_,"[WIZGF!]T!\CKQFDYC%7K!?TVSUJ\#[CO
MBLP_[O1[3Q\^VW@CK1?[6ZCTMA64GK$_]0UXQKXKC/VH!?6+GK%[QNX9>RMN
MP#/VW6#L^X?'3U\WN=U\_8'\=/!'" !PSN/ZJHZZQX>'/VUP6 W@GW<\Y'_*
MO(@FRYLS7;N!36_\$?Y\-QC<^9K70."FE'??\/ARG7,ON%*9"EX<=_L!O"J.
MTB28I%E0S%201]^#.:PTRP,%8!L'_RH3%1SV.L&@-SCI4$UGF,'G18H+'*\L
MP#] 5 P6600?+F$OP4+!W^-N\'46Y0%7B\(VX!0'HS"?!0"9>1[D)>XY#RY^
M>2M;!SB-(JH?#=))\*+7/;OEAO&-"A8:92K,E2QR9!:Y@K?!+N%J >+!N%1X
M+/UKW&@PCF +16!:HHW2O,AEG9/*9F0@&NU\(KF-@<YM=!\S,.L$ *DB"F-X
M=SJ9Y*H(ADN$CKR^OEO8SL+ISL9KZC? QA$<7]^^AQ^ETRR<=_#I066/S:=Q
MEL!#].40^/>@!X#$?\!2_<I&=!7P0>6(74V%;:"#X,=90O_^^>(#0(-6/H\*
M>._H%O#YATI4!EB ]_MF#+^*\B(#:KM4P?N&,,#=('BR#0"\-;C"*KCNG[$>
M/3)C767D=V"LAYL9:VA_OYZ#= +;3$#O-P06-2Y'A6&"Z43E.?P+;B-7V64T
M4I[S;!/G^8C6D,J+X&,":*T\EVD 342@(4JJD)9(X\$M"9:>@S^..QC\78 :
M (PK7G8;8=]*M%P957+?H/\U^F\9C5%M0UB]#1>(UP%HTVF9C:PL;.7>[X'C
M/!T-_0AT[LB!/E^BW%!7VPRV^\:A?ZM@%H(V,RF)?0#6!RE(:5(37'%>S+*T
MG,Z8Z80Q27\%I".$PW\>@(WQ#5;)U:C,HB)2%<FNE\!W?/S]<P>86!RG5P>D
MCTQ ITFFG>#-UT_:ELEIY7D9%]&"%:!+4!F"10Q00=,V1WV$EZSI55=RJ"R,
M<BHR"\+I-%-3?!RUEO[)H<-+X9-IEN9XVG2DU#@/)EDZKYP4MVP/M6MJQ^Y@
M\QLRH)NP 31-U(WI]L^Z/6N.P^9 409%.DT S5&I'XE=C"1!-P]X\1_^5$@#
MD-EH_XBC(Q$;]"$(DQ(,@@Q)(F-$-:C_!I XQFV==H-_HWJ?P&+: [&(TR7O
M<H&I6MDEZ^IS4)YAP9Q_!'02@.PGW5B)+0_J,2)K@K8!*!)S_(#<I?B(K*7,
M)G'#VM\03*(D3, JB(-)K+Y'0_)@D)Z?JTU[F8?+( +;9%00A$)^D-;&K131
MG"@^!9  V2#9(06AZ:2F2Y<IN$^CN3":10HVBXN$ )Q1M" S :X+]".X^KS^
M#KA1H.P2K(DT6\)Y@ 5-<]*/^.JL[X1N2O]#\Q@X:UJY!W/KE@UVX+A).*6[
M!%3*M7\-]@7,"+]G)++<$A;,P5+$S>%6%]%"P8O%B ,>\A<MW"$&A8= MW7!
MMHV^)HTR.2J$H!4.X::T[689[\_HX%'#PG#0M1S78:SLW8F0.0#M1M3!C6XF
M&N$8DC@<IN;D(&$!SPG0F53JAED6)E.-V2E8FHM%FA45KZ/P3'@AVG!P*""+
M,;PB;]8]GRF[^I@@IB2*K=RKJ&#YNB+IV%,0*Z0$H.UW"CX>PDVP:@_\#<DQ
MC/,T&*H ,&T:H<< K@:P7Z&OHEP0<2W@/KX#CA9@! 0O!C7WGH.$-7D(7ZKO
MHQG>.E$6+]<_ZAR?ONJ<]DZ"?!9F[+R$C8(]$E!+P& _S3KTP$AE11CA6RZ1
MC#- +(2L*!U7A%',R.)(E?5U7G8 QX;(@K7'4]B$1C6]O.$2!V, H2+H\IDJ
M#D^7*0!2AH9;O'W7?Q44@#Z*>#PZ0T_@DQ4L[H(-:\!E+D #V^H:!H"P1X;9
MBY/NJ37BM)H!3#(;1;E1-=*RR M\&6RB"4Y(OA= [@#RM^93H.H\+YGONFL"
M7"9E'./:(?^'7$-F,;H?X/3=X$.9(8$#!YD$25HPN5_A&B!N%$![C+[J,J^B
MW(V./7",V=5C.UNL'U^.^8O9;Q<^4L%O*;SGM!/\VQP>91X\6R8A\#[V+"$_
M0?W/"CE8MA#&A50(.(/#+.-<7<W0B4>"%%2!_RG## 0I$,D71:P-8>201Y3
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M[ 4%UPA/+W2B->;D:"$1O*G-_G1K*Y\)B[ZIYS.8I!C&(Z9,27\6MMS94<<
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MDI^Q^2 ]<==BMM9)ZLJ+JU8ORBPOE4=WC^X/@.XU.TE1^!(')<"&!(\Y0I^
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M<5N0N]:*1TR/F(^"F%20[&HQ)H_,[8V5UUO'-?#8=4EKS>W9:QS98[?'[@?
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M36TLK3Y)>2A1=7WD4;'&[+&@3B0WL-",=#&"-"_*Y)5[C&[';_QZ^WU+2YP
M-H@)JE:T@Z/:MQ70C%I&@L!5P>M$C-KCFE/<-$95<C&#(4FG6"14;*&6^]S=
M1TTB%O$3;CYZ]M6;;Y]]G&LZ4M?V5B\RM#!R/>N_S#\:?S55VGFTQL6AL+*C
MBV4J##BJKJ#?B_9->*U:*!%HY0$?D2WN'BASW^X27FAHRTJK$N&[[T>='9G
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M+N#JV)EAO&__ZRN39_#3>X"&(7KMJ7)#4:O;3XA"_: "\:!A$(3'?$9F]!G
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M 6>7YPFTKV_0_<IM',^6-M]D> 8XY[J--UAJ?:'9^F+S#9.DQ'=#QTGFGLT
M@@W[ ]NU>544LJ<HP-4G+T"='DH"/WL(EG0KKB4@:0 ;RW=9L4-+",%!6ZGM
M=/3X&O!3X'5ORZ$.K77A7!L7>"JD^J(-"H^36_#G:F>58;2D$N)"[":.T?.X
MDFER*]4>3=&3<H:B,:SU'WZ?V[_65!M?@PC5N#^>S/.,B<83 D%;#;P;[:N$
M.U'P*A$.'@SG!6X>>Y!A+WBM9ENYW1EO.7&6-QVC/VH?YQ07\XZ$KZ(T=8S
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MT;*3REWB==2-[<W;"^SUE"1,[:&\ZYA(9A:.+5#>!W9YVEBB"V]'[W4];P+
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M558FFS1W@L5<$:$LI(.5(ITD[$92@CW@ #&F#>;A[IXL;$CE9G6AJ%-H7CA
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MB? E&*Q%[&%^J_T[F/IFW?>18U:Z:\ZX?8'L 2^M:B#^=6?9BPCK.=^0UC;
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MHB2=Z7<5:_,!;\&YC*HU-)_D(;D:IJ$633MMA>-5M/:$ )K$]LS%R>385IA
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M.RK4=!OJ!MMKD-RIIY57_T.H8I2JOQ:5"GE>+]QF 7EI,KX0':1>,2"WG0\
M?EN$',08S4Z0A(U16PB0FBIV@H2X$ XE9]G5"%4_XUY5N=._K7+'*HC#Z<7F
MFTZK@C8C!I''4"3)5L"66PAB[GFIM<E/S*^ U6%FS\2[>SVA'^JL^8JOUS2A
M3<\UR5/Y3[='NFE(JAOWH1>\/!7EVPRUERZU!$=5>U?W70N'A="4*]G\(0[/
M&U;0VZNO8#"R((CX=&!DD $>LH1B9S#=J^+OK;>_"(&#:[\+2,J;;QI#3)_]
M\<_Q"_<_#!<2"R,#$[D"*DA*"%:0U4D<YEPY4ZQD3#"=C#-\ #<2==9A'.B;
M"830&(5Y"1N#GPI?2U>?VKU8/M!V7%[2=;EE]01"%()OL-?]%)O?'!&*M(PF
M.",@X5MTZ\' /]FP5D_+_2.[PB=W[2;DLR#$DS^!8A>-#LS> +OP15= "\+_
MZ<X&+%WZ5*0C2E)6NY(.Z-M7A)H4?BI7YAD0CJ Z5?>>!% B $\!=&;?B!JB
MZ;*C,"#&H]<RSTPO5V*G"N<U<)*1S$VDBL/>!G7B8D%_A[+N,&+B0<BS!-7/
M4BQM2W5?_P[N8[/B+W_M^,L_K/C+%7_Y,^(O__?$1EJMI4$7/YYO9O.YL"#'
MO>DL[9K*'3Z736!>UKIS8#8L$1WL*.7Y20$!1Q\H&L@I=9Q*=YJ/1M9:/VY(
M<;U8WH-$' =JX'&@8$Y&Z:NH4&8F"."00T;)?*#/539.MP<47(>=RR_Y1OAB
MBP\IZ>6I:G@=I;2+FG$("_15\)(#XQE6/#Z2J_<[I,(R^\&=V4++ 2.EDH<*
M M!&W-2\+%/2ICO;33T47NAZDC#M,"A)(%"S/)\LYB/&I!*9O)\6*1+&EB4I
M"Q3L6YY.^G%B@#")3%)3GN5*J3=/]7\:VD3VU!ZI@!0B(/>^]O6.C4I;L <.
MIOD+A@1NJ$N@125I55!5 'QS[D'#S&)B)\-/W!')L+ M.QVPT.AEMR67Y_R;
M'4J>T!FL %Q 4X/JX&J"5+)Q(#)%\(^ A,[PUA+# X5?@YG@P;H,.V9(S\I=
MN:_.]8ZPK_4X!9F95V^^1^[0A=ZA0AXX?G>I40UDI17-A=2O]HF&T:6,:JZI
MBCM^2!BW;H9Q$U")1/)3ZVN?*%XJW+(>A2U)-/<B_;P@5'(&%#<M4-X>W V]
MN/E\[BHA?WNNN@G(#G:-OO5OIYOG/6H2M>6!.LI:/' 7C%<IS:LSF0OV!1<U
MYTJ7L-N,T;FP0;0JM;EIW.4'V>T]%\*XQ$#^7:K,Z*LUSO>#Y/.N4OEK>0PQ
M:W;)_SV[\>FBMP[TL&PM:7RC7^:LK0R89+TMG>&-ZN?<^@5O?]R^SCPDW4EX
M&*4:H7:*'BPE0WR\5&PH,&6(F@8XB%VE<*U^B(?,59"[ZX./>>%LS:V6NW9#
M&*-[VSV,,4$53@.N)+BX"X3!'^AXF/>77K_,'^QV+J&A \8'3R8$47A"L6FJ
M(\Y'ZS1P1E)K"\%H"+D"NG>F6^=]G.=:Z:5?.OG5--_@'U^G8U=GDXYCA<46
M(Z<M)/93A/;S//;9'*'2[NEO$+O#M $>_.C97_[V>GCV,5W[+Z]>^[ 63BV*
M_]SOCU.])XHM*! Z(]WY2)NI%H3.5_0!W!^XH*!=0&[X\0:<?\X>OFV%P8,0
M&*^ZJ=W5C,[ZJSOXG).00I:Y!XW7;ZCU*EE4W4;;)MHNI@C&$N@+-RR/3*OD
M'3DW<#FF\,()<!_LAV'374^$,<XWU!?WL[EGR#GO%QM[PD3^WKAU=RO/-?R=
M'38%?_+, <!CO8LSAY_-P]3C8!Z7W^RE*3V@DA%XQ(00_% ^8^/VK9P)UOYS
M A=LQU2_]R\99XH*&?NQ_?2!% N.0WC/;'HU#VMQH]2+83S>S"T:D0?2->B[
M 3C:5KBJQ&H:4Q@J*EXM69J7M.J8R+P29G!Q63@+LIM:6%[X9-[U$ZBP[.!.
M.YVW(  \:*<A=%<MX(4^?JG*G D:Y%-@*<K%HT+'N3K^61]MZ60UCB U(#H5
M#,45T@4;;R+PD;!-HBYEC**-$O!4ZN<R8,M67JO0[J !(ZB#^ZIGGP5C1= 0
MPCX8<G>/A2T/AQ?.SY_/4TNV[/Z4K-3'M)Q*QX\LS5D%#%*[R<[K@=1(U W.
M]0!BJ<&&BQ&8QJW+KJ.=P]\>HKT7FQ^0,NJ7.G-?=7!7KLN?<5]3)D5;@*J,
MQBI7RN'5X)[ X+(R8*;PT&T;"=%6"UPM\$G:7AA(K:E@9**_4+O?L*3MGUU,
MNAK@:H _OP%2@_38^=82E01J3=-<)B3]*G<D.WOD<)( JRYVM@-8*[>T7U)F
MW^%^!6>Z,M2"AB"/M2 S0#+BKJ4\](8;9S&?6:*UX0%:!KUQ-CVU7-,5@G#/
M%WZ;*5P9-$PE@6;-?<$=<U]]9<;)<K=4:&LOYCJE[AXP_UP4M^?L?O*-PG#B
M\G$\"8-PR(R/SEM2 TM/;Z+0#>!]Z5J>W>-Z;5H_9)9\RB_2WF5(#3<N3?9O
MXX*X[HL.\[=OOHST0NFC0A)#LDHCM:!*# Z7040@+KX07;?THVK&/O:=2])P
M3SPIS(2:OH%;[ND5"".F[0/(&%V75)"-H&G7A^I@# Z_4?:A&;(]YK6R=(:^
M(Y(!E]_HLQTZIC%8YL,M>#PQ+5_Z@4;)QE]L7KIW+%D]/XCW5?+3P=>IS,B0
MGUSV2_+@5X7,GCDZ9-D(!<%X!]UFH2AMNHY:9U-2\QG/CAE[#^/\IOGE8:FA
MKR2I.=])J'S+>\ /*V?"W;6J0NO*_X76/-RF)FL@M<680=Y4O8AO7E#?L6)2
M.AS).ZZ:]:B4F(SN,R;:9MR3,\53?9&=[Y5U]8U5?MHB-)0$UGFI1K3+L+V)
M\Y)AJ]?P)=NH%SES6!ZB0$S="[!L"VR9M9VICT8C.!:W&H9KIU;*GP $ ?K;
M=,/$_*)NMP=5; -7S:O^;*_BE_EVN)#J'HS?MG.I>_?6*F>&Q TR<O&=J\E-
MT]TG_/IF[6281%OHSC4VG?+QT\U5(]RKN^*II=G5E0_T5X]'_>.*1UWQJ!^,
M1_V-QO4O?6=*26XB#?@;G2YP1N,8-_!,/5<#$0+9$/[15P<7X2'YE^C/G*5V
MY(3.OWZQF;>]1DW5Y])U1??"S^_K,=.[KQC]X?,AWZ<C(NARW/HVRBV&KGA\
M0U""1Q[OV;(>C6\-?L@M2MM00E3W&Q9(/S#Z,Y=0?4*9B'Q]?AQX;<A9MBL%
MKLR"."P?A7N/R"*7P&&::BR-L%9&N*GO4<8P6#$C@7*[A\:4:BY4[%H3=)+V
M"G(D_C)W*VB#N2OO3F)K?(Y9VZ2O\<.=%AI+J3B'T&3I@^TR^OCZT.V(<<M2
MB(VT8C4R'26BIWDR^K7 +824A6A%W3WP4[2(TS$GEN1)*FB"Y-3.>.;YGRRO
M)?)F9KX?J,V=0XPP-R8"XRR5%^@3.>,3;-N"]6A2H\\O?<ZV SV?H((U1_-9
M38Y A=ZN'X>GC)IS%N9!&\6#!947\U%_84['_ KY]8DI2@J3?GH-PH0K:_4=
M"TQY2WB@&>S1E"@ .*S0QC90O')_5P-AQ*"4%B9?MLP%-(E&"&TW'+ AK27.
M.TZ)"'/<M=P-;UO)HL@H"3<M*$=GWG^G"1.%2N[J?C>=L>%WU2U42->/'C:M
M !1K_G+RNP"#P5>(-&@"HJ/45\R^C$H=X?/N"\?[RCF#2619%A;6F?2P0<6"
MF,!P\4-3\[P!1070 (H T5R^)*10&C00CQ[>2GS#M''I_"5)H5K8H?#Y8^_K
MG54:O,A0C0% 9>!@OJQ#DS;CO,+&?UJ/0]4<]$7\H^HN1$.!>LO;4ZVE&S,]
M*I"<NHU@X7WUCRJBCLHCCU+H'[X636QA/E9]*:;I:VN>^(TN)=^X*%.VCC\\
M@ TR):\%AU)$7D$0FKXR*&I$0CESQ &%":-Z\.&*%[(["[FF+<6%ZI2[4]/*
M2\O(843+A 0BY(?AB!9,DUS2<1=;#XVY$D/U_D+$\+*?M.IVZ,MI'UZ2>7$R
MB6<,Q I@/M)>BJRQ<,&7V4&Y]?-B\UWTS>SG/69+"\;DSBDVDOA151?3#@0\
M2@)3-*A!AB,'?PDL)SW^/UQ:-&"BC.<H/?,YM25HP(JF$E1!T?JN6XEM$=V;
MH<7FU:=C9SLMS!IJ%/;WEJ8F?AA+I30HMWU7[@L](\/Y9F\3T1S."WV&AAHM
M4E6MXEJK*>#2Z4^!-;V$'4C=P4W8X&EB2=,P360S"KEK\[!NZ[F=@95)>"?0
M-"&>E(7'#P.!*FA)ZU88:RTV[^K=.R@88%K+'6'/]^Z+]0YE6!(W>E<%Z+K6
MV+-?:_E:G!V<ZBU!6^]A#_28G/W7.T(08CT12=,_XN5AAB=FNL#RL6(L<:$[
MNW KXD(;$BDF5OW*3JGX6\\NL6 ,S9;EL5O9+('.Q'M>F0.-S(-2]Z 5X#[=
MR[3HG,*0(AFEF?7UF4=4=I;()ZR'UX%'F=C$O0X5DVU0!T$:*(%4UUGGJ-S*
M7#O=.!?'"'6H=NTIPKW*D!N2'/5ED>%H8(0R22D3?2X6)4E1XJ5"7T#[-"*G
MBN22]\K59MF!X(EC872,R BG]ET+S"IHT5K.X_;D@@>5?:ED@7TC I^2\)M[
M690K1EAX,R[JN7][LN8)N'D(@)P]-4EI&Z-S3#?M@= .]9!YSX"IW\ [F:<?
MX3*.)?ZET;/,LL4=;>::.PBO"1D8I?L=4<>#9%ZZ4U36HPP6KDF_,36::*+=
MO8.F@'0/ZAXR"6"4;K&?=+C6S\47.G?K=NVQZX^B8XAMXC*AEO]5O7>G#1'X
MTO*Q%R264YK-,B_E^6$B_Q3+'<@>ULG1[XA-6_0M^!\U^L&A%,)>G(0\TO &
M7S50R9/1T8(S,3X4"4E_Z>20TGS!]T.I>\R4>N:'E%X-Y":0P7NC.N2"L6 F
M18Q'T#4-&[-L>,?Z3C*/HNN-D&>=$A$E2U\@$SEQ#_$GUQ,*W]G&5P5UYT>4
M&=9$@4/(K^K!*U!+MAF'/<9#*>:$73B5UK$_B M2Y;!A!<>FV\)0>(0>N;J[
M@FYV)L'5UGTHJ)WJGN;4>(8?=2HX],V[BI-%MTN0T8?[,MSU46ZNGASE/W25
ME6DKZ/Y@SV\KKE;>81<0ID-F&@IBTA"27F5V3@F.5;(IEN4R.D76OF]3R:_Y
M3 P9BP%@;(SDS.YJ=T&9!L-+H1?L7VJ,]J%&"85A?BC$EVR<T99$]57QEPA
MS>:KQN2WT_Y8<8B@IM[ 5.#^G4><6 <]?#7'')?.;<*K@@E]DTP8P8;4["5
M)<N'O1LA%#RO.VLOO#,OY54G<=P&!&E(%<62+'@=3J;+M'4WXC>B.P+Y;LHQ
M8=LV>+R%^]2YM+X#[38*QY[$XB7S4>@[&NGU:^7J2+T]\O&'!B>#3MBASMB"
MH+GL:0I':_))Q=^\"WT!\/6+KHEEY:?6R$'?H!BL!WO2TA)W39 *W/$<-FWF
M&ND*JGA$TN&>I>;L;FJ%J03IYHO-@_[4WZD'Y0S HU#=$#78@.!#M1=&KH+7
M0_!G6F0C?9VYNPJ?8!44?C-!=23\X=5\7V8YXQ&]&7XS1OY\0\3U)5A@BC!
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M';G[_]E[TR:WC2QK^*\P],8\(45 -;;;O8T_R;*[VS/MML-R/_T918)%M$"
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MOSN*9I0\3T827WLVW_;A=M\C$.,(W_R1@&*$&D]!$L\>[.<*+/Z%XXJE[=M
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MG,I6F%-PUZ(%1NH)3]*(9H6[<LY6NZ#N7SECGQ#-Y]5C265=G&"C8+.X8,Z
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MJ2**869</(9845O]]E!&BV7(WK#(&<"UD&)E5RFC]CTP>JBG#XU!VY?]-"V
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M?_Q\P3P>(TYZ2@O+%I5>76'.E*N\4\) 3IKT6"XW[*Q61+M$ +=(/Y,9G]G
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M XN,;IP>&%O+\C'XF!>,PI(EK9JZSI0JI;49&2""=X "C508X8$-OD=@V>&
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M+2&B$YXN3-%A!C+&5N>:]I4>C)O-FQJ]K6'956W8@5Q9/&C)=KX?JA^J[<1
MJ7].Q/\NMWK=M7>]]D%8!Z>8' PC5XLD:QL&@ 'W-FEAU/YS"N_\:1&&[9/?
M\D!]$UR+S^N[S>=5"-1KB@\^)]^/AO<Y!O*;SS__G"CG:20IB0L? #06#SJD
M;=GWX6UVP$<,>()P=X\!(G0C!P15VX?)<G**%')HOIBY_/GAPS<///BBH0O;
M>*RG(W7W;K9A9].(8K=7/YR@12WV 8CKO;PD'K$0T0:'&AVTY"Y-$ 4[BJW
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M];Z.8'>Z[>?3[JX:N;5)MKCBX73O<AA$N)?*[QC/H:7YO*B4F+@XX^59 E!
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MOF#M#F!JQC""$D%N&<#$VO%H.(:JXJHLRDD\T0_6Q76NQL@Q@]_(H2W5I\Q
MNE'3L\<H8]CS2M"=UA>2\8$)4GK?-4PF")9*1LUXJ$R=_JRX /87&1NL=1F%
MI#5".OW4K[^P43D,0]<CNYZ1*8TD:CI4SWC1IKJAPN@HZZ%PA:FF=H4=IAWQ
M]1LN]X;7GR0J4/*7:TRU<RQ67#+B^_,R'MP:L8)MVOF$>IQX#5E7@H+3:=@\
MS2F9NQVR-0OI;&"2(]N@KL$#@T]#&+>>;^IR#8Y26HQ;CYUFU_6H=H<8C'*S
MO)"/M78EIB!%H=ZYXC./9+XIS3T15GIT /A10FH)=,)8IP@HU<W@/D*P;[]K
M+.G]%@;XLRP%W'OC]KON=_]*?9!7PX+_VPU5"!*[AR)/2$WNJ$O:4H8G+<?J
MX:>](UE.4IQ4I:,+"CMXVU..$T:"J$Y:_!I%9)]KB62%"$@731K%;,L)$KZC
MDS[W*-XUP:-3_8Y:(;H14:6]0S%S>5*5""\!<T5, N^]Z'>*R*M'ANUY?5/=
M%)LW\IW?6D+@^]?4Z/'".^0*!L"%>#,+M1:[,;3UX#>*MVA'HWL(:Z)Z:5C3
M2 +I1V.6'(AM9)D1B9R59B!<,&/Y:.K-K\>)7QR_F;>HI1X<GN,%9[:=B,]5
MSR,]IR/CRY]DBJ2)Z2M#C'U+&IQRF*$I:@MTEWXDO4P?__&/O[O2$_65&XSO
MB5::X%R<,/TR+(7N"!+HW>:UOI_\SCJE/OICL5@:>:6.N=?Z["]???OJU;,7
MH N3;A5)C.W-C=O6_78Z#CCTO0+09:9T"S2%QYZ5 \(+T]U6P^M9@I6SC)M9
M^:"C-+I"GX!)[!_)4^0-6=2QH'TB-59X; 0R;.^$,[&5:=G\3:,/Y,#]$TE+
M!AZFKP[D0]Q7B2GC?2;.G+J;WB'L6N-0TV,E%>;@5@T !D_5EE:2LT1P*/5^
M9(HUYU:B"U$,!<)&5?G2O#REK 8MUSHQQ=1<A0,P9H0DL)*?,O).148J_AB<
MVUN.N[==WR.&YM9>(LO6NR=W$8$G\LS'EQ22.LZZRR&BJR*$55V-U<XC< O.
MO336XT7 DR-VO0(<7X:@'UC=[]%612@J(\,:JN0ME]E)OF;200QZT801@]<B
M=R3<;&9+FCOE>&$PN+6:Q4/[+O%2+XQ=7"D7(A4=)J+2G!A-F>P8>3OJ&1T&
MX;YG;*QT&6,3-52^0O^=%HXE@8;ZE9?+R'0HO XV)GROK4L";O(9_JW</O:U
M_B%W%KB?ZB^^XYFQ'WZ2;XA]_?I;:N/$\I622.*8('+BAPF+R28VN-S<#L(0
M=T$A6P5*B4O=<]D.*WZV]=H5=_=+Q-W]=L7=K;B[E90L,Z#LT^&L'*+I=N?P
MN_A*AQ!+\-%;#<PSDS/NW+ O7H*=Q7(Y<19,BZ#+>U/D:="QQ,?I\+3SE%T-
M0Z2SFT6T:QQ[@M/?>TL<F&O#&+.%^2 DWE"DJX*7UY $X]V!3UP\H,6OJ6\;
M7>#4S0TC<SR-[%I[GRTV*6#R?F#G;EY28(_+R^_ [])F>1Z++:< ;%@J<G&5
MV41SEN[OL3W&>G1<BE4T0;28_TBZDB@M7)K <5=(!""T6PSC5T8 ?GG%QDBZ
M0;(OP=-Y -6, 8A\OD/R, K<Y$2\-(Y(I,+D6QWWN"1)C"1OFX( GC2B:R":
M5B%COH:(XG_[41('Z@+ZHE8NHF ^R(&Z#<8C"1(O)<PBXE&[;:7H15\\QRPB
M"2L'VS81>V'GL$8VX<*CM"<E8T[__4]"4<*:3&(-P:F4^,.1O7H74_D4ST@(
M$TD#-#[@R$ XZ"(81*FD;%W-GZ\,&VQ7#6'BREV23*P'1T^,BS#\U60PXV2@
M32:FWGUUP%(!N_MN:Y-DM;R[$,N?-*6 ?J[SK)%*N[6'JMF_])@N*YYP;HZ
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M1$B''6?3^#/G:C%0N72V5.)DB5RXVF6Z)5(1TM-Q@8H$)A>3>TFX=4V.$ ^
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M$)=]KG]48*"-^ASP\1#)9P^1''F(I(=(/B!$\OZ\ZC;E<_I1293BHZE-^F@
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M#Z;%106/!D]O,5LHDV"7?LM!4<;K, %EJ(F6?F6BI6#M](9FCH)1V!V,D4"
MU##]Z222/^D.8;:]1JVM&?P,)].860N%S&S=TGQZU!]>T7P:?AGV^T-^"A\)
M7SONU:OT!U+I3PY\/9!Y]2K](57ZDUO55ZCT'TUC5Z_2O4H_ -7SL"I]V!O\
MUP'I(:_3OPZ=/GQF9CHJ[JMT_F^.2AZ<!W_T/O0N>D8Y#T8G?=*]0M99NUQ?
M-.F?7J_!OW:M[0O0'B9$/NB]^^7#4^L:KZ:?V=0]+,R5R.N"__>W]S\'[U*D
M_I^IX&TVJRCJ3+'?P6MI)""_1OK7*%-,1Q^NURK,=</T=TCN$!)U>O V+,.
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MOBE(>V>8_7OWE*3Y/4Y7149,*3&C;J![4-F7#RTX8.EE#W1M-]G1H^>M>81
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MB5:7>A'9U?-@180W,(&#(:;=H]KUU,@JKH0^Z?  -+4V_ YW63GGRQRGH ?
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M(OK_/B%+ I%E%TE*!>2LTS5NAO:87CP?XR"#0@PBPQ:*=.K>K6;_79^'I^E
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M::T9%065,I@\;Q4'3?"#W<]- ?R@(S>WW,X]0$[M ,N_3@@S=&>\T/%W>&T
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M)"F5\$VK%EW=3>M%E*.5Q]RI%T5@S3LGDI'>=I=W=2>ZXV5*<6'CE*S5(^[
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MT8N_26?EGKP -5200[\"040I6GL]#'.B;K2S\Y-[V\-N0.W>>=C@Q^##+DE
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MS><T$^6@%YB12,Y(KLZ(U[TWK$7#R/37FKJL-")D*6!(]O4^4\*S<JS+C$7
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M1_2L2$9UQO.&'(6'&.(JZF;H0#AIRM><\=TV<[3=RF FE_$R25?T];\*8PQ
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M>:^C35#@I_)RO .W"O1#'1:(],3CN3(D^H*89\W;<:!,"T&_G=G+SX-931<
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M)]=);_$:@ 'BQSLB0.UMK6 DI9XKB2)&]5"XT<K,C\.2V-V?,B@@S/3EO2L
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M.2QM,EVZ%B;%?$WJL)GH:H7@&('4YOC1G#><CZB@;IN1XN)9+%7GV2V#G*'
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M^J+@]Q0QWW>0UV>;_=:TL4"P#)61T;_^RP\?CH__I"A'$8S)?EP[SD&P7V&
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MBGJ8)[2&3Q+GA%C$@M.8+<31&[4_XY%YGJ?+K 8:S/'.K5_XR3(G;S@SN\6
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MDJ^A%LA#%#XRFS0Y271=A'Z3Z+YI>KYX,$#RZR;-G]"2$"-:#%A?R5=1E+Q
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MT1."KF:(=W;8K*M+*Z@?>9QA$=&+4M#9_O5??OAP?/PG/1[&0:&C%_*BPRC
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MPI@HQK[.<;!WEJNDJU3'X$$ZDOC!,:=C^*D<^HQF^!!!'K/P K'4B3RIJ0L
M86<\-N#R9C&S"RII;4)T4X8^)>5I.$(R;RF,2W-BM_X>TU^E\FTN75]HQI[4
MZQ5X!<NE%<TQ55+S"R.%*U %@[S465UJ5\<AZOJ-ERY2ZEI@%6!O<$IM6D8
MY0EQR#QGY'G56](!LYH=()/-"/-KPNFSBU.RMD";XHBXQJ\Y$<FB9_PQB?.G
M?<TQ_=PRU!]C43UWQ71)X/RCDRS+A^XLRX<&>&L%!;H$87:+ ?66W-TB:G_C
M18#78@(G82BPM89=+5$!!!J<'#E2ADZ+P;^M1DG'U\#8V72^"' ] ;*0RNGT
ME>ET49N4P8 RVZ@9,#D!+"JJ.;E'C3/(DR8$N,D.A$0=4665^J:&+@B#0175
M5AE-IXDA!EDJ69^I,5Z: \'B4L?L9-/PV^L?*,5U6+Z^B7.(P^00.4_%:H%O
M?Z^S9.'N;"T*H96E8D.V[[HUA*@\!H:R =SD"I"W.!\4VDX.0:6_(E_0S/FN
MD$8%;??GO%D6:X TW=2R?$JBX'*U3I-G%L4W+.Q!4$0J28=AZ>!L)CH8(9##
M 2ILPS^G238X@4M0GU'(BYR=>J*'&:)]N"XW:(-C-5FK'\_.:PZ:95L]-OLQ
M3 _7PV(RJN5O5F;P 2\3<IK.?5ZH#&++\#K%?LAC@\E?$68?*2S.*DES'CA\
M6!-2B@NEE"E+N)B-1R!LU8[;H_3RG+!Z8K0D=X\:U',*>'0RP4K49J:CKC9W
MKVGQ/NMI&52D>_ZOWFK]IY.N4MUHYL;2_E<O#<$,1842R,O?\Y41=(35&4A-
M?NSJ0DH&6(B>[V#\=_@1WJY;O(;K(7XTIP1PRDB2=@O]89XO':62DK<N^=^3
M1HNEHO#/7\.]0V2AQ-U#DK*BIJH1@<H'RM],?\N?O!CI#_T*W5M?.R-,5TH2
M#N+<9H;T?>J!)G*W73TDT;XQ;HP&8D0F.UIU4=P,N4?9'NEEH3\.\79U52PJ
M?%2TA1/OE%W&6X&Z"Q\2N\]HK<9QRA:ILU#"-U05HR$*J;;X#*,2D(<D1J6F
M@3G23"VQ7;_=J["<,Z=:IR5F]3 PE1)(S&(;I^YP+FWO:0U7LIY;]CX[Y#E+
M\[_+!.:?_Q][[[8<.8XD"OY*6N_+6;/.[LKJRW2M[3R$;G4T1ZG0D915UF<?
MRB@2$6(7@]20#*6BOWX!\$[B2H*$DXR'Z<E2 "#<X7#XW1')^W][]5TG&" /
MU9<96;(QNOWZ =77LF;5&:HIB$U=>8VV*=WUYB%EUK/+<GVQCDYM[_B_&M:M
MFJWO?KP*QYG5@IH%"J.$D:2#W-)0&F"FR2LP 4BIOLX5 $8WA1**T=7NXTN"
M_ON(Z>#ZG=R7(04SRZ4^T;4FJW\Y,)R+$Q4PSY@[8=S 4@/R[)V@7GP,B+"]
MJA?9]0'%>_SIG^/H>_I*4.^$IV&MU8HE/V5K?LH7G0DLC+9J$P-4W(B-Y]%&
M7$Y  J]OP[R\L(&"5N7"-*3[LQ\6I8LGBR4P"EL !BPB>Y)6WE<1N=%])6N\
M"&T(_NG_R]8!ONV&J[?8^P0U$M\HY23'V.G?#;((_BS7@;YO5N2J/]7FF2D9
M@\S)-(RN5=MB'E#PC(B-O)G)[86]X6%;!^_&/I.:_G1I+G\\5Z N1T\<-[?]
M@+/S*378@2"PC0D3@E(O.GX31-_OHY"4_+ZE_5"Q_(:5@[RR(OZWF_KOK?#2
M@95%:%T?\EW:2)8672\_396Q\N.?JJ\W@FPGJT,R-88:E_/X]A90C0ZS?J^"
M/MI]"J/P,\7;KL04P9M?8;'<TV@E3FCY:]*F=B@UT%:WTQUI.W:".L5O4W3(
M,NH'*;74OY[DH2$^7G."UJM&H2FY:RNZY8]Y[$#Q _E"415B5(:++UY\#-"7
M'R[^]F43QX?(\W<^\G;]&Z#A%1_IBB]TQ:_YBF.V%C,-2;O5[_PA:O2%QLR-
MP/.) /3Y2\.P5\ V<L.$LC+F?A^CO9.B(5G_C>J7Q8+CQAX:!:/3MV+>X#1[
M6DP."[LKY6A!.YWVHB#"=L8&OG_@SM3-2>^B<$\V<(5>4A(9.,@@1A;[3!#V
MB2R'M6J\X&2V,3.0-!M.8G#2)CBCLIC_<L*C$Y^V(>J6</L>&5'V\D_0RI#,
MTG7X;Y-HLF/ FI/AHF&L$V@!Z)<_?OKQAQ]_G* &F(N(WXOVN?23WR]CY/DI
M^=? <FC5LC1L@R[[B:P[(Y "%C1DH3_6 ?KCI[P^QH1U,HK"L\0&_<AL8#O0
M*%\L2I.E:LO.!Z!N+=V% ,9R0\3U;L+>^%!U>Y\R*H00Q__@I)A:[!>G"LK4
MP6[CP<P+>@-3)H4;Y_<M0;MC<.?OM'6G3O\+49)R]IE/Y#LS!+5^O#DD@?^.
M:"0CL[[ #&$,F.?82<:>\"#916N&^!RS.+ 7?F?JP@61W]>)?)%F  WJ, JZ
M;[=@G =P;9L@A2"IM9MW)VPWSXG#&5K,HQ6*\ZD*Q9FZA(=1 .NU.T0@3EZQ
MPQ"4=08C@F\25F((ID &SDS@X 3PO>61;NY4P/SKF*0TB_HY>D0N9L!^@.Y1
M>AMBMH7NH@3_G?;1P?*#[R'OXH2?V7K_G,JM/-#!6FV%A-:6>R%Y%Y^RW9"_
M9RV&\LV0 .K_0?:#C___KO46RO<T97=!"(ALDE2Y'X*VN$0G*3(1X-V0OY)_
MT^?JF.&P9E:>P#-?!2]04O\6^FFR.::O4>S_NW?%EB)"E*[VQT_5>O. HME7
M*@/EF('BC Y*UC2KJKB]>7?\@"B?-U'\Y 1HD*^^7E3\4[DR;11&UOXTB9O>
M.'#MCF^+!))1,=TNA \H)L939X^V.RJ[9/4RM[NLQ$^C=V:MKN90:U_Y5:)<
M9Z&NV8=I59^L\E&K=6B]K.?(W<RGP4FABU>XV+9PL2UQL>7C8@FH:-A,&[01
MEE21E%31J D5C8^)XEW"(@A+[&"$!0YJ^LB4R#H!DJ<_YMT@R=](&&(48FF#
ME!'+Q:#Q->3Q\%'7MNX+R>I_' MDO-505(N'+#\WNF'..1%6G6Q";^.Z\=$)
MADKLQ8I9 9]\S2E#) >6CL:/U@[YZ1%_YC;,:L0!R/:L[8J(Y-F^5H!*5MKE
M+EMV?.G=)OP_9?"'-*K+FQH#5;KE#58/XTN\AWT4#TP9I4M]*M8"OG5&AN@T
M^Y^N!'XK=*TH>/D0^[TS[>P4QN^$!1:@?**PG$_*:")[6;7T;0KD<CV'6)@:
MR67H[$A3S'F5;^Z!#97BS>%XY6U& 8E1A7SF(&E6T+\GI=V U,_O#:U&]7P*
M[^2>N-QDT-]*T#[5W#:")E'^#>V^?DKY_E^*@P /0EU>2?XXF1&JYB;,LS=J
M5J=L,P/MD76O89$@TK R9<:GN4'9=?#:@(Z7N#C09,*HQSV9N80&]V4Q?7T[
M)K632.%O.:CM-@]HG*Q%U?#=-P,9,R"R&I^?W'%AJ'1K?!'QF.0APFPS^#_^
MVV7D]=49<^TZ7Y'$N),U/^%%/Y%5YP$+PUPP-4 E<RJJF6YWN?T:\^$HH7QS
M**,JEB:^BW+Q3\7J$[*M>CD4K ;C?;R1T)NL;["9LBCELH6%8M*RP?V!8EH.
M*V#>\O4^X?.J/ [C)@R2NW87N1B8URA$@UHOTF4^T75&;HAH8M/-C, >.]_$
M;F.O3NP6W\?_E&PA'_%G$N6#WM+/&0KSZ;LX.A3R&O'2-*U7)88B_AB*C#_;
MW/AMZ,:$<*]0]O^?7K'\1')(FSFZM3:#';CTE[ *=I5[5@K4>410)E>3Q)_X
M'7DW47QS))Z'H@-1'?#>B]@_\;NL[T<4G[(,R,YYM@> .*V'&.T0ELR\F@:4
MM:)B'0M_- A@2#XSHV</"Q+.4!!@L._WB04&9R@(,*X/;T%T0N@)WUC?16Q?
MQ'T49B9^ZG9(:/A+_7?2'>L^2O^)4A*DN@])/"$+$:-]S#YCX5HQKY/4/Q!)
MJDA5PL!]Z; =O>D@**=)U8(V%7GBC?QFR-<  3AY]OPL"AJ?U"6--MHC+ <W
MQ0.%X2# :3D'B["V*S\XXK]V+*4L$#67L'];;^\O/G_YX0>.#-#XU?YF<]&Y
MR*DE1)29:6I"93.=ER=]:RQA'VP2^4O9PHOC_OX<.YC]N]0&04.!_R<*B'Q9
M\LG"4MR5T'NN ^)NWB',"%&32U+E8E?4HV==1_DLJ\"1ECE?_= _' _="]CY
M$<0Y9/96DDF:Y]#G=BH6]GEC00!").K;$&^(^GQNPQ1AUIP^8@'C>K=#)&P4
M55''/)%<>0$0(+/4(<E[)IEB_?94A1T(WTJQJIJ^1EY6H)4*C9V_(D3JK9.>
M5.W+-F0M$.?+K&Q=6#VOCNB?R(F?OT>L<U:<:O\M?.24FNP\=KR!]D&X\.,#
MOCNOSF&#AS@'AR-\<<;9!V"#J<*C<7:/^!(0E2R[&K>TYA+A>UAWZ]3:>O(_
M.( .7 _$W:N8QU7.,3DAC+_ZZ>LM9I[OOG?,S83U<,9,^&1=4;-? (&T3C #
MWY3'&0H"C'80PVVXB^(#/98[/T2D2C)3'U:9!P+ +,GZV?G(U:8+%**=SY3Y
M.$/M,ZVO3GJ,,5/9[@I'Q38N7!5L04]CFGWPZ,W([L05WG"XS[(D?G&"(\I:
M"VR*Q@)%T'/V8U=+[+N2?230S#/')VILIM,F63I<E8&623A=U5AY)@ @(ZIT
M4,W]-GR(HST)CN!;/"3C[0-$9,OMKKAHG?TW?P;!#S%%^"DB%FA,'E@5VOOX
M1<VTW:_.OZ+X,G"2I.H0Q1&X=98  ;:(,UP27T6<8!JCMA7\[Y1 ](1<<FP<
M@_"@!>T3[CWZ_L\H_KUI7N+(N(*Q,,ZVU=2T+-W,/#?>8!"@- TS5UB?(/%;
M<8(%+:Q6Q*4@_(4%FO)D$*"R[)NE^OXM).UBR&-&[-TN'IH];:J&4NE"]F]@
MI1-Q7CFQ,T!O.H@3;T?9W(;UBJ:<^!SMR2! Y7J"%6,F=.;;)^6'V'_'W 9O
MUJ5:?,?><1,=8\[CHC$7Q,DVF6S.48E?ADFU_-$ @>&:;QC#0&S_9ZR@QTY
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M-]VE+GL)#DYGOGT9M8APS9R8#K704J]F<A\5BG;6A+1K$E6>"N)<\XXNN7"
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MD$[+1<L106RR^E001$PEJQ>Y\/4BUQ!;+J2,,>._%T_TT0E(B,N/7!EPVFV
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M88#"KK&:;?H>?:<_Z51G;<T$ 61I6!;18&>0_3>+83GAQ8'S1H+ /W7"EA4
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M<.T50)QATR:<6;XWQ_0UBDG/4;D5N3W#_DD*&QGE65R]2YJ+5P%QHJ5*40_
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MU8AGQFL,L)YG4!8RPU^H[[;]&PC<JN=O] @K$JP" GA9"QS%JD;"N2  ;=4
MXSNIF -!@%#2DC@^G#',/A/^Z@=8OHI"E#^0'>[;'@ "X[6>#"U=]S:D-=S)
M X^?_^Q'A4KVRLO8/[',:7"9/X9"ST)SD/77)TM9N_%9!9]9O]O'=2UHH8AC
MD)7=D$\!<8,4H@+ 10+DVNPE_KOO.L%S[#L!PT#$&@4"Y[60TN()R'(K+IR
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M8.D=_MQAS8PL,H7AUK4[S'H]K,S0H' 4O_LN2MB*'7<@B#O#3#OGQOCR1X,
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MISJGY+KT6,AZ\:B;*,;[=1'RDAO\:.31'?X[$MX3U=GVB[/5V+AZ9>7N%/N
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M+)#FZJ+?TGG=L("#9IN!AOM['32F'.36:%]1>=]7@26CKOSR%5%51U:!8F&
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M2!=$_XXZ57?ZK+#XBEHZQ:(*5 F)H3UJ807 AA<IH+V.4*R&3=YHNVUR7J/
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M9ICM*)^RAK@K]!8CUZ>'S0&X,020%D#E<W(9CS&)!=04^]FS1Q&9+U4EYO9
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MG]PQC?CC6T^H::V 6D;+EZAE 9\::=]&\8]@Q1K.@H"EH65W9,\L.C^5COP
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M([ "_(G;HHYQKW0H&#O*B>DP\(?HR= /@BD;[?#JMUMI)*OW_45;]QW>_YI
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MOF,[2\]Y[A+"LW*L7=7T3P'UV>Q$UY["_YY0_JZH^\1O.SP2YUWL_]X]:N=
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M  N\>B@4G<LTS%_J5I\IA[$V'[^^^HH^=M<(^$ ?8S?.JC<QX0&(AK7M0-T
M*LZ,$ZG7>_V]'< //Q)>.L[<B/6/&XT*D642MM>TNX"T W4'Z@[4)Q+.M]V>
M]!ANO'.4QP?VK!I5UK&3EG]<^6L@O-7[HE]GWYBU\\>GPYUV_[C$M=*9.VL6
M^7] _LL>A'T@]AW;67GB<Y<4GI1S[2JG'P74)[,;77LF_WM"^;NB[B._^_!
MG'?Q_T?PJIT3/<IIV6.=CVT/EKNP_S3#_INQ@'SIC=O?PP,[_NF%3Y :<-S,
M&EL\3L3R \3"(0SI/30=)N9T_X_PB"@JNE"95#U;/$5:K^#@\RD,/] Y]:,?
MX;_$KE]VB/_M7HY=>?NU/\@E7$?A^29Z!Q9-7!5JD E;2CZ+J77-=_S[RRMO
M+=/;T"*?-8KXCA&H;/<Z\Y=8;#PON6IEA9)"H5KHH?4#$S<;$/%PN^0C")56
MQ'.,.3&74SZSOK8:=N@]^--GPXY_@_Y_4$L#!!0    ( &>A!EUQ?0WM[P8
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M2P$"% ,4    " !GH09=LZM#D"A)!P SMPH $@              @ $
M:6UG,3(R.#,R,#8S7S N:G!G4$L! A0#%     @ 9Z$&7<K7#%AA[P( ?&TA
M !$              ( !6$D' &EN86(M,C R-C V,S N:'1M4$L! A0#%
M  @ 9Z$&7?*?@5-E$P$ _+\0 !$              ( !Z#@* &EN86(M,C R
M-C V,S N>'-D4$L! A0#%     @ 9Z$&7<VB7MHE"0  ]3\   \
M     ( !?$P+ &EN86(M97@S,5\Q+FAT;5!+ 0(4 Q0    ( &>A!EU#^>'.
M.@D  "1    /              "  <Y5"P!I;F%B+65X,S%?,BYH=&U02P$"
M% ,4    " !GH09=<7T-[>\&  "I2   #P              @ $U7PL :6YA
B8BUE>#,R7S$N:'1M4$L%!@     &  8 =0$  %%F"P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>inab-20260630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:inab="http://in8bio.com/20260630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="inab-20260630.xsd" xlink:type="simple"/>
    <context id="C_810c253b-a933-4a17-9491-34d6f79e7d1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_82df8d9b-ab44-4186-a2a5-46f09cf06bab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:AtmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_848a1210-eb49-4891-935b-80b8db44acbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8515f78c-3e2e-4acd-a27d-497da68551e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <instant>2026-08-03</instant>
        </period>
    </context>
    <context id="C_86e4d9d6-3ea9-4abe-9133-f643a5892564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:Pre-FundedWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_875d9953-bc37-4aec-b5bd-7626c7b4a282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_882fd2d9-5d3b-4094-8326-9d116fa514c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_896afe2a-d0f7-4ab2-995a-8bb585b17a31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_8bad56db-9715-48c8-9c43-9f6171f27068">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8cdfe491-a6d3-4390-9fa9-14cf4c1ff8ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inab:UABRFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inab:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_8e7cb988-8a3c-49f0-9463-9aace8979b6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_8ef8b035-bbb2-4994-a1c6-11a275ba8551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8f720d50-af6e-4211-a827-c117c09d5ba6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareInternallyDevelopedAndPurchasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_919d5a0e-62fb-40f3-a669-87d5a9aef2e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:Pre-FundedWarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_95149714-844a-412e-967f-b79e9e655892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_96ec57a8-e87b-4138-894b-a4270326d386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_97223205-5221-4961-859d-ce78102dadb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inab:BirminghamAlabamaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_974cfe0d-089e-4c95-bae7-273d520e56db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:SecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="C_97eade55-36d8-4746-9262-d58691399e1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_991adedc-6fe1-457b-a3c6-48d3d6844dc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-100Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_997b28c3-e27a-4857-b095-ed0f479b1617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_999469ac-65fe-4335-aa47-cdaa7da3a24c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a174a2f5-f61d-4549-a8ce-e3d8bb86274b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_a63f502f-f8b0-4607-a47f-5d8632401b59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_a808f64c-72ae-4532-9ed3-19e39e466b41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a8fe38f0-fd45-4ec0-b678-619335c250dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_aa26e47b-c5bc-46bb-be5a-e667b328aaff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:SecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="C_aa7edcfc-6c9b-4838-92c4-14a3be2c97a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-400Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ab1c1654-f49e-44dd-932a-984720cd913c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_acfff60e-a022-428e-8f12-c565b3924d5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ad33d33e-a055-4025-8be6-a7a64988ccbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-200Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ade5bfd8-e223-4fa2-b9eb-073902595766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:ExchangedPre-FundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_aea50f9a-5f2f-47c2-a9b6-328cfc5db21b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesCWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_b0893cee-3d08-4109-a7b3-cdad0a9d269d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_b24663f5-7497-4a9d-bd5e-d59f159c16de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-100Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_b28d3e5d-1b32-48f8-88d7-6fb7eab46cd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_b30464c5-22d4-4239-98ad-7e811345c69c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_b52b4906-2f95-41dc-9fd6-f217e9324069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-29</startDate>
            <endDate>2021-07-29</endDate>
        </period>
    </context>
    <context id="C_b5b1abb1-d97e-42f9-9b1f-61a28dbce843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_b5d20a02-97de-4fad-9d67-9830ebf05b96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_b5ee527e-59c0-4072-8224-1ae00b09c2d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_b8e4b9eb-c72b-49a4-a984-af719c089c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_ba318ec4-b114-42ad-878b-e7d896f93026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_bc76b556-a6fe-4d1d-ae30-4ebf8174f5cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_bd29102c-0440-4bf5-9ff4-5120f836ab06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyThreePre-FundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_bdbee5c1-4fcd-4d7f-ba39-f1599229cc82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_be7c85de-8249-4726-abb3-64537317fe59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inab:BirminghamAlabamaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_c8b1b3b9-2703-4083-a3de-9b291dc7e209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:AtmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_c96bc108-9aae-4257-b173-6aafb51ec3cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ca9afdc9-8b69-4eef-878d-9bfdecad710f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-400Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_cc023649-9aca-4bc0-a9c8-0b9537dfc5f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesCWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_cdfcacfd-7d70-4257-9404-6c997e9aadc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="C_d0886603-a24d-4329-9904-e737992b8142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d1b51327-f920-40af-87a2-b87c1de36678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d225c8bf-ce7a-4314-8a8d-a6a85def5b00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_d253db46-30ee-4977-a335-6cf4430b34fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_d340d6b3-3a2d-4be6-b670-fb1812ea56c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d465b573-e7bb-4e0a-993f-63f0094f2438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <context id="C_d489f32d-49f5-485e-b567-6dfcd8ad3fb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_d4c94038-e53d-43c3-abc6-12d9c67c6468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_d4f58c1a-28e8-4e00-ac1b-fdb6c3f10ee4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_d60a61e2-303c-4252-a580-f819f238b08c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:AtmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_d6a03d66-c6db-44b9-acc8-f36f9f7a7dd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:TwoThousandTwentySixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_d771653f-d6e1-42de-90fd-133dbbf26d13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_d7b166d9-02a0-43d4-9686-85c3222aedbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_d9315813-0e95-4466-96f4-8eb12df54e55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_d9a12ffb-2ec7-4e7c-a5a8-b1e4e74bf9f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_dc8de850-dafa-4740-ad94-9a138121ba04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_deaddb12-fb85-43b4-a749-9236251e774e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_def38031-424d-4460-9cf3-5076e5af20ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inab:BirminghamAlabamaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-15</startDate>
            <endDate>2021-09-15</endDate>
        </period>
    </context>
    <context id="C_def65cee-ee7e-4161-a3b8-a9cb4d0e2897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_df7a4eb8-2669-4de2-88f2-acbd258098aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_dff100d2-ec00-417b-a887-37746b72d7f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_e188bb86-a5e4-4b84-9bc7-9b343c8b614c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_e1d35277-d874-4b8a-81ba-2d210f518638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e34a25b4-4b7a-448a-bf63-cb6e13b70301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_e53c5f60-4e1c-4ab5-8af8-680ceacbe890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_e59a07f5-ac54-4de1-8e72-5db165f3214b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_e699a5d1-4c74-4461-a49a-dd3300a4a440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_e772d115-96f1-449b-a86e-07213323f1c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_e7dbcb37-cd29-432c-9337-b9e4bc5c8fbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:GeneralAndAdministrativeExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_e92bc1aa-c2db-46f5-9911-334ad58821cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_eee3fb2b-1cc6-48f7-8f7d-17cd8e684af5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_eee4484b-9c91-4075-99a6-ba3ae7b09a52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inab:SecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="C_ef18a21f-14bd-4046-a4f2-3da805a9ad98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-29</instant>
        </period>
    </context>
    <context id="C_f08181e7-c1bc-4a25-bac2-7766dac1a770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f400a42d-0c03-47f8-b36b-2ccfd408dc51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:ExchangedPre-FundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="C_f7dd2334-9796-45e3-9723-b8b13243babf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_fa2c336e-3ddc-4b2c-b8dd-0e2b1adc5db0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_fdc21c59-3c61-4c15-b2c9-ab66b200f940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-200Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_00c2fbee-81a5-4d69-b099-7ec1b71252fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_0499d8bf-2153-47ac-bbac-d9cd024bdf7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="C_05ec3e90-967f-458c-97d3-d68b6e3dd286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <instant>2025-06-01</instant>
        </period>
    </context>
    <context id="C_0da20066-bceb-4489-961d-fc1d7a76f4a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_0e88d318-dcf6-40a9-820a-70d59c10d5b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_0f67f5a8-7d2f-4836-8132-a9140b0a5dee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_13d21bb4-b59b-41aa-aa09-28b17f1305e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="C_141ba882-944c-447d-9a26-353741846e49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyFourPre-FundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_14ed354b-9858-4395-9f4f-fe4f90a1c437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_15a832e8-0165-4101-a163-3b54c4539b18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyFourPre-FundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_17a4c689-e630-472c-a467-89020ee064f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_198b97c6-3cda-418e-8a12-84c85860d2ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-100Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_19bfb4fa-92ca-4246-b1e1-4e59f4934b59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_19eea9f4-a3b3-4fe1-9029-8ab4452c1378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_1adb25df-3d32-4ebb-8981-405b9b8ebad8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1e264363-061d-4fec-ab8f-4a6fcd04c71e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_212bcbdc-62a3-49ef-86ac-994d2b61a1ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_2175d4db-6a33-4fb4-85e3-1bf2eeb93e8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_23c7fe2f-970c-4999-b6a8-53f62effb0b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_2444ac2d-b0ac-4470-ad12-9bfaa60d8a45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_2a7caeb1-9103-4d4c-8f98-d37f1a6de338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2af03440-5a2f-4e6d-b44b-a6ccc55a7aa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_2b8acd72-67e8-49aa-b360-6976c9610ae0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="C_2c0017d1-6285-4171-90ff-3fa0920d4f40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_2c1c8162-f3f4-43b5-b9b1-dfa4747b48c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-200Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_2c9be926-d525-4e32-aec7-2f538b535820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_2f17ba0a-7fb9-42d7-bb76-df75063b2d08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_30289466-5d5a-4f6a-a4fe-1eb69daf93bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_3308162f-a2dc-4d95-879d-976b215e5b9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inab:UABRFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inab:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_35dd4b27-e1ca-484c-8fc2-9fea1443f2b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inab:UABRFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inab:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_35e2df7a-828c-48a5-bbac-98bd4ed637bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_38b6bbc9-cfd4-42cc-abf5-b90814c910dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_3a6247f8-75f6-40db-a461-ec966fedb821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3d1767c5-7281-45dd-b1c5-54289525b7fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3eba5499-8b2d-4237-9df4-85ecab51e9df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3ef9e3d2-ac68-4df4-9377-90cb029dcf78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_3f9adad1-5ca0-4a1c-aed8-aaf191bcb64e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inab:SeriesABWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_4136a492-9cb7-4b0d-90cb-607bc2ed4239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="C_41f9322c-2c47-48ad-880f-4d68924f360c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inab:UABRFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inab:EmoryLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_4222be5a-0c57-4a3d-b834-e0e79efc53a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareInternallyDevelopedAndPurchasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_4236eadf-0539-4ef9-8e90-18421e8dedb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_42cc5669-934a-4055-a8d8-921ebecf0195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inab:BirminghamAlabamaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_47b31919-5ee3-4679-8cae-28d91f22238b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_4c61b704-66e8-4b64-a193-bc2b42ce834b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-200Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_4c7d1dff-7913-4872-846a-511db2a788b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4e1d52b8-2e75-4fad-91a5-2c9038ff8c4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-100Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_4e6b6762-f427-4f1a-938b-da78f831260d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="C_50d59e7d-433d-43f6-a235-2ab99ee775ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_51057659-704a-481e-b321-6c1fd355a269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_51d9da6d-b9b1-4235-b9df-47c847a8337b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_5278b2a4-3328-41ca-a1e8-91dc5a129b3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_53a7b24c-e727-4468-a624-795e8b95e8d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-400Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_53e8ca8d-054b-421a-aeaf-137116bc56c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_55665991-ca2b-41b7-8b4e-3d3f94dda5c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_59cd43a9-96e0-48e2-a9e4-f951fd28b4a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyThreePre-FundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5fdb3891-da52-4136-be69-6649196b8db1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inab:INB-400Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5ff0bb53-9ba3-44b1-99fb-5976079d7285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesCWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_615b0689-2e71-471d-b476-8b5d53cc4a55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:TwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_6422bdd1-8860-4052-ba54-1d6d60b3e10a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:PrivatePlacementTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_6512d216-0c5d-4efe-bd6d-d941a05aec24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inab:JanuaryOneTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inab:AmendedAndRestatedEquityIncentivePlanTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="C_652cd561-42c7-41d5-a3df-59ea80bfee2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inab:UABRFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inab:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_65a4b151-c941-4db6-b342-71c02c307b1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">inab:SeriesABWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_665131ec-5814-4fa4-93a2-5d902fd95bbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_6719b59d-803e-4f87-b7ca-224b48a13129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_68f1e9fb-5b0b-4695-96b7-d28a72a0181a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_6d0dc760-5d42-43c3-8497-ef5beb5bf865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:ExchangedPre-FundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="C_6d2dbaaf-c0a6-4697-b08e-5a209319a860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_6e10ca35-ecc2-4490-8426-dd8b4a7de900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_6e764d9e-722e-4667-9043-0080eb8701ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_6f1b8905-5d9c-4b4c-a19f-0b6187fb5d06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6f940d37-a954-49ae-b661-7826cc32ebbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inab:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_70daad7c-cf08-4f1a-979c-b2e231f3779a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_71b5319c-c74f-48c0-b513-7d988c5197cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inab:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_722ff75a-27ec-4522-80bd-b43a8403d7ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:StatementOfIncomeLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:ResearchAndDevelopmentExpense</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_76bcec81-1928-48a5-ae1a-c034ec20dc20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7af2a072-2c87-47d1-ad7d-8dab6874c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inab:BirminghamAlabamaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_7ed27e52-d578-4124-a699-38d69b156df6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001740279</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>inab:Segment</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_d8859f73-a74d-4435-9c12-18ab0671866c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_560563ca-36d0-401a-bd8e-26c4f3cb4ba1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_c7752722-91a6-4727-a73d-62a48909c881">0001740279</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_18ec0a2d-15fb-4d1b-8eb9-326323c5cd58">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_a73bde2d-28e7-4c1c-b9f5-7ba0bc2bc617">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_12e055d4-cd9a-41cd-93c5-adaa38a1314e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_918c5c1b-4508-4ce5-9258-ac344e65a824">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_0b98a488-0099-46ee-91bd-9cfec30f3b96">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_3a882774-2868-4968-8d78-251311af291d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_ec668c9c-4366-4b57-bb86-1bc0bf7ef533">001-39692</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_5e5dd7e5-bc72-42f9-9540-defaa4b829f8">IN8BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_64a4fb6e-8083-4021-b9b4-c4b0836576b4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_9919159f-51d9-494a-9f6c-1e0ef1d199f4">82-5462585</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_613c70a1-533b-4e14-9336-ca826112cd6e">350 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_6baa146c-5278-44bc-b97f-f4f8fa8367c0">Suite 5330</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_21444f2a-6046-4b32-b968-25bd41735c6f">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_8d81cf83-47e9-4f70-aaf5-79f6b075acc6">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_1007387f-70fb-4b74-8301-d06e7c165f0d">10118</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_6d2800ec-c71b-4801-b568-bb870334bba6">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_de2ed9d1-e279-4ebb-a8c9-5aa4875e4fff">600-6438</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_8d32cc00-a2d9-4881-ae5b-5b5abc7d32a1">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_b79f445d-bc20-4aaa-b541-36d6c876fea7">INAB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_46cb41f6-5dca-4c00-aa52-acf8d8e5fa50">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_8c28090c-9e76-4330-bcd0-70d6d235e50d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_e80f19bb-ce04-49d6-9c68-bf723bf87b52">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_dda64a96-679f-4e17-9625-7c94f8747546">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_bfcff022-db08-4987-9b9e-a38d8a6a4c5d">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_09b776c8-e0dc-46be-a9ee-0cedbfc07048">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_19d8f803-3d5d-48b6-b4df-1b1b692fe508">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_b4b537f3-3aa5-4cd3-b15b-6833ad719401">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_8515f78c-3e2e-4acd-a27d-497da68551e4"
      decimals="INF"
      id="F_71f5ba01-120b-4844-a141-f8d53a536cec"
      unitRef="U_shares">9858383</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_0d8238e8-5caa-4e9a-9928-bddd1d9a8d3f"
      unitRef="U_USD">17956000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_c3f66b38-2df9-42b1-9cdf-f502806cf788"
      unitRef="U_USD">27092000</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_fc4f9bed-b847-4f54-aec2-894988f10352"
      unitRef="U_USD">540000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_a2fad889-3bcd-40e5-a778-e1d5ed9721a8"
      unitRef="U_USD">788000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_6e699885-cede-4825-8e7b-d4dbdb72e927"
      unitRef="U_USD">18496000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_ae50709c-d8c4-4a56-a784-214c10049281"
      unitRef="U_USD">27880000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_c6e41298-62cc-4444-8cfd-dc623b05f6e8"
      unitRef="U_USD">1600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_645d1a48-eb19-4252-baea-b75aac2f8fa7"
      unitRef="U_USD">1858000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCash
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_f78a64c7-75d2-4e54-8396-5c2e1fb1c403"
      unitRef="U_USD">176000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_12389d0b-66e2-4895-a148-d0da1bf3610d"
      unitRef="U_USD">220000</us-gaap:RestrictedCash>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_fbef6728-f446-4a2e-a1e2-ba50a344cb58"
      unitRef="U_USD">125000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_bc5a1f02-f8b3-4b95-a5e7-a8a499073bd9"
      unitRef="U_USD">296000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_6e522586-d8f5-402f-9252-2689cae6ecb6"
      unitRef="U_USD">1246000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_25eaf803-0452-4edb-b82c-39dbeff02fd9"
      unitRef="U_USD">1882000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_f5a08cd8-648a-429e-b979-76915575a8e6"
      unitRef="U_USD">102000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_db7cb6f0-01c7-45e2-b57f-dd37c3a39bb0"
      unitRef="U_USD">146000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_9334be02-6a23-458e-8538-f3cf6d52fce1"
      unitRef="U_USD">3249000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_ee92cbbe-2c41-4b07-a9ac-d678e6d35b37"
      unitRef="U_USD">4402000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_e338ff0a-7c9e-4347-83b6-84071d81c221"
      unitRef="U_USD">21745000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_e3da31e1-a0ba-4132-8d4c-5c7f9b7a82ec"
      unitRef="U_USD">32282000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_7fd0d015-d9f3-4c66-a4b3-b22b023feb56"
      unitRef="U_USD">444000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_9d7b56eb-920c-47de-aced-63cf399f3bd0"
      unitRef="U_USD">309000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_69a9988f-fb22-498a-9dac-5384b323343d"
      unitRef="U_USD">761000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_38ffb37f-f2a7-4389-9813-486aaf4abc5e"
      unitRef="U_USD">1633000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_0638276e-1702-470b-9cb0-d549ddcbd569"
      unitRef="U_USD">126000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_38d48ba6-e722-4b6e-ba88-0151fb20080f"
      unitRef="U_USD">295000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_47473bfa-59b1-4c2b-8c73-c2fd2840cb18"
      unitRef="U_USD">923000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_df0df7dd-2b3d-47b5-a5b0-018050dd1a5b"
      unitRef="U_USD">924000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_9b478d50-9d44-4821-82e9-a2525089276f"
      unitRef="U_USD">2254000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_79440745-823e-42e1-b4b9-49d841bc2fad"
      unitRef="U_USD">3161000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_78763102-061a-4f8a-b992-95c274f98526"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_2cf81ba3-bdc1-4bc7-9e8f-793b8ba6ce6e"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_bcd5de24-198f-4dc2-9ee4-23c4067757f3"
      unitRef="U_USD">1128000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_36dbb8ba-160e-4c73-b5ea-bd30de203c03"
      unitRef="U_USD">1563000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_4585b322-7236-42ec-a79c-55986b5f62ba"
      unitRef="U_USD">1128000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_4d1d89d2-dea2-490e-aa62-f7b9fec281fd"
      unitRef="U_USD">1563000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_7782a7e1-d989-403c-bd49-590d86d7a13b"
      unitRef="U_USD">3382000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_c03c19c1-5318-4444-87d8-605fc9475ff0"
      unitRef="U_USD">4724000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_aa40f82b-0a87-45e6-a4f2-6a2f6d8c9f3f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="INF"
      id="F_609235f9-8b20-4b08-8926-98522a8db2ab"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_0c7546f8-8957-4e8f-b60e-cbb4945be81a"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="INF"
      id="F_f5b7402b-ce7e-46c6-b287-c7fae2b741e1"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_3ce21684-862b-4715-949e-0f1259d10190"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_35f329c0-1312-48be-b5e7-1ca094cf6af1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="INF"
      id="F_2c447b58-62e5-49a3-90a0-f7dcb82c9edd"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="INF"
      id="F_d616065a-4683-474e-bcdd-cc13108d66b5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_5daf64d1-f53f-4796-b33c-1fde7866b699"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_94feeb45-0908-4fce-8dbb-b3fef085a6a4"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_d0a29492-3060-4b1f-b5f6-de77e7b7cae8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="INF"
      id="F_1184eca5-be43-4bdc-a92e-efe5f23faae7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_834336c6-9de1-44c3-b2a5-a207dbac31e4"
      unitRef="U_shares">490000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="INF"
      id="F_0c1e8d3c-7110-40c5-9855-b8d0b16700b8"
      unitRef="U_shares">490000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_7ab6a304-d211-427f-9bd6-a53f88ca978d"
      unitRef="U_shares">9853121</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_a08cf0fc-fef4-4126-8e70-c269f7f7bf6b"
      unitRef="U_shares">9853121</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="INF"
      id="F_4526a703-bffe-49f8-9e63-61e128dcc3f3"
      unitRef="U_shares">9766132</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="INF"
      id="F_c7249552-98d9-4044-87ac-5939d026b189"
      unitRef="U_shares">9766132</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_370d18c0-150a-409d-9b0e-37b1687b0e54"
      unitRef="U_USD">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_0c53d308-7bf9-45f7-9b3f-79ddae959134"
      unitRef="U_USD">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_3ddb49e6-9efe-4f3d-90a7-6bde17f9f129"
      unitRef="U_USD">169320000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_aa91b422-477e-4d1a-952b-4ed9b2d415dd"
      unitRef="U_USD">168644000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_65289ada-73ae-4035-b9ea-96d8992a9bc8"
      unitRef="U_USD">-150967000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_88706058-4fa0-4bf5-93b8-b7011f3f0767"
      unitRef="U_USD">-141096000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_e71c3479-8065-4808-8bf7-0bd472abbad3"
      unitRef="U_USD">18363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_42313ea4-0a70-4492-8745-1a14cd8473d5"
      unitRef="U_USD">27558000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_34751ec5-a1f6-4f2c-8ef2-110ff2bb5277"
      unitRef="U_USD">21745000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_29d5f2be-3d2f-4286-9ab8-ed3fe7766755"
      unitRef="U_USD">32282000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_a2ead263-4bbe-48fa-882c-2e6c45c7e54d"
      unitRef="U_USD">2493000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_401ab91b-b5bc-4768-9eb5-5c9be85849d1"
      unitRef="U_USD">2487000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_9f9c1226-1ca8-4ce1-9b7e-4a7e9e997a25"
      unitRef="U_USD">5106000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_a8e62539-acb5-454f-b095-4d7501dbb76f"
      unitRef="U_USD">5459000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_8273570c-6190-4f8b-b4ef-fb8c68d37636"
      unitRef="U_USD">2442000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_ff77584c-5e74-4a46-93b1-acd49526210d"
      unitRef="U_USD">2714000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_c80ea1d0-44e7-4399-9df1-a50ae4fd8975"
      unitRef="U_USD">5095000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_694c2498-fc49-4079-bae8-53a9d101a34e"
      unitRef="U_USD">5402000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_d0837b01-3036-4401-98c3-d83e0bb7607d"
      unitRef="U_USD">4935000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_a3116c44-8a9b-4076-bb99-41c3a62475a6"
      unitRef="U_USD">5201000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_eefe9aa0-e7ef-483e-910a-d25956f43e5b"
      unitRef="U_USD">10201000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_ad85ea07-c397-41a5-a6a9-13fb8f3469fc"
      unitRef="U_USD">10861000</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_9a97fa6d-9da2-4f31-a1b7-7c261d5f2c09"
      unitRef="U_USD">154000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_43cb1297-5003-4a5e-9b9a-359b713dade6"
      unitRef="U_USD">107000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_00567391-3e65-423d-bc23-0b2ab8518d19"
      unitRef="U_USD">330000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_dbc555ba-587c-4bc9-8339-84d62bb016b4"
      unitRef="U_USD">217000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_d0ddb91f-fc45-4bf3-9755-3b3c130e4352"
      unitRef="U_USD">-4781000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_61fa8fd9-f8e2-4210-a1f6-739b87c2dca0"
      unitRef="U_USD">-5094000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_370f3ad7-4f06-4555-902e-583cf2a73fb5"
      unitRef="U_USD">-9871000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_0d72f061-29be-4813-acf1-efe511cd24e5"
      unitRef="U_USD">-10644000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_dcb97b13-e303-463e-80af-103d077b7d76"
      unitRef="U_USD">-4781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_f02e768a-1242-4f3a-b830-ea5b2b0fd7d0"
      unitRef="U_USD">-5094000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_3ff13a48-1937-4b80-8937-224760cd785e"
      unitRef="U_USD">-9871000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_d5ac5b19-271a-48d0-b900-1d440a770493"
      unitRef="U_USD">-10644000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="2"
      id="F_43fb2e35-8a04-4350-a83c-62ef3138821d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="2"
      id="F_58d442d6-2685-40e3-896a-1f27ba7975b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="2"
      id="F_40862018-ca6f-4bc3-8ea7-b0ccb8ef40ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="2"
      id="F_ffa00432-2c64-4c81-9ba0-adb1f8729dd8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="2"
      id="F_53ad4dad-8596-4ce3-bb2b-b7307b0c9356"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="2"
      id="F_890c8f2a-22c6-497c-a1f3-953c4d93604b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="2"
      id="F_ae1f7546-5c1a-4ee8-913c-64f1de888cac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="2"
      id="F_3725d7f8-dd38-47e9-9784-83549eca5f7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="INF"
      id="F_107fd8a6-01bb-4d8d-a9e4-2dc7f7ed9f9b"
      unitRef="U_shares">19467091</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="INF"
      id="F_e701fc01-3222-4bda-b8fc-f90691c52fb8"
      unitRef="U_shares">19467091</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="INF"
      id="F_31dd06b2-e64d-404b-8418-0afac011aefa"
      unitRef="U_shares">4119153</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="INF"
      id="F_4aa5ae8f-d338-45e5-95b4-1c08a2d5551c"
      unitRef="U_shares">4119153</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="INF"
      id="F_ae7fa5eb-e603-4e10-8852-92aae4d27b0d"
      unitRef="U_shares">19468087</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="INF"
      id="F_2afb20e6-daba-4a98-8a1d-0808a26aa807"
      unitRef="U_shares">19468087</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="INF"
      id="F_0e3a0361-9c17-424c-821f-288a91852291"
      unitRef="U_shares">2920157</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="INF"
      id="F_69ffcd5a-80a5-4883-8fd0-45436001806a"
      unitRef="U_shares">2920157</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_d0886603-a24d-4329-9904-e737992b8142"
      decimals="INF"
      id="F_88fa32c1-36d1-4829-a67b-b66927b13738"
      unitRef="U_shares">2416066</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_d0886603-a24d-4329-9904-e737992b8142"
      decimals="-3"
      id="F_cc4c5c01-c05f-4623-9210-13aeafc82543"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d340d6b3-3a2d-4be6-b670-fb1812ea56c6"
      decimals="-3"
      id="F_722463d3-1f54-40a0-87bd-b75ccae582ef"
      unitRef="U_USD">136127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1adb25df-3d32-4ebb-8981-405b9b8ebad8"
      decimals="-3"
      id="F_7d685d2e-664e-482c-8498-c6c59b88842c"
      unitRef="U_USD">-121656000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_76bcec81-1928-48a5-ae1a-c034ec20dc20"
      decimals="-3"
      id="F_4a80b300-6c78-4b68-97cd-0f6771629716"
      unitRef="U_USD">14478000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0f67f5a8-7d2f-4836-8132-a9140b0a5dee"
      decimals="INF"
      id="F_24a83f4a-7350-4950-9621-e47620552eed"
      unitRef="U_shares">245428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0f67f5a8-7d2f-4836-8132-a9140b0a5dee"
      decimals="-3"
      id="F_3f57d2ec-aa0e-48a3-b9ac-f3904452b5af"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e188bb86-a5e4-4b84-9bc7-9b343c8b614c"
      decimals="-3"
      id="F_d073a333-eabe-4298-8b89-6429325aa8b4"
      unitRef="U_USD">3734000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c96bc108-9aae-4257-b173-6aafb51ec3cc"
      decimals="-3"
      id="F_7469dd04-2ad1-43d3-a5f8-a3053aa1ac95"
      unitRef="U_USD">3735000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <inab:StockIssuedDuringPeriodSharesSeriesCWarrantsExercised
      contextRef="C_0f67f5a8-7d2f-4836-8132-a9140b0a5dee"
      decimals="INF"
      id="F_9af372e4-b465-4f98-a518-bc53594010cc"
      unitRef="U_shares">47088</inab:StockIssuedDuringPeriodSharesSeriesCWarrantsExercised>
    <inab:StockIssueDuringPeriodValueSeriesCWarrantsExercised
      contextRef="C_e188bb86-a5e4-4b84-9bc7-9b343c8b614c"
      decimals="-3"
      id="F_c9c84f6d-6947-438b-9681-a7ad2472c170"
      unitRef="U_USD">383000</inab:StockIssueDuringPeriodValueSeriesCWarrantsExercised>
    <inab:StockIssueDuringPeriodValueSeriesCWarrantsExercised
      contextRef="C_c96bc108-9aae-4257-b173-6aafb51ec3cc"
      decimals="-3"
      id="F_edf5df99-5982-4c40-883d-ea660778b645"
      unitRef="U_USD">383000</inab:StockIssueDuringPeriodValueSeriesCWarrantsExercised>
    <inab:Stock-BasedCompensationExpense
      contextRef="C_e188bb86-a5e4-4b84-9bc7-9b343c8b614c"
      decimals="-3"
      id="F_aa69cffe-135e-47c2-8964-0180a0a667c6"
      unitRef="U_USD">831000</inab:Stock-BasedCompensationExpense>
    <inab:Stock-BasedCompensationExpense
      contextRef="C_c96bc108-9aae-4257-b173-6aafb51ec3cc"
      decimals="-3"
      id="F_97702608-09bc-4c20-a3cf-5db4caa4c609"
      unitRef="U_USD">831000</inab:Stock-BasedCompensationExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_97eade55-36d8-4746-9262-d58691399e1f"
      decimals="-3"
      id="F_782cdc9f-9aae-4946-a97e-de38efaca09f"
      unitRef="U_USD">-5550000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c96bc108-9aae-4257-b173-6aafb51ec3cc"
      decimals="-3"
      id="F_61702626-6ef0-40a6-b912-696b32710120"
      unitRef="U_USD">-5550000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_1e264363-061d-4fec-ab8f-4a6fcd04c71e"
      decimals="INF"
      id="F_57f3e6ed-baf3-49bb-a055-ef3d5d7dcbe6"
      unitRef="U_shares">2708582</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1e264363-061d-4fec-ab8f-4a6fcd04c71e"
      decimals="-3"
      id="F_2bab2d68-a8d3-4b6b-b25d-61036d0fa408"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_deaddb12-fb85-43b4-a749-9236251e774e"
      decimals="-3"
      id="F_7841e2ae-f152-4017-aa4e-59b1ba45e19d"
      unitRef="U_USD">141075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2c9be926-d525-4e32-aec7-2f538b535820"
      decimals="-3"
      id="F_2c30d810-c810-46e4-8ed4-7e9fedd3dcbd"
      unitRef="U_USD">-127206000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d489f32d-49f5-485e-b567-6dfcd8ad3fb9"
      decimals="-3"
      id="F_c9597a74-5db6-4522-a6f0-9f74ddfa4229"
      unitRef="U_USD">13877000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6e10ca35-ecc2-4490-8426-dd8b4a7de900"
      decimals="INF"
      id="F_ad36cfe4-d780-4a42-a557-9cc7f141a118"
      unitRef="U_shares">1058861</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6e10ca35-ecc2-4490-8426-dd8b4a7de900"
      decimals="-3"
      id="F_ae2040ba-edc0-42b2-9e07-cec9ccc09815"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3d1767c5-7281-45dd-b1c5-54289525b7fe"
      decimals="-3"
      id="F_c03337bf-e316-4d51-9587-568e4ac1a375"
      unitRef="U_USD">3615000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_f9467cbc-d005-4d38-aeae-973097c839b0"
      unitRef="U_USD">3617000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <inab:StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised
      contextRef="C_6e10ca35-ecc2-4490-8426-dd8b4a7de900"
      decimals="INF"
      id="F_6920e5a2-5153-4018-86b4-83c77154cba0"
      unitRef="U_shares">310696</inab:StockIssuedDuringPeriodSharesSeriesAAndBWarrantsExercised>
    <inab:StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised
      contextRef="C_3d1767c5-7281-45dd-b1c5-54289525b7fe"
      decimals="-3"
      id="F_e6725740-decf-4cfa-a142-354d6f0cd9ed"
      unitRef="U_USD">1884000</inab:StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised>
    <inab:StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_283f4161-752f-4484-84f1-1822e6a22898"
      unitRef="U_USD">1884000</inab:StockIssuedDuringPeriodValueSeriesAAndBWarrantsExercised>
    <inab:Stock-BasedCompensationExpense
      contextRef="C_3d1767c5-7281-45dd-b1c5-54289525b7fe"
      decimals="-3"
      id="F_34622706-4656-4126-9f28-349ac2d2eb43"
      unitRef="U_USD">955000</inab:Stock-BasedCompensationExpense>
    <inab:Stock-BasedCompensationExpense
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_8e8396da-5e1b-4b91-a1d1-961ff42f3926"
      unitRef="U_USD">955000</inab:Stock-BasedCompensationExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_8ef8b035-bbb2-4994-a1c6-11a275ba8551"
      decimals="-3"
      id="F_00b8cf38-32ae-4eca-9e5d-845ad75845e1"
      unitRef="U_USD">-5094000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_59b19735-8d3f-45e1-9c4b-8469a3db239d"
      unitRef="U_USD">-5094000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_665131ec-5814-4fa4-93a2-5d902fd95bbe"
      decimals="INF"
      id="F_5ddec5c6-ab9b-48f9-9d55-ff4da217f114"
      unitRef="U_shares">4078139</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_665131ec-5814-4fa4-93a2-5d902fd95bbe"
      decimals="-3"
      id="F_58d405c4-49a2-4611-bd85-cc3dfdd98b70"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ba318ec4-b114-42ad-878b-e7d896f93026"
      decimals="-3"
      id="F_8d5b8c4e-eabe-4001-89f4-71a645206c81"
      unitRef="U_USD">147529000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6e764d9e-722e-4667-9043-0080eb8701ce"
      decimals="-3"
      id="F_03df1d61-2532-4c1e-8deb-8ba6e5bccc75"
      unitRef="U_USD">-132300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0da20066-bceb-4489-961d-fc1d7a76f4a5"
      decimals="-3"
      id="F_e21e1aee-15d7-4950-880f-1cdf65196e1f"
      unitRef="U_USD">15239000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_6f1b8905-5d9c-4b4c-a19f-0b6187fb5d06"
      decimals="INF"
      id="F_ba4bbdff-2aa4-474a-91c3-2c1ef6c55a48"
      unitRef="U_shares">9766132</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6f1b8905-5d9c-4b4c-a19f-0b6187fb5d06"
      decimals="-3"
      id="F_cb679ebc-166e-4e62-8068-125f41eeed39"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2a7caeb1-9103-4d4c-8f98-d37f1a6de338"
      decimals="-3"
      id="F_45c99f40-692d-49fa-8b8f-a40f09d554f1"
      unitRef="U_USD">168644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f08181e7-c1bc-4a25-bac2-7766dac1a770"
      decimals="-3"
      id="F_4817ee99-ee6c-48cc-931f-f216531a04d3"
      unitRef="U_USD">-141096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_a7d10c14-3f8a-46bc-9d13-51a301ecff5e"
      unitRef="U_USD">27558000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_212bcbdc-62a3-49ef-86ac-994d2b61a1ff"
      decimals="-3"
      id="F_fdf84f19-9ef8-4ed5-82fb-d5c6234a9748"
      unitRef="U_USD">88000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_d9a12ffb-2ec7-4e7c-a5a8-b1e4e74bf9f6"
      decimals="-3"
      id="F_7167f541-5176-4204-9b70-e47173f48449"
      unitRef="U_USD">88000</us-gaap:PaymentsOfStockIssuanceCosts>
    <inab:StockIssuedDuringPeriodSharesSeriesAWarrantsExercised
      contextRef="C_a8fe38f0-fd45-4ec0-b678-619335c250dd"
      decimals="INF"
      id="F_23a96342-8aeb-4a85-a167-fd2fdb6cacdd"
      unitRef="U_shares">80957</inab:StockIssuedDuringPeriodSharesSeriesAWarrantsExercised>
    <inab:StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue
      contextRef="C_212bcbdc-62a3-49ef-86ac-994d2b61a1ff"
      decimals="-3"
      id="F_01cae2a2-a2d4-49e9-b9d5-5ef88a06ca08"
      unitRef="U_USD">0</inab:StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue>
    <inab:StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue
      contextRef="C_d9a12ffb-2ec7-4e7c-a5a8-b1e4e74bf9f6"
      decimals="-3"
      id="F_63d6153e-8034-45a1-8781-2cf8f8e07a04"
      unitRef="U_USD">0</inab:StockIssuedDuringPeriodValueSeriesAWarrantsExercisedValue>
    <inab:Stock-BasedCompensationExpense
      contextRef="C_212bcbdc-62a3-49ef-86ac-994d2b61a1ff"
      decimals="-3"
      id="F_89de0c52-15dd-40a8-81c9-1875c7538cb8"
      unitRef="U_USD">401000</inab:Stock-BasedCompensationExpense>
    <inab:Stock-BasedCompensationExpense
      contextRef="C_d9a12ffb-2ec7-4e7c-a5a8-b1e4e74bf9f6"
      decimals="-3"
      id="F_68ddb86d-0a7d-46b5-a23c-6345a47a06c1"
      unitRef="U_USD">401000</inab:Stock-BasedCompensationExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_fa2c336e-3ddc-4b2c-b8dd-0e2b1adc5db0"
      decimals="-3"
      id="F_fdc30d69-cd31-4f85-974b-ae49d77c26e9"
      unitRef="U_USD">-5090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d9a12ffb-2ec7-4e7c-a5a8-b1e4e74bf9f6"
      decimals="-3"
      id="F_3eb49d71-b54b-4f5d-8fb1-d198f2ac3f0c"
      unitRef="U_USD">-5090000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_5278b2a4-3328-41ca-a1e8-91dc5a129b3b"
      decimals="INF"
      id="F_d875ef15-491b-4022-95a5-d52c978e5661"
      unitRef="U_shares">9847089</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5278b2a4-3328-41ca-a1e8-91dc5a129b3b"
      decimals="-3"
      id="F_c0eaaeae-eb28-4836-a2a1-0b385f8a74ee"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a174a2f5-f61d-4549-a8ce-e3d8bb86274b"
      decimals="-3"
      id="F_a9ad7310-fa81-4a64-8adc-f78e51d70040"
      unitRef="U_USD">168957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_47b31919-5ee3-4679-8cae-28d91f22238b"
      decimals="-3"
      id="F_d18bee01-fc5c-491a-96e2-cd2a2dca6aaa"
      unitRef="U_USD">-146186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e53c5f60-4e1c-4ab5-8af8-680ceacbe890"
      decimals="-3"
      id="F_e249cd15-0dc3-44a1-9d64-f77cc93b1aa9"
      unitRef="U_USD">22781000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e772d115-96f1-449b-a86e-07213323f1c3"
      decimals="INF"
      id="F_0c63c55e-f54c-4a7a-973a-4b8863b43643"
      unitRef="U_shares">6032</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_eee3fb2b-1cc6-48f7-8f7d-17cd8e684af5"
      decimals="-3"
      id="F_a5db9991-e8c3-4fe0-93a3-e5e2b02941bc"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_90b102b9-06ce-4abe-aace-5487e0307e12"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <inab:Stock-BasedCompensationExpense
      contextRef="C_eee3fb2b-1cc6-48f7-8f7d-17cd8e684af5"
      decimals="-3"
      id="F_0cc6323c-499d-4e5e-9a6b-57fc6556867d"
      unitRef="U_USD">352000</inab:Stock-BasedCompensationExpense>
    <inab:Stock-BasedCompensationExpense
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_cc070e87-a8c6-463f-8e70-d297e6fbdddb"
      unitRef="U_USD">352000</inab:Stock-BasedCompensationExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_896afe2a-d0f7-4ab2-995a-8bb585b17a31"
      decimals="-3"
      id="F_143d79c1-2c55-418d-89cf-24c3cdcc639b"
      unitRef="U_USD">-4781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_6100338b-6c68-44b4-ab69-bd884e056ae0"
      unitRef="U_USD">-4781000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_b5ee527e-59c0-4072-8224-1ae00b09c2d8"
      decimals="INF"
      id="F_6a2595ff-aceb-4232-b0b4-a4edbf870784"
      unitRef="U_shares">9853121</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b5ee527e-59c0-4072-8224-1ae00b09c2d8"
      decimals="-3"
      id="F_68df0b86-a86f-4b00-9f88-2e8bde8ce102"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2444ac2d-b0ac-4470-ad12-9bfaa60d8a45"
      decimals="-3"
      id="F_d1bf1bdc-8280-432b-84f6-03c36c2dbbde"
      unitRef="U_USD">169320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d225c8bf-ce7a-4314-8a8d-a6a85def5b00"
      decimals="-3"
      id="F_1d25e0d6-032b-4d4e-bcce-d0c306b040ea"
      unitRef="U_USD">-150967000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_11dd549f-e8e2-4033-82c2-a80eda103135"
      unitRef="U_USD">18363000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_e517dd76-5981-4061-a125-a507c12828ce"
      unitRef="U_USD">-9871000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_3b880e09-c652-4959-8eb3-bdca81b644ed"
      unitRef="U_USD">-10644000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_6147d81d-2a0e-41a9-ad7a-7be19b8069ed"
      unitRef="U_USD">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_1d848527-bbe2-4b07-a2a1-e28466ff1c60"
      unitRef="U_USD">511000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_98fcc277-e75f-46c7-8eaa-529b71544f44"
      unitRef="U_USD">753000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_8c34c866-6082-454e-85a4-da36cc4508c4"
      unitRef="U_USD">1786000</us-gaap:ShareBasedCompensation>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_a12414da-dbd7-43e1-99f7-30c1dfbcd4e6"
      unitRef="U_USD">170000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_3ff3e9b6-2d05-4557-b253-496de7b9104d"
      unitRef="U_USD">526000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_b78d9458-263a-4979-a195-39d1979055e2"
      unitRef="U_USD">287000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_54e04fb1-4ec7-4e2b-be01-63664d72b66b"
      unitRef="U_USD">416000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_5ed09108-1809-4f78-98f4-ff1fb9d0c580"
      unitRef="U_USD">-248000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_acdae92a-8aa1-40d4-9ee7-593aa366eb5a"
      unitRef="U_USD">-943000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_598520ab-5337-48e4-9ce3-333388419c2a"
      unitRef="U_USD">-44000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_0011b0dc-fbf5-49c5-863b-0f665235671c"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_aa30c8ec-2d09-4342-8886-86b81e48dd19"
      unitRef="U_USD">135000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_9e8bc646-9fb7-4ba4-a8ca-59c9db65904c"
      unitRef="U_USD">-10000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_3ae30c8f-4977-41df-82b5-fa2a5ab4eaa2"
      unitRef="U_USD">-872000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_b748ec4e-7aa5-4631-bb3d-2d1a89f4d160"
      unitRef="U_USD">-412000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <inab:IncreaseDecreaseShortTermOperatingLeaseLiabilities
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_23343f6c-3a28-4145-bfe7-e3dba5b649b0"
      unitRef="U_USD">348000</inab:IncreaseDecreaseShortTermOperatingLeaseLiabilities>
    <inab:IncreaseDecreaseShortTermOperatingLeaseLiabilities
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_a5c83fcd-6582-44e6-82d3-40d3b2d638aa"
      unitRef="U_USD">225000</inab:IncreaseDecreaseShortTermOperatingLeaseLiabilities>
    <inab:IncreaseDecreaseLongTermOperatingLeaseLiabilities
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_d8bfa399-65e8-46fc-bc9a-3f8cddd38c65"
      unitRef="U_USD">-434000</inab:IncreaseDecreaseLongTermOperatingLeaseLiabilities>
    <inab:IncreaseDecreaseLongTermOperatingLeaseLiabilities
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_104f276e-7e77-4c63-a0c2-137cfcc76279"
      unitRef="U_USD">-390000</inab:IncreaseDecreaseLongTermOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_cee723f3-5e06-4550-9198-9adf08832f86"
      unitRef="U_USD">-8692000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_cdee2e71-0101-4df7-be38-d7d5a3b4e456"
      unitRef="U_USD">-7049000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromProductiveAssets
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_ed7e92a9-3486-4604-be69-fae7a7164e57"
      unitRef="U_USD">242000</us-gaap:PaymentsForProceedsFromProductiveAssets>
    <us-gaap:PaymentsForProceedsFromProductiveAssets
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_2c9279c0-9bbf-48df-be4a-dce26f314835"
      unitRef="U_USD">0</us-gaap:PaymentsForProceedsFromProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_cabeaa42-933b-4e3a-ad13-c921ee7b464f"
      unitRef="U_USD">-242000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_8751ec3f-0f8a-451b-85cd-cb161a3a11ff"
      unitRef="U_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_2be3952c-9581-4e26-ad44-554ac6d0e1a6"
      unitRef="U_USD">77000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_803f9668-dcaa-4ffe-9ccb-656c40786ff6"
      unitRef="U_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_57314fed-619e-4f6f-bbce-19e106ce759f"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_ad7cc827-df9f-4efc-b18d-5185d58e22cc"
      unitRef="U_USD">7352000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_65a4b151-c941-4db6-b342-71c02c307b1a"
      decimals="-3"
      id="F_ff5e74dc-01b4-427d-a4bc-f50b5f3b4294"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_3f9adad1-5ca0-4a1c-aed8-aaf191bcb64e"
      decimals="-3"
      id="F_b508dcbc-b93b-4cf7-9c11-191989a92db3"
      unitRef="U_USD">1884000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_51d9da6d-b9b1-4235-b9df-47c847a8337b"
      decimals="-3"
      id="F_4c6c1872-b956-43cc-9545-93e2db842a78"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_999469ac-65fe-4335-aa47-cdaa7da3a24c"
      decimals="-3"
      id="F_153c89cb-ed4c-4d42-a38e-126e6e1e7d42"
      unitRef="U_USD">383000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_fd8b3e2b-c521-4c57-8717-022585942fd1"
      unitRef="U_USD">169000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_f84f6999-ec7f-43f6-ab4b-ed7be92e2575"
      unitRef="U_USD">459000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_fd443646-7f8a-40cc-a4d7-5ffe1616ddd2"
      unitRef="U_USD">-246000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_395de476-ef2f-4c08-90df-70f4f6292979"
      unitRef="U_USD">9160000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_490a65fe-d772-4e92-9ae4-020b03cd4815"
      unitRef="U_USD">-9180000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_9c02cb95-5fa5-4a48-8902-687827a53bf3"
      unitRef="U_USD">2111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_c729ef68-881a-44bf-804e-ba42b10a0eea"
      unitRef="U_USD">27312000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_76bcec81-1928-48a5-ae1a-c034ec20dc20"
      decimals="-3"
      id="F_0cc25666-dcc8-49af-96c7-ce5ee85b5bcd"
      unitRef="U_USD">11386000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_61ee9ec3-0730-4adf-b357-2f92153bb52a"
      unitRef="U_USD">18132000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0da20066-bceb-4489-961d-fc1d7a76f4a5"
      decimals="-3"
      id="F_684ca2ef-6d84-4b54-95a6-ca26531fccac"
      unitRef="U_USD">13497000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:Cash
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_6495bf39-d90a-4db1-9ddd-8977e26d3f29"
      unitRef="U_USD">17956000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_0da20066-bceb-4489-961d-fc1d7a76f4a5"
      decimals="-3"
      id="F_a2cc2d9d-af4d-435b-b7e9-aa3d1a29cd64"
      unitRef="U_USD">13226000</us-gaap:Cash>
    <us-gaap:RestrictedCash
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_6309f659-1ae4-462e-a15f-beb8090bf12a"
      unitRef="U_USD">176000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_0da20066-bceb-4489-961d-fc1d7a76f4a5"
      decimals="-3"
      id="F_6e761f06-334b-4fd4-ba40-def786e36eae"
      unitRef="U_USD">271000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_af035f65-25be-41b7-96b5-092185c4112c"
      unitRef="U_USD">18132000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0da20066-bceb-4489-961d-fc1d7a76f4a5"
      decimals="-3"
      id="F_498e359e-5f28-4a4e-99d3-7c135c363d6b"
      unitRef="U_USD">13497000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <inab:LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_43068fc9-9826-4273-837e-f19df1fbe9bc"
      unitRef="U_USD">-349000</inab:LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities>
    <inab:LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_f85d9b17-be89-44e8-ba24-bb2c0818a908"
      unitRef="U_USD">-1287000</inab:LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities>
    <us-gaap:NatureOfOperations
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_ecda3385-2757-4fe5-bdcf-fc1b821c62a6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. ORGANIZATION AND NATURE OF OPERATIONS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Organization and Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IN8bio, Inc. (the "Company") is a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta ("&#x3b3;&#x3b4;") T cell product candidates and T cell engagers for cancer and autoimmune diseases. The Company&#x2019;s pipeline is anchored by INB-600, its proprietary, internally developed &#x3b3;&#x3b4; T cell engager ("TCE") platform, which has potential applications across oncology and autoimmune indications. The Company&#x2019;s most advanced product candidates are INB-100, currently in an ongoing investigator-sponsored Phase 1 clinical trial of acute myeloid leukemia ("AML"), and INB-200/400, evaluating its DeltEx Drug Resistant Immunotherapy ("DRI") in patients with newly diagnosed glioblastoma ("GBM"). In addition, the Company&#x2019;s DeltEx platform has yielded a broad portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing a range of potential applications, from solid tumors and hematological cancers to autoimmune diseases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Incysus, Inc. ("Incysus") was a corporation formed in the State of Delaware on November 23, 2015 and Incysus, Ltd. was incorporated in Bermuda on February 8, 2016. Incysus was the wholly owned United States subsidiary of Incysus, Ltd. On May 7, 2018, Incysus, Ltd. reincorporated in the United States in a domestication transaction (the "Domestication") in which Incysus, Ltd. converted into a newly formed Delaware corporation, Incysus Therapeutics, Inc. ("Incysus Therapeutics"). On July 24, 2019, Incysus Therapeutics merged with Incysus. Incysus Therapeutics subsequently changed its name to IN8bio, Inc. in August 2020. Following the Domestication in May 2018 and the merging of Incysus Therapeutics and Incysus in July 2019, the Company does not have any subsidiaries to consolidate. The Company is headquartered in New York, New York.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 5, 2025, the Company effected a reverse stock split at a ratio of one-for-thirty (the "Reverse Stock Split"). Pursuant to their terms, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all outstanding stock options and warrants, and the number of shares of the Company&#x2019;s common stock authorized for issuance pursuant to the Company&#x2019;s equity incentive plans was reduced proportionally. The Reverse Stock Split did not reduce the number of authorized shares of common stock and did not alter the par value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would have otherwise been entitled to receive a fractional share received a cash payment in lieu thereof. The Reverse Stock Split affected all stockholders proportionately and did not affect any stockholder&#x2019;s percentage ownership of the Company&#x2019;s common stock (except to the extent that the Reverse Stock Split resulted in any stockholder owning only a fractional share). All share and per share amounts of common stock disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis in all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, the Company has funded its operations primarily with proceeds from various public and private offerings of its common stock, preferred stock and warrants. The Company has incurred recurring losses and negative operating cash flows since its inception, including net losses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;151.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company continues to deploy cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility. These cash preservation measures may impact the Company's ability and the timing to execute its strategy. This includes the Company's ability to achieve the anticipated milestones and the timing of data releases and/or regulatory filings for its preclinical and clinical programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has not yet generated product sales and as a result has experienced operating losses since inception. The Company expects to incur additional losses in the future as it advances its product candidates through clinical trials, grows its clinical, regulatory and quality capabilities, and incurs costs associated with operating as a public company. The actual amount of cash that the Company will need to operate is subject to many factors. Based on the Company&#x2019;s business strategy, its existing cash of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2026 is not anticipated to fund the Company&#x2019;s projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company&#x2019;s ability to continue to operate as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company continues to maintain cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility. To continue to fund the operations of the Company beyond this time period, management has developed plans, which primarily consist of pipeline prioritization, raising additional capital through some combination of equity and/or debt offerings, including through ATM offerings and private placements of securities, and identifying strategic collaborations, licensing or other arrangements to support development of the Company&#x2019;s product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Company&#x2019;s private placement completed in December 2025, the Company may also be eligible to receive up to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in additional gross proceeds in exchange for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,579,706&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to the achievement of certain milestone-driven conditions related to preclinical data for the Company's CD19 targeting INB-619 product candidate. In addition, the Company may receive up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of proceeds from the exercise of its outstanding Series B ordinary warrants ("Series B warrants") if not otherwise redeemed by the Company and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from the exercise of its outstanding Series C common stock purchase warrants ("Series C warrants"). See Note 7, Warrants, for additional information. There is no assurance, however, that the Company will receive any additional proceeds or that any additional financing or any revenue-generating collaboration will be available when needed, that management of the Company will be able to obtain financing or enter into a collaboration on terms acceptable to the Company, or that any additional financing or revenue generated through third-party collaborations will be sufficient to fund the Company's operations through this time period. If additional capital is not available on a timely basis, or at all, the Company will have to significantly delay, scale back or discontinue its research and development programs. If the Company becomes unable to continue as a going concern, it may have to terminate its operations and dispose of its assets and might realize significantly less than the values at which they are carried on its financial statements. These actions may cause the Company&#x2019;s stockholders to lose all or part of their investment in the Company&#x2019;s common stock. The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_30289466-5d5a-4f6a-a4fe-1eb69daf93bc"
      decimals="-5"
      id="F_9ff58322-700b-4033-aafc-545a1a6ee4a3"
      unitRef="U_USD">-9900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_df7a4eb8-2669-4de2-88f2-acbd258098aa"
      decimals="-5"
      id="F_56695fc4-c12b-4b32-badc-a67731b8ed49"
      unitRef="U_USD">-10600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_8e7cb988-8a3c-49f0-9463-9aace8979b6d"
      decimals="-5"
      id="F_961f1d9a-0367-448f-baf0-569d3ecb6f99"
      unitRef="U_USD">151000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-5"
      id="F_ebca9c4b-6b31-46f4-9b68-138b094ad8e2"
      unitRef="U_USD">18000000</us-gaap:Cash>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba"
      decimals="-5"
      id="F_94e51cda-51e5-4906-9780-758bd2ed78a7"
      unitRef="U_USD">20100000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_e1d35277-d874-4b8a-81ba-2d210f518638"
      decimals="0"
      id="F_f05bd3fa-596a-4511-9e8b-b885fad6f662"
      unitRef="U_shares">14579706</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0e88d318-dcf6-40a9-820a-70d59c10d5b7"
      decimals="-5"
      id="F_b3b7dbcd-2e55-451c-859e-658f2bb57a8b"
      unitRef="U_USD">2300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_00c2fbee-81a5-4d69-b099-7ec1b71252fc"
      decimals="-5"
      id="F_f5e6c6f4-814b-4ee9-b5fa-c150305cb556"
      unitRef="U_USD">6700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_a0467b90-3771-46e8-a8cc-79faa93eaf9a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the notes thereto, are included in the Company&#x2019;s Annual Report on Form 10-K (the "Annual Report") that was filed with the Securities and Exchange Commission ("SEC") on March 12, 2026. Since the date of that filing, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States ("U.S. GAAP").&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto in the Annual Report. The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company&#x2019;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and the related valuation allowance, stock-based compensation, the useful lives of property and equipment and the valuation of warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash and restricted cash. All of the Company&#x2019;s cash and restricted cash is deposited in accounts with major financial institutions. Such deposits are in excess of the federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation and amortization of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s respective assets are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:78.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:55.128%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.564%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:38.462%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.564%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;The shorter of the useful life of the leasehold improvement or the remaining term of the lease&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated and amortized in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the condensed balance sheets and any gain or loss is reflected in the condensed statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Capitalized Software&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes the application development phase costs of internal use software in accordance with Accounting Standard Codification ("ASC") Topic 350-40, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangibles-Goodwill and Other-Internal Use Software&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Capitalized costs will be amortized on a straight-line basis over the estimated useful life of the asset upon completion.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker ("CODM") in deciding how to allocate resources and assess performance. The Company has one operating segment, which is the business focused on the discovery, development and commercialization of gamma-delta T cell product candidates and TCEs for cancer and autoimmune diseases. The CODM is the Company&#x2019;s Chief Executive Officer ("CEO"). The CEO manages the Company&#x2019;s operations, assesses performance for the operating segment and decides how to allocate resources based on net loss, which is reported on the condensed statements of operations. All of the Company&#x2019;s long-lived assets are held in the United States. For additional segment information, see Note 13, Segments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Standards Updates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has evaluated all issued and unadopted Accounting Standards Updates issued by the Financial Accounting Standards Board, and believes the adoption of these standards will not have a material impact on the condensed financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_3508b313-74c8-4c7c-9019-db3eca8a0d2a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the notes thereto, are included in the Company&#x2019;s Annual Report on Form 10-K (the "Annual Report") that was filed with the Securities and Exchange Commission ("SEC") on March 12, 2026. Since the date of that filing, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_6aaba374-4f77-4fca-956a-0692a6fefa9a">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States ("U.S. GAAP").&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <inab:UnauditedInterimFinancialInformationPolicyTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_88c6dcec-c9dc-431d-a8b6-795883d7604a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto in the Annual Report. The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company&#x2019;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.&lt;/span&gt;&lt;/p&gt;</inab:UnauditedInterimFinancialInformationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_8d18dfc8-bc58-4e88-8a4b-f101ced12518">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and the related valuation allowance, stock-based compensation, the useful lives of property and equipment and the valuation of warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_cae20a09-32d9-4ce9-869a-fcbec9b0103d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash and restricted cash. All of the Company&#x2019;s cash and restricted cash is deposited in accounts with major financial institutions. Such deposits are in excess of the federally insured limits.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_a1816cdc-ba63-4279-b877-3daed2b1be53">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation and amortization of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s respective assets are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:78.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:55.128%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.564%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:38.462%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.564%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;The shorter of the useful life of the leasehold improvement or the remaining term of the lease&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated and amortized in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the condensed balance sheets and any gain or loss is reflected in the condensed statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <inab:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_f4fcfe6c-f8d1-48ca-afbf-eb6bb10ddf6a">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s respective assets are as follows:&lt;/span&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:78.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:55.128%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.564%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:38.462%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.564%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #ffffff;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;The shorter of the useful life of the leasehold improvement or the remaining term of the lease&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated and amortized in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the condensed balance sheets and any gain or loss is reflected in the condensed statements of operations.&lt;/span&gt;&lt;/p&gt;</inab:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_2f17ba0a-7fb9-42d7-bb76-df75063b2d08"
      id="F_7d7987cf-75b1-4991-a59b-6b95205da6f9">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_19eea9f4-a3b3-4fe1-9029-8ab4452c1378"
      id="F_52900a44-ceaa-475b-993e-35d21e419f5a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_51057659-704a-481e-b321-6c1fd355a269"
      id="F_a9dc1164-7164-4770-8fc1-f61a47387a7d">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_68f1e9fb-5b0b-4695-96b7-d28a72a0181a"
      id="F_dd81fe11-73d7-45f5-9a5e-95e54f0d5ef5">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_8f180c2e-7e82-4af3-a57d-d41f0f8cbaf4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Capitalized Software&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes the application development phase costs of internal use software in accordance with Accounting Standard Codification ("ASC") Topic 350-40, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangibles-Goodwill and Other-Internal Use Software&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Capitalized costs will be amortized on a straight-line basis over the estimated useful life of the asset upon completion.&lt;/span&gt;&lt;/p&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_ace285e3-f97e-4e33-b550-d1642735d880">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker ("CODM") in deciding how to allocate resources and assess performance. The Company has one operating segment, which is the business focused on the discovery, development and commercialization of gamma-delta T cell product candidates and TCEs for cancer and autoimmune diseases. The CODM is the Company&#x2019;s Chief Executive Officer ("CEO"). The CEO manages the Company&#x2019;s operations, assesses performance for the operating segment and decides how to allocate resources based on net loss, which is reported on the condensed statements of operations. All of the Company&#x2019;s long-lived assets are held in the United States. For additional segment information, see Note 13, Segments.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_69e27fd7-dd97-494b-8d66-6b5146777e26">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Standards Updates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has evaluated all issued and unadopted Accounting Standards Updates issued by the Financial Accounting Standards Board, and believes the adoption of these standards will not have a material impact on the condensed financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_8d5a4c56-2076-4206-864d-d5ff5a310f76">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_95123818-1959-44ab-ac35-c31bb8f34b3f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_ac2217fd-a22a-4ac3-a769-d52030b4bff2"
      unitRef="U_USD">176000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_6a0b1dd2-da62-49e8-aa77-169346152ba9"
      unitRef="U_USD">529000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_33181561-c0b5-4dc6-b2ba-8bd1ac4450a0"
      unitRef="U_USD">364000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_dbd947f2-53d8-48d0-85fa-c7953fda102b"
      unitRef="U_USD">259000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_1947e260-c2ff-46f2-b56b-411083f979ae"
      unitRef="U_USD">540000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_890dcf8e-8fa0-49ce-be37-045d14e5e8cd"
      unitRef="U_USD">788000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_38582771-48ff-4496-a805-47b8713e7090">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the three months ended June 30, 2026 and 2025, respectively, and was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the six months ended June 30, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_f81bb26e-baa0-4277-a3a2-c28e2d03eacb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bdbee5c1-4fcd-4d7f-ba39-f1599229cc82"
      decimals="-3"
      id="F_93046344-385d-42df-b21b-80694ee8de0d"
      unitRef="U_USD">627000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a808f64c-72ae-4532-9ed3-19e39e466b41"
      decimals="-3"
      id="F_fe73853b-6a0b-481c-8555-60248e79a3a7"
      unitRef="U_USD">385000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2f17ba0a-7fb9-42d7-bb76-df75063b2d08"
      decimals="-3"
      id="F_8d7f7f14-e3f1-442c-9b67-41a001d3a0e6"
      unitRef="U_USD">402000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4c7d1dff-7913-4872-846a-511db2a788b0"
      decimals="-3"
      id="F_88fe1e8f-7f67-4bed-9c8b-e30461241efe"
      unitRef="U_USD">402000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4222be5a-0c57-4a3d-b834-e0e79efc53a5"
      decimals="-3"
      id="F_9fd80de3-2e00-4a84-bebf-8873f2f49f0f"
      unitRef="U_USD">346000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8f720d50-af6e-4211-a827-c117c09d5ba6"
      decimals="-3"
      id="F_37b1f684-4806-40b4-bf05-f311f9e3bda6"
      unitRef="U_USD">346000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a63f502f-f8b0-4607-a47f-5d8632401b59"
      decimals="-3"
      id="F_6df8c207-2db1-4993-bb40-affb5a0c188f"
      unitRef="U_USD">3924000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_55665991-ca2b-41b7-8b4e-3d3f94dda5c4"
      decimals="-3"
      id="F_c92bbcfc-a56e-4c31-bc06-3e0c6ef736ea"
      unitRef="U_USD">3924000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_8d5a18ef-d49e-405c-ad31-45f7deab52d0"
      unitRef="U_USD">3699000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_ef46f11c-52c8-4108-b7b4-01a3d8b7dba8"
      unitRef="U_USD">3199000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_f2e3fcd7-93e4-4d5c-a884-95fc40fd0380"
      unitRef="U_USD">1600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_827b1417-3519-45cb-ac09-af8abe10fe2d"
      unitRef="U_USD">1858000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-5"
      id="F_52b51922-9585-4a3d-bb3a-d114859a116f"
      unitRef="U_USD">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-5"
      id="F_97898c65-bdd3-42d3-9754-136c7a85057d"
      unitRef="U_USD">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-5"
      id="F_02ac2087-dee5-4c4d-a215-7471b49457cf"
      unitRef="U_USD">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-5"
      id="F_1e64b007-6800-4e74-8c9e-d5730d88c155"
      unitRef="U_USD">500000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_68e86610-bcdf-41fe-b9df-21636d86c080">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued legal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <inab:AccruedExpensesAndCurrentLiabilitiesTableTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_c69366d9-8f66-477b-884c-47a4c2816119">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued legal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</inab:AccruedExpensesAndCurrentLiabilitiesTableTextBlock>
    <inab:AccruedClinicalTrials
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_53d203f8-2742-494b-b928-9b198832a196"
      unitRef="U_USD">5000</inab:AccruedClinicalTrials>
    <inab:AccruedClinicalTrials
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_97556226-55c1-4a0c-839c-009bf88cbd6e"
      unitRef="U_USD">46000</inab:AccruedClinicalTrials>
    <inab:AccruedResearchAndDevelopment
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_26abe417-494b-4434-a390-948bd9738727"
      unitRef="U_USD">0</inab:AccruedResearchAndDevelopment>
    <inab:AccruedResearchAndDevelopment
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_247f28bc-6d4e-47a3-98c9-85c5f3940902"
      unitRef="U_USD">12000</inab:AccruedResearchAndDevelopment>
    <inab:AccruedCompensation
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_b02fd4a9-a7a8-4481-b491-7c1ae6405fa0"
      unitRef="U_USD">712000</inab:AccruedCompensation>
    <inab:AccruedCompensation
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_4520da88-7149-4622-8331-99d2b80f50bf"
      unitRef="U_USD">1305000</inab:AccruedCompensation>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_76659918-6a7f-4db6-b76f-a578471d8fd0"
      unitRef="U_USD">23000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_d6584b17-dbb3-47c6-a4f3-e6220785dff0"
      unitRef="U_USD">207000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_4b1c5308-6c85-43a5-aa9a-ff319ab1a69e"
      unitRef="U_USD">21000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_ebecfda4-6e2e-42c9-8a7d-019658ffedca"
      unitRef="U_USD">63000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_89142ffb-7e2a-41b6-9556-8e6ee7f0f925"
      unitRef="U_USD">761000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_eaf7525b-b3fe-4f1f-801f-16a326166929"
      unitRef="U_USD">1633000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_d4c67327-7595-45ee-820a-fd10e78a095a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. STOCKHOLDERS' EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s authorized capital stock consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, all with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;490,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares are designated as common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares are designated as preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ATM Facility&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 2022, the Company entered into a Controlled Equity Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; sales agreement with Cantor Fitzgerald &amp;amp; Co. ("Cantor Fitzgerald") and Truist Securities, Inc. ("Truist") under which Cantor Fitzgerald and Truist agreed to act as sales agents to sell shares of the Company&#x2019;s common stock, from time to time, in an at-the-market offering program. In March 2024, the Company delivered a termination notice to Truist, removing them as sales agent under the sales agreement, and on May 29, 2026, the Company and Cantor mutually agreed to terminate the sales agreement effective at the close of business on May 29, 2026.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2025, the Company filed a shelf registration statement on Form S-3 (File No. 333-291393) (the "Shelf Registration Statement") with the SEC, which became effective on May 20, 2026, which permits the issuance and sale by the Company of up to a maximum aggregate offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of its common stock, preferred stock, various series of debt securities, warrants to purchase common stock, preferred stock or debt securities, rights to purchase equity or debt securities, and/or units to purchase any combination of such securities. On June 1, 2026, the Company entered into a Capital on Demand&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Sales Agreement sales agreement, (the "Sales Agreement") with JonesTrading Institutional Services LLC ("JonesTrading") with respect to an at-the-market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, through or to JonesTrading (the &#x201c;ATM Program&#x201d;) pursuant to the Shelf Registration Statement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under current SEC regulations, if at any time the Company's public float is less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and for so long as the Company's public float remains less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, the amount the Company can raise through primary public offerings of securities in any 12-month period using shelf registration statements is limited to an aggregate of one-third of the Company's public float, which is referred to as the baby shelf rules. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company's calculated public float was less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,865,253&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, of its common stock under the ATM, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the six months ended June 30, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,032&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock under the ATM Program, resulting in net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;after deducting sales agent fees and other offering expenses. As of June 30, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million remained available for the sale of common stock under the ATM Program.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_f34c22e4-54b7-47e8-ab9f-0d6c7727157a"
      unitRef="U_shares">500000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="4"
      id="F_69e44533-bfc1-4910-90fe-111d91fd2687"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_87d5e39a-8367-481c-b7d8-dc1491c55a3b"
      unitRef="U_shares">490000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="INF"
      id="F_92c274f6-6227-4b99-8fc7-bf01f0f662a9"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_aa26e47b-c5bc-46bb-be5a-e667b328aaff"
      decimals="-5"
      id="F_9d155993-5e62-44b1-b02d-31ff1cd56b23"
      unitRef="U_USD">200000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <inab:PublicFloat
      contextRef="C_974cfe0d-089e-4c95-bae7-273d520e56db"
      decimals="-5"
      id="F_a3798c34-25c4-423b-b481-4932a6ff3929"
      unitRef="U_USD">75000000</inab:PublicFloat>
    <inab:PublicFloat
      contextRef="C_eee4484b-9c91-4075-99a6-ba3ae7b09a52"
      decimals="-5"
      id="F_5c318c74-6678-446f-b01c-0a3d03893172"
      unitRef="U_USD">75000000</inab:PublicFloat>
    <inab:PublicFloat
      contextRef="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba"
      decimals="-5"
      id="F_1943825e-5e05-4fb3-a9f3-33337f61545b"
      unitRef="U_USD">75000000</inab:PublicFloat>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_82df8d9b-ab44-4186-a2a5-46f09cf06bab"
      decimals="0"
      id="F_e45aa0f6-bfa3-4bb5-8232-635766bb6331"
      unitRef="U_shares">1865253</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_82df8d9b-ab44-4186-a2a5-46f09cf06bab"
      decimals="-5"
      id="F_13786172-0b5a-4b40-8ed1-d6cbbeb38b8c"
      unitRef="U_USD">8600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_d60a61e2-303c-4252-a580-f819f238b08c"
      decimals="0"
      id="F_feffedcc-ea01-4243-a87d-35573b99866d"
      unitRef="U_shares">6032</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_d60a61e2-303c-4252-a580-f819f238b08c"
      decimals="-3"
      id="F_0a10a3f5-522f-45c8-8a01-f3c03d8dffb9"
      unitRef="U_USD">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <inab:CommonStockAvailableForSaleAmount
      contextRef="C_c8b1b3b9-2703-4083-a3de-9b291dc7e209"
      decimals="-5"
      id="F_ddc5824a-4c78-4c07-98bd-24e7002e5da7"
      unitRef="U_USD">2800000</inab:CommonStockAvailableForSaleAmount>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_3dd6e3b8-f8c4-4555-a144-a987bdb05ee7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. WARRANTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Company issued pre-funded warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,141&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock ("2023 Pre-Funded Warrants"), &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;394,118&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series A warrants and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;394,118&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series B warrants in a private placement. The 2023 Pre-Funded Warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.003&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, are exercisable immediately and are exercisable until the 2023 Pre-Funded Warrant is exercised in full. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a 2023 Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the 2023 Pre-Funded Warrants terms. The 2023 Pre-Funded Warrants meet the criteria for permanent equity classification. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2026, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2023 Pre-Funded warrants issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Series A warrants were issued with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The Series A warrants were exercisable immediately. The Series A warrants meet the criteria for permanent equity classification.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the closing of the Company's private placement in October 2024, the Company amended certain of the Company&#x2019;s outstanding Series A warrants, representing approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;390,462&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, to (i) reduce the exercise price from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and (ii) extend the termination date of such Series A warrants to October 4, 2025. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2026, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;all Series A warrants have expired and there are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series A warrants outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Series B warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The Series B warrants are exercisable immediately and will expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 13, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Series B warrants allow the Company to redeem such warrants at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Series B warrant upon the Company&#x2019;s public announcement of its INB-100 data for all enrolled patients covering a period of at least 22 months, along with certain stock price and trading volume requirements. Holders of Series B warrants may choose to exercise such warrants at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share prior to such redemption. The Series B warrants meet the criteria for permanent equity classification. In April 2025, the Company entered into Amendment No. 1 to Securities Purchase Agreement (the "SPA Amendment") to amend the restrictions on certain equity sales by the Company set forth in the Securities Purchase Agreement, dated September 30, 2024, by and among the Company and the investors party thereto. In consideration for the SPA Amendment, the Company amended the Company's outstanding Series B warrants, representing approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303,574&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock, to (i) reduce the exercise price from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,964&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series B warrants were issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2024, the Company issued pre-funded warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188,227&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ("2024 Pre-Funded Warrants") and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,044,726&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series C warrants in a private placement. The 2024 Pre-Funded Warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.003&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, were exercisable immediately and are exercisable until the 2024 Pre-Funded Warrant is exercised in full. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a 2024 Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the 2024 Pre-Funded Warrants terms. The 2024 Pre-Funded Warrants meet the criteria for permanent equity classification. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,593&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2024 Pre-Funded Warrants were outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Series C warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The Series C warrants are exercisable immediately and will expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 4, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Series C warrants meet the criteria for permanent equity classification. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;828,863&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series C warrants were outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2025, the Company entered into privately negotiated letter agreements with certain holders of outstanding Series A warrants and Series B warrants (the "Participating Holders") to (i) exercise, for cash, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239,293&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series A warrants and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series B warrants for the purchase of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;310,696&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, in each case at a reduced exercise price of (a) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for Participating Holders who are directors or executive officers of the Company and (b) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for all other Participating Holders and (ii) exchange certain Series A warrants and Series B warrants for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,014&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants (the "Exchanged Pre-Funded Warrants"), in each case for a cash payment of (a) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per warrant share for Participating Holders who are directors or executive officers of the Company and (b) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per warrant share for all other Participating Holders (the "Warrant Exchanges"), for aggregate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Exchanged Pre-Funded Warrants issued in connection with the Warrant Exchanges have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.003&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. Each Exchanged Pre-Funded Warrant is exercisable immediately and will be exercisable until such Exchanged Pre-Funded Warrant is exercised in full. In lieu of a cash payment to the Company in payment of the aggregate exercise price upon exercise of an Exchanged Pre-Funded Warrant, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Exchanged Pre-Funded Warrants. Under the terms of the Exchanged Pre-Funded Warrants, the Company shall not effect the exercise of any portion of any Exchanged Pre-Funded Warrant, and a holder shall not have the right to exercise any portion of any Exchanged Pre-Funded Warrant, to the extent that after giving effect to such exercise, the holder (together with its affiliates and any other persons acting as a group together with the holder or any of its affiliates) would beneficially own in excess of 4.99% or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, as applicable, of the number of shares of common stock outstanding immediately after giving effect to such exercise. However, a holder may, upon written notice to the Company, increase or decrease such percentage to any other percentage not in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;provided that any increase or decrease in such percentage will not be effective until 61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;days &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;after such notice is delivered to the Company. The Exchanged Pre-Funded Warrants meet the criteria for permanent equity classification. As of June 30, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,732&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of these Exchanged Pre-Funded Warrants were outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2025, the Company issued pre-funded warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,452,677&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (the "2025 Pre-Funded Warrants") in a private placement. The 2025 Pre-Funded Warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, were exercisable immediately and are exercisable until the 2025 Pre-Funded Warrant is exercised in full. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a 2025 Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the 2025 Pre-Funded Warrants terms. The 2025 Pre-Funded Warrants meet the criteria for permanent equity classification. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,452,677&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2025 Pre-Funded Warrants were outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, we had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,620,002&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,964&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series B warrants, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;828,863&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series C warrants outstanding. Of these, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,452,677&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167,325&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.003&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The Series B warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and will expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 13, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Series C warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and will expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 4, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_59cd43a9-96e0-48e2-a9e4-f951fd28b4a7"
      decimals="0"
      id="F_3e44ed17-5973-4e0e-8bbf-b07085e0bf16"
      unitRef="U_shares">19141</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_4236eadf-0539-4ef9-8e90-18421e8dedb1"
      decimals="0"
      id="F_ca2c78f6-2147-464c-88ce-82d2089f4428"
      unitRef="U_shares">394118</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_8bad56db-9715-48c8-9c43-9f6171f27068"
      decimals="0"
      id="F_f0397698-0b0e-4cc7-ba91-108431627fd2"
      unitRef="U_shares">394118</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d1b51327-f920-40af-87a2-b87c1de36678"
      decimals="3"
      id="F_50d9bf0b-873c-4675-9b4f-567a156bfa7f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.003</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_bd29102c-0440-4bf5-9ff4-5120f836ab06"
      decimals="0"
      id="F_13823725-bad8-4539-9e81-09d1fbc198b3"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_bd29102c-0440-4bf5-9ff4-5120f836ab06"
      decimals="0"
      id="F_1b8a6626-ed60-46ac-8bb5-797d7c208ff6"
      unitRef="U_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3ef9e3d2-ac68-4df4-9377-90cb029dcf78"
      decimals="2"
      id="F_054ffa33-4fbc-45db-9e58-ee74e4e436ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">37.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inab:WarrantsModificationDescription
      contextRef="C_dc8de850-dafa-4740-ad94-9a138121ba04"
      id="F_67374f35-8310-4e07-b56b-401f67c54f20">In connection with the closing of the Company's private placement in October 2024, the Company amended certain of the Company&#x2019;s outstanding Series A warrants, representing approximately 390,462 shares of the Company&#x2019;s common stock, to (i) reduce the exercise price from $37.50 to $13.50 per share and (ii) extend the termination date of such Series A warrants to October 4, 2025.  </inab:WarrantsModificationDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_6422bdd1-8860-4052-ba54-1d6d60b3e10a"
      decimals="0"
      id="F_68a8df4a-e76d-4437-9578-040fa22ffadc"
      unitRef="U_shares">390462</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f7dd2334-9796-45e3-9723-b8b13243babf"
      decimals="2"
      id="F_004702e3-f0e7-4481-b160-b2930279a7ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">37.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_b8e4b9eb-c72b-49a4-a984-af719c089c73"
      decimals="2"
      id="F_377a1e4a-aa9e-4fe2-a2da-8d1b7cc26511"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_35e2df7a-828c-48a5-bbac-98bd4ed637bc"
      decimals="0"
      id="F_62574ba3-6938-498e-81ed-5e275d8b23f3"
      unitRef="U_shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d7b166d9-02a0-43d4-9686-85c3222aedbc"
      decimals="2"
      id="F_1df5a8c3-89fa-4564-a2a4-a23332f9a8d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_d7b166d9-02a0-43d4-9686-85c3222aedbc"
      id="F_8ff989d8-e34e-4ff4-ad49-fe50f56b6231">2028-12-13</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="C_14ed354b-9858-4395-9f4f-fe4f90a1c437"
      decimals="2"
      id="F_0c9411a7-7f75-4eb2-81c8-57db15ca5777"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.3</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d7b166d9-02a0-43d4-9686-85c3222aedbc"
      decimals="2"
      id="F_a7eb5346-e548-4867-82dc-45fdc2454dfd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_4e6b6762-f427-4f1a-938b-da78f831260d"
      decimals="0"
      id="F_f13d5eb5-8ccb-4c79-a29b-162d9337748c"
      unitRef="U_shares">303574</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2175d4db-6a33-4fb4-85e3-1bf2eeb93e8b"
      decimals="2"
      id="F_a227cc07-0d61-4119-9ee5-e3cdd0141fce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6719b59d-803e-4f87-b7ca-224b48a13129"
      decimals="2"
      id="F_5aa7b6fe-cc32-4569-a2ee-463acf44bc56"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_d7b166d9-02a0-43d4-9686-85c3222aedbc"
      decimals="0"
      id="F_85884a04-966c-4538-9fe6-e432e92227f3"
      unitRef="U_shares">166964</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_b5b1abb1-d97e-42f9-9b1f-61a28dbce843"
      decimals="0"
      id="F_893bcc25-8b84-4226-9cb3-accfa087e9a0"
      unitRef="U_shares">188227</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_cc023649-9aca-4bc0-a9c8-0b9537dfc5f6"
      decimals="0"
      id="F_d97d0a8b-f728-4693-8475-8cb63d859e52"
      unitRef="U_shares">1044726</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_141ba882-944c-447d-9a26-353741846e49"
      decimals="3"
      id="F_f7de3044-f41b-4059-9efc-008fab007fb0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.003</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_15a832e8-0165-4101-a163-3b54c4539b18"
      decimals="0"
      id="F_4e23412c-8a53-407e-b0d0-8dfa0434baf9"
      unitRef="U_shares">164593</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_aea50f9a-5f2f-47c2-a9b6-328cfc5db21b"
      decimals="2"
      id="F_e85ec157-b923-460f-ab77-89af9175b0d1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_aea50f9a-5f2f-47c2-a9b6-328cfc5db21b"
      id="F_950b7362-122a-4444-bdf6-691f11a8e5ef">2027-10-04</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_aea50f9a-5f2f-47c2-a9b6-328cfc5db21b"
      decimals="0"
      id="F_624fa7ba-c221-43c0-aeff-03ef040c3a9d"
      unitRef="U_shares">828863</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_4136a492-9cb7-4b0d-90cb-607bc2ed4239"
      decimals="0"
      id="F_1c5b81f4-1a1e-4d15-a438-a2607ace3aeb"
      unitRef="U_shares">239293</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_cdfcacfd-7d70-4257-9404-6c997e9aadc3"
      decimals="0"
      id="F_4538b386-a67a-4926-bc4d-39b58bcb815c"
      unitRef="U_shares">71403</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_13d21bb4-b59b-41aa-aa09-28b17f1305e4"
      decimals="0"
      id="F_e8174b09-15e3-42ca-8845-f8864f766662"
      unitRef="U_shares">310696</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_4136a492-9cb7-4b0d-90cb-607bc2ed4239"
      decimals="2"
      id="F_5cab3bc4-e4b5-4220-ad44-aca7cf4415f3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_cdfcacfd-7d70-4257-9404-6c997e9aadc3"
      decimals="2"
      id="F_139f7553-df71-429c-810d-507c27e7f6c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_6d0dc760-5d42-43c3-8497-ef5beb5bf865"
      decimals="0"
      id="F_46cfa69e-6b5f-4917-be5d-7644c37b7fcd"
      unitRef="U_shares">41014</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_4136a492-9cb7-4b0d-90cb-607bc2ed4239"
      decimals="2"
      id="F_d9078dc0-7a33-4050-9522-93e0159bddac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_cdfcacfd-7d70-4257-9404-6c997e9aadc3"
      decimals="2"
      id="F_6dea3769-fb9b-4ed8-854f-2366fdbca34d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_f400a42d-0c03-47f8-b36b-2ccfd408dc51"
      decimals="-5"
      id="F_61b6fc5e-a618-47d1-b9c3-4478ebbed8e7"
      unitRef="U_USD">1900000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6d0dc760-5d42-43c3-8497-ef5beb5bf865"
      decimals="3"
      id="F_e7c87fa6-8c49-4ce3-99d0-eef8a2a791bf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.003</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inab:AffiliatesPercentageOfWarrants
      contextRef="C_f400a42d-0c03-47f8-b36b-2ccfd408dc51"
      decimals="4"
      id="F_096aed0e-566f-4dc7-bc87-6e57de0ac443"
      unitRef="U_pure">0.0999</inab:AffiliatesPercentageOfWarrants>
    <inab:IncreaseOrDecreasePercentageOfWarrants
      contextRef="C_f400a42d-0c03-47f8-b36b-2ccfd408dc51"
      decimals="4"
      id="F_43cfd6ce-4184-40ef-b521-0bb74dd26b51"
      unitRef="U_pure">0.1999</inab:IncreaseOrDecreasePercentageOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_ade5bfd8-e223-4fa2-b9eb-073902595766"
      decimals="0"
      id="F_fbe64545-ce84-4745-a0a5-b692aa438f51"
      unitRef="U_shares">2732</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_875d9953-bc37-4aec-b5bd-7626c7b4a282"
      decimals="0"
      id="F_33ec9f4d-7a39-4abe-a287-50ca1170f7aa"
      unitRef="U_shares">9452677</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_875d9953-bc37-4aec-b5bd-7626c7b4a282"
      decimals="4"
      id="F_8a554132-7b41-4480-9f2e-c1b6730c0c79"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_615b0689-2e71-471d-b476-8b5d53cc4a55"
      decimals="0"
      id="F_1225ddf3-2e6e-4c5f-b55b-86b36561f2e4"
      unitRef="U_shares">9452677</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_e34a25b4-4b7a-448a-bf63-cb6e13b70301"
      decimals="0"
      id="F_618ea081-3cf2-4bf5-a5b2-f766e5490fab"
      unitRef="U_shares">9620002</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_dff100d2-ec00-417b-a887-37746b72d7f8"
      decimals="0"
      id="F_2c2d9125-3e18-4c78-b85c-85885b6e3cb4"
      unitRef="U_shares">166964</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_5ff0bb53-9ba3-44b1-99fb-5976079d7285"
      decimals="0"
      id="F_deeaeefb-9608-4301-aaec-5753a69f100e"
      unitRef="U_shares">828863</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_86e4d9d6-3ea9-4abe-9133-f643a5892564"
      decimals="0"
      id="F_d80babcc-bb6b-45b8-a3a3-8c4d5b6199c1"
      unitRef="U_shares">9452677</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d9315813-0e95-4466-96f4-8eb12df54e55"
      decimals="4"
      id="F_dab116c6-2d41-4661-9af0-5f9c8b779f43"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_919d5a0e-62fb-40f3-a669-87d5a9aef2e1"
      decimals="0"
      id="F_a99f317a-66d7-4902-9f3a-7724570ff61d"
      unitRef="U_shares">167325</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e34a25b4-4b7a-448a-bf63-cb6e13b70301"
      decimals="3"
      id="F_56043a2f-6918-4f94-869e-9dc8fc6db41d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.003</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_dff100d2-ec00-417b-a887-37746b72d7f8"
      decimals="2"
      id="F_d5a98247-8403-4f40-ac1c-d56471cc32ef"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_dff100d2-ec00-417b-a887-37746b72d7f8"
      id="F_04bfce91-4e3f-47bc-a7b8-031fc9c981b1">2028-12-13</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5ff0bb53-9ba3-44b1-99fb-5976079d7285"
      decimals="2"
      id="F_50ee5fa6-4108-4e71-94d9-bbd37d06456d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_5ff0bb53-9ba3-44b1-99fb-5976079d7285"
      id="F_4be08ad5-a70b-4abf-8352-0ede874ddf81">2027-10-04</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_e615e071-6455-455e-9ec9-1272ba07bf63">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. STOCK-BASED COMPENSATION&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 7, 2018, the Company established and adopted the 2018 Equity Incentive Plan (the "2018 Plan") providing for the granting of stock awards for employees, directors and consultants to purchase shares of the Company&#x2019;s common stock. Upon the effectiveness of the 2020 Plan (as defined below), the 2018 Plan was terminated and no further issuances were made under the 2018 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2018 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2020 Equity Incentive Plan (the "2020 Plan") was approved by the Company's Board of Directors and the Company&#x2019;s stockholders and became effective on July 29, 2021. Upon the effectiveness of the 2023 Plan (as defined below), the 2020 Plan was terminated and no further issuances were made under the 2020 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Amended and Restated 2023 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Amended and Restated 2023 Equity Incentive Plan (the "2023 Plan") was approved by the Company's Board of Directors and the Company&#x2019;s stockholders and became effective on June 15, 2023. Upon the effectiveness of the 2026 Plan (as defined below), the 2023 Plan was terminated and no further issuances were made under the 2023 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2023 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Amended and Restated 2026 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Amended and Restated 2026 Equity Incentive Plan (the "2026 Plan") was approved by the Company's Board of Directors and the Company&#x2019;s stockholders and became effective on May 7, 2026. The Board of Directors, or a committee thereof, is authorized to administer the 2026 Plan. The 2026 Plan provides for the grant of Incentive Stock Options ("ISO") within the meaning of Section 422 of the Internal Revenue Code of 1986 as amended, to employees, and for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to the Company&#x2019;s employees, directors and consultants and any Company affiliates&#x2019; employees and consultants. The number of shares initially reserved for issuance under the 2026 Plan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,054,937&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which automatically increases on January 1 of each year for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; commencing on January 1, 2027 and ending on (and including) January 1, 2037, in an amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of common stock, plus the total number of shares of common stock issuable upon settlement of pre-funded warrants (if any), in each case, outstanding on December 31 of the preceding year, or a lesser number of shares determined by the Board of Directors no later than the last day of the immediately preceding year. The maximum number of shares of common stock that may be issued upon the exercise of ISOs under the 2026 Plan is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2026, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,474,975&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were available for grant pursuant to the 2026 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2020 Employee Stock Purchase Plan (the "2020 ESPP") was approved by the Board of Directors and the Company&#x2019;s stockholders and became effective on July 29, 2021. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,666&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were initially reserved for issuance under this plan, which automatically increases on January 1 of each year by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the outstanding number of shares of common stock on the immediately preceding December 31; and (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,333&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or such lesser number of shares as determined by the Board of Directors. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock had been issued under the ESPP and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,260&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;remained available for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;future &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;issuance under the ESPP. The Board of Directors or designated committee has not set an offering period and the Board of Directors elected not to increase the number of shares of common stock reserved for future issuance under the ESPP as of January 1, 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is a summary of the stock option award activity during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2026:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:49.59%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.602%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.962%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.602%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.142000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number&lt;br/&gt;of Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;502,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,083,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at June 30, 2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,579,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.85&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at June 30, 2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;415,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.72&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options expected to vest as of June 30, 2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,164,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value of options granted during the six months ended June 30, 2026 and 2025 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;1.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. The aggregate intrinsic value is calculated as the difference between the exercise price and the market price of the Company&#x2019;s common stock at June 30, 2026 and December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the six months ended June 30, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the assumptions and the Company&#x2019;s methodology for developing each of the assumptions used: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.663%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102.98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96.66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; 6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Volatility&#x2014;The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of comparable public companies over the expected term. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Expected life&#x2014;The expected term represents the period that the Company&#x2019;s stock option grants are expected to be outstanding. The expected term of the options granted to employees and non-employee directors by the Company has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&#x2014;The risk-free rate for periods within the estimated life of the stock award is based on the U.S. Treasury yield curve in effect at the time of grant. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Dividend rate&#x2014;The assumed dividend yield is based upon the Company&#x2019;s expectation of not paying dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2026 and 2025 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; related tax benefits from stock-based compensation expense were recognized for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2026 and 2025. As of June 30, 2026, there was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2b8acd72-67e8-49aa-b360-6976c9610ae0"
      decimals="0"
      id="F_d74714d8-09ee-4c92-91c0-4a672cb0c2bf"
      unitRef="U_shares">4054937</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <inab:SharesReservedOfIssuanceUnderPlanIncreaseDuration
      contextRef="C_d465b573-e7bb-4e0a-993f-63f0094f2438"
      id="F_f22efa26-79c4-4757-94dc-2653dc44d25e">P10Y</inab:SharesReservedOfIssuanceUnderPlanIncreaseDuration>
    <inab:PercentageOfTotalNumberOfSharesOfCommonStockOutstanding
      contextRef="C_d465b573-e7bb-4e0a-993f-63f0094f2438"
      decimals="2"
      id="F_6a16f16c-4a55-46a6-92d0-9d7a1e1e4460"
      unitRef="U_pure">0.05</inab:PercentageOfTotalNumberOfSharesOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6512d216-0c5d-4efe-bd6d-d941a05aec24"
      decimals="-6"
      id="F_501eee3f-5183-40a8-99e0-174469356c24"
      unitRef="U_shares">20000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_d6a03d66-c6db-44b9-acc8-f36f9f7a7dd0"
      decimals="0"
      id="F_c5e99b41-017c-4359-991e-6945031f9f52"
      unitRef="U_shares">2474975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ef18a21f-14bd-4046-a4f2-3da805a9ad98"
      decimals="0"
      id="F_5b13a8dc-710b-4696-959b-a9f4bda94394"
      unitRef="U_shares">6666</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <inab:PercentageOfTotalNumberOfSharesOfCommonStockOutstanding
      contextRef="C_b52b4906-2f95-41dc-9fd6-f217e9324069"
      decimals="2"
      id="F_e45af353-542a-4e04-8ac6-7c8704ca5901"
      unitRef="U_pure">0.01</inab:PercentageOfTotalNumberOfSharesOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="0"
      id="F_7f833b89-53cf-4300-8abe-32772e2c7c09"
      unitRef="U_shares">13333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_ab1c1654-f49e-44dd-932a-984720cd913c"
      decimals="0"
      id="F_34a82ea7-7082-4023-8c24-fe1eebde8b2b"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2c0017d1-6285-4171-90ff-3fa0920d4f40"
      decimals="0"
      id="F_2d5b2b12-5b5e-4cbc-b132-943640f53622"
      unitRef="U_shares">26260</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_54a8bdda-9a7d-450b-99a0-f42dff6e45b3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is a summary of the stock option award activity during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2026:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:49.59%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.602%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.962%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.602%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.142000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number&lt;br/&gt;of Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;502,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,083,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at June 30, 2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,579,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.85&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at June 30, 2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;415,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.72&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options expected to vest as of June 30, 2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,164,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="0"
      id="F_2abef2cf-edbd-4b7e-99b8-785ed22e9088"
      unitRef="U_shares">502027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="2"
      id="F_68f439c8-921b-455d-bdd5-a8749d70a406"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">50.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_3eba5499-8b2d-4237-9df4-85ecab51e9df"
      id="F_f3379405-ff24-4c16-84b1-b506c04a5cd2">P8Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_5aedac8f-e138-47d1-88fb-74d7d9c0feca"
      decimals="-3"
      id="F_d010aa1a-5f94-4ab1-bf0f-2b4c7beeda65"
      unitRef="U_USD">41000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="0"
      id="F_05d89429-1766-4084-9020-91eed4facc11"
      unitRef="U_shares">1083658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="2"
      id="F_10081257-7acc-4f8d-9634-6b53fcdf5cf1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="0"
      id="F_7b10f16d-c765-4927-a29f-b05f6619ee0e"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="0"
      id="F_d715bcba-d3b4-4354-bfc4-ef82dbe1a575"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="0"
      id="F_12c18285-bc2e-40a1-9327-184f425789b6"
      unitRef="U_shares">5723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="2"
      id="F_1a4f0500-0704-4388-af76-ed10a6038472"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="0"
      id="F_3946c90c-d421-400e-b189-572abf70944d"
      unitRef="U_shares">1579962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="2"
      id="F_be47c4ac-fbd8-4ef9-b0ee-99561f36f18f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_97a62b08-e69d-49f3-a8a7-b2ae7211c5d3">P8Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_8ce5cd43-e704-4a6a-b335-a238482fed9a"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="0"
      id="F_e629313c-c2f2-44e4-9750-8f78e1456fce"
      unitRef="U_shares">415044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="2"
      id="F_d78c0ada-37c7-4207-82a3-2b06aa86417e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">56.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_cc89537a-a754-4fff-a32a-6c3477c6e80b">P6Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_e9d94523-fe02-4fdf-8a08-f4cc73e9a93e"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="0"
      id="F_a8198ade-8c9f-475b-aeb4-58651b071e1a"
      unitRef="U_shares">1164918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="2"
      id="F_d0a5c621-aabe-4af9-abd8-90c53b742bc6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_2b8d22ad-bc61-47de-aa0d-dbe2c2725c8f">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_dc666dc7-692f-4604-9b5f-b3b787c68d2b"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="2"
      id="F_cf1d001c-8f99-492f-a365-741e35d15a25"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="2"
      id="F_d09c0b9e-5072-4927-8bae-e6ebde43b944"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_2b04697a-095e-409c-be01-475f18e5f259">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the assumptions and the Company&#x2019;s methodology for developing each of the assumptions used: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.663%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102.98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96.66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; 6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_882fd2d9-5d3b-4094-8326-9d116fa514c2"
      decimals="4"
      id="F_4cdd666a-f54a-4032-ad5f-dc7fe2bef4a0"
      unitRef="U_pure">1.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba"
      decimals="4"
      id="F_b3fee29e-c6e8-4288-8961-8d829e5b2002"
      unitRef="U_pure">1.0298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_acfff60e-a022-428e-8f12-c565b3924d5e"
      decimals="4"
      id="F_0fe0dfa3-4d87-48db-a3b5-e29319600348"
      unitRef="U_pure">0.9666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_e699a5d1-4c74-4461-a49a-dd3300a4a440"
      decimals="4"
      id="F_e9f0bfd1-5689-4192-b89f-56bbaaa8b8df"
      unitRef="U_pure">0.9924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_882fd2d9-5d3b-4094-8326-9d116fa514c2"
      id="F_3342540c-f28e-4b90-a13b-0eeca16f06af">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba"
      id="F_d013f505-413b-44fb-b40a-fd57e2941f8b">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_acfff60e-a022-428e-8f12-c565b3924d5e"
      id="F_bc60455e-1188-45e3-ae71-73150f254d9c">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e699a5d1-4c74-4461-a49a-dd3300a4a440"
      id="F_c66ff5ab-ebe3-4ba5-b14f-62da6d5783cd">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_882fd2d9-5d3b-4094-8326-9d116fa514c2"
      decimals="4"
      id="F_4d9ae34e-d6ad-485f-a668-0547e42902ca"
      unitRef="U_pure">0.0383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_e18de340-3840-49e9-a880-e2fa0ca3b8ba"
      decimals="4"
      id="F_9d06462f-f383-4fba-bce3-328b94dcc28e"
      unitRef="U_pure">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_acfff60e-a022-428e-8f12-c565b3924d5e"
      decimals="4"
      id="F_f3268d71-311c-474a-b92a-9e7377fb8f78"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_e699a5d1-4c74-4461-a49a-dd3300a4a440"
      decimals="4"
      id="F_1b46a14d-2cbe-43d1-915b-87de56c2d7ad"
      unitRef="U_pure">0.0424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="2"
      id="F_9d83024d-c50a-4165-a5b8-b71c1e866bed"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="2"
      id="F_440f8909-ee01-4c44-bfc3-86e8f516c455"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_51539bac-c85c-4b73-b3a0-61c5d3a1c2d5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2026 and 2025 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_722ff75a-27ec-4522-80bd-b43a8403d7ca"
      decimals="-3"
      id="F_2b56d92f-660d-4dad-99e1-fc70c3f4c6ff"
      unitRef="U_USD">131000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_95149714-844a-412e-967f-b79e9e655892"
      decimals="-3"
      id="F_13f99873-5336-4faa-b18e-bef35c31733b"
      unitRef="U_USD">298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_23c7fe2f-970c-4999-b6a8-53f62effb0b9"
      decimals="-3"
      id="F_789b6be5-f58e-4ef6-8b38-9ad70de6b9e5"
      unitRef="U_USD">298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d4c94038-e53d-43c3-abc6-12d9c67c6468"
      decimals="-3"
      id="F_49cfd92e-3634-48c4-a0e1-168b51d77796"
      unitRef="U_USD">584000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e7dbcb37-cd29-432c-9337-b9e4bc5c8fbd"
      decimals="-3"
      id="F_6bc6d3ec-5475-4819-97f1-6b0197d258ef"
      unitRef="U_USD">221000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_848a1210-eb49-4891-935b-80b8db44acbb"
      decimals="-3"
      id="F_aaee0c4e-6263-4c0e-bb8e-8652336a8893"
      unitRef="U_USD">657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_def65cee-ee7e-4161-a3b8-a9cb4d0e2897"
      decimals="-3"
      id="F_5debe02c-5e10-469b-b0ee-98b9fa42f9c8"
      unitRef="U_USD">455000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b0893cee-3d08-4109-a7b3-cdad0a9d269d"
      decimals="-3"
      id="F_ca37ccac-4fcc-4cb4-821f-2613e1516bb4"
      unitRef="U_USD">1202000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_a507d613-dd81-4cc7-ad79-c3c979687720"
      unitRef="U_USD">352000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_bd85df66-0d82-449c-85b5-5e9bc6d738dd"
      unitRef="U_USD">955000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_8c6e9c17-62d8-48e7-a7b1-1e047e2f3336"
      unitRef="U_USD">753000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_c61326df-478e-4a05-81c2-aa9beec9548d"
      unitRef="U_USD">1786000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-6"
      id="F_ea52ecff-14a8-4ccd-a5e4-4ff014707922"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-6"
      id="F_d3ee543a-da96-4f67-bdff-ba5ca42f32f5"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-6"
      id="F_3d84bf0d-46f5-425c-81aa-f4158af930ab"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-6"
      id="F_05b708a0-aaa8-497b-87f9-01108adce726"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_2af03440-5a2f-4e6d-b44b-a6ccc55a7aa3"
      decimals="-5"
      id="F_d5998282-ad36-4be4-885c-d7902b66488c"
      unitRef="U_USD">2700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_a6750676-d94d-4f09-8595-41d7d93d8ab1">P2Y3M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_72ec421d-2e46-443c-a2dc-87cace6e8a99">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. LICENSE AGREEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Emory University, Children&#x2019;s Healthcare of Atlanta, Inc. and UAB Research Foundation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2016, the Company entered into an exclusive license agreement with Emory University, Children&#x2019;s Healthcare of Atlanta, Inc. and UAB Research Foundation ("UABRF"), as amended from time to time (the "Emory License Agreement"). The Emory License Agreement was amended in October 2017 and July 2020. Under the Emory License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy related patents and know-how related to gamma-delta T cells developed by Emory University, Children&#x2019;s Healthcare of Atlanta, Inc. and UABRF&#x2019;s affiliate, the University of Alabama at Birmingham, to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents or otherwise incorporate or use the licensed technology. Such exclusive license is subject to certain rights retained by these institutions and also the U.S. government.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In consideration of the license granted under the Emory License Agreement, the Company paid Emory University a nominal upfront payment. Between March 2017 and August 2020, the Company issued UABRF an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,046&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock in satisfaction of these antidilution rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company is required to pay Emory University development milestones totaling up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, low-single-digit to mid-single-digit tiered running royalties on the net sales of the licensed products, including an annual minimum royalty beginning on a specified period after the first sale of a licensed product, and a share of certain payments that the Company may receive from sublicenses. In addition, in the event no milestone payments have been paid in certain years, the Company will be required to pay an annual license maintenance fee. The Emory License Agreement also requires the Company to reimburse Emory University for the cost of the prosecution and maintenance of the licensed patents. Pursuant to the Emory License Agreement, the Company is required to use its best efforts to develop, manufacture and commercialize the licensed product, and is obligated to meet certain specified deadlines in the development of the licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company may terminate the Emory License Agreement at will at any time upon prior written notice to Emory University. Emory University has the right to terminate the Emory License Agreement if the Company materially breaches the agreement (including failure to meet diligence obligations) and fails to cure such breach within a specified cure period, if the Company becomes bankrupt or insolvent or decides to cease development and commercialization of the licensed product, or if the Company challenges the validity or enforceability of any licensed patents.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Exclusive License Agreement with UABRF&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2016, the Company entered into an exclusive license agreement with UABRF, as amended from time to time (the "UABRF License Agreement"). The Company amended the UABRF License Agreement in December 2016, January 2017, June 2017 and November 2018. Under the UABRF License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy-related patents related to the use of gamma-delta T cells, certain CAR-T cells and combination treatments for cellular therapies developed by the University of Alabama at Birmingham and owned by UABRF to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents. Such exclusive license is subject to certain rights retained by UABRF and also the U.S. government.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In consideration of the license granted under the UABRF License Agreement, the Company paid UABRF a nominal upfront payment and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,041&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock to UABRF, which were subject to certain antidilution rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company is required to pay UABRF development milestones totaling up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, lump-sum royalties on cumulative net sales totaling up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, mid-single-digit running royalties on net sales of the licensed products, low-single-digit running royalties on net sales of the licensed products, and a share of certain non-royalty income that the Company may receive, including from any sublicenses. The UABRF License Agreement also requires the Company to reimburse UABRF for the cost of the prosecution and maintenance of the licensed patents.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the UABRF License Agreement, the Company is required to use good faith reasonable commercial efforts to develop, manufacture and commercialize the licensed product.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The term of the UABRF License Agreement will continue until the expiration of the licensed patents. The Company may terminate the UABRF License Agreement at will at any time upon prior written notice to UABRF. UABRF has the right to terminate the UABRF License Agreement if the Company materially breaches the agreement and fails to cure such breach within a specified cure period, if the Company fails to diligently undertake development and commercialization activities as set forth in the development and commercialization plan, if the Company underreports its payment obligations or underpays by more than a specified threshold, if the Company challenges the validity or enforceability of any licensed patents, or if the Company becomes bankrupt or insolvent.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_35dd4b27-e1ca-484c-8fc2-9fea1443f2b0"
      decimals="0"
      id="F_d0a874b6-37de-4e01-b14f-505321c6fd7f"
      unitRef="U_shares">5046</us-gaap:CommonStockSharesIssued>
    <inab:MilestonePayment
      contextRef="C_8cdfe491-a6d3-4390-9fa9-14cf4c1ff8ce"
      decimals="-5"
      id="F_05daf15c-36da-45e0-a3d7-21b55efd64a2"
      unitRef="U_USD">1400000</inab:MilestonePayment>
    <inab:LicenseAgreementDescription
      contextRef="C_41f9322c-2c47-48ad-880f-4d68924f360c"
      id="F_623a5a6f-2104-430a-a731-97e46491496f">The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later.</inab:LicenseAgreementDescription>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_652cd561-42c7-41d5-a3df-59ea80bfee2e"
      decimals="0"
      id="F_3fc9e4ba-9d0a-41e2-b52e-d3317d4693d8"
      unitRef="U_shares">3041</us-gaap:CommonStockSharesIssued>
    <inab:MilestonePayment
      contextRef="C_8cdfe491-a6d3-4390-9fa9-14cf4c1ff8ce"
      decimals="-5"
      id="F_9ee423b8-b8e2-4cab-9926-609892b8db80"
      unitRef="U_USD">1400000</inab:MilestonePayment>
    <inab:RoyaltiesOnCumulativeNetSales
      contextRef="C_3308162f-a2dc-4d95-879d-976b215e5b9d"
      decimals="-5"
      id="F_1d0cac4f-05cf-439a-972b-aab730bcc8fb"
      unitRef="U_USD">22500000</inab:RoyaltiesOnCumulativeNetSales>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_2efa0864-c1fe-4c88-9327-21f52ae89f49">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. NET LOSS PER SHARE&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of pre-funded warrants to purchase shares of common stock. Diluted net loss per share is the same as basic net loss per share for the periods presented since the effects of potentially dilutive securities are antidilutive given the net loss of the Company.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:48.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average number of shares used in computing net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,467,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,119,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,468,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,920,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.09%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.658%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,338,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;504,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,073,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;482,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series B warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;333,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;363,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series C warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;828,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;997,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;828,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,008,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,334,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,052,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,069,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,159,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-5"
      id="F_3d87c7f6-d7bc-4627-82a0-2e411bf4d562"
      unitRef="U_shares">9600000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_6381d6fa-f9ad-467e-86f5-010d3ae9b951">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:48.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average number of shares used in computing net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,467,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,119,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,468,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,920,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_50d31e98-ca69-46df-9d62-494782021f65"
      unitRef="U_USD">-4781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_126a80f9-21c0-4a13-844d-0e4866a9f1a9"
      unitRef="U_USD">-5094000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_a4f004d5-9302-462b-b630-64a4d812676c"
      unitRef="U_USD">-9871000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_52c33009-4b63-401e-8713-24a706dc774b"
      unitRef="U_USD">-10644000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="2"
      id="F_097afcae-8c94-4167-b02c-a2a0d594ed10"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="2"
      id="F_f4146884-2498-4c1d-8b7b-a00908e7772c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="2"
      id="F_e345aa2a-9a40-4360-bbf3-feecfeeb494e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="2"
      id="F_84659dd3-9ae7-4065-b776-c069ffa73469"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="2"
      id="F_e726509f-4849-4136-84d9-2399cf7f1433"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="2"
      id="F_8192b35c-cc08-4dbe-8636-09f6b296bf88"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="2"
      id="F_ae955c4a-62b7-47e2-8931-cedbf4641f79"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="2"
      id="F_ef3abf66-1b81-48b9-8d8a-451a9317b4e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="INF"
      id="F_6ff5b286-43f7-4f70-9ac7-7f8f3bc0d075"
      unitRef="U_shares">19467091</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="INF"
      id="F_55feb1e3-0a9f-4a8c-af41-dc6a059dd8b4"
      unitRef="U_shares">19467091</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="INF"
      id="F_d03d4b67-b91c-4bf1-bd94-4af17bcb12cc"
      unitRef="U_shares">4119153</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="INF"
      id="F_198ea69f-07e9-469d-92b4-436d10512c7b"
      unitRef="U_shares">4119153</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="INF"
      id="F_6df24eb3-6104-4618-b5a8-655c19a312fb"
      unitRef="U_shares">19468087</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="INF"
      id="F_b42ca94f-c8fd-4d99-b6be-086c55e491b2"
      unitRef="U_shares">19468087</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="INF"
      id="F_9dfe37bf-798e-4397-8b5a-c0a10c4f6664"
      unitRef="U_shares">2920157</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="INF"
      id="F_942a82ea-d13b-42a0-b617-6a0e45409840"
      unitRef="U_shares">2920157</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_4cf270ee-4a4c-45c0-9ad5-bc9e690d2506">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.09%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.658%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,338,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;504,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,073,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;482,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series B warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;333,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;363,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series C warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;828,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;997,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;828,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,008,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,334,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,052,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,069,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,159,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d253db46-30ee-4977-a335-6cf4430b34fa"
      decimals="0"
      id="F_01f9020c-4c44-41e2-a041-12dd4de08ab9"
      unitRef="U_shares">1338242</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_71b5319c-c74f-48c0-b513-7d988c5197cd"
      decimals="0"
      id="F_d9acd1a6-f2fd-4a14-ac83-304f0ec87e43"
      unitRef="U_shares">504132</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_38b6bbc9-cfd4-42cc-abf5-b90814c910dd"
      decimals="0"
      id="F_4d0fd327-b7bd-4256-9bc1-a9deffbcbb7d"
      unitRef="U_shares">1073566</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_19bfb4fa-92ca-4246-b1e1-4e59f4934b59"
      decimals="0"
      id="F_44984662-311f-42df-bda7-035e8e325a2b"
      unitRef="U_shares">482622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e59a07f5-ac54-4de1-8e72-5db165f3214b"
      decimals="0"
      id="F_2fc7caee-c200-4489-9232-83a55332c2ee"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3a6247f8-75f6-40db-a461-ec966fedb821"
      decimals="0"
      id="F_278c960a-b274-47fe-84da-1658ed98c005"
      unitRef="U_shares">217793</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_810c253b-a933-4a17-9491-34d6f79e7d1e"
      decimals="0"
      id="F_f92020ce-a0a5-4b98-9b63-007b5b8aaeae"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d771653f-d6e1-42de-90fd-133dbbf26d13"
      decimals="0"
      id="F_f3389141-0b14-4e60-9723-21050e424efc"
      unitRef="U_shares">305137</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d4f58c1a-28e8-4e00-ac1b-fdb6c3f10ee4"
      decimals="0"
      id="F_9be60f14-3787-4ee8-a5de-6a8a0cc4c6bd"
      unitRef="U_shares">166964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b28d3e5d-1b32-48f8-88d7-6fb7eab46cd1"
      decimals="0"
      id="F_832c4aa0-e200-4b3e-bc60-305ed411d558"
      unitRef="U_shares">333424</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6d2dbaaf-c0a6-4697-b08e-5a209319a860"
      decimals="0"
      id="F_dd801ad2-fd3d-4212-9954-c08cc7f82e5e"
      unitRef="U_shares">166964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_96ec57a8-e87b-4138-894b-a4270326d386"
      decimals="0"
      id="F_3f5d0756-f352-4717-844b-67dd7743767b"
      unitRef="U_shares">363603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_50d59e7d-433d-43f6-a235-2ab99ee775ac"
      decimals="0"
      id="F_2eb48a6c-9bab-4d20-9a22-cf50d6d45fee"
      unitRef="U_shares">828863</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e92bc1aa-c2db-46f5-9911-334ad58821cb"
      decimals="0"
      id="F_d5d1b050-8b46-41a2-b5e9-e17c9fbd9dce"
      unitRef="U_shares">997638</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bc76b556-a6fe-4d1d-ae30-4ebf8174f5cf"
      decimals="0"
      id="F_a2ad3c0d-50a4-4024-9bdf-6c2d635781ba"
      unitRef="U_shares">828863</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6f940d37-a954-49ae-b661-7826cc32ebbc"
      decimals="0"
      id="F_b9dec17c-2624-4066-a02c-97d99efadc0b"
      unitRef="U_shares">1008304</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="0"
      id="F_f900f740-b5db-42d9-9fc7-430c154a1179"
      unitRef="U_shares">2334069</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="0"
      id="F_275bb2a4-b751-436f-827b-c9c93966fca1"
      unitRef="U_shares">2052987</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="0"
      id="F_6549dd51-cbff-4c49-8928-135e310b3e67"
      unitRef="U_shares">2069393</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="0"
      id="F_4206596e-cec9-4ad8-8db0-691de0afdf04"
      unitRef="U_shares">2159666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_44c3dba2-ff78-4041-9556-31c7342828dc">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intellectual Property&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has existing commitments to the licensors of the intellectual property which the Company has licensed. These commitments are based upon certain clinical research, regulatory, financial and sales milestones being achieved. Additionally, the Company is obligated to pay a single-digit royalty on commercial sales on a global basis of licensed products under the Emory License Agreement and the UABRF License Agreement. The royalty term is the later of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years from first commercial sale or expiration of the last-to-expire component of the licensed intellectual property.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred costs related to such legal proceedings.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <inab:RoyaltyTerm
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_5cf394f4-412f-4e64-ac62-7add59661d5a">P15Y</inab:RoyaltyTerm>
    <inab:LeaseOfLesseeDisclosureTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_b8e30786-cdd0-4a18-8ba6-d172a0954554">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12.  EQUIPMENT AND Facility LEASES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has historically entered into lease arrangements for its facilities. As of June 30, 2026, the Company had four operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective date. The Company&#x2019;s leases generally do not include termination or purchase options.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company entered into an agreement with an equipment leasing company in 2018, which provided up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for equipment purchases in the form of sale and leasebacks or direct leases. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2026, the Company has two active &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;leases from the leasing company. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company entered into an agreement with another equipment leasing company in the second quarter of 2023. As of June 30, 2026, the Company had one active lease from this leasing company. In June 2024, the Company entered into two new finance lease agreements with another leasing company. The terms of these lease are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The equipment leases require three advance rental payments to be held as security deposits. The security deposits held amounted to approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2026 and December 31, 2025, respectively, and are included in other non-current assets on the condensed balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has an operating lease for office space in Birmingham, Alabama, which was modified and expanded in March 2024 for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;60-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term ending in March 2029, with an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to extend five years, resulting in an increase to both the right-of-use assets and operating lease liabilities.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. In April 2025, the Company terminated its operating lease for additional unutilized office space in Birmingham, Alabama. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid a one-time termination fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and paid five monthly payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, beginning on June 1, 2025.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As of October 1, 2025, there were no payments remaining.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has an operating lease for office space in New York, New York, with a term that commenced on September 15, 2021, and continues through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has identified an embedded lease within the University of Louisville Manufacturing Services Agreement, as the Company has the exclusive use of, and control over, a portion of the manufacturing facility and equipment of the facility during the contractual term of the manufacturing arrangement. The commencement date of the embedded lease was August 4, 2022 and it continues through August 2028.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The operating leases require security deposits at the inception of each lease. The security deposits amounted to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2026 and December 31, 2025. As of June 30, 2026 and December 31, 2025, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was included in restricted cash.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table contains a summary of the lease costs recognized and other information pertaining to the Company&#x2019;s finance and operating leases for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2026 and 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of finance lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other Lease Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liability&#x2009;&#x2013;&#x2009;finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liability&#x2009;&#x2013;&#x2009;operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term&#x2009;&#x2013;&#x2009;finance leases (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term&#x2009;&#x2013;&#x2009;operating leases (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&#x2009;&#x2013;&#x2009;finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&#x2009;&#x2013;&#x2009;operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the undiscounted cash flows to the operating and finance lease liabilities at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2026 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remainder of 2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: short-term lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</inab:LeaseOfLesseeDisclosureTextBlock>
    <inab:SaleLeasebackTransactionAmountHeldForEquipmentPurchases
      contextRef="C_53e8ca8d-054b-421a-aeaf-137116bc56c1"
      decimals="-5"
      id="F_7c3a2ea1-424e-473e-8220-eedcf94659c4"
      unitRef="U_USD">2500000</inab:SaleLeasebackTransactionAmountHeldForEquipmentPurchases>
    <us-gaap:SaleLeasebackTransactionDescriptionOfAssetS
      contextRef="C_b30464c5-22d4-4239-98ad-7e811345c69c"
      id="F_f2341d3f-67aa-4e31-8760-ec92535b2087">The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.</us-gaap:SaleLeasebackTransactionDescriptionOfAssetS>
    <us-gaap:SecurityDeposit
      contextRef="C_17a4c689-e630-472c-a467-89020ee064f2"
      decimals="-5"
      id="F_5b28456c-a559-42e7-82a1-61ffd83b667d"
      unitRef="U_USD">100000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_997b28c3-e27a-4857-b095-ed0f479b1617"
      decimals="-5"
      id="F_b1a159bf-d4cf-447a-8d8b-e9c9b903b804"
      unitRef="U_USD">100000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_7af2a072-2c87-47d1-ad7d-8dab6874c286"
      id="F_167cf052-2a6a-4f05-916c-a25dd4284591">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_42cc5669-934a-4055-a8d8-921ebecf0195"
      id="F_7c9d16aa-0494-4af1-9958-60d31a7ec288">option to extend five years, resulting in an increase to both the right-of-use assets and operating lease liabilities.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <inab:OneTimeTerminationFeeDescription
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_e9a69f0c-fce6-46b4-b8f4-4d66feceaa38">The Company paid a one-time termination fee of $0.1 million and paid five monthly payments of $20,000, beginning on June 1, 2025.</inab:OneTimeTerminationFeeDescription>
    <inab:TerminationFee
      contextRef="C_0499d8bf-2153-47ac-bbac-d9cd024bdf7f"
      decimals="-8"
      id="F_cbf3e5c4-652c-44f9-be7c-8b321946dae4"
      unitRef="U_USD">100000000</inab:TerminationFee>
    <inab:MonthlyPayments
      contextRef="C_05ec3e90-967f-458c-97d3-d68b6e3dd286"
      decimals="-3"
      id="F_034983b2-6a6a-48d6-98fd-14004564b1b5"
      unitRef="U_USD">20000000</inab:MonthlyPayments>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_def38031-424d-4460-9cf3-5076e5af20ee"
      id="F_fc738797-4004-42a5-a908-d814cd11c7ba">March 2027</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:SecurityDeposit
      contextRef="C_be7c85de-8249-4726-abb3-64537317fe59"
      decimals="-5"
      id="F_e1507674-797a-4ef0-a524-80a4035b706c"
      unitRef="U_USD">200000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_97223205-5221-4961-859d-ce78102dadb4"
      decimals="-5"
      id="F_e45f8b91-eb6f-447c-bcaf-76ff8aac6497"
      unitRef="U_USD">200000</us-gaap:SecurityDeposit>
    <us-gaap:RestrictedCash
      contextRef="C_97223205-5221-4961-859d-ce78102dadb4"
      decimals="-5"
      id="F_fc26620f-710c-4b76-b284-3dd2c4161984"
      unitRef="U_USD">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_be7c85de-8249-4726-abb3-64537317fe59"
      decimals="-5"
      id="F_feafb40c-77de-4d1e-ba51-3d1bd14e8f02"
      unitRef="U_USD">200000</us-gaap:RestrictedCash>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_d83b4631-ea8d-4559-ada2-d2dde6352f6c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table contains a summary of the lease costs recognized and other information pertaining to the Company&#x2019;s finance and operating leases for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2026 and 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of finance lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other Lease Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liability&#x2009;&#x2013;&#x2009;finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liability&#x2009;&#x2013;&#x2009;operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term&#x2009;&#x2013;&#x2009;finance leases (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term&#x2009;&#x2013;&#x2009;operating leases (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&#x2009;&#x2013;&#x2009;finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&#x2009;&#x2013;&#x2009;operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <inab:AmortizationOfFinanceRightOfUseAssets
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_d17c43e8-41dc-4bd0-b9ee-3c6885f7d9d9"
      unitRef="U_USD">62000</inab:AmortizationOfFinanceRightOfUseAssets>
    <inab:AmortizationOfFinanceRightOfUseAssets
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_9c404d9f-95fb-42f1-9613-49ee3bfd61bd"
      unitRef="U_USD">525000</inab:AmortizationOfFinanceRightOfUseAssets>
    <inab:AmortizationOfFinanceRightOfUseAssets
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_407ac3bb-16cc-4f28-a939-6d53a208d7c5"
      unitRef="U_USD">170000</inab:AmortizationOfFinanceRightOfUseAssets>
    <inab:AmortizationOfFinanceRightOfUseAssets
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_891acc03-5550-41fc-9054-13d6ff7a9188"
      unitRef="U_USD">765000</inab:AmortizationOfFinanceRightOfUseAssets>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_0cf83cc0-4614-4849-b261-265c4e8f4bfd"
      unitRef="U_USD">4000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_8e6249c8-0dc1-4da5-9b5a-9c5fdf9ddecd"
      unitRef="U_USD">43000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_0deb75d3-67c9-4c87-aa94-d3d268204413"
      unitRef="U_USD">12000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_4231a40b-0b49-444a-8bf0-a979cb434c1c"
      unitRef="U_USD">71000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_19f408b6-8b86-4397-96da-7c821f661186"
      unitRef="U_USD">216000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_3ca44af7-bf9b-4850-9dc2-eefa0651dc27"
      unitRef="U_USD">339000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_48e0517c-bef2-4ef0-b889-e8339ed104d2"
      unitRef="U_USD">445000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_2b37dfae-41de-4f20-88e3-9398f71814b1"
      unitRef="U_USD">646000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_c75ae8fa-5267-4ed8-91e8-a0eac17f704f"
      unitRef="U_USD">19000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_4d6aa652-00c7-45d9-bb9b-82f71e5aded2"
      unitRef="U_USD">183000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_fb357631-4354-41ff-b86d-7ecfb560a0f9"
      unitRef="U_USD">35000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_ee8339dc-3546-4a79-8704-3e9e2ad9f0c8"
      unitRef="U_USD">248000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_b4e02f1b-583b-4903-b4ac-e79c30fab108"
      unitRef="U_USD">27000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_e7dbe08c-8b28-4255-8f06-6dff94ab3918"
      unitRef="U_USD">32000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_af32a07e-4729-4465-9de3-3a69ba722790"
      unitRef="U_USD">55000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_9bce462a-9a13-4c7e-b047-448829433b09"
      unitRef="U_USD">62000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_c2a64772-3847-4fc5-82ea-b1040a8b9367"
      unitRef="U_USD">328000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_00aed576-e3ed-42f5-8286-09db0adbbfec"
      unitRef="U_USD">1122000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_86ce6655-a3b2-489e-8bd8-b4cd6573642b"
      unitRef="U_USD">717000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_575341fd-28f8-43ab-9893-53d063565c1f"
      unitRef="U_USD">1792000</us-gaap:LeaseCost>
    <inab:CashPaidForAmountsIncludedInFinanceLeases
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_88cc376e-c397-4470-9f61-4b9700fb67a6"
      unitRef="U_USD">13000</inab:CashPaidForAmountsIncludedInFinanceLeases>
    <inab:CashPaidForAmountsIncludedInOperatingLeases
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_573647b4-7fb5-40aa-99b3-ed5450a37c29"
      unitRef="U_USD">245000</inab:CashPaidForAmountsIncludedInOperatingLeases>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      id="F_4ac45b20-f12b-4da9-8658-710a600d7a89">P0Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      id="F_4a4a9408-f05c-48f7-97f2-16399d398d18">P2Y1M28D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="3"
      id="F_989a365b-fea0-4e12-935d-16725645f099"
      unitRef="U_pure">0.139</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="3"
      id="F_0e252bc0-8ba0-4f7a-990e-28b628ca6efe"
      unitRef="U_pure">0.149</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <inab:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_80b2c514-131a-4d44-89f0-2f6343edafc2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the undiscounted cash flows to the operating and finance lease liabilities at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2026 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remainder of 2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: short-term lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</inab:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_e81c6b6c-ccc6-4db5-9a04-739f214d0f98"
      unitRef="U_USD">130000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_2206e9ff-e9c8-42c8-a64a-2516c6c0cf18"
      unitRef="U_USD">620000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_ff5c0a6c-0e97-4b6b-8834-70ef5da72b02"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_68fb72bb-f938-439b-a15e-862ac4d22035"
      unitRef="U_USD">1019000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_390585a0-b8d8-4c2d-b7eb-8edaa08e4800"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_6cc43d25-feac-4fc2-ba5f-92aca4a95871"
      unitRef="U_USD">680000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_ccb8b81e-6da6-4c58-9b06-1b69055f2c37"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_8f1d896d-36c0-4f61-a1ac-ffa456657ac9"
      unitRef="U_USD">66000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_cbb9e3b4-5df4-4187-acfc-72d9b349d219"
      unitRef="U_USD">130000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_28a4339e-21fb-4196-b5a9-40e3ff45cd12"
      unitRef="U_USD">2385000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_7a7acba2-e3fd-410a-bd0d-00d243dcc90a"
      unitRef="U_USD">4000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_e9e18ad0-5b44-484c-9bc5-90e02c51075b"
      unitRef="U_USD">334000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_358689ad-fe67-470a-a1eb-ba7c3989a1fe"
      unitRef="U_USD">126000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_e4ecfb9a-f2ed-4a00-be95-ebaf0f2f21eb"
      unitRef="U_USD">2051000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_c5b749ad-b872-4d68-ac21-44f664ee3f4d"
      unitRef="U_USD">126000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_b9d1b930-1793-4344-91ed-2c43c9c80f8b"
      unitRef="U_USD">923000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_86e09385-bb31-4ff0-8d06-9db6b838934b"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b5d20a02-97de-4fad-9d67-9830ebf05b96"
      decimals="-3"
      id="F_2f745e47-95f8-47b5-962a-180392301407"
      unitRef="U_USD">1128000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_d2db2f21-1b2d-4e05-b309-285d2fd40f16">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13.  SEGMENTS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the CODM or decision making group in making decisions on how to allocate resources and assess performance. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;segment&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; focused on the discovery, development and commercialization of gamma-delta T cell product candidates and TCEs for cancer and autoimmune disease. The CODM is the Company&#x2019;s CEO. The CEO manages the Company&#x2019;s operations, assesses performance for the operating segment and decides how to allocate resources based on net loss, which is reported on the condensed statements of operations. Depreciation expense, amortization expense, stock-based compensation expense, and non-cash lease expense are significant noncash items included in net loss reviewed by the CFO and CEO and are reported on the condensed statements of cash flows. The measure of segment assets is reported on the condensed balance sheets as total consolidated assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents certain financial data for the Company&#x2019;s reportable segment:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.41%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;INB-100 research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;INB-200 research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;INB-400 research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related indirect research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Segment net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment items include preclinical expenses, interest income and other income.&lt;/span&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="0"
      id="F_2eb80b65-5b79-48cb-a215-4c76cae17019"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <inab:NumberOfReportableSegmentsNotDisclosedFlag
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_a929cd00-7c75-483e-b41a-4b3107188ca5">false</inab:NumberOfReportableSegmentsNotDisclosedFlag>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      id="F_89db627a-b77c-4b17-8e49-b424b66fb67b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents certain financial data for the Company&#x2019;s reportable segment:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.41%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;INB-100 research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;INB-200 research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;INB-400 research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related indirect research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Segment net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment items include preclinical expenses, interest income and other income.&lt;/span&gt;&lt;/span&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_b24663f5-7497-4a9d-bd5e-d59f159c16de"
      decimals="-3"
      id="F_79e7ed7c-f973-48c5-9ce7-bc4f59b6da63"
      unitRef="U_USD">245000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_198b97c6-3cda-418e-8a12-84c85860d2ae"
      decimals="-3"
      id="F_37225e08-f60e-4ec5-a39a-ce19100c0a42"
      unitRef="U_USD">228000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_4e1d52b8-2e75-4fad-91a5-2c9038ff8c4d"
      decimals="-3"
      id="F_e8df30c6-645b-4588-8045-c5067df6c503"
      unitRef="U_USD">623000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_991adedc-6fe1-457b-a3c6-48d3d6844dc5"
      decimals="-3"
      id="F_2b05787c-38ae-4251-8ace-d99afe41cdf4"
      unitRef="U_USD">454000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_fdc21c59-3c61-4c15-b2c9-ab66b200f940"
      decimals="-3"
      id="F_7ec9fa9a-c81b-41fb-ada4-49aa1bd50e06"
      unitRef="U_USD">21000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_ad33d33e-a055-4025-8be6-a7a64988ccbc"
      decimals="-3"
      id="F_337f1612-9690-4c96-8f97-9f3adac61ec2"
      unitRef="U_USD">5000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_4c61b704-66e8-4b64-a193-bc2b42ce834b"
      decimals="-3"
      id="F_bb7a3945-596e-4b99-95d0-863c9e730512"
      unitRef="U_USD">57000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_2c1c8162-f3f4-43b5-b9b1-dfa4747b48c7"
      decimals="-3"
      id="F_ab71e92e-f7b6-4803-85d9-41a65cef90e7"
      unitRef="U_USD">15000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_53a7b24c-e727-4468-a624-795e8b95e8d3"
      decimals="-3"
      id="F_8224f95a-05b6-4954-8d41-39845bf15f4e"
      unitRef="U_USD">27000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_aa7edcfc-6c9b-4838-92c4-14a3be2c97a1"
      decimals="-3"
      id="F_e6013616-cd27-46d8-9af1-f82a9264d424"
      unitRef="U_USD">181000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_ca9afdc9-8b69-4eef-878d-9bfdecad710f"
      decimals="-3"
      id="F_dac2df2b-5fa4-4863-9d3b-a04a693672e4"
      unitRef="U_USD">68000</inab:SegmentResearchAndDevelopmentExpenses>
    <inab:SegmentResearchAndDevelopmentExpenses
      contextRef="C_5fdb3891-da52-4136-be69-6649196b8db1"
      decimals="-3"
      id="F_30ddef5b-90b9-4cd2-95ab-6ea32edf2ecc"
      unitRef="U_USD">626000</inab:SegmentResearchAndDevelopmentExpenses>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_9bfae27c-a512-49ee-82c2-a87315990ab9"
      unitRef="U_USD">1266000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_d878bb23-ef88-4979-a39f-0e52a7e7b19f"
      unitRef="U_USD">1241000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_58d758de-2517-4487-a1c7-c89965d8c742"
      unitRef="U_USD">2577000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_3e51a188-d1b2-4737-93a9-560aa0d3e3b4"
      unitRef="U_USD">2501000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_69370843-6490-43fb-9be1-c754bdde0037"
      unitRef="U_USD">2442000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_54bbbce3-9ecd-4567-9e8a-17f9c6d3f29d"
      unitRef="U_USD">2714000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_6dfa6cd9-b56a-4286-81e9-3f4b9e856242"
      unitRef="U_USD">5095000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_b9144b2a-eb94-4a0a-bd95-de54473e8281"
      unitRef="U_USD">5402000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_6d39d48d-314f-467d-8a4c-4e7dff4734f8"
      unitRef="U_USD">780000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_25611ed4-88a8-4ad4-9cb3-b05b081e1023"
      unitRef="U_USD">725000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_ae5f322f-0da7-45ed-a4ad-2c5c44deaae9"
      unitRef="U_USD">1451000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_bf054062-3810-4cc0-b368-e33f58f1a8b6"
      unitRef="U_USD">1646000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      decimals="-3"
      id="F_adb3f311-e705-4ba2-980d-c99534f1c0c6"
      unitRef="U_USD">-4781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_70daad7c-cf08-4f1a-979c-b2e231f3779a"
      decimals="-3"
      id="F_a0c4a542-f37b-4549-90ca-9701045c2121"
      unitRef="U_USD">-5094000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7ed27e52-d578-4124-a699-38d69b156df6"
      decimals="-3"
      id="F_856e4879-c74a-41ab-938b-66a9ceed6c49"
      unitRef="U_USD">-9871000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2dfaff44-5138-4a28-b638-d4a7160c2b7b"
      decimals="-3"
      id="F_fe74cea3-08e9-4b5d-9659-9e650aeee033"
      unitRef="U_USD">-10644000</us-gaap:NetIncomeLoss>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      id="F_780b95bc-8bcd-4c30-879c-79c3949cc233">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      id="F_f9529e9f-a387-4dd6-9a33-e3571323446a">false</ecd:NonRule10b51ArrAdoptedFlag>
    <inab:Rule10B51Arrmodifiedflag
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      id="F_49b31795-51a3-4441-9f82-729adaf8576a">false</inab:Rule10B51Arrmodifiedflag>
    <inab:Nonrule10B51Arrmodifiedflag
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      id="F_03ce8597-51bc-407d-98a8-2b51cd8a9024">false</inab:Nonrule10B51Arrmodifiedflag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      id="F_4a644057-2373-4638-a9ad-ad459c590212">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_d8bdd2b1-2838-46d0-9ed9-c9955ef43e9e"
      id="F_b77f7f23-4204-4ad7-b2ab-0f9aa93c2a5b">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_24a83f4a-7350-4950-9621-e47620552eed"
          xlink:label="F_24a83f4a-7350-4950-9621-e47620552eed"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c0eaaeae-eb28-4836-a2a1-0b385f8a74ee"
          xlink:label="F_c0eaaeae-eb28-4836-a2a1-0b385f8a74ee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ba4bbdff-2aa4-474a-91c3-2c1ef6c55a48"
          xlink:label="F_ba4bbdff-2aa4-474a-91c3-2c1ef6c55a48"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6a2595ff-aceb-4232-b0b4-a4edbf870784"
          xlink:label="F_6a2595ff-aceb-4232-b0b4-a4edbf870784"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_cb679ebc-166e-4e62-8068-125f41eeed39"
          xlink:label="F_cb679ebc-166e-4e62-8068-125f41eeed39"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_68df0b86-a86f-4b00-9f88-2e8bde8ce102"
          xlink:label="F_68df0b86-a86f-4b00-9f88-2e8bde8ce102"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_57f3e6ed-baf3-49bb-a055-ef3d5d7dcbe6"
          xlink:label="F_57f3e6ed-baf3-49bb-a055-ef3d5d7dcbe6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5ddec5c6-ab9b-48f9-9d55-ff4da217f114"
          xlink:label="F_5ddec5c6-ab9b-48f9-9d55-ff4da217f114"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_2bab2d68-a8d3-4b6b-b25d-61036d0fa408"
          xlink:label="F_2bab2d68-a8d3-4b6b-b25d-61036d0fa408"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ae2040ba-edc0-42b2-9e07-cec9ccc09815"
          xlink:label="F_ae2040ba-edc0-42b2-9e07-cec9ccc09815"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ad36cfe4-d780-4a42-a557-9cc7f141a118"
          xlink:label="F_ad36cfe4-d780-4a42-a557-9cc7f141a118"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_88fa32c1-36d1-4829-a67b-b66927b13738"
          xlink:label="F_88fa32c1-36d1-4829-a67b-b66927b13738"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_cc4c5c01-c05f-4623-9210-13aeafc82543"
          xlink:label="F_cc4c5c01-c05f-4623-9210-13aeafc82543"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0c63c55e-f54c-4a7a-973a-4b8863b43643"
          xlink:label="F_0c63c55e-f54c-4a7a-973a-4b8863b43643"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_58d405c4-49a2-4611-bd85-cc3dfdd98b70"
          xlink:label="F_58d405c4-49a2-4611-bd85-cc3dfdd98b70"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9af372e4-b465-4f98-a518-bc53594010cc"
          xlink:label="F_9af372e4-b465-4f98-a518-bc53594010cc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6920e5a2-5153-4018-86b4-83c77154cba0"
          xlink:label="F_6920e5a2-5153-4018-86b4-83c77154cba0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3f57d2ec-aa0e-48a3-b9ac-f3904452b5af"
          xlink:label="F_3f57d2ec-aa0e-48a3-b9ac-f3904452b5af"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d875ef15-491b-4022-95a5-d52c978e5661"
          xlink:label="F_d875ef15-491b-4022-95a5-d52c978e5661"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_23a96342-8aeb-4a85-a167-fd2fdb6cacdd"
          xlink:label="F_23a96342-8aeb-4a85-a167-fd2fdb6cacdd"
          xlink:type="locator"/>
        <link:footnote id="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d" xlink:label="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect a one-for-thirty reverse stock split effected in June 2025. See Note 1, Organization and Nature of Operations, for details.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_24a83f4a-7350-4950-9621-e47620552eed"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c0eaaeae-eb28-4836-a2a1-0b385f8a74ee"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ba4bbdff-2aa4-474a-91c3-2c1ef6c55a48"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6a2595ff-aceb-4232-b0b4-a4edbf870784"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cb679ebc-166e-4e62-8068-125f41eeed39"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_68df0b86-a86f-4b00-9f88-2e8bde8ce102"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_57f3e6ed-baf3-49bb-a055-ef3d5d7dcbe6"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5ddec5c6-ab9b-48f9-9d55-ff4da217f114"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2bab2d68-a8d3-4b6b-b25d-61036d0fa408"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ae2040ba-edc0-42b2-9e07-cec9ccc09815"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ad36cfe4-d780-4a42-a557-9cc7f141a118"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_88fa32c1-36d1-4829-a67b-b66927b13738"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cc4c5c01-c05f-4623-9210-13aeafc82543"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0c63c55e-f54c-4a7a-973a-4b8863b43643"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_58d405c4-49a2-4611-bd85-cc3dfdd98b70"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9af372e4-b465-4f98-a518-bc53594010cc"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6920e5a2-5153-4018-86b4-83c77154cba0"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3f57d2ec-aa0e-48a3-b9ac-f3904452b5af"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d875ef15-491b-4022-95a5-d52c978e5661"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_23a96342-8aeb-4a85-a167-fd2fdb6cacdd"
          xlink:to="FNT_a9c5353c-d22b-46a6-8ae3-4eb60c80a80d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_ae5f322f-0da7-45ed-a4ad-2c5c44deaae9"
          xlink:label="F_ae5f322f-0da7-45ed-a4ad-2c5c44deaae9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bf054062-3810-4cc0-b368-e33f58f1a8b6"
          xlink:label="F_bf054062-3810-4cc0-b368-e33f58f1a8b6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6d39d48d-314f-467d-8a4c-4e7dff4734f8"
          xlink:label="F_6d39d48d-314f-467d-8a4c-4e7dff4734f8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_25611ed4-88a8-4ad4-9cb3-b05b081e1023"
          xlink:label="F_25611ed4-88a8-4ad4-9cb3-b05b081e1023"
          xlink:type="locator"/>
        <link:footnote id="FNT_b5be1cbe-74b4-4707-a935-4de0fdbab18f" xlink:label="FNT_b5be1cbe-74b4-4707-a935-4de0fdbab18f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items include preclinical expenses, interest income and other income.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ae5f322f-0da7-45ed-a4ad-2c5c44deaae9"
          xlink:to="FNT_b5be1cbe-74b4-4707-a935-4de0fdbab18f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bf054062-3810-4cc0-b368-e33f58f1a8b6"
          xlink:to="FNT_b5be1cbe-74b4-4707-a935-4de0fdbab18f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6d39d48d-314f-467d-8a4c-4e7dff4734f8"
          xlink:to="FNT_b5be1cbe-74b4-4707-a935-4de0fdbab18f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_25611ed4-88a8-4ad4-9cb3-b05b081e1023"
          xlink:to="FNT_b5be1cbe-74b4-4707-a935-4de0fdbab18f"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
